<SEC-DOCUMENT>0001193125-20-252381.txt : 20201026
<SEC-HEADER>0001193125-20-252381.hdr.sgml : 20201026
<ACCEPTANCE-DATETIME>20200923165022
ACCESSION NUMBER:		0001193125-20-252381
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200923
DATE AS OF CHANGE:		20200923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Benitec Biopharma Inc.
		CENTRAL INDEX KEY:			0001808898
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39267
		FILM NUMBER:		201192525

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 14, 114 WILLIAM ST
		CITY:			MELBOURNE, VIC
		STATE:			C3
		ZIP:			3000
		BUSINESS PHONE:		61(0)3 8692-7222

	MAIL ADDRESS:	
		STREET 1:		LEVEL 14, 114 WILLIAM ST
		CITY:			MELBOURNE, VIC
		STATE:			C3
		ZIP:			3000
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d899221d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Report Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended June&nbsp;30, 2020 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="left"><B>Transition Report under Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39267</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Benitec Biopharma Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">84-462-0206</FONT></FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>3940 Trust Way Hayward, California</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94545</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(510) <FONT STYLE="white-space:nowrap">780-0819</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, par value $0.0001</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BNTC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>None </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the
registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has
filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted and posted pursuant to Rule 405
of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated
filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Accelerated&nbsp;Filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#146;s assessment of the effectiveness of its internal
control over financial reporting under Section&nbsp;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The aggregate market value of the Registrant&#146;s common
equity held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> based upon the closing price of the Registrant&#146;s securities on the Nasdaq Capital Market of $7.65 on December&nbsp;31, 2019 and giving effect to the <FONT
STYLE="white-space:nowrap">Re-domiciliation</FONT> (as defined herein), was approximately $5,875,207. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">There were 1,108,374 shares of the Registrant&#146;s
common stock, $0.0001 par value per share, outstanding on September 15, 2020. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">None </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL REPORT ON FORM <FONT STYLE="white-space:nowrap">10-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>PART I</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_1">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_2">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1B.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_3">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_4">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_5">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_6">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>PART II</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_7">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_8">Selected Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_10">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_11">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_12">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_13">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9B.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_14">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>PART III</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_15">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">III-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_16">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">III-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_17">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">III-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_18">Certain Relationships and Related Transactions, and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">III-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_19">Principal Accountant Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">III-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>PART IV</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_20">Exhibits and Financial Statement Schedules</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">IV-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_21">Form <FONT STYLE="white-space:nowrap">10-K</FONT> Summary</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">IV-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc899221_22">Signatures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">IV-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS ANNUAL REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, the terms &#147;Benitec,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148;
and similar terms used in this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> refer (i), prior to the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> (as defined herein) to Benitec Biopharma Limited (BBL), an Australian
corporation, and its subsidiaries, and (ii), following the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including Benitec Limited). Any references to &#147;Benitec
Limited&#148; or &#147;BBL&#148; refer to Benitec Biopharma Limited, an Australian corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references to &#147;$&#148; in this
Annual Report refer to U.S. dollars. All references to &#147;A$&#148; in this Annual Report mean Australian dollars. As of June&nbsp;30, 2020, the rate of exchange of U.S. dollars to Australian dollars was 1.4541&nbsp;AUD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> is June 30. References to a particular &#147;fiscal year&#148; are to our fiscal
year ended June&nbsp;30 of that calendar year. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report includes information with respect to market and industry conditions and market share from third-party sources or based upon
estimates using such sources when available. We believe that such information and estimates are reasonable and reliable. We also believe the information extracted from publications of third-party sources has been accurately reproduced. However, we
have not independently verified any of the data from third-party sources. Similarly, our internal research is based upon our understanding of industry conditions, and such information has not been verified by any independent sources. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRADEMARKS AND TRADENAMES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have proprietary and licensed rights to trademarks used in this Annual Report which are important to our business, many of which are
registered under applicable intellectual property laws. These trademarks include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BENITEC BIOPHARMA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">BENITEC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GIVING DISEASE THE SILENT TREATMENT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SILENCING GENES FOR LIFE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for convenience, trademarks and trade names referred to in this Annual Report appear without the &#147;<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#148; or &#147;<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>&#148; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest
extent possible under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#146; trade names, trademarks or service marks to imply a
relationship with, or endorsement or sponsorship of us by, any other companies. Each trademark, trade name or service mark of any other company appearing in this Annual Report is the property of its respective holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our
control. All statements, other than statements of historical fact included in this Annual Report, regarding our strategy, future operations, financial position, projected costs, prospects, plans and objectives of management are forward-looking
statements. When used in this Annual Report, the words &#147;could,&#148; &#147;believe,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;continue,&#148; &#147;predict,&#148;
&#147;potential,&#148; &#147;project,&#148; or the negative of these terms, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements
involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these
forward-looking statements. These risks, uncertainties and factors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our plans to develop and potentially commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation and completion of preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and sufficiency of patient enrollment and dosing in any future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the availability of data from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and outcome of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated delays; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales, marketing, manufacturing and distribution requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market competition and the acceptance of our products in the marketplace; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of novel AAV vectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the plans of licensees of our technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical utility and potential attributes and benefits of ddRNAi and our product candidates,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">including the potential duration of treatment effects and the potential for a &#147;one shot&#148; cure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on our relationships with collaborators and other third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses, ongoing losses, future revenue, capital needs and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business
plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and the duration of our patent portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of local, regional, and national and international economic conditions and events; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the disease caused by the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> virus, which may adversely impact our business and preclinical and future clinical trials; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as other risks detailed under the caption &#147;Risk Factors&#148; in this Annual Report and in other reports filed with the SEC. Although we believe
that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and important factors currently known by us and our expectations of the
future, about which we cannot be certain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based the forward-looking statements included in this Annual Report on information
available to us on the date of this Annual Report or on the date thereof. Except as required by law we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise. You are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including annual reports on
Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All forward-looking statements included herein or in documents incorporated herein by reference are expressly qualified in their entirety by
the cautionary statements contained or referred to elsewhere in this Annual Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_1"></A>Item&nbsp;1. Business. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Company Overview </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We endeavor to
become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (&#147;Benitec&#148; or the &#147;Company&#148; or in the third person, &#147;we&#148; or &#147;our&#148;) is a
development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called <FONT STYLE="white-space:nowrap">DNA-directed</FONT> RNA interference, or
ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and
life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">BB-301</FONT> is the most advanced ddRNAi-based genetic medicine currently under development by Benitec. <FONT STYLE="white-space:nowrap">BB-301</FONT> is an internally optimized,
<FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy agent that is designed to both silence the expression of mutated, disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and replace the mutant genes
with normal, &#147;wild type&#148; genes (to drive restoration of function in diseased cells). This fundamental approach to disease management is called &#147;silence and replace&#148; and this biological mechanism offers the potential to restore
the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and, potentially, fatal effects of Oculopharyngeal Muscular Dystrophy (OPMD).
<FONT STYLE="white-space:nowrap">BB-301</FONT> has been granted Orphan Drug Designation in the United States and the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the combination of the targeted gene silencing effects of RNAi and the durable transgene expression achievable via the use of modified
viral vectors, the silence and replace approach has the potential to produce long-term silencing of disease-causing genes along with simultaneous replacement of wild type gene function following a single administration of the proprietary genetic
medicine. We believe this novel attribute of the investigational agents under development by Benitec may facilitate the achievement of robust clinical activity while greatly reducing the dosing frequencies traditionally expected for medicines
employed for the management of chronic diseases. Additionally, the establishment of chronic gene silencing and gene replacement may significantly reduce the risk of patient <FONT STYLE="white-space:nowrap">non-compliance</FONT> during the course of
medical management of potentially fatal clinical disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require additional financing to progress our product candidates
through to key inflection points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary technology platforms are designated as
<FONT STYLE="white-space:nowrap">DNA-directed</FONT> RNA interference, or &#147;ddRNAi&#148;, and &#147;silence and replace&#148;. ddRNAi is designed to produce long-term silencing of disease-causing genes, by combining RNA interference, or RNAi,
with viral delivery agents typically associated with the field of gene therapy (i.e. viral vectors). Modified AAV vectors are employed to deliver genetic constructs which encode short hairpin RNAs that are, then, serially expressed and processed, to
produce siRNA molecules within the transduced cell for the duration of the life of the target cell. These newly introduced siRNA molecules drive long-term, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potentially permanent, silencing of the expression of the disease-causing gene. The silence and replace approach further bolsters the biological benefits of long-term silencing of disease-causing
genes by incorporating multifunctional genetic constructs within the modified AAV vectors to create an <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy agent that is designed to both silence the expression of mutated, disease-causing
genes (to slow, or halt, the underlying mechanism of disease progression) and, simultaneously, replace the mutant genes with normal, &#147;wild type&#148; genes (to drive restoration of function in diseased cells).&nbsp;This fundamentally distinct
approach to disease management offers the potential to restore the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and, potentially, fatal effects of diseases like
Oculopharyngeal Muscular Dystrophy (OPMD). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Traditional gene therapy is defined by the introduction of an engineered transgene to correct
the pathophysiological derangements derived from mutated or malfunctioning genes. Mutated genes can facilitate the intracellular production of disease-causing proteins or hamper the production of critical, life-sustaining, proteins, and the
introduction of a new transgene can facilitate the restoration of production of normal proteins within the diseased cell, thus, restoring natural biological function. Critically, the implementation of this traditional method of gene therapy cannot
eliminate the expression, or the potential deleterious effects of, the underlying mutant gene (as mutant proteins may be continually expressed and aggregate or drive the aggregation of other native proteins within the diseased cell). In this regard,
the dual capabilities of the proprietary silence and replace approach to silence a disease-causing gene via ddRNAi and simultaneously replace the wildtype activity of a mutant gene via the delivery of an engineered transgene could facilitate the
development of differentially efficacious treatments for a range of genetic disorders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Re-domiciliation</FONT>
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2020, or the Implementation Date, the <FONT STYLE="white-space:nowrap">re-domiciliation,</FONT> or the <FONT
STYLE="white-space:nowrap">Re-domiciliation,</FONT> of Benitec Biopharma Limited, a public company incorporated under the laws of the State of Western Australia, or Benitec Limited, was completed in accordance with the Scheme Implementation
Agreement, as amended and restated as of January&nbsp;30, 2020, between Benitec Limited and us. As a result of the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> our jurisdiction of incorporation was changed from Australia to Delaware,
and Benitec Limited became our wholly owned subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> was effected
pursuant to a statutory scheme of arrangement under Australian law, or the Scheme, whereby on the Implementation Date, all of the issued and outstanding ordinary shares of Benitec Limited were exchanged for newly issued shares of our common stock,
on the basis of one share of our common stock, par value $0.0001 per share, for every 300 ordinary shares of Benitec Limited issued and outstanding. Holders of Benitec Limited&#146;s American Depository Shares, or ADSs (each of which represented 200
ordinary shares), received two shares of our common stock for every three ADSs held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock began trading on The Nasdaq Capital
Market, or Nasdaq, at the start of trading on the Implementation Date under the symbol &#147;BNTC.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of RNAi and the siRNA Approach
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mutation of a single gene can cause a chronic disease via the resulting intracellular production of a disease-causing protein
(i.e. an abnormal form of the protein of interest), and many chronic and/or fatal disorders are known to result from the inappropriate expression of a single gene or multiple genes. In some cases, genetic disorders of this type can be treated
exclusively by &#147;silencing&#148; the intracellular production of the disease-causing protein through well-validated biological approaches like RNA interference (&#147;RNAi&#148;). RNAi employs small nucleic acid molecules to activate an
intracellular enzyme complex, and this biological pathway temporarily reduces the production of the disease-causing protein. In the absence of the disease-causing protein, normal cellular function is restored and the chronic disease that initially
resulted from the presence of the mutant protein is partially or completely resolved. RNAi is potentially applicable to over 20,000 human genes and a large number of disease-causing microorganism-specific genes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g03y85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A small double stranded RNA, or dsRNA, molecule (A, Figure 1), comprising one strand known as the sense
strand and another strand known as the antisense strand, which are complementary to each other, is synthesized in the laboratory. These small dsRNAs are called small interfering RNAs, or siRNAs. The sequence of the sense strand corresponds to a
short region of the target gene mRNA. The siRNA is delivered to the target cell (B, Figure 1), where a group of enzymes, referred to as the <FONT STYLE="white-space:nowrap">RNA-Induced</FONT> Silencing&nbsp;Complex, or RISC, process the siRNA (C,
Figure 1), where one of the strands (usually the sense strand) is released (D, Figure 1). RISC uses the antisense strand to find the mRNA that has a complementary sequence (E, Figure 1) leading to the cleavage of the target mRNA (F, Figure 1). As a
consequence, the output of the mRNA (protein production) does not occur (G, Figure 1). Several companies, including Alnylam Pharmaceuticals Inc. (&#147;Alnylam&#148;), Arbutus Biopharma Corp. (&#147;Arbutus&#148;), and Dicerna Pharmaceuticals Inc.
(&#147;Dicerna&#148;), utilize this approach in their RNAi product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Importantly, many genetic disorders are not amenable to
the traditional gene silencing approach outlined in Figure 1, as the diseased cells may produce a mixture of the wildtype protein of interest and the disease-causing, mutant variant of the protein, and the underlying genetic mutation may be too
small to allow for selective targeting of the disease-causing variant of the protein through the use of siRNA-based approaches exclusively. In these cases, it is extraordinarily difficult to selectively silence the disease-causing protein without
simultaneously silencing the wildtype intracellular protein of interest whose presence is vital to the conduct of normal cellular functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary silence and replace technology utilizes the unique specificity and robust gene silencing capabilities of RNAi while overcoming
many of the key limitations of siRNA-based approaches to disease management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the standard RNAi approach, double-stranded siRNA is
produced synthetically and, subsequently, introduced into the target cell via chemical modification of the RNA or alternative methods of delivery. While </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efficacy has been demonstrated in several clinical indications through the use of this approach, siRNA-based approaches maintain a number of limitations, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical management requires repeat administration of the siRNA-based therapeutic agent for multiple cycles to
maintain efficacy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Long-term patient compliance challenges due to dosing frequencies and treatment durations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Therapeutic concentrations of siRNA are not stably maintained because the levels of synthetic siRNA in the target
cells decrease over time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novel chemical modifications or novel delivery materials are typically required to introduce the siRNA into the
target cells, making it complicated to develop a broad range of therapeutics agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential adverse immune responses, resulting in serious adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Requirement for specialized delivery formulations for genetic disorders caused by mutations of multiple genes;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">siRNA acts only to silence genes, and cannot be used to replace defective genes with normally functioning genes.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Approach to the Treatment of Genetic Diseases&#151;ddRNAi and Silence and Replace </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary silence and replace approach to the treatment of genetic diseases combines RNAi with wildtype gene replacement to drive
sustained silencing of disease-causing genes and concomitant restoration of functional wildtype genes following a single administration of the therapeutic agent. Benitec employs ddRNAi in combination with classical gene therapy (i.e. transgene
delivery via viral vectors) to overcome several of the fundamental limitations of RNAi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The silence and replace approach to the treatment
of genetic disorders employs adeno-associated viral vectors (&#147;AAVs&#148;) to deliver genetic constructs which may, after a single administration to the target tissues: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chronically express RNAi molecules inside of the target, diseased, cells (to serially silence the intracellular
production of mutant, disease-causing, protein and the wildtype protein of interest); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Simultaneously drive the expression of a wildtype variant of the protein of interest (to restore native
intracellular biological processes); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AAV vectors can accommodate the multi-functional DNA expression cassettes containing the engineered wildtype
transgenes and the novel genes encoding short hairpinRNA/microRNA molecules (shRNA/miRNA) that are required to support the development of therapeutic agents capable of the achievement of the goals of the silence and replace approach to therapy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our silence and replace technology utilizes proprietary DNA expression cassettes to foster continuous production of
gene silencing shRNAs and wildtype proteins (via expression of the wildtype transgene). A range of viral and <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy vectors can be used to deliver the DNA construct into the nucleus of the
target cell and, upon delivery, shRNA molecules are expressed and subsequently processed by intracellular enzymes into siRNA molecules that silence the expression of the mutant, disease causing protein (Figure 2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the silence and replace approach (Figure 2): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A DNA construct is delivered to the nucleus of the target cell by a gene therapy vector (A)&nbsp;such as an AAV;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Once inside of the nucleus, the DNA construct drives the continuous production of shRNA
molecules&nbsp;(B)&nbsp;which are processed by an enzyme called Dicer into siRNAs (C); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The processed siRNA is incorporated into RISC and silences the target gene using the same mechanism shown in
Figure 1; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">When the DNA expression cassette is additionally comprised of a wildtype transgene, upon entry of the DNA
construct into the nucleus of the target cell via the use of the AAV vector, the DNA construct also drives the continuous production of wildtype protein (to restore native intracellular biological processes). </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g05l69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to discover, develop and commercialize treatments that leverage the capabilities of ddRNAi
and the silence and replace approach to disease management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For selected product candidates, at the appropriate stage, we may collaborate
with large biopharmaceutical companies to further <FONT STYLE="white-space:nowrap">co-develop</FONT> and, if approved, commercialize our ddRNAi-based and silence and replace-based products to achieve broad clinical and commercial distribution. For
specific clinical indications that we deem to be outside of our immediate areas of focus (e.g. HBV), we will continue to <FONT STYLE="white-space:nowrap">out-license,</FONT> where appropriate, applications of our ddRNAi and silence and replace
technology to facilitate the development of differentiated therapeutics, which could provide further validation of our proprietary technology and approach to disease management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cash and cash equivalents will be deployed to advance our product candidate <FONT STYLE="white-space:nowrap">BB-301</FONT> for OPMD and,
while we are not actively working on the development of <FONT STYLE="white-space:nowrap">BB-103</FONT> for the treatment of HBV due to our current liquidity and funding, we will seek a strategic partnership to support its development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Oculopharyngeal Muscular Dystrophy&#151;OPMD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPMD is an insidious, autosomal-dominant, late-onset degenerative muscle disorder that typically presents in patients at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">40-to-50</FONT></FONT> years of age. The disease is characterized by progressive swallowing difficulties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(dysphagia) and eyelid drooping (ptosis). OPMD is caused by a specific mutation in the poly(A)-binding protein nuclear 1, or PABPN1, gene. OPMD is a rare disease; however, patients have been
diagnosed with OPMD in at least 33 countries. Patients suffering from OPMD are well-identified, and significant geographical clustering has been noted for patients with this disorder, which could simplify clinical development and global
commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BB-301</FONT> is an internally optimized,
<FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy agent that is designed to both silence the expression of mutated, disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and replace the mutant genes
with normal, &#147;wild type&#148; genes (to drive restoration of function in diseased cells). This fundamental approach to disease management is called &#147;silence and replace&#148; and this biological mechanism offers the potential to restore
the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and, potentially, fatal effects of Oculopharyngeal Muscular Dystrophy (OPMD).
<FONT STYLE="white-space:nowrap">BB-301</FONT> has been granted Orphan Drug Designation in the United States and the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of September&nbsp;3, 2019, the License and Collaboration Agreement with Axovant was terminated. As a result, all rights and licenses which Benitec had granted to Axovant to develop and commercialize <FONT STYLE="white-space:nowrap">BB-301</FONT> and
related gene therapy product candidates terminated. We are now solely responsible for the costs in connection with the development and commercialization of the <FONT STYLE="white-space:nowrap">BB-301</FONT> product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to such termination, the Benitec team endeavored to conduct several additional exploratory nonclinical analyses in order
to&nbsp;potentially&nbsp;improve the biological efficacy of <FONT STYLE="white-space:nowrap">BB-301</FONT> via further&nbsp;optimization of the route of administration employed to dose the target muscle tissues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hepatitis B </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is developing <FONT
STYLE="white-space:nowrap">BB-103</FONT> for the treatment of HBV. Results of in vivo and in vitro studies, from December 2016, March 2016 and December 2015, demonstrated the potential utility of an approach that combines RNAi with gene therapy to
treat HBV. In April 2017, the Company completed a <FONT STYLE="white-space:nowrap">pre-IND</FONT> submission with the FDA in which the feedback provided by the agency included details regarding steps required to initiate a clinical trial for <FONT
STYLE="white-space:nowrap">BB-103.</FONT> As noted, due to our current liquidity and funding, the Company is seeking strategic partnerships to complete the IND enabling studies for <FONT STYLE="white-space:nowrap">BB-103.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the
combination of our proprietary ddRNAi technology and our deep expertise in the design and development of genetic medicines, and specifically ddRNAi-based therapeutics, will enable us to achieve and maintain a leading position in gene silencing and
gene therapy for the treatment of human disease. Our key strengths include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A first mover advantage for ddRNAi-based therapeutics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A proprietary ddRNAi-based silence and replace technology platform that may potentially enable the serial
development of single-administration therapeutics capable of facilitating sustained, long-term silencing of disease-causing genes and concomitant replacement of wildtype gene function; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A proprietary AAV vector technology which improves the endosomal escape capability of virus produced in insect
cells using a baculovirus system. This technology has broad application in <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The capabilities to drive the development of a pipeline of programs focused on chronic diseases with either large
patient populations, including Chronic Hepatitis B virus infection, or rare diseases, which may potentially support the receipt of Orphan Drug Designation, including OPMD; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A growing portfolio of patents protecting improvements to our ddRNAi, and silence and replace, technology and
product candidates through at least 2036, with additional patent life anticipated through at least 2040. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet
medical need via the application of the silence and replace approach to the treatment of genetic disorders. We apply the following general strategy to drive the Company towards these goals: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively develop proprietary and partnered programs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to explore and secure research and development partnerships with global biopharmaceutical companies
supported by the differentiated nature of our scientific platform and intellectual property portfolio. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our senior
leadership team will continue to explore partnership opportunities with global biopharmaceutical companies, as we expect that the unique attributes of the proprietary ddRNAi and silence and replace approaches, and the breadth of potential clinical
indications amenable our proprietary methods, to support the formation of collaborations over a broad range of diseases with significant unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to actively protect our intellectual property and proprietary technology. These efforts are central to the growth of our business and
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Seeking and maintaining patents claiming our ddRNAi and silence and replace technologies and other inventions
relating to our specific products in development or that are otherwise commercially and/or strategically important to the development of our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Protecting and enforcing our intellectual property rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strategically licensing intellectual property from third parties to advance development of our product
candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our current product candidates and their development status: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Table 1. Pipeline: Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B Virus Infection </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g47i71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BB-301</FONT> is a late-stage nonclinical investigational agent currently
in development for the treatment of Oculopharyngeal Muscular Dystrophy. <FONT STYLE="white-space:nowrap">BB-301</FONT> is the lead pipeline program for Benitec, and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies are currently being
conducted. A summary of the <FONT STYLE="white-space:nowrap">BB-301</FONT> program is provided in Figure 3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g07a13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BB-103</FONT> has demonstrated robust nonclinical activity during the
evaluation of this agent for the treatment of Chronic Hepatitis B Virus infection. Benitec is currently seeking strategic partners to advance <FONT STYLE="white-space:nowrap">BB-103</FONT> through <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">In-House</FONT> Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">BB-301</FONT> for Treatment of Oculopharyngeal Muscular Dystrophy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPMD is an insidious, autosomal-dominant, late-onset, degenerative muscle disorder that typically presents in patients at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">40-to-50</FONT></FONT> years of age. The disease is characterized by progressive swallowing difficulties (dysphagia) and eyelid drooping (ptosis). OPMD is caused by a specific mutation in
the poly(A)-binding protein nuclear 1, or PABPN1, gene. OPMD is a rare disease, however, patients have been diagnosed with OPMD in at least 33 countries. Patients suffering from OPMD are well-identified, and significant geographical clustering has
been noted for patients with this disorder, which could simplify clinical development and global commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PABPN1 is a
ubiquitous factor that promotes interaction between the poly(A) polymerase and CPSF (cleavage and polyadenylation specificity factor) and, thus, controls the length of mRNA poly(A) tails, mRNA export from the nucleus, and alternative poly(A) site
usage. The characteristic genetic mutation underlying OPMD results in trinucleotide repeat expansion(s) within exon 1 of PABPN1 and results in an expanded poly-alanine tract at the <FONT STYLE="white-space:nowrap">N-terminal</FONT> end of PABPN1.
The mutation generates a protein with an <FONT STYLE="white-space:nowrap">N-terminal</FONT> expanded poly-alanine tract of up to 18 contiguous alanine residues prone to form aggregates called intranuclear inclusions (INIs). The INIs that sequester
wildtype PABPN1 could also contribute to loss of the function phenotype associated with OPMD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Current OPMD Treatments and Products
in Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No curative or disease-modifying therapies currently exist for OPMD patients. Surgical interventions can be
undertaken for palliative purposes, including the use of cricopharyngeal myotomy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investigational therapies that have been explored,
unsuccessfully, in the past include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intravenous administration of trehalose; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The use of autologous myoblast transplant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Our Lead, Silence and Replace-Based, OPMD Therapeutic Agent&#151;</I></B><B><FONT
STYLE="white-space:nowrap">BB-301</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BB-301</FONT> is composed of a modified AAV serotype 9
(AAV9) capsid that expresses a bifunctional construct under the control of a single muscle specific <FONT STYLE="white-space:nowrap">Spc5-12</FONT> promoter to achieve <FONT STYLE="white-space:nowrap">co-expression</FONT> of both the codon-optimized
PABPN1 mRNA and two shmiR molecules directed against wild type and mutant PABPN1, and the agent is<B> </B>designed to correct the genetic defect underlying OPMD following a single localized administration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">BB-301&#151;Design</FONT> and Mechanism of Action </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BB-301</FONT> is designed to target two distinct regions of the PABPN1 mRNA via the concomitant expression of
two distinct shmiRs from a single DNA construct and the simultaneous expression of a codon-optimized, siRNA-resistant, version of the wildtype PABPN1 gene <I>(Figure 4)</I>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 4 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g52s92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In collaboration with researchers at the Royal Holloway University of London and the Institut de Myologie
in Paris, we developed a ddRNAi construct expressing three shRNAs against three distinct regions of PABPN1 mRNA and observed effective silencing of the PABPN1 gene <I>in vitro </I>using this ddRNAi construct. Furthermore, as part of this
collaboration, we have generated a gene expression construct that produces a siRNA-resistant version of the wildtype PABPN1 gene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
subsequent studies undertaken exclusively by Benitec, a second set of target regions within PABPN1 were identified for therapeutic development and shmiRs designed against these regions. Additional shmiRs have also been designed for the original
shRNA developed in collaboration with Royal Holloway University of London and the Institut de Myologie. The &#145;silence and replace&#146; construct, designated <FONT STYLE="white-space:nowrap">BB-301,</FONT> incorporates the two best performing
shmiRs, and the gene expression construct that produces a siRNA-resistant version of the wildtype PABPN1 gene, under the control of a muscle-specific promoter. The mechanism of action of <FONT STYLE="white-space:nowrap">BB-301</FONT> is shown in
Figure 5. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 5 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g07b91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In initial <I>in vivo </I>studies evaluating the use of direct intramuscular injection of <FONT
STYLE="white-space:nowrap">AAV-based</FONT> constructs with the potential to drive the desired silence and replace approach in the A17 transgenic mouse model of OPMD at the Royal Holloway University of London and the Institut de Myologie, we
observed decreases in muscle fibrosis, increases in cross sectional area of the treated muscles, decreases in intranuclear inclusions, and normalization of muscle strength. These nonclinical results were published in <I>Nature Communications </I>in
April 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In subsequent studies, Benitec demonstrated in a key <FONT STYLE="white-space:nowrap">non-clinical</FONT> model (the A17
mouse model) that a single intramuscular injection of <FONT STYLE="white-space:nowrap">BB-301</FONT> results in robust intracellular silencing of PABPN1 protein production and concomitant expression of the normal, biologically functional PABPN1
protein. In the A17 mouse model, the treatment restores muscle strength and muscle weight to wild type levels and improves other physiological hallmarks of the disease (Figure 6a, Figure 6b, Figure 6c, Figure 6d): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Multiple A17 animal cohorts received single doses of <FONT STYLE="white-space:nowrap">BB-301</FONT> (over a range
of doses spanning 4x10<SUP STYLE="font-size:85%; vertical-align:top">8</SUP> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vg/muscle-to-7.5x10</FONT></FONT><SUP STYLE="font-size:85%; vertical-align:top">11</SUP> vg/muscle) and,
following <FONT STYLE="white-space:nowrap">BB-301</FONT> administration, each cohort was observed for <FONT STYLE="white-space:nowrap">14-</FONT> weeks </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">BB-301</FONT> was injected into the Tibialis Anterior (TA) muscle of 10 week <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">old-to-12</FONT></FONT> week old animals, and <FONT STYLE="white-space:nowrap">14-</FONT> weeks post administration each A17 cohort was anesthetized and the contractile properties of the
injected TA muscles were analyzed via <FONT STYLE="white-space:nowrap">in-situ</FONT> muscle electrophysiology </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intermediate doses of <FONT STYLE="white-space:nowrap">BB-301</FONT> resulted in 75% silencing of PABPN1 and 26%
replacement of wild type PABPN1 activity, leading to full restoration of muscle strength, clearance of INIs, and a reduction of fibrosis </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An additional experiment conducted over the course of <FONT STYLE="white-space:nowrap">20-weeks</FONT>
demonstrated that more modest doses of <FONT STYLE="white-space:nowrap">BB-301</FONT> (which supported only partial resolution of the disease phenotype at <FONT STYLE="white-space:nowrap">week-14)</FONT> were, surprisingly, able to facilitate
significant benefit at <FONT STYLE="white-space:nowrap">20-weeks,</FONT> as evidenced by full restoration of all parameters relating to muscle strength, weight and INI formation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6a. Dose-Dependent shRNA Expression </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g50e09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6b. Dose-Dependent PABPN1 Inhibition and Transgene Expression </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g83i97.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6c. Dose-Dependent Decreases in Intranuclear Inclusions </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g87u54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6d. Dose-Dependent Increases in Muscle Force </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g54l59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Development Plans for <FONT STYLE="white-space:nowrap">BB-301</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;8, 2020, Benitec announced the initiation of the <FONT STYLE="white-space:nowrap">BB-301</FONT> Tissue Transduction Study in large
animal subjects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">BB-301</FONT> Tissue Transduction Study is the first of
three planned <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies that will be conducted in large animals. These <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies will be carried out under the guidance of the scientific team at
Benitec, with key elements of the study design and execution conducted in close collaboration with a team of leading experts in both medicine and surgery that have been deeply engaged in the treatment of OPMD patients for several decades.&nbsp;The <FONT
STYLE="white-space:nowrap">BB-301</FONT> Tissue Transduction study, along with the subsequent <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, will be conducted in canine subjects and will support the validation and optimization of the
newly designed method of <FONT STYLE="white-space:nowrap">BB-301</FONT> administration, confirm the efficiency of vector transduction in the key tissue compartments underlying the natural history of OPMD, confirm the optimal drug doses in advance of
initiation of human clinical studies, and facilitate observation of key toxicological data-points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">BB-301</FONT> Tissue Transduction Study is designed as an <FONT STYLE="white-space:nowrap">8-week</FONT> study in Beagle dogs to confirm the transduction efficiency of <FONT STYLE="white-space:nowrap">BB-301</FONT>
upon administration via direct intramuscular injection into specific anatomical regions of the pharynx through the use of an open surgical procedure.&nbsp;This new route of <FONT STYLE="white-space:nowrap">BB-301</FONT> administration was developed
in collaboration with key surgical experts in the field of Otolaryngology, and this novel method of <FONT STYLE="white-space:nowrap">BB-301</FONT> dosing will significantly enhance the ability of a treating physician to accurately administer the <FONT
STYLE="white-space:nowrap">AAV-based</FONT> investigational agent to the muscles that underlie the characteristic deficits associated with the progression of OPMD.&nbsp;It is important to note that prior
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies of <FONT STYLE="white-space:nowrap">BB-301</FONT> have reproducibly validated the robust biological activity achieved following direct intramuscular injection.&nbsp;As an example, direct
injection of <FONT STYLE="white-space:nowrap">BB-301</FONT> into the tibialis anterior muscles of A17 mice facilitated robust transduction of the targeted skeletal muscle cells and supported complete remission of the OPMD disease phenotype in this
animal model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim data for the <FONT STYLE="white-space:nowrap">BB-301</FONT> Tissue Transduction Study is expected in late 2020 or
early 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">BB-103</FONT> for the Treatment of Hepatitis B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are seeking strategic partners to continue the development of <FONT STYLE="white-space:nowrap">BB-103</FONT> for the treatment of HBV.
Results of in vivo and in vitro studies, from December 2016, March 2016 and December 2015, have, we believe, demonstrated the potential utility of an approach that combines RNAi with gene therapy to treat HBV. The Company is seeking strategic
partnerships to complete the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">BB-103.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The human hepatitis B virus is a small DNA virus that, according to the World Health Organization, infects up to 240&nbsp;million people
worldwide, resulting in up to 780,000 deaths per year. HBV infection can lead to differential outcomes, ranging from a silent, acute phase infection that can be resolved via the inherent action of the immune system, to a chronic infection requiring
life-long therapy. In the case of a chronic HBV infection, the presence of viral proteins, particularly the hepatitis B surface antigen, causes hepatic inflammation, liver dysfunction, acute hepatic failure, cirrhosis and/or hepatocellular
carcinoma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Current Hepatitis B Treatments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HBV predominantly exists as eight genotypes, designated A through H, with distinct geographic distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to GlobalData, a market research firm, the global hepatitis B therapeutics market was worth $2.4&nbsp;billion in 2014 and is
expected to reach a total value of $3.0&nbsp;billion by 2024 at a Compound Annual Growth Rate of 2.4%. The current standards of care for HBV consist of antivirals composed of nucleotide and nucleoside analogues, or NUCs, and, less commonly,
interferon therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of the currently employed <FONT STYLE="white-space:nowrap">anti-HBV</FONT> therapies can provide long-term viral
load suppression, however, these therapeutic agents have modest cure rates and possess the additional risk of driving the development of drug-resistant mutations. The long-term use of interferon, particularly in high doses, may also be associated
with significant side effects, including nausea, vomiting, shortness of breath, dizziness and fatigue, adding to issues with patient compliance for the course of treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ddRNAi-based Hepatitis B <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Therapeutic-BB-103</FONT></FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BB-103</FONT> is a ddRNAi-based
therapeutic designed to target the liver and inhibit viral replication and surface-antigen production. The initial <I>in vivo</I> data for <FONT STYLE="white-space:nowrap">BB-103</FONT> suggest that joint administration of <FONT
STYLE="white-space:nowrap">BB-103</FONT> and a NUC could support reactivation of the host immune response which is believed to be essential for the achievement of cure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BB-103-Design</FONT></FONT> and Mechanism of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The design of the <FONT STYLE="white-space:nowrap">BB-103</FONT> DNA construct takes advantage of the structure of the HBV genome. The
hepatitis B virus is a small DNA virus with four overlapping open reading frames, meaning several genes are produced from the same DNA sequence by shifting the starting point of the translation process <I>(Figure 7B)</I>. These four genes are known
as the core, surface, X and polymerase genes. The core gene encodes the core nucleocapsid protein, which is important in viral packaging and thought to help stabilize cccDNA, and the hepatitis B <FONT STYLE="white-space:nowrap">e-antigen.</FONT> The
surface gene encodes proteins, including <FONT STYLE="white-space:nowrap">s-antigen.</FONT> The X gene encodes the X protein, which has properties that may be relevant to liver carcinogenesis. The polymerase gene encodes a large protein with
functions critical for viral packaging and replication. Although HBV is a DNA virus, it replicates through an RNA intermediate. <FONT STYLE="white-space:nowrap">BB-103</FONT> targets the viral mRNA at three overlapping regions of the genome
<I>(Figure 7A and Figure 7B)</I>, simultaneously silencing the surface, X, core and polymerase genes. As a result, we believe that the long-term suppression of HBV viral replication, through silencing of the polymerase gene and the HBV RNA used for
replication, the inhibition of HBV viral proteins production, including <FONT STYLE="white-space:nowrap">s-antigen</FONT> production, through silencing of the surface gene, and the inhibition of the cccDNA, through silencing of the core protein
gene, could lead to eradication of HBV infection in patients by a single administration of <FONT STYLE="white-space:nowrap">BB-103</FONT> when paired with a NUC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>In Vitro Development Highlights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bioinformatics analysis of the major HBV genotypes, A through H, has identified several well-conserved regions of the genome for targeting
with ddRNAi therapeutics, and we have designed and evaluated numerous shRNAs to target these regions. The most advanced nonclinical construct is illustrated in Figure 7A. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 7 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g21f21.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 8 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g899221g72g00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regarding the mechanism of action of <FONT STYLE="white-space:nowrap">BB-103,</FONT> the DNA construct is
delivered to the nucleus of hepatocytes via an AAV8 vector. Upon reaching the nucleus the construct expresses three distinct shmiRs that are processed intracellularly to produce siRNAs that cleave the HBV mRNA and, thus, prevent the virus from
replicating and producing viral proteins. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec seeks to actively procure rights to and protect the intellectual property and proprietary technology that it believes is important to
its business. Such intellectual property rights include patents claiming our ddRNAi and silence and replace technologies, as well as <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets related to our product candidates and proprietary
technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ddRNAi-based treatment of Hepatitis B </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Benitec patent portfolio includes four patent families relevant to Benitec&#146;s ddRNAi-based candidate for treatment of hepatitis B virus
(HBV) infection <FONT STYLE="white-space:nowrap">(BB-103).</FONT> This includes three patent families directed to RNAi agents targeting HBV and Benitec&#146;s AAV patent family which covers the delivery system for
<FONT STYLE="white-space:nowrap">BB-103.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first patent family directed to RNAi agents targeting HBV, entitled &#147;<I>HBV
Treatment (HBV family #1)</I>&#148;, relates to single-stranded RNA and shRNA sequences to a range of target regions of the hepatitis B viral genome. Although drafted to explicitly cover shRNAs (as this was the RNAi format under development at the
time), the claims encompass shRNAs comprised within a microRNA backbone (i.e., short hairpin microRNA (shmiR)) which is the format of RNAi currently in use within Benitec&#146;s HBV program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A further patent family relating to shRNA sequences to a range of additional target regions of the hepatitis B viral genome was filed. This
patent family is entitled &#147;<I>Reagents for treatment of hepatitis B virus (HBV) infection</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>and use thereof (HBV family #2)</I>&#148; and, although drafted to cover shRNAs (as this was the RNAi format under development at the time), the claims encompass shRNA and shmiR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third patent family relevant to HBV relates to the development of constructs. This patent family, entitled &#147;<I>Reagents for treatment
of hepatitis B virus (HBV) infection and use thereof (HBV family #3)</I>&#148;, was filed to cover single and triple shmiR constructs currently under development at Benitec. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ddRNAi-based treatment for OPMD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec&#146;s patent portfolio for OPMD includes five patent families relating to shRNA and shmiRs targeting PABPN1 (the causative gene for
OPMD), as well as &#145;silence and replace&#146; therapeutics and treatment strategies for OPMD. These five families cover the OPMD therapeutic candidate, <FONT STYLE="white-space:nowrap">BB-301,</FONT> under development at Benitec, treatment
strategies for OPMD that silence PABPN1 which is causative for OPMD and replace with functional PABPN1, and Benitec&#146;s AAV patent family which covers the delivery system for <FONT STYLE="white-space:nowrap">BB-301.</FONT> <FONT
STYLE="white-space:nowrap">BB-301</FONT> is a &#145;silence and replace&#146; construct encoding two shmiRs targeting the endogenous PABPN1 (including variants causative of OPMD) internally designated <FONT STYLE="white-space:nowrap">shmiR-13</FONT>
and <FONT STYLE="white-space:nowrap">shmiR-17,</FONT> as well as a codon-optimized PABPN1 replacement construct, the transcript of which is not targeted by <FONT STYLE="white-space:nowrap">shmiR-13</FONT> and
<FONT STYLE="white-space:nowrap">shmiR-17.</FONT> Both shmiRs and the codon-optimized PABPN1 replacement construct are under the control of a muscle-specific promoter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first patent family, entitled &#147;Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof (OPMD family
#1)&#148;, arose out of a collaboration with Royal Holloway University of London (RHUL) and relates to three shRNA target regions within PABPN1. RHUL assigned its ownership interests in this patent family to Benitec, and the PCT application and the
related U.S. priority document were filed solely in the name of Benitec. This patent family is directed to RNAi agents targeting specific regions within mutant PABPN1 variants causative of OPMD, as well as use of those RNAi agents in combination
with PABPN1 replacement constructs to treat OPMD. More specifically, this family includes claims covering shmiR17 of <FONT STYLE="white-space:nowrap">BB-301</FONT> This patent family entered the national/regional phase in October/November 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second patent family, entitled &#147;Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof (OPMD family
#2)&#148; relates to a second set of target gene sequences within PABPN1 as well as &#145;silence and replace&#146; construct <FONT STYLE="white-space:nowrap">BB-301</FONT> under development at Benitec. The PCT application and the related U.S.
priority document were filed solely in the name of Benitec, and this family entered the national/regional phase in June/July 2019. This patent family is directed to RNAi agents targeting specific regions within mutant PABPN1 variants causative of
OPMD, as well as &#145;silence and replace&#146; constructs and use of same for treatment of OPMD. More specifically, this family includes claims covering shmiR13 and shmiR17 of <FONT STYLE="white-space:nowrap">BB-301</FONT> separately, as well as
the full <FONT STYLE="white-space:nowrap">BB-301</FONT> &#145;knockdown and replacement&#146; construct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third patent family, entitled
&#147;Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) (OPMD family #3)&#148; has been filed to pursue claims which are broadly directed to the &#145;silence and replace&#146; treatment concept for OPMD, relying on RNAi agents to
knockdown PABPN1 and replacement with functional PABPN1 which is not targeted by the RNAi agents. The claims in this application are not limited to <FONT STYLE="white-space:nowrap">BB-301.</FONT> This patent family exists as a PCT application and
was filed solely in the name of Benitec. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A fourth patent family, entitled &#147;Methods for Treating Oculopharyngeal Muscular Dystrophy
(OPMD) (OPMD family #4)&#148; has been filed to specifically claim the OPMD therapeutic candidate developed by Benitec, <FONT STYLE="white-space:nowrap">BB-301</FONT> (described herein). This patent family exists as a PCT application and was filed
solely in the name of Benitec. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AAV with modified phospholipase domain </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Benitec patent portfolio includes a single patent family, entitled &#147;<I>Adeno-associated virus (AAV) with modified phospholipase
domain</I>,&#148; which relates to an AAV having a modified phospholipase (PLA2) domain in the capsid. The modified AAV will be used as the delivery system for the OPMD therapeutic candidate and the HBV therapeutic candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware of a third party patent directed to AAV vectors that expires in 2026. In the
event we receive regulatory marketing approval before the expiration date it may be necessary for us to obtain a license to the patent in order to commercialize. We cannot guarantee the availability of the license or that it can be obtained on
commercially reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Know-How</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection of ddRNAi and other technology and our product candidates, we also rely on proprietary <FONT
STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent, as valuable intellectual property for our business. This <FONT STYLE="white-space:nowrap">know-how</FONT> is related to the areas of, among others,
identifying nucleic acid targets for ddRNAi technology and designing ddRNAi constructs for targeting preferred genes. We have implemented a number of security measures designed to safeguard our <FONT STYLE="white-space:nowrap">know-how</FONT>
including limiting access to our research facilities, databases and networks. We also seek to protect our <FONT STYLE="white-space:nowrap">know-how</FONT> by way of confidentiality agreements when engaging with external providers for progressing our
pipeline of therapeutic candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Laws and Regulations Regarding Patent Terms </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal terms of the patents in the countries in which they are obtained. In most countries in
which we file, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent term may be shortened if a patent is terminally disclaimed over
another patent or as a result of delays in patent prosecution by the patentee. A patent&#146;s term may be lengthened by a patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent. The patent
term of a European patent is 20 years from its filing date, which, unlike in the United States, is not subject to patent term adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> biologic may also be eligible for patent term
extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term
extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the biologic is under clinical testing regulatory review. Patent extension cannot extend the remaining term
of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved biologic may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that
covers an approved biologic although the eligibility requirements for any duration of such extension vary. In the future, if and when our products receive FDA approval, or approval from an equivalent regulatory body in another jurisdiction in which
patent protection is sought or obtained, we expect to apply for patent term extensions on patents covering those products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Our trademarks include registrations for company branding and product names for our pipeline in development. Several of the trademarks that we
use in connection with our business are described below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trade Mark (program)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Jurisdiction</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BENITEC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1103049</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;Mar&nbsp;2006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BENITEC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">86795296</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21 Oct 2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BENITEC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1728797</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16 Oct 2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BENITEC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14680003</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15 Oct 2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">European Union</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BENITEC BIOPHARMA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1448046</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13 Sep 2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BENITEC BIOPHARMA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4636053</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11 Feb 2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GIVING DISEASE THE SILENT
TREATMENT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1851660</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14 Jun 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GIVING DISEASE THE SILENT
TREATMENT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1389399</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15 Feb 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">European&nbsp;Union</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SILENCING GENES FOR LIFE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1448041</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13 Sep 2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Australia</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SILENCING GENES FOR LIFE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4807242</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22 Dec 2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">United&nbsp;States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Registered</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture of the complex biological products required for gene therapy is complex and difficult. We do not currently own or operate
manufacturing facilities for the production of preclinical, clinical or commercial quantities of any of our product candidates. We are exploring long- term manufacturing alliances with a number of potential partners to investigate manufacturing
processes in order to produce materials at reasonable scale and cost of goods to support future commercialization efforts. We do not have a long-term agreement with any <FONT STYLE="white-space:nowrap">third-party</FONT> manufacturer, but we plan to
establish such a relationship with an appropriate manufacturer to serve our long-term needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing is subject to extensive
regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Our contract manufacturing organizations
manufacture our product candidates under cGMP conditions. cGMP is a regulatory standard for the production of pharmaceuticals that will be used in humans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet
established sales, marketing or product distribution operations because our product candidates are in preclinical or clinical development. If we receive marketing and commercialization approval for any of our product candidates, we intend to market
the product through strategic alliances and distribution agreements with third parties. In certain cases, we may market an approved product directly worldwide or in selected geographical segments. The ultimate implementation of our strategy for
realizing the financial value of our product candidates is dependent on the results of clinical trials for our product candidates, the availability of funds and the ability to negotiate acceptable commercial terms with third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical
industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product
candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our proprietary
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology and scientific expertise in gene silencing using ddRNAi provide us with competitive advantages, we face potential competition from many different sources, including larger and
better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions and governmental agencies and public and private research institutions that may develop potentially competitive products or
technologies. We are aware of several companies focused on developing gene therapy or gene silencing product candidates, including Alnylam, Arbutus and Arrowhead-developing siRNA-based therapeutics for hepatitis B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not aware of any companies developing a gene therapy or gene silencing approach for OPMD. Our product candidates, if approved, would
also compete with treatments that have already been approved and accepted by the medical community, patients and third-party payers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many
of our competitors and potential competitors, alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product
candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated
among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and subject registration for clinical studies, as well
as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will face intense and increasing competition as new products enter the market and advanced technologies become
available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of competition and the availability of reimbursement
from government and other third- party-payers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for
their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that our therapeutic products, if approved,
will be priced at a significant premium over competitive products and our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of competitive products including biosimilar or generic
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This increasingly competitive landscape may compromise the development of our product candidates. For example, improvements in
the efficacy, delivery and success rates of competitors&#146; product candidates, in conjunction with a reduction in the price and duration of their treatments, diminished partnering interest from pharmaceutical companies in our product candidate <FONT
STYLE="white-space:nowrap">TT-034</FONT> for the treatment of HCV. This caused us to announce in February 2016 the discontinuation of our program to develop <FONT STYLE="white-space:nowrap">TT-034</FONT> before the conclusion of its clinical trial,
despite the promising clinical results regarding the safety of that product candidate achieved to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a pharmaceutical and biological product company that wishes to conduct clinical trials and ultimately obtain marketing approval in the
United States, we are subject to extensive regulation by the FDA, and other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, the Public Health Service Act, or PHS Act, and their implementing
regulations set forth, among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record keeping, reporting, distribution, import, export, advertising
and promotion of our products. A failure to comply explicitly with any requirements during the product development, approval, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
post-approval periods, may lead to administrative or judicial sanctions. These sanctions could include the imposition by the FDA or an IRB, of a suspension on clinical trials, refusal to approve
pending marketing applications or supplements, withdrawal of approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the discussion below focuses on regulation in the United States, we anticipate seeking approval for the testing and marketing of our
products in other countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some
significant aspects of regulation in the European Union are addressed in a centralized way through the EMA, but country-specific regulation remains essential in many respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government regulation may delay or prevent testing or marketing of our products and impose costly procedures upon our activities. The testing
and marketing approval process, and the subsequent compliance with appropriate statutes and regulations, requires substantial time, effort, and financial resources, and we cannot be certain that the FDA or any other regulatory agency will grant
marketing approvals for our products or any future products on a timely basis, if at all. The FDA&#146;s or any other regulatory agency&#146;s policies may change and additional governmental regulations may be enacted that could prevent or delay
regulatory approval of our products or any future products or approval of new indications or label changes. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative, judicial, or
administrative action, either in the United States or abroad. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Developments in Regulation of Gene Therapy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has provided guidance for the development of gene therapy products. For example, the FDA has established the Office of Tissues and
Advanced Therapies (formerly Office of Cellular, Tissue and Gene Therapies) within CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. In
addition, the FDA has issued a growing body of clinical guidelines, chemical, manufacturing and control, or CMC, guidelines, regenerative medicine guidelines a and other guidelines, all of which are intended to facilitate industry&#146;s development
of gene therapy products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, Section&nbsp;3033 of the 21st Century Cures Act created a new product category called
&#147;regenerative medicine advanced therapy&#148;, or the RMAT designation. The RMAT designation gives the sponsor of a new investigational biologic access to increased meeting opportunities with the FDA, in a manner comparable to those offered to
sponsors of therapies designated as &#147;breakthrough therapies&#148; by the FDA. Because the designated products meet the criteria for unmet medical need in the treatment of a serious condition, they may be eligible for priority review, in which
the initial assessment of the BLA is reduced from 12 months to eight months, and accelerated approval, which bases approval on an effect on a predictive surrogate endpoint or an intermediate clinical endpoint. RMATs qualifying for such accelerated
approval may be able to satisfy licensing requirements through commitment to post-approval clinical studies as well as real-world data such as patient registries and health record analysis. The eligibility of the RMAT-designated product for these
expedited programs can be discussed with the FDA at specific development meetings, but we do not know whether any of our current or future product candidates will be eligible for RMAT designation. We believe the increased access to the FDA during
early development is a benefit for sponsors, because the typical Type B development meetings are normally restricted to one each at the stages of <FONT STYLE="white-space:nowrap">pre-IND,</FONT> end of Phase
<FONT STYLE="white-space:nowrap">II/pre-Phase</FONT> III and <FONT STYLE="white-space:nowrap">pre-BLA</FONT> submission. In addition, the option to qualify for a fast- track program, also based on the potential to serve an unmet medical need in the
treatment of a serious condition, allows for a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;rolling review&#148; of parts of the BLA, which can be submitted for assessment following agreement of a review timetable with CBER. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA plans to include certain gene therapy products that permanently alter tissue and produce a sustained therapeutic benefit as part of
the products that will meet the definition of being eligible to come under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the pathway enabled by RMAT designation. RMAT designation enables gene therapy products to access the FDA&#146;s existing expedited programs to help foster the development and approval of gene
therapy products. Our product candidates may not be eligible for RMAT designation now or in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, the EMA approved a
second gene therapy product called Strimvelis, the first approved <I>ex vivo </I>stem cell gene therapy, to treat patients with a very rare disease called <FONT STYLE="white-space:nowrap">ADA-SCID</FONT> (Severe Combined Immunodeficiency due to
Adenosine Deaminase deficiency). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, the FDA approved the first gene therapy product in the United States. The FDA approved
Kymriah (tisagenlecleucel) for the treatment of certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Kymriah is a genetically-modified autologous <FONT STYLE="white-space:nowrap">T-cell</FONT> immunotherapy.
Because of the risk of cytokine release syndrome and neurological events, Kymriah is being approved with a REMS. In December 2017, the FDA approved Luxturna (voretigene <FONT STYLE="white-space:nowrap">neparvovec-rzyl),</FONT> a gene therapy to
treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the United States that targets a disease caused by mutations in a specific
gene. To date, the FDA has approved a total of four gene therapy products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, for premarket approval purposes, the FDA regulates gene therapy products as biologics under the FDC Act, the PHS Act and
related regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The steps required before a new biologic may be marketed in the United States generally include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nonclinical pharmacology and toxicology laboratory and animal tests according to good laboratory practices, or
GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission of an IND application which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adequate and well-controlled human clinical trials according to GCPs and any additional requirements for the
protection of human research subjects and their health information to establish the safety and efficacy of the investigational product for each targeted indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission of a biologics license application, or BLA, to the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA&#146;s <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of manufacturing facilities to assess
compliance with cGMPs and, if applicable, the FDA&#146;s good tissue practices, or GTPs, for the use of human cellular and tissue products to prevent the introduction, transmission, or spread of communicable diseases; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA&#146;s audit of clinical trial sites that generated data in support of the BLA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA approval of a BLA, which must occur before a product can be marketed or sold. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Product Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any biologic in humans, the product enters the nonclinical, or preclinical, testing stage. Nonclinical tests include laboratory
evaluations of product chemistry, toxicity, and formulation, as well as animal studies to assess the potential safety and activity of the product. The conduct of nonclinical tests must comply with federal regulations and requirements including GLPs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where a gene therapy trial is conducted at, or sponsored by, institutions receiving NIH funding for recombinant DNA research, prior to
the submission of an IND to the FDA, a protocol and related documentation is submitted to and the trial is registered with the NIH Office of Science Policy, or OSP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The product sponsor then submits the results of the nonclinical testing, together with manufacturing information, analytical data, any
available clinical data or literature, and a proposed clinical protocol, to the FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in an IND, which is a request for authorization from the FDA to administer an investigational product to humans. Some nonclinical testing may continue even after the IND application is submitted.
IND authorization is required before interstate shipping and administration of any new product to humans that is not the subject of an approved BLA. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA, within the <FONT
STYLE="white-space:nowrap">30-day</FONT> time period, raises concerns or questions about the conduct of the clinical trial and places the clinical trial on a clinical hold. In such case, the IND sponsor must resolve any outstanding concerns with the
FDA before the clinical trial may begin. Further, an IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that site. If the site has an IBC, it may also have to
review and approve the proposed clinical trial. Clinical trials involve the administration of the investigational product to patients under the supervision of qualified investigators following GCPs, requirements meant to protect the rights and
health of patients and to define the roles of clinical trial sponsors, investigators, and monitors. Clinical trials are conducted under protocols that detail, among other things, the objectives of the clinical trial, dosing procedures, subject
selection and exclusion criteria, the parameters to be used in monitoring safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur, and the efficacy criteria to be evaluated. Each protocol
involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. The informed written consent of each participating subject is required and the form and content of the informed consent must be
approved by each IRB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical investigation of an investigational product is generally divided into three phases. Although the
phases are usually conducted sequentially, they may overlap or be combined in some cases. The three phases of an investigation are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase I includes the initial introduction of an investigational product into humans. Phase I clinical trials may
be conducted in patients with the target disease or condition or on healthy volunteers. These studies are designed to evaluate the safety, metabolism, pharmacokinetics and pharmacologic actions of the investigational product in humans, the side
effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. During Phase I clinical trials, sufficient information about the investigational product&#146;s pharmacokinetics and pharmacological effects may be
obtained to permit the design of Phase II clinical trials. The total number of participants included in Phase I clinical trials varies, but is generally in the range of 20 to 80. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase II includes the controlled clinical trials conducted to evaluate the effectiveness of the investigational
product for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with the product. Phase II
clinical trials are typically well- controlled, closely monitored, and conducted in a limited patient population, usually involving no more than several hundred participants. Phase IIa trials provide information on the impact of dose ranging on
safety, biomarkers and proof of concept, while Phase IIb trials are patient dose-ranging efficacy trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase III clinical trials are controlled clinical trials conducted in an expanded patient population at
geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the investigational product has been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety,
to establish the overall benefit-risk relationship of the product, and to provide an adequate basis for product approval. Phase III clinical trials usually involve several hundred to several thousand participants. In most cases, the FDA requires two
adequate and well controlled Phase III clinical trials to demonstrate the efficacy of the product. FDA may accept a single Phase III trial with other confirmatory evidence in rare instances where the trial is a large multicenter trial demonstrating
internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial
would be practically or ethically impossible. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual progress reports detailing the results of the clinical trials must
be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse events; any findings from other studies, tests in laboratory animals or <I>in vitro </I>testing that suggest a significant risk for human subjects; or any clinically important increase in
the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for
reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. The FDA typically recommends that sponsors
observe subjects for potential gene therapy-related delayed adverse events for a <FONT STYLE="white-space:nowrap">15-year</FONT> period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in
person or by questionnaire, of trial subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decision to terminate a clinical trial of an investigational biologic may be made by
the FDA or other regulatory authority, an IRB, an IBC, or institutional ethics committee, or by a company for various reasons. The FDA may place a clinical hold and order the temporary, or permanent, discontinuation of a clinical trial at any time,
or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. If the FDA imposes a clinical hold, trials may not
recommence without FDA and IRB authorization and then only under terms authorized by the FDA and IRB. In some cases, clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor, or the clinical monitoring
board or DSMB. This group provides authorization for whether or not a trial may move forward at designated check points. These decisions are based on the limited access to data from the ongoing trial. The suspension or termination of a clinical
trial can occur during any phase of clinical trials if it is determined that the participants or patients are being exposed to an unacceptable health risk. In addition, there are requirements for the registration of ongoing clinical trials of drugs
and biologics on public registries and the disclosure of certain information pertaining to the trials as well as clinical trial results after completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational
product information is submitted to the FDA in the form of a BLA for a biologic to request marketing approval for the product in specified indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human gene therapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic
interventions, there can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of human gene therapy products, or
that the data generated in these trials will be acceptable to the FDA to support marketing approval. The NIH and the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System, which includes information
on gene transfer trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these trials. Over the last several years the FDA has issued helpful guidance on development of gene therapy products and shown a
willingness to work closely with developers, especially with those working in orphan disease areas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Biologics License Application
Approval Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain approval to market a biologic in the United States, a BLA must be submitted to the FDA that
provides data from nonclinical studies and clinical trials and manufacturing information establishing to the FDA&#146;s satisfaction the safety, purity, and potency or efficacy of the investigational product for the proposed indication. The BLA must
be accompanied by a substantial user fee payment unless a waiver or exemption applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will initially review the BLA for
completeness before it accepts it for filing. Under the FDA&#146;s procedures, the agency has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#146;s threshold determination that
the application is sufficiently complete to permit substantive review. After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, which includes
determining whether it is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective for its intended use, and whether the product is being manufactured in accordance with cGMP, to assure and preserve the product&#146;s identity, safety, strength, quality, potency and
purity, and in accordance with biological product standards. The FDA will inspect the facilities at which the product is manufactured to ensure the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to
assure consistent production of the product within required specifications. For a human cellular or tissue product, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs. These are FDA regulations that
govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into
a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. Additionally, before
approving a BLA, the FDA may inspect one or more clinical sites to assure compliance with GCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines the application,
manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information, or corrective action for a manufacturing facility. This may significantly
delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy
analyses provided in the BLA. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee.
The FDA also may determine a REMS is necessary to assure the safe use of the biologic, in which case the BLA sponsor must submit a proposed REMS. The REMS may include, but is not limited to, a Medication Guide, a communications plan, and other
elements to assure safe use, such as restrictions on distribution, prescribing, and dispensing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA completes its initial
review of a BLA, it will either license, or approve, the product, or issue a complete response letter to communicate that it will not approve the BLA in its current form and to inform the sponsor of changes that the sponsor must make or additional
clinical, nonclinical or manufacturing data that must be received before the FDA can approve the application, with no implication regarding the ultimate approvability of the application. If a complete response letter is issued, the sponsor may
either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing and
approval process for both a drug and biologic requires substantial time, effort and financial resources and this process may take several years to complete. Data obtained from clinical trials is not always conclusive and may be susceptible to
varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental
approvals, which could delay or preclude us from marketing our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product candidate intended to treat a rare disease or
condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing
and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product candidate. Orphan product designation must be requested before submitting a BLA. After the FDA
grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and
approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product candidate that has orphan designation subsequently receives the first FDA
approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the
same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the
orphan product has exclusivity or obtain approval for the same product but for a different indication than the one for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for
seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our product candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. If a drug or
biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the European Union has similar, but not
identical, benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that
meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the
condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic or drug may request the FDA to designate the biologic or drug as a fast track
product at any time during the clinical development of the product. Unique to a fast track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor
provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first
section of the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for
other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it would, if approved, be a significant improvement in the safety,
effectiveness, treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new biological or drug product designated for priority review
in an effort to reduce the review period from 12 to eight months. Additionally, a product may be eligible for accelerated approval. Biological or drug products studied for their safety and effectiveness in treating serious or life-threatening
illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has
an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint. As a condition of approval, the FDA may require that a sponsor of a biological or drug
product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of
promotional materials, which could adversely impact the timing of the commercial launch of the product. Lastly, under the provisions of the new Food and Drug Administration Safety and Innovation Act, enacted in 2012, a sponsor can request
designation of a product candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is defined as a drug or biological that is intended, alone or in combination with one or more other drugs or biological, to treat a serious or
life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biological may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. Drugs and biologicals designated as breakthrough therapies receive the same benefits as drugs and biologicals with Fast Track designation. In addition, the FDA must take certain additional
actions, such as intensive guidance on an efficient drug development program (beginning as early as Phase 1), and organizational commitment involving senior managers, intended to expedite the development and review of an application for approval of
a breakthrough therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast Track designation and breakthrough therapy designation may expedite the product
development and approval process, and priority review may expedite the approval process. However, these three paths do not change the standards for approval. Accelerated approval designation changes the standards for product approval and thus may
expedite the development and/or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>FDA Additional Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These
<FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 clinical trials may be made a condition to be satisfied for continuing drug and biologic approval. The results of Phase 4 clinical trials can confirm the efficacy of a product candidate and
can provide important safety information. In addition, the FDA has expressed statutory authority to require sponsors to conduct post-market studies to specifically address safety issues identified by the agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and
dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of an onerous REMS, restrictions on distribution, or post-marketing study requirements. Further, even after regulatory
approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. In addition, we cannot predict what adverse governmental
regulations may arise from future U.S. or foreign governmental action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Medical Device Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contemplated diagnostics, for use with certain of our therapeutic products, are regulated by FDA as in vitro diagnostic, or IVD, medical
devices. Such IVD devices must comply with applicable FDA <FONT STYLE="white-space:nowrap">IVD-specific</FONT> regulations as well as FDA regulations applicable more broadly to medical devices. These FDA regulations include requirements for
registering establishments with FDA; listing IVD devices with FDA; reporting certain adverse events related to IVD devices to FDA; complying with the Quality System Regulation (current good manufacturing practices for devices); labeling IVD devices;
and obtaining premarket approval or clearance prior to marketing IVD devices (unless exempt). There are also regulations covering the requirements for investigational devices and the conduct of clinical investigations of devices. Like drugs and
biologics, failure to comply with applicable device/IVD requirements can result in legal or administrative enforcement actions against an IVD device firm, its officers or employees, and/or its products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>FDA Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us or on our behalf pursuant to FDA approvals are subject to continuing regulation by the FDA,
including requirements for record-keeping, reporting of adverse experiences with the biologic or drug, and submitting biological product deviation reports to notify the FDA of unanticipated changes in distributed products. Manufacturers are required
to register their facilities with the FDA and certain state agencies, and are subject to periodic announced or unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose certain quality
processes, manufacturing controls and documentation requirements upon us and our third-party manufacturers in order to ensure that the product is safe, has the identity and strength, and meets the quality, purity and potency characteristics that it
purports to have. In November 2013, the Drug Quality and Security Act, or DQSA, became law and establishes requirements to facilitate the tracing of prescription drug and biological products through the supply distribution chain. This law includes a
number of new requirements that are being implemented over time and require us to devote additional resources to satisfy these requirements, including serializing the product and using new technology and data storage to electronically trace the
product from manufacturer to dispenser. If our products are not covered by the serialization and tracing requirements of the DQSA, they may be subject to state pedigree and traceability requirements. We cannot be certain that we or our present or
future suppliers will be able to comply with the cGMP and other FDA regulatory requirements. If our present or future suppliers are not able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with these requirements, the FDA may halt our clinical trials, refuse to approve any BLA, force us to recall a product from distribution, shut down manufacturing operations or withdraw
approval of the applicable BLA. Noncompliance with cGMP or other requirements can result in issuance of warning or untitled letters, civil and criminal penalties, seizures, and injunctive action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other federal and state agencies closely regulate the labeling, marketing and promotion of drugs and biologics. Government
regulators, including the Department of Justice and the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities, recently have increased their scrutiny of the promotion and marketing of drugs and
biologics. While doctors are free to prescribe any product approved by the FDA for any use, a company can only make claims relating to safety and efficacy of a product that are consistent with FDA approval, and the company is allowed to market a
product only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion must, among other things, be appropriately balanced with important safety information and otherwise
be adequately substantiated. Failure to comply with these requirements can result in adverse publicity, warning or untitled letters, corrective advertising, injunctions, potential civil and criminal penalties, criminal prosecution, and agreements
with governmental agencies that materially restrict the manner in which a company promotes or distributes products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric
Research Equity Act </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, as amended, a BLA or supplement must contain data to assess
the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Manufacturers must
submit a pediatric study plan to the IND not later than 60 days after the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 2 meeting with the FDA; if there is no such meeting, before the initiation of any
phase 3 studies or a combined phase 2 and phase 3 study; or if no such study will be conducted, no later than 210 days before a marketing application or supplement is submitted. The intent of PREA is to compel sponsors whose products have pediatric
applicability to study those products in pediatric populations, rather than ignoring pediatric indications for adult indications that could be more economically desirable. The FDA may grant deferrals for submission of data or full or partial
waivers. By its terms, PREA does not apply to any product for an indication for which orphan designation has been granted, unless the FDA issues regulations stating otherwise. Because the FDA has not issued any such regulations, submission of a
pediatric assessment is not required for an application to market a product for an orphan-designated indication. In a July 2018 guidance, the FDA announced that it does not expect to grant any additional orphan drug designations to drugs for
pediatric subpopulations of common diseases (i.e., diseases or conditions with an overall prevalence of 200,000 or greater). Pediatric subpopulation orphan designations that have already been granted will not be affected by this change. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the timing, duration and specifics of FDA marketing approval of our product candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review
process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT>
the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological is eligible for the
extension and the application for the extension must be submitted prior to the expiration of the patent and within sixty days of approval of the biological product. The USPTO, in consultation with the FDA, reviews and approves the application for
any patent term extension or restoration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biologics Price Competition and Innovation Act of 2009, which was included within the
Patient Protection and Affordable Care Act, created an abbreviated approval pathway for biological products shown to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be similar to, or interchangeable with, an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product, and grants a reference biologic twelve years of exclusivity from the
time of first licensure. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies,
animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product
and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the
reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still
being worked out by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of exclusivity in the United States. Pediatric exclusivity, if
granted, provides an additional six months of exclusivity to be attached to any existing marketing exclusivity, e.g., twelve year exclusivity, or patent protection for a drug. This six month exclusivity, which runs from the end of other exclusivity
protection or patent delay, may be granted based on the voluntary completion of a pediatric trial in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government regulation outside the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials and any commercial sales and distribution of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product,
we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar
process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a request for a clinical trial authorization, or CTA, must be submitted to
each country&#146;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a country&#146;s requirements, clinical trial development may proceed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, product approval or licensing, pricing and reimbursement vary from
country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of a biological product under European Union regulatory systems, we must submit a marketing authorization
application. The application required in the European Union is similar to a BLA in the United States, with the exception of, among other things, country-specific document requirements. The European Union also provides opportunities for market
exclusivity. For example, in the European Union, upon receiving marketing authorization, a new biological generally receives eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents
regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a biosimilar application. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a biosimilar marketing
authorization can be submitted, and the innovator&#146;s data may be referenced, but no biosimilar product can be marketed until the expiration of the market exclusivity. The innovator may obtain an additional one year of market exclusivity if the
innovator obtains an additional authorization during the initial eight year period for one or more new indications that demonstrate significant clinical benefit over existing therapies. This data and market exclusivity regime in the European Union
of a total of 10 or 11 years protects against generic competition, but does not protect against the launch of a competing product if the competitor, rather than referencing the clinical data of the originator, has conducted its own clinical trials
to support its marketing authorization application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drugs in the European Union are eligible for
<FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity. This <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at
any time if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise
clinically superior; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant consents to a second orphan medicinal product application; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant cannot supply enough orphan medicinal product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical Coverage, Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our products, when and if approved for marketing, will depend, in part, on the extent to which our products will be covered by
third-party payers, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations. These third-party payers are increasingly reducing reimbursements for medical products, biologicals,
drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls, restrictions on coverage and reimbursement and requirements for
substitution of interchangeable products. Adoption of price controls and cost containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results.
Decreases in third-party reimbursement for our product candidates or a decision by a third-party payer not to cover our product candidates could reduce physician usage of our products once approved and have a material adverse effect on our sales,
results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state and foreign
governments. Third-party payers are increasingly challenging the prices charged for drug products and medical services, examining the medical necessity and reviewing the cost effectiveness of drug products and medical services, in addition to
questioning safety and efficacy. If these third-party payers do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be
sufficient to allow us to sell our products at a profit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and likely
will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. In March 2010, the
Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, was enacted. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way
healthcare is financed by both governmental and private insurers. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created
measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby
triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect
through 2024 unless additional Congressional action is taken. In January 2013, former President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers,
including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently do not have any products on the market, we may be subject to additional healthcare regulation and enforcement by the
federal government and by authorities in the states and other countries in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician
sunshine and open payment laws and regulations, many of which may become more applicable to us if our product candidates are approved and we begin commercialization. If our operations are found to be in violation of any of such laws or any other
governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from
participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we
had 14 full-time employees, 9 of whom have a Ph.D. or other post-graduate degrees. Of these full-time employees, 10 are engaged in research and development activities and 4 are engaged in finance, legal, human resources, facilities and general
management. Our employees are located in Sydney and Melbourne, Australia and at our scientific laboratories located in Hayward, California. None of our employees is represented by any labor union. As of June&nbsp;30, 2020, 12 of our employees were
located in Hayward, California, and 2 of our employees were located in Sydney and Melbourne, Australia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a Delaware corporation on November 22, 2019 and completed the Re-domiciliation April 15, 2020. Our predecessor, Benitec
Limited, was incorporated under the laws of Australia in 1995. Our principal executive offices are located at 3940 Trust Way, Hayward, California 94545. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our telephone
number is (510) 780-0819, and our Internet website is www.benitec.com. The information on, or that can be accessed through, our website is not part of this Annual Report and is not incorporated by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_2"></A>Item&nbsp;1A. Risk Factors. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below
together with all of the other information contained in this Annual Report, including our consolidated financial statements and the related notes, before deciding to invest in our securities. The risks and uncertainties described below and in the
documents incorporated by reference herein are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the
following risks actually occurs, our business, financial condition, results of operations and prospects could be materially and adversely affected, and the trading price of our common stock could decline. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition, Capital Requirements and Largest Shareholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. If we are unable to
achieve or sustain profitability, the market value of our common stock will likely decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we had
accumulated losses of $116.6&nbsp;million. We have devoted most of our financial resources to research and development, including our clinical and preclinical development activities. To date, we and our predecessor have financed our operations
primarily through the issuance of equity securities, research and development grants from the Australian government and payments from our collaboration partners. We do not expect to generate any significant revenue for the foreseeable future, and we
expect to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval process for product candidates. The amount of our future net
losses is uncertain and will depend, in part, on the rate of our future expenditures. Our ability to continue operations will depend on, among other things, our ability to obtain funding through equity or debt financings, strategic collaborations or
additional grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses, and we may incur operating losses for the foreseeable future. We
anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and preclinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the scope of our current preclinical studies for our product candidates or initiate clinical, additional
preclinical or other studies for product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop the manufacturing process for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add additional manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify and validate additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies, which
may or may not include those related to our ddRNAi technology and delivery vectors for our therapeutic candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, protect and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a public company in the United States and our
product development and future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter issues with any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of
securities analysts or investors, which could cause the price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never generated any revenue from product sales and may never be profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate significant revenue and achieve profitability depends on our ability to, alone or with strategic collaboration
partners, successfully complete the development of and obtain the regulatory approvals for our product candidates, to manufacture sufficient supply of our product candidates, to establish a sales and marketing organization or suitable third-party
alternative for the marketing of any approved products and to successfully commercialize any approved products on commercially reasonable terms. All of these activities will require us to raise sufficient funds to finance business activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past we received milestone payments from our collaborative partners. However, we do not anticipate generating revenue from
commercializing product candidates for the foreseeable future, if ever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate future revenues from commercializing
product candidates depends heavily on our success in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing proof of concept in preclinical studies and clinical trials for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully initiating and completing clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting and expanding our intellectual property portfolio, and avoiding infringing on
intellectual property of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining successful licenses, collaborations and alliances with third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a sustainable, scalable, reproducible and transferable manufacturing process for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide products
and services adequate, in amount and quality, to support clinical development and commercialization of our product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and commercializing any product candidates for which we obtain regulatory and marketing approval,
either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance of any product candidates that receive regulatory approval as viable treatment
options; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining favorable coverage and reimbursement rates for our products from third-party payers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and validating new product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of developing product candidates for ddRNAi-based and antisense
<FONT STYLE="white-space:nowrap">RNA-based</FONT> therapeutics contains a number of inherent risks and uncertainties. For example, with regard to ddRNAi, it may not be possible to identify a target region of a disease-associated gene that has not
been previously identified and/or patented by others, resulting in restrictions on freedom to operate for that target sequence. Silencing the target gene may not ultimately result in curing the disease as there may be more factors contributing to
the development of the disease than the target gene. Silencing the target gene using ddRNAi may lead to short-term or long-term adverse effects that were not predicted or observed in preclinical studies. The delivery of the DNA construct to the
target cells may not be possible, or complete or adequate to provide sufficient therapeutic benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if one or more of our product candidates is approved for commercial sale, we may incur
significant costs associated with commercializing any approved product candidate. As one example, our expenses could increase beyond expectations if we are required by the United States Food and Drug Administration (&#147;FDA&#148;) or other
regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may
need to obtain additional funding to continue operations, which could have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to continue our efforts to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain capital
when needed may negatively impact our ability to continue as a going concern. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing ddRNAi products is expensive, and we
expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates in preclinical studies and in future clinical trials and as we undertake preclinical
studies of new product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, our cash and cash equivalents were $9.8&nbsp;million. We estimate our
existing cash and cash equivalents, together with the net proceeds of our planned financings, will be sufficient to fund our operations until approximately the first quarter of 2022. However, our operating plan may change as a result of many factors
currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government grants or other third-party funding, strategic alliances and licensing arrangements or a
combination of these approaches. In addition, because the length of time and activities associated with successful development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development
and any approved marketing and commercialization activities. In any event, we will require additional capital to obtain regulatory approval for our product candidates and to commercialize any product candidates that receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may compromise our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will
be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt,
by us, or the possibility of such issuance, may cause the market price of our common stock to decline. If we incur indebtedness we may be required to agree to restrictive covenants, such as limitations on our ability to incur additional debt,
limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could compromise our ability to conduct our business. We could also seek financing through arrangements with collaborative
partners at an earlier stage than would otherwise be desirable and we may be required to relinquish rights to some or all of our technologies or product candidates or otherwise agree to terms unfavorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis or on acceptable terms, we may be required to significantly curtail, delay or discontinue
one or more of our research or development programs or the commercialization of any approved product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nant Capital, LLC is our largest
shareholder and may have interests that are different from ours and our other shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nant Capital, LLC, or Nant Capital,
holds 26.4% of our outstanding common stock as of September&nbsp;15, 2020. Nant Capital appointed Dr.&nbsp;Jerel Banks to the board of directors of Benitec Limited, and Dr.&nbsp;Banks remains on our Board of Directors (the &#147;Board&#148;) and is
Chief Executive Officer of the Company. Prior to joining the Company, Dr.&nbsp;Banks was the Chief Investment Officer of Nant Capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also entered into an exclusive sublicense agreement with an affiliate of Nant Capital and
a research collaboration agreement with Nant Capital pursuant to which we agreed to develop and commercialize an epidermal growth factor receptor, or EGFR, antisense RNA product candidate for head and neck squamous cell carcinoma (HNSCC), which we
call <FONT STYLE="white-space:nowrap">BB-401.</FONT> We terminated the exclusive sublicense agreement for convenience, with the termination effective as of June 2020, because the <FONT STYLE="white-space:nowrap">BB-401</FONT> program has been
terminated. Prior to termination of the exclusive sublicense agreement, we were required to make periodic payments to Nant Capital&#146;s affiliate for so long as the agreement remained in effect, as well as contingent milestone and royalty payments
in connection with the development and sale of the licensed technology. The Company accrued a milestone payment in December of 2018 of $300,000 (AUD 425,411), which was anticipated to be paid to NantWorks, LLC under the sublicense agreement; however
it was later determined that this milestone was not required to be paid and the accrual was reversed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of its ownership of our
common stock and its nomination of a director to our Board, Nant Capital may exert influence over us, including election of our Board, corporate transactions and strategic decisions. The interests of Nant Capital may differ from or conflict with the
interests of our other shareholders. In the future, if Nant Capital does not support a merger, tender offer, sale of assets or other business combination because it judges that transaction to be inconsistent with Nant Capital&#146;s investment
strategy, we may be unable to enter into or consummate a transaction that would enable other shareholders to realize a premium over the then-prevailing market prices for our common stock. Furthermore, if Nant Capital sells substantial amounts of our
common stock to enhance its liquidity position, fund alternative investments or for other reasons, the trading price of our common stock could decline significantly, and other shareholders may be unable to sell their shares of our common stock at
favorable prices. We cannot predict or control how Nant Capital may use the influence it has as a result of its common stock holdings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be
unable to conduct and conclude clinical trials for our product candidate for OPMD if we are unable to raise additional financing. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sufficient funds at this time to complete the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies for <FONT
STYLE="white-space:nowrap">BB-301</FONT> however, we expect that we will need to raise additional funds to initiate and complete the clinical studies for <FONT STYLE="white-space:nowrap">BB-301.</FONT> If we are unable to raise additional funds, and
thus unable to continue our studies, our business operations may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Product Development and Regulatory
Approval of Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are based on ddRNAi and silence and replace technology. Currently, no product
candidates utilizing ddRNAi technology or silence and replace technology have been approved for commercial sale and our approach to the development of ddRNAi technology and silence and replace technology may not result in safe, effective or
marketable products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have concentrated our product research and development efforts on our ddRNAi technology and silence and
replace technology, and our future success depends on successful clinical development of these technologies. We plan to progress our product candidates using our ddRNAi technology and our silence and replace technology for the treatment of the
life-threatening conditions of OPMD and hepatitis B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scientific research that forms the basis of our efforts to develop product
candidates is based on the therapeutic use of ddRNAi, and the identification, optimization and delivery of ddRNAi-based product candidates is relatively new. The scientific evidence to support the feasibility of successfully developing therapeutic
treatments based on ddRNAi is preliminary and limited. There can be no assurance that any development and technical problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can
be solved. We may be unable to reach agreement on favorable terms, or at all, with providers of vectors needed to optimize delivery of our product candidates to target disease cells and we may also experience unanticipated problems or delays in
expanding our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing capacity or transferring our manufacturing process to commercial partners, any of which may prevent us from completing our preclinical trials, initiating clinical trials or
commercializing our products on a timely or profitable basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only a few product candidates based on ddRNAi have been tested
in either animals or humans, and a number of clinical trials conducted by other companies using other forms of RNAi technologies have not been successful. We may discover that application of ddRNAi does not possess properties required for a
therapeutic benefit, such as the ability to continually express shRNAs for the period of time required to be maximally effective or the ability of viral vectors or other technologies to effectively deliver ddRNAi constructs to target cells in
therapeutically relevant concentrations. In addition, application of ddRNAi-based products in humans may result in safety issues. We currently have only limited data, and no conclusive evidence, to suggest that we can effectively produce effective
therapeutic treatments using our ddRNAi technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are early in our product development efforts and our current product candidates are still in
preclinical development. We may not be able to obtain regulatory approvals for the commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of biologics is subject to extensive regulation
by the FDA and other regulatory authorities, and these regulations differ from country to country. We do not have any products on the market and are early in our development efforts. All of our ddRNAi&nbsp;product candidates and our silence and
replace product candidates are in preclinical development. Our current product candidates are subject to the risks of failure typical for development of biologics. The development and approval process is expensive and can take many years to
complete, and its outcome is inherently uncertain. In addition, the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily
predict final results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not submitted a marketing application, or received marketing approval, for any of our product candidates
and will not submit any applications for marketing approval for several years. We have limited experience in conducting and managing clinical trials necessary to obtain regulatory approvals, including marketing approval by the FDA. To receive
marketing approval, we must, among other things, demonstrate with evidence from clinical trials that the product candidate is both safe and effective for each indication for which approval is sought, and failure can occur in any stage of
development. Satisfaction of the marketing approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the biopharmaceutical product. We cannot predict
if or when we might receive regulatory approvals for any of our product candidates currently under development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and foreign
regulatory authorities also have substantial discretion in the biopharmaceutical product approval process. The numbers, types and sizes of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the
product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to
gain marketing approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions, and there may be varying interpretations of data obtained from preclinical studies or clinical trials, any of
which may cause delays or limitations in the marketing approval or the decision not to approve an application. Regulatory agencies can delay, limit or deny marketing approval of a product candidate for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of any future
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that
a product candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of any future clinical trials may not meet the level of statistical or clinical significance required
by the FDA or comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patients recruited for a particular clinical program may not be sufficiently broad or representative to
assure safety&nbsp;and effectiveness&nbsp;in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of any future clinical trials may not confirm the positive results from earlier preclinical studies
or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from any future clinical trials of our product candidates may not be sufficient to the
satisfaction of FDA or comparable foreign regulatory authorities to support the submission of a biologics license application, or BLA, or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or
elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may only agree to approve a product candidate under
conditions that are so restrictive that the product is not commercially viable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory agencies may change their approval policies or adopt new regulations in a manner rendering our
clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in obtaining or failure to obtain required approvals could
materially and adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact the price of our common stock. Furthermore, any
regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a BLA from the
FDA or marketing approval from applicable regulatory authorities outside the United States. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. If we fail to obtain FDA approval to market our product candidates, we will be
unable to sell our product candidates in the United States, which will significantly impair our ability to generate revenues. In addition, failure to comply with FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory requirements may,
either before or after product approval, if any, subject us to administrative or judicially imposed sanctions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or
planned trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the products, manufacturers or manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">civil and criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizures, detentions or import bans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voluntary or mandatory product recalls and publicity requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">total or partial suspension of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of restrictions on operations, including costly new manufacturing requirements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending BLAs or supplements to approved BLAs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we do receive regulatory approval to market a product candidate, any such approval
may be subject to limitations on the indicated uses for which we may market the product. It is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain the appropriate
regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates, generating
revenues and achieving and sustaining profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because our ddRNAi and silence and replace product candidates are considered gene therapies,
it is difficult to predict the time and cost of product candidate development as well as subsequently obtaining regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the
safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more
expensive and take longer than for other pharmaceutical product candidates. The FDA and comparable foreign regulatory authorities have relatively limited experience with ddRNAi-based and silence and replace-based therapeutics, which makes it
difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States or other countries. We and our current collaborators, or any future collaborators, may never receive
approval to market and commercialize any product candidate. Even if we or a collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired and may require
labeling that includes significant use or distribution restrictions or safety warnings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory requirements governing gene and cell
therapy products have changed frequently and may continue to change in the future. Also, before a clinical trial can begin at any institution, that institution&#146;s institutional review board, or IRB, and its institutional biosafety committee, or
IBC, if it has one, have to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or comparable foreign regulatory
bodies to change the requirements for approval of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These committees and advisory groups and the new
guidelines they promulgate and new requirements they may impose may lengthen the clinical development and regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions
and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these
regulatory committees and advisory groups, and comply with applicable guidelines and requirements as they may change from time to time. If we fail to do so, we may be required to delay or discontinue development of our product candidates. These
additional processes may result in a development, review and approval process that is longer than we otherwise would have expected for our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval
necessary to bring a potential product to market would delay or prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Positive results from preclinical studies of our product candidates are not necessarily predictive of the results of our planned clinical trials of our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Positive results in preclinical proof of concept and animal studies of our product candidates may not result
in positive results in clinical trials in humans. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in preclinical development or early stage
clinical trials, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or safety or efficacy observations made in clinical trials, including adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and
many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory authority approval. If we fail to produce positive results in our clinical
trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be negatively impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issues that may impact delivery of our therapeutics to the cell could adversely affect or limit our ability to develop and commercialize product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful clinical development of ddRNAi-based therapeutics and silence and replace-based therapeutics is largely
dependent on using the appropriate delivery methodologies, including viral vectors, to obtain therapeutically relevant concentrations of the DNA constructs that express the shRNAs and engineered transgenes in the appropriate target cells. To develop
effective product candidates, we will need to license delivery technologies from third parties or develop delivery technologies with research collaborators. Although delivery technologies, including AAV vectors, have been identified and are well
defined for specific tissue types, we continue to seek vectors with ideal delivery properties for indications we are pursuing, including OPMD. The tissue tropism and other physical properties of AAV vectors are limited and may not be effective for
other product candidates or delivery into a wide array of tissues types. AAV vectors can also trigger immune responses in some patients, and those patients will not derive clinical benefit from administration of a product candidate unless steps are
taken to clinically address the issue. If we or our collaborators are not successful in identifying effective delivery methodologies to achieve a therapeutically relevant concentration for our product candidates in the target tissues, we may not
succeed in developing marketable products. In addition, if we are unable to reach agreement on favorable terms, or at all, with providers of any effective vectors that we do identify, we may not succeed in completing our clinical trials or
commercializing our products on a timely or profitable basis, if at all<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use AAV vectors as part of our ddRNAi and silence and
replace approaches for several indications. As such, we require licenses and the ability to manufacture large quantities of AAV particles under the FDA&#146;s current good manufacturing practices, or cGMP, requirements and those of comparable
foreign regulatory authorities in order to commercialize a product candidate using an AAV vector. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll patients in
any&nbsp;future clinical trials, and patients could discontinue their participation in our current and&nbsp;any future clinical trials, which could delay or prevent our current and any future clinical trials of our product candidates and make those
trials more expensive to undertake. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in current and any future clinical trials
of our product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. Patients may be unwilling to participate in any future
clinical trials because of negative publicity from adverse events in the biotechnology, RNAi or gene therapy industries. Patients may be unavailable for other reasons, including competitive clinical trials for similar patient populations, and the
timeline for recruiting patients, conducting trials and obtaining regulatory approval of potential products may be delayed. If we have difficulty enrolling a sufficient number of patients to conduct any future clinical trials as planned, we may need
to delay, limit or discontinue those clinical trials. Clinical trial delays could result in increased costs, slower product development, setbacks in testing the safety and effectiveness of our technology or discontinuation of the clinical trials
altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired
characteristics to achieve diversity in a trial, to complete any future clinical trials in a timely manner. Patient enrollment is affected by factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">finding and diagnosing patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design of the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the product candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of competing therapies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions of the potential advantages of the product being studied in
relation to other available therapies, including any new products that may be approved for the indications we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to monitor patients adequately during and after treatment; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any potential collaborators plan to seek initial marketing approval for our product candidates in the United States, Canada, Europe and
Israel. We may not be able to initiate or continue any future clinical trials in a timely manner if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory
agencies. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in establishing or managing relationships with contract research organizations, or CROs, clinical
sites and physicians; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to locate and engage qualified local consultants, physicians and partners; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements,
including the regulation of biopharmaceutical and biotechnology products and treatments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, patients enrolled
in current and&nbsp;any future clinical trials may discontinue their participation at any time during the trial as a result of a number of factors, including experiencing adverse events, which may or may not be judged related to our product
candidates under evaluation. The discontinuation of patients in any one of our trials may cause us to delay or discontinue our clinical trial, or cause the results from that trial not to be positive or sufficient to support either partnering with a
pharmaceutical or biotechnology company to further develop and commercialize the product candidate or filing for regulatory approval of the product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in any future clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable
regulatory authorities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of any of our product
candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical trials are expensive and time-consuming, and their outcome is uncertain. We may experience delays in
initiating and completing any clinical trials that we are conducting or intend to conduct as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and we do not know whether our ongoing or planned clinical trials will begin or
progress on schedule, need to be redesigned, enroll patients on time or be completed on schedule, or at all. We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology or other data to support the initiation of human
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching consensus with regulatory agencies on trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining required IRB or IBC approval at each clinical trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our clinical trials, including as a result of the
current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical trial
operations or trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties or us to adhere to clinical trial requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s good clinical practices, or GCP, or applicable regulatory
requirements in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to manufacture, test, release, import or export for use sufficient quantities of our product candidates
for use in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product candidate in accordance with cGMP requirements or applicable regulatory
guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the testing, validation and manufacturing of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the delivery of our product candidates to the clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its
potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical trial protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or
regulators may require us, to conduct additional clinical trials or discontinue product development programs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity, duration and impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a clinical trial may be suspended or discontinued by us, our collaborators, the IRBs or the IBCs at the sites
in which such trials are being conducted, the data safety monitoring board, or DSMB, for such trial, or by the FDA or comparable foreign regulatory authorities due to a number of factors, including the imposition of a clinical hold or termination of
a trial due to failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, unforeseen safety issues or adverse side effects of our product candidate, or a product candidate from another company that
shares similar properties, failure to demonstrate adequate benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience
discontinuation of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates may
be eliminated or delayed. Furthermore, many of the factors that lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we or our third-party collaborators make significant manufacturing or
formulation changes to our product candidates, we or they may need to conduct additional studies to bridge the modified product candidates to earlier versions to ensure comparability,&nbsp;safety and efficacy of the two different product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to commercialize our programs and product candidates. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market
before we do, which could impair our ability to successfully commercialize our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the results of&nbsp;our current
or&nbsp;any future clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to obtain, or be delayed in obtaining, marketing approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">need to change the way the product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities withdraw their marketing approval of the product after granting it;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities impose restrictions on distribution of the product in the form of a risk evaluation
and mitigation strategy, or REMS, or modified REMS, that limit our ability to commercialize the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to the addition of labeling statements, such as warnings or contraindications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be sued and held liable for harm caused to patients; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and impair our ability to
commercialize our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, principal investigators for our clinical trials may serve as scientific advisors or
consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the
financial relationship may have affected the interpretation of any particular study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which
could result in the delay or rejection of any BLA we submit to the FDA or any comparable foreign regulating authorities. Any such delay or rejection could prevent us from commercializing our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates and the process for administering our product candidates may cause undesirable side effects or have other properties that could
delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treatment with our product candidates may produce undesirable side effects or adverse reactions or events. For example, the AAV vector and
related capsid protein, which we are currently using to deliver many of our ddRNAi and silence and replace product candidates, could cause adverse immunological side effects due to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preexisting and/or recall responses to the naturally occurring virus from which the vector is engineered, or to the DNA construct product itself. These responses may also interfere with
therapeutic efficacy if not identified and managed optimally. Preexisting immune responses to AAV manifesting as neutralizing antibodies are common within the general population and may be a limitation to the enrollment of patients in gene therapy
clinical trials using AAV vectors, the successful use of AAV vectors in gene therapy clinical trials and the market acceptance of product candidates, if approved, that are delivered using AAV vectors. Patients with neutralizing antibodies to AAV
will not derive clinical benefit from administration of such a product candidate unless steps are taken to clinically address the issue and those treatments themselves may cause adverse effects. In previous clinical trials undertaken by other
companies involving systemic administration of AAV viral vectors for gene therapy, some subjects experienced adverse events, including the development of a negative T cell response against the AAV capsid protein. If our vectors cause similar adverse
events, we may be required to delay or discontinue further clinical development of our product candidates. It is also possible that we may discover new adverse events related to AAV or other vectors, which could potentially enhance the risk to
patients who use our product candidates delivered with that vector. Additionally, the procedure used to administer the treatment could result in undesirable health effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such adverse events occur, our current and&nbsp;any future clinical trials could be suspended or discontinued and the FDA or comparable
foreign regulatory authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. The product-related side effects could affect patient recruitment or the ability of enrolled
patients to complete the trial. If we elect or are required to delay, suspend or discontinue any clinical trial of any of our product candidates, the commercial prospects of such product candidates will be harmed and our ability to generate product
revenues from any of these product candidates will be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any of our biopharmaceutical product candidates receive marketing approval, the FDA could require us to adopt a REMS to
ensure that the benefits of the product outweigh its risks, which may include, among other things, a medication guide outlining the risks of gene therapies for distribution to patients and a communication plan to patients and healthcare
practitioners. Other elements to assure safe use in a mandated REMS could include, but are not limited to, restrictions upon distribution and prescribing, additional prescriber training, establishment of patient registries and other measures that
could limit commercialization of the product. Comparable foreign regulating authorities might require adoption of measures similar to a REMS. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, a
number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to
patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product candidate is administered or conduct additional clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm
our business, prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to successfully develop related diagnostics for our therapeutic product candidates,
or experience significant delays in doing so, we may not achieve marketing approval or realize the full commercial potential of our therapeutic product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may develop related diagnostics for some of our therapeutic product candidates. Such related diagnostics are subject to regulation by the
FDA and typically to comparable foreign regulatory authorities as medical devices and typically require separate regulatory approval or clearance prior to commercialization. Marketing approval or clearance of the diagnostic will require sufficient
data to support its safety and efficacy. In addition, at least in some cases, the FDA and comparable foreign regulatory authorities may require the development and regulatory approval or clearance of a related diagnostic as a condition to approving
our therapeutic product candidates. While we have some limited experience in developing diagnostics, we plan to rely in large part on third parties to perform these functions. We may seek to enter into arrangements with one or more third parties to
create a related diagnostic for use with our current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any third parties that we engage to assist us
are unable to successfully develop or obtain marketing approval or clearance for related diagnostics for our therapeutic product candidates, or experience delays in doing so: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of relevant product candidates may be delayed or impaired altogether if we are unable to
appropriately select patients for enrollment in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relevant therapeutic product candidate may not receive marketing approval if its effective use depends on a
related diagnostic in the regulatory authority&#146;s judgment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not realize the full commercial potential of any therapeutic product candidates that receive marketing
approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations targeted by our therapeutic product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events were to occur, our business would be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or if we will obtain regulatory approval to
commercialize a product candidate or the approval may be for a more narrow indication than we expect. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize a
product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes
in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or comparable foreign regulatory authority recommends <FONT STYLE="white-space:nowrap">non-approval</FONT> or
restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product
development, clinical trials and the review process. Regulatory agencies may also approve a treatment candidate for fewer or more limited indications than requested, may not approve the price we intend to charge for our product candidate, may limit
our ability to promote the product, may impose significant limitations upon the approval of the product, including, but not limited to, narrow indications, significant warnings, precautions or contraindications with respect to conditions of use, or
may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. The FDA or
comparable foreign regulatory authorities may impose a REMS or other conditions upon our approval that limit our ability to commercialize the product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inadequate funding for the FDA and other government agencies could hinder their ability to hire and
retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our
business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be
affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have
fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is
inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be
reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the
FDA, had to furlough critical employees and stop critical activities. Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the FDA postponed most inspections of foreign manufacturing facilities and products,
postponed routine surveillance inspections of domestic manufacturing facilities and is conducting only teleconference meetings. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material
adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated
uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report to the FDA adverse
events and any failure of a product to meet the specifications in the BLA. FDA guidance advises that patients treated with some types of gene therapy undergo <FONT STYLE="white-space:nowrap">follow-up</FONT> observations for potential adverse events
for as long as 15 years. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional
materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable foreign, federal and state laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, product manufacturers and their establishments, products and applications are subject to payment of user fees/or and continual
review and periodic inspections by the FDA and comparable foreign regulatory authorities for compliance with cGMP and comparable foreign requirements, and adherence to commitments made in the BLA. If we or a regulatory agency discover previously
unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing
facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply
with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue a warning letter asserting that we are in violation of the law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek an injunction or impose civil or criminal penalties or monetary fines; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to permit government reimbursement of our product by government-sponsored third-party payers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve a pending BLA or supplements to a BLA submitted by us for other indications or new product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize our product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to allow us to enter into or continue supply contracts, including government contracts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in
response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the
United States, which would limit our market opportunities and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of a product candidate in
the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in
other foreign countries or by the FDA. Sales of our product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a
product candidate, comparable regulatory authorities of foreign countries must also approve the manufacturing and marketing of the product candidates in those countries. Approval procedures vary among jurisdictions and can involve requirements and
administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for
reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Even if a product candidate is approved, the FDA or comparable regulatory
authorities in other countries, as the case may be, may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or reporting as
conditions of approval. Regulatory authorities in countries outside of the United States also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Regulatory approval of a
product candidate in one country does not ensure approval in any other country, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in other countries. Also, regulatory
approval for any of our product candidates may be withdrawn based on adverse events reported or regulatory decisions made in other countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive
applicable marketing approvals, our target market will be reduced, our ability to realize the full market potential of our product candidates will be compromised and our business may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future prospects may also depend on our collaborators&#146; ability to successfully develop a pipeline of additional product candidates, and we and
our collaborators may not be successful in efforts to use our platform technologies to identify or discover additional product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform
technology. We do not have any products on the market and are early in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development efforts. All of our product candidates are in preclinical development. Our product candidates derived from our platform technology may not successfully complete investigational new
drug, or IND, enabling studies, and our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. Our and our collaborators&#146; research methodology may be unsuccessful in
identifying potential product candidates, our potential product candidates may not demonstrate the necessary preclinical outcomes to progress to clinical studies, or our product candidates may be shown to have harmful side effects or may have other
characteristics that may make the products unmarketable or unlikely to receive marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may
be forced to discontinue our development efforts for a program or programs. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential
programs or product candidates that ultimately prove to be unsuccessful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain orphan drug exclusivity, where relevant, in
all markets for our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of our current pipeline product candidates, only our silence and replace therapeutic for
the treatment of OPMD has been designated with orphan drug status. In January 2018, the FDA granted such designation after our candidate for the treatment of OPMD had been designated an orphan drug in January 2017 by the European Commission.
Regulatory authorities in some jurisdictions, including the United States, may designate drugs or biological products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan
drug if it is a product intended to treat a &#147;rare disease or condition&#148;, which is generally defined as any disease or condition which affects less than 200,000 individuals in the United&nbsp;States. The FDA may also designate a product as
an orphan drug if it is intended to treat a disease or condition which affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making a drug or biological product available in
the United States for this type of disease or condition will be recovered from sales of the product candidate. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it
has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for such indication for that time period. The applicable period is seven years
in the United States. Orphan drug exclusivity may be lost if the FDA or the European Medicines Agency, or the EMA, determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of
the drug to meet the needs of patients with the rare disease or condition. While there is no guarantee, FDA orphan drug designation may provide a range of benefits, including a potential fast track process for clinical regulatory approval, potential
tax credits for qualified clinical trials and an exemption from FDA application user fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for
a product in the United States or for additional products in the European Union, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition, and the same drug could be
approved for a different condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug, made by a competitor, for the same condition if the FDA concludes that the competitive product is clinically superior in that
it is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, the EMA can approve a competitive product if the orphan drug no longer meets the criteria for orphan designation (including sufficient
profitability), if the competitive product is safer, more effective or otherwise clinically superior, or if the orphan drug cannot be supplied in sufficient quantities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our prospects for successful development and commercialization of our products are dependent to varying degrees upon the research, development,
commercialization, and marketing efforts of any potential collaborators. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third parties for certain aspects of the
research, development, commercialization and marketing of our current and any future product candidates. Other than as provided for in our collaboration agreements, we have no control over the resources, time and effort that our collaborators may
devote to the development of product candidates. We are dependent on our collaborators to conduct some aspects of the research and development of each of our product candidates, and expect to need access to them to facilitate and/or to complete the
regulatory process. We will likely rely on a pharmaceutical company for the successful marketing and commercialization of any such product candidates for which they/we receive approval, if any. There can be no guarantee at this stage that we will
conclude a partnership with such a company on favorable terms, or at all, nor even if we do so, that success will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
ability to recognize revenues from successful potential collaborations may be impaired by multiple factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator may shift its priorities and resources away from our programs due to a change in business
strategies, or a merger, acquisition, sale or downsizing of its company or business unit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator may cease development in an area that is the subject of a collaboration agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator may change the success criteria for a particular program or product candidate in development,
thereby delaying or ceasing development of such program or product candidate in development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with development or commercialization obligations may not commit sufficient financial or human
resources to the development, marketing, distribution or sale of a product, or may otherwise fail in development or commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with manufacturing responsibilities may encounter regulatory, resource or quality issues and be
unable to meet demand requirement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator could independently develop, or develop with unrelated parties, products that compete directly or
indirectly with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator may exercise its rights under the agreement to discontinue our collaboration;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a dispute may arise between us and a collaborator concerning the development or commercialization of a product
candidate, resulting in a delay in milestones, royalty payments, or discontinuation of a program and possibly resulting in costly litigation or arbitration that may divert management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator may not adequately protect the intellectual property rights associated with a product candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator may use our proprietary information or intellectual property in such a way as to expose us actual
or threatened litigation from a third party, patent office proceedings or other risks that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a&nbsp;collaborator may&nbsp;own or <FONT STYLE="white-space:nowrap">co-own,</FONT> or have a license to use,
intellectual property rights associated with a product candidate that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our potential collaborators do not perform in the manner we expect or fulfill their responsibilities in a timely manner, or at all, the
development, regulatory and commercialization process could be delayed or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discontinued or otherwise be unsuccessful. Conflicts between us and our collaborators may arise. In the event of discontinuation of one or more of our collaboration agreements, it may become
necessary for us to assume the responsibility for any such product candidates at our own expense or seek new collaborators. In that event, we likely would be required to limit the size and scope of one or more of our independent programs or increase
our expenditures and seek additional funding, which may not be available on acceptable terms or at all, and our business may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on
third parties to conduct our preclinical studies and clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have the ability to conduct all aspects of our
preclinical testing or any future clinical trials ourselves. We are dependent on third parties to conduct the preclinical studies for our product candidates and will depend on third parties to conduct any future clinical trials for our product
candidates, and therefore the timing of the initiation and completion of these trials and studies is reliant on third parties and may occur at times substantially different from our estimates or expectations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of clinical trials, we expect to rely on CROs and third-party collaborators to conduct any future clinical trials in accordance
with our clinical protocols and regulatory requirements. We expect our CROs, investigators and third-party collaborators will play a significant role in the conduct of these trials and subsequent collection and analysis of data. There is no
guarantee that any CROs, investigators or the other third-party collaborators on which we rely for administration and conduct of our future clinical trials will devote adequate time and resources to such trials or perform as contractually required.
If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements or otherwise performs in a substandard manner, any future clinical trials may be extended, delayed or
terminated. If our current or any of our future clinical trial sites terminates for any reason, we may lose all of the information on subjects enrolled in any such clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot contract with acceptable third parties on commercially reasonable terms, or if these third parties do not carry out their
contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed or discontinued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In all events, we are responsible for ensuring that each of our preclinical studies, and our future clinical trials are conducted in
accordance with the general investigational plan and protocols for the study or trial. The FDA requires clinical trials to be conducted in accordance with current GCP, including for conducting, recording and reporting the results of clinical trials
to assure that data and reported results are credible and accurate and that the rights and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these
responsibilities and requirements, and any failure to satisfy these responsibilities and requirements, whether caused by us or by third parties upon whom we rely, could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and
clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on
third-party supply and manufacturing partners to manufacture and supply the materials for our research and development and preclinical and clinical study supplies. We do not own manufacturing facilities or supply sources for such materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that our supply of research and development, preclinical and clinical development biologics and other materials will
not be limited, interrupted or restricted in certain geographic regions, be of satisfactory quality or continue to be available at acceptable prices. Replacement of a third-party manufacturer could require significant effort, cost and expertise
because there may be a limited number of qualified replacements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing process for a product candidate is subject to FDA and foreign regulatory
authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP.
In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or
interrupted for other reasons, we may be forced to manufacture the materials ourselves or enter into an agreement with another third party, which would be costly and delay any future clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original
manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party. These factors increase our reliance on our manufacturers and may require us to
obtain a license from a manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and
procedures that comply with quality standards and with all applicable regulations and guidelines of the FDA and comparable foreign regulatory authorities. The delays and costs associated with the verification of a new manufacturer could increase our
costs and delay the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to rely on third-party manufacturers for preclinical and
clinical grade product candidates and if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to
perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates,
or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#146;s failure to execute on our manufacturing requirements could adversely affect our business
in a number of ways, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to conduct necessary preclinical studies to progress our product candidates to clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or continue any future clinical trials of product candidates under development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of the cooperation of a collaborator; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting our product candidates to additional inspections by regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease distribution or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands
for our products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers may be subject to damage or interruption from, among other things,
fire, natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster, power loss, telecommunications failure, unauthorized entry, computer viruses,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, acts of terrorism, human error, vandalism or sabotage, financial insolvency, bankruptcy and similar events. These risks include the impact of
the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our third party partners will depend on future developments, which are highly uncertain and cannot
be predicted, including new information which may emerge concerning the severity of the coronavirus, the geographic spread of the disease, the duration of the outbreak, and the actions to contain the coronavirus or treat its impact, including travel
and other social distancing restrictions in the United States and other countries, among others. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our licensees or collaborators may disagree over our right to receive payments under any
potential collaboration agreements with them, potentially resulting in costly litigation and loss of reputation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to
receive payments under any <FONT STYLE="white-space:nowrap">out-license</FONT> and collaboration agreements depends on our ability to clearly delineate our rights under those agreements. We have licensed and may license additional portions of our
intellectual property to our collaborators with the intent that our collaborators will develop product candidates based on our ddRNAi or other technology to address specific conditions. However, a collaborator may use our intellectual property
without our permission, dispute our ownership of intellectual property rights, or argue that our intellectual property does not cover, or add value to, any product candidates they develop. If a dispute arises, it may result in costly patent office
procedures and litigation, and our collaborator may refuse to pay us while the dispute is ongoing. Furthermore, regardless of any resort to legal action, a dispute with a collaborator over intellectual property rights may damage our relationship
with that collaborator and may also harm our reputation in the industry. Even if we are entitled to payments from our collaborators, we may not actually receive these payments, or we may experience difficulties in collecting the payments to which we
believe we are entitled. After our collaborators launch commercial products containing our licensed traits, we will need to rely on the good faith of our collaborators to report to us the sales they earn from these products and to accurately
calculate the payments we are entitled to, a process that will involve complicated and difficult calculations. Although we seek to address these concerns in our license and collaboration agreements by reserving our right to audit financial records,
such provisions may not be effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have only limited experience in regulatory affairs and intend to rely on consultants and other third
parties for regulatory matters, which may affect our ability or the time we require to obtain necessary regulatory approvals. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have limited experience in filing and prosecuting the applications necessary to gain regulatory approvals for gene therapy or ddRNAi product candidates. Moreover, the product candidates that are likely to result from our development programs are
based on novel technologies that have not been extensively tested in humans. The regulatory requirements governing these types of product candidates may be less well defined or more rigorous than for conventional products. As a result, we may
experience a longer regulatory process in connection with obtaining regulatory approvals of any products that we develop. We intend to rely on independent consultants for purposes of our regulatory compliance and product development and approvals in
the United States and elsewhere. Any failure by our consultants to properly advise us regarding, or properly perform tasks related to, regulatory compliance requirements could compromise our ability to develop and seek regulatory approval of our
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will
discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to manufacture our
product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our technology and product candidates, we may, at times, share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and
consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite these contractual
provisions, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by potential competitors, are inadvertently incorporated into the technology of others, or are disclosed or used
in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, discovery by a third party of our trade secrets or other unauthorized use or
disclosure would impair our intellectual property rights and protections in our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements
typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration.
In other cases, publication rights are controlled exclusively by us or we may share these rights with other parties. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these
agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not entered into agreements with any third-party manufacturers to support commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet secured manufacturing capabilities for commercial quantities of our product candidates or established facilities in the desired
locations to support commercialization of our product candidates. We intend to rely on third-party manufacturers for commercialization, but have not entered into any agreements with such manufacturers to support our product candidates currently in
development. We may be unable to negotiate agreements with third-party manufacturers to support our commercialization activities on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may encounter technical or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or
with available funds. Currently, we do not have the capacity to manufacture our product candidates on a commercial scale. In addition, our product candidates are novel, and only one manufacturer currently has experience producing our product
candidates on a large scale. If we are unable to engage manufacturing partners to produce our product candidates on a larger scale on reasonable terms, our commercialization efforts will be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we timely develop a manufacturing process and successfully transfer it to the third-party manufacturers of our product candidates, if
such third-party manufacturers are unable to produce the necessary quantities of our product candidates, or do so in compliance with cGMP or with pertinent foreign regulatory requirements, and within our planned time frame and cost parameters, the
development and sales of our product candidates, if approved, may be impaired.&nbsp;In some jurisdictions, approval of the manufacturer may be required.&nbsp;There is no guarantee such approval can be obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to enter into agreements with third parties to commercialize our product candidates or establish sales and marketing capabilities to
market and sell our product candidates, we may be unable to generate any revenues. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales and marketing
organization and have no experience selling and marketing pharmaceutical products. To successfully commercialize any product candidates that may be approved, we will need to develop these capabilities, either through our relationships with
collaborators or our own. We may seek to enter into collaborations with other entities to utilize their marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our future
collaborators do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our
business. The establishment and development of our own sales force or the establishment of a contract sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be
certain that we will be able to successfully develop this capability. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales
personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we
may be unable to compete successfully against these more established companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Physicians, patients, third-party payers or others in the medical community may not be receptive to
our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if
we obtain approval for a product candidate, we may not generate or sustain revenue from sales of the product if the product cannot be sold at a competitive cost or if it fails to achieve market acceptance by physicians, patients, third-party payers
or others in the medical community. These market participants may be hesitant to adopt a novel treatment based on ddRNAi or silence and replace technology, and we may not be able to convince the medical community and third-party payers to accept and
use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety and efficacy of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative convenience and ease of administration of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any adverse side effects associated with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any approvals and the countries in which approvals are obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in any labeling approved by the FDA or comparable foreign regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions upon the approval imposed by FDA or comparable foreign regulatory authorities, including, but not
limited to, a REMS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to try new treatments and of physicians to prescribe these treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of government and other third-party payer coverage and adequate reimbursement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of alternative effective treatments for the disease indications our product candidates are
intended to treat and the relative risks, benefits and costs of those treatments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we are focused on the emerging
therapeutic modality of ddRNAi, and silence and replace these risks may increase if new competitors are able to market ddRNAi-based therapeutics or silence and replace-based therapeutics or if these treatments become less favored in the commercial
marketplace. In addition, we believe that one of the benefits of our ddRNAi and silence and replace technologies is the expected length of time of the effects. If our treatments do not have a long-term effect after administration, such a development
would likely significantly and adversely affect market acceptance of our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional risks apply in
relation to any disease indications we pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the United States or European Union. If pricing is not approved or
accepted in the market at an appropriate level for any approved product for which we pursue and receive an orphan drug designation, such product may not generate enough revenue to offset costs of development, manufacturing, marketing and
commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, for a period of time. Orphan exclusivity could temporarily delay or block approval of one of our products if a competitor obtains orphan
drug designation for its product first. However, even if we obtain orphan exclusivity for one of our products upon approval, our exclusivity may not block the subsequent approval of a competitive product that is shown to be clinically superior to
our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size
for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a product, which could result in significant changes in our business plan and have a material adverse effect on our
business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other public health crises may
materially and adversely affect our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other public health crises may materially and adversely affect our business, financial condition and results of operations. The development and commercialization of our products is
dependent on the efforts of our third-party collaborators, as we rely on third-parties to conduct our preclinical studies and clinical trials, and for our supply of research and development, preclinical and clinical development biologics and other
materials. Accordingly, our operations and supply chain could be subject to significant disruptions to the extent that our third-party partners are impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or the associated
governmental actions.&nbsp;There may be related restrictions or delays with respect to clinical trials and preclinical studies, as well as the export, import or shipment of raw materials, drug substance or drug product that could materially delay
our business or clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, certain of our research and development efforts are conducted globally, including our ongoing
development of our silence and replace therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to initiate clinical sites and enroll patients despite the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had also implemented work-from-home measures for the majority of our employees
between March 2020 and June 2020, resulting in a reduction of laboratory work and a halt of <FONT STYLE="white-space:nowrap">non-essential</FONT> business travel. As we transition our employees back to our premises, there is a risk that <FONT
STYLE="white-space:nowrap">COVID-19</FONT> infections occur at our offices or laboratory facilities and significantly affect our operations. Additionally, if any of our critical vendors are impacted, our business could be affected if we become
unable to timely procure essential equipment, supplies or services in adequate quantities and at acceptable prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak has caused significant disruption to the global economy and in the global and U.S. financial markets. This could impact our ability to raise additional funding, which may not be available on
acceptable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> impacts our results will depend on
future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the actions to contain
<FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, among others. In addition, due to the speed with which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation is developing and evolving, there is uncertainty around its
ultimate impact on public health, business operations and the overall economy; therefore, the negative impact on our financial position, operating results and liquidity cannot be reasonably estimated at this time, but the impact may be material.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face competition from entities that have developed or may develop product candidates for our target disease indications, including companies
developing novel treatments and technology platforms based on modalities and technology similar to ours. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and
commercialization of pharmaceutical products is highly competitive. We compete with a variety of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research
institutions. Our competitors have developed, are developing or could develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by
the medical community, patients and third-party payers, and any new treatments that enter the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be a significant number
of products that are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing, and may in the future try to develop, product candidates.&nbsp;This increasingly
competitive landscape may compromise the development of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware of multiple companies that are working in the field of RNAi therapeutics,
including Alnylam, Arbutus, Arrowhead, Silence Therapeutics plc, RXi Pharmaceuticals Corporation, Quark Pharmaceuticals, Inc., Marina Biotech, Inc. and Dicerna. Arrowhead, Arbutus and Alnylam are all developing siRNA-based therapeutics for Chronic
Hepatitis B Virus Infection, or HBV. Some of our current product candidates, if approved, would compete with approved and currently marketed treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our ddRNAi-based product candidates would compete with antisense and other <FONT STYLE="white-space:nowrap">RNA-based</FONT>
pharmaceutical products currently under development. Like RNAi therapeutics, antisense products target mRNA with the objective of suppressing the activity of specific genes. The development of antisense products is more advanced than that of RNAi
therapeutics, and antisense technology may become the preferred technology for products that target mRNAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors have
significantly greater financial, technical, manufacturing, marketing, sales and supply resources and experience than we have. If we successfully obtain approval for any product candidate, we will face competition based on many different factors,
including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these
products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and
sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> before we recover the expense of developing and commercializing our
product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A variety of risks outside of our control associated with international operations could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved for commercialization, it is our current intention to market them on a worldwide basis, either
alone or in collaboration with others. In addition, we conduct development activities in various jurisdictions throughout the world. We expect that we will be subject to additional risks related to engaging in international operations, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of biopharmaceutical products in foreign countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in Australia or the United&nbsp;States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters,
including earthquakes, typhoons, floods and fires and disease pandemics and epidemics, including the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The insurance coverage and reimbursement status of newly approved products is uncertain. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability of coverage and adequate reimbursement by governmental and private payers is essential for most patients to be able to afford
expensive treatments. Sales of our product candidates will depend substantially, both in the United States and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and
similar healthcare management organizations, or reimbursed by third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is
provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what
extent a new medicine will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as
ours, as there is no body of established practices and precedents for these new products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intended use of a biopharmaceutical product
by a physician can also affect pricing. For example, CMS could initiate a National Coverage Determination administrative procedure, by which the agency determines which uses of a therapeutic product would and would not be reimbursable under
Medicare. This determination process can be lengthy, thereby creating a long period during which the future reimbursement for a particular product may be uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market
regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries is likely to put pressure on the pricing and usage of any of our product candidates that may be approved for marketing in the
future. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems can be substantially lower than in the United
States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the
cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we
are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue
and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and other third-party payers, in the United States and abroad, to cap or reduce
healthcare costs, have resulted in legislation and reforms such as, in the United States, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care Education Reconciliation Act, or the ACA. The ACA may cause such
organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. In addition, other legislative changes have been adopted since the
ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year effective April 2013 that, due to subsequent legislative amendments to the statute, will stay in effect through 2029 unless
additional Congressional action is taken. Note, however, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which was signed into law on March&nbsp;27, 2020, designed to provide financial support and resources to individuals and
businesses affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, suspended the 2% Medicare sequester from May&nbsp;1, 2020 through December&nbsp;31, 2020, and extended the sequester by one year, through 2030. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January 2017, President Trump has signed Executive Orders and other directives
designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and
replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have passed. On December&nbsp;22, 2017, President Trump signed into law federal
tax legislation commonly referred to as the Tax Cuts and Jobs Act (the Tax Act), which includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the
ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; The 2020 federal spending package permanently eliminated, effective
January&nbsp;1, 2020, the <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> &#147;Cadillac&#148; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&nbsp;1, 2021, also eliminates the health insurer
tax. The Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare Part D drug plans. In December 2018, the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS)
published a final rule permitting further collections and payments to and from certain <FONT STYLE="white-space:nowrap">ACA-qualified</FONT> health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome
of federal district court litigation regarding the method CMS uses to determine this risk adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2018, a Texas
U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Act. Additionally, on December&nbsp;18, 2019, the U.S. Court of Appeals for the
5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&nbsp;2, 2020, the
United States Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when the Supreme Court will make a decision. It is also unclear how such litigation and other efforts to repeal and replace the ACA
will impact the ACA and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since
the ACA was enacted. In January 2013, former President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the
government to recover overpayments to providers from three to five years. This law may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if
approved, and accordingly, our financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience pricing pressures in connection with the sale of any of our
product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription
pharmaceutical products and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. We cannot predict what healthcare reform initiatives may be
adopted in the future. It is possible that additional governmental action is taken to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Further federal, state and foreign legislative and regulatory developments are likely, and
we expect ongoing initiatives to increase pressure on biopharmaceutical product pricing. Such reforms could depress pricing for any product candidates that we may successfully develop and for which we may obtain regulatory approval and may
negatively affect our overall financial condition and ability to develop additional product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. tax law may materially
adversely affect our financial condition, results of operations and cash flows. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recently enacted the Tax Act has significantly
changed the U.S. federal income taxation of U.S. businesses, including by reducing the U.S. corporate income tax rate, limiting interest deductions, permitting immediate expensing of certain capital expenditures, modifying or repealing many business
deductions and credits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CARES Act modifies certain provisions of the Tax Act, including increasing the amount of
interest expense that may be deducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Act as modified by the CARES Act is unclear in many respects and could be subject to
potential amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these
U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities. Our analysis and interpretation of this legislation is preliminary and
ongoing. Some of the changes made by the tax legislation may adversely affect us. We continue to work with our tax advisors and auditors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors
to consult with their legal and tax advisors with respect to such legislation and its potential effect on an investment in our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with third-party payers, healthcare professionals and customers in the United States and elsewhere may be subject to anti-kickback,
fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to significant penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our relationships with third-party payers, healthcare professionals and customers may expose us to broadly applicable fraud and abuse and other
healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we sell, market and
distribute any biopharmaceutical products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in which
we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good
or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims
Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid
programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually
identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Open Payments program, created under the ACA, and its implementing regulations, which requires
certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the CMS information
related to payments or other transfers of value </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
made to physicians, and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members by the
90th day of each subsequent calendar year, and disclosure of such information will be made by CMS on a publicly available website; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payers, including private insurers; state and foreign laws that require
biopharmaceutical or biotechnology&nbsp;companies to comply with the industry&nbsp;voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to
healthcare providers; state and foreign laws that require biopharmaceutical or biotechnology manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;
and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties,
including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a
material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or
administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or
compromise our ability to conduct our business or obtain regulatory approvals for our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gene therapy remains a
novel technology and no gene therapy product utilizing ddRNAi or silence and replace has been approved to date in the United States. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the
acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product
candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our
business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Our product candidates, including our viral delivery systems, could produce adverse
events. Adverse events in our clinical trials or following approval of any of our product candidates, even if not ultimately attributable to our product candidates, could result in increased governmental regulation, unfavorable public perception,
potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not successfully engage in strategic transactions or enter into new collaborations, which could adversely affect our ability to develop and
commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may consider additional strategic transactions, such as collaborations, acquisitions, asset purchases or sales and <FONT
STYLE="white-space:nowrap">out-</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations,
including with major biotechnology or pharmaceutical companies. The competition for collaborators is significant, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we
may not be able to maintain any new or existing collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator discontinues the
collaboration. Any such collaboration, or other strategic transaction, may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other charges, increase our expenditures, pose significant integration or implementation
challenges or disrupt our management or business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These transactions would entail numerous operational and financial risks, including
exposure to unknown liabilities, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or
goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers
or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any
collaboration or other strategic transaction that would be beneficial to us could delay and make more expensive the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any
product candidate that reaches market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any inability to attract and retain qualified key management and technical personnel would impair our
ability to implement our business plan. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success largely depends on the continued service of key management and other
specialized personnel, including Dr.&nbsp;Jerel Banks (Chief Executive Officer) and Ms.&nbsp;Megan Boston (Executive Director). The loss of one or more members of our management team or other key employees or advisors, if not adequately replaced,
could delay or increase the cost of our research and development programs and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us
particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and the specialized nature of the regulatory
approval process for our product candidates. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key
person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel,
as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government
entities and other organizations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our collaborations with outside scientists and consultants may be subject to restriction and change.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We work with medical experts, chemists, biologists and other scientists at academic and other institutions, and consultants who
assist us in our research, development and regulatory efforts, including the members of our scientific advisory board. In addition, these scientists and consultants have provided, and we expect that they will continue to provide, valuable advice
regarding our programs and regulatory approval processes. These scientists and consultants are not our employees and may have other commitments that would limit their future availability to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, we are
limited in our ability to prevent them from establishing competing businesses or developing competing products. For example, if a key scientist acting as a principal investigator in any of our future clinical trials identifies a potential product or
compound that is more scientifically interesting to his or her professional interests, his or her availability to remain involved in any future clinical trials could be restricted or eliminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may experience difficulties in managing our growth and expanding our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience in development and commercialization of pharmaceutical products. As our product candidates continue to advance
through preclinical studies and any future clinical trials and potentially toward regulatory approval and commercial sale, we will need to expand our development, regulatory, manufacturing and sales capabilities or contract with other organizations
to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to
continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may
discover deficiencies in existing systems and controls. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators, CROs, consultants and
vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and insider trading. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, CROs, consultants,
commercial partners and vendors. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and comparable foreign regulators, provide accurate information to the FDA and comparable foreign regulators,
comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of any future clinical trials, which could result in
regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any
such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative
penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations,
any of which could adversely affect our ability to operate our business and our results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could face potential product liability and, if successful claims are brought against us, we may
incur substantial liability and costs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of our product candidates in clinical trials and the sale of any products for which
we may in the future obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise
coming into contact with our product candidates. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition,
regardless of merit or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of our business reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs due to related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our product candidates, if approved for commercial sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased cost, or impairment of our ability, to obtain or maintain product liability insurance coverage.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry combined general public and products liability (including human clinical trials extension) insurance of
$20&nbsp;million (per any one occurrence) and $10&nbsp;million (per any one occurrence and in the aggregate), respectively. We believe our product liability insurance coverage is sufficient in light of our current clinical programs. However, we may
not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidates, we intend to expand our insurance coverage to include
the sale of commercial products, but we may not be able to obtain or maintain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded against other pharmaceutical companies
in class action lawsuits based on pharmaceutical products, or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of our common stock to decline
and, if judgments exceed our insurance coverage, could materially and adversely affect our financial position. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product
candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or
require us to suspend or discontinue our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our product candidate, the investigation into the circumstance may be time-consuming or
inconclusive. These investigations may harm our reputation, delay our regulatory approval process, limit the type of regulatory approvals our product candidates receive or maintain, and compromise the market acceptance of any of our product
candidates that may in the future receive regulatory approval. As a result of these factors, a product liability claim, even if successfully defended, could hurt our business and impair our ability to generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our development partners, third-party manufacturers and suppliers use biological materials and may use hazardous materials, and any claims
relating to improper handling, storage or disposal of these materials could be time consuming or costly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our development
partners, third-party manufacturers and suppliers may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our
third-party manufacturers and suppliers also produce </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hazardous waste products. National, state and local laws and regulations in the United States and other countries govern the use, generation, manufacture, storage, handling and disposal of these
materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development and commercialization efforts. In addition, we cannot
entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies
specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an
amount exceeding our resources, and any future clinical trials, regulatory approvals or product commercialization progress could be suspended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may use our limited financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of
success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product
candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and
future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable
rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product
candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer and information technology systems, or those of our collaborators and other development partners, third-party CROs or other
contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our product development programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer and information technology systems and those of our current and any
future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cyber-attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could
cause interruptions of our operations. While we have not experienced any material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our
development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. For example, the loss of clinical trial data from ongoing or future clinical trials or data from preclinical studies could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to manufacture our product candidates and will rely on third parties to conduct future
clinical trials, and similar events relating to their computer systems could also have similar consequences to our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed and become more expensive. As a result of <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees that are working remotely, which may create additional opportunities for cybercriminals
to exploit vulnerabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyber-attacks, breaches, interruptions or other data security incidents could result in legal claims or
proceedings, liability under federal or state laws that protect the privacy of personal information, regulatory penalties, significant remediation costs, disrupt key business operations and divert attention of management and key information
technology resources. In the United States, notice of breaches must be made to affected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals, the U.S. Secretary of the Department of Health and Human Services, or HHS, and for extensive breaches, notice may need to be made to the media or U.S. state attorneys general. Such a
notice could harm our reputation and our ability to compete. HHS has the discretion to impose penalties without attempting to resolve violations through informal means. In addition, U.S. state attorneys general are authorized to bring civil actions
seeking either injunctions or damages in response to violations that threaten the privacy of state residents. There can be no assurance that we, our collaborators, CROs, vendors, and any other business counterparties will be successful in efforts to
detect, prevent, protect against or fully recover systems or data from all break-downs, service interruptions, attacks or breaches of systems. In addition, we do not maintain standalone cyber-security insurance and have limited insurance coverage in
the event of any breach or disruption of our or our collaborators&#146;, CROs&#146;, or vendors&#146; systems, including any unauthorized access or loss of any personal data that we may collect, store or otherwise process. The costs related to
significant security breaches or disruptions could be material and exceed the limits of any insurance coverage we may have. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or
inappropriate disclosure of confidential or proprietary information, including data related to our personnel, we could incur liability and the further development and commercialization of our product candidates could be delayed and our business and
operations could be adversely affected and/or could result in the loss or disclosure of critical or sensitive data, which could result in financial, legal, business or reputational harm to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current laboratory operations are concentrated in one location and any events affecting this location may seriously compromise our ability to
operate our business and continue the development of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current laboratory operations are located in our
facility situated in Hayward, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, including the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, power shortage,
telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize the facility, may compromise our ability to operate our business, particularly on a daily basis, cause us financial losses
and inhibit or delay our continued development of our product candidates. Loss of access to this facility may result in increased costs, delays in the development of our product candidates or interruption of our business operations. As part of our
risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at this facility, we cannot assure you that the amounts of insurance will be
sufficient to satisfy any damages and losses. If our facility is unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any
business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The investment
of our cash and cash equivalents is subject to risks which may cause losses and affect the liquidity of these investments. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2020, we had $9.8&nbsp;million in cash and cash equivalents. We historically have invested substantially all of our available cash and cash equivalents in cash deposits meeting the criteria of our investment policy, which is focused on
the preservation of our capital. These investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments, which would have a negative effect on our financial results.
In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations,
liquidity and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain or protect sufficient intellectual property rights related to our product candidates, we may not be able to obtain exclusivity
for our product candidates or prevent others from developing similar competitive products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, <FONT
STYLE="white-space:nowrap">know-how,</FONT> trade secret protection and confidentiality agreements&#151;both that we own or possess or that are owned or controlled by our licensors and licensed to us&#151;to protect the intellectual property related
to our technology and product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process, also known as patent prosecution, is expensive and
time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our
current licensors or licensees, or any future licensors or licensees, will fail to identify or obtain sufficient protection for patentable aspects of inventions made in the course of development and commercialization activities before it is too late
to obtain patent protection on them. Therefore, our patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing
of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, patent term adjustments, etc., although we are unaware of any such defects. If we or our
current licensors or licensees, or any future licensors or licensees, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our current licensors or licensees, or any
future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of
our patents or patent applications, such patents or applications may be invalid and unenforceable in circumstances where it is not possible to remedy those material defects. Any of these outcomes could impair our ability to prevent competition from
third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and pharmaceutical field
involves complex legal and scientific questions and can be uncertain. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our product candidates in the
United States or other jurisdictions. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. There is no assurance that all of the potentially relevant prior art
relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents
cover our product candidates, third parties may initiate opposition, interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, nullification or derivation action in court or before patent offices
or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Furthermore, even if our patents and patent applications are unchallenged, they may not
adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or have <FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect to our programs or product
candidates fail to issue, or are revoked, if the breadth or strength of our patent protection is threatened, or if our patent portfolio fails to provide meaningful exclusivity for our product candidates, it could dissuade companies from
collaborating with us to develop product candidates and threaten our ability to commercialize future products. Any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the successful
commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent
applications in the United States and most other countries are confidential for a period of time (up to 18 months) after filing, we cannot be certain that we or our licensors were the first to file any patent application related to a product
candidate. Furthermore, if third parties have filed such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent applications before March&nbsp;16, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject
matter covered by the patent claims of our applications. If third parties have filed such applications on or after March&nbsp;16, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our
invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date
or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, and in most other jurisdictions with a patent system, the natural expiration of a patent is generally 20 years after its
filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to
competition from competitive medications, including biosimilar or generic medications. This risk is material in light of the length of the development process of our products and lifespan of our current patent portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary <FONT
STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve
proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. However, trade secrets can be difficult to protect. What constitutes a trade secret and what protections are available for trade
secrets varies from state to state in the United States and country by country worldwide. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific
advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by measures designed to maintain the physical security of our premises and physical and electronic security of our information
technology systems. Security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known to or be independently discovered by competitors. Although we expect all of our
employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology to enter
into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise
gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets can be difficult to detect, could impair our competitive position and may
have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others
may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including
information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the
outcome is unpredictable. Further, the laws of some foreign countries such as India and China do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant
problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the <FONT STYLE="white-space:nowrap">non-patented</FONT> intellectual property related to our
technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on license relationships with a number of third parties for portions of our intellectual
property, including platform technology patents relating to our ddRNAi technology. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
<FONT STYLE="white-space:nowrap">in-licensed</FONT> certain intellectual property from third parties, including technology related to ddRNAi and antisense RNA. In some cases, our licenses to intellectual property are
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> and the licensors may license the technology to our competitors in the same field, which may result is significant competition for us. In other cases, our licenses to intellectual property are
exclusive only for a specific field of use (such as human therapeutics), and the licensors retain rights to practice the licensed intellectual property themselves and to grant licenses to third parties in other fields. Such third parties may develop
improvements to the licensed intellectual property that are not licensed to us, which could block our ability to continue developing the product candidate covered by the licensed intellectual property, unless we negotiate a license. Such third
parties may also disclose competitively-sensitive information about the licensed intellectual property that diminishes its value. In other cases, our licenses are for research purposes only. Upon regulatory marketing approval of our product
candidates it may be necessary for us to obtain a broader license in order to commercialize. We cannot guarantee the availability of the broader license or that it can be obtained on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on some of these third party licensors to file and prosecute patent applications and maintain patents and otherwise protect the
intellectual property we license. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights we license, and therefore cannot guarantee that these
patents and applications will be prosecuted or enforced in a manner consistent with the best interests of our business. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and
regulations or will result in valid and enforceable patents and other intellectual property rights. Additionally, we may not be able to control the publication or other disclosures of research carried out by our licensors relating to technology that
could otherwise prove patentable. Pursuant to the terms of some of our license agreements with third parties, some of our third-party licensors have the right, but not the obligation, to control enforcement of our licensed patents or defense of any
claims asserting the invalidity of these patents. Even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors, and cannot guarantee that we would receive it and on what terms. We cannot be certain
that our licensors will allocate sufficient resources or prioritize their or our prosecution or enforcement of such patents or defense of such claims to protect our interests in the licensed patents. If we cannot obtain patent protection, or enforce
existing or future patents against third parties, our competitive position and our financial condition could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our
obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold rights under license or sublicense agreements with third parties that are important to our business. Under our
existing license and sublicense agreements, we are subject to various obligations, including diligence obligations with respect to development and commercialization activities and payment obligations. In spite of our efforts, our licensors may
conclude that we have materially breached our obligations under such license agreements and terminate the license agreements, thereby removing or limiting our ability to develop and commercialize product candidates and technology covered by these
license agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to obtain additional licenses from third parties to advance our research or allow commercialization of
our product candidates, such as if we identify new technology that would advance our programs or if an existing license agreement is terminated. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In
that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many cases, patent prosecution of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology is controlled solely by the licensor.
If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual
property. In some cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners and the value
of the licensed patents may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property is of critical importance to our business and
involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of a licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under any collaborative relationships we might enter into in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms,
we may be unable to successfully develop and commercialize the affected product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our results of operations will be affected by the level
of royalty payments that we are required to pay to third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to license agreements that require us to remit
royalty payments and other payments related to <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. Under our <FONT STYLE="white-space:nowrap">in-license</FONT> agreements, we may pay
<FONT STYLE="white-space:nowrap">up-front</FONT> fees and milestone payments and be subject to future royalties. We cannot precisely predict the amount, if any, of royalties we will owe in the future, and if our calculations of royalty payments are
incorrect, we may owe additional royalties, which could negatively affect our results of operations. As our product sales increase, we may, from time to time, disagree with our third-party collaborators as to the appropriate royalties owed, and the
resolution of such disputes may be costly, may consume management&#146;s time, and may damage our relationship with our collaborators. Furthermore, we may enter into additional license agreements in the future, which may also include royalty,
milestone and other payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The licenses we may grant to our collaborators and other licensees to use our ddRNAi and other technology may be
exclusive to the development of product candidates for certain conditions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the
<FONT STYLE="white-space:nowrap">out-licenses</FONT> we may grant to our collaborators to use our ddRNAi and other technology may be exclusive to the development of product candidates for certain conditions, so long as our collaborators comply with
certain requirements. That means that once our ddRNAi technology is licensed to a collaborator for a specified condition, we are generally prohibited from developing product candidates for that condition and from licensing the ddRNAi to any third
party for that condition. The limitations imposed by these exclusive licenses could prevent us from expanding our business and increasing our development of product candidates with new collaborators, both of which could adversely affect our business
and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our development and
commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the patents and proprietary
rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent
infringement lawsuits, interferences, oppositions and inter partes review proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third
parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of
infringement of the patent rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without
authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications
can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be accused of infringing. In addition, third parties may obtain patents in the future and claim
that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process, methods of use or formulations of any of our product candidates, any DNA
constructs formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or
until such patents expire. In either case, such a license may not be available on commercially reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making
claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would
involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including
treble damages and attorneys&#146; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Even
if a license can be obtained on acceptable terms, the rights may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to
obtain a required license, we may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to
sustain our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to gene therapy product components and processes for
our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently, we have certain
rights to intellectual property to develop our current gene therapy product candidates. However, our product candidates may require specific formulations to work effectively and efficiently and rights to such formulations may be held by others. In
addition, we may need additional intellectual property rights as we develop future product candidates. In particular, we are aware of a third party patent directed to AAV vectors that expires in 2026. In the event we receive regulatory marketing
approval before the expiration date it may be necessary for us to obtain a license to the patent in order to commercialize. We cannot guarantee the availability of the license or that it can be obtained on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other
third-party intellectual property rights from third parties that we identify on terms that we find acceptable, or at all. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more
established companies are also pursuing strategies to license or acquire third-party intellectual property rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization
capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or
development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such
right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property
rights to other parties, potentially blocking our ability to pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a
competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to
successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and
unsuccessful, and issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file
infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable or is not infringed, or may refuse to stop the other
party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or
interpreted narrowly and could put our patent applications at risk of not issuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in patent litigation in the United
States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or <FONT
STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement,
during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior
art, of which we and the patent examiner were unaware during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT
STYLE="white-space:nowrap">re-examination,</FONT> post grant review, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such proceedings could result in revocation, amendments to our patent claims or statements
being made on the record such that our claims may no longer be construed to cover our product candidates. Outcomes or statements on the record in one country could have a disadvantageous effect on prosecution or enforcement of a patent or patent
application in another country. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that no invalidating prior art exists or that the
patent examiner was aware of all material prior art during prosecution. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce or defend the
patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted, enforced and defended in a manner consistent with the best interests of our business. If a defendant were to prevail on
a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology. Such a loss of patent protection could have a
material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property rights. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our
technical and management personnel from their normal responsibilities. In addition, enforcement of a favorable decision by a court can depend on cooperation of a governmental authority which may or may not be available in every jurisdiction. Such
litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our patents and patent applications filed in the United States before March&nbsp;16, 2013, interference proceedings provoked by third
parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to
our interests and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in
countries where the laws may not protect those rights as fully as in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of
discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the
results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could cause the trading price of our common stock to fall. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of
third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of
our key employees and personnel are or were previously employed at universities, medical institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our
employees, consultants and independent contractors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or our employees, consultants or
independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#146;s former employer or other third parties. Litigation may be
necessary to defend against these claims. Furthermore, universities or medical institutions who employ some of our key employees and personnel in parallel to their engagement by us may claim that intellectual property developed by such person is
owned by the respective academic or medical institution under the respective institution intellectual property policy or applicable law. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs, be a distraction to management and other employees, and damage our relationships with the academic
and medical institutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents
or other intellectual property. We may in the future have ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend
against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to
use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid
to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various corresponding governmental patent agencies outside of the United States
require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which
<FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the biotechnology industry involve both technological and legal complexity, and it therefore is costly, time-consuming and inherently uncertain. In addition, on September&nbsp;16, 2011, the Leahy-Smith America Invents Act,
or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important change introduced by the Leahy-Smith Act is that, as of March&nbsp;16, 2013, the United States transitioned to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same
invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will
require us to be cognizant going forward of the time from invention to filing of a patent application. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the Leahy-Smith Act are changes that limit where a patentee may file a patent infringement suit
and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared
to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be
insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the
third party as a defendant in a district court action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent U.S. Supreme Court rulings such as Association for Molecular Pathology v.
Myriad Genetics, Inc. (Myriad I); BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig. (Myriad II); and Promega Corp. v. Life Technologies Corp. have also narrowed the scope of patent protection available in certain circumstances and
weakened the rights of patent owners in some situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once
obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing
patents and patents that we might obtain in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success depends, in part, on our ability to protect our intellectual property and our technologies
outside the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to obtain and maintain patent and trade secret
protection for our technologies, our traits, and their uses, as well as our ability to operate without infringing upon the proprietary rights of others outside the United States. If we do not adequately protect our intellectual property, competitors
may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries around the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal
and state laws in the United States. In addition, we may at times <FONT STYLE="white-space:nowrap">in-license</FONT> third-party technologies for which limited international patent protection exists and for which the time period for filing
international patent applications has passed. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and
into the United States or other jurisdictions. Potential competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to
territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, if approved, and our patents or other intellectual property rights may not be
effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending
intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly
those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to an Investment in Our Common Sock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price and trading volume of our common stock may be volatile and may be affected by economic conditions beyond our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be highly volatile and subject to wide fluctuations. In addition, the trading volume of our common
stock may fluctuate and cause significant price variations to occur. If the market price of our common stock declines significantly, you may be unable to resell your shares of our common stock at or above your purchase price, if at all. We cannot
assure you that the market price of our common stock will not fluctuate or significantly decline in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some specific factors
that could negatively affect the price of our common stock or result in fluctuations in its price and trading volume include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or expected fluctuations in our operating results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates or recommendations by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic decisions by us or our competitors, such as acquisitions, collaborations, divestitures, spin-offs,
joint ventures, strategic investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the passage of legislation or other regulatory developments in the United States and other countries affecting us
or our industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in trading volume of our common stock on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our executive officers or our shareholders in the future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions in the financial markets or changes in general economic conditions, including as a result of the
current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market has experienced and is
currently experiencing significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not
relate to the operating performance of the companies represented by the stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not continue to
develop or may not be liquid enough for you to sell your shares of our common stock quickly or at market price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our
common stock is listed on Nasdaq, if an active public market in the United States for our common stock does not continue to develop, the market price and liquidity of our common stock may be adversely affected. The price of our common stock may
decline, which means you may experience a decrease in the value of your shares of our common stock regardless of our operating performance or prospects. In the past, following periods of volatility in the market price of a company&#146;s securities,
shareholders often instituted securities class action litigation against that company. If we were involved in a class action suit, it could divert the attention of senior management and, if adversely determined, could cause us significant financial
harm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not continue to publish research or reports, or if they publish adverse or misleading research or
reports, regarding us, our business or our market, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our
common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If no additional securities or industry analysts commence coverage of us, our stock price could be
negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the
expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock
price or trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to establish and maintain proper internal financial reporting controls, our ability to produce
accurate financial statements or comply with applicable regulations could be impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;404(a) of the Sarbanes-Oxley
Act requires that our management assess and report annually on the effectiveness of our internal controls over financial reporting and identify any material weaknesses in our internal controls over financial reporting. Although Section&nbsp;404(b)
of the Sarbanes-Oxley Act requires our independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
controls over financial reporting, we rely on the exemption provided in the JOBS Act, and consequently will not be required to comply with SEC rules that implement Section&nbsp;404(b) of the
Sarbanes-Oxley Act until such time as we are no longer an emerging growth company and are an accelerated or large accelerated filer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
presence of any material weaknesses in our internal control over financial reporting could result in financial statement errors which, in turn, could lead to errors in our financial reports and/or delays in our financial reporting, which could
require us to restate our operating results. We might not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section&nbsp;404(a) of the Sarbanes-Oxley Act. In order to maintain and
improve the effectiveness of our disclosure controls and procedures and internal controls over financial reporting, we will need to expend significant resources and provide significant management oversight. Implementing any appropriate changes to
our internal controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management&#146;s
attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to conclude that we have effective internal controls over financial reporting, investors may lose confidence in our operating
results, the price of our common stock could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, our common stock may
not be able to remain listed on Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never declared or paid dividends on our common stock and we do not anticipate paying dividends in
the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. For the foreseeable future, we
currently intend to retain all available funds and any future earnings to support our operations and to finance the growth and development of our business. Any future determination to declare cash dividends will be made at the discretion of our
Board, subject to compliance with applicable laws and covenants under current or future credit facilities, which may restrict or limit our ability to pay dividends, and will depend on our financial condition, operating results, capital requirements,
general business conditions and other factors that our Board may deem relevant. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. As a result, a return on your investment in our securities will only occur
if the price of our common stock appreciates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to purchase common stock could result in
substantial dilution to the percentage ownership of our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that significant additional capital will be needed
in the future to continue our planned operations. To raise capital, we may sell common stock or other securities convertible into or exchanged for our common stock in one or more transactions, and in a manner we determine from time to time and at
prices that may not be the same as the price per share paid by other investors, and dilution to our stockholders could result. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into
common stock, in future transactions may be higher or lower than the price per share paid by other investors. New investors could also receive rights, preferences and privileges senior to those of existing holders of our common stock. In addition,
in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock, we may be required to proportionally adjust the conversion price, exercise price or number of shares issuable upon exercise of any
outstanding warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company as defined in the JOBS Act and the reduced disclosure requirements applicable to emerging
growth companies may make our common stock less attractive to investors and, as a result, adversely affect the price of our common stock and result in a less active trading market for our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
emerging growth companies. For example, we have elected to rely on an exemption from the auditor attestation requirements of Section&nbsp;404 of the&nbsp;Sarbanes-Oxley&nbsp;Act relating to
internal control over financial reporting, and we will not provide such an attestation from our auditors for so long as we qualify as an emerging growth company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may avail ourselves of these disclosure exemptions until we are no longer an emerging growth company. We cannot predict whether investors
will find our common stock less attractive because of our reliance on some or all of these exemptions. If investors find our common stock less attractive, it may cause the trading price of our common stock to decline and there may be a less active
trading market for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will cease to be an emerging growth company upon the earliest of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the end of the fiscal year in which the fifth anniversary of the completion of our initial public offering
occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the end of the first fiscal year in which the market value of our ordinary shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end of the second quarter of such fiscal year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the end of the first fiscal year in which we have total annual gross revenues of at least $1.07&nbsp;billion; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which we have issued more than $1&nbsp;billion
<FONT STYLE="white-space:nowrap">in&nbsp;non-convertible&nbsp;debt</FONT> securities in any rolling&nbsp;three-year&nbsp;period. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our corporate governance structure may prevent our acquisition by another company at a premium over the public trading price of our shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that the acquisition of a majority of our outstanding voting stock by another company could result in our stockholders receiving
a premium over the public trading price for our shares. Provisions of our restated certificate of incorporation and our amended and restated bylaws, each as amended, and of Delaware corporate law could delay or make more difficult an acquisition of
our company by merger, tender offer or proxy contest, even if it would create an immediate benefit to our stockholders. Furthermore, our certificate of incorporation also provides for a classified board of directors with directors divided into three
classes serving staggered terms. These provisions may have the effect of delaying or preventing a change in control of us without action by our stockholders and, therefore, could adversely affect the price of our stock or the possibility of sale of
shares to an acquiring person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a result of the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> we are required to comply with the
domestic reporting regime under the Exchange Act and will incur significant legal, accounting and other expenses, and our management will be required to devote substantial additional time to new compliance initiatives and corporate governance
matters. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> we no longer qualify as a &#147;foreign
private issuer&#148; under the rules and regulations of the SEC. While we were a foreign private issuer, we were exempt from compliance with certain laws and regulations of the SEC, including the proxy rules, the short-swing profits recapture rules
and certain governance requirements, such as independent director oversight of the nomination of directors and executive compensation. In addition, we were not required to file annual, quarterly and current reports and financial statements with the
SEC as frequently or as promptly as U.S. companies registered under the Exchange Act. As a result of becoming a U.S. domestic company, we are no longer entitled to &#147;foreign private issuer&#148; exemptions and must report as a domestic U.S.
filer, including filing quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and proxy statements under Section&nbsp;14 of the Exchange Act. In addition, our
&#147;insiders&#148; are now subject to the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act and we are no longer exempt from the requirements of Regulation FD promulgated by the SEC under the
Exchange Act. Moreover, as a domestic filer, we are required to comply with the corporate governance obligations imposed by Nasdaq and no longer have the option to follow our home country rules in lieu of such obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory and compliance costs associated with the reporting and governance
requirements applicable to U.S. domestic issuers may be significantly higher than the costs we&nbsp;previously&nbsp;incurred as a&nbsp;foreign private issuer. As a result, we expect that the loss of foreign private issuer status will increase our
legal and financial compliance costs and will make some activities highly time-consuming and costly. In addition, we need to develop our reporting and compliance infrastructure and may face challenges in complying with the new requirements
applicable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price and trading volume of our common stock may be volatile and may be affected by economic conditions beyond our
control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be highly volatile and subject to wide fluctuations. In addition, the trading
volume of our common stock may fluctuate and cause significant price variations to occur. If the market price of our common stock declines significantly, you may be unable to resell your shares of common stock at or above your purchase price, if at
all. We cannot assure you that the market price of our common stock will not fluctuate or significantly decline in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some
specific factors that could negatively affect the price of our common stock or result in fluctuations in their price and trading volume include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or expected fluctuations in our operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates or recommendations by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in trading volume of shares of our common stock on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of shares of our common stock by us, our executive officers or our shareholders in the future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions in the financial markets or changes in general economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Although we are required to use our reasonable best efforts to have an effective registration statement covering the issuance of shares of common stock
underlying certain of our outstanding warrants at the time that holders of our warrants exercise their warrants, we cannot guarantee that a registration statement will be effective, in which case holders of our warrants are entitled to a cashless
exercise of their warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of certain of our warrants, we are obligated to have an effective registration statement
covering the resale of the shares of common stock underlying such warrants. If no registration is effective at the time a warrant holder seeks to exercise their warrants, we would be obligated to issue shares to such warrant holder in a
&#147;cashless exercise&#148; in exchange for such holder&#146;s warrants, in which case we would not receive the cash that we would otherwise receive in an exercise of warrants for cash. On April&nbsp;22, 2020, shortly after the Company completed
the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> one of the warrant holders executed a cashless exercise of its warrants. The investor received 37,417 shares in exchange for warrants exercisable for 107,095 shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_3"></A>Item&nbsp;1B. Unresolved Staff Comments. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_4"></A>Item&nbsp;2.
Properties.</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters and our research and development facility is located in Hayward, California, and consists of
approximately 7,295 square feet of leased office space under a lease that expires in June 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management believes that these facilities
are suitable and adequate to meet our anticipated needs.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_5"></A>Item&nbsp;3. Legal Proceedings.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently a party to any material legal proceedings.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_6"></A>Item&nbsp;4. Mine Safety Disclosures.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_7"></A>Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common
stock trades on Nasdaq under the symbol &#147;BNTC.&#148; Prior to the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> the American Depositary Shares of Benitec Limited traded on Nasdaq under the same trading symbol and the ordinary shares
of Benitec Limited traded on the Australian Stock Exchange (&#147;ASX&#148;). In connection with the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> Benitec Limited&#146;s ordinary shares were delisted from the ASX. On September 22, 2020,
the closing sale price of our common stock as reported on Nasdaq was $6.05 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 15, 2020, we had approximately 3,348 record holders of our common stock. The number of record holders is based on the actual
number of holders registered on the books of our transfer agent and does not reflect holders of shares in &#147;street name&#148; or persons, partnerships, associations, corporations or other entities identified in security position listings
maintained by depository trust companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We never have declared or paid any cash dividends on our capital stock. Currently, we anticipate that we will retain all available funds for
use in the operation and expansion of our business and do not anticipate paying any cash dividends for the foreseeable future. Any future determination relating to dividend policy will be made at the discretion of our Board and will depend on our
future earnings, capital requirements, financial condition, prospects, applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits, and other factors that our Board deems relevant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Sales of Unregistered Securities</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 4, 2018, Benitec Limited issued 36,442,672 ordinary shares (which were converted to 121,475 shares of common stock as part of the
Re-domiciliation) to existing shareholders. The shares were priced at A$0.17 per share. This issuance was exempt from registration under the Securities Act in reliance on Regulation&nbsp;S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2019, Benitec Limited entered into a securities purchase agreement (&#147;SPA&#148;) with certain sophisticated and
professional investors in the United States to issue 2,800,000 American Depositary Shares (&#147;ADSs&#148;), with each ADS representing 20 fully paid ordinary shares (which were converted to 186,666 shares of common stock as part of the <FONT
STYLE="white-space:nowrap">Re-domiciliation),</FONT> at a purchase price of US$0.70 per ADS, in a registered direct offering. The Investors were also issued warrants to purchase up to 412,890 ADSs (representing 27,526 shares of common stock after
the <FONT STYLE="white-space:nowrap">Re-domiciliation)</FONT> in aggregate, at a purchase price per warrant equal to US$0.6999 per ADS to be issued on exercise of the warrant <FONT STYLE="white-space:nowrap">(&#147;Pre-Funded</FONT> Warrants&#148;).
The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were exercisable at any time from issue, in whole or in part, at an exercise price of US$0.0001 per ADS issued on exercise (subject to certain adjustments), provided that the beneficial
ownership of the relevant Investor in the total number of ADSs on issue not exceed 9.99%. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have all been exercised. This issuance was exempt from registration under the Securities Act of
1933, as amended (the &#147;Securities Act&#148;) in reliance on Section&nbsp;4(a)(2). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2020, the Company completed the <FONT
STYLE="white-space:nowrap">Re-domiciliation.</FONT> In connection with the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> Benitec issued 1,070,957 shares of common stock, on the basis of one share of common stock for every 300 ordinary
shares of Benitec Limited issued and outstanding prior to the <FONT STYLE="white-space:nowrap">Re-domiciliation.</FONT> The <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> was effected pursuant to a statutory scheme of arrangement under
Australian law (the &#147;Scheme&#148;). The issuance of Benitec&#146;s shares of common stock in the Scheme was exempt from registration under the Securities Act in reliance on Section&nbsp;3(a)(10). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;22, 2020, Benitec issued 37,417 shares of common stock in connection with a
cashless exercise of warrants exercisable for 107,095 shares of common stock. The issuance was exempt from registration under the Securities Act in reliance on Section&nbsp;3(a)(9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purchases of Equity Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not
applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_8"></A>Item&nbsp;6. Selected Financial Data. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company and not required to provide this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_9"></A>Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of financial condition and operating results together with our
consolidated financial statements and the related notes and other financial information included in Item 8 in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors,
such as those set forth in the section of the Annual Report captioned &#147;Risk Factors&#148; and elsewhere in this Annual Report, our actual results may differ materially from those anticipated in these forward-looking statements. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We endeavor to become the
leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (&#147;Benitec&#148; or the &#147;Company&#148; or in the third person, &#147;we&#148; or &#147;our&#148;) is a
development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in&nbsp;Hayward, California. The proprietary platform, called <FONT STYLE="white-space:nowrap">DNA-directed</FONT> RNA interference, or
ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and
life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">BB-301</FONT> is the most advanced ddRNAi-based genetic medicine currently under development by Benitec. <FONT STYLE="white-space:nowrap">BB-301</FONT> is an internally optimized,
<FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy agent that is designed to both silence the expression of mutated, disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and replace the mutant genes
with normal, &#147;wild type&#148; genes (to drive restoration of function in diseased cells).&nbsp;This fundamental approach to disease management is called &#147;silence and replace&#148; and this biological mechanism offers the potential to
restore the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and, potentially, fatal effects of Oculopharyngeal Muscular Dystrophy (OPMD). <FONT
STYLE="white-space:nowrap">BB-301</FONT> has been granted Orphan Drug Designation in&nbsp;the United States&nbsp;and the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the combination of the targeted gene silencing effects of RNAi and the durable transgene expression achievable via the use of modified
viral vectors, the silence and replace approach has the potential to produce long-term silencing of disease-causing genes along with simultaneous replacement of wild type gene function following a single administration of the proprietary genetic
medicine. We believe this novel attribute of the investigational agents under development by Benitec may facilitate the achievement of robust clinical activity while greatly reducing the dosing frequencies traditionally expected for medicines
employed for the management of chronic diseases.&nbsp;Additionally, the establishment of chronic gene silencing and gene replacement may significantly reduce the risk of patient <FONT STYLE="white-space:nowrap">non-compliance</FONT> during the
course of medical management of potentially fatal clinical disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all dollar amounts in this section are
provided in thousands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2020, or the Implementation Date, the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> of Benitec Limited, a public
company incorporated under the laws of the State of Western Australia, or Benitec Limited, was completed in accordance with the Scheme Implementation Agreement, as amended and restated as of January&nbsp;30, 2020, between Benitec Limited and us. As
a result of the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> the jurisdiction of incorporation was changed from Australia to Delaware, and Benitec Limited became our wholly owned subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> was effected pursuant to a
statutory scheme of arrangement under Australian law, or the Scheme, whereby on the Implementation Date, all of the issued and outstanding ordinary shares of Benitec Limited were exchanged for newly issued shares of our common stock, on the basis of
one share of our common stock, par value $0.0001 per share, for every 300 ordinary shares of Benitec Limited issued and outstanding. Holders of Benitec Limited&#146;s American Depository Shares, or ADSs (each of which represented 200 ordinary
shares), received two shares of our common stock for every three ADSs held. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">COVID-19</FONT> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, an outbreak of a novel strain of coronavirus was identified in Wuhan, China. This virus continues to spread globally, has
been declared a pandemic by the World Health Organization and has spread to nearly every country, including Australia and the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society,
which has resulted in and will likely continue to result in significant disruptions to businesses and capital markets around the world. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and
cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our research and development efforts are conducted globally, including the ongoing development of our silence and replace
therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to initiate preclinical and clinical studies despite the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.<B> </B>As
we continue to actively advance our preclinical programs, including our ongoing tissue transduction studies for <FONT STYLE="white-space:nowrap">BB-301,</FONT> we are in close contact with our principal investigators and preclinical trial sites,
which are primarily located in the France, and are assessing the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our studies and the expected development timelines and costs of all of our product candidates, on an ongoing basis. In
light of recent developments relating to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#146;s updated industry guidance for
conducting clinical trials issued on March&nbsp;18, 2020, we have experienced delays to the original timeline regarding the initiation and anticipated completion of the ongoing <FONT STYLE="white-space:nowrap">BB-301</FONT> <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> development work. The initiation of the <FONT STYLE="white-space:nowrap">BB-301</FONT> tissue transduction study, which represents a key component of the
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> work, was delayed by several months, however, the study has been recently initiated and the dosing of the initial preclinical cohorts has proceeded without incident. We will continue to evaluate
the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and expect to reevaluate the timing of our anticipated preclinical and clinical milestones as we learn more and the impact of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> on our industry becomes more clear. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had also implemented work-from-home measures for
the majority of our employees between March 2020 and June 2020, resulting in a reduction of laboratory work and a halt of <FONT STYLE="white-space:nowrap">non-essential</FONT> business travel. As we transition our employees back to our premises,
there is a risk that <FONT STYLE="white-space:nowrap">COVID-19</FONT> infections occur at our offices or laboratory facilities and significantly affect our operations. Additionally, if any of our critical vendors are impacted, our business could be
affected if we become unable to timely procure essential equipment, supplies or services in adequate quantities and at acceptable prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Axovant
Termination </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec&#146;s License and Collaboration Agreement, dated July&nbsp;9, 2018, with Axovant Sciences GmbH, or Axovant, was
terminated as of September&nbsp;3, 2019. As a result, all rights and licenses which Benitec had granted to Axovant to develop and commercialize <FONT STYLE="white-space:nowrap">BB-301</FONT> and related gene therapy product candidates terminated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to such termination, the Benitec team endeavored to conduct several additional exploratory nonclinical analyses in order
to&nbsp;potentially&nbsp;improve the biological efficacy of <FONT STYLE="white-space:nowrap">BB-301</FONT> via further&nbsp;optimization of the route of administration employed to dose the target muscle tissues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nonclinical data derived from <I>in vivo</I> evaluations of
<FONT STYLE="white-space:nowrap">BB-301</FONT> in two distinct large animal species suggested the existence of an opportunity to further improve the biological efficacy of the compound via additional optimization of the proprietary delivery method
employed to dose key target tissues that underlie the morbidity and mortality associated with the natural history of OPMD.&nbsp;The initial biological efficacy profile observed for <FONT STYLE="white-space:nowrap">BB-301</FONT> following <I>in
vivo</I> testing in the A17 mouse model of OPMD, including full correction of the disease phenotype, remained unchanged.&nbsp;However, the Benitec management team desired to complete a series of exploratory analyses prior to the formal IND filing
and the subsequent initiation of clinical testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the experimental work noted above would have delayed the initiation of
the <FONT STYLE="white-space:nowrap">BB-301</FONT> clinical study beyond the timelines that were initially outlined by Axovant following the execution of the License and Collaboration Agreement between Benitec and Axovant.&nbsp;As such, Axovant
elected to terminate the License and Collaboration Agreement between Benitec and Axovant, and all rights and licenses granted to Axovant terminated,&nbsp;including the rights to <FONT STYLE="white-space:nowrap">BB-301,</FONT> which was in
preclinical development for the treatment of OPMD, and all other early stage research collaboration programs that were governed by the agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Nonclinical Programs </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nonclinical
research efforts supporting the development of ddRNAi-based therapeutic agents and silence and replace-based therapeutic agents targeting the treatment of Chronic Hepatitis B Virus Infection (&#147;HBV&#148;) and
<FONT STYLE="white-space:nowrap">Age-Related</FONT> Macular Degeneration (&#147;AMD&#148;) have concluded and are no longer being continued by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Workforce Reduction </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31,
2019, Benitec announced the completion of a workforce reduction of approximately 50%. Through this streamlining of operations, the Company retained staff members who are key to the achievement of the core research and development goals.&nbsp;The
rationalization of resources was deemed to be supportive of an extended financial runway for the Company while allowing Benitec to continue to advance the <FONT STYLE="white-space:nowrap">BB-301</FONT> program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Royalties, milestone payments and other license fees </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay royalties, milestone payments and other license fees in connection with our licensing of intellectual property from
third parties, including as discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into an exclusive sublicense agreement with NantWorks, LLC,
pursuant to which we agreed to make certain milestone and royalty payments, as well as periodic payments for so long as the agreement remained in effect. In December of 2018, the Company accrued a milestone payment of USD 300,000 (AUD 425,411),
which was anticipated to be paid to NantWorks, LLC under the sublicense agreement. It was later determined that the milestone was not required to be paid and, therefore, the accrual was reversed in December of 2019. We terminated the exclusive
sublicense agreement for convenience, with the termination effective as of June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have collaborated with Biomics Biotechnologies
Co., Ltd., or Biomics, pursuant to several collaboration agreements in relation to single-stranded RNA and shRNA sequences for treatment of hepatitis B. In July 2015, we entered into an <FONT STYLE="white-space:nowrap">earn-out</FONT> agreement with
Biomics which confirmed Benitec&#146;s ownership of certain patents resulting from the collaboration in exchange for an upfront payment and equity issuance to Biomics and a share of certain future licensing revenue received by Benitec. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Foreign Currency Translation and Other Comprehensive Income (Loss) </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s functional currency and reporting currency is the United States dollar . BBL&#146;s functional currency is the Australian
dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction
date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#146; equity as &#147;Accumulated other comprehensive income (loss).&#148; Gains and losses
resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past Benitec Limited has generated revenue from its operations through two activities: revenue from customers and revenue from
government research and development grants. In the fiscal year ended June&nbsp;30, 2020, the Company generated funds primarily from capital raising activities. The Company has not generated any revenues from the sales of products. Revenues from
licensing fees and interest income are included in the revenue from customers line item on our statements of operations and comprehensive income (loss). The Research and Development Tax Incentive is recognized as Government research and development
grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our licensing fees have been generated through the licensing of our ddRNAi technology to biopharmaceutical companies, and in the
fiscal year-ended June&nbsp;30, 2019, revenue was generated through a License and Collaboration Agreement with Axovant Sciences (the &#147;Axovant Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our revenues for each of the periods set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government research and development grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues from customers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;9, 2018, the Company entered into the Axovant Agreement. The Axovant Agreement granted Axovant Sciences an exclusive worldwide
license to develop, manufacture, and commercialize products containing the Company&#146;s product known as <FONT STYLE="white-space:nowrap">BB-301,</FONT> which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Service
revenue consists of payments for services provided to Axovant Sciences pursuant to the Axovant Agreement. On June&nbsp;6, 2019, the termination of the Axovant Agreement was announced. The termination of the Axovant Agreement was effective as of
September&nbsp;3, 2019. The termination discharges all future performance obligations under the contract at the termination date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
the year ended June&nbsp;30, 2020, the Company recognized $97 in customer revenues, as compared to $11,551 for the comparable year ended June&nbsp;30, 2019. The decrease in revenues from customers is due to the termination of the Axovant Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Government research and development grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has historically received, but is currently not receiving, grants through the Australian federal government&#146;s Research and
Development Tax Incentive program, under which the government provides a cash refund for the 43.5% of eligible research and development expenditures by small Australian entities, which are defined as Australian entities with less than
A$20&nbsp;million in revenue, having a tax loss. The Research and Development Tax Incentive grant is made by the Australian federal government for eligible research and development purposes based on the filing of an annual application. Prior to the <FONT
STYLE="white-space:nowrap">Re-domiciliation,</FONT> this grant was available for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to our activities in
Australia, did not exceed half the expenses for the relevant activities and were approved by the Australian government. Grants are recorded when a reliable estimate can be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended June&nbsp;30, 2020, we recognized $5 in government research and development grants, as compared $648 for the comparable
year ended June&nbsp;30, 2019. The decrease in grant revenue is due to excluding the OPMD program from the R&amp;D claim of the grant from the Australian government. Further, the Company no longer continued the nonclinical research efforts targeting
the treatment of Chronic Hepatitis B Virus Infection (HBV) and AMD in the fiscal year ended June&nbsp;30, 2020. The decrease in grant revenue is a result of Benitec no longer claiming the grant from the Australian government due to the <FONT
STYLE="white-space:nowrap">Re-domiciliation</FONT> of Benitec to the United&nbsp;States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet
invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts
can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and
Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries, related benefits, travel, and
equity-based compensation expense. General and administrative expenses also include facility expenses, professional fees for legal, consulting, accounting and audit services and other related costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses may increase as the Company focuses on the continued development of the <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> OPMD program. The Company also anticipates an increase in expenses relating to accounting, legal and regulatory-related services associated with maintaining compliance with the exchange listing and the
SEC requirements, director and officer insurance premiums and other costs associated with being a domestic public company after the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> and no longer a &#147;foreign private issuer&#148; under SEC
rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our expenses for each of the periods set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties and license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended June&nbsp;30, 2020, we incurred ($185) in royalties and license fees, as compared to
$435 for the comparable year ended June&nbsp;30, 2019. The decrease in royalties and license fees for the year is primarily due to the Company determining that there was no longer a requirement to pay a previously anticipated milestone of $300. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended June&nbsp;30, 2020, we incurred $3,001 in research and development expenses, as compared $4,567 for the comparable year
ended June&nbsp;30, 2019. The decrease in research and development expenses is primarily due to the Company being reimbursed $606<B> </B>by Axovant Sciences for costs relating to the OPMD program in fiscal year 2020 and the termination of the AMD
program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense was $5,567 and $4,614 for the years ended June&nbsp;30, 2020 and 2019, respectively. The
increase was due to increases in corporate costs offset by decreases in payroll, travel, and consultant costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our other income (loss) for each of the periods set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Income (Loss):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency transaction loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The other income, net during the year ended June&nbsp;30, 2020 totaled $7, which consists of foreign currency
transaction loss, interest income, other income, unrealized loss on investment. During the year ended June&nbsp;30, 2019, other income, net totaled $26. Foreign currency transaction loss has increased due to a change in foreign exchange rates.
Interest income decreased due to fewer transactions with interest. Other income, net increased due to <FONT STYLE="white-space:nowrap">COVID-19</FONT> stimulus incentives from the Australian government. Unrealized loss on investment decreased due to
the change in fair market value of the investments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred cumulative losses and negative cash flows from operations since our predecessor&#146;s inception in 1995, except for
the year ended June&nbsp;30, 2019 where we had a net income of $2,609 and generated positive cash flows of $4,790 from operating activities. The Company had accumulated losses of $116.6&nbsp;million as of June&nbsp;30, 2020. We expect that our
research and development expenses may increase due to the continued development of the OPMD program. It is also likely that there will be an increase in the general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and administrative expenses due to the obligations of being a domestic public company in the United States as a result of the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> and no
longer a &#147;foreign private issuer&#148; under SEC Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had no borrowings for the years ended June&nbsp;30, 2020 and 2019 and do
not currently have a credit facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we had cash and cash equivalents of $9.8&nbsp;million. Cash in excess of
immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts. Our short-term investments consist of term
deposits with maturity within 180 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the net cash flow activity for each of the periods
set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended June&nbsp;30, 2020 was $7,535. Net cash provided by operating activities for the year
ended June&nbsp;30, 2019 was $4,790. Net cash used in operating activities was </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">primarily the result of our net loss and change in working capital,
partially offset by equity-based compensation expense and the lease liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended June&nbsp;30, 2020 and 2019 was $94 and $400, respectively, and primarily related to
purchases of equipment in 2020 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $1,770 and $0 for the years ended June&nbsp;30, 2020 and 2019, respectively. Cash from financing
activities related to the issuance of ordinary shares, including $2,250 in gross proceeds from a private placement and entitlement offer for the year ended June&nbsp;30, 2020, partially offset by $480 in share issue transaction costs. There were no
private placements for the year ended June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The future of the Company as an operating business will depend on its ability
to generate revenues mostly from licensing, strategic alliances and collaboration arrangements with pharmaceutical companies. While we continue to progress discussions and advance opportunities to engage with pharmaceutical companies and continue to
seek licensing partners for ddRNAi in disease areas that are not our focus, there can be no assurance as to whether we will enter into such arrangements or what the terms of any such arrangement could be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have established some licensing arrangements, we do not have any products approved for sale and have not generated any revenue from
product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or
future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until we establish significant revenues from licensing programs, strategic
alliances or collaboration arrangements with pharmaceutical companies, or from product sales, we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of
product candidates and begin to prepare to commercialize any product that receives regulatory approval. We are subject to the risks inherent in the development of new gene therapy products, and we may encounter unforeseen expenses, difficulties,
complications, delays and other unknown factors that may adversely affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our cash and cash equivalents
together with the net proceeds of a planned public offering of common stock will be sufficient to fund the Company&#146;s operations at least for the next twelve months. In connection with the Company&#146;s planned public offering, on
August&nbsp;14, 2020, the Company filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with
research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs of our planned clinical trials for our ddRNAi and silence and replace product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs of our planned preclinical studies for our ddRNAi and silence and replace product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of product candidates that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and costs of seeking regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revenue received from commercial sales of any of our product candidates that may receive regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may
establish; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the
licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual
property rights and defending against intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we need to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and
technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commercial Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;9, 2018, the Company entered into an Agreement with Axovant Sciences. The Agreement granted Axovant Sciences an exclusive
worldwide license to develop, manufacture, and commercialize products containing the Company&#146;s product known as <FONT STYLE="white-space:nowrap">BB-301,</FONT> which was designed for the potential treatment of Oculopharyngeal Muscular
Dystrophy. On June&nbsp;6, 2019, the termination of the Agreement with Axovant Sciences was announced. The termination of the Agreement was effective as of September&nbsp;3, 2019. The termination discharges all future performance obligations at
termination date under the contract. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had no material <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as of June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States
of America requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of Notes to the consolidated financial statements included in Item 8 in this Annual Report describes the significant accounting
policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A critical accounting policy is defined as one that is both material to the presentation of the Company&#146;s consolidated financial statements and requires
management to make difficult, subjective or complex judgments that could have a material effect on the Company&#146;s financial condition or results of operations. Specifically, these policies have the following attributes: (1)&nbsp;the Company is
required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2)&nbsp;different estimates the Company could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a
material effect on the Company&#146;s financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimates and assumptions about future events and their effects
cannot be determined with certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as
additional information is obtained and as the Company&#146;s operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition,
management is periodically faced with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section above entitled &#147;Risk Factors.&#148;
Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that the Company&#146;s consolidated financial statements are fairly stated in
accordance with accounting principles generally accepted in the United States of America, and provide a meaningful presentation of the Company&#146;s financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes that the following are critical accounting policies: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
adopted and implemented on July&nbsp;1, 2018, ASC 606&#151;&#147;<I>Revenue from Contracts with Customers</I>&#148; (&#147;ASC 606&#148;). ASC 606 did not have a material impact on the consolidated financial statements. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon implementation of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC&nbsp;606. In doing so, management
considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the
contract was within the scope of ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <FONT
STYLE="white-space:nowrap">know-how</FONT> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <FONT
STYLE="white-space:nowrap">know-how</FONT> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT>
has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing revenues </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from
licensees of the Company&#146;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is
estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the
performance obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance
obligations and reports these amounts as other liabilities in the statement of financial position. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a
receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the
Company&#146;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the
customer&#146;s subsequent sales of product occurs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Services revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services
revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance
obligation over time where the Company retains the right to payment for services performed but not yet completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, &#147;<I>Stock Compensation</I>&#148;. ASC&nbsp;718
requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and
<FONT STYLE="white-space:nowrap">non-employee</FONT> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> and accounts for <FONT STYLE="white-space:nowrap">non-employee</FONT>
share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. There was no cumulative effect of adoption on July&nbsp;1, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting
Standards recently adopted </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ASU <FONT STYLE="white-space:nowrap">2016-02</FONT></B>&#151;In February 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02:</FONT> &#147;<I>Leases</I> (Topic 842)&#148; whereby lessees will need to recognize most leases on their balance sheet as a right of use asset and a lease liability. This guidance is effective for interim
and annual reporting periods beginning after December&nbsp;15, 2018. The Company adopted this ASU effective July&nbsp;1, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of whether an arrangement is or contains a lease is based on the substance
of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has undertaken a detailed review and has concluded that it will have a material impact on its financial position on the
transactions and balances recognized in the consolidated financial statements when it is first adopted for the year ending June&nbsp;30, 2020 due to the material size of lease entered into by the Company.&nbsp;The Company&#146;s only lease is the
lease on its research and development facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ASU <FONT STYLE="white-space:nowrap">2018-07</FONT></B>&#151;In June 2018, the
Financial Accounting Standards Board (the &#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2018-07</FONT> &#147;<I>Compensation&#151;Stock Compensation</I> (Topic 718)&#148;. This update is
intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> (for example, service providers, external legal counsel, suppliers, etc.). The ASU
expands the scope of Topic 718, Compensation&#151;Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> for
goods and services. Consequently, the accounting for share-based payments to <FONT STYLE="white-space:nowrap">non-employees</FONT> and employees will be substantially aligned. The Company adopted this ASU, effective July&nbsp;1, 2019.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Accounting Standards and Interpretations not yet mandatory or early adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ASU <FONT STYLE="white-space:nowrap">2016-13</FONT></B>&#151;In June 2016, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2016-13:</FONT> &#147;<I>Financial Instruments&#151;Credit Losses</I> (Topic 326)&#148;. This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition
of management&#146;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold
of being probable. This guidance is effective for interim and annual reporting periods beginning after December&nbsp;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&#147;SRC&#148;) as of
November&nbsp;15, 2019. As such, ASU <FONT STYLE="white-space:nowrap">2019-10:</FONT> &#147;<I>Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&#148; </I>amended the effective date for the Company to be for
reporting periods beginning after December&nbsp;15, 2022. The Company will adopt this ASU effective July&nbsp;1, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_10"></A>Item&nbsp;7A. Quantitative and Qualitative Disclosures about Market Risk.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company and not required to provide this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc899221_11"></A>Item&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Supplementary Data. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC.</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin899221_1">Report of Independent Registered Public Accounting Firm &#150; Squar Milner
 LLP</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin899221_2">Report of Independent Registered Public Accounting Firm &#150; Grant Thornton
 Audit Pty Ltd</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin899221_3">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin899221_4">Consolidated Statements of Operations and Comprehensive Income
(Loss)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin899221_5">Consolidated Statements of Stockholders&#146; Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin899221_6">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin899221_7">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin899221_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Benitec Biopharma Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheet of Benitec Biopharma Inc. and its subsidiaries (the &#147;Company&#148;) as of June&nbsp;30, 2020, the related consolidated statements of operations and other comprehensive income (loss), stockholders&#146;
equity and cash flows for the year then ended, and the related notes to the consolidated financial statements (collectively, the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of June&nbsp;30, 2020, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the&nbsp;Public Company Accounting Oversight
Board (United States) (&#147;PCAOB&#148;)&nbsp;and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ SQUAR MILNER LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s
auditor since 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Campbell, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 23,
2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin899221_2"></A>Report of independent registered public accounting firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors and Shareholders </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Benitec Biopharma
Limited </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the financial statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying consolidated balance sheets of Benitec Biopharma Limited and subsidiaries (the &#147;Company&#148;) as of June 30, 2019, the related consolidated statement of comprehensive income, changes in shareholders&#146; equity,
and cash flow for the year ended June 30, 2019, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of
the Company as of June 30, 2019, and the results of its operations and its cash flow for the year ended June 30, 2019, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for opinion</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON AUDIT PTY LTD </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor from 2010 to 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 14, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin899221_3"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except par value and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value&#151;10,000,000 shares authorized; 1,108,374 and 856,765 shares
issued and outstanding at June&nbsp;30, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin899221_4"></A>Consolidated Statements of Operations and Comprehensive Income (Loss) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government research and development grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties and license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency transaction loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,021,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin899221_5"></A>Consolidated Statements of Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(112,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock sold for cash, net of offering costs of $240</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance and exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, net of
transaction costs of $240</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cashless exercise of purchase warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures of share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(116,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin899221_6"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee benefit payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issues of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement of operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin899221_7"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. is a
corporation formed under the laws of Delaware, United States, on November&nbsp;22, 2019. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#147;BBL&#148;). BBL
was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, since 1997. Since then, the Company has focused on the development of novel genetic medicines. The proprietary platform, called <FONT
STYLE="white-space:nowrap">DNA-directed</FONT> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;27, 2019, BBL announced its intention to <FONT STYLE="white-space:nowrap">re-domicile</FONT> from Australia to the United
States of America (the <FONT STYLE="white-space:nowrap">&#147;Re-domiciliation&#148;).</FONT> BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of affecting the <FONT
STYLE="white-space:nowrap">Re-domiciliation,</FONT> acquired all of the outstanding BBL shares. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares in the <FONT STYLE="white-space:nowrap">Re-domiciliation.</FONT> In
accordance with the U.S. Securities and Exchange Commission&#146;s (&#147;SEC&#148;) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company&#146;s common stock have been retroactively adjusted in these consolidated
financial statements to reflect the 300:1 exchange ratio share consolidation in the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> as if it occurred on July&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BBL announced that the transaction to redomicile from Australia to the United States was fully implemented on April&nbsp;15, 2020. The <FONT
STYLE="white-space:nowrap">Re-domiciliation</FONT> was approved by BBL shareholders at a Scheme Meeting held on March&nbsp;26, 2020 and confirmed by the Supreme Court of Queensland on March&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term the &#147;Company&#148; refers to (i), prior to the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> to BBL, an Australian
corporation, and its subsidiaries, and (ii), following the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL).&#147; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Benitec Biopharma Inc. common stock issued in connection with the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> trade
on The Nasdaq Capital Market LLC (&#147;Nasdaq&#148;) under the symbol &#147;BNTC&#148;, and Benitec Biopharma Inc. continues to be subject to the reporting requirements of the SEC and applicable corporate governance rules of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> BBL became a wholly owned subsidiary of Benitec Biopharma Inc.
and delisted from the ASX on April&nbsp;15, 2020. On August&nbsp;14, 2020 BBL had a change of company status and became a Proprietary Limited company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s fiscal year end is June 30. References to a particular &#147;fiscal year&#148; are to our fiscal year ended June&nbsp;30 of
that calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company are presented in United States dollars and consist of Benitec
Biopharma Inc. and the entities it controls: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal place of<BR>business/country of<BR>incorporation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Proprietary Limited (&#147;BBL&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Australia Proprietary Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;Kingdom</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">USA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">USA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RNAi Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">USA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tacere Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">USA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Proprietary Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of Presentation and Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became
the historical financial statements of the combined company upon consummation of the <FONT STYLE="white-space:nowrap">Re-domiciliation.</FONT> As a result, the financial statements included in this report reflect (i)&nbsp;the historical operating
results of BBL and subsidiaries prior to the <FONT STYLE="white-space:nowrap">Re-domiciliation;</FONT> (ii)&nbsp;the combined results of the Company, BBL, and subsidiaries following the completion of the
<FONT STYLE="white-space:nowrap">Re-domiciliation;</FONT> and (iii)&nbsp;the Company&#146;s equity structure for all periods presented<B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated financial statements included in this report have been prepared in accordance with accounting principles
generally accepted in the United States of America (&#147;US GAAP&#148;) and pursuant to the rules and regulations of the SEC. In the opinion of the Company&#146;s management, all adjustments (consisting of normal recurring adjustments and
reclassifications and <FONT STYLE="white-space:nowrap">non-recurring</FONT> adjustments) necessary to present fairly our financial position, results of operations, and cash flows for the fiscal years ended June&nbsp;30, 2020 and 2019 have been made.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#147;FASB&#148;) Accounting Standards Codification
(&#147;ASC&#148;). This is the source of authoritative US&nbsp;GAAP recognized by the FASB to be applied to <FONT STYLE="white-space:nowrap">non-governmental</FONT> entities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements include the Company&#146;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.
The Company views its operations and manages its business in one operating segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with US&nbsp;GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation
due to certain average exchange rates applied in lieu of spot rates on transaction dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Translation and Other Comprehensive
Income (Loss) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BBL&#146;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian
dollar has been translated into United States dollar &#147;$&#148; and/or &#147;USD&#148; as the reporting currency. Assets and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.
Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#146; equity as
&#147;Accumulated other comprehensive income (loss).&#148; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, and 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing
the consolidated financial statements were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange rate on balance sheet dates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USD: AUD Exchange Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average exchange rate for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USD: AUD Exchange Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange rate used to translate amounts in AUD into USD for the year ended June&nbsp;30, 2018 is 0.7385 as of the balance
sheet date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with US&nbsp;GAAP using ASC 820, <I>Fair Value Measurements.</I> For
certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair
value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation
techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad
levels. The following is a brief description of those three levels: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted
prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unobservable inputs in which little or no market data exists, therefore developed using estimates and
assumptions developed by us, which reflect those that a market participant would use. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#146;s cash and cash equivalents, trade and other
receivables, and trade and other payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of June&nbsp;30, 2020, and 2019, the Company had no financial assets or
liabilities measured at fair value on a recurring basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with
financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial
instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has
not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade and Other Receivables </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis
of individual customer and historical <FONT STYLE="white-space:nowrap">write-off</FONT> experience. The Company&#146;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property
and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or
otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="61%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Software</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-4</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab&nbsp;equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-7</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Furniture&nbsp;and&nbsp;fixtures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-7</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Computer&nbsp;hardware</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-5</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leasehold&nbsp;improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shorter of the lease term or estimated useful lives</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying
amount of an asset exceeds its estimated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined
using the asset&#146;s expected future discounted cash flows or market value, if readily determinable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade and other payables </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to
their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australian Goods and Services Tax (&#147;GST&#148;) and other similar taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues, expenses, and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown
inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash
flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At lease commencement, the
Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily
determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The
Company records a corresponding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to
the lessor prior to the lease commencement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&nbsp;the lease
liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> lease asset
based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives
received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basic and Diluted Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding
during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are
considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net
income (loss) per share when their effect is anti-dilutive. As of June&nbsp;30, 2020, and 2019, there were 145,421 and 38,326 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share
because their effect was anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted ASC 606 &#150; <I>Revenue from Contracts with Customers </I>(&#147;ASC 606&#148;) on July&nbsp;1, 2018. The adoption of ASC
606 did not have a material impact on the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon adoption of ASC 606, the Company recognizes revenue in
accordance with that core principle by applying the following steps: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management
considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the
contract was within the scope of ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated
<FONT STYLE="white-space:nowrap">know-how</FONT> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from
each other. Judgements were made in relation to the transfer of the license and <FONT STYLE="white-space:nowrap">know-how</FONT> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to
the point at which the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining
benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Licensing revenues </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#146;s intellectual property reflects the transfer of a right to use the intellectual property as it
exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a
significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these
amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated
balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Royalties
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#146;s intellectual property reflect a right to use the intellectual property as it exists at
the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#146;s subsequent sales of product occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Services revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services
revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance
obligation over time where the Company retains the right to payment for services performed but not yet completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Research and
Development Grants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government grants are recognized at fair value where there is reasonable assurance that the grant will be
received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant income is generated through the Australian federal government&#146;s Research and Development Tax Incentive program, under which the
government provides a cash refund for the 43.5% (2019: 43.5%) of eligible research and development expenditures. This grant is available for our research and development activities in Australia, as well as activities in the United States to the
extent such U.S.-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will not be claiming the Australian Government research and development grants going forward due to the <FONT
STYLE="white-space:nowrap">Re-domiciliation</FONT> of the Company to the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and
development expenses relate primarily to the cost of conducting clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials. Clinical development costs are a significant component of research and development expenses. Estimates have
been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the
number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical
trial partners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, <I>Stock Compensation</I>. ASC&nbsp;718 requires the fair value of all
share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> share-based
compensation at fair value using the Black-Scholes Option Pricing Model.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted FASB Accounting Standard Update
(&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2018-07</FONT> and accounts for <FONT STYLE="white-space:nowrap">non-employee</FONT> share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair
value of such awards over the service period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United
States Internal Revenue Service, respectively. The Company follows </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ASC 740 <I>Accounting for Income Taxes</I>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred
income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and
rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#147;more likely than not&#148; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#146;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive
loss is defined as a change in equity during a period from transactions and other events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The Company records unrealized foreign currency translation loss which
qualifies as other comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Standards recently adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02:</FONT> <I>Leases </I>(Topic 842) whereby lessees will
need to recognize most leases on their balance sheet as a right of use asset and a lease liability. This guidance is effective for interim and annual reporting periods beginning after December&nbsp;15, 2018. The Company adopted this ASU effective
July&nbsp;1, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and
requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s only lease is the lease on its research and development facilities.&nbsp;The Company&#146;s existing lease
commitments&nbsp;are set out in Note 10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT>
<I>Compensation &#150; Stock Compensation</I> (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> (for
example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation &#150; Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based
payments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> for goods and services. Consequently, the accounting for share-based payments to <FONT STYLE="white-space:nowrap">non-employees</FONT> and employees will be substantially
aligned. This standard is effective for financial statements issued by public companies for the annual and interim periods beginning after December&nbsp;15, 2018. The Company adopted this ASU on July&nbsp;1, 2019. There was no effect on the
financial statements on adoption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Accounting Standards and Interpretations not yet mandatory or early adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13:</FONT> <I>Financial Instruments &#150; Credit Losses</I>
(Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#146;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized
only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
periods beginning after December&nbsp;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&#147;SRC&#148;) as of November&nbsp;15, 2019. As such, ASU
<FONT STYLE="white-space:nowrap">2019-10:</FONT> <I>Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</I> amended the effective date for the Company to be for reporting periods beginning after
December&nbsp;15, 2022. The Company will adopt this ASU effective July&nbsp;1, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in conformity with US&nbsp;GAAP, which contemplate continuation of the
Company as a going concern. For the fiscal years ended June&nbsp;30, 2020, and 2019, the Company had a net (loss) income of $(8.3) million and&nbsp;$2.6&nbsp;million, respectively, and net cash (used in) provided by operations of $(7.5) million and
$4.8&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, the Company had $9.8&nbsp;million in cash and cash equivalents. The Company
has incurred operating losses and negative cash flows from operations since inception, except for the year ended June&nbsp;30, 2019. Management believes the Company&#146;s existing cash together with the net proceeds of a public offering of common
stock will be sufficient to fund the Company&#146;s operations at least for the next twelve months. In connection with the Company&#146;s public offering, on August&nbsp;14, 2020, the Company filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management having performed a review of the cash flow forecasts, considering the cash
flow needs of the Company, believe that current funding and the proceeds of the upcoming capital raise will be sufficient for a period of at least twelve months from the date of this report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although management believes that the additional required funding will be obtained, there is no guarantee the Company will be able to obtain
the additional required funds on a timely basis or that funds will be available on acceptable terms. If such funds are not available when required, management will be required to curtail its expenditures, which may have a material adverse effect on
its future cash flows and results of operations, and its ability to continue operating as a going concern. The accompanying financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a
going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Revenue </B>(US$&#146;000) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Revenues from customers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On July&nbsp;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. Pursuant to
the Agreement, the Company granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&#146;s product known as <FONT STYLE="white-space:nowrap">BB-301,</FONT> which was designed for the
potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of payments for the Company&#146;s intellectual property related to <FONT STYLE="white-space:nowrap">BB-301</FONT> and the transfer of the right to use the
intellectual property of the Company&#146;s <FONT STYLE="white-space:nowrap">BB-301</FONT> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On
June&nbsp;6, 2019, the termination of the License and Collaboration Agreement with Axovant was announced. The termination of the Agreement was </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
effective as of September&nbsp;3, 2019. The termination discharges all future performance obligations under the contract at the termination date. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Other revenues (US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government research and development grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Disaggregated revenue&nbsp;(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Licensing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalties</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Development<BR>activities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred at a point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">$4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">$97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Disaggregated revenue&nbsp;(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal year ended June&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Licensing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalties</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Development<BR>activities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred at a point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Cash and Cash equivalents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at Bank</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term Deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Trade and other receivables </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research&nbsp;&amp; development grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company had a contract asset of $0 and approximately $1.7M as of June&nbsp;30, 2020, and 2019,
respectively, related to the contract with Axovant which is included in other receivables on the consolidated balance sheet. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Other assets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market value of listed shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Property and equipment, net </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $190,000 and $158,000 for the fiscal years ended June&nbsp;30, 2020 and 2019,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Trade and other payables </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2019, the Company adopted ASC 842,<I>&nbsp;Leases</I>&nbsp;(&#147;ASC 842&#148;). ASC 842 requires lessees to recognize at the
lease commencement date a lease liability, which is the lessee&#146;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset, which is an asset that represents the lessee&#146;s right to use, or control the use of, a specified asset for the lease term. Lessees and lessors
must either (i)&nbsp;apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or (ii)&nbsp;recognize a
cumulative-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect adjustment to the opening balance of retained earnings in the period of adoption. The Company elected to use the cumulative-effect transition method upon adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 842 also allows lessees and lessors to elect certain practical expedients. The Company elected the following practical expedients: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transitional practical expedients: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company need not reassess whether any expired or existing contracts are or contain leases.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company need not reassess the lease classification for any expired or existing leases (that is, all existing
leases that were classified as operating leases in accordance with the previous guidance will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with the previous guidance will be
classified as finance leases). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company need not reassess initial direct costs for any existing leases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hindsight practical expedient: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company elected the hindsight practical expedient in determining the lease term (that is, when considering
lessee options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease
requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#146;s lease does not contain any residual value guarantees or material restrictive covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon adoption of ASC 842, the Company recognized on its consolidated balance sheet as of July&nbsp;1, 2019 an initial measurement of
approximately $579,000 of operating lease liabilities, and approximately $579,000 of corresponding operating <FONT STYLE="white-space:nowrap">right-of</FONT> use assets, net of tenant improvement allowances. There was also no cumulative effect
adjustment to retained earnings as a result of the transition to ASC 842. The Company recorded the initial recognition of the operating lease as a supplemental noncash financing activity on the accompanying consolidated statement of cash flows. The
adoption of ASC 842 did not have a material impact on the Company&#146;s consolidated statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tables below show the
changes during the year ended June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="40%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Operating&nbsp;lease&nbsp;right-of-use&nbsp;assets</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement at July&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of right of use asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="29%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating&nbsp;lease&nbsp;liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement at July&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments on operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: <FONT STYLE="white-space:nowrap">non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, the Company&#146;s operating lease has a remaining lease term of
1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal years ended June&nbsp;30, 2020 and 2019, total lease expense under operating leases was
approximately $208,000 and $221,000, respectively, and was recorded in general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Stockholders&#146; equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;30, 2019, BBL entered into a securities purchase agreement (&#147;SPA&#148;) with certain sophisticated and professional investors (&#147;Investors&#148;) in&nbsp;the United States&nbsp;to issue 186,666 shares of common stock at a
purchase price of&nbsp;US$10.50&nbsp;per share, in a registered direct offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2019, the Investors were issued 4 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants that are exercisable into
27,526 fully paid shares of common stock should the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants be exercised in full <FONT STYLE="white-space:nowrap">(&#147;Pre-Funded</FONT> Warrants&#148;). The exercise price for the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants is US$10.50 per share issued on exercise of a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were exercisable at any
time from issue, in whole or in part, provided that the beneficial ownership of the relevant investor in the total number of shares on issue could not exceed 9.99%. All of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been
exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2019, the Investors were issued 4 Purchase Warrants that were exercisable into 214,190 fully paid shares
of common stock should the Purchase Warrants be exercised in full (&#147;Purchase Warrants&#148;). The exercise price for the Purchase Warrants is US$10.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in
whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (December 6, 2024). On April&nbsp;22, 2020, the Company issued 37,417 shares of common stock in connection with a cashless exercise of Purchase
Warrants exercisable for 107,095 shares of common stock. The Company did not have an effective registration statement registering, the resale of the Warrant Shares by the Holder at the time the Holder wanted to exercise the warrant therefore the
Holder carried out a cashless exercise. The formula for conducting a cashless exercise was outlined in the Warrant agreement. Based on this formula, the Holder would have been entitled to receive 107,095 shares of common stock if they had exercised
the Purchase Warrants for cash. Because of the cashless exercise, the holder received 37,417 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity related to warrants during for the fiscal years ended&nbsp;June 30, 2020 and
2019,&nbsp;is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>from Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average&nbsp;Exercise<BR>Price (per share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at July&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cashless exercise</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Employee Share Option Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the <FONT
STYLE="white-space:nowrap">Re-domiciliation,</FONT> the Company assumed BBL&#146;s obligations with respect to the settlement of options that were issued by BBL prior to the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> pursuant to the
Benitec Officers&#146; and Employees&#146; Share Option Plan (the &#147;Plan&#148;). This includes the Company&#146;s assumptions of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised
entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited
circumstances . Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the organization, and certain other conditions have been satisfied, generally the
employee has 12 months to exercise their options or the options are cancelled. After the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> no new options have been or will be issued under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity related to equity awards, which comprised of stock options during the&nbsp;fiscal years&nbsp;ended June&nbsp;30, 2020 and 2019,
respectively,&nbsp;is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>Remaining&nbsp;Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at July&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.83&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.58 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.89 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.59 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity-based Compensation Expense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of each equity award on the grant date using the Black-Scholes option-pricing model with the following
assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">102.9-104.1</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">102.9-104.1</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.28-1.67</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.28-1.67</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility. </I>Due to the lack of Company-specific historical or implied volatility data, the
Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies in the life sciences industry. The Company selected the peer group based on comparable characteristics, including development
stage, product pipeline and enterprise value. The Company computed historical volatility data using the daily closing prices for the selected companies&#146; shares during the equivalent period of the calculated expected term of the equity-based
awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own share price becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Life. </I>The expected life represents the period that the equity awards are expected to be outstanding. For stock options with
service conditions, it is based on the &#147;simplified method&#148; for developing the estimate of the expected life. Under this approach, the expected life is presumed to be the midpoint between the average vesting date and the end of the
contractual term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free Interest Rate. </I>The Company bases the risk-free interest rate assumption on
U.S. Treasury constant maturities with maturities similar to those of the expected term of the equity award being valued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected
Dividend Yield. </I>The Company bases the expected dividend yield assumption on the fact that it has never paid<I> </I>dividends and does not expect to pay dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the
equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Share-Based Compensation Expense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The classification of share-based compensation expense for the fiscal years ended: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&nbsp;June 30, 2020, and 2019, there was $242,000 and $907,000, respectively, of unrecognized share-based
compensation expense related to shares of common stock issued under the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax effects of significant items comprising the Company&#146;s deferred taxes are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 13,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards
be recorded as an asset to the extent that management assesses that realization is &#147;more likely than not.&#148; Realization of the future tax benefits is dependent on the Company&#146;s ability to generate sufficient taxable income within the
carryforward period. Because of the Company&#146;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and,
accordingly, has provided a valuation allowance. As of June&nbsp;30, 2020, and 2019, the Company established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The valuation allowance increased by $2,215 during the year ended June&nbsp;30, 2020. Net
operating losses and tax credit carryforwards as of June&nbsp;30, 2020 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, federal (post-December 31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Do&nbsp;not&nbsp;expire</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, federal <FONT STYLE="white-space:nowrap">(pre-January</FONT> 1,
2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2034-2036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2031-2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Do not expire</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits, foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective rate of the Company&#146;s provision (benefit) for income taxes differs from the federal
statutory rate as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development incentive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.87</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.74</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42.3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24.12</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign tax rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the U.S., various state jurisdictions and Australia. The Company&#146;s
tax returns for the tax years 2014 through 2019 are open and are subject to examination by federal taxing authorities and the Company&#146;s tax returns for tax years 2011 through 2019 are subject to examination by state taxing authorities. The
Company is not currently undergoing a tax audit in any federal, state or Australian jurisdiction. The Company does not have any uncertain tax benefits &#147;(UTBs)&#148; as of June 30, 2020 and does not expect its UTBs to change significantly over
the next 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the fiscal year ended June 30, 2019, the Company was domiciled in Australia where the statutory rate was 27.5%. As
a result, the presentation of the tax disclosures, including effective tax rate, were based on Australian statutory rules. In the fiscal year ended June 30, 2019, the net operating losses presented in the effective tax rate could also be viewed as a
chance in valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&nbsp;382 places a limitation (&#147;Section&nbsp;382 Limitation&#148;) on
the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a change
in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section&nbsp;382 Limitation. Due to these &#147;change in ownership&#148; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual
limitation regarding their utilization against taxable income in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Australian income tax legislation, losses can be
utilized by the Company if it satisfies firstly the Continuity of Ownership Test (&#147;COT&#148;) or if failing that, the Similar Business Test (&#147;SBT&#148;). Broadly, the COT requires a company to show that it maintained continuity of majority
beneficial ownership from the beginning of the year in which a loss is incurred to the end of an income year in which a tax loss is sought to be recouped. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SBT requires a company to demonstrate that a &#147;similar business&#148; has been maintained from the time when the COT is failed and throughout the period until the end of the income year that
the losses are being recouped. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#147;CARES&#148;) Act was enacted
and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities, and makes
certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a five-year net operating loss carryback for certain net operating losses, suspension of the annual deduction limitation
of 80% of taxable income for certain net operating losses, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified
improvement property. The CARES Act also provides other non-tax benefits to assist those impacted by the pandemic. The Company evaluated the impact of the CARES Act and determined that there is no material impact to the income tax provision for the
fiscal year ended June 30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net
operating losses and limits the use of research tax credits for 2020, 2021 and 2022, respectively. The Company evaluated the impact of AB 85 and determined that the new legislation did not materially impact the Company&#146;s income tax provision
for the fiscal year ended June 30,2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Commitments and contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Contract commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for
termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;18, 2012, the Company announced the appointment of Synteract, Inc. as its Clinical Research Organization responsible for the progression of <FONT STYLE="white-space:nowrap">TT-034</FONT> into Phase I/IIa clinical trials in the U.S. The
Company has negotiated a contract for Synteract to continue to manage the Phase I/IIa clinical trial and the long-term patient follow up through 2016 and beyond. The Company announced on February&nbsp;20, 2016 that it was terminating the HCV
program, and at the end of the 2018 financial year had assumed all patients would remain in the study and the follow up would continue to 2021 at a maximum cost of $462,000. However, in July 2018, the Company applied to the FDA for, and the FDA
approved, the discontinuation of the study which will result in minimal costs being incurred in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no contingent
liabilities as of June&nbsp;30, 2020 and 2019, respectively. See Note 10 above for lease commitments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Contingencies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a
party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Related party transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following transactions occurred with related parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal services paid/payable to a law firm in which a director of the Company is a partner and has
a beneficial interest.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All transactions were made on normal commercial terms and conditions and at market rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2018, the Company accrued a milestone payment of $300,000 (AUD 425,411) payable to NantWorks, LLC pursuant to a sublicense
agreement.&nbsp;It was later determined that the milestone was not required to be paid and therefore the accrual was reversed in December 2019. NantWorks, LLC is an affiliate of Nant Capital which owns 26.44% of the issued and outstanding common
stock of the Company as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Earnings (Loss) per share </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Income (Loss) attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">8,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used in calculating basic and diluted earnings per
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,021,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted earnings (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">($</TD>
<TD VALIGN="bottom" ALIGN="right">8.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outstanding options to acquire ordinary shares are not considered dilutive for the fiscal years ended
June&nbsp;30, 2020 and June&nbsp;30, 2019, because they are anti-dilutive, as the strike price was higher than the share price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Subsequent events
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is closely monitoring the impact of the pandemic of the novel strain of coronavirus
<FONT STYLE="white-space:nowrap">COVID-19</FONT> <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> on all aspects of its business and geographies, including how it will impact its team members, suppliers, vendors and business partners.
While the Company did experience some disruption from <FONT STYLE="white-space:nowrap">COVID-19</FONT> through the delay of the initiation of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials through the date of issuance, of these
financial statements, it is unable to predict the impact that <FONT STYLE="white-space:nowrap">COVID-19</FONT> will have on its financial position and operating results due to numerous uncertainties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;14, 2020, the Company filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-246314)</FONT> with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_12"></A>Item&nbsp;9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item 9 was previously reported in the Company&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> that was filed with the SEC on June&nbsp;5, 2020, and amended on August&nbsp;19, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_13"></A>Item&nbsp;9A. Controls and Procedures.</B><B><I>&nbsp;</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our
disclosure controls and procedures pursuant to Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the Securities Exchange Act of 1934, as of June&nbsp;30, 2020.&nbsp;In designing and evaluating our disclosure controls and procedures, our
management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applied its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. Based on&nbsp;this evaluation, our principal executive officer and principal financial officer concluded that, as of June&nbsp;30, 2020, our disclosure controls and procedures were effective to
provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#146;s rules and forms,
and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive and principal financial officer, has evaluated any changes in our internal control over
financial reporting that occurred during the three months ended June&nbsp;30, 2020, and has concluded that there was no change that occurred during the three months ended June&nbsp;30, 2020 that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Report on Internal Control over Financial Reporting</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act. Our management, with the participation of our principal executive and principal financial officer, conducted an evaluation of the effectiveness of our internal control over
financial reporting based on the framework in<I> Internal Control &#150; Integrated Framework (2013)</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management has concluded that
our internal control over financial reporting was effective as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Effectiveness of Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is
required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging
growth company and a smaller reporting company, and therefore our independent registered public accounting firm has not and is not required to issue issued a report on the effectiveness of internal control over financial reporting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_14"></A>Item&nbsp;9B. Other Information.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_15"></A>Item&nbsp;10. Directors, Executive Officers and Corporate Governance. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information covering our current directors and executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerel Banks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Director, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi(1)(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis(1)(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Smith (1)(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Jerel Banks </I></B>has been a Director since October 2016, Chairman of our Board since October
2017 and Chief Executive Officer since June 2018. Dr.&nbsp;Banks was formerly the Chief Investment Officer of Nant Capital, LLC our deemed affiliate. Prior to joining Nant Capital, LLC, Dr.&nbsp;Banks served as vice president, portfolio manager and
research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset
Management from 2011 to 2012. From 2008 to 2011, Dr.&nbsp;Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth,
Texas. Dr.&nbsp;Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr.&nbsp;Banks earned an M.D. from the Brown
University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Banks&#146; experience in the healthcare industry and finance provides valuable experience and guidance to the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Megan Boston </I></B>has previously been Chief Executive Officer and Managing Director of several companies, including entities listed
on the Australian Stock Exchange. With over 13 years of experience, Ms.&nbsp;Boston has been a director across a range of industries where she chaired company boards as well as board <FONT STYLE="white-space:nowrap">sub-committees</FONT>
particularly in the area of finance and risk management. Specifically, Ms.&nbsp;Boston has been a Director of Benitec since August 2016 and Executive Director since June 2018. From 2014 until joining Benitec, Ms.&nbsp;Boston was CEO of listed
companies on the Australian Stock Exchange, Omni Market Tide Ltd and Rision Ltd. Previously, Ms.&nbsp;Boston held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for
PricewaterhouseCoopers. Ms.&nbsp;Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms.&nbsp;Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Ms.&nbsp;Boston&#146;s operational and financial infrastructure experience gives her the necessary skills and qualifications
to serve as a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>J. Kevin Buchi </I></B>has been a Director since April 2013. Mr. Buchi previously served as
Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical
Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to
December 2010, Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr.&nbsp;Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Dicerna Pharmaceuticals, Inc.
(Nasdaq: DRNA. Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on his broad executive experience in the biotechnology industry, we believe Mr.&nbsp;Buchi has the appropriate skills and qualifications
to serve on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Peter Francis </I></B>has been a director since February 2006 and was previously Chairman of the Board until
October 2017. Since 1993, Mr.&nbsp;Francis has been a partner at Francis Abourizk Lightowlers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and
licensing and provides legal advice to corporations and research bodies. Mr.&nbsp;Francis completed his studies in law and jurisprudence at Monash University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on his substantive intellectual property background and experience with our company, we believe Mr.&nbsp;Francis has the appropriate
skills and qualifications to serve on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Edward Smith</I></B> has been a director since April 2020.&nbsp;Edward brings more
than 20 years of experience in executive finance and operations leadership in the biotechnology industry to our Board. Mr.&nbsp;Smith currently serves as the Chief Financial Officer of Marinus Pharmaceuticals, Inc. (Nasdaq:&nbsp;MRNS), a
clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Prior to the start of his tenure at Marinus Pharmaceuticals in 2013, Mr.&nbsp;Smith
served as the CFO of PolyMedix, Inc., and before his time at PolyMedix, Inc. he served as the executive director of finance at InKine Pharmaceutical Company, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on his extensive finance and operations background in the biotechnology industry, we believe Mr.&nbsp;Smith has the appropriate skill
and qualifications to serve on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers and no
arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our directors or members of senior management was selected as such, except Dr.&nbsp;Banks was appointed by Nant Capital as a Director in
October 2016 following the acquisition by Nant Capital, LLC of 19.9% of Benitec&#146;s then-outstanding ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The business
addresses for each of our directors and executive officers is 3940 Trust Way, Hayward, California 9454. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Classified Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s business and affairs are managed under the direction of the Board. The Board currently consists of five directors,
comprising the Company&#146;s Chief Executive Officer, Executive Director and three outside directors. The Board has determined that five directors, three of whom are independent, is the appropriate size for the Company. The number of directors is
fixed from time to time by resolution of the Board pursuant to the Company&#146;s amended and restated certificate of incorporation (the &#147;Certificate&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Company&#146;s current directors will continue to serve as a director until the election and qualification of his or her
successor, or until his or her earlier death, resignation, or removal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Certificate provides that the Board is divided into three classes with
staggered three-year terms. Only one class of directors is elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective terms. The Board is designated as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mr.&nbsp;Smith is a Class&nbsp;I director, and his initial term will expire at the annual meeting of stockholders
to be held in 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Messrs. Buchi and Francis are Class&nbsp;II directors, and their initial terms will expire at the annual meeting
of stockholders to be held in 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mr.&nbsp;Banks and Ms.&nbsp;Boston are Class&nbsp;III directors, and their terms will expire at the annual
meeting of stockholders to be held in 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional directorships resulting from an increase in the number of
directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the Company&#146;s directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board currently
has, and appoints the members of, a standing Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Each of those committees has a written charter approved by the Board. The current charter for each standing
Board committee is posted under &#147;Governance&#148; in the Investor Relations section of the Company&#146;s website, www.benitec.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board determined that each of Messrs. Buchi, Francis and Smith is independent under the Nasdaq listing standards, and Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. Pursuant to Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)(iv)(A)(2)</FONT> under the Exchange Act, the Company&#146;s audit committee consists entirely of independent directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>Audit Committee</U></I>: Messrs. Buchi (Chairman), Francis and Smith. The purpose of the Audit Committee is to assist the board in
fulfilling its oversight responsibilities with respect to (i)&nbsp;the integrity of the Company&#146;s financial statements, (ii)&nbsp;the Company&#146;s compliance with legal and regulatory requirements, and (iii)&nbsp;the independent
auditors&#146; qualifications, independence and performance. The Audit Committee is also responsible for preparing a report to be included in the Company&#146;s annual proxy statement, advising and consulting the management and the Board regarding
the Company&#146;s financial affairs, and appointing, overseeing and approving compensation for the work of the Company&#146;s independent auditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined that Messrs. Buchi, Francis and Smith each meet the independence requirements of Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and the applicable Nasdaq rules. Our Board has determined that Mr.&nbsp;Smith is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the
requisite financial sophistication as defined under the applicable Nasdaq rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>Compensation Committee</U></I>: Messrs. Francis
(Chairman), Buchi and Smith. The Compensation Committee establishes and administers the Company&#146;s policies, programs and procedures for compensating and providing benefits to its executives and Board. The Committee&#146;s responsibilities
specifically include reviewing and approving the goals and objectives relevant to the chief executive officer&#146;s and other executive officers&#146; compensation, evaluating the performance of the chief executive officer and other executive
officers in light of those goals and objectives, and making recommendations to the Board with respect to <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation. The Committee is also responsible for making recommendations to the
Board with respect to incentive-compensation plans and equity-based plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><U>Nominating and Corporate Governance Committee</U></I>:
Messrs. Francis (Chairman), Buchi and Smith. The Nominating and Corporate Governance Committee manages all aspects of the governance of the Company&#146;s Board. The Committee&#146;s responsibilities include identifying individuals qualified to
become members of the Board, recommending candidates to fill Board vacancies and newly created director positions, recommending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether incumbent directors should be nominated for <FONT STYLE="white-space:nowrap">re-election</FONT> upon the expiration of their terms, recommending corporate governance guidelines applicable
to the Board and to the Company&#146;s employees, overseeing the evaluation of the Board and its committees, and assessing and recommending Board members to the Board for committee membership. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider</B><B><I> </I></B><B>Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No member of our compensation committee is or has been our current or former officer or employee. None of our executive officers served as a
director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our compensation committee during the fiscal year ended
June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics and Business Conduct </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a Code of Ethics and Business Conduct as of April&nbsp;14, 2020, which sets out the standards of behavior that apply to
every aspect of our dealings and relationships, both within and outside the company. The following standards of behavior apply to all directors, executive officers and employees of the company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with all laws that govern us and our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">act honestly and with integrity and fairness in all dealings with others and each other; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoid or manage conflicts of interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use our assets responsibly and in the best interests of the company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be responsible and accountable for our actions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Code of Ethics and Business Conduct is available on our website at www.benitec.com. Any amendments made to the Code of Ethics and Business
Conduct will also be available on our website, within four business days of any such amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_16"></A>Item&nbsp;11. Executive Compensation. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; we have opted to comply with the scaled executive
compensation disclosure rules applicable to &#147;smaller reporting companies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers, or our
&#147;NEOs&#148;, for the fiscal year ended June&nbsp;30, 2020 were Dr.&nbsp;Jerel&nbsp;A. Banks, our Executive Chairman and Chief Executive Officer, and Megan Boston, our Executive Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion of our compensation program prior to the completion of the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> reflects
the compensation program of Benitec Limited, and of the Company for periods following the completion of the <FONT STYLE="white-space:nowrap">Re-domiciliation.</FONT> This discussion may contain forward-looking statements that are based on our
current plans, considerations, expectations and determinations regarding future compensation programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation earned by our NEOs during the fiscal year ended June&nbsp;30, 2020 and the
fiscal year ended June&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer and <BR>Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Jerel&nbsp;A. Banks, M.D. Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,704</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">431,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Chairman and Chief Executive <BR>Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,296</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,775</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,975</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,737</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,463</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Boston&#146;s salary was paid in Australian dollars and has been converted to U.S. dollars using a
conversion rate of A$1.00 to $0.671, and A$1.00 to $0.715, for the fiscal years ended June&nbsp;30, 2020 and June&nbsp;30, 2019, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect cash bonuses awarded to the NEOs after review by the Remuneration Committee of the board of
directors of Benitec Limited (the &#147;Remuneration Committee&#148;), and individual performance for the prior fiscal year. The amount of cash bonuses earned in respect of the fiscal year ended June&nbsp;30, 2020 is not calculable through the
latest practicable date. The Compensation Committee expects to determine such bonuses in November 2020, and the amounts of these bonuses will be disclosed in a filing by the Company in a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> under Item 5.02(f) once the amounts are determined. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount represents the aggregate grant date fair value of stock and option awards granted by the Company in the
fiscal year ended June&nbsp;30, 2020, computed in accordance with FASB ASC Topic 718. For further information on how we account for stock-based compensation, see Note 11 to the Company&#146;s consolidated financial statements for the year ended
June&nbsp;30, 2020 included in this Annual Report. These amounts reflect the Company&#146;s accounting expense for these awards and do not correspond to the actual amounts, if any, that will be recognized by the NEOs. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Boston&#146;s performance-based cash bonus was paid in Australian dollars and has been converted to
U.S. dollars using a conversion rate of A$1.00 to $0.715. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect company-paid health and life insurance premiums. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the Company&#146;s compulsory contributions to Ms.&nbsp;Boston&#146;s superannuation account.
The superannuation contributions were paid in Australian dollars and were converted to U.S. dollars using a conversion rate of A$1.00 to $0.671, and A$1.00 to $0.715, for the fiscal years ended June&nbsp;30, 2020 and June&nbsp;30, 2019,
respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this table include compensation paid by Benitec Limited prior to the completion of the <FONT
STYLE="white-space:nowrap">Re-domiciliation.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use base
salaries to recognize the experience, skills, and responsibilities required of all of our employees, including our NEOs. Base salaries are reviewed annually by our Board. For the year ended June&nbsp;30, 2020, the annual base salaries for each of
Dr.&nbsp;Banks and Ms.&nbsp;Boston were $400,000 and A$330,000 ($221,430) (Ms.&nbsp;Boston&#146;s salary has been converted using a conversion rate of A$1.00 to $0.671), respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bonus Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
awarded our NEOs annual discretionary bonuses. Prior to the completion of the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> the Remuneration Committee determined the amount of any annual discretionary bonus payment following the
completion of the applicable fiscal year, based on Benitec Limited&#146;s overall performance and the achievement of key strategic objectives. For fiscal year 2019, performance bonuses were based on achieving certain clinical, development and
operational milestones. The actual annual cash bonuses awarded to our NEOs for fiscal year 2019 performance are set forth above in the &#147;Summary Compensation Table&#148; in the column titled &#147;Bonus.&#148; For the fiscal year ended
June&nbsp;30, 2020, the annual discretionary bonuses are not calculable through the latest practicable date. The Compensation Committee expects to determine such bonuses in November 2020, and the amounts of these bonuses will be disclosed in a
filing by the Company in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> under Item 5.02(f) once the amounts are determined. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity or Equity-Linked Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not have a formal policy with respect to the grant of equity incentive awards to our NEOs, we believe that equity grants provide
our NEOs with a strong link to our long-term performance, create an ownership culture and help to align the interests of our NEOs and our shareholders. In addition, we believe that equity grants with a time-based vesting feature promote executive
retention because this feature incentivizes our NEOs to remain in our employment during the vesting period. The equity awards held by our NEOs are described in more detail in the &#147;Outstanding Equity Awards at Fiscal <FONT
STYLE="white-space:nowrap">Year-End&#148;</FONT> table below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements with our NEOs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to employment agreements with each of our NEOs. These employment agreements provide for &#147;at will&#148; employment and may
be terminated at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreement with Dr.&nbsp;Jerel&nbsp;A. Banks, M.D. Ph.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, Tacere Therapeutics, Inc., a subsidiary of the Company, entered into an employment agreement with Dr.&nbsp;Banks setting
forth the terms of his employment as Executive Chairman and Chief Executive Officer of Benitec Limited. In connection with the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> Dr.&nbsp;Banks was appointed Executive Chairman and Chief
Executive Officer of the Company. The agreement provides for Dr.&nbsp;Banks&#146; employment and sets forth his (i)&nbsp;annual base salary, (ii)&nbsp;discretionary annual bonus, (iii)&nbsp;eligibility to participate in employee benefit plans,
(iv)&nbsp;eligibility for accrued paid vacation, (v)&nbsp;expense reimbursements in accordance with Company policy, (vi)&nbsp;eligibility to participate in the Company&#146;s Share Option Plan (as defined below), (vii) post-employment obligations to
refrain from soliciting our employees for one year following the end of employment, and (viii)&nbsp;certain <FONT STYLE="white-space:nowrap">non-disparagement</FONT> obligations. Dr.&nbsp;Banks&#146; employment agreement also provides for
confidentiality of information and ownership of proprietary property restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreement,
Dr.&nbsp;Banks&#146; employment is &#147;at will&#148; and can be terminated at any time. However, the Company must provide Dr.&nbsp;Banks with at least six months&#146; prior notice (or pay in lieu of notice) prior to any termination.
Dr.&nbsp;Banks may terminate his employment on no fewer than six months&#146; prior written notice to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any provisions in the employment agreement, the Company may terminate
Dr.&nbsp;Banks&#146; employment immediately without prior notice to Dr.&nbsp;Banks if he (a)&nbsp;commits any serious or persistent breach of any of the provisions of the employment agreement, (b)&nbsp;commits any act of willful or serious
misconduct or negligence in the discharge of his duties, (c)&nbsp;becomes of unsound mind or under the control of any committee or officer under any law relating to mental health, (d)&nbsp;is convicted of a felony, which in our reasonable opinion
affects Dr.&nbsp;Banks&#146; position, or (e)&nbsp;becomes permanently incapacitated by accident or illness from performing duties under the employment agreement for a period aggregating more than three months in any
<FONT STYLE="white-space:nowrap">six-month</FONT> period, or for any period beyond three consecutive months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreement with Megan Boston
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2018, Benitec Limited entered into an employment agreement with Megan Boston for the position of Executive Director. In
connection with entering into the employment agreement, Ms.&nbsp;Boston ceased serving as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director of the Company. Ms.&nbsp;Boston remains on the Board as an executive director. The employment
agreement provides for Ms.&nbsp;Boston&#146;s employment and sets forth her (i)&nbsp;annual base salary, (ii)&nbsp;discretionary annual bonus, (iii)&nbsp;superannuation contribution, (iv)&nbsp;eligibility for accrued paid vacation, (v)&nbsp;expense
reimbursements in accordance with Company policy, and (vi)&nbsp;post-employment obligations to refrain from soliciting our employees for one year following the end of employment. Ms.&nbsp;Boston&#146;s employment agreement also provides for
confidentiality of information and ownership of proprietary property restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreement,
Ms.&nbsp;Boston&#146;s employment is &#147;at will&#148; and can be terminated at any time However, the Company must provide Ms.&nbsp;Boston with at least six months&#146; prior notice (or pay in lieu of notice) prior to any termination.
Ms.&nbsp;Boston may terminate her employment on no fewer than six months&#146; prior written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any provisions in
the employment agreement, the Company may terminate Ms.&nbsp;Boston&#146;s employment immediately without prior notice to Ms.&nbsp;Boston if she (a)&nbsp;commits any serious or persistent breach of any of the provisions of the employment agreement,
(b)&nbsp;commits any act of willful or serious misconduct or negligence in the discharge of her duties, (c)&nbsp;becomes bankrupt or makes any arrangement or composition with her creditors, (d)&nbsp;becomes of unsound mind or under the control of
any committee or officer under any law relating to mental health, (e)&nbsp;is convicted of any criminal offense other than an offense which in our reasonable opinion does not affect Ms.&nbsp;Boston&#146;s position, or (f)&nbsp;becomes permanently
incapacitated by accident or illness from performing her duties under the employment agreement for a period aggregating more than three months in any <FONT STYLE="white-space:nowrap">six-month</FONT> period, or any period beyond three consecutive
months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding outstanding equity or equity-linked awards for each of our NEOs as of June&nbsp;30, 2020.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>Option&nbsp;Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)&#151;Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)&#151;Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Jerel&nbsp;A. Banks, M.D. Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/26/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/26/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Chairman and Chief Executive Office</I>r</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/12/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/12/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the awards in this table were granted under the Share Option Plan, the terms of which are described
below under &#147;&#151;Equity Incentive Compensation Plans&#151;Share Option Plan.&#148; The share amounts and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
exercise prices of the awards shown in this table have been adjusted to reflect the terms of the <FONT STYLE="white-space:nowrap">Re-domiciliation.</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to each of the option awards vest in substantially equal installments on each of the first,
second and third anniversaries of the grant date, generally subject to continued employment through the applicable vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Elements of Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Benefits and
Perquisites </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer participation in broad-based retirement, health and welfare plans to all of our colleagues, including our
NEOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> defined contribution retirement plan that provides eligible
U.S. employees (including Dr.&nbsp;Banks) with an opportunity to save for retirement on a <FONT STYLE="white-space:nowrap">tax-advantaged</FONT> basis. Plan participants are eligible to defer eligible compensation subject to applicable annual
Internal Revenue Code limits. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Internal Revenue Code with the 401(k) plan&#146;s related trust intended to be tax exempt under Section&nbsp;501(a) of the Internal Revenue
Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We contribute to the Australian superannuation scheme that provides eligible Australian employees (including Ms.&nbsp;Boston) with an
opportunity to save for retirement on a <FONT STYLE="white-space:nowrap">tax-advantaged</FONT> basis. We pay superannuation in accordance with legislative requirements and our minimum contribution is set by legislation. We offer flexibility for
salary sacrifice to be added to the superannuation scheme and any actual increase in our contribution to the superannuation scheme is subject to legislative rules at the time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination or Change in Control Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreements with our NEOs provide for specified notice periods (or pay in lieu of notice) if the Company terminates the
employment of our NEOs under certain circumstances, as described above in the &#147;Employment Agreements with our NEOs&#148; section. Our NEOs are not eligible to receive any additional payments or benefits in connection with their termination of
employment or in connection with the Company&#146;s change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Compensation Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Benitec Officers&#146; and Employees&#146; Share Option Plan (&#147;Share Option Plan&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Implementation Date, <FONT STYLE="white-space:nowrap">the&nbsp;Re-domiciliation&nbsp;of</FONT> Benitec Limited was completed, resulting
in the Company becoming the ultimate parent company of the Benitec group of companies (the &#147;Scheme&#148;). Pursuant to the Scheme, the Company assumed Benitec Limited&#146;s obligations with respect to the settlement of options (the
&#147;Options&#148;) that were issued by Benitec Limited prior to the Implementation Date pursuant to the Share Option Plan.&nbsp;This includes the Company&#146;s assumption of the Share Option Plan and all award agreements pursuant to which each of
the Options were granted. Accordingly, any exercise of the Options (subject to vesting conditions being met) entitles the holder to one share of the Company&#146;s Common Stock for every 300 ordinary shares of Benitec Limited the holder of the
Option would have been entitled to receive upon exercise of such Option. The exercise price of the Options was also adjusted in connection with the Scheme.&nbsp;Other than as described above, the terms of the Share Option Plan and the Options
remained unchanged following the Implementation Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Implementation Date, no new options or other equity awards will be
issued under the Share Option Plan. The Company intends to present a new equity incentive plan for approval by the Company&#146;s stockholders at the Company&#146;s next annual meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the material terms of the Share Option Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our Board, or duly authorized persons, administers the Share Option Plan. Under the Share Option Plan, the Board has
power to determine appropriate procedures for administration consistent with the Share Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. The Share Option
Plan provides for an employee (including any director, a part-time employee or consultant) of the Company and its subsidiaries to be deemed an eligible employee by the Board (&#147;Eligible Employee&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Application for Options</I>. The Board may from time to time, in its absolute discretion, issue written invitations to Eligible Employees
to apply for up to a specified number of Options. The invitation will include: (i)&nbsp;the method of calculation of the exercise price, (ii)&nbsp;the period or periods during which all or any of the Options may be exercised, (iii)&nbsp;the number
of shares over which the Option may be granted, (iv)&nbsp;the dates and times when the Options expire, (v)&nbsp;any Exercise Conditions (as defined in the Share Option Plan) that apply to the Options, and (vi)&nbsp;the date and time by which the
application for Options must be received by the Company. Upon receipt of the invitation the Eligible Employee must send the person identified by the Company to receive the application, the Eligible Employee&#146;s completed application. The
application must be received from the Eligible Employee within a specified period listed in the invitation. The Eligible Employee may apply for the number of Options specified in the invitation or part thereof (but the application must be made in
multiples of 1,000 Options). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. The maximum number of shares that may be issued pursuant to awards under Share
Option Plan, subject to certain adjustments is 5% of the current number the Company&#146;s ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Grant</I>. Once the
Company has received and accepted the Eligible Employee&#146;s application for Options, the Company may: (i)&nbsp;grant the Options to the Eligible Employee or (ii)&nbsp;procure the grant of the Options by a third party. The grant will be based on
the terms set out in the Share Option Plan and upon such additional terms and conditions as the Board determines. Options will have a maximum exercise period of seven years. Notwithstanding the above, following the Implementation Date, no new
options or other equity awards will be issued under the Share Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. The invitation to receive Options is
not transferable and an Eligible Employee may only apply for the Options on his or her behalf and not on behalf of another person or entity unless that other person or entity is controlled by or otherwise associated with the Eligible Employee,
agrees to be bound by the Share Option Plan and the terms of issue of the Options as if it were an Eligible Employee, and is approved by the Board. The Option may be transferred or encumbered: (i)&nbsp;by force of law upon death to the
Participant&#146;s legal personal representative, (ii)&nbsp;upon bankruptcy to the Participant&#146;s trustee in bankruptcy, or (iii)&nbsp;with the prior written approval of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Termination of Employment</I>. If a Participant (as defined in the Share Option Plan), who was an employee of the Company or one of its
subsidiaries, dies prior to exercising the Option or the Participant terminates employment by reason of Retirement (as defined in the Share Option Plan), the Board may exercise discretion to allow the Options to be exercised by the Participant for a
period of up to six months following the Participant&#146;s termination due to death or retirement, even if certain Exercise Conditions had not been met. If a Participant, who was an employee of the Company or one of its subsidiaries, terminates
employment for any other reason, the Board may exercise discretion to allow the Options to be exercised by the Participant for a period of up to three months following the Participant&#146;s termination of employment, even if certain Exercise
Conditions had not been met. If a Participant, who was an employee of the Company or one of its subsidiaries, dies prior to exercising the Option, the Participant terminates employment by reason of Retirement or terminates employment for any other
reason, and the Exercise Conditions have been met, the Participant may exercise the Options for a period up to 12 months following termination, with such period to be determined by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any of the foregoing, if, in the opinion of the Board, a Participant acts
fraudulently or dishonestly or is in breach of his or her obligations to the Company or any of its subsidiaries, then the Board of Directors may deem any unexercised Options held by the Participant to have lapsed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transactions</I>. If a Takeover Bid (as defined in the Share Option Plan) is made or a Change in Control (as defined in the Share Option
Plan) occurs, the Board may (unless, in the opinion of the Board, an intention to make an equivalent offer to the Participants to acquire all or substantial portion of their Options is given) give written notice to each Participant of the Takeover
Bid or Change in Control. If a Takeover Bid is made or a Change in Control occurs after the Exercise Condition has been met, but before an Option has been exercised, the Option will be exercisable for a period of 30 days from the date of the notice.
If a Takeover Bid is made or a Change in Control occurs before an Exercise Condition has been met, the Board may determine that all or part of those Options will be exercisable for a period of 30 days from the date of the notice. The Board may also
exercise its discretion to permit the exercise of the Options upon certain other corporate transactions, including but not limited to the voluntary winding up of the Company, where an order is made for the compulsory winding up of the Company. If an
Acquiring Company (as defined in the Share Option Plan) obtains control of the Company as a result of a Takeover Bid, a Change in Control or a proposed scheme or arrangement between the Company and its shareholders, and both the Company and the
Acquiring Company agree, a Participant may upon the exercise of the Participant&#146;s Options, the Participant may elect to acquire shares in the Acquiring Company or its parent, on substantially the same terms and subject to substantially the same
conditions as the Participant may exercise Options to acquire shares, but with appropriate adjustments to the number and kind of shares subject to the Options, as well as to the exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company issues shares pro rata to the Company&#146;s shareholders by way of bonus issue, Participants will be entitled to exercise
Participant&#146;s Options, to receive in addition to the shares in respect of which the Options are exercised and without the payment of any further consideration, an allotment of as many additional shares as would have been issues to a shareholder
who, on the date for determining entitlements under the bonus issue, held shares equal in number to the shares in respect of which the Options are exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain other transactions, including if shares are offered pro rata for subscription by the Company&#146;s shareholders or
upon the reorganization of the Company, the number of Options to which each Participant is entitled to or the exercise price of the Options or both as appropriate will be adjusted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment. </I>Our Board may amend the Share Option Plan at any time. However, no amendment to the Share Option Plan or the Options
may be made which reduces the rights of Participants in respect of Options granted to them prior to the date of the amendment, other than in certain limited situations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the total compensation paid to the Company&#146;s directors for the year ended June&nbsp;30, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward F. Smith<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For information regarding the compensation of Dr.&nbsp;Banks and Ms.&nbsp;Boston, see &#147;Summary
Compensation Table.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fees paid to Mr.&nbsp;Buchi and Francis were paid in Australian dollars and has been converted to U.S. dollars
using a conversion rate of A$1.00 to $0.671 for the fiscal year ended June&nbsp;30, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the Company&#146;s compulsory contributions to Mr.&nbsp;Francis&#146;s superannuation account.
The superannuation contribution was paid in Australian dollars and has been converted to U.S. dollars using a conversion rate of A$1.00 to $0.671 for the fiscal year ended June&nbsp;30, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Smith was appointed to the Board on April&nbsp;14, 2020. Amounts reflect the total fees paid to
Mr.&nbsp;Smith for his service in fiscal year 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each director, the aggregate number of option awards
outstanding at fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> for the year ended June&nbsp;30, 2020 is set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Director Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors is paid an annual fee in respect of their service on the Board.
Mr.&nbsp;Buchi&#146;s annual fee is $51,432. Mr.&nbsp;Francis is paid a base fee of $46,970. In addition, the Company makes a superannuation contribution on Mr.&nbsp;Francis&#146; behalf in the amount of $4,462. Fees paid to Mr.&nbsp;Buchi and
Francis were paid in Australian dollars and have been converted to U.S. dollars using a conversion rate of A$1.00 to $0.671. In accordance with Mr.&nbsp;Smith&#146;s Director Appointment Letter, he will be entitled to earn an annual fee of $50,000
in respect of his service on the Board. Upon their appointment as executive officers and employees, Dr.&nbsp;Banks and Ms.&nbsp;Boston no longer receive annual fees with respect to their service on the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc899221_17"></A>Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding the beneficial ownership of the Company&#146;s common stock as of
September&nbsp;15, 2020 by (i)&nbsp;each person or group of persons known by us to beneficially own more than five percent of our common stock, (ii)&nbsp;each of our named executive officers, (iii)&nbsp;each of our directors and (iv)&nbsp;all of our
directors and executive officers as a group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table gives effect to the shares of common stock issuable within 60 days of
September&nbsp;15, 2020 upon the exercise of all options and other rights beneficially owned by the indicated stockholders on that date. Beneficial ownership is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3</FONT>
promulgated under Section&nbsp;13 of the Securities Exchange Act and includes voting and investment power with respect to shares. Percentage of beneficial ownership is based on 1,108,374 shares of common stock outstanding at the close of business on
September&nbsp;15, 2020. Except as otherwise noted below, each person or entity named in the following table has sole voting and investment power with respect to all shares of our common stock that he, she or it beneficially owns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated below, the address for each beneficial owner listed is c/o 3940 Trust Way, Hayward, California 94545. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nant Capital, LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">26.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerel A. Banks<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Executive Officers and Directors As a Group </B>(5 persons)<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent of the Company&#146;s outstanding common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on the information included in the Form 3 filed by Nant Capital, LLC on April&nbsp;27, 2020. Represents
195,372 shares held directly by Nant Capital, LLC and 97,686 shares of common stock held by Merrill Lynch (Australia) Nominees Pty Limited for the account of Nant Capital, LLC. The address of the principal business office of Nant Capital, LLC is
9922 Jefferson Blvd, Culver City, CA, 90232. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents stock options to acquire 22,222 that have vested or will vest within 60 days of September 15, 2020.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 333 shares held by Boston Super Invest Pty A/C Boston Family Super that Megan Boston has sole voting
power over and stock options to acquire 5,555 shares of common stock that have vested or will vest within 60 days of September 15, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 4,827 shares of common stock and stock options to acquire 2,800 shares of common stock that have
vested or will vest within 60 days of September 15, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 4,738 shares of common stock held by the Francis Family Superannuation Fund, 300 shares held directly
by Mr.&nbsp;Francis, and stock options to acquire 4,666 shares of common stock that have vested or will vest within 60 days of September 15, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 10,198 shares of common stock and stock options to acquire 35,243 shares of common stock that have
vested or will vest within 60 days of September 15, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the number of securities to be issued under our equity plans, the weighted-average exercise
price of options issued under our equity plans and the number of securities remaining available for future issuance under our equity plans, in each case as of June&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities&nbsp;to&nbsp;be<BR>issued upon<BR>exercise<BR>of outstanding<BR>options,<BR>warrants<BR>and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average<BR>exercise&nbsp;price&nbsp;of<BR>outstanding<BR>options,<BR>warrants and<BR>rights<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>remaining available<BR>for future issuance<BR>under equity<BR>compensation plans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc899221_18"></A>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Certain Relationships and Related Transactions, and Director Independence. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since July&nbsp;1, 2017 to which we have been a party in which the amount involved exceeded or
will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct
or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also describe below certain other
transactions with our directors, executive officers and stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nant Capital, LLC </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In October 2016, Benitec Limited entered into a strategic relationship with Nant Capital. As part of that
strategic relationship, Benitec Limited initially issued Nant Capital ordinary shares which became an aggregate of 195,372&nbsp;shares of common stock following the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> for a combined total
consideration of $6.1&nbsp;million. Jerel Banks, our Chairman and Chief Executive Officer, was initially appointed to the board of directors of Benitec Limited by Nant Capital. In connection with his separation from Nant Capital, Nant Capital agreed
to pay Dr.&nbsp;Banks an annual separation payment (starting with calendar year 2018), in cash not later than March 15th of each year, equal to a fixed percentage of the amount by which the net increase in the fair market value of the 293,058 shares
of Company common stock that Nant Capital owns (the &#147;Nant Shares&#148;) exceeds a 10% hurdle with respect to each calendar year. Dr.&nbsp;Banks does not own (beneficially or of record) any of the Nant Shares, nor does he have any right to vote,
sell or dispose of the Nant Shares (or cause them to be voted, sold or disposed of), but for purposes of calculating his separation payment he can require Nant Capital to treat some or all of them as having effectively been sold prior to the end of
a calendar year performance period. Dr.&nbsp;Banks has no obligation or responsibility to manage the Nant Shares. The arrangement is in effect and Dr.&nbsp;Banks has not accrued any payments thereunder. The Company is not a party to this
arrangement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2016, Benitec Limited entered into an exclusive sublicense agreement with NantWorks, LLC, an
affiliate of Nant Capital, pursuant to which we obtained a sublicense to intellectual property relating to our product candidates for the treatment of HNSCC, including <FONT STYLE="white-space:nowrap">BB-401.</FONT> We terminated the exclusive
sublicense agreement for convenience, with the termination effective as of June 2020, because the <FONT STYLE="white-space:nowrap">BB-401</FONT> program has been terminated. Prior to termination of the agreement, we were required to make periodic
payments to NantWorks, LLC for so long as the agreement remained in effect, as well as contingent milestone and royalty payments in connection with the development and sale of the licensed technology. In fiscal year 2017, we made license payments to
NantWorks, LLC of $30,000, and reimbursed patent expense of $35,014. In fiscal year 2018, we paid (i) $4,125, as reimbursement in patent application extension, (ii) $30,000 in annual maintenance fee and (iii) $30,000 in annual maintenance fee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In January 2017, Benitec Limited entered into a research collaboration agreement with Nant Capital pursuant to
which we agreed to advance the clinical development of <FONT STYLE="white-space:nowrap">BB-401,</FONT> a recombinant DNA construct that produces an antisense RNA with specificity against EGFR for the treatment of HNSCC. The research collaboration
agreement with Nant Capital allocates the $4.1&nbsp;million received from Nant Capital in the March 2017 private placement first to the development of <FONT STYLE="white-space:nowrap">BB-401</FONT> and <FONT STYLE="white-space:nowrap">BB-501.</FONT>
Nant Capital will have a controlling vote on the joint steering committee that directs and oversees such development of <FONT STYLE="white-space:nowrap">BB-401</FONT> and <FONT STYLE="white-space:nowrap">BB-501</FONT> until those funds have been
expended. The <FONT STYLE="white-space:nowrap">BB-401</FONT> and <FONT STYLE="white-space:nowrap">BB-501</FONT> programs have been terminated and, as a result, this collaboration is no longer active. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2018, the Company accrued a milestone payment of $300,000 (AUD 425,411). It was later determined that
the milestone was no longer required to be paid and therefore the accrual was reversed in December 2019. Further, the Company accrued a License fee payable in December 2018 of $40,000 (AUD 56,721) which was reversed in January 2019, when the Company
received the invoice from NantWorks LLC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Related Parties </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legal services at normal commercial rates totaling A$726, or $509, for fiscal 2019, A$8,212, or $6,079, for
fiscal 2018 and A$191,050, or $146,841 for fiscal 2017 were provided by Francis Abourizk Lightowlers, a law firm in which Mr.&nbsp;Peter Francis is a partner and has a beneficial interest. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annabel West, the wife of Greg West, our former Chief Executive Officer, was employed by us as a part-time
clerical and administrative assistant. Annabel West was paid wages of A$42,278, or $31,298, and A$36,248, or $27,860, respectively, for fiscal 2018 and fiscal 2017. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review and approval of related party transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our related parties include our directors, director nominees, executive officers, holders of more than five percent of the outstanding shares
of our common stock and the foregoing persons&#146; immediate family members. We review relationships and transactions in which the Company and our related parties are participants to determine whether such related persons have a direct or indirect
material interest. As required under SEC rules, transactions that are determined to be directly or indirectly material to a related party are disclosed in the appropriate SEC filing. In addition, the Audit Committee reviews and approves any related
party transaction that is required to be disclosed. Set forth below is information concerning transactions with our related parties that is required to be disclosed under SEC rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification and Severance agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors and executive officers which require us to indemnify such individuals to the
fullest extent permitted by Delaware law. Our indemnification obligations under such agreements are not limited in amount or duration. Certain costs incurred in connection with such indemnities may be recovered under certain circumstances under
various insurance policies. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed against a director or executive officer, we are unable to determine the maximum amount of
losses that we could incur relating to such indemnities. Historically, any amounts payable pursuant to such director and officer indemnities have not had a material negative effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered into severance and change in control agreements with certain of our executives. These agreements provide for the payment
of specific compensation benefits to such executives upon the termination of their employment with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc899221_19"></A>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Principal Accountant Fees and Services. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate fees billed to the Company for services during the fiscal years ended June&nbsp;30, 2020 and 2019
by our independent registered public accounting firm, Squar Milner LLP (&#147;Squar Milner&#148;): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Fee Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Related Fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit Fees consist of fees billed for professional services rendered for the audit of the Company&#146;s
consolidated annual financial statements included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and review of the interim consolidated financial statements included in the Company&#146;s Quarterly Reports
on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and services that are normally provided by independent registered public accounting firms in connection with statutory and regulatory filings or engagements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit-Related Fees consist of fees billed for assurance and related services rendered that are reasonably
related to the performance of the audit or review of the Company&#146;s consolidated financial statements and are not reported under &#147;Audit Fees.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax Fees were billed for professional services including assistance with tax compliance and the preparation of
tax returns, tax consultation services, assistance in connection with tax audits and tax advice related to mergers, acquisitions and dispositions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee, or a designated member thereof, <FONT STYLE="white-space:nowrap">pre-approves</FONT> 100% of all audit, audit-related, tax
and other services rendered by the independent registered public accounting firm to the Company or its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART IV </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc899221_20"></A>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to
the Index to the Consolidated Financial Statements included in Item 8 of this report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Required information is included in the notes to the consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1552795/000156459020011511/bntc-ex994_10.htm">Amended and Restated Scheme Implementation Agreement (incorporated by reference to Exhibit&nbsp;99.4 of the Current Report on Form <FONT
STYLE="white-space:nowrap">6-K</FONT> of Benitec Biopharma Limited (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-37518)</FONT> furnished on March&nbsp;18, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex31_43.htm">Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s
 Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on April&nbsp;15, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex32_42.htm">Amended and Restated Bylaws of Benitec Biopharma Inc. (incorporated by reference to Exhibit&nbsp;3.2 to the Registrant&#146;s Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed on April&nbsp;15, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex41_105.htm">Form of common stock certificate of Benitec Biopharma Inc. (incorporated by reference to Exhibit&nbsp;4.1 to the Registrant&#146;s Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed on April&nbsp;15, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1552795/000119312519258712/d812687dex994.htm">Form of Purchase Warrant (incorporated by reference to Exhibit 99.4 of the Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;
6-K</FONT> of Benitec Biopharma Limited (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-37518)</FONT> furnished on September&nbsp;30, 2019) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d899221dex43.htm">Description of Registrant&#146;s Securities </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1552795/000119312517190236/d406425dex101.htm">Share Subscription Agreement, dated October&nbsp;
24, 2016, between Nant Capital, LLC and Benitec Biopharma Limited (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> of Benitec Biopharma Limited (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-218400)</FONT> filed with the SEC on June&nbsp;1, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1552795/000119312515230004/d907977dex105.htm">Commercial Lease Agreement between Hayward Point Eden I Limited Partnership and Benitec Biopharma Limited (incorporated by reference to Exhibit
 10.5 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> of Benitec Biopharma Limited (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-205135)</FONT> filed with the SEC on June&nbsp;22, 2015) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1808898/000119312520220358/d11440dex103.htm">Employment agreement between Megan Boston and Benitec Biopharma Limited dated July&nbsp;
11, 2018 (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Benitec Biopharma Inc. (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-39267)</FONT> filed with the SEC on August&nbsp;14, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1808898/000119312520220358/d11440dex104.htm">Employment agreement between Dr.&nbsp;Jerel&nbsp;A. Banks and Tacere Therapeutics, Inc. dated September&nbsp;
11, 2018 (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Benitec Biopharma Inc. (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-39267)</FONT> filed with the SEC on August&nbsp;14, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1552795/000119312517190236/d406425dex103.htm">Research Collaboration Agreement, dated January&nbsp;
27, 2017, between Benitec Biopharma Limited and Nant Capital, LLC (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> filed with the SEC on June&nbsp;1, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1552795/000119312519258712/d812687dex992.htm">Form of Securities Purchase Agreement, dated September&nbsp;
30, 2019, between Benitec Biopharma Limited and the Purchasers (incorporated by reference to Exhibit 99.2 to Form <FONT STYLE="white-space:nowrap">6-K</FONT> of Benitec Biopharma Limited (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-37518)</FONT> filed with the SEC on September&nbsp;30, 2019) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex101_41.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#146;s Form <FONT STYLE="white-space:nowrap">8-K
</FONT> filed on April&nbsp;15, 2020) </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IV-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1552795/000119312516450930/d131177dex42.htm">Benitec Officers&#146; and Employees&#146; Share Option Plan (incorporated by reference to Exhibit 4.2 of the Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> of Benitec Biopharma Limited (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-209398)</FONT> filed on February&nbsp;3, 2016)) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1808898/000119312520220358/d11440dex109.htm">Form of Option Award Agreement under the Benitec Officers&#146; and Employees&#146; Share Option Plan (incorporated by reference to Exhibit 10.9
to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Benitec Biopharma Inc. (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-39267)</FONT> filed with the SEC on August&nbsp;14, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d899221dex211.htm">List of significant subsidiaries </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d899221dex311.htm">Certification of Principal Executive Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d899221dex312.htm">Certification of Principal Financial Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d899221dex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d899221dex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Instance Document**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document**</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates a management contract or compensatory plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed or furnished herewith </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Attached as Exhibit 101 to this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> are the
following materials, formatted in XBRL (eXtensible Business Reporting Language): (i)&nbsp;Consolidated Balance Sheets as of June&nbsp;30, 2020 and 2019; (ii)&nbsp;Consolidated Statements of Operations and Comprehensive Loss for the Years Ended
June&nbsp;30, 2020 and 2019; (iii)&nbsp;Consolidated Statements of Stockholders&#146; Equity for the Years Ended June&nbsp;30, 2020 and 2019; (iv)&nbsp;Consolidated Statements of Cash Flows for the Years Ended June&nbsp;30, 2020 and 2019; and
(vi)&nbsp;Notes to the Consolidated Financial Statements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IV-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements and Schedules of Subsidiaries and Affiliates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc899221_21"></A>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Form <FONT STYLE="white-space:nowrap">10-K</FONT> Summary. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IV-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc899221_22"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized, in the city of Hayward, State of California, on the 23rd day of September 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BENITEC BIOPHARMA INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dr.&nbsp;Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dr.&nbsp;Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BY THESE PRESENTS, each person whose signature appears below constitutes and appoints Dr.&nbsp;Jerel Banks and Megan Boston his true and
lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities to sign any
and all amendments to this annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby
ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dr.&nbsp;Jerel Banks</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dr.&nbsp;Jerel Banks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(principal executive officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;23,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Megan Boston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Director, Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(principal accounting and financial officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;23,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J. Kevin Buchi</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J. Kevin Buchi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;23,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Francis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Peter Francis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;23,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward Smith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Edward Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;23,&nbsp;2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IV-4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>d899221dex43.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of the Registrant&#146;s Securities Registered Pursuant to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Section&nbsp;12 of the Securities Exchange Act of 1934, as amended </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The summary of the general terms and provisions of the registered securities of Benitec Biopharma Inc. (&#147;Benitec,&#148; &#147;we,&#148; or
&#147;our&#148;) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (our &#147;certificate of incorporation&#148;) and our
Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> (our &#147;Bylaws&#148; and, together with our certificate of incorporation, our &#147;Charter Documents&#148;), which are filed as exhibits to this Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and are incorporated by reference herein. We encourage you to read our Charter Documents and the applicable provisions of the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;) for
additional information. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 10,000,000 shares of our common stock, par value $0.0001 per share. During the <FONT
STYLE="white-space:nowrap">Re-domiciliation,</FONT> all of the issued and outstanding ordinary shares of Benitec Limited were exchanged for newly issued shares of common stock of the Company, on the basis of one share of the Company&#146;s common
stock for every 300 ordinary shares issued and outstanding. As a result of the <FONT STYLE="white-space:nowrap">Re-domiciliation,</FONT> Benitec Limited is a wholly-owned subsidiary of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights.</I>
Subject to preferences that may be applicable to any then outstanding preferred stock, holders of the Company&#146;s common stock are entitled to receive dividends, if any, as may be declared from time to time by the Company&#146;s Board out of
legally available funds. Dividends may be paid in cash, in property or in shares of common stock, subject to the provisions of the Certificate and applicable law. Declaration and payment of any dividend will be subject to the discretion of the
Board. The time and amount of dividends will be dependent upon the Company&#146;s financial condition, operations, cash requirements and availability, debt repayment obligations, capital expenditure needs, restrictions in the Company&#146;s debt
instruments, industry trends, the provisions of Delaware law affecting the payment of distributions to stockholders and any other factors the Board may consider relevant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I><B><I> </I></B>Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of
the stockholders, including the<B><I> </I></B>election of directors. The Company&#146;s stockholders do not have cumulative voting rights in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights.</I> In the event of the Company&#146;s liquidation, dissolution or winding up, holders of the Company&#146;s common
stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company&#146;s debts and other liabilities and the satisfaction of any liquidation preference granted to the
holders of any then outstanding shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences.</I> Holders of the Company&#146;s common stock have
no <FONT STYLE="white-space:nowrap">pre-emptive,</FONT> conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to the Company&#146;s common stock. The rights, preferences and privileges of the
holders of the Company&#146;s common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that the Company may designate in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fully Paid and Nonassessable</I>. All outstanding shares of the Company&#146;s common stock are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Annual Stockholder Meetings.</I><B><I> </I></B>The Certificate and Bylaws provide
that annual stockholder meetings will be held at a date, place (if any) and time, as exclusively selected<B><I> </I></B>by the Board. To the extent permitted under applicable law, the Company may but is not obligated to conduct meetings by remote
communications,<B><I> </I></B>including by webcast. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of the Certificate and Bylaws and DGCL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of the DGCL, the Certificate and Bylaws could make the following transactions difficult: (i)&nbsp;acquisition of the Company by
means of a tender offer; (ii)&nbsp;acquisition of the Company by means of a proxy contest or otherwise; or (iii)&nbsp;removal of incumbent officers and directors of the Company. It is possible that these provisions could make it more difficult to
accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in the best interests of the Company, including transactions that might result in a premium over the market price for the Company&#146;s
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions
are also designed to encourage persons seeking to acquire control of the Company to first negotiate with the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware
Anti-Takeover Statute.</I><B><I> </I></B>The Company is subject to Section&nbsp;203 of the DGCL, which prohibits persons deemed &#147;interested stockholders&#148; from engaging in a<B> </B>&#147;business combination&#148; with a publicly-held
Delaware corporation for three years following the date these persons become interested stockholders<B> </B>unless the business combination is, or the transaction in which the<B> </B>person became an interested stockholder was, approved in a
prescribed manner<B> </B>or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or<B> </B>within three years prior to the determination of interested
stockholder status did own, 15% or more of a corporation&#146;s voting stock, and a &#147;business<B> </B>combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder.
The existence<B> </B>of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the Board, such as discouraging<B> </B>takeover attempts that might result in a premium over the market price of the
Company&#146;s common stock. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Special Stockholder Meetings. </I>The Bylaws provide that a special meeting of
stockholders may be called by (i)&nbsp;the Chairman of the Board, if any, (ii)&nbsp;the President or Chief Executive Officer, or (iii)&nbsp;the Board pursuant to a resolution adopted by a majority of the total number of directors then in office.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Requirements for Advance Notification of Stockholder Nominations and Proposals. </I>The Bylaws establish advance notice procedures
with respect to stockholder proposals and the nomination of candidates for election as directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of the Board of Directors; Election and
Removal of Directors; Filling Vacancies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Board consists of five directors and the Board may, from time to time, fix
the authorized number of directors by resolution of the Board. The Board is divided into three classes, designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Directors need not be stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors shall serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders
at which such director was elected. The term of each director shall continue until the election and qualification of his or her successor and be subject to his or her earlier death, disqualification, resignation or removal. Except as otherwise
provided by the DGCL, the Certificate or the Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by a duly authorized and executed proxy at the
meeting and entitled to vote on the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law or by the Certificate, any director of the entire
Board of the Company may be removed without cause by the affirmative vote of a majority of the holders of the Company&#146;s then-outstanding common stock entitled to vote generally at an election of directors. Furthermore, any vacancy on the
Company&#146;s Board, however occurring, including a vacancy resulting from an increase in the size of the board, may be filled only by a majority vote of the Board then in office, even if less than a quorum, or by the sole remaining director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment of the Certificate and Bylaws. </I>The Certificate may be amended in any manner permitted under the DGCL and the Bylaws may be
amended by the vote or written consent of holders of a majority of the outstanding shares entitled to vote. The Board may also amend the Bylaws, other than a bylaw or amendment thereof specifying or changing a fixed number of directors or the
maximum or minimum number or changing from a fixed to a variable board or vice versa. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Certificate and Bylaws provide that the Company is required to indemnify its directors and officers to the fullest extent not
prohibited by Delaware law. The Bylaws also obligates the Company to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding upon delivery to the Company of an undertaking, by or on behalf
of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision, from which there is no further right to appeal, that such indemnitee is not entitled to be indemnified for such expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by the DGCL, or any other applicable law, the Company, upon approval by the Board, may purchase insurance on
behalf of any person required or permitted to be indemnified pursuant to the Bylaws. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forum for Adjudication of Disputes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate provides that, unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive forum
for (i)&nbsp;derivative actions or proceedings brought on behalf of the Company, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or employee of the Company to the Company or the Company&#146;s
stockholders, (iii)&nbsp;an action asserting a claim arising pursuant to any provision of the DGCL, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine shall be a state or federal court located within the state of
Delaware. The Certificate further provides that the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for any complaint asserting a cause of action arising under the
Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for the Company&#146;s common stock is Computershare Trust Company, N.A. The transfer agent and
registrar&#146;s address is 250 Royall St., Canton, Massachusetts 02021. Listing. Our common stock is listed on Nasdaq under the symbol &#147;BNTC.&#148; </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d899221dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSIDIARIES OF THE REGISTRANT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Jurisdiction of Incorporation or
Organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Proprietary Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Australia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Australia Proprietary Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Australia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RNAi Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tacere Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>d899221dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to SEC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rule&nbsp;13a-14(a)/15d-14(a)</FONT></FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Dr.&nbsp;Jerel Banks, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma
Inc. for the year ended June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;September 23, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dr.&nbsp;Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:&nbsp;Dr.&nbsp;Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;Chief Executive Officer (principal executive officer)</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>d899221dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to SEC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rule&nbsp;13a-14(a)/15d-14(a)</FONT></FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Megan Boston, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma
Inc. for the year ended June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;September 23, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:&nbsp;Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;Executive Director (principal financial officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>d899221dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to Section&nbsp;1350 of Chapter&nbsp;63 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Title&nbsp;18 of the United States Code </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma&nbsp;Inc. (the &#147;Company&#148;) for the
year ended June&nbsp;30, 2020, as filed with the Securities and Exchange Commission (the &#147;Report&#148;), I, Dr.&nbsp;Jerel Banks, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act
of 1934. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dr.&nbsp;Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr.&nbsp;Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">September 23, 2020</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 has been provided
to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification
is being furnished pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that
section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>d899221dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to Section&nbsp;1350 of Chapter&nbsp;63 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Title&nbsp;18 of the United States Code </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma&nbsp;Inc. (the &#147;Company&#148;) for the
year ended June&nbsp;30, 2020, as filed with the Securities and Exchange Commission (the &#147;Report&#148;), I, Megan Boston, Executive Director of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act
of 1934. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">September 23, 2020</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 has been provided
to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification
is being furnished pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that
section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>bntc-20200630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-September-2020 [09:50:01] {PM}-->
<xbrli:xbrl xmlns:bntc="http://www.benitecbiopharmainc.com/20200630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31">
<link:schemaRef xlink:type="simple" xlink:href="bntc-20200630.xsd" />
<xbrli:context id="PAsOn06_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P11_27_2019To11_27_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-11-27</xbrli:startDate>
<xbrli:endDate>2019-11-27</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_15_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-15</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:NantWorksLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NolFromTwoThousandEighteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolUptoTwoThousandEighteenMemberBNTCPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NolUptoTwoThousandEighteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_GrantMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_RoyaltyMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_ServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_ServiceMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_RoyaltyMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NolFromTwoThousandEighteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolUptoTwoThousandEighteenMemberBNTCPeriodAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NolUptoTwoThousandEighteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bntc:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolUptoTwoThousandEighteenMemberBNTCPeriodAxis_YearTwoThousandAndThirtySixMemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NolUptoTwoThousandEighteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bntc:YearTwoThousandAndThirtySixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyOneMemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bntc:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bntc:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2014MemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2014Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2019Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2011MemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2011Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2019Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_GrantReceivableOnResearchAndDevelopmentExpendituresMemberusgaapConcentrationRiskByBenchmarkAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bntc:GrantReceivableOnResearchAndDevelopmentExpendituresMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis">bntc:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis_SuspensionOfAnnualDeductionLimitationMemberBNTCEventAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis">bntc:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="bntc:EventAxis">bntc:SuspensionOfAnnualDeductionLimitationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_CaliforniaAssemblyBillEightyFiveMemberBNTCUnexpectedEventAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis">bntc:CaliforniaAssemblyBillEightyFiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:NantWorksLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_GrantMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_LicenseMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_RoyaltyMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_ServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_LicenseMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_RoyaltyMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_LegalExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bntc:LegalExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_GrantReceivableOnResearchAndDevelopmentExpendituresMemberusgaapConcentrationRiskByBenchmarkAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bntc:GrantReceivableOnResearchAndDevelopmentExpendituresMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_AUsrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-07-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To12_31_2018_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:NantWorksLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bntc:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PrefundedWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_BeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PrefundedWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PurchaseWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-06</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-04-22</xbrli:startDate>
<xbrli:endDate>2020-04-22</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-04-22</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To06_30_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_14915311" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">9801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_14915312" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">15718000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsAndOtherReceivablesNetCurrent id="Factid_14915313" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">59000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:AccountsAndOtherReceivablesNetCurrent id="Factid_14915314" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">2536000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_14915315" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">949000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_14915316" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">502000</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_14915317" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">10809000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_14915318" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">18756000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_14915319" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">374000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_14915320" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">470000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:DepositAssets id="Factid_14915321" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">9000</us-gaap:DepositAssets>
<us-gaap:DepositAssets id="Factid_14915322" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">9000</us-gaap:DepositAssets>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_14915323" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">395000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:Assets id="Factid_14915325" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">11587000</us-gaap:Assets>
<us-gaap:Assets id="Factid_14915326" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">19235000</us-gaap:Assets>
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent id="Factid_14915327" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">741000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent id="Factid_14915328" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">2494000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent id="Factid_14915329" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">203000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent id="Factid_14915330" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">147000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent id="Factid_14915331" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">192000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_14915333" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1136000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_14915334" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">2641000</us-gaap:LiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent id="Factid_14915335" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">213000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:Liabilities id="Factid_14915337" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1349000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_14915338" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">2641000</us-gaap:Liabilities>
<us-gaap:CommonStockValue id="Factid_14915341" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue id="Factid_14915342" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">1000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_14915343" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">128826000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_14915344" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">127327000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_14915345" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">-116636000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_14915346" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">-108870000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Factid_14915347" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">-1953000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Factid_14915348" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">-1864000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity id="Factid_14915349" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">10238000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915350" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">16594000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_14915351" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">11587000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_14915352" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">19235000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_14915353" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_14915354" contextRef="PAsOn06_30_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:NetIncomeLoss id="Factid_14915355" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-8274000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_14915356" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">2609000</us-gaap:NetIncomeLoss>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_14915357" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">190000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_14915358" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">158000</us-gaap:DepreciationDepletionAndAmortization>
<bntc:AmortizationOfRightOfUseAssets id="Factid_14915359" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">184000</bntc:AmortizationOfRightOfUseAssets>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Factid_14915361" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Factid_14915362" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-7000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:UnrealizedGainLossOnInvestments id="Factid_14915363" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:UnrealizedGainLossOnInvestments id="Factid_14915364" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-21000</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:ShareBasedCompensation id="Factid_14915365" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">237000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_14915366" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">672000</us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables id="Factid_14915367" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-2396000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables id="Factid_14915368" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-607000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets id="Factid_14915369" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">457000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets id="Factid_14915370" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">9000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:CommitmentsAndContingencies id="Factid_14915371" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_14915372" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<bntc:IncreasedecreaseInAccountsAndOtherPayables id="Factid_14915373" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-1696000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
<bntc:IncreasedecreaseInAccountsAndOtherPayables id="Factid_14915374" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">740000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
<us-gaap:CommonStockSharesAuthorized id="Factid_14915375" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF">10000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Factid_14915376" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued id="Factid_14915377" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="INF">856765</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesAuthorized id="Factid_14915378" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="INF">10000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesOutstanding id="Factid_14915379" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding id="Factid_14915380" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="INF">856765</us-gaap:CommonStockSharesOutstanding>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Factid_14915381" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">57000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Factid_14915382" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-15000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<bntc:IncreaseDecreaseInLeaseLiabilities id="Factid_14915383" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-174000</bntc:IncreaseDecreaseInLeaseLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_14915385" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-7535000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_14915386" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">4790000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_14915387" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">95000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_14915388" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">404000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Factid_14915389" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Factid_14915390" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">4000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_14915391" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-94000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_14915392" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfCommonStock id="Factid_14915393" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">2250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfStockIssuanceCosts id="Factid_14915395" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">480000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_14915397" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">1770000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_14915399" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-5859000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_14915400" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">4390000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_14915402" contextRef="PAsOn06_30_2018" unitRef="Unit_USD" decimals="-3">11879000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_14915403" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-58000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_14915404" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-551000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="Factid_14915407" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">579000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915423" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">97000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915424" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">11551000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueNotFromContractWithCustomerOther id="Factid_14915425" contextRef="P07_01_2019To06_30_2020_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">5000</us-gaap:RevenueNotFromContractWithCustomerOther>
<us-gaap:RevenueNotFromContractWithCustomerOther id="Factid_14915426" contextRef="P07_01_2018To06_30_2019_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">648000</us-gaap:RevenueNotFromContractWithCustomerOther>
<us-gaap:Revenues id="Factid_14915427" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">102000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_14915428" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">12199000</us-gaap:Revenues>
<bntc:RoyaltiesAndLicenseFees id="Factid_14915429" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-185000</bntc:RoyaltiesAndLicenseFees>
<bntc:RoyaltiesAndLicenseFees id="Factid_14915430" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">435000</bntc:RoyaltiesAndLicenseFees>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_14915431" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">3001000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_14915432" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">4567000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_14915433" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">5567000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_14915434" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">4614000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses id="Factid_14915435" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">8383000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_14915436" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">9616000</us-gaap:OperatingExpenses>
<us-gaap:SharesOutstanding id="Factid_14915463" contextRef="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">856765</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_14915464" contextRef="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915465" contextRef="PAsOn06_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">127715000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915466" contextRef="PAsOn06_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-112539000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915467" contextRef="PAsOn06_30_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1333000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915468" contextRef="PAsOn06_30_2018" unitRef="Unit_USD" decimals="-3">13844000</us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_14915470" contextRef="P07_01_2018To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">672000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_14915472" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">672000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_14915476" contextRef="P07_01_2018To06_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-531000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:NetIncomeLoss id="Factid_14915480" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2609000</us-gaap:NetIncomeLoss>
<us-gaap:StockholdersEquity id="Factid_14915482" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_14915483" contextRef="P07_01_2019To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">186666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_14915485" contextRef="P07_01_2019To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1720000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_14915488" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">1720000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<bntc:IssuanceAndExerciseOfPrefundedWarrants id="Factid_14915489" contextRef="P07_01_2019To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">27526</bntc:IssuanceAndExerciseOfPrefundedWarrants>
<bntc:CashlessExerciseOfPurchaseWarrants id="Factid_14915493" contextRef="P07_01_2019To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">37417</bntc:CashlessExerciseOfPurchaseWarrants>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_14915495" contextRef="P07_01_2019To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_14915498" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">237000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_14915502" contextRef="P07_01_2019To06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-89000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:NetIncomeLoss id="Factid_14915506" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-8274000</us-gaap:NetIncomeLoss>
<dei:DocumentType id="Factid_14915509" contextRef="P07_01_2019To06_30_2020">10-K</dei:DocumentType>
<dei:DocumentAnnualReport id="Factid_14915510" contextRef="P07_01_2019To06_30_2020">true</dei:DocumentAnnualReport>
<dei:AmendmentFlag id="Factid_14915511" contextRef="P07_01_2019To06_30_2020">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate id="Factid_14915513" contextRef="P07_01_2019To06_30_2020">2020-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus id="Factid_14915514" contextRef="P07_01_2019To06_30_2020">2020</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_14915515" contextRef="P07_01_2019To06_30_2020">FY</dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_14915516" contextRef="P07_01_2019To06_30_2020">Benitec Biopharma Inc.</dei:EntityRegistrantName>
<dei:EntityFileNumber id="Factid_14915517" contextRef="P07_01_2019To06_30_2020">001-39267</dei:EntityFileNumber>
<dei:CurrentFiscalYearEndDate id="Factid_14915518" contextRef="P07_01_2019To06_30_2020">--06-30</dei:CurrentFiscalYearEndDate>
<dei:EntityWellKnownSeasonedIssuer id="Factid_14915519" contextRef="P07_01_2019To06_30_2020">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers id="Factid_14915520" contextRef="P07_01_2019To06_30_2020">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus id="Factid_14915521" contextRef="P07_01_2019To06_30_2020">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityShellCompany id="Factid_14915522" contextRef="P07_01_2019To06_30_2020">false</dei:EntityShellCompany>
<dei:EntityFilerCategory id="Factid_14915523" contextRef="P07_01_2019To06_30_2020">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:EntitySmallBusiness id="Factid_14915524" contextRef="P07_01_2019To06_30_2020">true</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany id="Factid_14915525" contextRef="P07_01_2019To06_30_2020">true</dei:EntityEmergingGrowthCompany>
<dei:EntityExTransitionPeriod id="Factid_14915526" contextRef="P07_01_2019To06_30_2020">true</dei:EntityExTransitionPeriod>
<dei:EntityAddressCountry id="Factid_14915528" contextRef="P07_01_2019To06_30_2020">CA</dei:EntityAddressCountry>
<dei:EntityAddressPostalZipCode id="Factid_14915529" contextRef="P07_01_2019To06_30_2020">94545</dei:EntityAddressPostalZipCode>
<dei:Security12bTitle id="Factid_14915530" contextRef="P07_01_2019To06_30_2020">Common stock</dei:Security12bTitle>
<dei:TradingSymbol id="Factid_14915531" contextRef="P07_01_2019To06_30_2020">BNTC</dei:TradingSymbol>
<dei:SecurityExchangeName id="Factid_14915532" contextRef="P07_01_2019To06_30_2020">NASDAQ</dei:SecurityExchangeName>
<dei:EntityCommonStockSharesOutstanding id="Factid_14915533" contextRef="PAsOn09_15_2020" unitRef="Unit_shares" decimals="INF">1108374</dei:EntityCommonStockSharesOutstanding>
<dei:EntityListingParValuePerShare id="Factid_14915534" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</dei:EntityListingParValuePerShare>
<dei:EntityPublicFloat id="Factid_14915535" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0">5875207</dei:EntityPublicFloat>
<dei:EntityCentralIndexKey id="Factid_14915537" contextRef="P07_01_2019To06_30_2020">0001808898</dei:EntityCentralIndexKey>
<us-gaap:OperatingIncomeLoss id="Factid_14915538" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-8281000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_14915539" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">2583000</us-gaap:OperatingIncomeLoss>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="Factid_14915540" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-88000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="Factid_14915541" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-75000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:InterestIncomeExpenseNonoperatingNet id="Factid_14915542" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">62000</us-gaap:InterestIncomeExpenseNonoperatingNet>
<us-gaap:InterestIncomeExpenseNonoperatingNet id="Factid_14915543" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">122000</us-gaap:InterestIncomeExpenseNonoperatingNet>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_14915544" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">34000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:UnrealizedGainLossOnInvestments id="Factid_14915546" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:UnrealizedGainLossOnInvestments id="Factid_14915547" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-21000</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:NonoperatingIncomeExpense id="Factid_14915548" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">7000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_14915549" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">26000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_14915552" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-89000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_14915553" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-531000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="Factid_14915554" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-89000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="Factid_14915555" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">-531000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_14915556" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-8363000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_14915557" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">2078000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_14915560" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">-8.10</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_14915561" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2">3.05</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_14915562" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_shares" decimals="0">1021193</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_14915563" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_shares" decimals="0">856765</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<dei:EntityInteractiveDataCurrent id="Factid_14915564" contextRef="P07_01_2019To06_30_2020">Yes</dei:EntityInteractiveDataCurrent>
<us-gaap:StockholdersEquity id="Factid_14915565" contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">127327000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_14915566" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">856765</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_14915567" contextRef="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-108870000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915568" contextRef="PAsOn06_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1864000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_14915570" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_14915571" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915572" contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">128826000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915573" contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-116636000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_14915574" contextRef="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1953000</us-gaap:StockholdersEquity>
<dei:DocumentTransitionReport id="Factid_14915580" contextRef="P07_01_2019To06_30_2020">false</dei:DocumentTransitionReport>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915583" contextRef="PAsOn06_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915586" contextRef="PAsOn06_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915587" contextRef="PAsOn06_30_2019_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915589" contextRef="PAsOn06_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915590" contextRef="PAsOn06_30_2019_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915592" contextRef="PAsOn06_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915593" contextRef="PAsOn06_30_2019_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915595" contextRef="PAsOn06_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915596" contextRef="PAsOn06_30_2019_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915598" contextRef="PAsOn06_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915599" contextRef="PAsOn06_30_2019_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915601" contextRef="PAsOn06_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915602" contextRef="PAsOn06_30_2019_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_14915604" contextRef="PAsOn06_30_2020_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<dei:EntityIncorporationDateOfIncorporation id="Factid_14915606" contextRef="P07_01_2019To06_30_2020">2019-11-22</dei:EntityIncorporationDateOfIncorporation>
<bntc:CommonStockSharesRedomiciliationDescription id="Factid_14915607" contextRef="P11_27_2019To11_27_2019">one Benitec Biopharma Inc. share for every 300 BBL shares</bntc:CommonStockSharesRedomiciliationDescription>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_14915608" contextRef="P07_01_2018To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1060000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_14915609" contextRef="P07_01_2018To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1060000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_14915610" contextRef="P07_01_2019To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-508000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_14915611" contextRef="P07_01_2019To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">508000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:DueFromBanks id="Factid_14915647" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">5231000</us-gaap:DueFromBanks>
<us-gaap:DueFromBanks id="Factid_14915648" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">10779000</us-gaap:DueFromBanks>
<us-gaap:TimeDepositsAtCarryingValue id="Factid_14915649" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">4570000</us-gaap:TimeDepositsAtCarryingValue>
<us-gaap:TimeDepositsAtCarryingValue id="Factid_14915650" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">4939000</us-gaap:TimeDepositsAtCarryingValue>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915662" contextRef="P07_01_2019To06_30_2020_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">93000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915663" contextRef="P07_01_2019To06_30_2020_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915673" contextRef="P07_01_2018To06_30_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">10273000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915674" contextRef="P07_01_2018To06_30_2019_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915675" contextRef="P07_01_2018To06_30_2019_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">1095000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:GrantsReceivableCurrent id="Factid_14915692" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">636000</us-gaap:GrantsReceivableCurrent>
<us-gaap:OtherReceivablesNetCurrent id="Factid_14915693" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">59000</us-gaap:OtherReceivablesNetCurrent>
<us-gaap:OtherReceivablesNetCurrent id="Factid_14915694" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">1900000</us-gaap:OtherReceivablesNetCurrent>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915700" contextRef="P07_01_2019To06_30_2020_ServiceMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915701" contextRef="P07_01_2019To06_30_2020_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915703" contextRef="P07_01_2019To06_30_2020_RoyaltyMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">93000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915705" contextRef="P07_01_2019To06_30_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">93000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915706" contextRef="P07_01_2018To06_30_2019_LicenseMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">10136000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915709" contextRef="P07_01_2018To06_30_2019_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">10136000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915710" contextRef="P07_01_2018To06_30_2019_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915711" contextRef="P07_01_2018To06_30_2019_RoyaltyMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915712" contextRef="P07_01_2018To06_30_2019_ServiceMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">1095000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_14915713" contextRef="P07_01_2018To06_30_2019_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">1415000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_14915714" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-6">0</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_14915715" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-5">1700000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:PrepaidExpenseCurrent id="Factid_14915717" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">861000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:SecurityDeposit id="Factid_14915718" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">69000</us-gaap:SecurityDeposit>
<bntc:Otherdeposits id="Factid_14915719" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">18000</bntc:Otherdeposits>
<bntc:MarketValueOfListedShares id="Factid_14915720" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1000</bntc:MarketValueOfListedShares>
<us-gaap:PrepaidExpenseCurrent id="Factid_14915722" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">375000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:SecurityDeposit id="Factid_14915723" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">103000</us-gaap:SecurityDeposit>
<bntc:Otherdeposits id="Factid_14915724" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">23000</bntc:Otherdeposits>
<bntc:MarketValueOfListedShares id="Factid_14915725" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">1000</bntc:MarketValueOfListedShares>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915729" contextRef="PAsOn06_30_2020_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">11000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915730" contextRef="PAsOn06_30_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">1109000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915732" contextRef="PAsOn06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">26000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915733" contextRef="PAsOn06_30_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">24000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915734" contextRef="PAsOn06_30_2019_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">11000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915735" contextRef="PAsOn06_30_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">1014000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915736" contextRef="PAsOn06_30_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">6000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915737" contextRef="PAsOn06_30_2019_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">32000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915738" contextRef="PAsOn06_30_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">77000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915739" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1170000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_14915740" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">1140000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_14915741" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">796000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_14915742" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">670000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:Depreciation id="Factid_14915745" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="0">190000</us-gaap:Depreciation>
<us-gaap:Depreciation id="Factid_14915746" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="0">158000</us-gaap:Depreciation>
<us-gaap:AccountsPayableTradeCurrent id="Factid_14915752" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">282000</us-gaap:AccountsPayableTradeCurrent>
<bntc:AccruedLicenceFeesCurrent id="Factid_14915753" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">54000</bntc:AccruedLicenceFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_14915755" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">155000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent id="Factid_14915756" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">250000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableTradeCurrent id="Factid_14915758" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">1474000</us-gaap:AccountsPayableTradeCurrent>
<bntc:AccruedLicenceFeesCurrent id="Factid_14915759" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">385000</bntc:AccruedLicenceFeesCurrent>
<bntc:AccruedResearchAndDevelopmentFeesCurrent id="Factid_14915760" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">498000</bntc:AccruedResearchAndDevelopmentFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_14915761" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">61000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent id="Factid_14915762" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">76000</us-gaap:OtherAccruedLiabilitiesCurrent>
<bntc:ScheduleOfEntitiesInControlTableTextBlock id="Factid_14915768" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements of the Company are presented in United States dollars and consist of Benitec Biopharma Inc. and the entities it controls: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:65%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal place of&lt;br/&gt;business/country of&lt;br/&gt;incorporation&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&amp;#8220;BBL&amp;#8221;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;United&amp;#160;Kingdom&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec Biopharma Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfEntitiesInControlTableTextBlock>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="Factid_14915769" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Benitec Biopharma Inc. is a corporation formed under the laws of Delaware, United States, on November&amp;#160;22, 2019. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&amp;#8220;BBL&amp;#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, since 1997. Since then, the Company has focused on the development of novel genetic medicines. The proprietary platform, called &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DNA-directed&lt;/div&gt; RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On November&amp;#160;27, 2019, BBL announced its intention to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domicile&lt;/div&gt; from Australia to the United States of America (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8220;Re-domiciliation&amp;#8221;).&lt;/div&gt; BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of affecting the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation,&lt;/div&gt; acquired all of the outstanding BBL shares. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation.&lt;/div&gt; In accordance with the U.S. Securities and Exchange Commission&amp;#8217;s (&amp;#8220;SEC&amp;#8221;) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company&amp;#8217;s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 exchange ratio share consolidation in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation&lt;/div&gt; as if it occurred on July&amp;#160;1, 2018.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;BBL announced that the transaction to redomicile from Australia to the United States was fully implemented on April&amp;#160;15, 2020. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation&lt;/div&gt; was approved by BBL shareholders at a Scheme Meeting held on March&amp;#160;26, 2020 and confirmed by the Supreme Court of Queensland on March&amp;#160;30, 2020.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The term the &amp;#8220;Company&amp;#8221; refers to (i), prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation&lt;/div&gt; to BBL, an Australian corporation, and its subsidiaries, and (ii), following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation,&lt;/div&gt; to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL).&amp;#8220;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The shares of Benitec Biopharma Inc. common stock issued in connection with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation&lt;/div&gt; trade on The Nasdaq Capital Market LLC (&amp;#8220;Nasdaq&amp;#8221;) under the symbol &amp;#8220;BNTC&amp;#8221;, and Benitec Biopharma Inc. continues to be subject to the reporting requirements of the SEC and applicable corporate governance rules of Nasdaq.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As a result of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation,&lt;/div&gt; BBL became a wholly owned subsidiary of Benitec Biopharma Inc. and delisted from the ASX on April&amp;#160;15, 2020. On August&amp;#160;14, 2020 BBL had a change of company status and became a Proprietary Limited company.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s fiscal year end is June 30. References to a particular &amp;#8220;fiscal year&amp;#8221; are to our fiscal year ended June&amp;#160;30 of that calendar year. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements of the Company are presented in United States dollars and consist of Benitec Biopharma Inc. and the entities it controls: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:65%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal place of&lt;br/&gt;business/country of&lt;br/&gt;incorporation&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&amp;#8220;BBL&amp;#8221;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;United&amp;#160;Kingdom&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec Biopharma Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align:center;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Factid_14915770" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On April&amp;#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon consummation of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation.&lt;/div&gt; As a result, the financial statements included in this report reflect (i)&amp;#160;the historical operating results of BBL and subsidiaries prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; (ii)&amp;#160;the combined results of the Company, BBL, and subsidiaries following the completion of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; and (iii)&amp;#160;the Company&amp;#8217;s equity structure for all periods presented&lt;div style="font-weight:bold;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;US GAAP&amp;#8221;) and pursuant to the rules and regulations of the SEC. In the opinion of the Company&amp;#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; adjustments) necessary to present fairly our financial position, results of operations, and cash flows for the fiscal years ended June&amp;#160;30, 2020 and 2019 have been made.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;). This is the source of authoritative US&amp;#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock id="Factid_14915771" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements include the Company&amp;#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock id="Factid_14915772" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates id="Factid_14915773" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The preparation of financial statements in conformity with US&amp;#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="Factid_14915774" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBL&amp;#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar &amp;#8220;$&amp;#8221; and/or &amp;#8220;USD&amp;#8221; as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&amp;#8217; equity as &amp;#8220;Accumulated other comprehensive income (loss).&amp;#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&amp;#160;30, 2020, and 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exchange rate on balance sheet dates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.6877&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.7014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Average exchange rate for the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.6711&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.7149&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exchange rate used to translate amounts in AUD into USD for the year ended June&amp;#160;30, 2018 is 0.7385 as of the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="Factid_14915776" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures its financial assets and liabilities in accordance with US&amp;#160;GAAP using ASC 820, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements.&lt;/div&gt; For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:9%;"&gt;Level&amp;#160;1:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:9%;"&gt;Level&amp;#160;2:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:9%;"&gt;Level&amp;#160;3:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of the Company&amp;#8217;s cash and cash equivalents, trade and other receivables, and trade and other payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of June&amp;#160;30, 2020, and 2019, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Factid_14915777" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:ConcentrationRiskCreditRisk id="Factid_14915778" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy id="Factid_14915779" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&amp;#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="Factid_14915780" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:36%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Lab&amp;#160;equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Furniture&amp;#160;and&amp;#160;fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Computer&amp;#160;hardware&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold&amp;#160;improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="Factid_14915781" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&amp;#8217;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<bntc:AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock id="Factid_14915783" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Australian Goods and Services Tax (&amp;#8220;GST&amp;#8221;) and other similar taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues, expenses, and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock>
<us-gaap:LesseeLeasesPolicyTextBlock id="Factid_14915784" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;After lease commencement, the Company measures its leases as follows: (i)&amp;#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&amp;#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock id="Factid_14915785" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basic and Diluted Net Income (Loss) Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of June&amp;#160;30, 2020, and 2019, there were 145,421 and 38,326 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock id="Factid_14915786" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company adopted ASC 606 &amp;#8211; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers &lt;/div&gt;(&amp;#8220;ASC 606&amp;#8221;) on July&amp;#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 3: Determine the transaction price. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&amp;#8217;s subsequent sales of product occurs. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<bntc:GovernmentResearchAndDevelopmentGrantsPolicyTextBlock id="Factid_14915787" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Government Research and Development Grants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant income is generated through the Australian federal government&amp;#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% (2019: 43.5%) of eligible research and development expenditures. This grant is available for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will not be claiming the Australian Government research and development grants going forward due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation&lt;/div&gt; of the Company to the United States.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:GovernmentResearchAndDevelopmentGrantsPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy id="Factid_14915788" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Factid_14915789" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company records share-based compensation in accordance with ASC 718, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock Compensation&lt;/div&gt;. ASC&amp;#160;718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company adopted FASB Accounting Standard Update (&amp;#8220;ASU&amp;#8221;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-07&lt;/div&gt; and accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:IncomeTaxPolicyTextBlock id="Factid_14915790" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Accounting for Income Taxes&lt;/div&gt;, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For uncertain tax positions that meet a &amp;#8220;more likely than not&amp;#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&amp;#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="Factid_14915791" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. The Company records unrealized foreign currency translation loss which qualifies as other comprehensive loss.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_14915792" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Accounting Standards recently adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-02:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;(Topic 842) whereby lessees will need to recognize most leases on their balance sheet as a right of use asset and a lease liability. This guidance is effective for interim and annual reporting periods beginning after December&amp;#160;15, 2018. The Company adopted this ASU effective July&amp;#160;1, 2019.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s only lease is the lease on its research and development facilities.&amp;#160;The Company&amp;#8217;s existing lease commitments&amp;#160;are set out in Note 10. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-07,&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Compensation &amp;#8211; Stock Compensation&lt;/div&gt; (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation &amp;#8211; Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; for goods and services. Consequently, the accounting for share-based payments to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; and employees will be substantially aligned. This standard is effective for financial statements issued by public companies for the annual and interim periods beginning after December&amp;#160;15, 2018. The Company adopted this ASU on July&amp;#160;1, 2019. There was no effect on the financial statements on adoption.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<bntc:NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock id="Factid_14915793" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;New Accounting Standards and Interpretations not yet mandatory or early adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-13:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Financial Instruments &amp;#8211; Credit Losses&lt;/div&gt; (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&amp;#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after December&amp;#160;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&amp;#8220;SRC&amp;#8221;) as of November&amp;#160;15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&lt;/div&gt; amended the effective date for the Company to be for reporting periods beginning after December&amp;#160;15, 2022. The Company will adopt this ASU effective July&amp;#160;1, 2023.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock id="Factid_14915794" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On April&amp;#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon consummation of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation.&lt;/div&gt; As a result, the financial statements included in this report reflect (i)&amp;#160;the historical operating results of BBL and subsidiaries prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; (ii)&amp;#160;the combined results of the Company, BBL, and subsidiaries following the completion of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; and (iii)&amp;#160;the Company&amp;#8217;s equity structure for all periods presented&lt;div style="font-weight:bold;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;US GAAP&amp;#8221;) and pursuant to the rules and regulations of the SEC. In the opinion of the Company&amp;#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; adjustments) necessary to present fairly our financial position, results of operations, and cash flows for the fiscal years ended June&amp;#160;30, 2020 and 2019 have been made.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;). This is the source of authoritative US&amp;#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements include the Company&amp;#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The preparation of financial statements in conformity with US&amp;#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBL&amp;#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar &amp;#8220;$&amp;#8221; and/or &amp;#8220;USD&amp;#8221; as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&amp;#8217; equity as &amp;#8220;Accumulated other comprehensive income (loss).&amp;#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&amp;#160;30, 2020, and 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exchange rate on balance sheet dates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.6877&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.7014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Average exchange rate for the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.6711&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.7149&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exchange rate used to translate amounts in AUD into USD for the year ended June&amp;#160;30, 2018 is 0.7385 as of the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures its financial assets and liabilities in accordance with US&amp;#160;GAAP using ASC 820, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements.&lt;/div&gt; For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:9%;"&gt;Level&amp;#160;1:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:9%;"&gt;Level&amp;#160;2:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:9%;"&gt;Level&amp;#160;3:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of the Company&amp;#8217;s cash and cash equivalents, trade and other receivables, and trade and other payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of June&amp;#160;30, 2020, and 2019, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&amp;#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:36%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Lab&amp;#160;equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Furniture&amp;#160;and&amp;#160;fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Computer&amp;#160;hardware&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold&amp;#160;improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&amp;#8217;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Australian Goods and Services Tax (&amp;#8220;GST&amp;#8221;) and other similar taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues, expenses, and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;After lease commencement, the Company measures its leases as follows: (i)&amp;#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&amp;#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basic and Diluted Net Income (Loss) Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of June&amp;#160;30, 2020, and 2019, there were 145,421 and 38,326 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company adopted ASC 606 &amp;#8211; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers &lt;/div&gt;(&amp;#8220;ASC 606&amp;#8221;) on July&amp;#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 3: Determine the transaction price. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&amp;#8217;s subsequent sales of product occurs. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Government Research and Development Grants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant income is generated through the Australian federal government&amp;#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% (2019: 43.5%) of eligible research and development expenditures. This grant is available for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will not be claiming the Australian Government research and development grants going forward due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation&lt;/div&gt; of the Company to the United States.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company records share-based compensation in accordance with ASC 718, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock Compensation&lt;/div&gt;. ASC&amp;#160;718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company adopted FASB Accounting Standard Update (&amp;#8220;ASU&amp;#8221;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-07&lt;/div&gt; and accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Accounting for Income Taxes&lt;/div&gt;, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For uncertain tax positions that meet a &amp;#8220;more likely than not&amp;#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&amp;#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. The Company records unrealized foreign currency translation loss which qualifies as other comprehensive loss.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Accounting Standards recently adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-02:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;(Topic 842) whereby lessees will need to recognize most leases on their balance sheet as a right of use asset and a lease liability. This guidance is effective for interim and annual reporting periods beginning after December&amp;#160;15, 2018. The Company adopted this ASU effective July&amp;#160;1, 2019.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s only lease is the lease on its research and development facilities.&amp;#160;The Company&amp;#8217;s existing lease commitments&amp;#160;are set out in Note 10. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-07,&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Compensation &amp;#8211; Stock Compensation&lt;/div&gt; (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation &amp;#8211; Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; for goods and services. Consequently, the accounting for share-based payments to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; and employees will be substantially aligned. This standard is effective for financial statements issued by public companies for the annual and interim periods beginning after December&amp;#160;15, 2018. The Company adopted this ASU on July&amp;#160;1, 2019. There was no effect on the financial statements on adoption.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;New Accounting Standards and Interpretations not yet mandatory or early adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-13:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Financial Instruments &amp;#8211; Credit Losses&lt;/div&gt; (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&amp;#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after December&amp;#160;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&amp;#8220;SRC&amp;#8221;) as of November&amp;#160;15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&lt;/div&gt; amended the effective date for the Company to be for reporting periods beginning after December&amp;#160;15, 2022. The Company will adopt this ASU effective July&amp;#160;1, 2023.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:RevenueFromContractWithCustomerTextBlock id="Factid_14915796" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Revenue &lt;/div&gt;(US$&amp;#8217;000) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenues from customers&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Licensing revenue*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,273&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;183&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Service revenue*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;97&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;11,551&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:2%;"&gt;*&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;On July&amp;#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. Pursuant to the Agreement, the Company granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&amp;#8217;s product known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301,&lt;/div&gt; which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of payments for the Company&amp;#8217;s intellectual property related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; and the transfer of the right to use the intellectual property of the Company&amp;#8217;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&amp;#160;6, 2019, the termination of the License and Collaboration Agreement with Axovant was announced. The termination of the Agreement was effective as of September&amp;#160;3, 2019. The termination discharges all future performance obligations under the contract at the termination date.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:77%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other revenues (US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Government research and development grants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;648&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;648&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:57%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal year ended June&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Licensing&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Royalties&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Development&lt;br/&gt;activities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;$4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;$97&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: 'times new roman';;height:16;"&gt;&lt;/td&gt;&lt;td colspan="16" style="font-family: 'times new roman';;height:16;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal year ended June&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Licensing&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Royalties&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Development&lt;br/&gt;activities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,136&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,136&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;137&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;183&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,415&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,273&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;183&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,551&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
<bntc:ScheduleOfEntityWideInformationOtherRevenueTableTextBlock id="Factid_14915798" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:77%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other revenues (US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Government research and development grants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;648&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;648&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfEntityWideInformationOtherRevenueTableTextBlock>
<us-gaap:DisaggregationOfRevenueTableTextBlock id="Factid_14915799" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:57%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal year ended June&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Licensing&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Royalties&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Development&lt;br/&gt;activities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;$4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;$97&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: 'times new roman';;height:16;"&gt;&lt;/td&gt;&lt;td colspan="16" style="font-family: 'times new roman';;height:16;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal year ended June&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Licensing&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Royalties&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Development&lt;br/&gt;activities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,136&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,136&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;137&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;183&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,415&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,273&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;183&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11,551&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock id="Factid_14915800" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash at Bank&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,231&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,779&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term Deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;4,570&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;4,939&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,801&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,718&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
<us-gaap:CashAndCashEquivalentsDisclosureTextBlock id="Factid_14915801" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Cash and Cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash at Bank&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,231&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,779&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term Deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;4,570&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;4,939&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,801&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15,718&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
<bntc:TradeAndOtherReceivablesDisclosureTextBlock id="Factid_14915802" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Trade and other receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research&amp;#160;&amp;amp; development grants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;636&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other receivables*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;59&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;59&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,536&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:2%;"&gt;*&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had a contract asset of $0 and approximately $1.7M as of June&amp;#160;30, 2020, and 2019, respectively, related to the contract with Axovant which is included in other receivables on the consolidated balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:TradeAndOtherReceivablesDisclosureTextBlock>
<us-gaap:OtherAssetsDisclosureTextBlock id="Factid_14915804" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Other assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;861&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;375&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Security deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;69&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;103&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;18&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;23&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market value of listed shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;949&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;502&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
<us-gaap:ScheduleOfOtherAssetsTableTextBlock id="Factid_14915805" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;861&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;375&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Security deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;69&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;103&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;18&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;23&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market value of listed shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;949&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;502&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock id="Factid_14915806" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,109&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;26&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;32&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;24&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;77&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,170&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,140&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(796&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(670&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;374&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;470&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Factid_14915807" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,109&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;26&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;32&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;24&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;77&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,170&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,140&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(796&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(670&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;374&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;470&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense was $190,000 and $158,000 for the fiscal years ended June&amp;#160;30, 2020 and 2019, respectively. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Factid_14915808" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Trade and other payables &lt;/div&gt;&lt;/div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:76%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Trade payable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;282&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;1,474&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued license fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;385&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued research and development fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;498&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;155&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other payables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;76&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;741&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,494&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:LesseeOperatingLeasesTextBlock id="Factid_14915810" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&amp;#160;1, 2019, the Company adopted ASC 842,&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;Leases&lt;/div&gt;&amp;#160;(&amp;#8220;ASC 842&amp;#8221;). ASC 842 requires lessees to recognize at the lease commencement date a lease liability, which is the lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control the use of, a specified asset for the lease term. Lessees and lessors must either (i)&amp;#160;apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or (ii)&amp;#160;recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company elected to use the cumulative-effect transition method upon adoption.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 842 also allows lessees and lessors to elect certain practical expedients. The Company elected the following practical expedients: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transitional practical expedients: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company need not reassess whether any expired or existing contracts are or contain leases. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company need not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with the previous guidance will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with the previous guidance will be classified as finance leases). &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company need not reassess initial direct costs for any existing leases. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hindsight practical expedient: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The Company elected the hindsight practical expedient in determining the lease term (that is, when considering lessee options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of the Company&amp;#8217;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&amp;#8217;s lease does not contain any residual value guarantees or material restrictive covenants. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon adoption of ASC 842, the Company recognized on its consolidated balance sheet as of July&amp;#160;1, 2019 an initial measurement of approximately $579,000 of operating lease liabilities, and approximately $579,000 of corresponding operating &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of&lt;/div&gt; use assets, net of tenant improvement allowances. There was also no cumulative effect adjustment to retained earnings as a result of the transition to ASC 842. The Company recorded the initial recognition of the operating lease as a supplemental noncash financing activity on the accompanying consolidated statement of cash flows. The adoption of ASC 842 did not have a material impact on the Company&amp;#8217;s consolidated statement of operations.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The tables below show the changes during the year ended June&amp;#160;30, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:56%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:40%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating&amp;#160;lease&amp;#160;right-of-use&amp;#160;assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Initial measurement at July&amp;#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;579&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(184&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at June&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;395&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:67%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:29%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&amp;#160;lease&amp;#160;liabilities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Initial measurement at July&amp;#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;579&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal payments on operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(174&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Operating lease liabilities at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;405&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;213&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Current portion at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;192&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&amp;#160;30, 2020, the Company&amp;#8217;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&amp;#160;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;207&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;218&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;425&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(20&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;405&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the fiscal years ended June&amp;#160;30, 2020 and 2019, total lease expense under operating leases was approximately $208,000 and $221,000, respectively, and was recorded in general and administrative expenses. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:SubsequentEventsTextBlock id="Factid_14915811" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16. Subsequent events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company is closely monitoring the impact of the pandemic of the novel strain of coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&amp;#8220;COVID-19&amp;#8221;)&lt;/div&gt; on all aspects of its business and geographies, including how it will impact its team members, suppliers, vendors and business partners. While the Company did experience some disruption from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; through the delay of the initiation of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials through the date of issuance, of these financial statements, it is unable to predict the impact that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; will have on its financial position and operating results due to numerous uncertainties.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On August&amp;#160;14, 2020, the Company filed a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;333-246314)&lt;/div&gt; with the SEC (the &amp;#8220;Registration Statement&amp;#8221;).&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:EarningsPerShareTextBlock id="Factid_14915812" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15. Earnings (Loss) per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:69%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net Income (Loss) attributable to common stockholders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;($&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,274&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,609&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of shares used in calculating basic and diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,021,193&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;856,765&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted earnings (loss) per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;($&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8.10&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3.05&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding options to acquire ordinary shares are not considered dilutive for the fiscal years ended June&amp;#160;30, 2020 and June&amp;#160;30, 2019, because they are anti-dilutive, as the strike price was higher than the share price. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Factid_14915813" contextRef="P07_01_2019To06_30_2020">&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:69%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net Income (Loss) attributable to common stockholders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;($&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,274&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,609&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of shares used in calculating basic and diluted earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,021,193&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;856,765&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted earnings (loss) per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;($&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8.10&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3.05&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<bntc:TradeAndOtherPayablesPolicyTextBlock id="Factid_14915814" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:TradeAndOtherPayablesPolicyTextBlock>
<us-gaap:RevenueNotFromContractWithCustomerOther id="Factid_14915815" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">5000</us-gaap:RevenueNotFromContractWithCustomerOther>
<us-gaap:RevenueNotFromContractWithCustomerOther id="Factid_14915816" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">648000</us-gaap:RevenueNotFromContractWithCustomerOther>
<bntc:GoingConcernDisclosureTextBlock id="Factid_14915817" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared in conformity with US&amp;#160;GAAP, which contemplate continuation of the Company as a going concern. For the fiscal years ended June&amp;#160;30, 2020, and 2019, the Company had a net (loss) income of $(8.3) million and&amp;#160;$2.6&amp;#160;million, respectively, and net cash (used in) provided by operations of $(7.5) million and $4.8&amp;#160;million, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of June&amp;#160;30, 2020, the Company had $9.8&amp;#160;million in cash and cash equivalents. The Company has incurred operating losses and negative cash flows from operations since inception, except for the year ended June&amp;#160;30, 2019. Management believes the Company&amp;#8217;s existing cash together with the net proceeds of a&amp;#160;public offering of common stock will be sufficient to fund the Company&amp;#8217;s operations at least for the next twelve months. In connection with the Company&amp;#8217;s&amp;#160;public offering, on August&amp;#160;14, 2020, the Company filed a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; with the SEC.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management having performed a review of the cash flow forecasts, considering the cash flow needs of the Company, believe that current funding and the proceeds of the upcoming capital raise will be sufficient for a period of at least twelve months from the date of this report. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Although management believes that the additional required funding will be obtained, there&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;is&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;no guarantee the Company will be able to obtain the additional required funds on a timely basis or that funds will be available on acceptable terms. If such funds are not available when required, management will be required to curtail its expenditures, which may have a material adverse effect on its future cash flows and results of operations, and its ability to continue operating as a going concern. The accompanying financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern.&lt;/div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:GoingConcernDisclosureTextBlock>
<bntc:ScheduleOfTradeAndOtherReceivablesTableTextBlock id="Factid_14915819" contextRef="P07_01_2019To06_30_2020">&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research&amp;#160;&amp;amp; development grants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;636&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other receivables*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;59&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;59&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,536&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:2%;"&gt;*&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had a contract asset of $0 and approximately $1.7M as of June&amp;#160;30, 2020, and 2019, respectively, related to the contract with Axovant which is included in other receivables on the consolidated balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfTradeAndOtherReceivablesTableTextBlock>
<us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock id="Factid_14915820" contextRef="P07_01_2019To06_30_2020">&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenues from customers&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Licensing revenue*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,273&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;93&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;183&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Service revenue*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;97&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;11,551&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="text-align:left;;vertical-align:top;;width:2%;"&gt;*&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;On July&amp;#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. Pursuant to the Agreement, the Company granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&amp;#8217;s product known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301,&lt;/div&gt; which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of payments for the Company&amp;#8217;s intellectual property related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; and the transfer of the right to use the intellectual property of the Company&amp;#8217;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&amp;#160;6, 2019, the termination of the License and Collaboration Agreement with Axovant was announced. The termination of the Agreement was effective as of September&amp;#160;3, 2019. The termination discharges all future performance obligations under the contract at the termination date.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
<bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts id="Factid_14915821" contextRef="P07_01_2019To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">50000</bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts>
<bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts id="Factid_14915822" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">50000</bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense id="Factid_14915826" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">184000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_14915827" contextRef="PAsOn06_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-3">579000</us-gaap:OperatingLeaseRightOfUseAsset>
<bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock id="Factid_14915828" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The tables below show the changes during the year ended June&amp;#160;30, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:56%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:40%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating&amp;#160;lease&amp;#160;right-of-use&amp;#160;assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Initial measurement at July&amp;#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;579&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(184&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at June&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;395&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:67%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:29%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&amp;#160;lease&amp;#160;liabilities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Initial measurement at July&amp;#160;1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;579&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal payments on operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(174&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Operating lease liabilities at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;405&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;213&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Current portion at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;192&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="Factid_14915829" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&amp;#160;30, 2020, the Company&amp;#8217;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&amp;#160;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;207&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;218&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;425&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(20&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;405&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:OperatingLeasePayments id="Factid_14915832" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">174000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeaseLiability id="Factid_14915833" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">405000</us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiability id="Factid_14915836" contextRef="PAsOn06_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-3">579000</us-gaap:OperatingLeaseLiability>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="Factid_14915839" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">207000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="Factid_14915840" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">218000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="Factid_14915841" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">425000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="Factid_14915842" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">20000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability id="Factid_14915844" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="0">579000</us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_14915845" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="0">579000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:LesseeOperatingLeaseRemainingLeaseTerm id="Factid_14915846" contextRef="PAsOn06_30_2020">P1Y11M15D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
<us-gaap:LesseeOperatingLeaseDiscountRate id="Factid_14915847" contextRef="PAsOn06_30_2020" unitRef="Unit_pure" decimals="4">0.0467</us-gaap:LesseeOperatingLeaseDiscountRate>
<us-gaap:OperatingLeaseExpense id="Factid_14915848" contextRef="P07_01_2019To06_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0">208000</us-gaap:OperatingLeaseExpense>
<us-gaap:OperatingLeaseExpense id="Factid_14915849" contextRef="P07_01_2018To06_30_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0">221000</us-gaap:OperatingLeaseExpense>
<us-gaap:RelatedPartyTransactionAmountsOfTransaction id="Factid_14915853" contextRef="P07_01_2018To06_30_2019_LegalExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
<bntc:MilestonePaymentAccruedDuringThePeriod id="Factid_14915854" contextRef="P01_01_2018To12_31_2018_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0">300000</bntc:MilestonePaymentAccruedDuringThePeriod>
<bntc:MilestonePaymentAccruedDuringThePeriod id="Factid_14915855" contextRef="P01_01_2018To12_31_2018_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_AUD" decimals="0">425411</bntc:MilestonePaymentAccruedDuringThePeriod>
<bntc:MilestonePaymentReversedDuringThePeriod id="Factid_14915859" contextRef="P07_01_2019To06_30_2020_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0">300000</bntc:MilestonePaymentReversedDuringThePeriod>
<bntc:MilestonePaymentReversedDuringThePeriod id="Factid_14915860" contextRef="P07_01_2019To06_30_2020_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_AUD" decimals="0">425411</bntc:MilestonePaymentReversedDuringThePeriod>
<bntc:EstimatedResearchCostsToBeIncurred id="Factid_14915862" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="0">462000</bntc:EstimatedResearchCostsToBeIncurred>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="Factid_14915875" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-299000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="Factid_14915876" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">169000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="Factid_14915877" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-7975000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="Factid_14915878" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">2440000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Factid_14915898" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">13153000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Factid_14915899" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">10632000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsCapitalLossCarryforwards id="Factid_14915901" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">250000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
<us-gaap:DeferredTaxAssetsOther id="Factid_14915902" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">209000</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsOther id="Factid_14915903" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">193000</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsGross id="Factid_14915906" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">13447000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsGross id="Factid_14915907" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">11075000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxLiabilitiesLeasingArrangements id="Factid_14915908" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">83000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="Factid_14915910" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">74000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
<us-gaap:DeferredIncomeTaxLiabilities id="Factid_14915912" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">157000</us-gaap:DeferredIncomeTaxLiabilities>
<us-gaap:DeferredTaxAssetsLiabilitiesNet id="Factid_14915916" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:DeferredTaxAssetsLiabilitiesNet id="Factid_14915917" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:OperatingLossCarryforwards id="Factid_14915918" contextRef="PAsOn06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis" unitRef="Unit_USD" decimals="-3">629000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards id="Factid_14915919" contextRef="PAsOn06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolUptoTwoThousandEighteenMemberBNTCPeriodAxis" unitRef="Unit_USD" decimals="-3">192000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards id="Factid_14915920" contextRef="PAsOn06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3">5314000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards id="Factid_14915923" contextRef="PAsOn06_30_2020_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3">45847000</us-gaap:OperatingLossCarryforwards>
<bntc:YearOfExpiryOfOperatingLossesCarryForwards id="Factid_14915925" contextRef="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolUptoTwoThousandEighteenMemberBNTCPeriodAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis">2034</bntc:YearOfExpiryOfOperatingLossesCarryForwards>
<bntc:YearOfExpiryOfOperatingLossesCarryForwards id="Factid_14915926" contextRef="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolUptoTwoThousandEighteenMemberBNTCPeriodAxis_YearTwoThousandAndThirtySixMemberusgaapTaxPeriodAxis">2036</bntc:YearOfExpiryOfOperatingLossesCarryForwards>
<bntc:YearOfExpiryOfOperatingLossesCarryForwards id="Factid_14915927" contextRef="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyOneMemberusgaapTaxPeriodAxis">2031</bntc:YearOfExpiryOfOperatingLossesCarryForwards>
<bntc:YearOfExpiryOfOperatingLossesCarryForwards id="Factid_14915928" contextRef="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis">2034</bntc:YearOfExpiryOfOperatingLossesCarryForwards>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Factid_14915929" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="INF">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Factid_14915930" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="INF">0.2750</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences id="Factid_14915931" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="3">-0.024</bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences>
<bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences id="Factid_14915932" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.0618</bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment id="Factid_14915934" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.1573</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="Factid_14915936" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.0687</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
<us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent id="Factid_14915937" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="4">-0.0074</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
<us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent id="Factid_14915938" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.0706</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
<bntc:EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards id="Factid_14915940" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="3">-0.423</bntc:EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Factid_14915941" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="4">-0.2412</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Factid_14915942" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="3">-0.073</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="Factid_14915943" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="4">0.0626</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations id="Factid_14915945" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="4">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations id="Factid_14915946" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Factid_14915947" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="0">2215</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
<us-gaap:OpenTaxYear id="Factid_14915949" contextRef="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2014MemberusgaapTaxPeriodAxis">2014</us-gaap:OpenTaxYear>
<us-gaap:OpenTaxYear id="Factid_14915950" contextRef="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis">2019</us-gaap:OpenTaxYear>
<us-gaap:OpenTaxYear id="Factid_14915951" contextRef="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2011MemberusgaapTaxPeriodAxis">2011</us-gaap:OpenTaxYear>
<us-gaap:OpenTaxYear id="Factid_14915952" contextRef="P07_01_2019To06_30_2020_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis">2019</us-gaap:OpenTaxYear>
<bntc:PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards id="Factid_14915953" contextRef="PAsOn06_30_2020_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.50</bntc:PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards>
<us-gaap:ForeignCurrencyExchangeRateTranslation1 id="Factid_14915959" contextRef="PAsOn06_30_2020" unitRef="Unit_pure" decimals="4">0.6877</us-gaap:ForeignCurrencyExchangeRateTranslation1>
<us-gaap:ForeignCurrencyExchangeRateTranslation1 id="Factid_14915960" contextRef="PAsOn06_30_2019" unitRef="Unit_pure" decimals="4">0.7014</us-gaap:ForeignCurrencyExchangeRateTranslation1>
<bntc:AverageForeignExchangeRateForThePeriod id="Factid_14915961" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="4">0.6711</bntc:AverageForeignExchangeRateForThePeriod>
<bntc:AverageForeignExchangeRateForThePeriod id="Factid_14915962" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.7149</bntc:AverageForeignExchangeRateForThePeriod>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915963" contextRef="P07_01_2019To06_30_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915964" contextRef="P07_01_2019To06_30_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915965" contextRef="P07_01_2019To06_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915966" contextRef="P07_01_2019To06_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915967" contextRef="P07_01_2019To06_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915968" contextRef="P07_01_2019To06_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915969" contextRef="P07_01_2019To06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_14915970" contextRef="P07_01_2019To06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="Factid_14915971" contextRef="P07_01_2019To06_30_2020_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:ForeignCurrencyExchangeRateTranslation1 id="Factid_14915972" contextRef="PAsOn06_30_2018" unitRef="Unit_pure" decimals="4">0.7385</us-gaap:ForeignCurrencyExchangeRateTranslation1>
<bntc:FinancialAssetsAtFairValue id="Factid_14915973" contextRef="PAsOn06_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</bntc:FinancialAssetsAtFairValue>
<bntc:FinancialAssetsAtFairValue id="Factid_14915974" contextRef="PAsOn06_30_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</bntc:FinancialAssetsAtFairValue>
<us-gaap:FinancialLiabilitiesFairValueDisclosure id="Factid_14915975" contextRef="PAsOn06_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure id="Factid_14915976" contextRef="PAsOn06_30_2019_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_14915977" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_shares" decimals="INF">145421</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_14915978" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_shares" decimals="INF">38326</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ConcentrationRiskPercentage1 id="Factid_14915979" contextRef="P07_01_2019To06_30_2020_GrantReceivableOnResearchAndDevelopmentExpendituresMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="3">0.435</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 id="Factid_14915980" contextRef="P07_01_2018To06_30_2019_GrantReceivableOnResearchAndDevelopmentExpendituresMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="3">0.435</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="Factid_14915986" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="3">1.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="Factid_14915987" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="3">1.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_14915988" contextRef="P07_01_2019To06_30_2020">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="Factid_14915989" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="4">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="Factid_14915990" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_pure" decimals="4">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="Factid_14915991" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="3">1.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="Factid_14915992" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="3">1.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_14915993" contextRef="P07_01_2018To06_30_2019">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="Factid_14915994" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="Factid_14915995" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_pure" decimals="4">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_14915996" contextRef="P07_01_2019To06_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">16000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_14915997" contextRef="P07_01_2018To06_30_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">87000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_14915998" contextRef="P07_01_2019To06_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">221000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_14915999" contextRef="P07_01_2018To06_30_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">585000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_14916000" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">237000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_14916001" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD" decimals="-3">672000</us-gaap:AllocatedShareBasedCompensationExpense>
<bntc:ClassOfWarrantsOrRightsGrantsInPeriod id="Factid_14916006" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_shares" decimals="0">241716</bntc:ClassOfWarrantsOrRightsGrantsInPeriod>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod id="Factid_14916007" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">10.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod>
<bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod id="Factid_14916008" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_shares" decimals="0">27526</bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod id="Factid_14916009" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">10.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod>
<bntc:ClassOfWarrantsOrRightsCashlessExerciseOfWarrants id="Factid_14916010" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_shares" decimals="0">107095</bntc:ClassOfWarrantsOrRightsCashlessExerciseOfWarrants>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants id="Factid_14916011" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">10.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding id="Factid_14916013" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">29.48</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_14916014" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">81591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_14916015" contextRef="P07_01_2018To06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">27333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Factid_14916016" contextRef="P07_01_2018To06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">22457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_14916017" contextRef="PAsOn06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">86467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Factid_14916018" contextRef="PAsOn06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">27022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Factid_14916019" contextRef="P07_01_2019To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">16306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_14916020" contextRef="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">70161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Factid_14916021" contextRef="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">41829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_14916022" contextRef="PAsOn06_30_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">92.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_14916023" contextRef="P07_01_2018To06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">43.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Factid_14916024" contextRef="P07_01_2018To06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">125.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_14916025" contextRef="PAsOn06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">64.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Factid_14916026" contextRef="PAsOn06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">64.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Factid_14916027" contextRef="P07_01_2019To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">102.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_14916028" contextRef="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">60.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Factid_14916029" contextRef="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">69.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:CommonStockSharesIssued id="Factid_14916034" contextRef="PAsOn09_30_2019_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF">186666</us-gaap:CommonStockSharesIssued>
<us-gaap:SaleOfStockPricePerShare id="Factid_14916035" contextRef="PAsOn09_30_2019_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="INF">10.50</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_14916036" contextRef="PAsOn09_30_2019_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF">27526</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_14916037" contextRef="PAsOn09_30_2019_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF">10.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<bntc:PercentageOfOwnershipOfCommonStockPostWarrantExcercises id="Factid_14916038" contextRef="PAsOn09_30_2019_BeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="INF">0.0999</bntc:PercentageOfOwnershipOfCommonStockPostWarrantExcercises>
<bntc:NumberOfSeriesWarrantsIssued id="Factid_14916039" contextRef="PAsOn09_30_2019_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF">4</bntc:NumberOfSeriesWarrantsIssued>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_14916041" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF">214190</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_14916042" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF">10.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<bntc:CashlessExerciseOfPurchaseWarrants id="Factid_14916043" contextRef="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">37417</bntc:CashlessExerciseOfPurchaseWarrants>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_14916044" contextRef="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">107095</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<bntc:NumberOfSeriesWarrantsIssued id="Factid_14916047" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF">4</bntc:NumberOfSeriesWarrantsIssued>
<us-gaap:WarrantsAndRightsOutstandingTerm id="Factid_14916048" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:WarrantsAndRightsOutstandingMaturityDate id="Factid_14916049" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">2024-12-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Factid_14916050" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="0">242000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Factid_14916051" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0">907000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:NetIncomeLoss id="Factid_14916052" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3">-8274000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_14916056" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">-8.10</us-gaap:EarningsPerShareBasicAndDiluted>
<bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock id="Factid_14916058" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&amp;#160;30, 2020, and 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exchange rate on balance sheet dates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.6877&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.7014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Average exchange rate for the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.6711&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;0.7149&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Factid_14916066" contextRef="P07_01_2018To06_30_2019_AUsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="INF">0.275</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<bntc:NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack id="Factid_14916067" contextRef="P07_01_2019To06_30_2020_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis">P5Y</bntc:NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack>
<bntc:PercentageOfAnnualTaxableIncomeEligibleForDeduction id="Factid_14916068" contextRef="P07_01_2019To06_30_2020_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis_SuspensionOfAnnualDeductionLimitationMemberBNTCEventAxis" unitRef="Unit_pure" decimals="2">0.80</bntc:PercentageOfAnnualTaxableIncomeEligibleForDeduction>
<us-gaap:IncomeTaxExpenseBenefit id="Factid_14916069" contextRef="P07_01_2019To06_30_2020_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis" unitRef="Unit_USD" decimals="INF">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Factid_14916078" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Related party transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following transactions occurred with related parties: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:83%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Legal services paid/payable to a law firm in which a director of the Company is a partner and has a beneficial interest.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All transactions were made on normal commercial terms and conditions and at market rates. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2018, the Company accrued a milestone payment of $300,000 (AUD 425,411) payable to NantWorks, LLC pursuant to a sublicense agreement.&amp;#160;It was later determined that the milestone was not required to be paid and therefore the accrual was reversed in December 2019. &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nant&lt;div style="display:inline;"&gt;W&lt;/div&gt;orks, &lt;/div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LLC&amp;#160;is an affiliate of Nant Capital which owns 26.44% of the issued and outstanding common stock of the Company as of June&amp;#160;30, 2020. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock id="Factid_14916079" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following transactions occurred with related parties: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:83%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Legal services paid/payable to a law firm in which a director of the Company is a partner and has a beneficial interest.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Factid_14916080" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Contract commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&amp;#160;18, 2012, the Company announced the appointment of Synteract, Inc. as its Clinical Research Organization responsible for the progression of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TT-034&lt;/div&gt; into Phase I/IIa clinical trials in the U.S. The Company has negotiated a contract for Synteract to continue to manage the Phase I/IIa clinical trial and the long-term patient follow up through 2016 and beyond. The Company announced on February&amp;#160;20, 2016 that it was terminating the HCV program, and at the end of the 2018 financial year had assumed all patients would remain in the study and the follow up would continue to 2021 at a maximum cost of $462,000. However, in July 2018, the Company applied to the FDA for, and the FDA approved, the discontinuation of the study which will result in minimal costs being incurred in the future.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no contingent liabilities as of June&amp;#160;30, 2020 and 2019, respectively. See Note 10 above for lease commitments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock id="Factid_14916081" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (loss) before provision for income taxes consisted of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(299&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;169&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(7,975&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;2,440&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(8,274&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;2,609&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%;font-family: times new roman;font-size: 10pt;margin-top: 0;margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The tax effects of significant items comprising the Company&amp;#8217;s deferred taxes are as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:72%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,632&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Capital losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;209&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;193&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Lease liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,447&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,075&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Less valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(13,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(11,075&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &amp;#8220;more likely than not.&amp;#8221; Realization of the future tax benefits is dependent on the Company&amp;#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&amp;#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. As of June&amp;#160;30, 2020, and 2019, the Company established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The valuation allowance increased by $2,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;215&lt;/div&gt; during the year ended June&amp;#160;30, 2020. Net operating losses and tax credit carryforwards as of June&amp;#160;30, 2020 are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:67%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&amp;#160;Years&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net operating losses, federal (post-December 31, 2017)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;629&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;Do&amp;#160;not&amp;#160;expire&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Net operating losses, federal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(pre-January&lt;/div&gt; 1, 2018)&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;192&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;2034-2036&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net operating losses, state&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,314&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2031-2034&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses, foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;45,847&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;Do not expire&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Tax credits, foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The effective rate of the Company&amp;#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:80%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal&amp;#160;Year&amp;#160;Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;21.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;27.50&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(2.4&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;6.18&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development expenditures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15.73&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development incentive&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(6.87&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Share-based payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(0.74&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.06&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(42.3&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(24.12&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(7.3&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign tax rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;6.26&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(0.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to taxation in the U.S., various state jurisdictions and Australia. The Company&amp;#8217;s tax returns for the tax years 2014 through 2019 are open and are subject to examination by federal taxing authorities and the Company&amp;#8217;s tax returns for tax years 2011 through 2019 are subject to examination by state taxing authorities. The Company is not currently undergoing a tax audit in any federal, state or Australian jurisdiction.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company does not have any uncertain tax benefits &amp;#8220;(UTBs)&amp;#8221; as o&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;f&lt;/div&gt;&amp;#160;June 30, 2020 and does not expect its UTBs to change significantly over the next 12 months.&lt;/div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the fiscal year ended June 30, 2019, the Company was domiciled in Australia where the statutory rate was 27.5%. As a result, the presentation of the tax disclosures, including effective tax rate, were based on Australian statutory rules. In the fiscal year ended June 30, 2019, the net operating losses presented in the effective tax rate could also be viewed as a chance in valuation allowance. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Internal Revenue Code Section&amp;#160;382 places a limitation (&amp;#8220;Section&amp;#160;382 Limitation&amp;#8221;) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section&amp;#160;382 Limitation. Due to these &amp;#8220;change in ownership&amp;#8221; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under Australian income tax legislation, losses can be utilized by the Company if it satisfies firstly the Continuity of Ownership Test (&amp;#8220;COT&amp;#8221;) or if failing that, the Similar Business Test (&amp;#8220;SBT&amp;#8221;). Broadly, the COT requires a company to show that it maintained continuity of majority beneficial ownership from the beginning of the year in which a loss is incurred to the end of an income year in which a tax loss is sought to be recouped. The SBT requires a company to demonstrate that a &amp;#8220;similar business&amp;#8221; has been maintained from the time when the COT is failed and throughout the period until the end of the income year that the losses are being recouped. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&amp;#8220;CARES&amp;#8221;) Act was enacted and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a five-year net operating loss carryback for certain net operating losses, suspension of the annual deduction limitation of 80% of taxable income for certain net operating losses, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. The CARES Act also provides other non-tax benefits to assist those impacted by the pandemic. The Company evaluated the impact of the CARES Act and determined that there is no material impact to the income tax provision for the fiscal year ended June 30, 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net operating losses and limits the use of research tax credits for 2020, 2021 and 2022, respectively. The Company evaluated the impact of AB 85 and determined that the new legislation did not materially impact the Company&amp;#8217;s income tax provision for the fiscal year ended June 30,2020. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock id="Factid_14916082" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (loss) before provision for income taxes consisted of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(299&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;169&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(7,975&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;2,440&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;times new roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(8,274&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;2,609&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="Factid_14916084" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%;font-family: times new roman;font-size: 10pt;margin-top: 0;margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The tax effects of significant items comprising the Company&amp;#8217;s deferred taxes are as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:72%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,153&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,632&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Capital losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;209&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;193&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Lease liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,447&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,075&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Less valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(13,290&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(11,075&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<bntc:DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock id="Factid_14916085" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The valuation allowance increased by $2,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;215&lt;/div&gt; during the year ended June&amp;#160;30, 2020. Net operating losses and tax credit carryforwards as of June&amp;#160;30, 2020 are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:67%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&amp;#160;Years&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net operating losses, federal (post-December 31, 2017)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;629&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;Do&amp;#160;not&amp;#160;expire&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Net operating losses, federal &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(pre-January&lt;/div&gt; 1, 2018)&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;192&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;2034-2036&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net operating losses, state&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,314&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2031-2034&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses, foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;45,847&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;Do not expire&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Tax credits, foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="Factid_14916086" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The effective rate of the Company&amp;#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:80%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal&amp;#160;Year&amp;#160;Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;21.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;27.50&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(2.4&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;6.18&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development expenditures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;15.73&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development incentive&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(6.87&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Share-based payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(0.74&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.06&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(42.3&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(24.12&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(7.3&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign tax rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;6.26&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(0.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.00&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_14916087" contextRef="PAsOn06_30_2018" unitRef="Unit_shares" decimals="0">38326</us-gaap:ClassOfWarrantOrRightOutstanding>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding id="Factid_14916088" contextRef="PAsOn06_30_2018" unitRef="Unit_USD_per_Share" decimals="2">82.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding id="Factid_14916090" contextRef="PAsOn06_30_2019" unitRef="Unit_USD_per_Share" decimals="2">82.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Factid_14916091" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Stockholders&amp;#8217; equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&amp;#160;30, 2019, BBL entered into a securities purchase agreement (&amp;#8220;SPA&amp;#8221;) with certain sophisticated and professional investors (&amp;#8220;Investors&amp;#8221;) in&amp;#160;the United States&amp;#160;to issue 186,666 shares of common stock at a purchase price of&amp;#160;US$10.50&amp;#160;per share, in a registered direct offering. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&amp;#160;30, 2019, the Investors were issued 4 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants that are exercisable into 27,526 fully paid shares of common stock should the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants be exercised in full &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&amp;#8220;Pre-Funded&lt;/div&gt; Warrants&amp;#8221;). The exercise price for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants is US$10.50 per share issued on exercise of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrant. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants were exercisable at any time from issue, in whole or in part, provided that the beneficial ownership of the relevant investor in the total number of shares on issue could not exceed 9.99%. All of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants have been exercised.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&amp;#160;6, 2019, the Investors were issued 4 Purchase Warrants that were exercisable into 214,190 fully paid shares of common stock should the Purchase Warrants be exercised in full (&amp;#8220;Purchase Warrants&amp;#8221;). The exercise price for the Purchase Warrants is US$10.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (December 6, 2024). On April&amp;#160;22, 2020, the Company issued 37,417 shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for 107,095 shares of common stock. The Company did not have an effective registration statement registering, the resale of the Warrant Shares by the Holder at the time the Holder wanted to exercise the warrant therefore the Holder carried out a cashless exercise. The formula for conducting a cashless exercise was outlined in the Warrant agreement. Based on this formula, the Holder would have been entitled to receive 107,095 shares of common stock if they had exercised the Purchase Warrants for cash. Because of the cashless exercise, the holder received 37,417 shares. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to warrants during for the fiscal years ended&amp;#160;June 30, 2020 and 2019,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&amp;#160;Stock&lt;br/&gt;from Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;average&amp;#160;Exercise&lt;br/&gt;Price (per share)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at July&amp;#160;1, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;38,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;82.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding and exercisable at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;38,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;82.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;241,716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(27,526&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;10.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cashless exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(107,095&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding and exercisable at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;145,421&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29.48&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Share Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation,&lt;/div&gt; the Company assumed BBL&amp;#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation&lt;/div&gt; pursuant to the Benitec Officers&amp;#8217; and Employees&amp;#8217; Share Option Plan (the &amp;#8220;Plan&amp;#8221;). This includes the Company&amp;#8217;s assumptions of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances . Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the organization, and certain other conditions have been satisfied, generally the employee has 12 months to exercise their options or the options are cancelled. After the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation,&lt;/div&gt; no new options have been or will be issued under the Plan.&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to equity awards, which comprised of stock options during the&amp;#160;fiscal years&amp;#160;ended June&amp;#160;30, 2020 and 2019, respectively,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:30%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&amp;#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average&lt;/div&gt;&lt;br/&gt;Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average&lt;/div&gt;&lt;br/&gt;Remaining&amp;#160;Contractual&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&amp;#160;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at July&amp;#160;1, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;81,591&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;92.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;3.83&amp;#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,333&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(22,457&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;125.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;86,467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;64.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;3.58 years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;64.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(16,306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;102.66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;70,161&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;60.42&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.89 years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercisable at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;41,829&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;69.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2.59 years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:65%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;102.9-104.1&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;102.9-104.1&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;5 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;5 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;1.28-1.67&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;1.28-1.67&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Expected Volatility. &lt;/div&gt;Due to the lack of Company-specific historical or implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies in the life sciences industry. The Company selected the peer group based on comparable characteristics, including development stage, product pipeline and enterprise value. The Company computed historical volatility data using the daily closing prices for the selected companies&amp;#8217; shares during the equivalent period of the calculated expected term of the equity-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own share price becomes available. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Expected Life. &lt;/div&gt;The expected life represents the period that the equity awards are expected to be outstanding. For stock options with service conditions, it is based on the &amp;#8220;simplified method&amp;#8221; for developing the estimate of the expected life. Under this approach, the expected life is presumed to be the midpoint between the average vesting date and the end of the contractual term. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Risk-free Interest Rate. &lt;/div&gt;The Company bases the risk-free interest rate assumption on U.S. Treasury constant maturities with maturities similar to those of the expected term of the equity award being valued. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Expected Dividend Yield. &lt;/div&gt;The Company bases the expected dividend yield assumption on the fact that it has never paid&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt; &lt;/div&gt;dividends and does not expect to pay dividends in the foreseeable future. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The classification of share-based compensation expense for the fiscal years ended: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal&amp;#160;Year&amp;#160;Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;87&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;221&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;585&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;237&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;672&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of&amp;#160;June 30, 2020, and 2019, there was $242,000 and $907,000, respectively, of unrecognized share-based compensation expense related to shares of common stock issued under the Plan. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="Factid_14916092" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to warrants during for the fiscal years ended&amp;#160;June 30, 2020 and 2019,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&amp;#160;Stock&lt;br/&gt;from Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;average&amp;#160;Exercise&lt;br/&gt;Price (per share)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at July&amp;#160;1, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;38,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;82.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding and exercisable at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;38,326&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;82.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;241,716&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(27,526&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;10.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cashless exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(107,095&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding and exercisable at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;145,421&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29.48&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock id="Factid_14916093" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to equity awards, which comprised of stock options during the&amp;#160;fiscal years&amp;#160;ended June&amp;#160;30, 2020 and 2019, respectively,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:30%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&amp;#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average&lt;/div&gt;&lt;br/&gt;Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average&lt;/div&gt;&lt;br/&gt;Remaining&amp;#160;Contractual&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&amp;#160;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at July&amp;#160;1, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;81,591&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;92.10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;3.83&amp;#160;years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,333&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(22,457&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;125.40&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;86,467&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;64.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;3.58 years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;64.20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;(16,306&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;102.66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;70,161&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;60.42&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.89 years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercisable at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;41,829&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;69.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2.59 years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Factid_14916094" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:65%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;102.9-104.1&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;102.9-104.1&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;5 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;5 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;1.28-1.67&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;1.28-1.67&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock id="Factid_14916095" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The classification of share-based compensation expense for the fiscal years ended: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal&amp;#160;Year&amp;#160;Ended&lt;br/&gt;June&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;87&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;221&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;585&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;237&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;672&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_14916096" contextRef="P07_01_2017To06_30_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis">P3Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_14916097" contextRef="P07_01_2018To06_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis">P3Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_14916098" contextRef="P07_01_2019To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Factid_14916099" contextRef="P07_01_2019To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_14916102" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="0">38326</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_14916103" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="0">145421</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:UnrecognizedTaxBenefits id="Factid_14916104" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="INF">0</us-gaap:UnrecognizedTaxBenefits>
<us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit id="Factid_14916105" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="INF">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
<bntc:PercentageOfTheOutstandingCommonStockHeldByTheInvestor id="Factid_14916107" contextRef="PAsOn06_30_2020_NantWorksLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4">0.2644</bntc:PercentageOfTheOutstandingCommonStockHeldByTheInvestor>
<bntc:DeferredTaxAssetsLeaseLiabilities id="Factid_14916108" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">85000</bntc:DeferredTaxAssetsLeaseLiabilities>
<us-gaap:OperatingLossCarryforwardsLimitationsOnUse id="Factid_14916109" contextRef="P07_01_2019To06_30_2020_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis">Do not expire</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
<us-gaap:OperatingLossCarryforwardsLimitationsOnUse id="Factid_14916110" contextRef="P07_01_2019To06_30_2020_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">Do not expire</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
<bntc:PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards id="Factid_14916111" contextRef="P07_01_2019To06_30_2020_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis">P3Y</bntc:PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards>
<us-gaap:IncomeTaxExpenseBenefit id="Factid_14916113" contextRef="P07_01_2019To06_30_2020_CaliforniaAssemblyBillEightyFiveMemberBNTCUnexpectedEventAxis" unitRef="Unit_USD" decimals="INF">0</us-gaap:IncomeTaxExpenseBenefit>
<dei:EntityAddressAddressLine1 id="Factid_14916116" contextRef="P07_01_2019To06_30_2020">3940 Trust Way Hayward</dei:EntityAddressAddressLine1>
<dei:CityAreaCode id="Factid_14916117" contextRef="P07_01_2019To06_30_2020">(510)</dei:CityAreaCode>
<dei:LocalPhoneNumber id="Factid_14916118" contextRef="P07_01_2019To06_30_2020">780-0819</dei:LocalPhoneNumber>
<bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock id="Factid_14916119" contextRef="P07_01_2019To06_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:36%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="width:61%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Lab&amp;#160;equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Furniture&amp;#160;and&amp;#160;fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Computer&amp;#160;hardware&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold&amp;#160;improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
<dei:EntityIncorporationStateCountryCode id="Factid_14916120" contextRef="P07_01_2019To06_30_2020">DE</dei:EntityIncorporationStateCountryCode>
<bntc:ClassOfWarrantsOrRightsGrantsInPeriod id="Factid_14916123" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_shares" xsi:nil="true" />
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod id="Factid_14916124" contextRef="P07_01_2018To06_30_2019" unitRef="Unit_USD_per_Share" xsi:nil="true" />
<dei:EntityIncorporationStateCountryCode id="Factid_14916972" contextRef="P07_01_2019To06_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_14916973" contextRef="P07_01_2019To06_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_14916974" contextRef="P07_01_2019To06_30_2020_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_14916975" contextRef="P07_01_2019To06_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X0</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_14916976" contextRef="P07_01_2019To06_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_14916977" contextRef="P07_01_2019To06_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_14916978" contextRef="P07_01_2019To06_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_14916979" contextRef="P07_01_2019To06_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Factid_14925715" contextRef="P07_01_2019To06_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:76%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Trade payable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;282&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;1,474&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued license fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;54&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;385&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued research and development fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;498&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;155&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;61&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other payables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;76&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;741&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,494&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Factid_14925729" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">13290000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance id="Factid_14925730" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">11075000</us-gaap:DeferredTaxAssetsValuationAllowance>
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_AUD">
<xbrli:measure>iso4217:AUD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bntc-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-September-2020 [09:50:01] {PM}-->
<schema targetNamespace="http://www.benitecbiopharmainc.com/20200630" elementFormDefault="qualified" xmlns:bntc="http://www.benitecbiopharmainc.com/20200630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
<link:definition>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Business" id="Business">
<link:definition>1008 - Disclosure - Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Basis of presentation and summary of significant accounting policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" id="GoingConcern">
<link:definition>1010 - Disclosure - Going concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Revenue" id="Revenue">
<link:definition>1011 - Disclosure - Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
<link:definition>1012 - Disclosure - Cash and cash equivalents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables" id="TradeAndOtherReceivables">
<link:definition>1013 - Disclosure - Trade and other receivables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/OtherAssets" id="OtherAssets">
<link:definition>1014 - Disclosure - Other assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1015 - Disclosure - Property and equipment, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
<link:definition>1016 - Disclosure - Trade and other payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Leases" id="Leases">
<link:definition>1017 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1018 - Disclosure - Stockholders' equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1020 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1021 - Disclosure - Related party transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
<link:definition>1022 - Disclosure - Earnings (Loss) per share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1023 - Disclosure - Subsequent events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1024 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" id="BusinessTables">
<link:definition>1025 - Disclosure - Business (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1026 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" id="RevenueTables">
<link:definition>1027 - Disclosure - Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
<link:definition>1028 - Disclosure - Cash and cash equivalents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesTables" id="TradeAndOtherReceivablesTables">
<link:definition>1029 - Disclosure - Trade and other receivables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsTables" id="OtherAssetsTables">
<link:definition>1030 - Disclosure - Other assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1031 - Disclosure - Property and equipment, net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
<link:definition>1032 - Disclosure - Trade and other payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" id="LeasesTables">
<link:definition>1033 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1034 - Disclosure - Stockholders' equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1035 - Disclosure - Income taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>1036 - Disclosure - Related party transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareTables" id="EarningsLossPerShareTables">
<link:definition>1037 - Disclosure - Earnings (Loss) per share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" id="BusinessSummaryOfEntitiesInControlDetail">
<link:definition>1038 - Disclosure - Business - Summary of entities in control (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" id="BusinessAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Business - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail">
<link:definition>1040 - Disclosure - Basis of presentation and summary of significant accounting policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<link:definition>1041 - Disclosure - Basis of presentation and summary of significant accounting policies - Summary of property and equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1042 - Disclosure - Basis of presentation and summary of significant accounting policies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" id="GoingConcernAdditionalInformationDetail">
<link:definition>1043 - Disclosure - Going concern - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" id="RevenueSummaryOfRevenueFromCustomersDetail">
<link:definition>1044 - Disclosure - Revenue - Summary of revenue from customers (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfOtherRevenueFromCustomersDetail" id="RevenueSummaryOfOtherRevenueFromCustomersDetail">
<link:definition>1045 - Disclosure - Revenue - Summary of other revenue from customers (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail" id="RevenueSummaryOfDisaggregationOfRevenueDetail">
<link:definition>1046 - Disclosure - Revenue - Summary of disaggregation of revenue (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" id="CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<link:definition>1047 - Disclosure - Cash and cash equivalents - Summary of cash and cash equivalent (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" id="TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail">
<link:definition>1048 - Disclosure - Trade and other receivables - Summary of trade and other receivables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical" id="TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical">
<link:definition>1049 - Disclosure - Trade and other receivables - Summary of trade and other receivables (Detail) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" id="OtherAssetsSummaryOfOtherAssetsDetail">
<link:definition>1050 - Disclosure - Other assets - Summary of other assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<link:definition>1051 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Property and equipment, net - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" id="TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<link:definition>1053 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" id="LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<link:definition>1054 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<link:definition>1055 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
<link:definition>1056 - Disclosure - Leases - Additional information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" id="StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<link:definition>1057 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" id="StockholdersEquityScheduleOfEquityAwardsDetail">
<link:definition>1058 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" id="StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail">
<link:definition>1059 - Disclosure - Stockholders' equity - Summary of equity-based compensation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" id="StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1060 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1061 - Disclosure - Stockholders' equity - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" id="IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail">
<link:definition>1062 - Disclosure - Income taxes - Summary of income (loss) before provision for income taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" id="IncomeTaxesSummaryOfCompanySDeferredTaxesDetail">
<link:definition>1063 - Disclosure - Income taxes - Summary of company's deferred taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" id="IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail">
<link:definition>1064 - Disclosure - Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" id="IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail">
<link:definition>1065 - Disclosure - Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1066 - Disclosure - Income taxes - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Commitments and contingencies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail" id="RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail">
<link:definition>1068 - Disclosure - Related party transactions - Summary of related party transactions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1069 - Disclosure - Related party transactions - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareSummaryOfEarningsLossPerShareDetail" id="EarningsLossPerShareSummaryOfEarningsLossPerShareDetail">
<link:definition>1070 - Disclosure - Earnings (Loss) per share - Summary of earnings (loss) per share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetailAlternate1" id="LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetailAlternate1">
<link:definition>1071 - Statement - Leases - Summary of maturities of the operating lease liabilities (Detail) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="RoyaltiesAndLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RoyaltiesAndLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceAndExerciseOfPrefundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IssuanceAndExerciseOfPrefundedWarrants" substitutionGroup="xbrli:item" />
<element name="CashlessExerciseOfPurchaseWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_CashlessExerciseOfPurchaseWarrants" substitutionGroup="xbrli:item" />
<element name="IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmortizationOfRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AmortizationOfRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreasedecreaseInAccountsAndOtherPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreasedecreaseInAccountsAndOtherPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreaseDecreaseInLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfEntitiesInControlAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherReceivablesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_TradeAndOtherReceivablesDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherPayablesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_TradeAndOtherPayablesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfTradeAndOtherReceivablesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfEntitiesInControlLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlLineItems" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedBblMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedBblMember" substitutionGroup="xbrli:item" />
<element name="BenitecAustraliaProprietaryLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecAustraliaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecIncMember" substitutionGroup="xbrli:item" />
<element name="RnaiTherapeuticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_RnaiTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="TacereTherapeuticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_TacereTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="BenitecLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLlcMember" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesRedomiciliationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_CommonStockSharesRedomiciliationDescription" substitutionGroup="xbrli:item" />
<element name="AverageForeignExchangeRateForThePeriod" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AverageForeignExchangeRateForThePeriod" substitutionGroup="xbrli:item" />
<element name="LabEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="FinancialAssetsAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_FinancialAssetsAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GrantReceivableOnResearchAndDevelopmentExpendituresMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" substitutionGroup="xbrli:item" />
<element name="Otherdeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_Otherdeposits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MarketValueOfListedShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_MarketValueOfListedShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedLicenceFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedLicenceFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedResearchAndDevelopmentFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedResearchAndDevelopmentFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClassOfWarrantsOrRightsGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsGrantsInPeriod" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsExcercisedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" substitutionGroup="xbrli:item" />
<element name="NumberOfSeriesWarrantsIssued" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_NumberOfSeriesWarrantsIssued" substitutionGroup="xbrli:item" />
<element name="PercentageOfOwnershipOfCommonStockPostWarrantExcercises" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" substitutionGroup="xbrli:item" />
<element name="SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SecuritiesPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="PrefundedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PrefundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PurchaseWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PurchaseWarrantsMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_DeferredTaxAssetsLeaseLiabilities" substitutionGroup="xbrli:item" />
<element name="DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PeriodDomain" substitutionGroup="xbrli:item" />
<element name="NolFromTwoThousandEighteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_NolFromTwoThousandEighteenMember" substitutionGroup="xbrli:item" />
<element name="NolUptoTwoThousandEighteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_NolUptoTwoThousandEighteenMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_YearTwoThousandAndThirtyFourMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtySixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_YearTwoThousandAndThirtySixMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_YearTwoThousandAndThirtyOneMember" substitutionGroup="xbrli:item" />
<element name="DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" substitutionGroup="xbrli:item" />
<element name="YearOfExpiryOfOperatingLossesCarryForwards" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_YearOfExpiryOfOperatingLossesCarryForwards" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" substitutionGroup="xbrli:item" />
<element name="PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" substitutionGroup="xbrli:item" />
<element name="NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" substitutionGroup="xbrli:item" />
<element name="PercentageOfAnnualTaxableIncomeEligibleForDeduction" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" substitutionGroup="xbrli:item" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_EventDomain" substitutionGroup="xbrli:item" />
<element name="SuspensionOfAnnualDeductionLimitationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SuspensionOfAnnualDeductionLimitationMember" substitutionGroup="xbrli:item" />
<element name="UnexpectedEventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_UnexpectedEventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="UnexpectedEventDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_UnexpectedEventDomain" substitutionGroup="xbrli:item" />
<element name="CoronavirusAidReliefAndEconomicSecurityActMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CoronavirusAidReliefAndEconomicSecurityActMember" substitutionGroup="xbrli:item" />
<element name="CaliforniaAssemblyBillEightyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CaliforniaAssemblyBillEightyFiveMember" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CommitmentsAndContingenciesDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CommitmentsAndContingenciesDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="EstimatedResearchCostsToBeIncurred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_EstimatedResearchCostsToBeIncurred" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LegalExpensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LegalExpensesMember" substitutionGroup="xbrli:item" />
<element name="NantWorksLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_NantWorksLlcMember" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentAccruedDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_MilestonePaymentAccruedDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfTheOutstandingCommonStockHeldByTheInvestor" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentReversedDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_MilestonePaymentReversedDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>bntc-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-September-2020 [09:50:01] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#OtherAssetsSummaryOfOtherAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetailAlternate1" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetailAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DepositAssets" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_BNTC_AmortizationOfRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_AmortizationOfRightOfUseAssets" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_DueFromBanks" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_TimeDepositsAtCarryingValue" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="loc_us-gaap_GrantsReceivableCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_BNTC_RoyaltiesAndLicenseFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_BNTC_RoyaltiesAndLicenseFees" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomerOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomerOther" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="16" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_SecurityDeposit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_Otherdeposits" xlink:label="loc_BNTC_Otherdeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_BNTC_Otherdeposits" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_BNTC_MarketValueOfListedShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_BNTC_MarketValueOfListedShares" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_BNTC_AccruedLicenceFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedLicenceFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:label="loc_BNTC_AccruedResearchAndDevelopmentFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedResearchAndDevelopmentFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetailAlternate1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_BNTC_DeferredTaxAssetsLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_BNTC_DeferredTaxAssetsLeaseLiabilities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="9" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:label="loc_BNTC_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BNTC_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:label="loc_BNTC_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BNTC_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" use="optional" order="8" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>bntc-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-September-2020 [09:50:01] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueSummaryOfOtherRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfOtherRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueSummaryOfDisaggregationOfRevenueDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesAdditionalInformationDetails" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CashAndCashEquivalents" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CashAndCashEquivalentsTables" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#OtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#OtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#OtherAssetsSummaryOfOtherAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#EarningsLossPerShare" roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#EarningsLossPerShareTables" roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactionsTables" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesTables" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#EarningsLossPerShareSummaryOfEarningsLossPerShareDetail" roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareSummaryOfEarningsLossPerShareDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747068" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_StatementTable_747523" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_747533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747525" xlink:to="loc_us-gaap_GrantMember_747533" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StatementTable_747147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrants_747181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedWarrants_747181" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_747182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_747182" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_747909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_747909" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:label="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" xlink:to="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747931" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_747935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_747935" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_RoyaltyMember_747417" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_ServiceMember_747418" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfOtherRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747389" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747389" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747386" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747386" xlink:to="loc_srt_ProductOrServiceAxis_747390" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747390" xlink:to="loc_srt_ProductsAndServicesDomain_747392" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747392_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747390" xlink:to="loc_srt_ProductsAndServicesDomain_747392_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_747393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747392" xlink:to="loc_us-gaap_GrantMember_747393" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747389" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747396" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747361" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747361" xlink:to="loc_us-gaap_StatementTable_747358" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_747367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_747367" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_747368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredOverTimeMember_747368" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_srt_ProductOrServiceAxis_747665" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747665" xlink:to="loc_srt_ProductsAndServicesDomain_747666" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747666_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747665" xlink:to="loc_srt_ProductsAndServicesDomain_747666_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_LicenseMember_747667" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_RoyaltyMember_747668" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_ServiceMember_747669" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747361" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_747486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_747486" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_StatementTable_748512" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_748517" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseLiability_747646" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747647" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_StatementTable_748057" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_748063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_748062" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_748063" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_748016" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_748015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_748015" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_748019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_TypeOfArrangementAxis_748019" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_748019" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_748019" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SecuritiesPurchaseAgreementMember" xlink:label="loc_bntc_SecuritiesPurchaseAgreementMember_748021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" xlink:to="loc_bntc_SecuritiesPurchaseAgreementMember_748021" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_748023_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_748023_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PrefundedWarrantsMember" xlink:label="loc_bntc_PrefundedWarrantsMember_748024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" xlink:to="loc_bntc_PrefundedWarrantsMember_748024" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember_748438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" xlink:to="loc_bntc_PurchaseWarrantsMember_748438" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_748029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" xlink:to="loc_us-gaap_RelatedPartyDomain_748029" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_748029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" xlink:to="loc_us-gaap_RelatedPartyDomain_748029_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="loc_us-gaap_BeneficialOwnerMember_748030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_748029" xlink:to="loc_us-gaap_BeneficialOwnerMember_748030" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_748439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_748439" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_748440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_748439" xlink:to="loc_us-gaap_EquityComponentDomain_748440" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_748440_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_748439" xlink:to="loc_us-gaap_EquityComponentDomain_748440_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_748441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_748440" xlink:to="loc_us-gaap_CommonStockMember_748441" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_748017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_CommonStockSharesIssued_748017" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_748018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_748018" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued_748031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_bntc_NumberOfSeriesWarrantsIssued_748031" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_748032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_748032" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_748033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_748033" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:label="loc_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises_748035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises_748035" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_748037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_748037" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_748038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_748038" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_748039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_748039" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_bntc_PeriodAxis_747818" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_PeriodAxis_747818" xlink:to="loc_bntc_PeriodDomain_747819" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747819_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_PeriodAxis_747818" xlink:to="loc_bntc_PeriodDomain_747819_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NolFromTwoThousandEighteenMember" xlink:label="loc_bntc_NolFromTwoThousandEighteenMember_747820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NolFromTwoThousandEighteenMember_747820" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NolUptoTwoThousandEighteenMember" xlink:label="loc_bntc_NolUptoTwoThousandEighteenMember_747821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NolUptoTwoThousandEighteenMember_747821" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747822" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747822" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747823" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747822" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747823_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747824" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_DomesticCountryMember_747825" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_747827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_ForeignCountryMember_747827" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_TaxPeriodAxis_747828" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_747828" xlink:to="loc_us-gaap_TaxPeriodDomain_747829" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747829_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_747828" xlink:to="loc_us-gaap_TaxPeriodDomain_747829_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtyFourMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtySixMember" xlink:label="loc_bntc_YearTwoThousandAndThirtySixMember_747831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtySixMember_747831" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtyOneMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_747834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwards_747834" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:label="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncomeTaxDisclosureLineItems" xlink:label="loc_bntc_IncomeTaxDisclosureLineItems_747872" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncomeTaxDisclosureTable" xlink:label="loc_bntc_IncomeTaxDisclosureTable_747855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_IncomeTaxDisclosureTable_747855" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747856" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747856" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747857" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747857_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747856" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747857_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_DomesticCountryMember_747858" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747859" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_TaxPeriodAxis_747860" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_747860" xlink:to="loc_us-gaap_TaxPeriodDomain_747861" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_747860" xlink:to="loc_us-gaap_TaxPeriodDomain_747861_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2014Member" xlink:label="loc_us-gaap_TaxYear2014Member_747862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2014Member_747862" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2019Member" xlink:label="loc_us-gaap_TaxYear2019Member_747863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2019Member_747863" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2011Member" xlink:label="loc_us-gaap_TaxYear2011Member_747864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2011Member_747864" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_747867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_747867" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_RangeAxis_747868" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_747868" xlink:to="loc_srt_RangeMember_747869" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747869_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_747868" xlink:to="loc_srt_RangeMember_747869_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747869" xlink:to="loc_srt_MinimumMember_747871" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_748278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_StatementGeographicalAxis_748278" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_748279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_748278" xlink:to="loc_srt_SegmentGeographicalDomain_748279" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_748279_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_748278" xlink:to="loc_srt_SegmentGeographicalDomain_748279_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_748280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_748279" xlink:to="loc_country_AU_748280" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis_748284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_EventAxis_748284" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_748285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_EventAxis_748284" xlink:to="loc_bntc_EventDomain_748285" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_748285_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_EventAxis_748284" xlink:to="loc_bntc_EventDomain_748285_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:label="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_EventDomain_748285" xlink:to="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_UnexpectedEventAxis" xlink:label="loc_bntc_UnexpectedEventAxis_748287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_UnexpectedEventAxis_748287" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain_748288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_UnexpectedEventAxis_748287" xlink:to="loc_bntc_UnexpectedEventDomain_748288" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain_748288_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_UnexpectedEventAxis_748287" xlink:to="loc_bntc_UnexpectedEventDomain_748288_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:label="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_747874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_OpenTaxYear_747874" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_748277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_748277" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:label="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:label="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_748283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_748283" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_748322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_748322" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_748323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_748323" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xlink:to="loc_bntc_PeriodAxis_747705" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_PeriodAxis_747705" xlink:to="loc_bntc_PeriodDomain_747706" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747706_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_PeriodAxis_747705" xlink:to="loc_bntc_PeriodDomain_747706_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EstimatedResearchCostsToBeIncurred" xlink:label="loc_bntc_EstimatedResearchCostsToBeIncurred_747709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_bntc_EstimatedResearchCostsToBeIncurred_747709" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747710" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747686" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747686" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747682" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747682" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747683" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747683" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747684" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747684_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747683" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747684_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_LegalExpensesMember" xlink:label="loc_bntc_LegalExpensesMember_747685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747684" xlink:to="loc_bntc_LegalExpensesMember_747685" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_747687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747686" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_747687" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NantWorksLlcMember" xlink:label="loc_bntc_NantWorksLlcMember_747693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_NantWorksLlcMember_747693" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_MilestonePaymentAccruedDuringThePeriod" xlink:label="loc_bntc_MilestonePaymentAccruedDuringThePeriod_747695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_bntc_MilestonePaymentAccruedDuringThePeriod_747695" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:label="loc_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor_747698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor_747698" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_MilestonePaymentReversedDuringThePeriod" xlink:label="loc_bntc_MilestonePaymentReversedDuringThePeriod_748360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_bntc_MilestonePaymentReversedDuringThePeriod_748360" use="optional" order="8" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>bntc-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-September-2020 [09:50:01] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" xlink:type="locator"/>
    <label xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <label xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</label>
    <label xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" xlink:type="locator"/>
    <label xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <label xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <label xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</label>
    <label xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</label>
    <label xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" xlink:type="locator"/>
    <label xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" xlink:type="locator"/>
    <label xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <label xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" xlink:type="locator"/>
    <label xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_dei_EntityListingParValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityListingParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listing, Par Value Per Share</label>
    <label xlink:label="lab_dei_EntityListingParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listing, Par Value Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingParValuePerShare" xlink:to="lab_dei_EntityListingParValuePerShare" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</label>
    <label xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</label>
    <label xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal place of business/country of incorporation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" xlink:type="locator"/>
    <label xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <label xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee benefits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, current portion</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Current portion at June&#xA0;30, 2020</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, less current portion</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: non-current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</label>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 13)</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value&#x2014;10,000,000 shares authorized; 1,108,374 and 856,765 shares issued and outstanding at June&#xA0;30, 2020 and 2019, respectively</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Initial measurement at July&#xA0;1, 2019</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset at June&#xA0;30, 2020</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit Assets</label>
    <label xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</label>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <label xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <label xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</label>
    <label xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Par Value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Shares Authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</label>
    <label xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:type="resource" xml:lang="en-US">Government research and development grants [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from customers</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:type="resource" xml:lang="en-US">Revenues from customers</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Disaggregated revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomerOther" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomerOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Not from Contract with Customer, Other</label>
    <label xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomerOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government research and development grants</label>
    <label xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomerOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomerOther" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomerOther" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</label>
    <label xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees" xlink:type="locator"/>
    <label xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties And License Fees</label>
    <label xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties and license fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RoyaltiesAndLicenseFees" xlink:to="lab_bntc_RoyaltiesAndLicenseFees" xlink:type="arc"/>
    <label xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties and license fees</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</label>
    <label xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (loss):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency transaction loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <label xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investment</label>
    <label xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency translation loss</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income (loss)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings (loss) per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Net Income (Loss) attributable to common stockholders</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares used in calculating basic and diluted earnings per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning (In shares)</label>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end (In shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock sold for cash, net of offering costs of $240</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock sold for cash, net of offering costs of $240, Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance and exercise of prefunded warrants</label>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance and exercise of pre-funded warrants, net of transaction costs of $240, Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:to="lab_bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance and exercise of pre-funded warrants.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cashless exercise of purchase warrants</label>
    <label xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise of purchase warrants (In shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CashlessExerciseOfPurchaseWarrants" xlink:to="lab_bntc_CashlessExerciseOfPurchaseWarrants" xlink:type="arc"/>
    <label xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cashless exercise of purchase warrants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, Forfeited</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture of share-based payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance and exercise of prefunded warrants net of transaction costs</label>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance and exercise of pre-funded warrants, net of transaction costs of $240</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:to="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance and exercise of pre-funded warrants, net of transaction costs.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</label>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments For Stock Issuance Costs</label>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share issue transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash from operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets" xlink:type="locator"/>
    <label xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Right of Use Assets</label>
    <label xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AmortizationOfRightOfUseAssets" xlink:to="lab_bntc_AmortizationOfRightOfUseAssets" xlink:type="arc"/>
    <label xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease in Accounts and Other Payables</label>
    <label xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:to="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accounts and other payables.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee benefit payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Lease Liabilities</label>
    <label xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease In lease liabilities.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in provided by operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issues of shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Initial measurement of operating lease right-of-use assets and liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract" xlink:to="lab_bntc_ScheduleOfEntitiesInControlAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GoingConcernAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernAbstract" xlink:to="lab_bntc_GoingConcernAbstract" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GoingConcernAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Going concern</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern Disclosure [Text Block]</label>
    <label xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going concern</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernDisclosureTextBlock" xlink:to="lab_bntc_GoingConcernDisclosureTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Going concern disclosure.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other receivables disclosure [Text Block]</label>
    <label xlink:label="lab_bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade and other receivables disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transactions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (Loss) per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation and Other Comprehensive Income (Loss)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Risk</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and Other Receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables [Policy Text Block]</label>
    <label xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:to="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade and other payables.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:label="loc_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australian Goods and Services Tax GST and other similar taxes [Policy Text Block]</label>
    <label xlink:label="lab_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Australian Goods and Services Tax ("GST") and other similar taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:to="lab_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Australian Goods and Services Tax GST and other similar taxes.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Research and Development Grants [Policy Text Block]</label>
    <label xlink:label="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government Research and Development Grants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:to="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Research and Development Grants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity-based Compensation Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards recently adopted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:label="loc_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Standards and Interpretations not yet mandatory or early adopted [Policy Text Block]</label>
    <label xlink:label="lab_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Standards and Interpretations not yet mandatory or early adopted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:to="lab_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Accounting Standards and Interpretations not yet mandatory or early adopted.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Table Text Block]</label>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of entities in control</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of entities in control.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:label="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Translation Rates [Table Text Block]</label>
    <label xlink:label="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of foreign currency translation and other comprehensive income (loss)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:to="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of foreign currency translation rates.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</label>
    <label xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of property plant and equipment useful lives.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of revenue from customers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entity Wide Information Other Revenue [Table Text Block]</label>
    <label xlink:label="lab_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of other revenue from customers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:to="lab_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of entity wide information other revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of disaggregation of revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of cash and cash equivalent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:label="loc_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Trade and other receivables [Table Text Block]</label>
    <label xlink:label="lab_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of trade and other receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:to="lab_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of trade and other receivables.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of property and equipment net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]</label>
    <label xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of supplemental balance sheet information related to leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of maturities of the operating lease liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of warrants or rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of equity awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of equity-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-basedcompensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of income (loss) before provision for income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of company's deferred taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Table Text Block]</label>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of net operating losses and tax credit carryforwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:to="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure details of operating loss carry forwards and tax credits.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary reconciliation of effective rate of the company's provision (benefit) for income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of related party transactions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of earnings (loss) per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTable" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems" xlink:to="lab_bntc_ScheduleOfEntitiesInControlLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <label xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited BBL [Member]</label>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited ("BBL") [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
    <label xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Limited [Member]</label>
    <label xlink:label="lab_bntc_BenitecLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Limited [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLimitedMember" xlink:to="lab_bntc_BenitecLimitedMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Inc [Member]</label>
    <label xlink:label="lab_bntc_BenitecIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecIncMember" xlink:to="lab_bntc_BenitecIncMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RNAi Therapeutics Inc [Member]</label>
    <label xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RNAi Therapeutics, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RnaiTherapeuticsIncMember" xlink:to="lab_bntc_RnaiTherapeuticsIncMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_TacereTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tacere Therapeutics Inc [Member]</label>
    <label xlink:label="lab_bntc_TacereTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tacere Therapeutics, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TacereTherapeuticsIncMember" xlink:to="lab_bntc_TacereTherapeuticsIncMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec LLC [Member]</label>
    <label xlink:label="lab_bntc_BenitecLlcMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec LLC [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLlcMember" xlink:to="lab_bntc_BenitecLlcMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited [Member]</label>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <label xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation Date Of Incorporation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_CommonStockSharesRedomiciliationDescription" xlink:label="loc_bntc_CommonStockSharesRedomiciliationDescription" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Shares Redomiciliation Description</label>
    <label xlink:label="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Re-domiciliation Description</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommonStockSharesRedomiciliationDescription" xlink:to="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:type="arc"/>
    <label xlink:label="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, shares, re-domiciliation description.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
    <label xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate on balance sheet dates, USD: AUD Exchange Rate</label>
    <label xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_AverageForeignExchangeRateForThePeriod" xlink:label="loc_bntc_AverageForeignExchangeRateForThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_AverageForeignExchangeRateForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Foreign Exchange Rate For The Period</label>
    <label xlink:label="lab_bntc_AverageForeignExchangeRateForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average exchange rate for the period, USD: AUD Exchange Rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AverageForeignExchangeRateForThePeriod" xlink:to="lab_bntc_AverageForeignExchangeRateForThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_AverageForeignExchangeRateForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average foreign exchange rate for the period.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <label xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member]</label>
    <label xlink:label="lab_bntc_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LabEquipmentMember" xlink:to="lab_bntc_LabEquipmentMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <label xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <label xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</label>
    <label xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
    <label xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies [Table].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies [Line Items].</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue" xlink:type="locator"/>
    <label xlink:label="lab_bntc_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Assets At Fair Value</label>
    <label xlink:label="lab_bntc_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_FinancialAssetsAtFairValue" xlink:to="lab_bntc_FinancialAssetsAtFairValue" xlink:type="arc"/>
    <label xlink:label="lab_bntc_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial assets at fair value.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</label>
    <label xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:label="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Receivable on research and development expenditures [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:to="lab_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Receivable on research and development expenditures [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</label>
    <label xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing revenue [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</label>
    <label xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</label>
    <label xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service revenue [Member]</label>
    <label xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Development Activities [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</label>
    <label xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services transferred at a point in time [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</label>
    <label xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services transferred over time [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DueFromBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Banks</label>
    <label xlink:label="lab_us-gaap_DueFromBanks" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash at Bank</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromBanks" xlink:to="lab_us-gaap_DueFromBanks" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimeDepositsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Deposits, at Carrying Value</label>
    <label xlink:label="lab_us-gaap_TimeDepositsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term Deposit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimeDepositsAtCarryingValue" xlink:to="lab_us-gaap_TimeDepositsAtCarryingValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Receivable, Current</label>
    <label xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research&#xA0;&amp; development grants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</label>
    <label xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</label>
    <label xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_Otherdeposits" xlink:label="loc_bntc_Otherdeposits" xlink:type="locator"/>
    <label xlink:label="lab_bntc_Otherdeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OtherDeposits</label>
    <label xlink:label="lab_bntc_Otherdeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other deposit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_Otherdeposits" xlink:to="lab_bntc_Otherdeposits" xlink:type="arc"/>
    <label xlink:label="lab_bntc_Otherdeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other deposits.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares" xlink:type="locator"/>
    <label xlink:label="lab_bntc_MarketValueOfListedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market value Of listed shares</label>
    <label xlink:label="lab_bntc_MarketValueOfListedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market value of listed shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MarketValueOfListedShares" xlink:to="lab_bntc_MarketValueOfListedShares" xlink:type="arc"/>
    <label xlink:label="lab_bntc_MarketValueOfListedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market value of listed shares.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</label>
    <label xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, gross</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</label>
    <label xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Licence Fees Current</label>
    <label xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued license fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedLicenceFeesCurrent" xlink:to="lab_bntc_AccruedLicenceFeesCurrent" xlink:type="arc"/>
    <label xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued licence fees current.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:label="loc_bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Fees Current</label>
    <label xlink:label="lab_bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:to="lab_bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:type="arc"/>
    <label xlink:label="lab_bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development fees current.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of right of use asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Initial measurement at July&#xA0;1, 2019</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities at June&#xA0;30, 2020</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on operating lease liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <label xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease has a remaining lease term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease discount rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Grants In Period</label>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:to="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights grants in period.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Excercised During The Period</label>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:to="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights excercised during the period.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:label="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Cashless Exercise Of Warrants</label>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:to="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights cashless exercise of warrants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Exercise price of class of warrants or rights outstanding</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercise price of class of warrants or rights outstanding and excercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price of class of warrants or rights outstanding.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Granted During The Period</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price of class of warrants or granted during the period.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Exercised During The Period</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted - average exercise price of class of warrants or exercised during the period.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Exercised During The Period Cash Less Exercise Of Warrants</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price of class of warrants or exercised during the period cash less exercise of warrants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock Options,Outstanding, beginning of period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Exercisable, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Exercise price, beginning of period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Exercise Price, Exercise price, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Exercise Price, Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Exercise Price, Forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Exercise Price, Exercisable, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Remaining Contractual Term, Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock option</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, Minimum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, Maximum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, Minimum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, Maximum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <label xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock issue price per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued" xlink:type="locator"/>
    <label xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Series Warrants Issued</label>
    <label xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of series of warrants issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NumberOfSeriesWarrantsIssued" xlink:to="lab_bntc_NumberOfSeriesWarrantsIssued" xlink:type="arc"/>
    <label xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of series warrants issued.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants convertible into shares of common stock on exercise</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercise price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:label="loc_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Ownership Of Common Stock Post Warrant Excercises</label>
    <label xlink:label="lab_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of beneficial ownership</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:to="lab_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of ownership of common stock post warrant excercises.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
    <label xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiry date of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognised share based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_SecuritiesPurchaseAgreementMember" xlink:label="loc_bntc_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <label xlink:label="lab_bntc_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities purchase agreement [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SecuritiesPurchaseAgreementMember" xlink:to="lab_bntc_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_PrefundedWarrantsMember" xlink:label="loc_bntc_PrefundedWarrantsMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prefunded Warrants [Member]</label>
    <label xlink:label="lab_bntc_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PrefundedWarrantsMember" xlink:to="lab_bntc_PrefundedWarrantsMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prefunded Warrants</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Warrants [Member]</label>
    <label xlink:label="lab_bntc_PurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase warrants [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PurchaseWarrantsMember" xlink:to="lab_bntc_PurchaseWarrantsMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase warrants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="loc_us-gaap_BeneficialOwnerMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_BeneficialOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Owner [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BeneficialOwnerMember" xlink:to="lab_us-gaap_BeneficialOwnerMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital losses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_bntc_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_bntc_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
    <label xlink:label="lab_bntc_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_bntc_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc"/>
    <label xlink:label="lab_bntc_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets lease liabilities.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:type="locator"/>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:to="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:type="arc"/>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure details of operating loss carry forwards and tax credits [Table ].</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period [Axis]</label>
    <label xlink:label="lab_bntc_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PeriodAxis" xlink:to="lab_bntc_PeriodAxis" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period [Axis]</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <label xlink:label="lab_bntc_PeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PeriodDomain" xlink:to="lab_bntc_PeriodDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_NolFromTwoThousandEighteenMember" xlink:label="loc_bntc_NolFromTwoThousandEighteenMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_NolFromTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NOL From Two Thousand Eighteen [Member]</label>
    <label xlink:label="lab_bntc_NolFromTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL From Two Thousand Eighteen [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NolFromTwoThousandEighteenMember" xlink:to="lab_bntc_NolFromTwoThousandEighteenMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_NolFromTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NOL from two thousand eighteen.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_NolUptoTwoThousandEighteenMember" xlink:label="loc_bntc_NolUptoTwoThousandEighteenMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_NolUptoTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NOL Upto Two Thousand Eighteen [Member]</label>
    <label xlink:label="lab_bntc_NolUptoTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL Upto Two Thousand Eighteen [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NolUptoTwoThousandEighteenMember" xlink:to="lab_bntc_NolUptoTwoThousandEighteenMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_NolUptoTwoThousandEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NOL upto two thousand eighteen [member].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <label xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <label xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <label xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</label>
    <label xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</label>
    <label xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtyFourMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyFourMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year Two Thousand And Thirty Four [Member]</label>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Two Thousand And Thirty Four [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_YearTwoThousandAndThirtyFourMember" xlink:to="lab_bntc_YearTwoThousandAndThirtyFourMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year two thousand and thirty four [Member].</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtySixMember" xlink:label="loc_bntc_YearTwoThousandAndThirtySixMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year Two Thousand And Thirty Six [Member]</label>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Two Thousand And Thirty Six Member [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_YearTwoThousandAndThirtySixMember" xlink:to="lab_bntc_YearTwoThousandAndThirtySixMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year two thousand and thirty six [Member].</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtyOneMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyOneMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year Two Thousand And Thirty One [Member]</label>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Two Thousand And Thirty One [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_YearTwoThousandAndThirtyOneMember" xlink:to="lab_bntc_YearTwoThousandAndThirtyOneMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_YearTwoThousandAndThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year two thousand and thirty one [Member].</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</label>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:to="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:type="arc"/>
    <label xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure details of operating loss carry forwards and tax credits [Line Items].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
    <label xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, expiration years</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:label="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:type="locator"/>
    <label xlink:label="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year Of Expiry Of Operating Losses Carry Forwards</label>
    <label xlink:label="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year of expiry of operating losses carry forwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:to="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:type="arc"/>
    <label xlink:label="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year of expiry of operating losses carry forwards.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory income tax rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:label="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:type="locator"/>
    <label xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation Percentage Permanent Differences</label>
    <label xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:to="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:type="arc"/>
    <label xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax reconciliation percentage permanent differences.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:label="loc_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:type="locator"/>
    <label xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation Percentage Net Operating Loss Carryforwards</label>
    <label xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:to="lab_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:type="arc"/>
    <label xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax reconciliation percentage net operating loss carryforwards.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax rate differential</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development incentive</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_IncomeTaxDisclosureTable" xlink:label="loc_bntc_IncomeTaxDisclosureTable" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncomeTaxDisclosureTable" xlink:to="lab_bntc_IncomeTaxDisclosureTable" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax disclosure [Table].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2014Member" xlink:label="loc_us-gaap_TaxYear2014Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TaxYear2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2014 [Member]</label>
    <label xlink:label="lab_us-gaap_TaxYear2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2014 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2014Member" xlink:to="lab_us-gaap_TaxYear2014Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2019Member" xlink:label="loc_us-gaap_TaxYear2019Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TaxYear2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2019 [Member]</label>
    <label xlink:label="lab_us-gaap_TaxYear2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2019 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2019Member" xlink:to="lab_us-gaap_TaxYear2019Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2011Member" xlink:label="loc_us-gaap_TaxYear2011Member" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TaxYear2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2011 [Member]</label>
    <label xlink:label="lab_us-gaap_TaxYear2011Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2011 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2011Member" xlink:to="lab_us-gaap_TaxYear2011Member" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
    <label xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_IncomeTaxDisclosureLineItems" xlink:label="loc_bntc_IncomeTaxDisclosureLineItems" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
    <label xlink:label="lab_bntc_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems" xlink:to="lab_bntc_IncomeTaxDisclosureLineItems" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax disclosure.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets increase in valuation allowance during the period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Tax Year</label>
    <label xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax year subject to examination</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Total Owneship Control To Be Maintained By The Current Shareholders For Availing Operating Loss Carry Forwards</label>
    <label xlink:label="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total owneship control to be maintained by the current shareholders for availing operating loss carry forwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:to="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of total ownership control to be maintained by the current shareholders for availing operating loss carry forwards.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Ownership Control For Which The Shareholders Are To Sustain Their Holding For Availing Operating Loss Carry Forwards</label>
    <label xlink:label="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:to="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:label="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:type="locator"/>
    <label xlink:label="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Years Of Certain Operating Losses That Can Be Carried Back</label>
    <label xlink:label="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of years of certain operating losses that can be carried back</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:to="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:type="arc"/>
    <label xlink:label="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of years of certain operating losses that can be carried back.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:label="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Annual Taxable Income Eligible For Deduction</label>
    <label xlink:label="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of annual Taxable income eligible for deduction</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:to="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of annual taxable income eligible for deduction.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense benefit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax benefits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</label>
    <label xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected change in unrecognised tax benefits in the next twelve months</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</label>
    <label xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU" xlink:type="locator"/>
    <label xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AUSTRALIA</label>
    <label xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australia</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis" xlink:type="locator"/>
    <label xlink:label="lab_bntc_EventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event [Axis]</label>
    <label xlink:label="lab_bntc_EventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Event [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EventAxis" xlink:to="lab_bntc_EventAxis" xlink:type="arc"/>
    <label xlink:label="lab_bntc_EventAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain" xlink:type="locator"/>
    <label xlink:label="lab_bntc_EventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event [Domain]</label>
    <label xlink:label="lab_bntc_EventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Event [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EventDomain" xlink:to="lab_bntc_EventDomain" xlink:type="arc"/>
    <label xlink:label="lab_bntc_EventDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:label="loc_bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suspension Of Annual Deduction Limitation [Member]</label>
    <label xlink:label="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Suspension Of Annual Deduction Limitation [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:to="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Suspension Of Annual Deduction Limitation</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_UnexpectedEventAxis" xlink:label="loc_bntc_UnexpectedEventAxis" xlink:type="locator"/>
    <label xlink:label="lab_bntc_UnexpectedEventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unexpected Event [Axis]</label>
    <label xlink:label="lab_bntc_UnexpectedEventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unexpected Event [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_UnexpectedEventAxis" xlink:to="lab_bntc_UnexpectedEventAxis" xlink:type="arc"/>
    <label xlink:label="lab_bntc_UnexpectedEventAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unexpected Event</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain" xlink:type="locator"/>
    <label xlink:label="lab_bntc_UnexpectedEventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unexpected Event [Domain]</label>
    <label xlink:label="lab_bntc_UnexpectedEventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unexpected Event [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_UnexpectedEventDomain" xlink:to="lab_bntc_UnexpectedEventDomain" xlink:type="arc"/>
    <label xlink:label="lab_bntc_UnexpectedEventDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unexpected Event</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act [Member]</label>
    <label xlink:label="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:to="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:label="loc_bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Assembly Bill Eighty Five [Member]</label>
    <label xlink:label="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California Assembly Bill Eighty Five [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:to="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">California assembly bill eighty five [member].</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable" xlink:to="lab_bntc_CommitmentsAndContingenciesDisclosureTable" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="lab_bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="arc"/>
    <label xlink:label="lab_bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_EstimatedResearchCostsToBeIncurred" xlink:label="loc_bntc_EstimatedResearchCostsToBeIncurred" xlink:type="locator"/>
    <label xlink:label="lab_bntc_EstimatedResearchCostsToBeIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Research Costs To Be Incurred</label>
    <label xlink:label="lab_bntc_EstimatedResearchCostsToBeIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated research costs to be incurred</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EstimatedResearchCostsToBeIncurred" xlink:to="lab_bntc_EstimatedResearchCostsToBeIncurred" xlink:type="arc"/>
    <label xlink:label="lab_bntc_EstimatedResearchCostsToBeIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated research costs to be incurred.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_LegalExpensesMember" xlink:label="loc_bntc_LegalExpensesMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_LegalExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Expenses [Member]</label>
    <label xlink:label="lab_bntc_LegalExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Expenses [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LegalExpensesMember" xlink:to="lab_bntc_LegalExpensesMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_LegalExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal expenses member.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal services paid/payable to a law firm in which a director of the Company is a partner and has a beneficial interest.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc"/>
    <loc xlink:href="bntc-20200630.xsd#bntc_NantWorksLlcMember" xlink:label="loc_bntc_NantWorksLlcMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_NantWorksLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Works LLC [Member]</label>
    <label xlink:label="lab_bntc_NantWorksLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantWorks, LLC [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NantWorksLlcMember" xlink:to="lab_bntc_NantWorksLlcMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_NantWorksLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nant Works LLC</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_MilestonePaymentAccruedDuringThePeriod" xlink:label="loc_bntc_MilestonePaymentAccruedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_MilestonePaymentAccruedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Accrued During The Period</label>
    <label xlink:label="lab_bntc_MilestonePaymentAccruedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment accrued during the period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MilestonePaymentAccruedDuringThePeriod" xlink:to="lab_bntc_MilestonePaymentAccruedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_MilestonePaymentAccruedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment accrued during the period.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:label="loc_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of The Outstanding Common Stock Held By The Investor</label>
    <label xlink:label="lab_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of the outstanding common stock held by the investor</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:to="lab_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:type="arc"/>
    <label xlink:label="lab_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the outstanding common stock held by the investor.</label>
    <loc xlink:href="bntc-20200630.xsd#bntc_MilestonePaymentReversedDuringThePeriod" xlink:label="loc_bntc_MilestonePaymentReversedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_MilestonePaymentReversedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Reversed During The Period</label>
    <label xlink:label="lab_bntc_MilestonePaymentReversedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment reversed during the period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MilestonePaymentReversedDuringThePeriod" xlink:to="lab_bntc_MilestonePaymentReversedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_MilestonePaymentReversedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment reversed during the period.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>bntc-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-September-2020 [09:50:01] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CashAndCashEquivalents" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#OtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#EarningsLossPerShare" roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CashAndCashEquivalentsTables" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#OtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesTables" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactionsTables" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#EarningsLossPerShareTables" roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueSummaryOfOtherRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfOtherRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RevenueSummaryOfDisaggregationOfRevenueDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#OtherAssetsSummaryOfOtherAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#LeasesAdditionalInformationDetails" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200630.xsd#EarningsLossPerShareSummaryOfEarningsLossPerShareDetail" roleURI="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareSummaryOfEarningsLossPerShareDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_747112" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_747113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentType_747113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_747125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AmendmentFlag_747125" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_747114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentAnnualReport_747114" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_747252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentTransitionReport_747252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_747133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFileNumber_747133" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_747131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityRegistrantName_747131" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_747126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentPeriodEndDate_747126" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_747127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalYearFocus_747127" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_747128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalPeriodFocus_747128" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_747132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCentralIndexKey_747132" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_747136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CurrentFiscalYearEndDate_747136" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_747137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_747137" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_747139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityVoluntaryFilers_747139" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_747140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCurrentReportingStatus_747140" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_747120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityInteractiveDataCurrent_747120" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_747142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFilerCategory_747142" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_747143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntitySmallBusiness_747143" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_747144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityEmergingGrowthCompany_747144" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_747151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityExTransitionPeriod_747151" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_747141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityShellCompany_747141" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_748327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityIncorporationStateCountryCode_748327" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_748405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressAddressLine1_748405" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_747161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressCountry_747161" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_747162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressPostalZipCode_747162" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_748406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CityAreaCode_748406" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_748407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_LocalPhoneNumber_748407" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_747163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_Security12bTitle_747163" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_747165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_TradingSymbol_747165" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_747166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_SecurityExchangeName_747166" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_747167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_747167" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_dei_EntityListingParValuePerShare_747170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityListingParValuePerShare_747170" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_747177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityPublicFloat_747177" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_746977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_AssetsAbstract_746977" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_746978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrentAbstract_746978" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_746981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_OtherAssetsCurrent_746981" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_746983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrent_746983" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_746986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_DepositAssets_746986" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_746988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_Assets_746988" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_746991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_746991" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_746995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrent_746995" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_747001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_Liabilities_747001" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747005" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_747013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquityAbstract_747013" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_747014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_CommonStockValue_747014" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquity_747018" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_747045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_747045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_747047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesIssued_747047" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_747049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_747049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_747061" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_747061" xlink:to="loc_us-gaap_StatementTable_747523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_747533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747525" xlink:to="loc_us-gaap_GrantMember_747533" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_us-gaap_StatementLineItems_747526" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747068" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747109" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747109" xlink:to="loc_us-gaap_StatementTable_747147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementLineItems_747150" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrants_747181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedWarrants_747181" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_747182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_747182" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747184" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747185" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747220" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747220" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_747054" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetIncomeLoss_747025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_747028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_747028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets_747029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_bntc_AmortizationOfRightOfUseAssets_747029" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_747030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_747030" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_747033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_ShareBasedCompensation_747033" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_747036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_747036" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_747037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_747037" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_747044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_747044" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_747048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_747048" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_747053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_747053" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747055" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_747056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_747056" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747057" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Business">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747291" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747291" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747261" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock_747262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747261" xlink:to="loc_bntc_GoingConcernDisclosureTextBlock_747262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Revenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747296" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747296" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_747405" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_TradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_bntc_TradeAndOtherReceivablesDisclosureTextBlock_747415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_747405" xlink:to="loc_bntc_TradeAndOtherReceivablesDisclosureTextBlock_747415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747424" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747424" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747548" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747548" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747580" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747580" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747939" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747939" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/EarningsLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747505" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_747506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747505" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_747506" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_747496" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_747497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_747496" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_747497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747292" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_747297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_747297" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_747299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_747299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_747301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_UseOfEstimates_747301" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_747305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_747305" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock" xlink:label="loc_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock_747310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock_747310" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock_747317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock_747317" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_747322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_747322" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock" xlink:label="loc_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock_747324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock_747324" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessTables">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747293" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:label="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock_747891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747293" xlink:to="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock_747891" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747293" xlink:to="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747316" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747316" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock_747334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747316" xlink:to="loc_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock_747334" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_747335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747316" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_747335" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_747406" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock" xlink:label="loc_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock_747420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_747406" xlink:to="loc_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock_747420" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747437" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747437" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747553" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747553" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747587" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747942" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_747946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_747946" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_747774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_747774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_747778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_747778" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock_747779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock_747779" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_747780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_747780" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747678" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_747679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747678" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_747679" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747510" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_747512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747510" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_747512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_747257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_747257" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CommonStockSharesRedomiciliationDescription" xlink:label="loc_bntc_CommonStockSharesRedomiciliationDescription_747258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" xlink:to="loc_bntc_CommonStockSharesRedomiciliationDescription_747258" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747895" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747895" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747896" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AverageForeignExchangeRateForThePeriod" xlink:label="loc_bntc_AverageForeignExchangeRateForThePeriod_747897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747895" xlink:to="loc_bntc_AverageForeignExchangeRateForThePeriod_747897" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747899" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747899" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_747909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_747909" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747924" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747924" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:label="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" xlink:to="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747931" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_747935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_747935" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747274" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetIncomeLoss_747276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_747399" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_747399" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_RoyaltyMember_747417" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_ServiceMember_747418" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfOtherRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_747384" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_747384" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747386" xlink:to="loc_srt_ProductOrServiceAxis_747390" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747390" xlink:to="loc_srt_ProductsAndServicesDomain_747392" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_747393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747392" xlink:to="loc_us-gaap_GrantMember_747393" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747386" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747389" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747389" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomerOther_747396" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747355" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747355" xlink:to="loc_us-gaap_StatementTable_747358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_747367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_747367" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_747368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredOverTimeMember_747368" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_srt_ProductOrServiceAxis_747665" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747665" xlink:to="loc_srt_ProductsAndServicesDomain_747666" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_LicenseMember_747667" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_RoyaltyMember_747668" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_ServiceMember_747669" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_us-gaap_StatementLineItems_747361" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747361" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks_747364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_DueFromBanks_747364" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue_747365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_TimeDepositsAtCarryingValue_747365" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747366" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_747408" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_747423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_747408" xlink:to="loc_us-gaap_GrantsReceivableCurrent_747423" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_747425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_747408" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_747425" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_747426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_747408" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_747426" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_747409" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_747442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_747409" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_747442" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747453" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_747454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_747454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_747455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_SecurityDeposit_747455" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_Otherdeposits" xlink:label="loc_bntc_Otherdeposits_747457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_Otherdeposits_747457" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares_747458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_MarketValueOfListedShares_747458" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_747459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsCurrent_747459" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_747486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_747486" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_747494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" xlink:to="loc_us-gaap_Depreciation_747494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747565" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_747566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_747566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent_747567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedLicenceFeesCurrent_747567" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_AccruedResearchAndDevelopmentFeesCurrent" xlink:label="loc_bntc_AccruedResearchAndDevelopmentFeesCurrent_747568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedResearchAndDevelopmentFeesCurrent_747568" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" xlink:to="loc_us-gaap_StatementTable_748512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_748517" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_StatementLineItems_748515" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747599" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747631" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_OperatingLeaseLiability_747638" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747645" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747645" xlink:to="loc_us-gaap_StatementTable_748057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_748063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_748062" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_748063" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_StatementLineItems_748060" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseLiability_747646" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747647" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747978" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod_747981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod_747981" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_747982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_747982" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:label="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants_747983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants_747983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod_747986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod_747986" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod_747987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod_747987" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants_747988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants_747988" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747990" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747949" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_747950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_747950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_747951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_747951" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_747953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_747953" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_747954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_747954" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_747955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_747955" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747962" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747962" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_748014" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_748015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_748014" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_748015" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_748019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_TypeOfArrangementAxis_748019" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_748019" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SecuritiesPurchaseAgreementMember" xlink:label="loc_bntc_SecuritiesPurchaseAgreementMember_748021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" xlink:to="loc_bntc_SecuritiesPurchaseAgreementMember_748021" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PrefundedWarrantsMember" xlink:label="loc_bntc_PrefundedWarrantsMember_748024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" xlink:to="loc_bntc_PrefundedWarrantsMember_748024" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember_748438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" xlink:to="loc_bntc_PurchaseWarrantsMember_748438" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_748029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" xlink:to="loc_us-gaap_RelatedPartyDomain_748029" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="loc_us-gaap_BeneficialOwnerMember_748030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_748029" xlink:to="loc_us-gaap_BeneficialOwnerMember_748030" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_748439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_748439" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_748440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_748439" xlink:to="loc_us-gaap_EquityComponentDomain_748440" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_748441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_748440" xlink:to="loc_us-gaap_CommonStockMember_748441" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_748016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_ClassOfStockLineItems_748016" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_748017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_CommonStockSharesIssued_748017" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_748018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_748018" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued_748031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_bntc_NumberOfSeriesWarrantsIssued_748031" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_748032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_748032" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_748033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_748033" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises" xlink:label="loc_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises_748035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises_748035" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_748037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_748037" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_748038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_748038" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_748039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_748039" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_747785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_747785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_747786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_747786" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" xlink:to="loc_us-gaap_NetIncomeLoss_747787" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_747804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_747804" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_747805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_747805" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_747806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_747806" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_bntc_DeferredTaxAssetsLeaseLiabilities_747807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_bntc_DeferredTaxAssetsLeaseLiabilities_747807" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_747808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_747808" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_747813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_747813" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_747810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_747810" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_747811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_747811" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_747812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_747812" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_747814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_747814" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747816" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747816" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_bntc_PeriodAxis_747818" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodAxis_747818" xlink:to="loc_bntc_PeriodDomain_747819" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NolFromTwoThousandEighteenMember" xlink:label="loc_bntc_NolFromTwoThousandEighteenMember_747820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NolFromTwoThousandEighteenMember_747820" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NolUptoTwoThousandEighteenMember" xlink:label="loc_bntc_NolUptoTwoThousandEighteenMember_747821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NolUptoTwoThousandEighteenMember_747821" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747822" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747822" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747823" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747824" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_DomesticCountryMember_747825" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_747827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_ForeignCountryMember_747827" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_TaxPeriodAxis_747828" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_747828" xlink:to="loc_us-gaap_TaxPeriodDomain_747829" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtyFourMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtySixMember" xlink:label="loc_bntc_YearTwoThousandAndThirtySixMember_747831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtySixMember_747831" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearTwoThousandAndThirtyOneMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_747834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwards_747834" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:label="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_747842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_747842" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:label="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences_747844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences_747844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_747845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_747845" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_747852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_747852" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_747847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_747847" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards" xlink:label="loc_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards_747848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards_747848" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_747849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_747849" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_747850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_747850" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_747851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_747851" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747854" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncomeTaxDisclosureTable" xlink:label="loc_bntc_IncomeTaxDisclosureTable_747855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747854" xlink:to="loc_bntc_IncomeTaxDisclosureTable_747855" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747856" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747856" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747857" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_DomesticCountryMember_747858" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747859" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_TaxPeriodAxis_747860" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_747860" xlink:to="loc_us-gaap_TaxPeriodDomain_747861" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2014Member" xlink:label="loc_us-gaap_TaxYear2014Member_747862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2014Member_747862" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2019Member" xlink:label="loc_us-gaap_TaxYear2019Member_747863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2019Member_747863" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxYear2011Member" xlink:label="loc_us-gaap_TaxYear2011Member_747864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2011Member_747864" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_747867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_747867" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_RangeAxis_747868" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_747868" xlink:to="loc_srt_RangeMember_747869" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747869" xlink:to="loc_srt_MinimumMember_747871" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_748278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_StatementGeographicalAxis_748278" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_748279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_748278" xlink:to="loc_srt_SegmentGeographicalDomain_748279" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="loc_country_AU_748280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_748279" xlink:to="loc_country_AU_748280" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis_748284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_EventAxis_748284" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_748285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_EventAxis_748284" xlink:to="loc_bntc_EventDomain_748285" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:label="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_EventDomain_748285" xlink:to="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_UnexpectedEventAxis" xlink:label="loc_bntc_UnexpectedEventAxis_748287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_UnexpectedEventAxis_748287" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain_748288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_UnexpectedEventAxis_748287" xlink:to="loc_bntc_UnexpectedEventDomain_748288" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:label="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_IncomeTaxDisclosureLineItems" xlink:label="loc_bntc_IncomeTaxDisclosureLineItems_747872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_IncomeTaxDisclosureLineItems_747872" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_747874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_OpenTaxYear_747874" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_748277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_748277" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:label="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:label="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_748283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_748283" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_748322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_748322" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_748323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_748323" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747703" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747703" xlink:to="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xlink:to="loc_bntc_PeriodAxis_747705" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodAxis_747705" xlink:to="loc_bntc_PeriodDomain_747706" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xlink:to="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_EstimatedResearchCostsToBeIncurred" xlink:label="loc_bntc_EstimatedResearchCostsToBeIncurred_747709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_bntc_EstimatedResearchCostsToBeIncurred_747709" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747710" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747681" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747681" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747682" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747682" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747683" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747683" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747684" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_LegalExpensesMember" xlink:label="loc_bntc_LegalExpensesMember_747685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747684" xlink:to="loc_bntc_LegalExpensesMember_747685" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747682" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_747686" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_747687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747686" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_747687" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_NantWorksLlcMember" xlink:label="loc_bntc_NantWorksLlcMember_747693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_NantWorksLlcMember_747693" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_747694" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_MilestonePaymentAccruedDuringThePeriod" xlink:label="loc_bntc_MilestonePaymentAccruedDuringThePeriod_747695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_bntc_MilestonePaymentAccruedDuringThePeriod_747695" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor" xlink:label="loc_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor_747698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor_747698" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200630.xsd#bntc_MilestonePaymentReversedDuringThePeriod" xlink:label="loc_bntc_MilestonePaymentReversedDuringThePeriod_748360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_bntc_MilestonePaymentReversedDuringThePeriod_748360" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/EarningsLossPerShareSummaryOfEarningsLossPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_748047" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_748048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_NetIncomeLoss_748048" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_748049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_748049" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_748050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_748050" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g899221g03y85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g03y85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1P<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ' "^<6@X0DE-! 0      $0< 5H  QLE1QP"   "B;4< E  "')R,C8W
M.#DT' (% "--:6-R;W-O9G0@5V]R9" M($9I9W5R92!2:61E<G,N9&]C>#A"
M24T$)0      $/C6KF5_IXIP;?TWIQ <M)(X0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              10   &'P         !
M                          $             !A\   10
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   10     %)G:'1L
M;VYG   &'P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   $4     !29VAT;&]N9P  !A\    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M=F+U^H3=TPO'C4]K_P#H@O<NV22XBJ@\">H_9'?K%.1@NP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]P-Q! WB_%P-7A0AZB &X._B6?75;AM[OP1G_>.=_1-9Q_\ \S5]\0=J'X4
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MSOZ)K._?-'J_B_VPFY5IXCZI\WF^_KU'NCZ]IK/_ 'S0;Q@;5S_\#YIND21
MO('U\EW>Q-PW?6:??]+O6X&KHJUF;DUVT6JVU1HM!]M@0*;1)L=;E/AK<CMN
M!51=2I3:B%8'H!G6S-1%6\7--1I?5FFWJ$J9PP8$.U[NK!;&(2KK$ZX0H9S+
MZ>_H.#8=8/F.>,ZR ^TK&'ICG22>Y ?]$IJAF^]W#A_#AYO.5J,CPTA.$@9
M& 0 ">/C].2<_')YUHU;I( @>:CEW<N54]G3\?S)'_O^O636^ >8<_+R1SJ>
MY3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH
M^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:
M;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3
MV1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3
MW*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V=
M'Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#
M3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:
M>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ
M>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>S
MH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X
M:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#
M3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=
M3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V
M='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W
M#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX
M:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1S
MJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>
MSH^/W#3>_#3V1SJ>Y3V='Q^X:;WX:>R.=3W*>SH^/W#3>_#3V1SJ>Y3V9'K^
MH:"IOW:>@1SJ>ZL5L6D"?OE@8SOG=)Q__ +4/_/38DD[4'&TJ'RXZ*U%R. '
MD_S5C=B_Z8O7!_:^GK]@JOJC]I7SH_PJ6:<_S_[*=;7\FG[?\QU*_B/3R"*I
MK*)HB:(FB)HB:(FB)HB:(J#[G8$XSDY\LX^C*@E0&?IQ]?&#TH,-Z(]?)%Q3
M**5!())/!"@04GT[4J[?$'H<$<<\#0[KMY ";2>MAQ=:%)(?T1Z'55FGG%+[
M5]G![3V*SDGG)!2,8&. I7KK0 %IP>'KSX6GH<572KR!).0?ZI\^[ R3G'P(
M/&?76:J1)SZ?P<J*IKFB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HBT5Y'ZC^K6J?B'K"*PFQ?\_WQ_ORNC]G[3TV7Q;;_D/BJ;]*?(*QFQ?]
M,7K@_M?3U^P57U1^TKYT?X5*4Y_G_P!E.MK^33]O^8ZE?Q'IY!%4UE$T1-$3
M1$T1-$31$T147G.Q*L9[NTD?3Z?GYS]0\_0]* ""3..&$6,+Y5SY1.VODX.F
M*I;PSJ3'N>_*[58]G;86E+<4U"K%VSH[SZ)56=;4EYJBTB(R_/GJ:6AV0MJ/
M ;=CKFID-0U$!B'J)=V#"+] -!USJT@L[MK?AR^CV7QGL_+N?+*BB/=6(JU*
M=Z?V=PFK-?HYV_M-=B-5]UMV9'M=,X,_PK6)$)ETIE-U$X=9<8$L/-+.L203
MOU'%P>XBT:B6R0@JD#W1.C-9S%N) <8POM$^2T^4#MGY1OIEHF]4"E,VS=M+
MGO6MN):33A<11+LA--.ONP%...O+HM09=$BG.O...</QUK6J,IQ?05D@V)#:
MRYY#B VDM9#!(!!%B0['DX?#\1@,RR/5&:Q2X;\Z0XM$>,TZ^^L!3O8TRA3B
MU=B0HG"4D^Z/3'KJTU0348'8>H65'UOJEVH6VR\BNRW&Y3%%DQ"FBU58DLW%
MXRJ&ZRM$3M4W51'<3$4,A;GN@'&N9VNSL=Y__D]G94@@ W!TQSPMCG5/M*A#
MKHK\OPFH1J*G?P+55-HAB:NF>.3[*.]!J*3 2E)[E2OXL>]QJ_;;,0QF6%,=
M[=RHU^"WIZH]JO%>8569Z76':A&6DT.J HF4B.F75XJDF,5*?I<5:9,]I/,1
M@A;AT.UH9S26F2!@L<M%S-B+NM$!G!RS&_,>L&R]?9>]-G7]/>IMLU"1.DLQ
MHLQTJID]IMF-.:;DPENJ>CMH:3/CK+\)3C@#K2%*&=*=ILZBP$N1\+M9K#+C
MEE-TFT^Z_C/)O6BQD=?'RPFRO2G:VZ5!V\KM+W"W^VXJ=ETR38K]NWJ_;$>5
M<MT4>ES*;5;QIM*:MJ+6F*)/DU*+2EU^/)6]'2VXDE0:4)8G<NY!8/2&>"+O
M&'R@ SPB_,N&87U(LSRI$0_E.NDY6ZE/V0F[BR4[DN3J1;M78A6=><ZUZ+>5
M6IL6H,VM4KQC41VVHM76F0$HB.U0*03VN+20HZ"L.Y#@L'9@#8@P[SH7C%A'
M,<.$E^@YY6)?<'Y:CJCMJI=4MWT*QNE%W:SIGW9N6P)MKW5N?/MW>F[J9;U7
M;I_M=M6TNHR4UBH3$.H#;,."0ET.++)0@I&-ZL_NTAY#[OSDV,"=>, &6B6+
MR,@<=)"D6W\M-'HW6SLYTX7_ +<,V;MMO;L/MQN+0[WJ#\L5*UK[W(H*:W1+
M6NA7$./!ER%M4*(\[%@N/3I+#Y?0SWMZUOU;IJ(  @"Q!8:BW6;,M>Z8 JUM
M)N^6Q@8RO:N?*OU^G= 6YW5K4K#H$C<"A[JWEL_MOMS39$]2+QNVG7T]9%K0
MDL2)+<J3*FNH34*A$I\Q2S&;=++C(/<B"NH @[I+B!8NQ)9L.'=Y0[KD@%AA
MQTP[/UG#3,WY/WJ_?ZS>FZV-WJO0HEGWPS5:]9NYMD1'3(-G7]:E2?I5?HSJ
M52)+\=*7XXE1V)+CCR8DEA3CBB>X]*7J#D4N(J!$N.+:-J,#51@Q(_EM(CO>
MX)XLIV(5W)2K&,C./AK!;#]5E;M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:*\C]1_5K5'Q
M#KY%%838O^?[X_WY71^S]IZ;+XMM_P A\@J;]*?(*QFQ?],7K@_M?3U^P57U
M1^TKYT?X5*4Y_G_V4ZVOY-/V_P"8ZE?Q'IY!%4UE$T1-$31$T1-$31$T1<9_
M&6\D@$GR&23CR\N >.?_ &&NE S#/IF&/FJ[/Q#>M5\T?^TT=)&Z/43TBV/N
M#M=1JC=$[8R\I=Q7);5*CKFS'K4K-)>AU2LLPFR7I;E)DQ*?_$L)4OV>3(=4
M/#:41*RQ!@R V<G.&YZ2FZ2[2Q9WCQ7QN0.O"FM=-@Z-OF,I_P# Z9M@+6J$
MP)6W?)W1_A"NY_X<T]0;\)OP:J]48+--3$]M$*<_$#W<I!'-I%3Q-V  <Y%P
M,G7DR3;P;-OUUROL\_V9_I%W,Z:>CFZ+NW0HU3MJK;Z7A#NZA6Q5FG(T^%:=
M)IJH5'JK\1W#L)57,V2M49U*74AAM:QA8.M[.#42P$"^CR1UAYA"&C2^DB/S
MU99]MZ9-W1MN+D%C6@J^;BEPUP(MO(N*G6LY(9J!,2;)16JLQ(@QUP8KSLM#
M;K2O'4T&4]JUI.K+5[H>XZ8@2?5Y0 $R6X^OUTU6'.A[$]5E&I=H4W_=QKDI
M%N6[L=1.X[][=I+Z]FGJJMMQP?@E2%?A9=1:7+P".]I2&U*!SKAN'JP(FGJ"
M7#%R>FI8+<$$0&.A,-!<"SY,D+C2=A.J0T252#T[UIAN99\>V5OIW\V\'A>Q
M;G#<1QXN*I(2W)=6DTY"B0D,+)SWC&K]F0V0[6!9QDNVDZVE !)#/@50XBP,
MW=O')7<O;+=5CM7G59KIRJJD5"[M^+K+ WWV]*>S>NU(UN(C,N&E8'\'A'\9
MM9RJ05$K" 03336S %Z=Z[2*ANV>0 +\8;$<"=T20_O.X!=H@>+/S"F7T;[=
M[FV,]?DW<G;^38BZQ0MN:-3FI-^4"]#-C67;2J"X\%T.+'$%Q:@7'DO]ZG'%
M>Y[H)&MD*J*JGI+5,8$8'<3 'U585 2QD]R8XX]%UB'ZB/DO.L"ZF>K_ &3V
MKJ&RU5V<ZHM[+<W^-Y7<BIM;DVW6J75[?G3K*9<:=]G5&<-!:>A3%M.1&J>]
M-;;6F2ZI.E5%;D7%1)<8?!MACI<9)$O<@&E@*2" 0)DO\YP0N7N-\E1U3U?J
M_C[N[8URP]K*7,W-L"\:SN19MWW#2U5"V+?I5.9K]OW3MHAQRF5NZ:JJ"Y"1
M<0;;2N/(*GL)42F54EZH<&H$D'X6-Q^(R\/?F5]R-V!299]3/!N"YEY?(B3K
MTLSJ?NZ9)L:%U.W-U/7)O]T^[I,,J<>I#$JK(J$&V[L6L+8?IM49+T:H1%L+
M:;44$*2CN&INU!B6!8,UB)RY+6X\ 6)V:*9W2[5<' MSP;\(NKN7O\EON-U-
M;H;S7SU&2[,I:=UND#:_:J.]9;KB)]F;W[?U&G5&+==#*$I3#ID273P]"4P4
M%IF2J*QVM) U134?B#0"\&0 ''.!P[I730_NEP( [ZS$F6>W..>W7R,?4O5]
MJ>D_8'>3>>+1=O=HMU-T-Z-Q[IVVJTNG7W4]QJLY-_@%6:!/=[VHZHCL@3)3
MJT*>:E+4M!"L$*::FF,;U-3D.;D/<R'<L\!<Y)#B&;(L9<OB_!ED3^3]Z#-S
M^AS?+J0A0=S:KN/T^;P3J)N#19%[UA^J[@QMV)*7V+WJ]7E$(9DMU[LC.N.*
M;"W'6"LJ4M:\ZI<5U.7IR7$G# 3S/0\: S^ZX(A@X;$W'9X!68-' "3CN YP
M,#[,<>OIJUN\\.G#CGU PMVLHFB)HB:HN'LX=%Q?%<^'_P NM[M),'H"/S1/
M%=^'_P NKN#4^'T1/%=^'_RZFY3J>X^B+DI)(!(P2 <?7K%0 +##>2+741:9
M'Q'YQJBE\TCF91,CXC\XU=W\5/=%34X0<#LQ]*DY_P Z<?1Y_3CRUH4 @3V,
M7Y(MOB*_]'YT_P#_ $U=P:GP^B*H@E0R?NP1]F"?/@^9^@G6*@Q8>OJBWZRB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+17D?J/ZM:H^(=
M?(HK";%_S_?'^_*Z/V?M/39?%MO^0^05-^E/D%8S8O\ IB]<']KZ>OV"J^J/
MVE?.C_"I2G/\_P#LIUM?R:?M_P QU*_B/3R"*IK*)HB:(FB)HB:(FB)HBV+0
ME8(.1D8)!P<'S'V_GUJFHCUG5%PI<"-*BNQI++<EAU);=9?0AYMUI?NK:<0M
M!0MM:2I"VU)4A2%*200=:IJ>*FYEE7OQ>T744%=!_1T;T.X;?39LR+P5*3-_
M#C>WUNB8F:E?B"8&A!$1,E+F'$NI8"PX YW=V"!V=!EB.+F!F'8.+^*N\6 A
MAAA\@#ZA2NAP6XG8AD);:;;2VA 0$%"4@!* $D)0V$  (0E* 0,#C4)8'+L
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MJ ?A!Z1YA4;.L/[U6(%HT$$CIT6G:$#!2I8'D/"2?HX/;_R/V<ZN]LV+@M<
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M@.+VSST5WJVAQ5U%[W<'CPNQ6U+*BON0"%X45-!#(4  1DI4,I3@YX(('.,
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M*IK*)HB:(FB)HB:(FB*DXYX8R1D 9_& /V#DG[!K=-((<DWQ^B*B912"2C&
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M<G3B^GKU16W$DJ6>U20"2D=QP<A1.<=P/(..-0[Q+9T'?YK JW0&$N2_/H^
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M>4T>\CM*BV%C/ED#.O(-I4,NUAZNO=1[-2&)#& X!?D6AI;#-:ZK;7].&_\
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MKR654UR1-$31$T1-$6BO(_4?U:U1\0Z^116$V+_G^^/]^5T?L_:>FR^+;?\
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M 4G!X.O%9Y$7E?8IJIJ -)<'1M'-B9&=%[;QN00@< 9/&?, A)S]OEY#6=T
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M)![PHY".W!U\[:;(T%R'!/NY+8;'9G7ZC8[<;2FD.Q.'AV#CAR/SF8:7&BG
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MB18L.76Z]69C42CV_3PXIP*D<1X["4=V6DA:7GB$A0*E J!!UX:]H!8V9SP
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MM=L:XC=EM1WL\VP6=W Q[%L!22320(.]4S&IW<2Y(S#N 9=96FDA2AGM"0
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MW$<+'O(60RA4.ET*##I5'I<2D4R TB-$@TV*S%BPV&4AM#3#+"&D-(4G"0D
MI0 E&><G0H )8U!I%1+CQ\=0^CK1(8, ,$7<<[B>5XLJE;K,&ATR75)SGAQ(
MJ'#VA0"GE]A4$(&<*6H@I2!D]W('!UHU  U.& .1)TYZ<UFUX\QT^JB;)_"N
MY50>J515)5"#[C<&$E12Q#B@?Q!,<I(=DKR?$<P3DYPD#.O.7K()?D26IF2
MSOX6OF+RUV;;M,QB#$".%@90.[N0@J*2?,@  J&.TC!!QC.B:J*!-)Z2Q@W8
M\'8\LK)I!DWEBYA[MHH%[J6NS&<? ;2 HJ0O@>:>X$_BY (!'/T$<:Z@L 6<
MV+2>[<!]67,^[4!Q#_%&A+7P='Y*(-*W/O+92](MXV/5'Z=4H3P<4R#(_!M6
MIB^U?X.FPTJ#9B+!QXCR/'"CD*! QD U'>! Q?@ 9MX=0T]; EB>0<GYDLOH
MGZ=M\;=Z@-L*'?M$=::D2VFXU<I*5%3U'K;385.ISX*<^%[Q=C'E*FG&U@D'
M4H-S#TN*J7D,<<,VU%UU<U@"1J8;1\9>.>BD0%(PE*2$D) 3GDH!3GWN2 <#
MT&1ZX!UU-C#Q;7@N:J>(G&0H'GUX^_!\\9'T:Y[A,VO!=^5D50'(R/(\C6+(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBX<]]B+
M$?DR7FX\>.TM]]]U:6FF6&DE;KKKBRE+;3;84MQQ2@E"4E1( )UTHST^:**M
MN]:?2E=2ZNU;N_&VM950+DIMIU7V&Y(2VH=<KM1%*I,9];CP:4W.J?\ P,:?
MWFGN2P6$2O$]TM^F!46((%X+YAHU)@66F=VYLSMP@1H-6EETM[]>72!MW6I=
M O;J!V\M^LT^K/T.7#EU98<%;B>SF52@N(A]ERH0Q*8,R&A2Y$8.MEUMM)!U
M/M*0X-1) =P(8L.1#P"W)-X?=Z/]1'30+U-/ZO\ IAJ>XL':>!OCMW,W&J-/
M34H%J,W%$759D5< U5 :9#I0J2*:#/\ 85K3.$0*?]G\/*M7[2C!#D;Q^=G#
MAG(TF57>!#L!#L+-U>]X;BNMM#K;Z2K\9N"1:/4!MA7OX,5"%3*^B%=,%;L"
M74:DU2:>'HJGD/J8FU-YJ!&F-MKB/2G$,H?4O(U!M*&)#@ L,DYM>)=\2H9,
M6#!],8[^0A7GO?=+;_;9=N)OR[J':W\+JY'M>V/PY4(U/56+@EDEBF0_:5-E
M^4L'"&$=RSD'!R,TU@&YW;6L8ZL!=_HM;HBD7R[AP'M>_#M#*WM0ZI>GFD[G
M2-FI^[]BP-T&(KDIZS)5=C-5A"D1'9ZF7FBM+1GB"P[-%-\7\(&,V7DQBT.X
MC7334Y(D7>S8B[Q%T;>@WIDPQW;N'8,Q>P?I-F=R-PND?JKL.SMK9VY]A75!
MZA(ET,[3FG5:')J-QU"TT/+K-0M1:4E1E6LIE;DAQ*4D>$XTKN!5G(J$8!(J
MAY8Q27 N8;,-DH=VH$.'8TN3PN-9SZ/RM=0>Q-]=+F\57L2Y%2(\ZF2_;+<N
M&*VZB/7J6T^MZG5J,6_=0Z]&;+$Y+:NX$.(<2E84G7?95TDEW!!]X9''BX=H
MNR\7M%!W8$!F)@CAE@'#3(-U,79;="/N#;X2]A%=IK?@5)A) 4Z@H2D2DMYR
M?/N6H @9!SYG7UMB:0'IWBV7ZY..=V?#_$VOL]5=61<7;4/PQ=9S/DUB/F5O
MC!) WFN\!1&,@4>U^?0_=KY6T+[7:'\3,[F";\^J^_L 1LMF#<4@'Z=++$1O
M'TL5_JE^5TZ@;<;;EQ+*H5$V8J=ZUMII*D0J<U:*%>R1EK2$>W5#!8B9)4AU
M9)26DJQSJJ((II8DD."'8'>GHQS'9=R!4)!:D 1DX?F[M+L5])]FVG1+)MFB
M6I;%.9I=!H$%BETN%%;2TPQ$BMAMI*0E*05'!4XK 4\\IQY94M94<.P(!R9U
MQXW<9ZML[K@E@P'NZ/.+\0W$KV"4*+8&2@YYX ..>#CZ?7/E^;4I+$N8;BSQ
MP^2YF_KT^O&RJCRQSQQS]'T^OUZE1<OJWEQ 46NHB:(FB)HB:(FB)HB:(FB)
MHB:(FB+0@'&?0Y_-\?B/HU140>&B)VC(.,8SY?3\=')N2>J+74<BQ9%0<REM
M:CCC!X&. <X/Q]/7_P!]T$DER3&9T3DH0=;^XLC;S:N94(3@$B)3+BN-#24I
M_C1;5*?G%D=Y\/+Y<0@E0(41@C!.L[2332+28%V!AK"9+V;54N ^I FV!Y51
MIA8Q[ ZX-PX]5I]&%1AYDW'M];(DKH5&[B]?UF/W;&K!'9A+<%IA4!R. "M9
M"SC/&Q00_O6X#0&7!UD!KZVY[T@-??;^4LUA<2_B;JK<77CN#7J;3Y9E18R:
MA3;/F)*:+25%E5WWF_9H2H=I*DP%,IJ:N"I2%>!QCD/>I>H$EV!9RP:Y :-+
M7 6[.W3#DB1Y\[Y4,-P^K2\ZE$JDN3)0L4^C;B5I:4TJ UV_P*ON!898/ 2I
M=;DR1*:(R([>3[H!.K3!(OJ;-TXPWY1EC4)#.+ O.AM;A=M%9)F^:O>+UY.5
M*4W)8MVY9E"<;6S$:+K\5NG%,Q"D)!5#[R$I;22DX..>-*GP2]FUS^N!PS1
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M>Z"!+FWCB9M\\L'D7-L/RL#Q7@IM<M-2<"W+>2K!X%(@9RH8[BHCD@>6/($
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M50ZE1J]064NK56*3/.'B&D$!UU@DK0I25$)& ">- W,//S7GV]-9!--1#L"
M3(,&P-\\22&SX3H_V\W%=>H=W7?.F4^U[9I$RDVM;,EMQ@K?J*DO3*C*84H
ME(<6VRH@*RX2#@'6ZB*BX<0 ';Y?1<?9MEM**G__ %C>OFHO C#N7:3 61X
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MI[5%1PG)( R%'T!(SC'IQZ^7&NE%B"]Y]:Z]$7 >ELQQXTA]B*A65=[[K;8
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MFB)HBXSY4,'/:C&%J!]['P'E@_GSKK18\_HBXSKJ4)[E$M #CO6@\#D*(7@
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M,8'$FVD8B\7&NBV]*6@P+9ZB[]IE%*^U%/?"U%AC)[(Z5MRBEY"$X3V+"!D
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M74U"#$G1Y,.;';EPY#:XTAE]OQD/-N@I=:<;(4%(6."D@A7.1QKI(O:.;D]
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MS67SYRJC4=II2E('O''<<^O;C./+E../+[=*BP+&8CK@>O-/7KU\EQZD?XC
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MNXNSL,QT1:@ # X UA%M+:#DE(R<DGZ3C)^C.!Y8\M:WJM?)%15&!7W)/;P
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M>7Z=+Y=5A$;&.5< #S(\OM\OB/H'PU#5209+_P S<FM-E#43^@/GX:+D@!(
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M3$-/4I:%L/-2@PAIP*1W/E#*2LN=AQ5N,::R!O5/3,R8-+2"_+/%:(!<!G
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M29;C:)=(JL,E$R+(20G*$K27&Y( 9=8*5H4H9UJBL5TDD,Q8@S/*_AR)5(D
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M/N)AM-3[S+JU,D1J<XTMJ>[-G1%NCVF8ZVRMH=-G415029! N[5%_A.CZO\
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M4TN , ^!8YLZI )]UP78!CI=]1#SD'4"8.UVS/3_ &Y0(L[;/;K;^!39R6Y
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M3@>\ 2.PI 4 21GC(SC/!Z4DD,&<,WY^O) 9<CCQ?G>_;C+T$04)4H9& %
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)(FB)HB:(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g899221g05l69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g05l69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '$2^<C8X0DE-! 0      $0< 5H  QLE1QP"   "B;4< E  "')R,C8W
M.#DT' (% "--:6-R;W-O9G0@5V]R9" M($9I9W5R92!2:61E<G,N9&]C>#A"
M24T$)0      $/C6KF5_IXIP;?TWIQ <M)(X0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              0F   %]          !
M                          $             !?0   0F
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   0F     %)G:'1L
M;VYG   %]     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   $)@    !29VAT;&]N9P  !?0    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M N#!=6(;;38QF5B7Q+MMCZ+?TO\ +6RLWHG3:L"BVP6NR+LZUV5D9#HE[WQ
M;'T*:JVLJIK_ '%HH*722224I))))3__T/54DD#*S*,6OU+G;0?H@:EQ_=8U
M!2=4,OK&)C$L!-MH_,9K']=_T6K&ZCUJVUCB]XQL;C:#J?Z[Q[G?\76L[$KZ
MIU33IE/I8_'VN[1O_6V^[?\ V/4_ZVC7=%]G2S.NY3FESK&XM78-,'_MQWN=
M_P!;62S..386X./;FVS[G-!C^W8=W_36]A?4_I]3A=G.=GW\DVZ,']6F?_/K
MK%N5UUU,#*VAC&B&M:( 'DT(VJN[R571/K)D:O\ 0P6^!.]__0]1O_35IGU-
M>_\ I?4KK!W;6 P?](VKIDD+*=' 9]2NBCZ?K6^;[#_Z+#$8?4_ZO :XI/F;
M+/\ THME)"U.(_ZG= =Q0YG]6RS_ +\]R [ZD]-&M-^32[MM>"/^DQ=$DE:G
ME;/JIU6K7%ZB+/Y%[-/\\&W_ *A4[L3K^)/VC!^T5C_"8QW?^!_3_P# EVR2
M-JH/"8/6*ZKG,HN=C/)W>F_V^[\]KF._1_R_<M[&Z_:V&Y5>X?Z2O0_YA]KO
M[*O]3Z5A9]1&10RY[=6.<(=I^:VQCJW^[_C%@7?5C,HK%_1\@OK(G[)D?DKL
M]O\ TVL_XU&QU11Z/3X^51DLWT/#P.8Y']9I]S49<+1U!].3Z5[7X.:S\UWM
M_P Q_P"Z[_MM=#@]<!(JS88[@6C1I_X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      #_X3__
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z
M,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W
M=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @
M(#QX;7 Z0W)E871E1&%T93XR,#(P+3 Y+3$W5# Y.C S.C(W*S U.C,P/"]X
M;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R
M:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,"TP.2TQ-U0P.3HS,3HS,BLP-3HS
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C M,#DM,3=4,#DZ,S$Z,S(K,#4Z,S \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C N," H5VEN9&]W<RD\+W!D9CI0
M<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @
M(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:3YR<C(V-S@Y-#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M
M($9I9W5R92!2:61E<G,N9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIF;W)M
M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @
M(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A
M;F-E240^>&UP+FEI9#HS1$8Q1C<P,SE!1CA%03$Q0D,P-$4X0C@U,$1$.#-"
M,#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT
M240^>&UP+F1I9#HS0D8Q1C<P,SE!1CA%03$Q0D,P-$4X0C@U,$1$.#-",#PO
M>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YX;7 N9&ED.C-"1C%&-S S.4%&.$5!,3%"0S T13A".#4P1$0X
M,T(P/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS
M0D8Q1C<P,SE!1CA%03$Q0D,P-$4X0C@U,$1$.#-",#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP.2TQ
M-U0P.3HS,3HR-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-#1C%&-S S.4%&.$5!,3%"
M0S T13A".#4P1$0X,T(P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 Y+3$W5# Y.C,Q.C,R*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS
M1$8Q1C<P,SE!1CA%03$Q0D,P-$4X0C@U,$1$.#-",#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP.2TQ
M-U0P.3HS,3HS,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#HS0T8Q1C<P,SE!1CA%03$Q0D,P-$4X
M0C@U,$1$.#-",#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#HS0D8Q1C<P,SE!1CA%03$Q0D,P-$4X
M0C@U,$1$.#-",#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C-"1C%&-S S.4%&.$5!
M,3%"0S T13A".#4P1$0X,T(P/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O
M;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( 50!Z ,!$0 "$0$#$0'_Q  ?   ! @<! 0
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M(])A,JC1V(+33*$I4VU"82A*2% ):\II+:\=)26PDE*L)('5K0&Z2@'+ !>
MFY.PW &*N.4(>A&^^C^E-Y\07AMV_P![[3JT&13*=2KQ%-F&V+F9@-)DTRK&
M.O[N?GMLI81-IHE*;^-A/E2762M*%H>Z"FE]@.$S@X.R[%[8PE0BRZ(Z@:J=
MIZ'RKS ?9[>*[?3P4>/R\O"WXIKPC.4;<O<:!9=?D716WJ+1:7>$B-(@;<IV
M1L2&S-4Q0K@=J5.AUJL2S3J;+5)$F7),FEJ><J+CP]-A=HC 8$ASHQWJD\P
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M0M"J27F*%!I]E1&_7TM^379IEU!YM1RE/D?#I#BR< '"L=A2">("?["T G2
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MDN9OUHN"M)P. BJSVS^B \4C'R*N_P# S_@\+8$+J)\R/>*@_&W(_)<"8R?
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M<;)"48#\]/U2E4SQV[JQ%M_>5"M.HL)("DM1)\*0L __ !S/D- D>YC\>P&
M-1_@W#_E:CD +STJW_ZC>1-H>I)?EAG[/:E+I'C_ (CKH;KVW4F(R%H"Y5,K
MC,Y2@<EU28[U,C='/(0'B",Y4/?*_P"&XEAP%H>FV,K2M[/C[;D[3U2'0H$G
M?K2PT#QJ[+U<J;GS:U;R @D+JU*6IA05U!0;^['Z@MWI *<N-M$8  !/&7\-
MY']"DU @](_W71;\7PB01<0>H:4(K3([ TN-M;V[470RT[2+^MM\/'H:0_/8
MILEU1& A$2HJCR^H<#"&QW^?&J$;Z_OWX5M_+9<?[6N,'RS6:OVTK9W,M&J6
MI76(M6H-=A.Q)K06AW+3J"CSF'$'*9#:B%,NH7TMN!*B% 8U6X"X$$QOL?9J
M]MQ_XRQI/B%7&>YMB_$GX1;JFW=M)+K-PVM)*>JHTN(FIN)@LD_"P;DMM;<I
M<M]A!6R9\( J4LNM%A \O6'+=9DEH#FT3QI.Y(($U)R$(&,;L[C7R5;7!^TT
MOZE,KI=S;;T%^OM%02E-2G4)U#A])#]/F1I<A+RE K4VB1'2E.4D)X MS&T?
MVL+Q,Y+.TMSV<5-Q-P!1(&I!3UD1ITI/+FW;\57BZZ;5H]!E4ZU)LEMF7$H$
M&11:*ZDJSY%<K=4"OO1E PI^'$>\F4V,EASV<G\F;A< B ,,;0 'T/7M!)@X
M'?)U,ST>D!T^'P4^ '9_PD5"[K]MNW:6QNQNFU =W#K]-:7'IC[T#SUMPZ'3
M'%*8HK"%R%.3G(*6GJQ(\MZ>7?AHP; $$$@"_P#J] (@1K#*VW=6%J!):B(?
M6-O4#-=%FO3D8"N<@IP"<@'WZ>P./8X&"-:7 FV3.N@/?WFLSDK&E5>M([GI
M//!(SQ^1(_GJG(3@VGQ_5*E\Q)4$@Y)]QV'YZGD*R&_!>6:54U2E&E*-*4:4
MHTI1I2C2E&E*-*4:4HTI1I2C2E&M[<#L/I2H#NK\_P"@U3B:>/VI4=9THTI1
MI2C2E&E*-*4:4HTI1I2C2E&E*-*52<4D)(7G'&#]3[CD9Q^?Z:O:$KF$,[C0
M5(!)0J1#C: 1DX)."<<G'('/MC]3QH?F,0A+]]:&TC/MX\T?+M4WGMX)SP 3
MSD9 '/M\\#3DZA^UZ3BH1VK#5>I4VGQUR:C,BPXB0"M^7):C-(R2"2XXMM((
MSDCJR$\^V# MN( PSJQ*]X\<187"UDPM?MM/JD,NF[7CXJMFK-<>CO78W69C
M.6W:?;S"ZH\TI!4.E2FRA )/=0=6 #\\ZVX=EUQ%N3]NF_L8KGO^*X-I*^:.
MTC0D% O(3Z#--;N_Q]N/%35G62<)6IMN36)9=*VSD!P0H80ZPO/.'7% =B3G
M.NK_ !+RH!+W&-8$C34/+KFN^-(!(@(L"3XZ0-9[8IM-U^*G>^YVEH-XKH+7
MGA;<:@16:2ZAC(_9*G-H,EWW&%J*5?O9.K#X6X76\QC-P&?5COVQ-<UW_J#2
M/+!EP7@H'100H)V%(E5:Y6JY*7)K-:J%4E2B7''YTV;(><X]2%K4^8ZL\_A;
M2GG/'(':+>'PS\MELA'#,22BO_+"G4F<+_BKD'>3+"@-)SHN_C%8<I0@X;:1
MTX..?PC.5<G '8\_UQH!82A: =2 #"EDX@C(<0ZYSQ;KR>8&[*D0=S*U 73.
M:@KI*.K(P3@>K(5V/XCGYC';Z:J>!:VPC@]_/,O,;!N0>+ "(0(#F=<'MY=!
M4,(Q@@XR, D@YQGW&"#]1CGC.AX-H2NQB0(^V  JM_[FV8"1]_3M@3C &,'!
M.#@XR#[$#.M0+1J)0,OKX:3HMYJV &"3X'1,G'CM4$N#G 4KN$X]0P >.1U<
M$_3/TQG4E7-2?327AJ-_"HDA<L;= >^W81JQ4%>@9=!0#R#TJ3D?J>/T'\>V
ML/Y2"I*160W 8TSF>@5#8Q U!)D^Y\ZLW:A3FSTNS8C6,=0<DM).?D>I:<$G
M@@CO\N^AXUQT\C^JH> ^KS'ZRIT>KJ!J]+"0#5Z4E/2,=51B#J&/=*GD@G(^
MN/ST_G+E(9QY:';/JZZ+."!;*%V<:OKD]=4YJD:]1@<*KE%&,8'WI3@1^8\\
M$<8X//?OSJQX\)#3ITR##Z9-6_C&]136J*K\%:HZ^#CIJL YSG':0?\ 0U'\
MZZ'<Q]_ H8I_'U]/W44UBDGM5*?D>R)T5?TXZ'C_ *&I_FZ'WT:]*D<$DDCS
M0UD2PX573<^*[RU)CNC/_=/-K(3],*).1CO^8]M4_F R2-!X:;1Z]ZPXEIP
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M;5Y"7+[VM@T^2[U)=J%-I=/JS*UD!*$%+L825K4DE2LJ[^_(UQGX:X?\ ,2
M!M&)[$*.U=-OQMN"+981)"4]L2!EEC>E1N7=G8BH49G<JW?*N*KV S\=2[2I
M<]5#F,2'>E'HHP4Q$=GH"BE/4W(*4]0 SJE_ Y%<0?ED21:"9Z#.27XAU?\
MS.%)%R!!%P@?+@E3'7<A9%.MLFN-W'0*%7ONNHTA56I[,\P*DT&9,54QH.]#
M[224)7CT]8.', @ \"A1',BP(?0G8Z_3QKILN8":N[ D'OZ;UNG6 XE'5A1!
M/3GG\_8?+M]?;5A@'H"??;>K06"=4(^P SMOIFJF1GD]SC/UY_RT8C<AU4@R
M90*:556DDJ2KVX//N"#C'\-"0)F"BJBKO6%*-*4:4HTI1I2C2E&E*-*4:4HT
MI1I2C2E&E*-;VX'8?2E0'=7Y_P!!JG$T\?M2HZSI1I2C2E&E*-*4:4HTI1I2
MH$A()/8:D DH4H!R >>?GP=00B1M2I2XD*Z3D'..1@?Q^6IY8;'J_I2I2\@$
MIZAD9X!S[9QQ[XU/(8D2&!KBE8^=,BQV77I+K3+2$DJ=>=2RE 'NI3I\L#@\
M]CCY\:N OE(;G<>JV]1WJ6!\QN%H! 9(&?K[%-CO_P 4>T-BN.1#<)N&KM']
MI3Z!TSU-K!(*'I[9^!BJXZ2EYQ*S\_E:WA<Q  )GWMC-4XOQ-M@)!>RDGMD(
M^/X91?GCDW"K0>CV72:7:,!,AUIF;/=<G51]DH(0IM+C;4>.\#ZDJ8<FI.,*
MPD]2>SA_"0&0"2T]]&2?UC9^?Q/CR)1+!P&>[49U:,: 4TRXK\O:])7Q5VW?
M7*R_UI*VY,IYJ*6STDM.P8Q--Z HDI4T"X,85PD8WX7PUJ)(,?\ (VEZY_XB
M#W.L@UR7_$WWZ7 '20"RWNW$O1(UJA.0>$Y!('L,9Y5QV!QQQCIQU#)UUV\/
MAV6FX6@GH,1G\3N23-8 7&]D :E7?5F9\( 52#/ 1V4""4D9*1[9R._S)![]
M]3SVS("WB*O=:QD3(EH_;*7>*.G((Y.$*ZNDI3Z4C(*AGT@=R>?EJIX@# 1Z
MN1))V(0>#@:Z<QX5X(0**P7KH<0^[\:QDVM4BDM>;5JG3*<WTY#LF:TA72,J
M!45$E*0 2I120 3G&-8L98!+&02 M7]H)[UL/A;B@KDR2P1I($3]<;JDRK&_
M6V%#)\ZYXT\D8/W6Q]ZH)]D]<<] SP"2"E/OCOJUU]HM@VXSS2<=89$,=A75
MP_A#:&+=@T?/F$:]'275#Q:VO%4J/1Z!5JF3U *DF)&B*/2"DA*4J5@D#L"H
M<\=6-<?^1)%R0QJ"\X0Z9WWK?_&N7,M=1.>KVU68+I-ZGXLKHD*4BG6W2X*P
M5#_>G94S!&0GK$D0@./W4D 8X)!SJP^(T0,:,^4_4D^%3_CE.+?_ "0[+7K]
M*T*;XE=T9H5_VM3X8ZL)%-@(B*2._"EJG!1&,Y5P?\<_\I$PRC#QU GH,;YQ
M6O\ B,(W01TF>B[Q%:?+WIW-J!Z95YUDI5DI2ER&GCV"?A0TZHCGA:4D9S@=
MR_RX$(DY!!>B'Z'?5V'PH#_KC8_O<X5:](NF])BE*?N&Z7\Y/[.75%9/?!2F
M2"C'R"3Q\\:Q/&M-Q)(>(NP.SA_<S3_&(5H#6^2IZF5MWUJ6$Q>E666X4>ZZ
M@LXZ@TQ6I+BB1PHE2%)3GG]X\G !SJ?YP,7#7)&\O.!KIBG^+<5"T@1Z=8[=
M4*V*-MCN_.6%1=O]P9X4#T!BWKBEE1XY!$%:59SQT*./EC46\?/]2#*<1Z?Z
MJP^'@C$#(8\1T@.=)*K('8W?)[*QLWN:OK[K%EW H=\\?]G@\_Y9 ][?SZH!
M0WCI,#]G>I'PX&;CTC1=2??>HG9+>YD8>VCW-;2,' LRXF3VSRM%.*L?,C!Q
MVYU7^<=-H(9><"?9I_ -"CNI(\Q["ZUC9UA;K4A"C+L6^J6E ]0D4.M-* ^H
M<82[G'S2!G/&,ZD?$VB!RSCY@9C'U76IM^')&I64&/U6L_$7="=4E:KFAR$
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M=*<7;OV6/@PMYV(ZO:R36)+!"DR*W=EVSDJ6,Y+D'[V-/5D\<M] SPG .HY
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M2HD]!P,9Q*@/JP.< 'OVQC.H-O,&0&<L-=4UMZMU)(MP3O! +T9$[^E)'7_
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M<PS'2GU%D)42$IZ0,A&02>H<8//'\QK1V@J 0/<ZU1D@#;WZ:56+?)'2D_O
M $YP?[Q.1^0P#P >^CMNV*W&/.C(P2*GST@#R_EU#&<=1/ [D_ID#Y#0.XO
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M2V4HXZ^M22<823QJ+[OY,$$&4<C= 9UTD#4JKV_#&[^V?^Q:C?7'A#--XO\
M\1=IVP9,&@]5TU=/[)M-/"!2HSB."F5*63U*;7^+I]*ND])P,:XN,;K9\ ,
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M$FFN1PG*BIE2<)% .(#%T.;3/-&03+ UV>N+&VPX) .,[IE%R\?>O/\ ;Q;
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M'<"Z(MR0+9I>V@5'C6*N"_&BRUO(+2%1Y<7TNJ6Z@NE'2D-X3C!4=9VNV_\
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MCY<39H__ )?\3SISVCKTD/Q1JPX%_P#WNZ%2!V-P?CC2KC_J?UW_ .>^X_\
M]?+'_P#+T_EL_P"OK?\ _"J_Q<;_ .X?_P"!/_\ JC_J?UW_ .>^X_\ ]?+_
M /N]/Y;/^OK?_P#"G\7&_P#N'_\ K/\ \J/^I_7?_GON/_\ 7R__ +O3^6S_
M *^M_P#\*?Q<;_[A_P#ZS_\ *@^#ZN__ #WW'_\ KY?_ -V,_EI_+9_U];__
M (4_BXW_ -P__P "/_\ 56;WA!N3)QOQN* GI029\[EI9<#R !+Q_P ,]_K[
M\:<XA EZ@7/Q&WAI4CX>\'F-Y)Z[Z3S%]BA]W*[46+*VVM"':T^YJO=DB"[(
M4:M5EN.SY2'7UN-!;JW77%M-(.,$D #C@@:<P1T3S#[5J+2,W N7!6(0)9Z:
MSJ*YG^-&D[S;D;KT(VIX?=X*_1;!M'=&VF;DMU%D.T:Y%[D6E]Q-288GWI2I
MT=JD2"%N(DQDK<"3@<@:PN!N)/(0 #/S&$<0;9);$^HJVL$$BU!VC0X1!93W
M]*:[2=M/$13Z]0JF?#3OHXU1;HVGN)]KX7;I/Q'^SO;^JV;/@M%>X2_*=J"Z
MBF>IQ72%M->6X#D:@V$DD6F0,M'Q\' U3PHT4,$P@Y&_A[BM53LEX@3:<:WG
MO#7OF78FVNPUFK<:A[<(COS-HO$&YN_)FM-?V]/EKK4%2*3%! 5'DI,A2>E1
MU!M(<F2)'<$@QEH0&"!C29"@88BTE$J8EGQ(+D12O[6VKOI9.].WNYL[PR[U
MQJ3:F]7BSO\ JC$]JP(R#3_$U4;>7'^(FQ[[>+:++:I;\JKJ^#?3.0OJC]*D
MYU8L2;2;1<;BP@CFYO3+P!HQ1/)MEXA+_P#$)'1CLLUU@H?B!LVJ;UW3L/*$
MZB7O;MO6_==%15VVHM,O>VZVT\IZHV5*4\[]^IH#[;,6OEMMM<%Z;'2EIY!<
M4G1V$\@30(+>9CS:U\C4BXHFZ0TDB%C[;$1M*C7S?-O;?VK7;WNRL4^WK7M^
MF3:O6ZO4EI@PZ="A1'Y3CSS[[T=:4)2PE.>A]3ZR&VT'K.(/R<MQ+$X<>'6)
M^TU+*NA70'XD/8H:I=$!3>/ :_>M7V9G7S>T:HTZ3NAN-N1N3;-&JT80ZC1;
M$NR[JC5;-A3(@;:,:>*"_"=GLK;2M#ZU!14<J+A ?,9',6 3@;^.?$+-5NP
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M[&F=;T^((PE2+4L-\2)BPIFIU]2DHBTW.0_&A/)45+4,%/F YZAG..W/Q>*
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MMV;HVBN=BO6Z^XJ.I255FCE93 K,(+2E;2F5Y;9G)/+4E"?-+8.,@#/F<7@
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MX_"!]>^O6^%XO\?PF)/%O4:*R<[_ $ KP_CR1\8^5CDX8)4')+/E[=<5]_\
M?@K5.LFS9R\M-EBLUIA?EO/-JPARC1 %=)8227WIA6M+JU&.DI+?&?$XS9*9
M&IP=$,[+8UW\'X2R_AVW7$@%% P9SKXY)G(JKX-/!O>'BUO-+*43+?VRM^2V
MJ\[T>BN*8=<0I/51:"MP*,RJU)E6)2 ZMNFH*G7TN.]!<\_C<4W%#NSAD967
M_P",N9S7=PN$+,3C23B#TZF1UQ7K<VJVEL/:*R*)85B4")0K>HT5,>)$C-MI
M<7@ NR)LA/4Y)EON#SGWG%%2W2,!. D86A@$\P*CYBSWF1.[V.IWNN++Y;L
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M7E,I$G;;S8[%E]+K,*5%1Y33BF68K;2C+6I3@AR'9L\.?$-%4=E#:^C6?-Q
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M2ZM"GU/OAY15D\(4X2Z6>$%1*\ X.LR;BAH"9SJY:S(@'.:L &22WV*&WO\
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M1VU:3*$9TWZZ]/"K"X@*".LU9FG1U>8@ESDG& E(2 >KI'3@* QP%<^_SUH
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MZ04V_<,PGBG1I,DA<6I@$8BR%=,C"BPL=*6QMP[CDH" "B0RNL,Z/OH:VYQ
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M6J_5Z<Q7KHMRNO.T&1:MO+J5=F5"+($"#(0@9#B%K)+V!"*T$@^?3-5@ZIF
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MERML*@):T!6#,;GJ<Z^$ZS1H\:@U3<I^XA0Z7/-^U>GVZ$5&FLJ5;BZ#2JC
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M&6D!TO*96I+;I("UH)2<*SV&IL" ^;F&,:OW]ZDEC='),'HD,KOGK2AHQU)
M4?4G&1C(R<@#Y=N3SP2,#5B4"1D=U[_3BHE#:5[]_6KGI'/?) !.>2!]?\<:
MS-Y<#[_CVZBI/*3QDJ('8$@C^&-/Y#J!]/S2JA (Q[8QJO,6W-*D+23[JX
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M/J:44)LT6EO&++FTNF5=<.NU=") #7GT^ER8J1^U6\AL%6LSQ"2A:2S_ &)
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M<R&6O.;?92"LH*T)7U)"E=.=/[(R -"%(]]JJ#$B2IVZ ;[^5+<E[RQZAA
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MHTI1I2C2E&E*-*4:4HTI4I0%')SR.GO[=]6%Q& /*:5B)S9<8<2,A64!!!*
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MM#>>F=<U)H5YP IVB7C ;2F9"D-@EHS0UY:Y\<+. VXHN-))<;4%)3K/B6.
M3&/1O T< F&:D#FD)X3@[8DJ,(->+5+*\06Y/ARJ;6W_ (D:+5Y]"8S%M[<:
M,HSTOPVCT1U5&2$=$YMY(RE;BQ,BH 1(2X$@"EI-I'.P%A!SS2R9$?9&G, 8
M!;1!QX2>N$))FGI0?$-LI4Z6BJ1=R[5^"+(?ZU5B/%6E(!*PMJ06U@HY!0A*
MEE60E)P1J]MP/_(6RT3R[:KR'CI4\UL&3":QWZ[ITW/</QIT*5+59^PU&F;G
M7Q+/D,2*5#>51(+BTD)E.R5)(E%D%2RTH--9RM2BE!!K=Q#!&^2/['1! XPX
MBHY@ 1:2-NQ49R]94K>K':3PFURXK@C[I>)*IF^+S?<3-A6N\5/T*@_]Y&2M
MO/EN%D ),-I"8B#RD*(TLLN-Q-R::*)<HG/2-LZ5 @,M$Z:B6#(\\^E/]C0&
M8;):C,(C1VT);98;0&V&FD("4H:8"0 A)2 #[ ]^V=C:$U*TP]_NE0%% H1G
MU&P>=NHI@/C8CT>5(V[IE<A"93YK5?1T+<Z'4N@4Q)<\S *5LAX*1SA!2E2<
M=!UE>'=:6'RN>^B"89,^M+QKJ27X)?OJQI3*[6N[<#8.HM2;9F2+LVZDNN*?
MI;BREZ&K/5Y48K\SX%:?Q)<"5)?4 <$# MRFP<ULL(<TBT= Y("$#5[O(7"X
MFW^I8*W6^HU8'AT9EOO4K+M>Y:I<=G2)9V<WGK/WE>6V<"OL6([3]SD,%=/H
M-RW1&:$B#M#?$Y"95=I<%V-"-:8:+B&R?,$V@7"+BADM7$@2+M$Y;((TJ2]D
M8U8 .HU:+(( A,BMGH/B!8N6CN6Q)J$.LUB@8@2:E:=&ET;;M4MQ2GUVY8U0
MJ9$^XDVQ$;8IM1JC:5H3)4H*<4WZR,VN"042A B!JFO]5 &^H:U)U)&A:C08
MR*1F^;FD--2?+<2B2H=:7<G*48P5%S'=)3D\DD@J(P=38WT$]' SVI?<1:44
MX"T9>O7UIQGV3=7GN^*V[$1RZEI_;*6BK@++C;WPU2:<CND'@)+Y]*BK!6>,
M$\UO/SV&9%P6O3!WT>B[7MDHG!1.= <H1UP.DUZ0JQ1:?7X4BF5FG,5.EU!E
MQB5!FM(D0W&748Z78SB2'.H<'V0>>X&!!)^8$CL01U"P1[WK4FTQ&7D"=VX[
MY(.NG.B^-C-Q_#9<TW<[P]A^K63*47[JVR)D/LM1TA3C\B)#;5URXK8QY:8O
M1.B9Z4%<=*TFEPNL)-H*_P"3&@4:PLGJX0JG+UDI%ZF9ASIURJ7K:[QE;/W]
M$0U5*S&L6Y6DI9J%O7,\(CS$I(!?3%EK;2R_&0LD-.'H*DCEL$'5A?:)@8>3
MEP"EZ@,#8T+/RDDD$K9E9:\TSUK9K[\6&QMBT]Z7+OJE561@&+3*"\U6:C->
M*24,,LL**$]:TA/45I5VRG3^6T$HME@@8[L!;$SG?*"!KRMAF1H0?>RQ30%4
MW>_QI5E#]1^\MK=C(;P6(;B'&I]SMAW*"8RPTN8ZZI"T^9)!A0DIZ6TK<<)-
M7?Q"1@1(8#TV<X,89) J!,+)@LH;@"NA^WFV-F[8T"#;=GV_&HT"*PVAU;92
MJ7,605+DU"20')<EUQ2ENK<)ZEK)&!QK6VVU)&#)62RYR1I,B,*)@-$8/4$:
M/K#V>U;Z['4I(!0M20G 2DCI*3PI*T*!"P<$!)R,?4ZL1;<$V.X/1=D?SFAN
M?B$7ON/?A3'?$%X3V[CJ+&Z.S:C9>ZU#=%2C.TUPT^#7G&4K66)K+12TF4\1
MT-NK269!46I*5-G(QOM3Y<!%  -(E&)'5Q)G+Y2-CJ=NH&KV B=!.)VJ\95.
M;<-C[^4U_;2^:<1'F5"HQGHE&JBVO+;;D,A39,=Q]?F^8T3Y/0@.!?0ZD"1Q
M0E<N;=0"W/9!K/U@&99'1Y/=99\33V[4OFT[O8=D6M<-#K[+12'7*3.8DAKJ
M2E2 ^EI:BRH@@A*P%$=M6_DL(-O,#<L#KC2H(G73.9Z5MGQ;)P4K2I). 0H<
MDYSP><#')X_PR%MJ#,HG(P/#W.U.6[8^53MOH</I.1V'((SQP,?GGN?II=:
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MRMZ)&J$X0G2K'42Q(D/EK')0F.IGI.2D@DG5#P]0)>' 6"'(>V$A"F;1:VX
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MM:UV5>P;]@S)]#E%VF-U]-:-,GS)\N.F@LN5P0 .ADG/+N0-RQC(S4E1<3(
M&9!&KF0]C6R5?[-C>Z;6*;:D*L;?TG92\9=8F[CT%J5.J=3M.3=-R0+ANW^Q
M4.K4>?2JS$N%ZT;0?JK%78B/S:U.NFKOS'5S6FD#P[BG:@2$ 8MS)#ZZ+&AJ
M&TR"B0--_F*VT72=*ZE>'&S=T;!V;LRS]VZO N:^+:@.T2IU^CE"8E9C1ITD
M4NH)BMTVEL05-4GX&$::TPN*R(P*%J)SK2VQ@ @A-=5()C2 B4=",4$$*ZW
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M9\RGK6U+BQ9S#TV,IM7EN^>PAPN-A"\I45(3S[_.1<)/,"-$6>OKMI0VLP"
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MH=.01GJ(^1'/)(UJ=+M!GJ#@^&:O;@XT0*Z_FF7>(#8>I5B:UNIME(=H.Y-
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M>,]]9F/5%IUV2A4&FNQ8[9 \U^22 *J^X$W'Y;A%ARBM<G:9Z!JK"T(R9R1
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M&B.L.4:7)HE.5*I7P@*6'(4H1'#$\I& A#*T)3@?LP0,6%EET$?,-2$?)X"
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M<H0JISN#?T%51M:W.L0FPB95XB5.QW0/A&VPKSW6U#)<X1+*V/CM**3"ZK!
M@HE,D@&=]^Q&5G2:3FD_:1>"2J5O=.UZ;OU:TJH;/T.N7)?2F&JHNG0Z):TH
M1KFF4FL)IXI=SFWY1$>O,T!^HOT]X%$Q27 <1S@ HH,,OZ?D9 :"-#<'*[*-
MLK:#XLFE#\0GC>\-/A778\??+<9FSYFX4*JS;*BHHE=K<ROL41-.55GHD&WJ
M94G_ "H**Q3@2ZA',QL)2<J(M_( %,VD@O1H$[+[:54IR8R0!&!W;0/W>;2'
MXY/#*[:UTWB-QH<>W[5K&WM"N&;-IU5@K@5G=*C4JOV) DLOT]#Z9E9I%7@2
MVDJ"2VEPA]*%I4A(7@#F )!RS\Q<!>+>>\BI*) V>A06^BA9#TZ3[5>.+PM[
MU;I7;LUMENY1;KW#LXU%NIT2 F>43/NB0F-6%V]4I<)NF7.U1Y"TL5)V@2JB
MF&YYB7U-^4K$\X)@GF<#(+4!=$2-,B),"X-( //T*\OKV>*V%AM)/X2$X.,<
MX&$_A2.1R<)[_EC6@[ 3IKUA?054IE%S[EEUS$^TZ1)5MS83C87\&W>BD2>C
M)Q-537O@QD8"EI81-*2H=0Y(P.!CQ?[6%.9[A+T>JWQ4,H#OY/ON,(;TZOPD
M*A/>&[:'X-2!&3:<4'I +@<#\CK"N/Q!>2KLKV.K<-&T"-V!YIZAA&"(A!58
M'E N$L$=I^F?9IS0Z<$)*<>D@)&!@9Y4<<9SR3D>V>=:3^_M[]:I5)72<Y'4
MKHQ[@9&,>H J.1VX(]L]M/JHW^O;7QJ1U:<^]U7GU_Z1C&@3_!-9=,DTL5V;
M*\05AF)3$42L7$\8S5"NUR=.=I-"J%.JTB'')83*,9QU"%*C!QDY3C.XG&+F
MQV.K>A3GM5C;#M)((G3'1#[T[O[$^/+C_9T;'?$?=@BNBY7:0W2*#5[;A,4K
M[\E-L,)I-<'WBPZA]N3YZGBH+=*U)4H9)GAA O\ ['MX2<EEZ]E53HMON7Z^
MU75P=U?G_0:<33Q^U14=9THTI1I2C2E&E*-*4:4K'O+Y45]@A9& !S@8&1E6
M3P. >,X/;6Y[."?):5(R%G'G%)15VMR:C<=1BTV;0:39SE DIA5=N/*DW)%K
M[H4F,ZIB4M5.<C1<^:A+S#J7%^E2 D<YGG)('*+$2+IYGEY2>(:ZU=$DX%T,
M:<J'O/;2K';S;IVU(;C=>N*MW[77)[E7D5NZGT3'F)[^&W&Z-'"4PJ' ;:'2
MW IC+#(&3GJ)U06HA$WEMF4>D1 #PTZE,?,!T6=@S+Z-^JI9&T-@#T@]7*B<
MGGVQR2 . !R .WSUN LR267Z1I[\*$S& $/+]FKD)"T_@20?D#@'@$E))ZB/
MZ:$@ O33QCZ1]JK5A-2M0*4(*E%:0I/5CJR"#A7LD)))2GWQ@]\UNN222'ZC
M:KVA@YVRHCH7U'H32/7GMBY68LAZQJ_,VZKTFILU677;=@4\FJ/Q&5L1X]?B
M3([K52B=*LK*AYG ]9UE=8;V;#RELD:D!=UJ&O U8VB-S!!.8Z+$8[S6.J#6
M^L2K6Y&I,ZQIM":IU)3<E3JE/J@KL^<VIP59Z#&IM0@PHS;P#9C)>0XAM:UE
M22@=&H(X@,FS(=Q9.K0!8"2[4)Y1)+2"  !TTG8^U5A[9U2==E>K=[7G4[KH
MM21(@TVQ)$.+#M6EPGGF);7GPV(X55*BAUI.9LU;JPCTI(.=6-GS$7$W@A"W
M0#8]MXSD:1:?E,@#KDGN8:T1>Q*:TT^!'B1V8D2*RS'B!"([+3+;$=A"<]*&
MF4("$I2.$](&.W?6HM2#! P$ NM5)V!#S.<^F?8K*)"!GJ3CI!.5#"CSWPGV
M&<9&<\:7<VGCC[U6J$GRRG!*?+Z3P!U9X_> R2!P<'CCMD#4$?*6 "8)6YS&
MNO>I&<$]BO?AU&M:57[7@5R-+22]#J#D&5!C5J$M+-:A(?:*.JGU#I4[#4A2
MPXV K"% *Z#C!I=;S6@EH,-@%:)(B8,D@8.M6*-R 1,LFX(Y.<8!PL^"/"W-
MY[2M%NF6W>="OBMQJNI2:IN13ULK:MU3(2(BI%$=IZY<ME8 $Z82J0"5*23@
MBM@XH! O!V?- E$&"3&='&HH5L"02V229#G8N7'I64F[8W5=58M:XKPO:M,I
MHD>#-DV1:$C[JM>?7:?->E&;-DC-8J,5[_=<TF9.7!66/4V4G(G^.]BXW%ZV
MVD -Y9;ZCUJ9(8* @O'7"2:P(EC1?(L)J.VAIF.TPTD]26FFFV$ G!60VVD(
M2I2E$J.,E14>VM4C "SC7_6JJA+)SYOZZ5=I9*3V2.<D]P<^W3Q]><C/OH[4
M"H<0(Z^E10M!QA 5W) /&#[X]^GMCOSR-"0T9:]3[-*U2L6W1KA0(]<IT.JQ
MVGXLF.U.80\W'DQ9!D-26&E(*6I+*NE2)",.$H&2/:#9:<ARU'D/?C5VP F5
M+\ ")[/0YI)J-9FZMJOWG)IFX?\ :QBHLR9=I46]:6TMN@S7I"W%1G*E2S$F
MRJ.A!#<1DN!QM 0"?2<XD<2V1=:88!$S#TQMKD8-2,FW(9 9+C2(78=] <>N
MU-YKKM)BF75>=(LFM/U5[XZ;MY3WENO41QOH1$9EUUZI/1*BM1*ESF TIH8"
M$@\@+;K@/FY2R^49"1$GJ_E+T6I7<R+Y2/%AF".TC94K5MVO3+<:C!ECXFHM
MPHM,DUN2A+]:J*8K2&P[4J@I =D.KZ"ZXLJ2C)ST9 UI;:/^.?\ DV7L^9Q
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M89I;53CSTSFY =94@-F!:2@1=,RY0,#U(/H8JW,2+@.<8C(* R%N\YVB5/\
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M51FAI*4@IF3J:_+25)"BA])*E#!UG;;\MKP 02-S<?R'L*WY= 98*(S%IE.
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M![09R!KFF?[EW^/#UNK6_$KX=;9KE\[876QY_B5M.@T>JL6:I*D-HI^\ED7
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M1;.Q]G5#<2>A*>ZVIL'X:AS1^ZKX:L.K:)Z2 <XOS@&3S&4!@)L>QH,JJD#
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M 064A$23L_'RFNMD*C4N(ZX_$IL.(^00IR/';:6I*E)6I*EMH002L!1;R4G
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M<=PIQZ?5T+;G^ Q\P*T(87OIXU/>??OW-)M+\*?B%NV='17]X+.L&W5,AF=
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M\XXP'0W$<;#K;:PVL(4M/I]*CKT+/B[+>'RW6W$S(2D_;L*\V_X*^ZX&V^T
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MUKZ22<D]&>D'@>H#JQD# [D&]?'Z8HS VQ CQS4PB( X[\8)]1XSW43U'O\
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--*4:4HTI1I2C2E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g899221g07a13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g07a13.jpg
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M4E56=I+1TM/7,;36(B-4=Y2SMM0D024F,C-"44-A9'+_Q  = 0$  @(# 0$
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M"^$T+^B4_P";CX,N#_FE1?-$_:'PD8\YUUKSQ8?@ST%\)H7]$I_S<?!EP?\
M-*B^:)^T/A(QYSKK7GBP_!GH+X30OZ)3_FX^#+@_YI47S1/VA\)&/.==:\\6
M'X,]!?":%_1*?\W'P9<'_-*B^:)^T/A(QYSKK7GBP_!GH+X30OZ)3_FX^#+@
M_P":5%\T3]H?"1CSG76O/%A^#/07PFA?T2G_ #<?!EP?\TJ+YHG[0^$C'G.N
MM>>+#\&>@OA-"_HE/^;CX,N#_FE1?-$_:'PD8\YUUKSQ8?@ST%\)H7]$I_S<
M?!EP?\TJ+YHG[0^$C'G.NM>>+#\&>@OA-"_HE/\ FX^#+@_YI47S1/VA\)&/
M.==:\\6'X,]!?":%_1*?\W'P9<'_ #2HOFB?M#X2,><ZZUYXL/P9Z"^$T+^B
M4_YN/@RX/^:5%\T3]H?"1CSG76O/%A^#/07PFA?T2G_-Q\&7!_S2HOFB?M#X
M2,><ZZUYXL/P9Z"^$T+^B4_YN/@RX/\ FE1?-$_:'PD8\YUUKSQ8?@ST%\)H
M7]$I_P W'P9<'_-*B^:)^T/A(QYSKK7GBP_!GH+X30OZ)3_FX^#+@_YI47S1
M/VA\)&/.==:\\6'X,]!?":%_1*?\W'P9<'_-*B^:)^T/A(QYSKK7GBQQJ=::
M4TQG<3"6T6?:X\K<O#B9F)F6BN/QZ+MB0 BP<ZJ);>3?3"FZB6<XQA1+?3.=
M<P?!I@E)&<.B-TI\LVY='E3:3,966:5MR8$AAPE).QD2C4@S(B4E2;D>2>$?
M&:OBRZV[4V#_ /J1*Q'AU6&ZD_TD.1Y\>0V:5%D9I)*R([I4E5C+IA3<MJZ6
M@X-.CCF80V7NMQ<"GY--NE(!\@305=(0N;*M4F[$BY),VZZD<D:#=HN1<M5Q
MI)MN^5;.5^*%.JV%ZM!H==FNUBCU=U46@U^2EM$^//2VMU%%K:VD-L2'9++;
MBJ;4D-LN27&G(TEM3ZFG7.:;"I.)Z5.K=#A-TBL4EHI5=H,93BX#\!3B6EUF
MBH=6X_';C/.-IJ-.6XZW&;=;DQG$L)<:1Y6]Z+1*S6YBL1U=*ZQFN_1!AK#5
M3.&ZIA5J@Y.E%DL9\W+O9TM[+TWSG;&C,<CE/">RSC&_E/AVQ3+K>-)5')Y9
M4O#NA#C1R49-JF+9;=GREHO8WC=7R5*CO9F.C1))K<TO4? ?AB+1L'1:N;2#
MJ6(=.9(?-)<8F&AUQJ#%0O631-(Y2HB(KNR%DK2)#9EI7SXF/LX< ' !P <
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
M' !P < *+[+)8Q2,])Z>31]&1S68!W&/Q*LS42)LI"*=(J8\FZ2B;P<EKG?3
M.-LI;J)YSG3?;7-%X2DVP17Y2;$_2XS=8B.?UF9E(DLU&*ZA6M*DNQDE=)D9
MI4I-[*,7?@X5?&E"C*S8J<AVD2VS_1=AU:,]3Y+:TZE)-J0H[&1V4E*B^,DC
M+P^[,_E_MS]MS/\ W^>'.$_^D'%WTW,_:(>V>#3Y X3^A8?[!BC.407@. #@
M X . #@ X . #@ X . #@ X . 'TQT_^26KO^74)_P#&AG/TVPA\DL+_ *NT
M3]V11^:^+?E5B;]8*S^\9(L7EB%?%*55<R5HR"R0"<.DL9VKJ0Z 5'QQ#"38
MWMNL01],T\FFF4%T\CLKK,]MEMDFCT<XROMEUE-.E85QFC%-0Q+ 11ZG3#PY
M42IZGI[9(;FF:Y"--FQ%H*3R?C%LF:S2T_'<TSXPTIN>*,'+PQ3\.3U5>FU(
ML0T\YR6(+AK<A$2(Z]![,R6A7*.+0\1()3S,AO0+BM)5U\NHI@\'\>+K/D.X
M[_KMO7U,$P#?O$ETZ;1MC,[,9WDZ%K!AQAW<;9BO6SRJG0&.,7KPL7C"L\'R
M(@. E4 Z"I-84V?!F22--\[V,]AED=O#X]XN*/>-;U2EJ9EG%X+V&DLP&676
M%5,*VCD!BLAL&02>Y8Q<DIK=-D!!V$13 JG&E%3YD4 3M[#YI"'Z S:P(M%1
MK_)) !H,M=K6,[Y[->R^W=;<+TZN>)SU9[?W/.:+ITW('DQA@*6RQFX+-8\D
M)FL1@E@HU?+9-&M \G-GQ3$1,7HEGHPL,#!9 6&&P\C!!BD=?:%,!!I,BN9;
M;?9Y2S*UQ(NP'B$T1UJOZG>NUELITA+;L,UQ'HK(!PJ.YB+8W;,]<UI!1KA4
MQ*@TGD#I_+6V&IK2OHM-OD2.=CCLYS&@A)B07 23,C,K9;-IV*Y^0L\[7V7,
M:X6YXP500VHHA9E7U/:=O%9U#*KLR/0[1./0Q7-?6/V@BG5Q4D3,DBQ-!D>&
MRZ3:KBP"+-ZB;<[!V#LP 8$GYX& DW.U[6O<]QD1G;V&5_K$L.^+UU8BS:;&
MY, NX'!XR'OLG%;)>UPDK!KB?=8CFT9O&.U238R%X_)EH*?0(L'3R5"XA&2B
M(4\:!R$G'0I(NW!HGT7R\5]5]A#J[>+[UJ6@<>G8.#WM,TRL,MNT9!'J_B,+
MGQ2!4]1Q@(#LBX)$=A]BF:]/5X)?R(0F+*UE-K ?RK9=TA%!9IV*+MF -$_:
M1;2S/4699:MMB&!E7C/=8HZ2DK856W92?A([[XO032!UK'BD1DV*"BL:L*VE
M(V0)ST,]<-XE6DK%6"H\)C13(L#RN*!N"<ST2BJP"29[BU:^D[?7D(WV&\:*
M@*J:7;&(/'9=)[4K[KU9MYUXUE#$7&X396:\I9A>.XE#320N+1#"7T1*M%6T
MQ-5L*AA=VT-"8U)3)D2Y8ZA)(,S*^HU$1]%SMX->R]^BPV1[D]_HMU-B&B3>
MNK"MFWC=!7/?<=@5>Q[!MB%AE+QL*0DTUL8HH2&J1V #Y%+(C'WKX4@=DSI8
MUG(*-%MV;S" 0E.EM(BN17,[:]WD%1Q_Q?>O&X <;E\4MH0%T$EPYFS!D*1>
MTZYN^&T [[%3ZAXO*'1UH=)3H'!P\CP/<DHR*B!DR"?1UC+5CR*C# SL&B=K
M^S;8SL1^"]O*,4V\8Z@C#AX%:5=V'AY59RB #G['K48*@Z4KE?7LWV7J)B;(
M@IJ<+(-;6JX 4/1W5B*<OQ?L]<=-FT.).A:#X&@>\C\!YGG8[%EJ^K/4)!67
MBRTC+C%70P]"[<;GYGK0$9D<]C\ W?TZ M+L/UKCO9F 0UN6W/J35XI)88;6
M;"M6<0)+C2S+ Z2[B</P[TJ TF6[:=KYV(S(SU;RZ+C 0KQH>KUC:HCH+7_8
M*6SI[9L7J@15\;B$!.SLK*)M55E7#$]<("+0>QP)J3B52S9,F*E4DC\JA)H;
M@;8<=B.?3K(/?W][[PT#WEOV[R+=O,OKU"XNHWB)1'N3<<Y@=:U?.!]: .NO
M7#L/$;BD#@2R92X5V&TG>S2,/X?Z7)J,EH^K"" Y)QLX,-S)8)-T%M0; %&2
M<Z :3+7KN9&6TK6^N^5AV>P/B2TUUVN%W2,BKJ^)O+QZE%,R+NLX(%D8!@9[
M+2:<0BD #H@0F )QJ7GLX@12)#D]&*C1H5?"W!5XP"[$RPP!),ROEM__ %*Y
M^SWO85HAXPO5=V C\K9QJ]GD:VB0B<VV<:UNV58=:HR;N*:4(Q(7OOB2X5#[
MXM*N)\!<LX*E8#UJPB)B4K-](GJU..@:)]&9V+I.Q'EY2UVUC^)>,-U731E+
MXW&+XC 4+'+2/Q0^;K5OD9;KJGK_ (WUAFD6JK41)2Q(]*$;KFD,AHMD7'Q]
M@7=2@<NS)[H-3.XL&B=KY;-N].D7L')(/%XZZQIF1:$:R[)J6/$W5S8M2E1]
M8"2=J4T"H&)5].[/F5B#64S6C.D1$1*V:S,BBL0E<N5E2,T%-XNT+O6QAL,!
MH'T6RL=RL=[D1%TW(_)X! EO'3Z(HFYL%]KV&MM"*ZL&P7+MN!BR^QM:J:F;
MW584("@4YMM,4Y;&H+N0<;.Y!&@,$,EH_(@D;FQDB'=(8!H'ETF1>4[%T>Y;
MQ()!XNU( 9,@VD8&<U2!@YFZFE["K>A3\1/X@$J[J^P[3AI#'Q$7*R8<_:3"
MNC0,R*8O'F#ZZ+_V*X!BY)K[.P_B&B=[:S.UK'EF=OKRMX]6O9]OWDKD=UTM
MWLO9E;7Y1L.I1F\?S*,W!5KV.SIVT3 A) (<0P<))2"/SM"3(2(2*"N(G)BS
M=*4+.XH=5"2(09&CPBV9%D=]5C][> [#2,7XO35M;-F1VS:;E].02K9I:(N0
M"9O'"[FZTHI5/2"&=NI&^=0V+/) $;R!/:0E!0X>.-G!T@CS022#D%')375-
M_$9:.19_I>(OTM&_@\AY[B&3/^.QT?B];0ZS3NUD-!<R<V.JT%M4JJ-O6D6J
M<5!C,XG*1Z/VP5@$OCXUE8T628BJVFDXG1XNN7CH&'$I%&9**$O?WV!H*,[?
M7<K7N5CN16U&)S,_&9Z<P*;6W")%O9:+FI*_E]E.C#:.1MT-F$;A#V"CS;N,
M#4YE\KQ(]9>Q8VN"EEDQ>OX%)1&#$C 2XC' )<LT""2H[6+7_'W][D(Y*/'"
MZ0PD-5YN6/YX$;V4+-25;15O7+Y*$PL%8^M5N9P8,B++(QF=1=Y*L.]A#JBC
MEO/2X$69DC >N%$D'C=[^_O[ T#/5_'.^S5D?AMLWCV$X&(< ' !P < ' !P
M < ' !P < ' !P < ' !P < ' !P I#LK^0*W?V$/_Y/?E(X2OD!B_Z J/\
MIUBZ\''R\PE].T__ #TCPY[,_E_MS]MS/_?YX9X3_P"D'%WTW,_:(>V^#3Y
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M$M^S5>A*LN% >R9'4&PQD?@T=#A1C%@DW:1;5IAW&41+Q15QNUB+GOZ?K/\
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MM,A)OJ6Y)2['T.*C)>2LE*6EW0;,U4WREBXAP < ' #Z8Z?_ "2U=_RZA/\
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M&HR\-BTB"1A^W9/*K 2F,[L ;Y33;Y(QV8,9:0,2,7'F35\[E^J9IV9?#?\
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M#7LS(PWM= R<U,1\^ILZC5GT-376/KR/5SHLN_7TJVG:)@P^4;+*Y]JF]S!
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MU]/;GC]GAR='5S"C5SEH:6M&PJXKVO(S8TY^1EHPRWDQDHE2L1).#XB32Z"
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MR"YVM?*YGY;%_ 3\AU8ZQEHZI$2?72BW\55AQ2N]XV[J6 K@\P Y*&DX,PC
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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M_P"K(S^AQ\&V >9^'_1D;[@?"+COG=7_ $E)_$#\'"A?A#7_ -61G]#CX-L
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M58P. MVF42*[$7AZIR%,O4VBT^FO%Q[:D(<)3L1:TJ2DBT5$5SM<YK\OKH^
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M-@,-/GCKCVXT0&,1BS+TA,L[&M7@1HY7N6VY["L9%>_29E_P.G"O&1ZL3XC
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M-H'2)AWI#I$2:)[Z2V/1!8\+WW.Q9,X%16?)@-)D5]UK]%RN5_?7EK&N$/\
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MQA%V]_?W\(C1//5E>_BV^#=OSM>PCC'Q?ZBGBE:,*[KZV8X]LZ3]52D0(W)
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MP < ' !P < ' !P < /IIJE?=W6->/ELXV<DH3%R;Q3_ .UGQ((R>O7&^?\
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M2!:0R$_(#Y4F=D$AD!4F;.&2+XH5?NWKI9?<(,S,[GF8M/@0' !P < ' !P
M< ' !P < ' !P < ' !P < *0[*_D"MW]A#_ /D]^4CA*^0&+_H"H_Y"A=>#
MCY>82^G8'^<D>'/9G\O]N?MN9_[_ #PSPG_T@XN^FYG[1#VWP:?('"?T+#_8
M,49RB"\!P < ' !P < ' !P < ' !P < ' !P ^F.G_R2U=_RZA/_C0SGZ;8
M0^26%_U=HG[LBC\U\6_*K$WZP5G]XR18O+$*^*HKNZ():1J< 8B]>NB%?%DP
M\@U=CUV27IU5R#5)=BJKCR.FJCD401QOG"2V-F_G[H:HK-U%:IAW&E!Q3-KD
M"D/O.R,/3"A5 G8[C*>,4N0TEQA2\G6E.19""59*KMW-!(6VI=IQ#@VN88AT
M2=5F6&H^((BIE/-J0V\OBTHCNJ0^A&;3J6Y4=9E\9!DYHDLUH<2BU^6L58>?
MEL>)!2-82MA7XN%W5<%BD3USAD*^IV#C9)+L,NONT00MF29&')/%]51$;>SF
M-L6(]JX<2Z6JOM'<,C$@%[(D%@RT3UY$669]-[>6Q]!;3N)0.\0'KX1LB'UE
MN]DPDQ-Y&WC0<B?&"P8T>X7ZM*=O]WLS8DCC>55TU9U BLL_:6!&HR<9G4LL
MU@^HM1$RJ$6^J_MM]8F2G>KI*E!6EH*]P>KR5;$"Y>/CY^I?E5Z0U^?CZ0]P
M=!LI+M*L!W9<,W+"G)0:W>*/6#8H.<.D$D7S7=4%CO:QWW6S\@F^>SW6O$Y;
M5AGL'2.+)>0SWC-(!FU8+B9NJ^R'4D6)RVC'MWVTO$<QY)4]B1I,MA&0B2A;
M#SU!/=Q@%CM>QVWVR&0@G8B@;1KTY;E:7A4-@U5&,F\26RX59$.E$ COR:9:
MDY%[=F 0R]CPC $;NF2,9($&^!H]1-\\RBU4T5V"+'JMGN%:..^'2!I$ -@N
M^XW5II!)2\.CXS,G5_U2VC$B?Q9['QLG9 SJTKT&E7<;(2R+,S[=BY75#.9*
M 1):-MS _#@)L=[6.^ZQWU7^K/P9C\S3NYUDA-TUCUV<VS#9#=MISH; Q=90
M^4Q:1S>-/#-;S6U!$@G449G?E%%H>4BD$**,)$\%[M7;TC'T$-=TC#9Q@%CL
M9VR(KW\9%]9BG;(\3&B:KM^RZGE<(O?U"F['INJ;5N /6VIJFX%,[Z$5X7K9
MC(9*//+'&[8MK:4*8.GR,7<-QY$MA)SMJW2W<\"=$[$>6=S(KYG;7;R'EK]@
MV"W[B]1T\V#A7M)UU2]TIT9%[3RM==;(ZUO)31;< 'C\[V4DNNL2-%3R:H(:
M,/98/7QI)82V15()*-]0BQY9'GJRU^#>(3^'WU'V.C6:5Y5PO"RE(2'L&VNQ
MO.86K1&E<1BQX[4Y5ZO:^DBS%D7Z4XE P-HURZRCLZ]9:[NDWZ.&>X-%6X[W
MM:V=]UM8GR7;KJDX4JE)#LSU_65O?.^*232N*O5%+?RF0R)WQ6.FLASM.\Z%
ML9$[8C&">=2OD&YQA[G"&06//(\M>6KP[AC4.X/7<\NX9UK9\-NPF'M>$TU,
M@U)R^'V69KJ8SL\K'1F+"%QV0N'L5'#7S9\J?5?HX>BV LP]W8*HB"66H+&6
MLK>'*XE,W[-];JS/FHI8W8&DX#*8W&UIE(HU,[3@T8D "(-T=7"TJ-AC1UD1
M%1Q)#?17<V_;-QFNF^FV77DWU\H+'N,1-UW7Z;,6,")ONV76IF/M-%BXK)Z[
MO.L6[:PVY,R^C@]Q"5EI/II*4'LA%DP+98)L]36-#GXK3;+YFX03!8]Q^0Q^
MY+W4Z=0SY5YE_:_K;%\0.4,H1.,R"\*S#XALT(DY4&8Q&59(29OB/R=R6@LV
M&I "V6A79[#Y2V]4PJ *ZM 6/<?D/9K\@DNW:'K3I-SU:;]A:/TL6+11>=R:
M![VM!=9A'H0U#-I$ZEYR-['L&!48:QYXS/.CKYF@,;!'C,LLZT8.D'"@+':]
MCMJO8[7W7$(<][>D3*& +%>]P^KC. 2MT=8Q>;.[]JIM%)&]BST"-D[,$?6E
M>@LLZC9"4QED?;L'3A4,YD0)$EHV4+,-7 +'<RL=RUE8[EX1'D?$,Z28+74(
M+]GJ4B6_7RPXU5EID9O8\1AH,#-Y?$TYE'0Z)N1&!PPGL3%Z&6B"X]RNCD[$
M9P \_P!KPN2M!@-%661YD9EEK(M?D_WU&+ILKL30%-1*/S^WKQJ&K8++7(]G
M%9G8ED0Z&122NRK'<H,;@)#(C(X286?BTE2;30>[<;.!J2K]/&S1+=;4!$9Z
MB,_!F)6<LZM8PJ%1DMA0>/+20'(I-'4CDL "53T;B MN<EDA"IOR#?8H#BX5
MVT,2(LQPNP""W3<@2<-FBZ2VP0*F5[B=4OE,G!1_9&B#MB.P#F3"*W!W#6Y"
M?GP[>$,+)U=A(KI*-2K]!W "HF:,W.B.K->*%1TEPYU!O$2&P38]QY:\M6=O
MKR\(Q$1[M=4Y9BKQRE_4Y%IQ;]>U_9L+JJ66U6(ZSG\7LX4/+0]PE%&4P)+$
M\EDR;9JQ=QUP;#E7><X!E"K;=!RL#1//([%ML=O+XA+#G:OJ_&8NI-Y%V.H<
M%#4H/$+.4E9:W8 /CFM;V"2(!H#8'MIU($AV85.3 DJ)ATIU<9"2<H-?CPCY
M\[9N$4P6/<>NVK:6LO"0STG[!T+"JM87C,;LJ6*TL5:!7XNW9%8L0#5D38R3
M9'2.O!T[(F&\7>M3VSA#4,X:E%4B>5DL,MU_2:^4%C/(B,SW6$;9=M.JY*05
MW$QW9:@2,HMY%ZXJB.L+AKUX;LUN-*D@1!> "VTA5>S!)D<"F0KE2/HD-$2P
M@H-4SJ\'NT406//(\M>1Y>$8$7W=Z8G8S-YH#[;]9C4.K-E'B-BRL1>U7DXW
M!!\NSKK%'TO.,I0N,CK23[[Z)1UP6=-$C:VV$1F[I7/F<!8]QYZLCS'+9_<K
MK%3]>57;<XNF ,JPNR?0*MJOL%A)@YB&S"262Z4;Q90/)1KUP&=@ED6[PJ0D
M2+U0,(!,"!LB\;C&+ITD B,[]!&9[-6O6(13_B&]-[IA<NFT<[ U8 ;5RSDY
M:SX].+#@D7E]6 (I-C,!>R6S(ZZDJKN#1Q\<"JJ!S4BRP8D1Q .\35U]IMD]
M@6/+(\]66OP;Q8B/<7J.Y9Q,BW[1]=EF$\CI67PEXE=5;[MI?$P3:3O#DHC2
MVLDRF;CH1K"IDX,&ANSD:+1B4F4?.4-013+4%CW'Y!@'/>_I"SA@*Q7G<3JX
MS@$H>G!L:FKN_:J;160D8P\!#Y,P"'UY6F+*/(X^E,9:'FK%RNN&<2(&D1T;
M;EF&' -%5[6.^ZQWW_4+=$7?2T@*#@@&WJO-F3$N/P 0($3^*$BA2>1./;2Z
M4PD<P9EEG;Z71J*:[2<_&VR2ID-'M=C1%DV&XRYP"Q[CWZMAZC%6S/O!TNKF
M12&(6!VYZR0>61+TGRKC$NOBKHY((SE$DQ#K:R ,7E+0B&W2+$QPU30BV;;I
MOGS1KMKA9PEIL"Q[C\A^'ZLQ,<=G.MNTXD=9:]@:3S8\.B2L_EL!Q:D&^647
M@J QN:7F4AC/MWVR&BS<,\9F'!\BS;"D!3QH15=:,W2"R@+':]CMOMEY10<@
M\3/HI&S-4-"'9^DU(A<P:U2L,N!G:M<.*5V<TX6K,)+XV4L[Y5Z1IC+-B%LQ
M-(1']7+A\^QL1SOHV]4UPN#1//(\K7*V>9&99> A=9;MIU7 2Z70 ]V5H().
MH!%5YU.X<7N&O1DGA<*:#6AEW+I6">R% G'HRT#OV!9T<+MF@QL+?L2"[E-F
M\;+*@L=KV.QZCMD>O[#\AB,-.Z_6$T^A.D.N>L; CTU/V?&?EY!;-K.106*&
M:>@SRQ)^REQYM,M,#UX_&&2C\HV'MBKH,V50)GVX@)OL5T!8RUD9;<R/;J'Y
M6[V=(VT.$6(Y[A=76T!D!,R%!35Q?M5H14T8CJP%O(!0D^K*M!9 D!6E,93-
M,6CI9R+VD0+UY)#!<?EP"Q[C\ABXZQN.HKL"DY'35I5W;,>"2 E$C)VM9I')
MR'$RD-A#8M'"1.,$B;)D=&Z.FJCX4Y62?-4W3959#1-PCMN R,M9&6W,K9;Q
M9' @. #@ X . #@ X 4AV5_(%;O["'_\GORD<)7R Q?] 5'_ $ZQ=>#CY>82
M^G:?_GI'ASV9_+_;G[;F?^_SPSPG_P!(.+OIN9^T0]M\&GR!PG]"P_V#%&<H
M@O LT-3EE2$2,-A8LY(L#3=T[#8;O16S\L@S>O!SC<:(V?ZEWV=7X]ZTT3:L
M55%EVRJ:.BFV/)FSP\&XFJ$2+-A4IV2Q.;=>A<6_$-^6VR\]'<5&B'(*6_9^
M.\T26F%*6XVI*"49"LS,8X:I\N3!FU1N._"<;:F&XQ+*/%<=99D(3)F$P<1B
M[$AEU2G7TI0AQ*EFDC'X T_8\F%L# .,KOV)55V@+SJ_$HNB2[)SNS=(#QSD
M@B1>+).T]VWH6S1111;&$T]=]]M<9B!@[$E4BL3(-+<?8E*>1%,I$1MV2MAP
MV741X[LAN0\M#J3:T&VE*4Y9"2-1D1S/QAARF2GX<ZIH8?BI:7)(X\MQJ,A]
MM+S2WY+4=<9E"FE$YIN.I2E!Z2C(B,Q T19)R22#-Q[Y<PN]T&(BD6BZA)4B
MHOAJFP38Z)Y<[O=W.<-]6NJ65]E\X2QIE3/F\T#<64[*1":CON3''RC(B(:6
MN2N2I?%)82RE)N*>4X?%DT236:_BDG2R&^7*C-QE37)#"(:&#DKE+=0F,B,E
M'&J?4^I1-I9)O_N&Z:B02/C&K1S$N>U?88XV)CCR&R!$V=U6W##\#EU5B>C7
MTGKF[+9'51)QJP]"MDCLFIM@?A%7+W*&$M\Z[A_"V(HTZ)37J-4$3IY+5"C\
MG6I<I+6EQRF#02D.$QH+Y0:5&4<D*-[BR2=M2QB?#TF%*J+-8IZX4$T)F2.4
M(2B,IW1XDGB6:5-F_IHY.2DD<C33Q/&:2;XIW"Y8PDC:'O(\5;RAZY8-&0-5
MHKJ_>+E?1>S,-$?)GUI,AA='=DLAE1!TFJFJBINGOKMGJ/42KQZFU1GJ=+:J
MC[D=IB"ME12'ER]#DO$HM_W4R"<0IEQ!J;=2M*T*4DR,=IJM4E^FN5AFH17*
M8RV^Z]-2\DV&41=+E)NKO_VU1S0LGD+)*VE)4E:241D,2R$D2)9H"9-%7!9^
M1;B6C'7S=5ER+ISHS;M-?/VUTPJHY4T1QY^VNN-]L>=MC'ESSJ,0Y,F8S 89
M4Y,?DMPV6"L2UR7729;9+2,DDI3JB05S(B,\S(LQVWI<>/%=G/.I;B,1W);K
MYW-"([39O..G8C,TI:2:SL1G8LB,\A,9)54_B0U8P>CB[46U>),'CYL\&%6S
M!ZOE7"#8BH)>OL#U5]D5=$-7OH/3*)[II><IKG7&XJ6%,04B,Y,GTUQJ*T\B
M.\^V]%E-QWW-(FVI*HC[_)UN&A:6R?XO34E24W41D--3<54"KR40X%10[*=:
M4^RPZS*BN/LMZ)N.1TRV&#D);):%.&SQF@E25*LDR,5[RO"PC)A@Q.0E&(4*
MS5(%22^K9BR1SIA5POOC.=4],J;Z:8VSC7.?+MOKC\7X\\[4*%*J,IB%"95(
ME25DVPR@TDIQ9D9DE)J-*;V(]9D60ZTR9&I\5^;,>3'BQD&X^\O2-+;96(U*
M))*58KEJ(S&,YU1V1W!X]^6?-!@MB[)$GZZ35B/8-EGCUXZ6VQHBV:M6^BB[
MA=7?.-$T44]U-]LXUUUSG.,<YHT:1,?9BQ&'I4F0XEIB/':6\^\ZL[(;::;2
MIQQQ9F1)0A)J49V(C,<,B1'B,.RI3[,:,PVIU^1(<0RRRT@KK<==<-*&VT$1
MFI:U$E)$9F9$.GSA',' #Z8Z?_)+5W_+J$_^-#.?IMA#Y)87_5VB?NR*/S7Q
M;\JL3?K!6?WC)%B\L0KXQ8\&$$+DG0H.+&.3#O+\NX'CVC)<J^VQYNSTDJV1
M24?.\ZYSC+EULJMG&?)G?R<ZL>#"B.278D.+%=F.G(EN1X[++DI\RL;TE;:$
MJ?=,C,C<=-2[?UAVI$V;+1':E2Y4EN&UQ$1N1(=>1%8([DS'0XM26&KY\6T2
M47SL,ISM#JCSH[^=%"O=5K FC:7TF.'0\?-!KJ+WWUB =B8SLZEVH#1G.X.1
M:3RH[/J^S8=@*K@%(8C9;<&1;DW#62Q<NHT%/!P9).U\CSVD=C+ZR,MY&6[,
MAI\6\$$!(AA"/R;M#84C$F0CF/G#!F*HO[",LWOAH+>',^)$9HZERR3V1O&:
MZEPN2KP X;.2.VT*=C'+1162;P16\?V$7\!.EG>VV_\ ^VE_L))57@YM84>B
MDUF%WBI=-PKFX-I"49UY9#AA*V]C=96762-*K^^/L?>4L8%X9&F>";EY\LWH
MLRTRUB ,%"HZ*&I-Y]S#2Z,K:LMY&>HB*QVU6$;C'@L.0-;3*AW?9445I"R*
MG 0^<-7'7.(/;EWL$)T@CO1_Y90>XI/,Y3M7D26B<:8S=O"@4.WE3$LY,1+6
MTUX)(9""+ -9F9':UC.Q;,U&K5X3\%K97S%]59X9YNN^JW:JB%;Y1VL[M(!W
M FKLC\+L-WH T&UD&JV*$5(G==_7M)3Y(4!#(Z$-]K1$-%&.S0+$VD*' P6H
M]_$09W,LLBV9>/41%GX!0\1\%C(GWBNY5V-0E)6Q8KWG!NUU*OF15,,5[MT=
MUAI<F9:%K3[ VQ/S.*]0ZXJ&6F)7.SQ^6-ITY!DI.,P$R4-CS(RWB37T;4G_
M /'2W$6N_LZ18-6^$\=JRXZKF@[L.!*5E6'9!CVH0A3^AD,62:LU;JVYZQ2<
M4O<J=J>1I7Q)ANVF .-9KYZ_!/$< GQ^0L681T'!I9&5LS*U[["5I;LSRM[=
M]\_<GA&UC;]U7MV+<S%@&NZS^Q/5"_*YL7Y!*D#U,Z=91-)!7T('JIS@8E*A
MMF#JD*MB!!RF$U I3ASC44<V"I;D@:9V(MA$96WWOGX2ONV%?40TLEW@GV%6
M,08ITQ9XJT9,'N?KLSK-2;1Z:.G%<4M'N[D&[+V$^GS&Q^QTDKJQMHPD%W)[
M1:KH30[*8)AR*7L-W*I>0(J@TL[G<LCO;?HF16RN6O:9^3(78Z\&*6*ZG9.R
M[9I!;2FCN=R6<&X_2QB,0DI,;$[@5OVPD6D8CL3O2/V%7<'4VKIM7S,;#+>%
MV2.U*.)P-MQE(4U$70-/HR+5?/4G1*^69[<RMLM;(9BFO!XD])$8FI'.S45-
MB7 ?,2N%E..M(FPWTNAP_N3;W<@ UK4A8UK3)O64K;R6XSL/-3.4C;>?D68B
M.3<,TC-A!1\A;@-1'?*VZQV_JDG/>5BZ,S/8=A>WAY^&6/Z'&#9+:U][6RUK
M",4C7CYX&LD5( 55Q.42.5BQ,L=32\K6C!8OH1/YSK[LH=3$'9KZ%"(V ,GT
MC*J;!"E:6RV=SW7\A9%LO<R+*X=FO#!C?9"2]K)D[L]6*RCL4+Z?IQ<NSA[U
M1_5YOJ#8!RR0*ZAL#.HG*9)'9W(" M*2!8[(:W-#68?5R"EK,_D6<"0?O[_\
M'T[A*M:VR^[:5MVXLM>>8T-/^#);Q6=26M1-I08!4-N]3+)JZ_K?<5@9G9>4
MRJX^S92W;%#5?'K,[$3*RJ[F#T.Z:$1=HS><W,R3-)O39T=(I8Y9.Q$G_P W
MSR&6GJ,R,[&5BOE8BM8[:_!;5EJR&Q%F^#0)EL?2Q#KQ2B4Z0[.]P.P&TF?0
M>?:"3D?[A/)-I**^F+6I[]I>P9,^AD?.M <?EF]J,19EL/?L91!2D:D1*-ZA
M&GG>VQ);#_1MGF1Z[:B_W%=2?P)@I\I- @OLH:@E.R^GI%5KN 0B%3$>3).2
MO76.]>P9N6J%KS-U$=S%&,7#21N:#4;%+>DVK%G$9K<,AC*3AL\ 2]^9W([F
M9;[[KEMU';,SM<Q/(YX,[1OJ8,RV\Q1J<RJMNY\$EYT?7-D$QQDKVUJ"C*79
MS)/6Y^R-VSO0K7,3I >BY1*V,;WF3<U[';/H8&"L6:H-/5KRT;9[C,]A%M/*
MQ%;+6.C._!ND<E"S,. [+@ ^3E@4U9T2+OJ>L9A*8/,*ZZ@1_I_*B(Z=U'VA
MIRP$M)7&(F E0)I&Y7$F@5XM)XK/D;;B<A38"0$JULM1&6RQE?2*Y&1ZC_A:
MQE<7GV=\-:8=A>O_ %MHAAV>-Q9*CJGDE2S"6EH4>?$;;'RFFFM0OI031K"V
M*5?A3K9)%Y($H\Y.R2KCBY5V(G5>3$4@P1;#*_O[^002K&9VOF1EGD1WOMO?
M=GGTB0W]X>\QM: ]7HU [^$UQ*^NM+6309"5'*>4L$1-X);U-@J?G3UE%$K/
MA:\3EB3:/#Y#$23B32L0$?X59F@,J9[YUR]_?R 2BN9F5[G?7:QE?H/>*=!>
M#^)"!Q8[%Y8<OAMY4#<V3/NI;(O'"5%=#F72)O$MML3U5;1M(4V[JS=27K.^
MH1<@XB.@HEKLI)E@G3/=L,LSRS4:K_5Y",4$MX/]KT^_ZTBJLM6.6E6\7OCH
M=,K@!':M"1FQ&RO5;KS&>LAJR(I9Y6S7V@F%D()"QQ[W/-X?)I(QDYHE@%.U
MP2Y,&0BUK%N#2+/(R_2(L]AG>QE;,[[<LBU7(AWFW@>S=6-5PQ/]Q6I.3T-7
M'5.KJ',@J4FU=#P,9ZBR2Z24#S8>:][-QRP):4/@KND V1EX#950$FQX:)DT
M>=B=6^H760TRN9VUZ1GGG\:VJY6*QEN/*Y'<; 7ET5GM<],NIE3==63B?67U
M"OV&7;$,B0L6=BC$C22M!I,2KBN[ONR+C)(#6UMB4.Q<//=B8X<$.U QAA8C
MPI&T&Q8!*(S5?4HK>#499^$BN=CONSRU2ZG^"=,8D.Z\S^V[,81N1A-:KDUU
M4PFPFQ@9O)Z6["VQ?=7Z0TU6-XUS50<D(<62R8'=)75=V 0)P&Y)58\CF2+T
MF2@BM[])GX-H&HL[%L,B/;F5CO>YGEX#WWU"RGW@;#,5[0L6!=CW863]=Z$Z
MXU/#9(QKB1QT>:F'7:XIE;3"?2AM7EV0.=)#96I-RXE['8=9<1E($CA"6!++
M2*I:(ZR&GF9VUFH[7_M%8]9:^D;@I^'AL&ZC]?NM4+M$/&I!0-]USV+%SIW
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M9'KL"7F5N+92ZTIYHDFXTEQ)N-DHKI-;9&:D$HLTFHB(RU7'6YQ#D'TQT_\
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M$K,K#8)&\LV@P#IA[*94*5E1"0-=S(\SRMN/]*YYEOWY>+4.*,^"W;["+RR
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M/I-5Q&;5\#6RK+5MT,M)>L:#"6BN_20>V',!DKB\;(,=P9JULBOB%\F-VJC
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M%TG+1VT<I:K-G35RCMNBX;N$=]%4%TM]TE4M]5$]MM=L9R =C@ X . #@ X
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M26ZJ>BJ^=\(I[[ZZJ+93TRIOA+3.<;*9TTQG??&F,YUTQG;/DQC.> ')P <
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M1*L1WZ+6RO8]Y%_N8\XZ7ZQ^*U2X_K4*>$KCI:L::Z]T Q6BT*EL2F580P?
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MR8$AL,,Q^-G#SYXVW$M0'HW3JM8M*U[&=\]A&661V\6\4'(^M'BAQGM79[2
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MK0N-8R42?FL;6./0Q/1L5K7\=RRS([EGGJ^,?V:+">J7B2]7.O,QKOKM7'8
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MZ;80^26%_P!7:)^[(H_-?%ORJQ-^L%9_>,D6+RQ"OAP < ' !P < ' !P <
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MH9%A%FSZ>NI14\5GT#4@EO@1P*0GX>5K>-QV3Z'D;%8&R9/&6,?PU].7OJ\
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M:]661D1;;ZM9;#(\AIE8M]^+7"VDTBN"79]\_KQSVOCW7.:1/IU#IV3[66W
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M[:XJUOC.VN,_+FW?Q9SC&?RMSCEHX.?DLW].XO\ _P#75P5GA#^5#GT)A/\
M_P G1!>7GZ?G:_O8_CR\BD!Y^GYVO[V/X\ 'GZ?G:_O8_CP >?I^=K^]C^/
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MZ'I3Z5COWCQVM<#WS/!7G5.ZP';+PO?/,9^:U#JX>[3IU^AZ4^E8[]X\=K7
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M=K7 ]\SP5YU3NL!VR\+WSS&?FM0ZN'NTZ=?H>E/I6._>/':UP/?,\%>=4[K
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MKB(KKSK3S2T;QY$'&=+J%0C0XM-Q51HJZA48T!E,:!7Z4R9<LJ$>&V1,PZI
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MU(BAY/."229W.V17N9ZLBN9>&VP1VP>_\!@_8^0]7Q=.WW9=@P\-5I^7E*]
M5TO$8T+N%U)&D+7($9=:$/+.=G&T1D*KY$0#)JM$1VWDT657;)+!%LKW(LS+
M.^RVXCWD,M$>_=&S3W*>QV4]T]_79"\>K4']= #4?0V7U^][ORZ<'O1GUO4(
MNO[E9A[ *MO7WA#TH7UH6/\ 77'J0-$\^@B4?@.UOVB%JF>V_5B.VDYH\_V/
MHT+<K'#O+ZJBMJ0EA83'+&*,YVZU?1!T:2/,]TH209R_T;EBDIO&5]3J>NXS
M7=SJ"QVO8[;[9;OK$6;][^DSO:#:->W/6USFS33J.5ULA===JZ3DZR?,A;L5
M%%$Y#LF>>-RQ,:&52&[.,Z&2#$/G_P#$GC=JH"Q[C\@[4^[G=<()$&,PTM6
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MC99<1H3$OR<*BY+"#K+9V'040RHJ&)E8\LRRZ-97U9_6-J>! < ' !P < '
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MQDH[+:9;=+85R)HFHR8\:*34]N%.)+#"64G$)AIAM"TFW!N: ;T. #@ X .
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M])AH)L8"Q@1&448V+!CGC8:/CZ285HV1&::M< N>JYV/,ROK/>,8?ZA=3Y5
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MC$IE9=$4U:)DI))2[AP4/G7FJQ0R176?$73ERKNKL$"2< ' !P < ' !P <
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MCI]2:C2(]0B27J7!9?8=AU!++:WHIFZAUIUMN,I>D:'6[)L>NO/G ^B!P <
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M0\3L4DKIK(I&V"33;4>PS,CZ%&G+Q%?Q'T$+^ZJ^*@VN;/5^IYM6!='L5=T
MZMS(N/C.[$?#7$3O?J4:[(R.[8ZW*%B)8?5D4D$(G55;CR3T@=UF[$4&1=D]
M"*)%0(,K7S*V=K]!VMEMV[K#V"X&(I#LK^0*W?V$/_Y/?E(X2OD!B_Z J/\
MIUBZ\''R\PE].T__ #TCPY[,_E_MS]MS/_?YX9X3_P"D'%WTW,_:(>V^#3Y
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MXU6;N4E$5,8SG&-]-L8SG_'@<8L+@ X . #@ X . #@ X . #@ X . #@ X
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M2197O\7:5LTF9EXCR\I&/9[@8AP < ' !P < ' !P < ' !P < ' !P < '
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IZ% 6MR#1H)N*80\LM!<R9(=4J14:BXV1(<FRE*42"-MA##1FV?\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g899221g07b91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g07b91.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2JF4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M    ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 =
M!U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&
MEN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M 2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F
M)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
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M!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M      #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F
M<      #A"24T#[0      $ "6     0 " )8    !  (X0DE-!"8
MX             /X   #A"24T$#0      !    '@X0DE-!!D       0
M >.$))30/S       )           ! #A"24TG$       "@ !
M(X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M    $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _
M@      '   /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M   /____________________________\#Z   .$))300(       0     0
M   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M            (W   # @         !                          $
M           P(   (W                      $
M      $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M   %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M  0G1O;6QO;F<   (W     %)G:'1L;VYG   # @    9S;&EC97-6;$QS
M   4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M    =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<F
MEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7
M!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "-P
M    !29VAT;&]N9P   P(    #=7)L5$585     $       !N=6QL5$585
M    $       !-<V=E5$585     $       9A;'1486=415A4     0
M  #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M  "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'
M0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F87
M5L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M  3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;V
MYG       X0DE-!"@       P    "/_         X0DE-!!$       $! #
MA"24T$%       !     4X0DE-! P     (!4    !    H    '8   '@
M#=0   '_D &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G
M1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M           0  ]M8  0    #3+4A0("
M                                   !%C<')T   !4    #-D97-C
M !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%
ME:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (
MAV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M   "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8V
MMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M           !)S4D="($E%0S8Q.38V+3(N,0
M                                          6%E:(        /-1
M$    !%LQ865H@                     %A96B        !OH@  ./4
M.06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V
M,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R
M!H='1P.B\O=W=W+FEE8RYC:
M                        !D97-C         "Y)14,@-C$Y-C8M,BXQ($
M1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14
M,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                          9&5S8P         L4F5F97)E;F-E(%9I97
M=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F
M5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                           '9I97<      !.D_@ 47RX $,\4  /MS
M $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                       H\    "<VEG(     !#4E0@8W5R=@
M0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &
M@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0
M#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6
M !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"#
M(4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ N
ML"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[
M/Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2
ML%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C
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M]B90!D@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 6L![0,!$0 "$0$#$0'_Q  >  $   <! 0$
M         0($!08'" ,)"O_$ '(0  $# P," P0""P8-#0H*"P$" P0%!A$
M!R$2,0@3010B46$5<187&",R0E6!D932"218H;'P)2<S-#925V*7F,'1U#A#
M1$=35&1R=++7X?$F*#=%:'-W@I*3-59C9W5VA[.TQ!E&2'B#A(BUMKC'_\0
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M<::<^[LOP=;:%X^U+M_^,D*P?WQ\^X _-I[Z^_*(WCZG]8G^YH\3W\.V_?\
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M4D80HS5D'J>_=_?2)CY#UM%/=O[J'O#MU9>W]ZW[M+M12W;KM6T=RJG85(W
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M6M2WTTG8V)1JVY<=O.U:CQZQ4*+<]!J:S ;ET^+4(]52F,_'#+4EYIT\/O\
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MB0H,ZO26)$EYAF9+BTZ$T^(;49ESR$N*:+JEK4A&?Z0AI"&D(XL\2_\ J@/
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M6DJ#;:>@=3BR.E*?51 &J"#SY9&X!Y>;9]+K\QZ?O$8VZ,F0PR]]"!KSFVW
MVX^I+K?6D$MNH*,I<03TJ'?(/'PCBWB/G>QN']\G%_8?[_*/;[9DGG^A+7<_
M[(5Q\,CIR?S?GQH5)'S^7ET(V?ZK\QUM^_ZP^V7)_)+7K_LD\\^GNCDCG_LT
MXD\^N^';ESA?F/3]^?Z=8@-S9!&126\#(_KA7)&<X]W''K]?U9I(Q=^7/PM^
MOR,+\QZ?O#[9DGG-(:X_X0KN>W'2?Y?A\>)Q)YYQY9V^?0POS#>'W?[0&YL@
MC/T2WSG'[X4#QZ8*._\ +H5 9!LSLV_KU]1;FOS'H?U_MUB/VS)';Z);SC/]
M<+[<9_$QGGX]_CH5) ^X(^F>O@#"_,>A_7^_2'VS)&2/HEKCU]H7C_F=_CGM
MZZ<26',^\,_ZG'5?F/0_K#[9DGG^A+> 3C[^O. ,YX0<CZ@='#[M[R6L1NXL
M(7Z>+?9_#>(?;-D9']"6L'//M"NX[<]/K\#@^O.A(<L]MLGZ!_;POS#^'V?[
MP^V;(_)#?YI"C\^X3CM_*-'3ZX!-\MR'7:%^8]/WA]LR2>U(;&?C(5\,_P!K
M]7\G?L*DCTP_[#^U\7A?F/3]_'WE]LV1R?HIKW3@CVA6?K'N@8T<..KD18#<
MV3@DTAKOC^N58^&>4X[Y[$X]?CHXQORWYX8M;W:\OT]'^X]^-H_;,D_DAO\
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M/([_ !].QYUEM@.]B6;H0V;,!OZ0A@GN?=QD]\]\\$G@C.,?FTL,9N!;!;<
M='P>>(0)Y)R>V"/>[<D\9SQVSD<X' /(#D_,%QT#6VZ<L7L$.A6!R?4]SD$
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M'.?3N3DYYX !^6HPL& L]A<,=FP#T)+GH8L0QQRL<8/(XX/;! [?Y<Y'.J2
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M =72<*XS@<=@ ,8 ]<=\G&/3G.EG +FP+N^3N]B,,P?$(AZ8ZL\  ]).">Y
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MSY0'2G\$D CL#Z_7^-CD^@P.-&?(%G:[6.3NUO'RBQ!2L9!.<'!QD@@Y)'!
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MVAB' BL-I2@8R0AM)</()4KK*L9*B3S\]F5-1.7WDZHG3%J425+6HD_.P!V
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MUMJ:M>$&N5RNVI46G]K:!1K1;DT9B +3N.FQH[5<CW ^JU*K';-2#:FJ>^Y
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M!W3H_46R'Y-AC8>(ON \(Z/M3^QVD^G[T3\NZU^G^367OWB$:PW'*?IV-U8
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MZ5F3,8*F@LVX9V+)M_9Q?/.ULB6#DV%WZ?I]O6*ZJ;\;50'7("KIBU&6)<N
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M:QOR(.2R1O<9RWKYPB'/&  $\9ZCD\Y'<Y"<Y)!&3SS@ZI:[N7NS [ 68=0
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M4A*7'$@#  6M(X41K.=^!'XT3YB)L[M'V7F3)?#P*7K.LDH*0I*>%Z"Q2%J
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M3_#G*C* EE6>$,[05^)78]:4H7I.H*0E(2E)HZ7A2$K,P( _,MP!9XVN.*[
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M! 9K;@\K.#D' L>GJCB'=SPJO5"KO7EM3.11:TM\S7J)YQ@QO:PHJ7)H\IE
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M. >>?\WIP>,:\D$A@V7?IOD!G/O,>VX.#$><^I!2?QN,\9Q_GQP>PQJ%9:Y
M(8?RWX<@'?9\DV9XN 19[; \]]L^K<HCQ\1S@_F [YYXS\<'O@]M4%1P$N'N
M0#<G#\VR?*T/-FN]^G)^E[?2&<<'@<\^IP>^,8^?KGN?74XE%B+XP VY(S^C
M>8A_?'K;E8PQ@>G8CGT'/KP2.WPP/XW&2Q!.6MDOZM9P+EX&]SGS?QY=/M$O
MQ&?3L>"/X^V ,C\^!C!RXB;%R+W=Q]O#'K>&7Z[D]?(&(X_ML9!(SQC!P?T\
M\<?6.=3B(P 7>S EQY7 8 M VRV2#XC^]FM;$!DX[C&!@#^(X],?(#G3B+AB
M"^X8 /:PY\P]V-H,Y'5AX;>Q;TB;GY8''S[9^K/;Y=_D!CQG+D$M>S9]=O&P
M\3/?OY1(02?3YX&?7X9)]1GZQWUD%\[=2 ?F1TM?8XB[\ACFW@_7S\8F .?7
M'/KCCTP/EQ\"#GOJ<>+)=V_D!Y7?)NY&20V(9]<#[>^7E*D@9QSW//<\#@?6
M0?3. ,^FLB5%KWQ8 #J2&Y-NY,&P!<GK[;?-^@WB/4 Y['X<YR.>PX &,>G&
M.<8E2@Q):Y W8,S@=#=]K9M#Z_;V_P F@,$CDG 'KD _,^N>W&?7@8U2I8#N
M,DCX6-Q=SELFYVS>!ON^^,$Y'UQRAR !W)."#SC(^1].XY^OTU273Q. /0M=
MCB[GIZ@W' ]<= 'YW:_KO$O4H$8'X1&>#CD>@&,>G88!Y&H!OO<;$^IW]&P<
M1(E.>P (/.>2E([$D<\_7SCD#'.H!@?RC&;F]G+>-@=X/SOXQTA:O]CU)[?U
MHCL<C\)7KZZSA&L-QQFMQO> _H>UW]/OS^?3'/IGU^1U#T^W3WX/NT09/C]A
M& %)'97NYQC!/Q!R,=^ !CU]>VL003B[>#[L,V]L;P^>VT0 R?=6>P"@1W([
MA7;CTP#QGMI?^IKFQLP&UR]PV6 ,6 2H@X44]\?$<C.!\!\^<\'XZBBS.7&1
M8-NSGU%O'-H0Z5^B^ 0,$$'G S\/4\CCOP=4%+8^;N #YE@,'%K0AA8!]\9'
MXV"5)P?EV]1V&K9PS@9V O:^+XY](0PO^WR3@GO[WU_#.0!V_/Q@3S%O*V>M
M\/;:$"A60>O"N ,9(YR,=OD?Y3Z:@4-@=R<9L^_7].B 0K)!5Z#.._;OCL0?
M4'M^<$N,IN'!=NEC@W/KOY,$/>Y3U9]<Y/ /88P<YSQW^&C[D'D7 ))WNX9F
M)NPW:$1"%<96<D?43@X^'H/CZ^F =.(!V%@6LS7>]NO4>MH1*4K)&%GN0<C.
M>#@GX<$?G].2-7C'R&&YLW6XN6ZYO"'2L'!5Z8'PS_GR.QP,CZM'!#MZ[!L^
M#'9\PB)2H=UG\X)XP,CC'\F/T' *L>%@.7,O9PWW?;!N@4J'(5T@\X[GT'<#
M]&<]S^:.#<@%[ #;/-KF_BPA )41RK/(YSC(QP,\G"B><=OAZ:<03AWO8;=2
MS8#[X]81,01@9/)(X) [\'Y=^1^CXZ)664+L-GQS&0^[?/E")<+/9><GN#]9
MP!Z''QXQ\]9<0<N_,N.N?!_KXPB1:O+2?,=0WC)*G'$H"@<\>\0!Z_7R?JG%
MX\@&8CGO?+VP(19Y=PT:%U>=4V"0/>0TKS5 ^@ 0#DCCN3C5+D.QL1Y\[XP3
MO^D1Q\G\HL$C<"CME08;ER".!TMAH''KUK*N.PP /3@>E"=RJW@X?-FZ$[[W
M>#\KV=L?7](QBKWV]/A3(D6%[,9,=YA,A3ZE/,EULI#J.E)3UHQUHXP% <=]
M9!(L'MBS >5WR"!;KRC$J9[$6SOY;6M=XP"Q=PZW*M2G1VZE(F.4P/T>3/J$
M%,>?)D4]]<9QQYM>2%*Z I*@3U)][().#!B GXG?P<MS+F[8#8VB@FSD8N/(
MW<68VZ7;QOC]UUIPE3]8?;!XZ?.0R@9^L#&2>.GM\=8@ !@!]_UM\G;=H&YR
M6M<$9?P+C 8_J8L$FY&1DRJT@G.<+G GM_>+.>>>V?T8T)YL/(<N?OG$%B;D
MW9B=LDA\\K>.XBS.W706\ERLL*.<C[ZXX> <>F,XSDYXQC5))(-G&[?6#$W9
MQ=ACIXVN387P]HMZ[XMM!P9JW,'_ %MA:\\$D]^<YSW[@''&-"I1L;^D.'D!
M<\S@WO9]F\SXQ2JW"MQ!4 Y-4 ?2*?0]Q[_)[<8]<<G1[\\F_B'+>[0;? 4&
M9]R/+F;#IU;Q.XM!'^MSB>>#'('Y_>Y4>!@=SWT<YM;DP^P]^)$ PLY%\7&1
M8<[./#?I(=QJ(!Q'FDGN T!\. 2>!W/Q^>JY#!R7%P][O;!8XZW.(C?S$*QR
M>X9W+W+O8GEAK1XN[B41UIUKV>H +;4CJ0D)5[Z2,H(/NG!/2OD)(SW!T/$
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MSGR#0@,D@\8)],C &1^;]."?EG2P!!'J1N0^[\KD.!?,(>]\1W4%9!Q\O3'
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M')[,>>X.XBXV]\XF][(R3CDXR,$$=SQR/3/;C'IS#8-CK<X=FV"CRMG=[(@
M>0%9.3W(SV.,$_GX!XSZ$DZO(LW2X#N.5W>UQ=GV#HCA0P<GZLD@\^I[#(P
M!W)U+&Q %G_RD6NW/<A^7@81 #D$J/;L!CI!R1U'OG^4X.!JB[@)L^7RQ&.G
M3%FA$3P2 1GGI.2"21P5@\9R0/0X ^!T-V.</8;&[$%QOS!VO"(84 ?PAV/?
M/?O@@9^'!)X[=M+."6W LQL;"]G\ &+#!#H8)&05=QR3QGG.3CL!V/'/Y]7?
M"=WVN68>9/6$ #GUXXP<'N.,\9(!&1CT&?KFVP+O9[MG&Y=NK@.3<(>]Z? X
MY&!@=TXX)],?/UY!6:_-G+C=[N.1>^YLQ8PB&%8'?ZOAD=OKSQCL,]\=SC(
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MH3Z7%VS=]1@K))1'JL-J<UCDA)?:<86!G SY!(&2.>-1ARZ\K[FW/JX:#$
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M=[<F+#KUV-H1'N.YS@<Y'!!& ,'G//8GD=B3C4+N"Y8FX9FMD^#6<,.@AX1
MDG@\=^,C&<G'./T@X& #ZZHL?%LYMG<#)R-R8>_=OL/*'5WSCOD$]^D8*N<D
M@CL,G/PSC1AB^UA@'8A@&N'Y9=GB%]FWR_V^<%'U_""<<9Q@9&>",G Q@]]
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MSL3AK/DVN6^8Y&$0(5GALA0]3CY>N<\?I X/;0$ &[@[,WBP//T=VO:$#C&
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M^H .>2?PO4]AC1]@X?=@ ]SG>PR/6\(B<'\+I5V_&SC.>>P!]> .V/GH+$@
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MXYXN>^XU/==0'%5.JNDE?O\ 4AM:ADEUT=0)YQY:/>/(R#@:R%U  6-NB=G
M=S@.<;WC$ N;O@D$'XL/T!PPY,"UXN]A[&;E[QNLU6HK<MZVE+!%1J+*VO-8
MX6!2Z:2A;O5U82\Z$M\=1*@<:ASDG8E\[/Z# LYY8R&XVZ&[V)<YL>H/0VCZ
M"[<;'6!MFRA='I:)E7Z 'ZY4P)50<5C"O*4YU)BMGC#; 2!@<DZ1?=K9Z1N#
M2+#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA&L]W]M:5NSM]<5DU5#8^E(+AIT
MM2.M=.JS \ZG3VL%*NIB4AM2TI4GS6BXRL]#B@:"1C>WW^H!B,"W3$<V^#+P
M]S]HZ%7[ANZ"W'O.NU&53DMXZE0*%37RPPA"N1FHR6G9Y6@^_%<B(7[S9 D
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MQ8V3VZ5T(4YT)M>F=2BA(4$I^\_A'H2$_ A/P&.U_'=9_P"\ZS_]9?ZQT/\
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M%M@W0GZ90X<6GQ8\&%':BPXC+<>-&80&V6&&DA#;3:$@)2A"0$I ' &L<Q0
M,14Z18:0AI"&D(:0AI"&D(:0AI"&D(:0AI"-'^)6=*IVPF[,N&5)D(L>NH2M
M!*5MI>A.,N.)(Y!;;6I8([8SKU-$2E>K:>E3%)JI1((<%CQ $<B0 >D>7K:S
M+TG4%)+$4LT L[<22E^ECG;(<VCXB;?;L7+3+<I5M6[:!K4ZU/IRL-U&/AUV
M+#J!'M4I]"(+CS"8;CK8;?$UMD%:$EA3RT+U]/J].DKG+G3ZD2D5'<RRDV"E
MH!X0D\0"G <C@)L64P('RVCK:B7*ER9-.F89'>S0L,2E*P I1^$E(2X+A7#=
M^'B9MPQ+^O\ =AU!A.S5P?2<*G0F*+3C2I%0IL2;*JSLZ35BN2RW)@.N09<V
MEM1FFYC2F9J4)]E]A92>@JDI M'_ $E)[M2U*FKXTH6I"4)0)82A1"R%I0M2
MB4'X23Q<1CT4U59PK TZ9WB$(3+EF45RPI<TK5,)5>4>$KE! "DLH#X>$"(4
M?<K=*2V*G4=I#4$4BFR)D!R>9L1;K3T:-2W/8$"+TU!:TCS'H2FWPXAQ;A1A
M 6"Z*@3_ (:-1*#,6$KX4I8%*E+^-E<2$C^E09B&<FPB*RO4!,70\7=(4M!7
MQI?B2)9X0$GB+!^ @N[D,Q&)7%N[?$&DS3<FVDZF19C)HSE8?DSH$F#)13)=
M.;C4>:N)BGI;9F)4_ 072XTWTDMMN%0YY&GTRUH[JN0LH/>"6$I(4DK2OBF)
MX_C!4FR]B0_$8Z\W4*M,M7?4:D!:3+[Q2EI*5A"I83+41\(X5 J0'X@"+ L/
MK'X0*A*J7ATVTD2U*6ZBDRHR5J))4S&J<UEGD\X2VA*!\D :^?\ :)"4:S6A
M."M*C=[JEH*K^+^<?0NS:U+T6B*BY"%)<Y9,Q0%]V#!^C;1GV\>ZM(V?M!V[
M:]1:Y6*.F0W!FFAL19"X(EA33,B8F3,AE$5Q\MQBXTI:DNO-@I /4/% ?W[\
M8]LEOE\R!'.?A*W]M"]H3.V]KV36J%(I+==K<YQC]\6Y3V)U;DRF 9TZJ2JD
MJ5/,P.EE3:T)?]H0R0PR""KER7??FS@_3Q^< =LGP8M]#XC-V<QW'J18:0AI
M"&D(:0AI"+57F_-HE8:$5^:7*7/1['%?]EDRNN*ZGV>/)ZD^SO/9\MI[J'E+
M4E>?=TB'!]_W\-X]J4CRZ73F_(=C=$&(CV9YWSWF.EAL>2\_E7G.M8Z''>H^
M8M)5DYSI 8PWOW^@BOTBPTA#2$-(0TA#2$-(0TA&M]VMMX&[5@UNP:I.D4V!
M75TOVF;$0VY*::I]7@51:8X=!;2Z^F$8Z7%I6EKS?,+;@3T*0^T:GVXL.B[
MW=&L6T;.GFS+O@S*S-O>14$S7*=7X*HL-JBU+S8[2HT*3%+;T)Q4IT+E+>:;
M9SG%))+G]AX![>0Y>4+"[#EY/]!GRCJ#4BPTA#2$-(115*G0JO3YU*J,=N5
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MR:^0+VC"R3XBYYGY\^@\=OHA:O\ 8[2?^2)'Z%*!_CU(R!?Y_*+4[_9[%_\
MH![_ /$'C5&_A]Q&)S_[XY_Y>G]N=HS74C.&D(:0AI"&D(:0AI"&D(:0AI"&
MD(:0AI"&D(:0AI"&D(:0AI"&D(^'O[I5)FUO=6):[CZVX3&WT41"KWFV'JQ+
MJ:)+J4<95^]62KDY"0..<_4>Q01*TY4]G4JL5Q@6/#*2@I /-U?>[6^6=N..
M?7?E2KA0JAX4DW"3.,P*5Y<(M9VN<-\CT[*J9"%N7%'0EOV1'6J+T ^3]&(
M'4X,J<-/(2G/!=2!DIP?H0U-W'<J)/%;B=@KO#:VW>%G%F)+9CY0.S7 E/%6
M) 3W5S+9S+,A@74P*C)P"X*@0XO$C>S;2$.)%T0E!Q/2,,MDI!:IS?\ NN#G
MV1M0S@D/)P3E/4.I$D R%)-R7)#L5DLP&ZC8# Z&*.SZ>%0_/2F4&LE-W1*
M_JRR 6#?SCI&R;(MR-9\"9#-6BSC+E,2.M*FVN@-1&(J4]/6<E?2% _!:0#R
M">G53U5*DJX%)X'3S)^(J(!+.+[OB[Q[&F42-/E+E&HESN):5<7P@)"4)0 W
M$7XB 3>SCH8[J\$=:E4SQ#V<F$X/*K$>ITN7Y:@I#T60PE9STY!2%,I4DG.#
MV(()UJG::4%Z-4\8+RU2YB7!LI)(L_\ XB"T;IV7F*EZQ3%!!$T+0HBX*% .
M00&(!;S%F<B/T!:^1Q]=AI"&D(:0BU5UKSZ)5V?9GIGFTR<W[)'?]F?E=<5U
M/L[,G(\AU[/EMO9'E+4%Y]W2(;!^5_3WYQ[4M'E4RG-^2Y&\N#%1[.Z[Y[K'
M2PVGR7'LGSG&\="W<GK4"K)SI%BOTA#2$-(0TA#2$-(0TA#2$-(0TA#2$81N
M)9JK]M2HVVU7*G;4J7Y+L*N4AQ2)M.EQW4NLO(2EQH/M]2<.QEN);>02E9*>
M#06Y><0@'(>+9MC?<:]J34F?9:O#JUJ55^UZXS6X8A37JA3D(0:B&VRIA4>J
M-],]@L.+0E#P02"G&I $'!=O'[QLK2+#2$-(1@>Y-LLW1:=0C"C4VN56F 5R
MW(=5\Y,07'2DJE4AU2XZVWD%$I* DI6$DJ <!1G2'O\ 6*RPJY5+BM.C5*O1
M(E-N%<1MJX:7#F,3FJ966DA,Z%Y\=:V^IIS"N@JZVTK2E?(.D(S#2$-(0TA#
M2$-(0TA#2$-(0TA#2$<@;WVA]$[EV/?T!C[Q7'S;EP=".#(;94JD2G%8*0HC
MKCIR/>*023QI[Z#F?H]]HQ(?(?D.O7IC8L][1U!:O]CU)^41(/UA2L_+.>^.
M,]LZ1E%I=P;]C#U30'L_GD<8^'?O^;Z[]Q]_?/\ 3'?DZAOT^=QCSN(S74C*
M&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(^47[H]MI-
M<>M3=2!'4[$9C_8Q7G4)*C'RZY)I3[O2,I9*UR(Y63@.NMIX"LZ^@=C*U/#4
M4"U,KB_,206#GAX9@#N.)@%8%AFT:!VSHE<5/7H!( ,B:1_3?BEJ(9@.)TN7
M )',-\3MTY-1?I\2C4VW[BJ;PJ=&JBY=+ILB3##,.HH=?CJD- XD%II7WH#!
M"T9/O#7TR@".-<Q<V2@=W-0$S)@2KB6@AQ@D.7=P W(./D&OS9ZY4NFD4=9.
M4)]-/5,D2%KE\,N<%J25)_JX4'X2&(:V .?6*#>+32&S:5VE23'R129YZO*C
MVLTYDE.3E5%FXSWZV^05JZ?6,RF=1-33NZB$]XG"C/M__M1:]@3>QC4D4NHI
M2.*@U%PE#_X$VS(H IPU[T\T\_C!-S'FS0+R0&PJTKN)0(62*3/(_>Z**ES'
MNY()I\G'8^^G(]XXIFTQ<"IIQ_.[3 [J5-9O#C3?H(J:74$A(-!J.)882)I#
MI%,E7/'=+S<\0Z@?;W]RVVTJU;KD2_*K2I].IUC4&120*E&<CON7#,6UTM]#
MR>LAJ$OSTKP"00,C &OF';JNE2I*J26M$Q=5."_@4"!)0"Y 2?ZE6+[NX+O'
MVS\.J&=,3(J9LF;*312#*4)R"@]^I6 % '^0OS#WV,?=?7RN/KT-(0TA#2$6
MJNM*>HE893&<F*=ID]M,1E_V5V45Q74B.U)*DB.X\3Y:'BI/EJ4%Y&,Z?.(?
M[XQOG;G'M2VRU3*<TIA<93<&*@QW'?/<8*&&TEE;^5><MLCH4[U'K(*LG.=(
M# BOTBPTA#2$-(0TA#2$-(0TA#2$-(0TA#2$:)W/6NP*S$WG=K=Q)MVVJ1,I
MMU6C28AJ,.K0Z@\REFLJBAYE,:31G@B5)GA#[OL+3C73T\&OD<_M$:[^_?3G
M>-U4^?%JD&'4H+H?A3XK$R(\D* =CR6TO,N * 4 MM:584 1G!&=2+%9I"&D
M(:0C0UI0F;!W6N6SZ3;%68MZ]XLK<%5Q>TJDT9FY')3$"H4=F*W&;8I(?: F
M(2MYQR6[U$ ]PY]-N?A^_*T3I]-AM9^GUQ&^=(L-(0TA#2$-(0TA#2$-(0TA
M#2$8??=.B5&VIR9;7F"&IBH1NV6Y<5U*F'1D'E!4>W."<$:>_"$7"U#FW:23
MC^M$]O\ CK_F=(@Z]<=#YQ9G_P"S^)QVH+OKZF1QGOZ#Y?Y3?T];M[S?KB;_
M /O>GPO[Z6C.=2,H:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI
M"&D(:0C'[IM:A7I0*G;%RTYBJT6KQ7(DZ%(22AQMP8"DJ!"VW6U86TZA25MK
M2%)((US4\^;2SI<^0LRYLM04A8R"/J#@@Y$<-1(E54F9(GH$R5,24K2=P?F"
M,@BX+$7$?%?>[P,;D6%.F5+;^+)ORT5N+>8;AAL7!38_?V>; ZDJG%H$I;D4
M\.+=">MR.QR#]+TOM115@0BL4FDJ6916_<S%?YDK 9 )8\*B&."1CYEJG9:O
MI)BUTB#5TQ45 );O4C 2M&599T.[ D %HY >L&^&9)A.V;=#4Q*RCV==!J27
MNO..GH,=)R>4XP<^I^.Q"JI+*%33E/""_?(9B]\D/:X)\ Y#:Z:.HX@DT\\+
M!_E,I8+JV9@0UG VYQTML_X+=W=R9T5ZNTB58=K%UM<NK5UCR)[S'!=13:0L
MB4Z^I(Z4.2T1HPZ@OS'.GH/BZCVETZA01)FIJYX_EERCQ(=RW>3!\( &0"H[
M,,GVM.[,ZC6K'>RE4DAW5-G#A41_R2G<EBP) 3DA3@Q]>Z?3[5\.%CVO;]!M
MZ0+.B31'N&O"5"CM41EUKJE71<#DIUIR2),E+;3HBI6X''480EM(U\QK:V?J
M%3,J:A?%,7C/"A(_EEI%V2D6'S,?4**BD:?3(IJ=)"$"Y-U+4?YEK-G4HW/H
M+1NQB;$DM17F)++K4YE+\1:'$D265MAU+C/.7$EM07E(.$\GC.NI';^\56D(
M:0AI"+37VO/H=98]C74/.I<]KV!N1[(Y-ZXKJ?96Y>1[,N1GRDOY'E*6',^[
MI#W[>/>E-^53*<U[.N)Y<&(CV5Q[VAR-T,-I\A;^3YRV<>6IW)\Q22O)SI#W
M[Q%?I"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0CS=:;?;6R\A#K3B2AQMQ(6A:5
M#!2I*@4J!'<$$:0C15FUARPKUD;7W7=M1N&H75*K]V61(J--<93&HPD1E/VS
M]*^>XU.F4Y;\A^,REACR::A(4HX0@5BS[.WOWO$%K<K#P;^_IXQOG4BPTA#2
M$:?WHH8G6U#N9%3N*FR-O:LQ>K2+:2A^?4VZ2VZJ52C!D28L28B;'6ML(E+4
MAI0#J$EQ*=4%GMD-[]OR(B'!L_3G]8V#:UQ4Z[K<HES4E:UTZN4V)4HA=3T.
MI:E-)<\MY/(2\THEIU()2'$*"21@F>_6*+Q?](0TA#2$-(0TA#2$-(0TA#2$
M6"Z<?8]5\YQ[&YV.#W3SG![=^VD(EM3^QVD^O[T3_P ]?\_\@TB ,(LLA6-P
M((Y&:&\#VP3Y^1\_ASV_EU;^H^3_ "O$.>O$"-L /G-GP_UC.]2,H:0AI"&D
M(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI")'%^6VXYCJZ$+7
MTY"<]*2K&3P,XQD\#N>-(1AMBW&Q>UMPKE51VZ6N8].;]C7)I]1<:,.:_#ZC
M,I[DB*LN>1YF&W5*;"O+<"5I4!D2H6"E-YCKB,0$F[!^;;[W(^<9KK&,HLER
M%T4&K%BC"X7Q">+-$+D=H5-T)RW%+LHB.WYBP/OCI"48ZNX&J/%L^_/$0^#Q
M\>MNKHW?M'Q(;=,;DP[LH-)%PU*B4>DUV54)U*IL2Z''&76(52?=?BS @O!/
MFHD.%"<(0A"<H![&WCZAK-:Y#MR<MO >8;8.S^#F[GH!C)>/M!J1E&L;UWDV
MUV^1*^RB[*7!E0X[TI^FM.JFU-N/'95(>?<@0TOR68[+*%.O27VVH[+:5./.
MH;2I0Z,[4:.1,3(5-[RI60F72R$KJ*J8I1 2E$B2E<Q142 /AN3F.C5:E0T0
M6:FIERRA)4I+\2PE*2I2BD.0E*05*46"4@DD",LM6XD7518M;:I=5I#$PN*C
MQ:RPQ&FKCA9#,HLL2)(;9E-]+S <6AWREI+C3:\I'/3SC42DS3)G2.(G_#J$
M!$T,2'4@*44OEE,H8(!<1V*><*B4B<$3):5N4IF !12_PJ8%09092;NQN ;1
M6UYGVFB5B/[(NH>?3)S7L#;XC.3?,BNH]E1)) 87(SY27B0&RL+R,:YXYB^W
MSCVI;?DTRG-&.J(6H,1OV1;OGKC=##:?9U/ D.J9QY:G 3UE)5DYTB# WM%?
MI%AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0C =R+7K-T6O/AVO6U6O=3;:7:'
M<3+*''Z?);<;>4T5%"GA#FAL1YK;*D+=CK4D*!P=![]^^C1"/%^C/X7&'VWB
M7;J_*/?5(EN4ZH(FU&WJE*MRXT"(_3W(U=I:S'FI,&2MR1'9D+1[3$#KBU+B
MNM+*R2=&@"#N'&1R\1GU9XV!I%AI"(*2E0*5 *2H$*2H @@\$$'@@C@@\'2$
M:*L.M&SKGO.P;NOINM5!MZ7>U!;J++L5^CV7,6RT(C\]X-P'V*=-\UIEN+TB
M)%Z ^"I15JL6! L;>=]G? Y6+](Q< D8Y[=/#DT;OBRHTV,Q,AOM2HLIEN1&
MDL.)=8?8=2%M/-.H)0XVXA06A:24J2002#J1E'OI"&D(:0AI"&D(:0AI"&D(
ML%TC-O58?\$7_P Y/U_R:0B%JG-NT@_\$1_SE?SSZZ@P,>7O]?$PBR2<_; @
M8[?0;V>V?ZX(YY]>WYN/AJQCEWNQ#=+)]_6,[TC*&D(:0AI"&D(:0AI"&D(:
M0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0C3.^VYE6VEL*=>E.M)R[HM/=;;J
M\5FH)@.0($DECZ2)5$EA]EA]QD2$=" AE:WEK#;:]/>'^X;YQB20W6WGL//'
MB1Y\U^#7?6M;B,2+(9LEB!2+99J51J5S1Y$6-$$FJU21,@TUBE0J?&CI>4A]
MP.N)=)4(YD. *D)&LE  VZ6RUO?,==A07N]N7T/R/WN([ZUC%AI"-#>(7<*3
MME92+G1:U*N"&W4X,.9.J[W[SM]<Q]#,&IR8J&%/R(J)BFD/K9E0U1DK#Q<4
M$E.B*74ZV=*I-+DT\VHFA9XZJ<94J4E">(J*4I*YRB/Y9252RHVXQ'CZWJ:M
M)H_S?="8A,Q"%K4HA,HS#PI6M(#J1Q$!1"AP@O=H^75X>*7=B_7$0Y=7JM,B
M/J]ID4:WF'(*S2&A&G34L1:>@U.5*73:1N5!;@S9<_-8LM*0'&9Z61LM+V!5
M,''K>KSJQ[?E:'_HZAXU<24I7-2M53,E\<VB4HKGE)E5!<.F/F%;VOU2L(EH
M*Y*%'B4B4DA?<I"5K*$2QQF894G4D!"U3/\ %HP+B9PIA8OALWSW%7"DS;<%
M+H;LV.FH)N)9IL%URER*=3[EBHB +G/0ZO.HNZ-"0X66T.6IN90I,=;[5,;:
M3[4L]ENSTI4G3:>FD3.%2@:24E<X]Z%KDK7.(<S):9M'-)*U*%313@IE3'CB
MI.S_ &@U8IF392D22M 6*E7=2U&4J7*J$"6W&9<U4K4Y +!Z74I*TVE@1]>M
MI;2KUA[;V=9ERUUJYJO;%$AT6176H[L4U)JGMB/%?>:>>D.>TF,AI,APND.O
M)6X D*"1INHU,JKK:FJDRC(ESYJIHE%05P%9=0! 2.%W(#6!:[1]:TBDJ*#3
M:.BJJA-5.I9")*IZ4J1W@ECA2HA2EGBX0.(E1=3D,"T9?7F@_1*PP8:Z@'J9
M/:,%N08BY@<BNH]E1*!!C*?SY27P1Y14',CISKI1Z4>]*;\JF4YH1U1/+@Q&
M_95O>T+C=##:?(4_D^<IG'EJ=R?,*2O/.D(K](0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA&B;[>F;;W+#W)5<%/H>VC,64SN#1S1U/.RJE/D08=(N!B1
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MBNI]F3()2&%/Y\M+Q4D-E062,9T@?>\>U+0&Z93FPPJ*&X,1 C*=#ZHX2PV
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MT@*SS^%\/F/4>N3D=M,.^&R6QY%R+A@UK!H1 8.4E(&,CA*AQSG)R> ?S\8
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MM^1!<<3Z6M?AAH%<DU6ERU:%J<E)5(U+2"BBG(F)#@S)<M"9,^5\"YBI<R6
M97 "L%8?7Z/M(LS!+K9+!2B$F6"2D%92E"D\2G*%3:>F=!*E5!G,."65#=E.
MJ<*IQFIL"2S-AO)2IF5'<#B%)6D*03@J)RE04.K"BE:%8(5QJ])VEU3LU5RM
M$[>2D2>\696G=I)*%)TVO +(EU;N:2M9@L*"9:R'!#@'9Y4Z34RTSJ>:B:A:
M4D%*@6!!+V9P01< %B#%SX'KW&!@^ASC!'(/.00001D8P=?14J"PE22%I(XD
MD$*"@P(90<$$-C)-^<9@9M?=W+B^X?D,8ZF/T'^&S<V!/\.%E7A=]8BTYFD4
M5=.J]6J<E+#/715JBN/NO/KRHE#:1C)4HCA.>-?&>TZ:?2]2KE3ERZ>G2LSB
MJ8H)0E,P<62W/%R^.4?7=$KDKT6FJ*F8E E2S+F3%J8?X1*7)5>X'[1CCU\[
MF^(60Y3=IS*L':HK7&J>Z-3AN,UZX6@>AYJQ(+Q!9;.'&OI>='\M*AU,I.4$
M_/%5VI]H%*E:454&EOPS=3FH4)\\.0I-"A1# L1WJTL-HXS55NKJ,N@*J2@<
MIF5RTD3IHP12I+-9_P#$4&W&Q.T[/\.6T=H1U]-J0KFJLC*JA<=YMLW17ZBZ
MK\-R5/J;3O).<(8:9;2"0$ $Z]2D[/:32)/^ZHJ9JO\ B5%8!4U$TEB2N9,!
MY"R0D6Q'?I]'T^G3_P !,^8;KG5($^:L[E2E@^@ &;7,8Q=WAIMPS%77M+->
MVFOV+]_B3[:_>MN560CE$:Y;<:3[#4(+H'E.>2VP^VA16VLK2!KK5?9RFX_S
M6DK.E5Z Z)E-\%/-4,(JJ<#@F2S<'A"5!WN0T<%1HTGB[^@4=/JDW2N3:5,(
M?X9TD?"M)>]@?&);!WUGQ*\SMIO?38UB[C$=-*FA2D6E?$9.4)J-MU%U:VT.
MNJ0X'*7*=1+:6VX$I4A.=2@UR8B>--UN6BAU'$I8)_*5J0P$RFF.4@J+@RE*
M"P00VP4FIK3-%'JB$TM9_P";5BGJDAAQR5DE())O+)<$$#!CH6NM^T4.KM)C
M>W^=2YR$PTOB/[9YD5U(CID]20QY^?+#_4D-]07U#&=;+GK'LG'Z>S]_ QB=
MRW]:&V-GQJ[>=4B6Y3HD"(V&'Y'M$E3PCH2B!";05OU"3U)+3:6$N+>4GJ!.
M<ZZ==7TFFR%5%9.1)E)PY^)1V3+0/B6HM9*03'7JJRGHI1G5,U,M W-U*/)"
M1\2E'DD&.>6:=NMXD7!,K+]9VCV8>4%PJ+!=73MQ+SBXPE^I34%U- I$G"E)
MBMMIG.LJ:45("E8UQ,O5.T1XYRIVDZ,H@HD(/=ZC6I!LJ:L%7Y>2L#^0?&I)
M=[V\9**[63QS%3=/TTL42T'@K*D<UKOW4HM9('$H&[;;KH>PFSEO4L4B!MS:
M;L8HZ'GJC1H54GRU$86[+GSV9$M]YPY6MQ3N2LE0 .O9D:%H]/*[J7IU(4D?
M$9DB7-6HLQ4J9,2I94<DOF\>E*TK3I,ONT4=.4G)7+1,43N2M8*B2;DDN3&J
MJ_X?ZS84Q^\/#K6E6C6$%4B;M[4Y#\G;NY$!(+D5--SYE#G/X4IJ;"?0RE\H
M\UI+(5CS)V@S:!9J^ST[\I-#JF:?-4I6GU(L2CNG!D+5?AF(4 %,X"00>C-T
MF92J-1H\S\O,=UTBU*51S@,I$M_\-1N0I) XF< $F,ZVOWWH=\39%H7'"?L7
M<VD)Z*W9-=*6)16WT)<G460H^15J4\M:51I,5QQ10M(<2E>0.YIFN2*Y:J2H
M0JAU.2PGT-0R5NP/>25$\,Z4IQPJ026R 8[5#J<NI4:><DTM;+83::;93L'5
M+.)B"38IO<.(WQKW8]2&D(:0AI"&D(:0AI"!( ))P!R2>P'Q.D(YUW"W:DF8
M[:EBD2JDKK8GU9L=;4$XPM$5?4$*>;'45O\ O-M%) "U@@#9B<>CW;/R)VB$
M\F.W06W_ $C05QU"D[7T!Z\+D3(K$QVH4JGN/%]@ON5&NU*-2X+3+DYQMH+>
MG3([0<<=!/7A/2.-=>JF5J94Q6G:95:O4RTE::"CF4R)ZY:!Q35IF5<V3*"9
M,L+F+"I@LDA(<WG'0R2E6H5U/IM,J9+E&JJ4SE2DS)TQ,N3+*9$N8LJFS2B6
MGX6XE!R$@MJA'B^V^4A2Q2ZN6TME\K]OH"4AKZ-N>K=1S4,X^CK,N>5SG+5)
MD 'J+:5^4:CMA_\ VZ[1N2S?G=!)?O*>78?Q)A_B55..IF)RQ:_Q'LEPE7^N
M>C!(3QO^6U0LCNZN<5'_ ',6[JAJE?\ Y2ND5"/%I8KSZXZ*+65O,JD!U":A
M0,),61;\5\$_2! +4BZ: T>P*JBP1[H<*7YKM> "?P[[1@$)8FMT%V*9RDYU
M(6X:><JY?X%9M&0KNRRB4I[8Z,5#B<?E]4#<"J9"G_W/^E573@V?_$&P)%SM
MG=U>\U87;-BS5VO%@TM5:KU1<73IM:5 <J,BDQVZ*W%??C1E+J$20S(ERT.>
M64#RV5Y"M>97R.W.I3)--_"*[L7IA"A7:K6S-/J]0GKX1,ET>EHI:FIE29AE
MJ$R=452%)0A20B6I0+>AIVI=DQWJY&ITG:.N0E*Y%%3)JY-+*E%:I2JFL5.D
MR5S$"8E4N7*DJ!4I)XE!)$9K4[<NVS84FOVS=M>N15/;,NHT"[9$.>S4X3*2
M[*13I42'3W8-12V@EAQSSHZBE2%M@+R/+K-&UWLY33=5T77]7UG\HE4^LTCM
M!.D5<JMII8*JA-'.IZ6C72U?".*2M7>RBQ2I =QZDBNTW59R*/4=,H=/[Y0E
M2*_2T3I"Z:8L\,HSY<R;/3/D<9:8$A$P@_"JS1M"DU2/6J73:S"+BXE3A1Y\
M?JZ02U):2XE*D^BV^KH6/1:%? $[M05LC4Z"CU&F4]-74LBKD*4!Q"7/EI6$
MJ8MQI<H6'LI)%Q'@U-/,I*F?2S@TVGG3),P#'%+44DC_ )5-Q)Z$1<0"#GWB
M0#W S@X/K@ ^HP3D'/Q&NV;C8#Q.QZ!R-B&#'RC@B'/'X0 YQ[O(QZ]^,C&,
M8Y[\YTMT=V?J_1KA\@@VQ:$/>)X*AG^7^^XR" /7'IJN &LW+%CRV+XY?2'O
MWZQ$%1QG..QR1V[\^HX&,]_AWU#9]BS"Q] 38YP .K0@<YR.H8/ X/Q[@\Y.
M<@#DY[=\&<,6=G.!;QPP9CTOR!1 94<GS ,D>[@@=_49^'U<8P=+@68MAP7N
M.0'B3DM!OM\KB(]/!X*L\DY')'XR1GN./SY! U"6.P.-V V!L.N2S!V)O""@
MH\$J)3R,8&>H<@=NV/3O@Y!.B2 !^EK&Q.6N?(\@;HI9,2/-:7'EM(?96"%-
M.!*ND=@K)Y2H9/204D']&LMK;AW;)9\9Y'=PX,0A\QZ4BM7%;T9^@>:[5K;J
M*%L,B2M2YM&6KE*D/%0\R&2 DM$>X,=)2.H:I./,#QVNUK;%^F&AT;]/8_M'
M2=J?V.TG_DB3Q\2M9/\ U_/5^<4!L1CLW_PBTGYT65G_ -[CC] _CTR? >>?
MI>_5K;QB,F^^+?Y1^^/H+;"TC*&D(:0AI"!. 3@G S@=S\AG S^?2$<&K\>E
MB4VPH=^WC8]SVS1JE?%UV:Q&G5.T':@]"M6X&[=J-PM4Q=>9GSX+,M]M$R#3
MHLVHQUI?2F,^RE#[H7]'\?")DLS_ " ;J[ON/)N<4->\8NQUAP+D?B[6W)]#
M6]>%RV$B?3[:MVDTBMW!3$O/71#H\JHU"G1I!]G90\^'%-*JCKJ(D=,J:VZP
MVO<]>>_L'G M;=\7=WSFV/E;QQJL>-GP\4-ZYJ/1]KYU1KNW-MU&J1:-$H-M
M12U*CPX%6K%OQ%"2I5'DLQI\5Y^3)9BTR8^2S&ER9""@5B/1\C$0<(8"SNWB
M-NANWR,;DW5\1&WFV]G656[RVKN.I2-QZ?.O$VE3Z)0:Q4H*J'0Q7ZI4*SF:
M*<Y+IM,8+OM+4E]YSR4ML%3G2WJ>_&+Y>S\G/WSSX*W,W[\/ED752]_[7V4G
M3;Z.XLV'/I>X%=JEK0Z'4SLK/N6DW/2X-%I%WI>DW/8\>-1J33G(\:GPW:D'
M:BQ3GT.OH<AGH/'?K?Q;'*(P%QXV+N^>?(8ORZ[\E>->AVG4KHV^J6Q<*V*,
M6]NXEM07ZC CTNY+AOMFPI]XVA5(46C*AP*];5,W AU#V=*9S-?9A5):'61'
M>*:Q+;V?P9QZ6^T5_GSW=^9&^V>@%XW)LEXHK*W*WXW'V;HELV]1F;#IRXMG
M5^F56#*F7'3K?JCU%NF"Y1XT&.N@QJ%7$=,-CVN2U.A26)S:6@Z4@?7V_P!_
M6 +]"7R"#;]'^?E&Q+OV.O'<&X:HN[=YKG3M]+E.N1+ M>G0[;3[&LCI@56X
MXSSU4J$?HZD.!H0U.I.2I/;6N5>B5E?43C5ZS5?P]:B44%+*13,@_P!$VI2I
M4V8G8@!'$,QX]1I=15S9GYC4I_Y12RI-)(EHD@)V0N<"9BPQ(4W#Q1NFS[(M
M.P*+'MZS:#3[>H\;);A4]D-)4L_AO/N$J>DON'EQ]]QQU9Y4LZ]BCHJ6@DII
MZ.1+IY*<(EI8$[E1NI2CNI1)/./2IZ:GI)8DTTI$J6+\* SG<DY).Y)),93K
MM1SPTA%/*B19T9^'-CLRXDEI;,B-):0\P^RXDI<:>:<2I#C:TDI6A:2E2200
M0=8K0B8E2%I2M"@4J2H!25)(8@@N"""000Q$124K24J 4E0(4E0!!!R"#8@Q
MR]+\-$JVJ@_4=CMRZ_M W,><D3;9CP8]T66^^[E3CT>@562W]&NN.%2W509;
M;:B?=92 !K65=FU4RU3-$U*HT@+65KIDRT55$I1_F*:>:H=VI1)<RU@<DB/#
M5HJI*RO3*V=IP4IUR$H3.IE<^&5,/P*.24EO^6/)/ANN"[WVU;W;O7'N72&E
MH6FT(%.CV7:LCH/4$U6'29;TRJ(ZB<-O36VN$Y0K&I_J[45:O^FM7J=2D@@B
MDERDT5,6_P#:IE+4N<#>RE@!V8C,_@TZH5_TGJ$ZME#%,A"::2K_ /$$LE2V
M-P.(#F\;<OZP:94-H[NV^MZG0Z33YMIU:DTVGP(S<>+'ZXCI9:9892E*>IT#
M.!E2U%2B223N&E&3IU31&3*1*DTTZ44RY:0E"4I4+!*68<VN8[]92(7IU31R
M4)EH73S):$I2 E+I+  ,,]1?<9C\S57HS;J*C0:]3V9+:79%/J5.G,(>:4]&
M<4P^T\PXGI*FW$+3GIZDE.4E)2-?=9<TC@G2ED$A,U$Q*FL64E22SAWL.MWC
MX?.D2YB)E/42DS$$J1,ES0Z%$&X(4&<WS<%B +F.>;HV4?8#DNRI:EQ>DARU
M:E*=0E+)3*96W0JXL/OTYU,>H5!N*S4&YD9EZ<Z^P_#=2AU'LR-4"P$U274,
M3TI!XB>$COY08+2I:$%1E\"B$CB"@PC4J[LTJ7Q3-+6Z!=5#.6H !06%)I:H
M\2I)X9LX2Q-"Y<M4U2D%!X2G55+K=>M6IOQ6S(M^KMY<F4F<R8J70E@%<QR.
MM2X\J R.E"9<!Z3'C6];,.(Q+1,J#B$\NH:9INM4<RDU"FI]0H9X")DJ8!-E
MS [\)!929@=PX0LSYZE@,@*/A4]55T,XH"ETE0D?XDB:@(!9+J7PN4+DBQ"Y
M9F)12T4M*%B;.('7=J5"I5>@T^JU"*:=)FH4ZF*5+ZA$*C[,^ZWT)++\E@(>
M5'ROV<J#(<6$A1^/SNPNIZ+/7)[(]KZ_2:%*B$Z=6TLK6*.23=0I5SYDN=(E
M)4%!("EIM=GCZ)05,VHHY,^HD]S,F)*@E+N)9)*%S$VX%K2RE)!4 Y'$H6C[
MH^&SPJ4-W;6Q*SNC.K=V!4-%P4NPJM(6U:%N2:BH2TK^AV2A-1G)4I3AD5!3
MK92[T)CI2!KYAJ?9]57JL^HU_5ZCM'/E3.%"ITJ7243H 2E2**0I4L\-PDK6
MIQE,?5]$T*4:*DG5BYT\% FRJ28HBGDE?Q7EI8+7N2HD.<$1] 66&8S+<>.T
MVPPRA+3++*$MM--H2$H;;;0 E"$) 2E*0     !KU  D!*0$I       P !8
M ; 1MH 2 E(  #     8  L .0CUU8L-(1AM\[?6=N30WK=O6A0J[2W2'$-2
MD$/19"0?+E0I391(ARFB<MOQW6W$GC)!(/3KJ"CU*0::MD(GRB7 6/B0H87+
M6&4A8V4D@[8)$=:JI*:ME&34RDS99N H72=E(4&4E0V*2#'-M7V!W<H-#K5'
MV]W_ +A;MMVES8\*V;MM^EW/+9:<C.(-/B7)*FP);33B26&')B7O9D*3U+4$
M%6O"3H6JTO\ AT':*IE4P?@E5=+)K5RP=D3EJEJ*4G^4+"F#!R!?RAI6H23P
M4FL39<@?RRY\A%2I Y)FJ4E1 VXL6=V>,IV[\-EO4651KMW"J]8W0OF!#BB%
M5+O=9D0+><0T@^10*)&4:3!#"NI")"42'E>\M+_O:[%)V=IY=0*VOGSM6K4D
MF7/K GNY+E_]WID_X,GHP4H.65>.6GT:2B:FIK)LS4*I)=,VH_DE'/\ @R0>
M! >_]1<DO>.F^W;6PQ[,-(0TA&L-R=G[$W5B1F[JI/54J<KS*+<5.>=IUQ4*
M0DJ4B12ZK%4B0PM"UJ6&U*<CJ4HJ6RH\Z\S4M(H=50D54H]Y++R*F4HRJF0H
M$D*E3DLI+$DL7227*78CHUNG4M>E(GRW6B\J<@E$Z40Y!ES$L0Q)+%TO=GBR
M;:[=W_8=1G)N#=ZJW]:OL@9I-,N&A4Z/5Z:XEPJ#DFX(CZ7*B$M%+67XC:U8
MZE')UPZ;IU?0S)@J-7G:A3%($F542):9THN;KJ$$&;8M>6DEG)>.*BHZNE6L
M3=0F5<CA:7+FRD"8@N3\4Y*OC8%KI!+.23&Z@01D$$'L1R#^?7LQZ<-(0TA#
M2$-(0TA'-^[&XTV1+78MHNJ]O</EUJI,KP(K120Y$:<3RVYR/:'0<MI/EIPH
MDZN 3OL.;<CTC%W+!B&O@[MAP?/#<[1@U#H<6B14LLX<?6 J3(4@];[F>P4?
MP4)*O=;'?'4H9/&))+Y <MT!N6L6P]P.6T7 QRY/]A;^T:SWYLJY;^V]D4"T
MH]'E5U-Q6C78K%=JTRBTUX6U<E,KRVGZC"HU>D,^<*?Y20BG/DE9R48.?5T:
MKD4-<F=4JFHDF152%&3*3-6/S$B9(!$M<V0D\/'Q76 X#/:/"[2:?5:GI:J6
MB3(54"JHJB6*B<N1*/Y6JE5!"YLN34+2");6E*=VMF/G^CPB^()$=; HNU72
MN*(I7]LRZ,]/V-;J6YUC.U!]X,[I39/23@+I,9HDB2XMG=SVHT12@>]U$<*@
MKA_(4Y<=_IT__O(LZM.2E[_\11;X6/SC_4CM&$*1W6CL9?=E]5J\"EU:E<'^
M$./AU:8LX^*2D.RU-7QO"GXAH\V7-30=J%&8JHDH5N==&&S4*AMW45CJ&U))
MZ%[>Q6DG'O)J3ZLI+#8<XU]I-#(0._U)D"6'_AU,#_AHKI8-]1(#BN62UWEI
M;^8\/(CL;VE0I:A)T8\1F%CJM9;O)NG3"W_1 LG^')',B:HABD/ENV$&Y_"K
M>IKN]]OTVBV3=ELBUV[^M&MU6[[;MNIQ;DGU]IN\R_:MO3[?BU$U(1H=75'E
M4H.-*1,EQ%  ]749E-VEI.YTB?,FU=-4?F/R-5*E4T^?+73IDDTI%3/ESE([
MOB5*XA,8NE*X[>CR:KL;J'YC7::5)H*RC%&-2H9TZMIJ6:FJF5"$5W%1TLRF
M3,[PIES^"9)<$3%RR+[[W$\35@3K>G6MLU7J3NYN;=4&32+4MJPY[%=]GEU)
MAR,W6KBJ4!3\*W+?I@<5)EU.IO,-CI;;92X\XA!\.C[.U8FB?K$A>FZ;)4%5
M4ZOE]T)DM)>9(DRI@"JB;-'^'W2$ETDN>&-FU+M90*D+I="JI>KZQ5(5*HJ?
M39J:@RYBP4BIJ)\HJETLB03QJG35) (2D J4!&XMLHM.LJT;0VTGW/!J]SVG
M;%'IE7\Z8E50ESQ%\R=/\A]8E+CR9JI2XRUI)#'0E1"DD#PJC\J9TXT-+*HJ
M/O5FEHZ>6B5)IY'$3*E2Y<M(0A(2W$$ )XBHC)C9:"54R*&DDUE3,K*R5324
M557.6J9,J:A* )TU2UDK5Q+XN$J)5P\()M&SC@^[V(P!PH@CCU^?<8'P].-<
M-W!8 7)&_CMT!\2_..W$F<Y&$].< <CD=7(."4Y) )[ @$]M2VQ+MR#AVR&N
MW+]1"(\<GD\>O5[N./7X]^?E@<:K7N&]+[D'."[^L(<*&> !ZD$GGG\'&3QZ
MC XP?3$?AL+O@;..1.,7N2Y]4/=[8SC@?A#X#J!/ QW&.1V ]=4/XYY,/^6P
M?D_@_2$1&204COG@E6"1QR 2 >3P03SS\G._4LPL>1(8]2XL!O"  R3A."?[
M[N, @<9/IZ<DD@:A+,'+GPVYC 'V%S:$#\"$@@ \$G&>KX<_,_(@'@:6-[E^
M8 <., ^71WW,(@.,I.. />YP0,8' SGXCGX]QID/L>8!9G<Y8>-_/$(F3P>
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M)N>Y*+06< A54J,:(I0)P"AIUQ+K@X/*$*['.NM4UM)2)XJJIDR!L9LQ*'\
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MYEP!QI?3E"T@C2$:+H%5KFTU:H-AW54+HOBE795K@?HE[S(<<QK::::54X]
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M@=\!( &"."#P2=?..8+N][Y+OFS.;>H$?1N7@ / !A\HGZ21@E1] 1GI'/<
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ME6G53!N"9)=Y:E-9:% !3$@!WZ4[2%4RC4Z/-_*SLJIE$FCG\PN7E"E?YDJ
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M'./B;\1UH>'#;JJW;6Y:'*TMI4.W:6AMV45U62VX(<NJ-Q4K=@T6,\D+GS7
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MN?Z)GY^]ZGN.=7_9-^&Y#_ZHZ=8$G_&U#E;-9OSZ9,/]=^UF^N59\44W5_\
MS&Y)/]H'P\[,#D;=TCOZS*MVY/8U$C&/A^?L=!^$OX;'_P":6G'&9VH6V_\
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M( $C^*'OJE0!"B9@2E1?9GC:J76M"HY$@R^R]-4:A*0..KKZVHJ9,R8'^/\
M) RY2=O@*E)L]R[T-3\-VSE;M"O65<5F0[BIET151Z]*K;CU2K4]:BE:9?TS
M)6[48LQEY*),9Z'(CJBR$)<9*%(!&T=CNS.D=A:H:EV=IU4^K$GO]7J)LRLU
M.K)4\P5-74JF3)DN:0\R2XD*_P#9@%AX':BLG=L:*9IFO=W5:8L (T^7+33T
MDCA<(7(DR0A$N;+=Y<Y([Y)_KCERDUKQ"^#A'V,W);5W^)?P_P -7DVG>EKA
MB;NYMS2 HI8H5T4!;GM5]080*8\&ITQQ$]N,U^^$!IMIE'UF;)T/M5Q5,B?2
M]G]:4 :FDJ'1IE?-8DSJ>=PM1K61Q+E3$J1Q*L7)(^32JCM+V'!I:JEK.U79
MN6/]SKJ3A7K&ER>)DT]52W77RY8(2B9+(6$CXB $I&32/'=2:Z6Z9M#L%X@-
MSKJD_>V*/(L:?MY2([Q!&*O==WLL4VG(0LH#J@W*..HH2K! X$]C)LG_ !-4
MUK1=/IDN\T5<NMFJ&3W5/3'O%EL72#@\X[:OQ"DU"A)T?LWVCU6K4"!*5I\S
M39*5 .$SJJK1W<MB0#\*OZB,7TG<_A<\16[$BL;C[OUNFVW;U5E0)MP^&/:6
MJU6B4^YJ3#(6]'NV^8M0BRJU6O*'6]'B,,0I+Z5H0X4+2DZ)K4W3NP7\1[1?
MA7V8HM3[2U4R1-URNU0SDS-4I*=Q..CZ<F:-.I-1"5+4BIG4\Z=/(2E;K8G8
M=/TG7NW2J/3/Q,[15&E]G92)J=.T/1B.ZI)TXO+3K&I<)KJVE<(2NGE39<F4
M252RE)8=W;%4O9JE6A'I6SUK6]9],@ L3;:IU-C4VK4B8WT)?8K3)83/?EMJ
MZ4N3Y2GE25 .><LDXZ&C]NZ;M[3G5)6I5%55I)174-8M:=1TZH2W>4M52K*5
MRC+4>$$([I8_D+%AL\[LA+[&D:=*TVFHJ4@*II]+*0:6LE*#IGR:A(/>\8NH
MK69H/\]V,6'Q"; ;3;OV\)M[F+:%S4 &=:.ZM)EL4&[[)K# #T6J4JNMEE]2
M&)#;3KM-?6_$FI2&WHZ\C&T47:U?99$RLJ:ZFD:5PD5\C4YR)>FSY/\ 7+G)
MGJ$OB4DD)6D]XE1!0ZB =<UGL?1=JQ+DBDF_Q260K3J_3Y9&I4D])!ES)$R4
M.\(2M(*T*)EJ /&+<0Y+VF\76YU,K]/\/>X<6C7)N'*F3*;MWOG4G)5M;>;K
M4F"E*4S$QWH;?1=[#9")E'C34B>[]]C=:BE4G7=>U9?:G1!VH_!K3Z;M!13J
M^90:HG4)U31R.S,Z7+XUU:I<^GE3]6TM2BE$F=1EDK(2HJ2E01R]GIT[L_K7
M^J/XJU4W2]212IJM)KJ65)FCM-(6H(1(2N7,7)T[5$@E4V14J*EI#I 44=[V
M6-J[\KGW^]-X+J5)4HK3 LU,6UJ5#ZO>#+:6D/R9(:/NA]]]2EX!4C))/SV7
MV&[4:B!.[2?B)KZJA1*A2]FA(T&@D.?^&@2T3I\_NWM,G+*EM\2;EOI2NT6C
M4@[O2>RVF"6 !WVKF9J=3,( '&>-2)4M[G@0@A)L%,S6^:G<_:7^BIJ]3W4L
M1KI^D8-0:CB\:!&2"7*C%J#*4?33#"$J4[%>9$C"@&R2E2M=2H';7L #7'4:
MWMWV5EAZVDJY<G_672I(_GK*>JEI U21+2DF93KE"8 1P%@I4<\K_5WM*U,*
M6G[-ZRK_ *O/D%9TFMF_TT\R0HG\DM1(")J%<#A3BX NM\>)39#;FT8%ZWCN
M+0Z32*LT%T:/YCTZO5ETK2CV&E6Y3VI-;F34/*2PZRW!4EEX@/.M#G7U_LLA
M7;2CIM0[-).J454@34U4ADR)26^/\S-F%":>9*(4F;+FJ1,2I*DE!(#_ #GM
M-J=#V/F39/:*IEZ;/E**!33>)=3/5A II$H+FSDS"1P3):%2R% E20Y&@(_C
M+W$N%EZK[?>#/?J[;31U+:N"JU"T[#ES&$XS)@VQ<4@UB0A2"%LI<$9;P.$A
M)SC<E=E-/D-*KNU6CTU5@R)<NIK$H/)=33@RPS7(=K/SC2D=N=4JD]_IO8?7
MZRBN143YM+I\Q2!E:*2I"IJP?Z+@JR&-HW-LIXH-L]\)52MZDN5FT-Q*$E)N
M+:Z_*:];M\T<$.$/IILL!NK0"E'F_2%(>F1DLJ;<>\E+J,^1JW9S4-'1*GS!
M*JJ&<3W&HT4T3Z.;CX>\0Y0NX'!-"5.X%P8]W0>UNE:^N;323/H=3IP#4Z1J
M,I5+7R 0IE"4MA.E_"5";)*T\)25!(4E^BPDY!*CG./PN<'USU<G@# &._PQ
MKPK-8;X;?-W%ACPMM&S7Z>G[QXF0REP1R^T'UD]+1>:#JP 20&NKK)Z>>!S@
M'MKC,R4)B9:IDH3""TKC2%D9LEPHAO\ E(8GG&80LI*PE10,KX24ARW\S,'=
MA?+1[%*ND$$9RH]QV(QC@_7W..#Z<:S)OT #@EFN[L?+9^487Z>G[Q,D>I5P
M00>4G.00/3!&>0>XY^ U02YR?(!NEV/*+'1MJG-NTC'^]$?\Y7\_A\-90C"J
MQ_X5+6YY^AJEQ\LCM\>_SQJM8WPUN=R.>WO,8$LK;^9@^[@.W@WB7MO&U=2,
MX:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0C':U!MZ*Z
MF\*K3(K\^VJ=478M4]A]KJ<"$MDNSVH"FVW)(,EMD!;+ *GRE*.E1P-"6!/*
M\9RY:ILR7*0W',6F6GB4$IXEJ"4\2B0 '(<DL!<XCY7V#LS5O'9>D#=[>.Q7
M+!\*EKW4[=NS>Q%3I35+J&Z]R#K9=W9WFH[[3BG&ER$N.VK;CHCJ3&+<^J-N
M+="%=)*5U*Q,F@HD(4\J40QF$8F307L"'0C_ -Y0=@/K%;J%!^'=#/T30:B1
M7=K*ZG5(U[7Y)$R5I,J:/CTO1)R6_P 1<M016U@*G+RY1 #QTKXJ_ KM#XE;
M8BN-T6D61NM:;=-D;;[H4:D0$5FVIE"2KZ(I<P&,M-4M)P'V2I6^^E49^$HI
M9#3S;+B.>=)$T @E$Q#F7,!92"<WW2?ZDFQ\6(U#LKVKJ.SE34HG2$:GHVJ(
M[C6M(JB54]?(4;K8J'!5ROYZ>H!"Y<S)*2H&R^$JXG;U:K^W6]6QM%V[WXV8
M<H-,N=ZEVTK[!KE@1XDR-:-Y;?5]YMYN52YM+D25)IZI/M]#=ERH3[2$D%4D
MS5K!3-24S4?S6(0K8*0<$* !."^1'+VMT#2]-52:IV?U!%?H&L"9-H!,F(_B
M%$N64]_0U\A(2J7-D+44)F!/=SD *22YCN6D4>E4"FQ*/1*?#I5*@-EF%3X#
M#<:)%:*U++;##24MMH*UJ44I2!U*)[DZYXTZ+EI"&D(:0AI"+17V?:*'6&/9
MF9OFTR<W[))>$>/*ZXSB?9WWR0&67L^6X[D>6A15D8SI ^_UORS%32T>73:>
MV66HWEP8J/9V7/-98Z6&T^4TZ.'&V\="'/QT@*]=(@P-[>^<5VD6&D(:0AI"
M&D(:0AI"&D(:0CD"8";]OXD@_P!%P,\G "> ,$8[)'!XYR!SIU^WO/H6C')4
M+CJ"=[VY'P\/&Y8R<GC'.,'&,=C@@'U[_  >HUBX#L7<V8Y+W%]OL>=S6<!W
M%MCS^I$"%9[#)'KU$ >N<'D_/DC@#2P<.S$<AF_IY;%X-R^9/[PZ2K!//.>Q
M))],#.!QV'8\ _'1TN1BS; ?WOY7;=['SX:\9,JDU^[JM>+E$B6M2)&Z46BV
M=1*'/F73(:VQ5*:ENUFOO5Q42G52H""]4&X!HB8XIC\1Q+P4HJUDS 6:^<"]
M\;CJ'S&(=R^+MZW]+>6-WNCOCB8:H<&L(VKK:G?H>\+DK#7T]%BQX5N68];"
M:E5:9+DP&7*NE^/=$%R*S[-$*I#$IA2NA*77(WJ68'Q<,.;;] 8KL+/X@A^6
M>?AN&C:NU_B;I&Y^Z-S[;T:U*O"C4$7"T+D=="HLF;;$V!!J,2;$1':$)<AZ
M>'::KVN49+#+CCJ(Y*$*I#;AL^N7-\<K?0P!L6)8WY?)@XZ_..G<*2,G@G S
MGCTXSG('RX/S[ZQ"G+.Q#^.2S;=7<^$7W[_?RC5]T;06;=-2%<=9GT.X.GH7
M7[:FNT:J.HP>D2GHQ"90!P0) 604@@]M:1KOX>]G-=K1JDR55Z5J[ *U;1*N
M9IM?- ?X9TR2R:@"S=ZA>!G$;!IO:?5=-I_RB5R:VBR*+49*:NG2>:$3+RB0
MX/ 4N+19H6PMB-2V9U<77KSELJ"F5WA5I-8920K*5)AN%,7J!Z2%%K@C.1KS
MJ7\*^RTNH15ZF=4[35$HO+/:/49VI2I:QA2::84T[A@Q*"00XCMS^V>LJE*D
MT?Y/2)2V"AI5,BD6H,0QFI!FL7QQ-%?NUL=MSO78S^W][T-IZBI6U*I,F"$0
M:M;-6CI(A5JW)[:"[2ZI")*V)+/&"IMQ*T*6-?5=&KZGL_.DS=*$JE3*1W7Y
M>7+2*9<C^JGFR0 E<E0 !2SN UVCY[KNBT':6CF4>K(74)F*$U%05J_,R)X_
MEJ9$XDKESD;*#.'!!23'+%(J7C2\/O1:<VQXOBOV[@@1[9O"E5N+;F[D2GM
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M?1-,_)\/]7:_9T@WT:'T32_R?#_5VOV=5SS/]\^L&%NF+GR]-H?1-,_)\/\
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9;2$MM(2VV@=*$(2$I2/@E(  'U#2&(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g899221g21f21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g21f21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &IJ^:! X0DE-! 0      %D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  5$96QT81P"!0 K36EC<F]S;V9T(%=O<F0@+2!"96YI=&5C
M("T@1F]R;2 Q,"U+(#@Y.3(R,0 X0DE-!"4      !![^!QJHC*1X[<@^,^/
M3;:(.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           "6    P\          0                         !
M          ,/   "6                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "6     !29VAT;&]N9P   P\    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   E@
M    4F=H=&QO;F<   ,/     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     ! E     0   *    ![   !X
MYJ   ! ) !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MW_3!+D^S73339'5'^RLC]YGWG_R*A;TC*?6YC;&,<>' NTT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M19,^[<M&<E".$9= 7,$9.4CG*@*J1\LF[30(HFGM*4<JA]D2FZ-]#NQ&%&)
MP?"-O=E=J&RVUVRNV&$RTI%FI7%9=^$3K8.-,_-TY AQ(8GL-?*OBNAN>XQ,
M-EH1!W@X<UVTVAG'PO:I[9G&<)<[#L2PJ;CQ8<&-*/;-0BZ5I,0'N#C"F&Q
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MLTD42  <B($[C"(F,(B(C7H:+&BQG[\5[HCJ 5<:T:T -:!DUK0 &M
M"ZRU)-R222;DDYDDW).I-RJHK31*(E$2B)1%\EFZ#@@IN$$5TQ\R+)D5(/XE
M.4Q1_91%:&^NG? N3RB3(N&<8WN E[=W18]N31P#0E#M._CESE$H&'M$I@$N
M]E$!HBBG,>RUZ-7#M:5M#'LMBB=4,)T9G$MZW=8#AH<1$W<V:6],LXPG:(_
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M'5T'GI5V5I,2 *,7!&Z%IPT:HLNW$RPO7*FC))$'BL7%]#1F[8 "M34ZBE;
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M4W&?PCWI]4&,_P!#8?\ BE?Z6IZQ_P#$4W&9[HKQ3ZH,9_H;#\<_W)7^FY_
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M +$?_P"^OH?IIM3_ &W._P"TS_@7U1Z5^GENJDNCB>UDUD5"+)* B[[B*)F
MY#EV['DIP P>FP#CBLV>A_T90W->S8W!VN80YKA#C5#@001^VS! ->2CMLMJ
M'M+78U.%I:6D%S*%KK$'[&OG<\2K_$(1,A$TR@4B92D(4/(I" !2E#[@   /
MN"NR&M#&M:T4:T!K0,@ * > %%QHDDDDU)))/$FY*W55$HB41*(HF9LZ=K@S
MI?L2_G;[D;6L2S[5EFUJQMKB1.8<WC=S.5@+GEYQ1V@LT68-[6<-XJ%02#QD
MCR4Z=4Q060$*#0&FMC;0$'WD>[@4O?G]?/A7W:J.?[B'*MU687\O,K)HWW;U
M@V9CFS$+;,X):@0=G2D1<1G$^1XT,^6D)^XXXSV279F3$&Q634H]C<"A=[D*
M5)II<4H.%/C>B<=<^%]?N5^<9=-D_;.<KPR?=T_&3%N!(2%P8WMEDBX+^3UV
M7JR:DR)<;XZQ2D6>R2S8C".[.\$(\O>/8NH>H2*6K74G@,AWPZ4*8U1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$46\+=4UNYJS!GS#\3:L["2> IB"AIJ9DG,<M'7 M.M7#M%:*1:*
MG=()MR-Q*J#PA#&,8.P! !K[6(X+%PZ0PN??'AQ&8I#B1(<-C7AT(0W!I$0N
M&Z22;;I.17SI3$63<U.RK8;V.DGL8]SB"UY>'$%H%P!NWJI25\5?12B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B+$/T'?[-KVCG_#C'O\ Z(DOZ\_S5SO:?_F_LE_X2:\S$AE<9P;_ )6Q
M[_OH'PB?+C\*++Q7!%R9*(E$2B)1%QUWC1J) <NFS<51TF"ZZ2(J#P&B H8H
MG'8@&B['D/G1%L/(,$E@;J/6B:XZ$$#N42+" AW ()F.!QV7D-%Y#D.*(MR3
MUFNF99%VV62(<$SJI+I*)E4$2@!#'(<2E.(F* %$0,(F*&MB%$6XCILJ9<J3
MA!0S8PD<E(LF<S<X!W"1<"F$4C 7D2J=H@'(AJB+:=XT3412.Z;$5<:%!,ZZ
M15%P-]D42"8#*=WIV ;?I1%R:(E$2B)1%M Q1,8H&*)B:[R@("8O<&R]P .R
M[#D-ZV'(<41;J(MH&*)A(!BB8H )B@("8H&WVB)=[ #:'0B&AT.O(:(MU$6T
M#%$PD Q1.4 ,8@"'<!3"(%,)=[ #"40 1#0B Z\AHBW41;3&*77<8I>XP%+W
M" =QAWHH;'DPZ'0!R.AT%$6HB  (B(   (B(CH  .1$1'@  /,:(MI5$S=O:
MH0W>3Q"=IBCWI\?&70CW$^(OQ!LOQ!SR%$6^B)1$HB41;2'(H4#IG*<@[T8A
M@,4="(#HQ1$!T(" Z'@0$/,*(MU$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%T]P_3GT%,?DR:/)<(1KP80
MTJDNO&A* @<67OR+99NX4:BN! 6(BNDH)!'M.4>:U(7J_6P_7!YA;[?6!A ?
MN5&]NEP(#J5I44JL(F^(;_5[OK-T[F\"6[U+;P!!(KG0@TRNO-[[,S,_4=>/
M7EU$Q4G8=IP2EY2YI[/8JHRIBV>I9(N+<:15L*"^*F=[)S#U!,@/3NP.S2=/
M4BG(@)1[:VQP_"8&S.$163,>+[/"]5AE##_N@3&[%=$C?9J&PX;"3N@'>(:<
MZC@>S\W/QL8G6F%"9ZYWK)T$.'JO4ES V'5U=YSW@?:WJ@.(L%Z6JZA7/THB
M41*(E$6)7K]PKU 9;RY;3C#,-;TTG;73!G5PU8WVWOH]G2%^.+MQ2-MQ;"0L
MV]K)"!OQW&HSIK:F7CQP+=)*0(4K9%1P];DMXU'#(:7![JL>EF6ODYO<F8'-
MR,,ZR;^1LG'37&#O)'3KU$W=E*96;='N.+<4>M\HVU=[+']A3@Y);3?TZUFK
M;F%4KJ1FWZSTZLFB\2@MS'P^[09T^#OOO[Y$PG2'U46Q84,C:]UK6U=V4L=0
M,,M9=I.,A!:EOS5AP5V78VOF\96][GF6K*_)F^)&R(I=-C%PZ+V.@UT7R\FW
M(=!*IY=>QW?QZ8&%XN<4-L:=.&&>J&$ZC,FV+:N)<R9%R3*Y.M.P(.Y)F:%6
M_+MN*Y;E3EU)R< 6,Z2-R)8<5/?1T5,13=-^9FBV:(3D/A;Y"W"M45#V%TS=
M8&:[[<8>R$C+X^?X4PU*8;2S+<4WEN;BEWK'($/-VID3$=S1$Q8![FN%M9D@
ME#&F9@\?)K/H%X=\ (JJ)+*9\/.U[?/QH$[^JFIU?RO6O9L[(&P-<MY/K6Q[
MB/&J+ANWMMI(#>,O<%_,;2R%=*\JTLV\IUS<]HV">3O",B+:MN:<*3B+1<]N
MS;4IHAY>RG7C;I3\58RTKC]HYD#ZO7$W?>1+(CU QC;$HI;6.6)OI>W+OR5U
M P%TWK+*WQC^$F65\0&/K:Q5+ ]<6Q;D1'3,F27E+(!C,I0C>5Z>-J\N1K^"
M*F\=9?\ :67/%V_]+ER/&Y=)!MWMV67)XG;1&,$;$M+'4#>C&Y8JZG<45);*
MF3+U9*6%.VX%P.0AV]W2I6UK1A[5)+NE>%ZW[MT^^B<?=W;X?=P;LSW[5$UY
M6Y<%LV4]CB7A:#B_K&QI-6I/JQ34MV,[KES8_P B/(7'LS$L[DQ\+:%A&2LS
MDW'H.G"29U4)HDJ15LX6^[OZ\JE='%-X]2=KXCZZLG,G74/?-X.U<,J8[DKZ
MQJ_A[P^E26+;T3?;2RK#6MN(;NX:UIQS*MD)"&M>1.]2:A)"WN9=N O6?=LO
M?[D[SY]V^15L</9.]IK<D/.W3,O,C$<8OOVS+;M"TIS'B*##,=OS%T(L9F:O
M&7F[ L"?=M6D$^45/)PUKX]*T6:-WSN.2;MW"#IXTR[\5-1XJML.7/U?CCOK
M<R2@_P W368G?3UA=>RT\@XV=P;:W\YM83(;G(5G8QME:%B(ZY;:M&YI)JRB
M)1HTEAEXXL6#JX[C(DC(*56U>7OHK4Y2SM[1/#5[9?B)RZ;O6LBSY%C:K2[E
M["?W ^5L9>9QK%V_D.TV\5B>(LBX<E7#(7#+,W4#'Y FU7@+.636Q(=:',_7
M=Z>=N/8"6\N_#2G&M:Y+K;CR5UW1*]]7';B74(\1NQG9-EV'DES8$G'7*_LZ
MU[FZFY&&F[MMMGCB]D[/N6=01Q^TN"1CL..3R3=U"I2D;:#>81D(MW3\?FEN
M7S.7T[LN]==1'M()+'S>?-$99ALNS)63*^L?M\.2#/'-@8K.YAB,LEVA>"=H
M77/+94D&2RKB3MIG!9*=,W+IXBOCR+3B3F5=]]_)%5>,[XZVLB92Z;6N:W67
M8X\3E;%<HV@+4QO<+'&EW8T3M*Y%[DOK*%WO[*MN3@KO9SZK5H\MR7+:#54G
M@)C99O$(Y3)Q^?@*#K\>JK#)&6?:0I9UOC&<#9=P/,4GN^6Q-"7NVM-JJ"T!
M,Q!\DHYA*](0$?"@H2(EL5HQY2F3=7#,Q2QDC.!!0)QRY?>BC!CJV^O&'E;Q
MO>'NWJ3BKPQYA^[KTC+7N&U59:T9^?7Q?TFR%NXQAVLS "S7AI"ZF&0V+N+A
M'9[@8C#2[5M)13]])O']3OOS4X>KO+76K;'4]:L#C-K<L1A3\E,9O%Y&U+,N
M6[EI4)^YKI99M779Q&,;Q8.;GLFQV43+V#'R]ZV W&XUVO>UOA-VK"ME5.-+
M^.O#DHJPW4OU\+3UH6EDR4S!:.9WD9<MQ,,<6IA2.?6A<DK$36,8S'L7<$TR
M9W:G$6-=-G3KF:R'+)7&S"W+XE+DC4YZ.3M,D0[E>^O'AWJKTX_/O0>"[L^3
M_:D6Y.X6<+O+GF37Q;UNWG*1LQ83\(B,O65R!)0=V8SG8^TL9S94K;MRP&C&
M=AE[GO;&:CB:=F>'NZ1;G^A&R_"W'[J(J0)U">TB:Q30%4,RRIX?,+DKQTUQ
M5.MUKQBGC)@L2VX=5YA1JY904,[7=HKQT_;]O0*H)"BPSO+E0!VX<,_?[Z]/
MKHB[<F6O:(6_C=DC:T'EN!RJV:H-;;QB&*#RF/G%B3MY7H>]K\N2ZW4;(&:9
M+M.)+'/K9MC\K$$GQB-6:,!/)21'C96G'RK\/)%-H]V=7UE]/6;V,G,7[==W
M6KGJS;;@LA_D"P=7^&$;B9XM?9#N^U;5A(@(ZY9FS23]_P#Y*HLX"4.8T.RC
M7<=<#U@X,_O??5%"/)G47[0QG=%MH8H0SS(1$?"7#;YI2]\%/&@7# N;$RH]
MMK*$Q9\#94FW<7$A<K+'Z#E%3(MB3@N14;K8:*C)BHS(MS/J)]I0Q'&;BW[8
MRK>DFSM^]X]A;,]84DP8Y$N=*4R0W@YR\+@D<3V.U-;94FMFE(6Y5.G69C6K
M9208P][C--V[>:Y>/?CY<PBM7*2WM#\F(1\M>E[]2]MP\5#7JPCGN+[:N=C.
M*SJRV$+EE8ZXXZ;P?9"SUO'@GD%I:$@VM0R'NT;^3C&Y+@7=O7,T^8H+FG?/
M.ET[XK(AT-Y1ZT;TSOD&*SNPF&M@(6X]<)1MP6Y<T2G 2+.?486L:W9*0QA9
M\&[4G+;*W?7$R87ID%0DB=5UXT$3^QB8<^^:++=51*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%;"S<.X^L&\\CW_ &M
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MFV6QW#Y+!)]LI C2+H\1AEH$9SH@>UM=Z*QSA8FPM>EJU5K0SMU*:_V5'4P
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M29=B4."0#ZU\B)XS+8='-.^Z$&T<TUH033G[H[JFY#]UAU,@/ @ 9FNP?_\
M5^OYCZ5MSZ1]KQ_TF/&5E1__ )+Z7]%CT(TK^B3^'_*V)9]/:5F!]C+F3-%^
M9URW;.1\R92R9"-,5L9QC'Y#O.5NQ&.E NJ/8B\CPE%%1:*':K*HJ^$)0.!A
M$2[YKMST:X_BN/R>*QL4F/:'RTW+PH+A#9##6/@N>\48UH-7 $5%<Z67A_\
M*R]&NQWHUQ_8Z2V.PLX7+XK@V)3<]#=,S$SZZ/ G8$&$\.F(D1S V&]PW6D
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MBV'B&(9)3PRK 5,HJ#\"3F\-.$XQ*0IP2,"/#:R6DIISHD0188WXD7?%B'D
M-!- 0 ++A.#XE@S=F]L<-AXH<+EL1EY7\W85/OBS,:+/2QA1XL8QY>7;#:(X
MAF!"!H0YP#OLBJQ_AZ&$-"(<\>NP#7 C^&OQKA@W@T$%OVJBURUP&H)R(K4!
MH!%ZY+K(W-+VH=36O"F1&E.?-7YZ2+']I%=][YJ4Z$+TMVTX%DTQNGD1&>G6
M$2+R<58W">#5;)O&+P5RI1P.B'4()"E$P%,!A,&_1_H:F=F(&!XF-H($2/$.
M(,]E=#A.B;L,0 (@.ZX4JX@T.HK6PKZ@]#4''(FRTT<*C0X;1BTP(N^]K?\
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M!;8"AIY472OI&]%TWMSBDEB,OBTM("5E'2SH<>%&>YY+VO#FF$QP#;$4-SP
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M(!DEM@L<\K\[C3S\D-B*"_#B#F;\Z'Z!9&XFS(: 0,_EE$EET$NX5G D!FB
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MZ\*\."P.3D7(V[(2D!(ME$7T4\4CI)$_B$[W2"H%76#0E-HQ"%<)BEK0@!2
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M>Z(>&?O.-4)&0\;BW'4$:FVM[W630 +P( 'D  .O3T#\ WQ\MC\QHL@@  <
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M@$=\>8^H4&EZF]32F5J^%AW44WTM84K7/3XK*I.1C:>MZ0C5_B;2\6^;+\;
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M;??96^REDJT,2V#<^1KYEV\/:]HQJTI*O%E"$^!, 22:( ?^^';Y=5-JT;D
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MUO-QD+@QV\E%3KR;)^Q*/COX19UXCIF=HF)T"',FKW@(5#Q&=.?D<O/2O.B
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M63CF1R\G+2[^^ GW+6:A4X8[2)BX1BI)G/+ ^D&KKQET$A(V!LU7%5P=)$H
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MG7C;@/H%OA7Z3R/9O1.!06;) IWCY+%$Q3@*O!#"!BB40WL.T/\ *"G?84%
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M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6TQ0, @.]"
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3HB41*(E$2B)1$HB41*(E$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g899221g47i71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g47i71.jpg
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M.$%25'=XM+:WTA<9(R0R,S515G.R)28V0V%UN$5QD?_$ !T! 0 " P$! 0$
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M7Q< V<V>FLKAYL!P:5UQK:.)6DPNQD810;08G#!&&: D1PPQQQ1(#ICB1(T
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M/DCG<+*.,?>**==?=6M7%P/9S9Z:WOFEP'!I2F-8U$ADPNQ<K%%B=S'%&I:
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MS[SJ\-M,LM-V12W'7%J2AMM"5+6M6$IQG.<8Y<[,;,*"S;/8"JJ"68X3AX
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MM'MA=3);VV/;27$\I*QPP8KB<LLA +$)&D[.Q"@L<@<@"3P!-8;O=]6'I/\
M4/\ GJV3[R\R^M?9GWNX%Y(P_P!'K#ZZ]J??+C_EC$?2:OF)ZH^IISIAO\^Y
MU%[V<G0M\Z@APYM>W=@+EQ(B3U]O V2BQI)5AR8Q'2!D3%%G M/(&+)C(]]]
MIQT(9;?%EV<V>&T5C ,!P80O@N*RO",+L1$TL=]@Z1R-'N-#21I+*J.0659)
M%4@.P/=BVEVC.S-_<':#&S.F.X3"DQQ6_,JQ28?C3R1+)O\ 6L<CQ1.Z!@K-
M'&S E%(H;O=]6'I/]0_YZMD^\O.UZU]F?>[@7DC#_1ZX7KKVI]\N/^6,1])K
M8Z_U&=;ML\O^*V]^JBR_!3#1,IF!VAMN8Q'#OO)'8?/S'SA&!&7R%)'8<(\6
MAXA:&6\J=4E&<$^ [(6VCJG!=F[?>,5CWV'89%O&4%F5-<*ZBJ@L0N9"@DY
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M,'<:J1=*O8Z&%+V&)EJX!+%5^8.\!,8++13D#/A%0LX%.Q<4=&G-M^4#)&,
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MC6-/B8]#NOZY--"N'CJ?BD@@U^:L,JZ.%*%ZUC8[1R76&/?VUT8;7%\/OO\
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M;BR75O*<?6IU2LY^.V\>.]3P;K&[V*+<Q;J)+R\5(H]"Z(U59 JJBY*JJ H
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M:?ZCZT]D\;O:'O\ W_CU]TM.2\ [QX7Y.LNAIWG.DOT3:?ZCZT]D\;O:'O\
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M&$ID(IV/,6E"VARR0\>,6TZMYJ3?1@3'=SLL#2K*RQ@JIA"LW7:LN*L&7F)
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MC8SIJ?*,'*B\V,R$.EPV1:ZR^!@5Q03#D'V'EJ\6MT$B04YC&<HO%4N'U/\
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M2KL%C.:=>Q#,1^/DI54+.LA1E!4, S &3&P)&7%>+<_ 9@9\W$',9$9YCCS
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M%^$8\'AGOW1+DQIQMUM6#L!I<SLN?6!]0&ANM&9((;,_BZK+$"4S.6O7P'.
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M#%P"^<[D=?\ I'6X[L;=)2\UCDO5-NTT>I-)R8N@<H1.L+*\8E5@S'4%ZX<
M6XY9&1&=>DY',9C)L@<U+ @D$<V78^#LYUK0'3]L T"N23C<5&B6;XH.!O29
M10K(HM\+.!JAQY20'0T#2A(3:58&(+( ;D8Q^28#8*\8W<WT :1068Q[[/2
M23  TJJ-0)*@GG #%6"EB,C C8Y<PSTY9]IOQ2?@/T9C/*DIH"_13,.X^B,=
M?GYF>KD0"R[)8,,GZ];XRD&P^$$18[+)KTY+")#22\RT\'XXI3K:&5IP6^@8
MOD6 1$D=B!I$<D+3*_!B2NA3GD"0<AD<\ZDQL,N;-B5 !XYJP4CX.)&7P5*+
MZ>[Y"XDI*93"AUZ!CSI67G32I0>):1%VCXI/1JL)B\2ZS39OQ0P'DT<M@L4I
MF18+\ARLEN%OH'*JFMI'956,!=9U1[W5Q;2%5,RQ+9J05(U9 C&PS)X 9YDY
MY#(Z<N;///AS?#S<:V.;U148GJE'T^VF5?J#]ZK=7RIT]OX70%.M12'GTGMB
MI9R2.[(..L*R'EK/BT(<:6G*LYI'<ROAINSI$H@EEX*=&J,.0-).>1T@'CGQ
M.1J2BB;=\=.I5SS&>1R[.679[5;)9.G^L2A;=9HLT+'[%7L'9$ /4)RQA'(+
MI5)#DI(6T%O!@Y(KYA(T82QD>84T-*.(42#@1IO+:L:7TB*9)D+0""WD,J1L
MI$TQ53$ S92 %@<TXIGI;-JG=@G2K=?J<:20<U7,YYCFYLLCS\X(%5>WH*ZE
MH"<B3JO.MS*9K-9<A9E1[5J<K58&MEC'@WD!I:43"1I21C69%<<I4PR5$"^4
MG#.M)V>K81F&61"A3>!U"[K>2F*,OUW-(PS4KJZPAVR4@U3=L3PR.>>D@YAM
M*AFR^0'LY<> SK.5+IUM,E:*S&6)8T?&%676<5;VPR'7)JK@;.5@BMN&,Y!=
M&05+@H6V+XA9S4=($!CS6 ,N*PFDM]&L<C1@LPCN7B) T2FVX2Y'4"51N?/3
MJ4,8]652L9) / :D#=L!_P 7YQ\QX'*L)9=8/SFQ,U35]9GB07+ JGC&%**(
MB2K$.>2&_P"(F#  &A!<-MM+?0>O*QW&C'\/9$RQA%H[@);B6YD0'=[X@ !A
M&5!&:!F+'/, J!GP&6K.A0EB$4GKM/;&?RY #X<^;GSRK<:!HH);-ALM[,8*
MJ<=K>Q7N *A"Y%L6PJKML"J<L/DC,1D\9,48Z4V2PX(,4X2[%$#I)C7WW<8I
M[Q@4CA4B4W$<$BN%+1[R)I5.6O22R@9',@ .#DX J5CS!9N(",XR.6K2P4CF
MX9'^78K7==ZB8M,E?I>> LL%3Z11+-L0< QKR.<GHV,RE,+$CGD )%QDQP@=
M,A+C@.CMLM/J''0X^QXO)/=&)8%0QO+-/';DCBB,WX[%0V?6@'2A<$DC,Y U
M"IGJ)U!50OQRS(_1XY9<>R0,N!R%:C$5B/OP*F:I$/Q,_!1]JM%S(*DG7ZO'
MTZ" CRF)01#@Y4R.^TZHT4P13\R\84]&X 2WDA0K.5Y# <Y7#([11P@+E*TK
ME@58YA"#UI4@)I ;5GD&-0NK\4',!F8_HA0!Q'9'9SXG/AESY5N /3;?S"<C
M.F5B-RNP4ZN!O2$D<AB2+V!'8DZ:2 L:**4^#.LJ2TTZI#;X)&5HEAX]#)#C
M.)K^!1GE(V4<TC!5!*B!M,P;-ADR'G',P_$+9C.PB8]H<57CGQ+#->8'@>WV
M.SE6NYTA>4,BX(1#!RTDZ4W"UTV7'&FY_P CMPU&=S#,NX2$8M=D(6(.+@Y!
MQ0X9L@,*Z S@E>3JN$DY%F10"\BJ2B9Q&8:S^,!NP"6TE06520QR$:&[.0)S
MR!(S.3:3EV#QX9 Y\"<LN-9PCISOP3DOB0(@(\6#@;'9) \PF59%3&5&PL5F
MR+91\#*-)=C) L)W#; B\201HQ4.J12YE*<8OX"%*AV+R1QJH"$ZI8S)'GU^
MD!E##,L-+ A].53NFX\P !))/84Y-V,^!(['$'AG7ZL.A9>H4V\62S3<6*?4
MYZH0P4:'Y<8Q-C6Z'?GP)<0] 'B?(S(Q#*P&W?$/>-P8W)IC71F&#$=ZDLL,
M<:.5ECF<LVE2AB<1LC+JSU!B0Q&8_%*Z@25&,JK$D AE '/F&!((/-ED,Q^_
M/(C(T%S=K'3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7<G0!^['9?
MYLYG^U-,YQ,>_(XO[2G]U-6S:_\ :-^H?_<M<R[G_=AVO_.5>O[42O.G:?DE
MK_9X?[M:P/\ CM^LWVFJUYL56G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4K](5A*TJ4A+F$J2K+:\KPA>,9QG*%9;4A>$JQCP590M"^S.?!4G/9G"E6A
M<]LSEYN<)>96(KPLK!#5\1@6-9F&HTH>M891&(,:*FC"\YPR.TP^H4T5;K:<
MJ\)#ZLNYUH;5(87@5Y"KF0DL4+ R9ELB$ YR2,U.1^#A5V<LP8@9@ 9#/+K>
M;/B3\O&LLK>EK<GKY./QM>>:V/.0MDLL&H>63#.S=?FDS\6<)AN93)C*9/R5
MA;/PFXPX*>8/EK&,C*&KU'%H@35)G;H\<;YKK"/'NV4]9H.:Z>.C/-5.?XV;
M>-FQX=>0S#CEF#GV\^WV>S5HO]2)@U0J\P(Z!);9"N&T;(?*24=)):AG=B!#
MQV9*!P&<'%.'C#-F);'D13@0</@+&'=<'<PSKBP4RR(=0MC%:QJBLO7BW).F
M3-2^DDKQ5E9LF!.1XWWIT@_IAG))'-K &8XY=CF(.7#*JO#WG: ;/K&VL0]8
MQ*:GKH-9K:%#3*A"H^.5(N!N3+69WQA)33\J:_XP-X!MQ;B4.LK9;0TG8-G$
MT=S$6DTW4C2R<4S#-IS"'1P&2*,F#'+LYG.J;PZD;(9Q@ <^1 SRSX]L]C*H
MY>Z; <Q1\E056>EM=D"9J]B6)+JEPXP"?S8X^">3F;S%EQ@1ZG&QW7XU4L@)
MUT;,GG#KJUR+1 9\GD"W ;>QYIH+L@C:0=9J5V4 G)M)(!T\*:SUO 9IEI/'
M, ',#GR(!YN&?PUN0'4[;(TR4.$IVOV7Y>U6RW%Y;!L[6')*ZP1D!.,NK:M:
M'C!%#R)Q(&)%TPJ+)+?1'%#!+P&G$V'1,JJ99R%BBA&;1GK(9!(G_P"K(,"J
MABH4.%&H%N-3O3F3I7BS,>?G8$$?C<W$Y9\V9RR'"M')V FZRU!1;24U,&@5
M)FKPDU4XLP^39:@\24I7'2Q)*?PV^_B=+QY68(\&MH8AUUL9U0[#2<P@W*S[
MH;PSRF5TE8*A+Z5D 8(2!H' $-F0 2,R:@MJTZN 5=(*C,Y#,C@6 SS//F*U
MZYWH^Y["F[_)LL%F2\^Y,K%(;<9'6TA]*A0WT D,.H:0*TP.[Y,4T[G"5*01
MAS/C.7AA6&!($) 1 @(XG/+BW7 C,DDY$$=C++A4,Q9BQXDG,C^7#+AV*V68
MW199K;HNZ2HJNM6P:8AY[R0<:63!/R<&T*R"^\([,O&X3V!"J>98DF67%-?[
M"4K<2O&EI'':FT#2&(H\>9*:PLFK4 0@7](Y$J2,_DJ3(3)O,AGF&RXY9C++
MLY]CMU:$CU!(!HM%Q6QHI-_C<[C;F"WP)I+=<;VI*))=>JKBI3 ;[Z8U9@3R
MYIF34"MX=8?E#F'BDZRV.<T^\+;A^I-"@I^$ZF7+*7K,P-04@(5##//+@#?>
M9*ND=<-YGSY#7[7CSY9\3G6EL=0MI9N%9V NMTPFYUR)9AW)\@*>R3/L#5PJ
MJBOSC#%B8"44Q#%99R[%"Q6"'61G3$$^3M)3F-C&8I(-Y,(9&+B,,F49,@E(
MC)C+9%QGDY?+,Y99FJ[TZ@^2Z@,L^/7#3IX\<N;AF,JB8WU:,1/P-B!J?DF-
M6KU#A7DT_P"/Q5%S&)U3GA_&+P/A;X2QAW!F6_$X1CQ7DGB_V/)-E&6U:Y?R
MH7>6:9;T)H]SST:>&G//LYYTWARRR7\3=Y\<]).?;RSS^#+X*EVWJ%M-X!L,
M;9JW3)$*>FHJRLCY#GVD0%BB*P#4&9:&RW8TK4LF#C06#@)E<O$%/#-/KCL*
M\9AR(K&.$QM')*IC1HR<T.\C:4RZ'SCY@[-I9-#@$C54-(S:LPO7'41D>#:=
M.8X\Y &>>8X<U5_6]ASU2'B68#Q4:]%V%NQN'!ES89<N0Q@7 8,SY%+C#%1H
M&1EK"9:&'(86:?G!6<%N8SGD@275KZX,AC (0A <]3)FI(9LQJXD'2N8X5 8
MKEEV"#V>.7,#QXCZ>)X\:WTGJ#MSLY<K$%"U>%DKZBP-V?$.U818^419H9N'
MDD&Q;UC)CI%M/83+!-28QK8,X<;(C)1E[+6,(LH@D,9>1U@,9CUF,LNZ?6FE
MMV&4\ C%"I:-54\V9DR,2S *"^H-D",PPR(Y_P!XSSXDFI2.H^Z^1YA2XNN2
M=77 V.M/563Q9#(I4+93HR1> 8*<L?P]'C1!4/'*KS$;,ALPZ6%H&;["2?&U
M-A#JUAI%EUQR;U=V'UQJRZB-WNV+AVWA9#KSX\PRG>MS9 KD1I.>61(.7/F,
MLAED1EV.<YZX+N6;%KT#6T5ZK^15>;LL[726V["')0I-H&'8*:CS8^Q".,X
M>#!/BCLX7,BFAM.+DWVG"V2<IM4,DDFN3.5(TD'X,JXB)(+*8R,V!97 R0JQ
MZT'(B Y  R'6EB.?,%@!S@CFR!'9!'/EPK7)[9%HL-^QLHLIMBU-R$+*,F"I
M=QADVOCQXT81X3[Q!#Q#:(P5P@DDA\DPG#I)+SK[SBU7CMXXX.IP,XM+J5.7
M%9"Q8<   =1    '   5!8EM6>39@YCMCFY\SV*W+O ; <L56LACL9(DT^Z6
M&]PH)@Y?P8U,6,T>0)8='$.%>7& EC^,BPFR6L!I?)92M;#[C><744&[DC4,
MHEAC@=E*ZBD:E0<RI 9E.3MEUV0)&H9U.\;4&.1TL6 RX9D@Y<..68X#/A60
MA^HJW0K].*'K].?*HLO>Y:O$%ASRUL8V'DQ<_'/I9L3#9 *'#7' %*1B08RV
MTAT\AK#C;M7L(G$JEY0)E@5P#'_W?3NV&<9(;K<FXZ2"<E!XU(E8:>"];JRS
MSYGSS'/S<21V<^SEPJO;9L"2N+%)%E8N%:&HE;$JD6R"B4:P;$!G%R+;<HMZ
M5(==?60<7AU\)P!66WLI1AO+;2F\\4"Q&8JSDS2-*VK2=+LJJ=.2CADJY!M7
M-\)JI8MIS ZT:1S\1F3QX]LGFRK;)K>USF-M@[I2-!1-S!(B24XBQ#\1)"X>
M.8B&$D!2,G(/9:(BQVP#&V2V$NL^&M'BB'%OYQ)91+:FSS=H2''7%=8UL7.1
M55&8<EES!R//F.%29&+B3@&&7,.'  <V?9 XUX,[B+'CKA -4BCIJES)C9$V
MK88L_P %QLQ$$&$@S,05BTXG!S6U'DL.-$RY<>\&IL%P'(C+++<FU!:*0S3;
MV$.HESBU,K@!E<;K=D=:",D!!&>>9)+7P8:5R;+->NR!',1UV8/8YR,JQ,KM
M>UR(E#8#=8K9FNH8V"KTU5WY>'F<!2)1A9F23&I5Q*'GW9$]*U1S,>UD<MT7
MQ7DW@-(LMM$IG+ R"X=7D20(Z9JJJ %TC@ J_C:CF <\\R1=B%RX%!D",P>?
M/GS^'L95M-<ZA;_5H2#B(G,8DJ"V"_LQFQ%9FR[#(6<T1R.E%RY;TVH20"EX
MUUX"4%< 3DMAYY:G<%/.$*QR6,$KNS:LG@%L8QH$:QJ=2Z0$S#*V3*<SI(&0
MR %2)64#++,.7S.9)8C(YG/B".![>9K&S^YI2R5^3K4C4:0F**LTO;(9D0";
M%349>?&:'FOBVVBP98; /6RV9F,EV9@ 4O&%@CBM-M,MV2T6.19%EF+B-(G+
M%#O5C)*;S\'F67,C4I1B/QB22:@OF"NE<B2PY^M)RST\>8Y<0<QVLJ_4'O.[
M0D_K^Q=D5+&:UK!M2K0\L.:X$B+-8F U*-;!D 'B"V(^87'#O)(90@,",:6T
MYD3"EP]G"Z3Q]<HN)!+(5(U%P4;@65@ 6341D>+,1EGP!V!4\#I&0S[7'G^?
M+Y .U6$M&SY:VP]5CI6(@4R=/A(ZLQ%J$:EF+#\785YQ^&BGU9EW(?.(O+OB
M1I%B(8F%#-M#OR+K>'<.Y([=(FE9&?3,[2/&=)3>/EK<=;KZ[+BI<IF20H)J
M"Q8+GEFH !XYY#/(<^7#/GRSX#C6?G=^[+L)S,B?+M8*'V"'LT9; R4H'M<?
M'QD8 4TTM;C>!QAHD3P1\H4EQW#CKV7%+^3&EE;QJ55#D8#;'-CQB9F9E.67
M%B[$G]PR%29')S)XZM?,/QL@ ?W #^>=>I.\9<@Z^$)J%)&C]F#83<X$8:RH
MBI623,L6!J;2M5G7*@GL2[&"AQ@9,>&82Z0RW%I0^[X06:!8!O9BUL?P,A,>
MM5W9CT'\%H92IR)9"YX$OF!3>'-CI7)_QAUV1Z[5G^-F./:.678K&2&X[');
M<9W.5%U[-I9FXVPH!0/*H@<RD2T,V"ZH7$QY?EMM08[RF<2:6G'6^Q:<LK6R
MJRVD:6IM%:3=F-H]6:F30^>H9Z-.9#%<].8'P\:%R9-YD,]0;+CEF.;LYY?O
MKQA-N3T!LV2VL#$UY5@E"K.8^ 0Q+N0C1%N"D0)E; Z)EN0QA;$L?Y.EV3>2
MPM["DXSAII*#VJ26RVS-)H41J&!0.1$RLF9T:>=%SR49@?#0.0^L 9\>''+K
M@0>SGV>W4JK;KN-0B8B*B417_MLBX$U0\D<QTZLNWJ&Q!6',8I![0SR7P\>,
M&Q*C2/D9GA%,YPM:\*B2TBE9V?7^$$(E4%=,FX?7'JS4G@<P=#+F.!H)&4 #
M+K=6D]D:ADV7'L_#GD>;LUL(?4CL (P:22/7WY'$EKN4ES2!)%3MD(U6.MBF
MIFDM2S+/B@<Y:(+3%MQBI$H8=TM;G@N)=H;" @KG)ITW"( 5RC%T<YM&:$YM
MQ UEM() RX92)6SSX$YH3S\2GXN?'L=G++/(9]FM3C=R[!A;.W9X6>-BO%6Q
MZYLUT4Z4<JC<T06LLASX",/*'=:?4ZZR[X]3I"F'%-^48SX*DY&M('BW;QJW
MX(0[PJN]T 9 :PH((YQED >.50)'!S#$==JRS.G,_!S5GF]^VQB&+KC$/6&Z
M^12[#11XCR>;4/&1%ILF+7.D@O*GLF9DSIEL9W))Q)K3(X@PK(R&4N)=H;*(
MN)"\AD$T<Y?- 6>*/=(& C"Z50D9*%)+$DYY92)" 0 ,M+*!QX!FU'+,\^?;
MSX "M=KFX;_79/,@N>-L;#M;D:<;#VLZ2FX<^I2S*&)"N/#O'-D#1CZ6F5);
MC2@'QW6&'A7V'&DJQ>2T@D72$$9WBS!X@J.LJDE9 0N189GBP8$$@@@U =@<
MR2W KDQ)!4_H\^8'R$9'B,C7E"[,.K)4DY7("O1 $W7;!5IR+:;EBF9B%LH[
M0\@*:>=+$S*<-^3"/@8#DA&0RA&B4,J==,459[=9 HD>1BDD<J,2H*/&<U*A
M4"<<V#:E.H,0> 73 8KGD ,U*D<>(//GF<^UED1ED/ASWMKJ5O:'FWG8RJE9
M&M%!M,>@@.9\7&D:T"; J<8(AB>8QF)#&0O!+1/E!ISC[[Y)ZWE)6C </AR(
M#2C5%/$V13-A<L6E8DQGKR<LB,@H  7+/.^];M#\9&[/Z R4<_-V^R>W6'F=
M[VJ=17GCHBL8FZ?8I*Q5&R,"RZ)BNNR=A5:'HX3"IIR,.C1YA:WX],W&RI@*
M''&AS4IRG*;I9Q)O &<I+&L<L9*Z) L>Z#') RL4X,8V0,0"1G4&1CES9J25
M8 YC,ZLN?(@'FS!RK<JKNF ?FMQ6.TUVNPIVP]>62#Q'00-E5%S5JL4[!S11
MTMEV>-D(\(M<41Y0B*D APW2F\QL>UXPIW&&6T<):1Q2.RP7$3ZG,>I(HT=
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M!O5E>O%*.7?P*I.QD%L)3]2N8A%BC)6$E0WG1 ):(,@Y67:LL\P1E\G-V_\
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MMM,\]1S5-XI3BE>P_P!\,?\ >:_\T\AN8_(?LI7*^QNL/3^M[M8:39,VG$W
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M]CKZHG]1>4Y/1*]T=?\ H)(S[6577PG'1UI_]MM=G8VE_"NW/PI\GRN)[/\
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M=;(D1(W2&VC&2T@L2R$$:QK4W&HKTK5->"5]N/=>G(3$H;&CGX\_P?#GV_\
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M5_2_6/\ *I//^Y?L%0^6J*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4J69_O&OQ0/\
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M.0YN!['9JV:<,Q^CGS<<R>?AP)(XY'(<>!'"JTAM7_=/86D$5T6\S(LP#IY
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> #9S/]J:9SB8]^1Q?VE/[J:MFU_[1OU#_P"Y:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g899221g50e09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g50e09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1V04&AO=&]S:&]P(#,N,  X0DE-! 0
M    '72^=4 X0DE-! 0      $D< 5H  QLE1QP"   "   < E  !41E;'1A
M' (% "M-:6-R;W-O9G0@5V]R9" M($)E;FET96,@+2!&;W)M(#$P+4L@.#DY
M,C(Q #A"24T$)0      $)@=ACNY800A_I,"B3AJ+[DX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ .__C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"
M24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              &5   "P@
M       !                          $              L(   &5
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   &5
M %)G:'1L;VYG   "P@    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !E0    !29VAT;&]N9P   L(
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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M@7.W4O),N=BT%W]8V.<4'J9'VO&,B/VK3K_UAR2D;\ZUEU[#FN&TD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@! P'$ P$1  (1 0,1 ?_$ !X   $% 0 # 0
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M]2A+$X0FW*+1H^8("BNF];!Z1;I]FJU-VA";0B+/!XVRW6Z2/*6/EJ%0,O\
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M)4^-G&8Y"9M=JILPI%QY[%#@1&MDNE<=N7-82.5XDP6;3D9',%T6CXYS'<K
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M()E(_?3[)VN>";AW=/EI%>FJF=.),\NJ?TH\ #/U/5P!U>7GVV$,44D.3]*
M1AP /RPIN3G;MNL_M"[H;@VX?Z_#'@(>F PC%L4S.%W2#=ZNF9[0)YX^?R$6
M]5)RG<KF=23U5%ZJ)G"(N% (;8=$)>3=W!80=>662E>F8AHE!GYJSUJ).UFI
M^%JU=?O%G*SDP0M-B4(6"CFI53"5JV;LVZ9EDT0*5PY SA4!4,(Z)H,@[#*2
MY]5)FB*C/'5Q69.X4J# 6K&7#=D'B$D)F=8QL@E32-AC*HS5E8EF=U85#N$W
MB1I)-^JUA1;(+(FDB)@].W:]HJ4C/_<*>.>PW-LTP^'[C2SWGK,4!27W!7E?
M"&/B0<[*7&]Y;E:NW,W=MD$@@HVM,*]+RII)=Z[.<KWSD$ ;-R]J41'< :=]
MYR^BI#?W Y,/7/N=%I%HHC1$:(C1%#=D^O9C'^"N0/\ ]O\ _;HBF31$:(C1
M$:(C1$:(O6LIV2*JNV_9)G4VWVWY"B;;?PWVVWT14XPMFR2S+?%'J\7Z 0@W
M4[!"Q;R"[MN]!H5?D>JE.FB0J@]GT)V9N7?H<=@TTE[VR;([_8J'+E;>XR,-
ML#O97),<A-N<Q2\P[%YC 7<1[@#<0W'W!UT533O<H[AZI,2+!8$'C9 AT%-B
MF$IA72((@4VX#\4PAU ?;L.EKV<>I90P"= _1=<*[7?U2,?.C]JY=PC5PX4V
M .=95H0ZAN4   YCF$=@ -M]@ .[1#-)W!U^S^G)07&6A_3,%VVU11&ZDC!I
MS\@S(Z(*C<RR#@XD!5,ITS&3$0'<H'*(]=C:#OOV4I)+QI!)XEW#Y]W*5PUV
M^1O+)]<YHC5"2L$/'RT@5H046B:ZX\RO8$.HJ<B0;"( 90VW7<P^%(8D?3O]
MU9<SJ UF^ZA5WE&DYFXIJ4RQ9E1I.Q"%,O-<FI6A6!H_] SZ""R:B9^4KV/0
MF6)BF.D5XT<=F<@B9(P )= S5'1FZEU*BQIW/&+3.X[A3%9N&A_+67"5P/>Y
M2TV/#5ZM%R:SUU9P[RPR;*<Q[.TYM622<5&10-XQ!]*-Y98!3W76(X,H8>9$
MB46M?MW+Z*,K?PK9)RO'V*Z7VVUEMEV1@,*#41:QCIQ5Z9.XHO49D]\T!N*Y
MUEHJX6Z&B$YXS4YEQCHUF5$ZBC5(Q@[VZ(PD,""[EI(,,;Y;P;;0%BOR=V4,
M%3[FY4[)=:LDM\*)O-Q8R4@G#-%QG>QTUI1)% JQ'0%1QNG%(*/6S4QQEB.U
M0((&3;I@H2<\G X7VOV4V#^2VO9(EMYIEZO)SM7@7&.Z0=Q6G"L:GCB<96YK
M8 L*0+BHYM9#W624C'C0P,MF+5-< !PL9.9\?;OW5?/.^5W!T[ZO.'#[Y/V1
MPBXM$>KD%E/UEOB2UXAQXB,4[;2C>&N4ZXLTG(6UR@\;F=O&TF[<-&A(QRWW
M9=FN*R+HNVJID(#@N_*W#WX.#72E>22GXF(1)9\HPS^9AHF6CZ6LTB7"H4IP
M[M]<L;9_$R)4(IPLN#>#5;G479 Y3,[Y573XQ#.SPOEM[SZ*DW:QD[EK[=[,
M\TO)2LH^2>SL+>X^+GWC:(3&6;1K]-V5VD[R:M87?:E=B(JV%M>8EJ]-R\RB
M4 DF<>3LBA=>XW]5/WGI^Z>M%\F@QJ&0H+(SN\FG)9EDIQ;9J.D0DGE>FJXZ
MP$RPXK"JUYZX<PI),LDT"P$F2,2O3ME%8]5P9)0Q=%7AF%@/5WXF1_#*P>*N
M$QQ0([ADK\K:4)JM<.M1G6#:%19&:,IBZ/6S&+@K25N4021&OPQI]BT;G Q2
MC-**%*4Z1#%(2Y)U+CJ3+-MM<2%=711&B(T1&B(T1&B(T1&B(T1&B(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T158XT8RKR_#ED&/N6*\DYIKSA
MO' _QSB.3=P]^GP+)-C)D@Y%C-5]RW.V4 KEP9.5;[MTU"CS@(E$D@@C(OTX
M@@K(C@.Q(,?QI5F^87X1^);AYQ5%8OM\+DQ]Q$9"DYY@^F'KA U<^!\2\NUG
M44ES+%%&255YD4V(?4T$% ,N:2]N^1.VF;$JDQ>DN1_;(L\L&A]9C-;$Y$XB
MDL?Y[PE@US0[*]#-"UF0C[VF>.3JT4ZK5>D+ O&+<[STFO)KMV!A*DFP\W(D
M?M#.>8 3&J'[>I9U7/*?E"&&-LIW.E!C62E:E3)UYCI[=?2[)L"N6$\<2N46
ME>+#[J/@@EJ_&I-5YT"&[&3D6J96QVZ;E9%W/?\ *$'O,0"VX=SP(NO3PD^4
M$A,_8VLF5KXXQ/2:I!QE,?JFJN07=M?P[BX 8&T7:F[F#B21;]-8R+8B;95X
M51<'!1,4J/,8M5  M/.'T(V*3LG>4LIV*K[D9A8*'+KXMQW,V"BNLA,)..6<
M2V2H#%K/+RD P@S+%6)$/*P[%FUG'"J2(335=%9--H*3I0H*269B3D'<2T^^
MC;IV</'$S'\2-@Q[?EV$#7#Q[;),"Z;1=LB[''@JFE7'*/,[;J).6+KS=5,'
M#&49LG150.= B[04G!RA<&T-N_1K>N2OOZ=A/LO&?QYK]]T1'IV$^R\9_'FO
MWW1$>G83[+QG\>:_?=%'&\['/DCT["?9>,_CS7[[HIYJ8F]H/V1Z=A!_SO&?
MQYM]]T5<;QL?MWR1Z=A/LO&?QYK]]T1_M8KT.YR%\T=;2\8/Y76_V\V_X,W?
M]4'3BCW:6RMD^:S7X,'39M9;&X<.$$$!M=F^KK*D32$#@[ @@HH8I-CB(;=?
MC"/3F$0UHFD@ ,XO$@Y9#)_6Y8H1;CK%WD//2[.I1G\O6.P9VLN/5GD8-3J;
MF$DHMPR(8CH57"30''G3TKDR2Z11<K; "9"E'EW'XO4! ,$^9F-I);T!&N<0
M5*@#F00[-?(9Q)+!R)&B1.)RQNCYGQ!'Q4\Z&,=QD\,@Q82JOHYT8A"&2\]:
MMUA;+F*8.9+S@A^4P"8NPAN,I((JL6 (A\QQ,CN25;N^8+:Y!P[#4/NV93YX
MA,DS=(PG2'M+LR<3,+S%5BGAVAF+EP9@XCW(.VRB+A-R!"G,D0#F!,JA!*&Q
MRCW@Y=A+/$M(G4C+MP!!9R1[EN (F[VZL>N8D&1>&:_(+/6A'BL'.'[ ZZ15
MCG5'F*)4A,!S"<Q]PV+\81#;;PELWM('T0<[N7?]ND-F,DA<)3YFSQTW,\=M
M6I5*<P @N%DD>?9$XB!14,'-L'>4.[O'J(CK55^+]';0,UINH"'J (.K.)86
M<>KWZK&GR1#IJWS?;W"[A!!'UI99^K*JIII?5 ?\FZAC%+\?IR[C\81 "[B.
MH/TU<1)8W);/4MKLM5WISM[!Y/!VO8W"^FCT["?9>,_CS7[[K+@7("(].PGV
M7C/X\U^^ZJCBV8EF/V1Z=A/LO&?QYK]]T51Z=A/LO&?QYK]]T4<,^42QSY(]
M.PGV7C/X\U^^Z)Y@SY:L?LCT["?9>,_CS7[[HCC?H?LCT["?9>,_CS7[[HCA
MP-;<D>G83[+QG\>:_?=$?+Z';[W1Z=A/LO&?QYK]]T1^.EC]O6R/3L)]EXS^
M/-?ONB>8,[QSS#^R/3L+]EXS^/-OONBI+(].P@_YXC.G3]?-?ONBC]L=S]+(
M].PGV7C/X\U^^Z)YA$WM![R1Z=A/LO&?QYK]]T1QV#F6'LCT["?9>,_CS7[[
MHCAGR9^2/3L)]EXS^/-?ONB.#KGD<N2/3L)]EXS^/-?ONB.!ZFQROW]T>G83
M[+QG\>:_?=%7;^"?9'IV$^R\9_'FOWW1$>G83[+QG3_SYM]]T1_IZH].PGV7
MC/X\U^^Z(CT["?9>,_CS7[[HC_;T='IV$^R\9_'FOWW1$>G83[+QG\>:_?='
M;WZ*./;(YAQZ(].PGV7C/X\U^^Z*O+<T>G83[+QG\>:_?=$?TE'IV$^R\9_'
MFOWW1 71Z=A/LO&?QYK]]T4>6SX'WLCT["?9>,_CS7[[HC@^HL<KH].PGV7C
M/X\U^^Z(_'H4>G83[+QG\>:_?=$) O\ 7O-'IV$^R\9_'FOWW1!4#:>1^R/3
ML)]EXS^/-?ONB.-^ASY2CT["?9>,_CS7[[HJO:C+Q3A0J*$DP66.(@1))VW4
M4.(!N(%(103&';V .BC]]\4H:*JA'E-F&2)3@LS!&XICLC35M>M8!N$#B=BZ
M?7NP0)[%&#9X*%%@HF_9*2U?"19JR+,179I*F4 HI]H(%0'($3J6%LSQ6('#
MS?H[AMXE:)D?AY\GAY1W&F-!QM)5O,%+<4JPW0+];GZC<L/*J1MBNTDS9>A7
M!5'KNQ(O63I[OV Q*9.8PY#/8R))=HB^HZ'4K9\Q#&JC]3P1.19H C,@BX7T
MHV;%53RI8,19-GFD]%V+&YIFPU1L98K!U%O;I4W5=DV\PTY%@%XSCI-=/LBJ
M!YL_2 W.H4@E-I<O1V<<"X>]CIORK>\\G=A*5MZMOG)W)$ZX>MG;F6BI6SI.
M(F9N3JMS%.+D221+')N5K>UJLVZ@VRY72<61LDT6/%J/6B#DA7^>_M9<2'DY
M,*OL5*X6OUDR)E?'+=I6F=:K^1I6#G4*62JF*6,5JQTZ\T.P<BS*,:Y<+"Y5
M68'50$Q>U4,9DWO/755R[B#J(N^G&PC9=$EY-SAHD[/.3"L-.-ZO.Q+IFOB^
M/DTX_';*<=T=GC92XQ<,S:(NH^R)T=@U@&ZC>0)&MD4S.T(TC]55T<HYU[O[
MRO=0^%S&N(LAU*M",MD1Q;T+S:+38\CJ1\_.3LLQC:S"Q*KP4(UA&)DAX1HT
MB(\C..;=FS;D[455C**J3,#B>C??=/IUE_3VYJUGJ=Q3\G5-^CT9^#ZJ(]3N
M*?DZIOT>C/P?48:!5SJ4>IW%/R=4WZ/1GX/JJ(]3N*?DZIOT>C/P?48"P Y*
MN3<D\T>I[%7R=4WZ/1GX/[M&&FGI;W4<ZWNCU.XI^3JF_1Z,_!]5%Z'6'\5%
M;.3%QW30$$%A ?@]&=!!,W_F^HPT#9Y6U0DYDGU6?7!_ 0LY,62&F8J.E(@;
M78@&-?-4'+'9L#KS< ;*D.CLB)2BD $#D$ Y1*(:T6SS&CZ:1,^KN5DP0:=@
M?O $AN0RDE=*4!"1?%1D>$CHF.8PQ$8!N2,:M$$&!45TXT5D@;$*5$"+"8PJ
M%Y-CB81-U'K6>D9AV9P+N\D-D[2^SJ$2187B[DWSX99M A6XCJI6JMG'#B%:
MK\1!(N8ZP*N4HF/:L2+J)I$%-18K=-,%#I@)@()]Q+S"!1#<=X/[I 'E'*>V
MRC):+L1K!V'0Y@?PEOBHIE1B\(TB>C:U",9J0M%2,\E6L:U0D'9G3!VLY%PZ
M32*NJ+A4H*+<QA[0X<Q]QZZ""3F<YN)#ZSJHX8-9^$,=<F'21DGI8*;4Y#AU
MNUB?5N$>3K>"EO-YE>-:+22/8 4$!3=G1,N042@ )<I]R   40TN7:;Q>-'-
MVLE+EP2"0>_;0$:9I'X7ZE6+1CA@E9*]#SJ;.I,EFA96/:OBMU3HG*<Z0.4E
M.S.<-P-MMN'0VX[ZM0DN07.F=^O,G64>:OO+-WGGDL;O)+5^"FLR7&'EX>.D
MHE3*.52'CGS-!RR,#8'PM0%NL0Z0^;\H=C\7=(0W)MMJ?VG2(X^]K<\EJHEQ
MP$<@_!K[P%]#MIH^(*JE&*N<8U-R$E(I1R94*_$@*9U"'/VAN=$NY"@380+N
M.XATVWU.7>?W/!0EM-9+"&V.J=08>Q2( /JZIO7][T9^#Z*H]3N*?DZIOT>C
M/P?1A=IU1S9XT7#)XPPS#,'<I+4BAQL:Q1.X>/GL+$MVK5 @;G57750*FFF4
M.\QC  >W2Z.WMWW9-JK5O MS6>%KE(I4HU:$35+)M(*&<1KU%40 BS%V@10C
MA(V_0Y=BCUV$0ZZ&(STTXNCY?0^]EQ147P\3\^2O5^HT&?<#YT5=W#15?D6#
M)RT*<RS-XLV$YD'9>0P"B9,3 (;&V'?:L1+:3ZCO)1WB<[N-'(]!EZ)]K8EQ
M&W(*B^/Z2D0 $>92!BR /*43" <R ;CR@([!N.P#TUF!9@JY-RZSIXKN(G#V
M**O5UL.XOQ_>;)-6^1@YXJ]02<DIL5!TVV7I_)2\1^9;X0?P]0>'CR]LFJO'
M.$YB.0E"^:,WU5O<V$"[R&%X:?LJG2G&E(%M4E56.$\&Q3JTR4Y)8KD)^LI_
M!N0QU7(G)$RI;'\W&R3M<RTV./C0S6&E8JLS$>[DO/%H]PW;E*M+?L([X[!#
MK=K\2=^/,NRFG,?%;5:$K1IJO8%Q>_KQL3TO*5X@9"*0^%DF%ZFY>MM*U44V
M[;L492$>1(R;_P ^17%>-<E $D#)<Y[?+OAWR:0XM;7=R_10<SXX) LM(PK[
M V G"]3@ZIDJP/H^.7-'SU,NCJ&:1]'KBIVPB2_0QYDJTLNOVK0R#50Q&28F
MV"1TV]D.5_F?0V<S(T=RWHK5\3_%-AS!EBR)C:*X=V*MWK>/UK95K%8JW5HV
MB6>63A5)\T'$N'4FPD9QXV:(*-'[.)07>LGBJ"CE!*/!=XDBP9LVMPMQ?]TI
M^8@DF^[W ?:\$_LF:OQVX%8R3&KN.#FW/KDBZ6BK/!QT3B0OH"6)8J)6&R)G
MKRY(1[Q*0D<AUY1NHR>.01;G="Y%([<2F19KC:T^GI(U0 F=)?>'YYJ#+GQR
ML;(9JMAG M8:I.KM.5UW%S>$U[Y98=&M8L7NDHU]#T.RNE)4Y)M@^9.99N=!
MFS8 5<J+DA!7.@9>B7>=#)O+2YN+YQ-E8*J9JGK=!NTU<+<,M3FI'AGP;G"I
M3,A(JR5?D)#*4]/0<M&.$TX-F*C]!S .VU6K[!\[-.OE&#929:F>F!O0. SY
M]+\64.=RQ\LC3GN(#]&>Y7"R3'N>,"8YRI.XMQW&3MIA?.)R,B8)N=E'RS9R
MNS?LR%>LDG2"B#A Y5FRP*&;J<R/;+<G:&)UBSZ=2K!>IW%/R=4WZ/1GX/J,
M- JYU*/4]BKY.Z;]'HS\'T8.[!]<U$>IW%/R=4WZ/1GX/JHCU.XI^3JF_1Z,
M_!]$1ZGL5?)W3?H]&?@^HPNP?5D<Z[<M$>IW%/R=4WZ/1GX/JHCU.XI^3JF_
M1Z,_!]$1ZGL5?)U3>G[WHS\'T^J(]3N*?DZIOT>C/P?1$>IW%/R=4WZ/1GX/
MJ,- JYU*/4[BGY.J;]'HS\'U5$>IW%/R=4WZ/1GX/HB/4[BGY.J;]'HS\'U&
M&@Z*N=3U1ZG<4_)U3?H]&?@^JHCU.XI^3JF_1Z,_!]$1ZG<4_)U3?H]&?@^B
M(]3N*?DZIOT>C/P?48:#HJYU/5'J=Q3\G5-^CT9^#Z,!8 *.=4H1>,L>0CYO
M)P])J\9(M3<[9\QA6#9T@<0V$R*Z2!5$S;=-RF =NFJB?&B*A'E-*_D"U<&.
M6Z_C%I>Y6V2"5;*2!QJZ38V^Q0J=FBE+% 1[\TC%*QZ<Q"D>L'+YN\(LV26$
MY2+% Z1B!G#YG-VL;L_L9R5'?)QT/"5;S:F]I' =Q4<.EM"BO6[W(.8,@/K3
M4%@$C4'\4FS<Y+LQ#R#Y8#*-G0P:)N4HB!FP&$A3@V#<2^KYZW@" T*D&/G%
M6P#?_0>ZW9T41HB-$1HBAJR?7MQE_!6__P#R'^_38?:/AHBF71$:(C1$:(C1
M$:(N=W^M'6W_ (NM_5FT4-CG"S*X*^MKL6_[J[2/4._XKSK]H>X>[N\=M4FP
M&C/KF6ZD;L39#8#0@!\I?ZL\WG-=+K]MWDK??I\&1\1_R<7U#PZ;==_FVW#0
M$ !WDW)AV@3#O.K:A0R2UP&TOR=A<$<DO\58"&=L*#T_Q58O;O\ J:8#L #X
M] Z^(!L(=^M#]-1<1;5W'NW49!RM&QG;N0S7N[6NG!Q<;?D>\>;[!^>:E]X?
M\6/>@> #[^[4H?(RU];3L,_2799,@-#LT_8%QM9D]),/T+U]#_B&;VVW#IM]
MW[NPCMU -9[@-Z.>KG4H,XSU!>;G<:90D3A"#_!XA_ UA[O\D?\ ZMOFVUJH
M &+:,S?S>P>\W4#?,'%SGDPXMOIR6,OD@_KZ6_Q_PIY;#IMN'20'Q^UOML(A
MK(S?N8X[]<F6ZLH?]/* Y[S8Y+:.ZY=<V/,$KBA2&0;-J8]AI5&8*Z.=9X=X
MDV R)VPIE(D4GG>_,4YQ$2%#8-QU?*6!R/\ #1UX;K!EX+@'I!?J-<C&2ND7
MN#Y@_HU%M)<Q.P]?:@]FY-C%-3JE03<2#I%HBHX.4YDT"*KG3(*JA2'$A.;F
M$"F$ V*(@10=ERRL;7@/(TK'I.$FQH"6;@5R5(J@F0'LS' $E52"0VW,0>?<
M2B B ;[:H@\CD]Q=M,^"@(-C:^TYWTG^%%O!?^P-@/=^=N+Z;;!WCW;A[=]#
M^HZ7>V9>+J1YC9] ]HN\<F?=0_P<]+M:>[K=+6'0 [@%[R]_LW^UUVU:KEF:
M':Q+%N$'G='^801\O&7O%H ^ZB7/?&"I=N+%;A3:U!U"JXGL],M"]S2G^U)/
MI2Z;5(8XT.1B@+0J?I,IQ44?."G[']3#G#ERSQ=XTOE]%K('<AN!$Q[<CM;O
MC+RAA#&..*T\RSBF(R]!66Y-8AA7W,?4W<<UEHR*E9D\W)NK2Y:1$<VAV$._
M,J_<+E% 2BB(E(<X@5#Y9:?LJ67'B3X1H>[7_&<WP2HR=RLKJ)M#F#1J^'9+
MUDLD&F09IK9WKM*Q*L4E48BA6:=BDYQPW=OXV1BW3<H&F%2)-N]NL]$F9AM3
MLX,;CL!2AD/.O!SBVUTJ\/<&)6;TI7HG-K_)2=:K3Q3&D3?'#VKPTR(3#U*7
M06DG\2XAE&=7;.C-@*195/LE3+"4O&OKMS421G%OP7M7K&%+P=>AI&G3,=EN
M2CC4K%P&I$%<58]I"9@*9I,K(JN)Y>48(&;Q1W%B;F4,+QHD1+F%%AERX*BF
MIKB;,\WLXREW(R:ZM%Q!9AX(J-<\H2]WH]0ON;:)C;T_;(U/'"TO9'%/7BS.
M48MU;G=?4KY#O(4JYVT4\G2.7+5,[5)L=0Y4#N^^_HI,;VD<+._-FW2&OQ8>
M3B;NHV>D?@HVG[,NX=*$/@V].K&E),)RH-URSC1IC]Q)QCY.Q'I1&PRB3<[M
M\6"68&< 5HJ!5BUC8&^4L3/'CNX>';;QS\&6,E&$SCC$M"L#5_<):+8V-LC4
M<:,DI%QC5>SS#U^^O+*N'CI5_"*/*XK'KAZ1=.16CG14N<Z.G??JHQ]-SZ<8
MXYJ58G/>!,B5"P5^'X4I*0;1G#9BB_.Z5:*SCNK1KW#MCD)YY UE)U89II"D
MBJ4]83;YRQ771B&#OSE2,66<"KL4((<!LQ>QX-SFZN5PVVB%N6$L?V2M8Q?8
M=K<E")*5_'D@RA(Y> AB*'3CTRL*\Z>1;1NX;D(Y;((+ 8B"I.U33.(E JIR
MT1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B*G7%-PV<+V5
MX^4O?$@[3@X-I2%Z#+623R+(X_@6-6DIMO,*-WD@G+Q4:T76E4D>SD%E4W0
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M6E9AHF;#6)NSZO9KJ1N)RY6B)RQBNK1LX_95ZP1LR::B4%SD9R0MRE.AYRD
M\JO9F !*)N@"'MT =]C3F1<MEL]XVT',O;T8:..^2Y^+G]KMC_\ A13N@!W[
MQDB&W7N[_P"SWZHO-R(W)&=[YF\O"@D<ZLR,SF.]D]9,=^%R^;CT]"3'3N$
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MT.Z "]50)%+?*+D%YB8Y7X**^$7BYXB7/%3!\.&6L\\/?%A$W/']AN25XP%
MJU]UC9U7EDRIMKFS;F6C#,)TI^PC5BK%<"Z'E$@E .9FU]\^< =VN5DL7(!
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M:1#&UJF ;_"BS5H',*X.:1M!VY5)4LD=ZVYE%?-46X&*!"IGCF3+CKWU=^9
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M=]%-6B(T1&B(T1&B(T1<[O\ 6CK_ $=;^K-HAL>_=9E\%?6V600[OA7:0_\
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MA_AU<^NW4=U76W0>[8>GM^;6B29:"!I?W B)ULZP2'89,2(8?,&9@,CND]\
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M<#D^*"@G'<1T1)( #BDEK6:;R;R;*$R) V%S(N]K&!!@7A<*!;67BKR$$RM
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MM.P[;7*V=/;U?>\?#</;T]FVUJ#$C++: 8/,N-^##)'"]WD1LP;WR69=Z_\
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M>@/4>@=P= U:_P!1Y:Z=/5,P\%LLPXYW<6F1DLRKUN/E=,VA_P";XS__ %P
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MW<NX1VZ+NN_?J.X]0[@^UWTL02S$,^[V]"&G4,&"E0(-.D-K=B?0"=87 _\
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M!]DAUW[OM=^@9B,X('.3_*W5R_L_^MHOO&>:T^D?VW>3-@ ?RM6^H]?\E%>
M=?YOM[:DEWR :<G;-AF[!_O@@-HY/JVD\-3#D0%_BM^OQA+H(CZ,L'LV#9(H
M]1_OX^(]-!YT83_V&K#J6ULJ;?SUB_"'2]Q<[!PZX_\ X44[;NW_ ,5R.WN'
MW^T-_#5,5VAY S!R[S4%I_\ )PSYEX9^'W9/:4W_ "+=]$>_T+,__P#']_Z.
MFVLR-OW0/;89OF<^23."_;X!Q_M^#<7OUW#Q]ON\?'WZ&"SVRR$FQ[;BJ+GI
M:<FY2>L0H?X.0_/M:1\ N=KZ?.+T.GLV#O\ FZ>.E5S#2 )V)L-9]=5G^[_K
MHQN!+^D+,J\_^%TS;U[V^,]O_:0/3^WV=X=._3/IMQ6\N9MRO:PXSDM9N*P-
M\SX)]S"W=/ ?RJVZ#]K?P\-4?HKEH$\\M9:-5<CLQX9?5=/%R'Z'*A!U_9'3
M0\-]O1DE[-P[ONAJ4AR,[::B[](EV4IS9\[<9=WB[Z\$\9K]JI>_]32?]<B'
MAIG/>V49;!2F1^I]^5NMM =$G<&&X4Z-]GP3B_Z_;^S5J@FUP=\_W?DHWS'<
M'_ZA1;PC#M<K#UZFO=R]W^6= ( '3I]KYNFH6W).M[-S!/LRA!<%F$ 3'ZJ<
MA;@=BN%]N'&1D3;Q90 C_P#>A0]_A_UCT#;6C%(&X/5_H!V50''_ &)X,3[]
MYE4E\KH&_%OP1[=_H?*O_1(<??K-/Z@'8$5?0?5:,TGC3RO/*ZVUX?/K(XM]
M]*@1^ZQ2$?Y]0R2=471G=\\C</Y!?1[I=D]:UMZJV=-E!2<(*E O*HDH78Q3
ME\! =PT$D)WW=09P=2+Z6IS61DWCF0D'<#&JNGCQ4R[EPH8X[JK*G$3'.;N$
MPB(B(#N.M57,-);@YC@)4SY>D7U(^O%1+PDC^?FT]W[.[H'L'J=YMW]!#8>H
M]_?J%P YR?U.G7FH0'!;(YW(+@\F(XC@DDW[<7)6X^$%X=?TT+]KH'3WZHLS
M&9:Y+.[: $R)9U"2Q@02)B-3F>6L):XHQ_1&X@ =MO@U-#]Q-YO[>@[AW>SQ
MZ:M/Z:^%+?\ R'T=:(@G9CD.?KPEE5[RQVP<&&!M^OZ(#$'N[Z];_P"C?W_-
MK-4N19QF7U]6<OP2C>XHK]"!^WU5[. 7ZP3 ?;/S?3Q_7([[[>_?^_49IWF>
M\OJ;LUA]^^#*[&B(T19DN%EC\8N0D3JK'131@3$2,J<R)!YX;J5(3"0@B FZ
ME* CN;VZU'E L9(/,N^\1=RRAG1G#[[:2?YR*WQ4[_D@L*]^WH.Q[B&P!MV1
MA'<1#NZ!X^[Q'06+O<6T-_;JV[C<Y'RQUE]A'!]U6SRR.WY"S#6_?Z_L. 'S
M^@[7[/\ NUG*+.+6S;6)5$ES=CU;[LKI< 8[X%:^ZPS ?<6#QU2.!BXS;Y7S
MT6:<[W><G /U5W-1:1HB-$1HB-$1HB-$1HBQ3\K]5L#X-X>LI<2Z_"-BS/N5
MLE6+$>+K :_$=LH!\DO+JPU/G+]+ME2^95JHNW:9%GX^;)MDW:7G;DK4@B6'
MOWZYIWW^RJQY.'ACS;C[B:I%YM_!]Y.C$U<+7)XZUTP!>FM@R7'#)1B1FK>%
M:-YZ2!PU=<P)/G!$#)>;@!RJ%(8IA#:V36^W>ZI=KO+F "V[ #C)DYK6G/=B
MRQ5^*_A)"$OLPSQ1;)7),5>J*PK[8T8Y&$QU/3S.:F[$7MGW9).FJ)&L:*3=
M#MR%5*NHKLD:J%I?_P 6R%_HWM=XS>S!Q.Y@G,]WQSC/)M[<^>3DM&T2C0[)
MVG4'_#ZGA*VS#W);=DO"E4"79Y.C3-$YH[TKDCR,8QI61TW0 K+]]GE"L-9K
M,<W<.-)=FX9RD_A#XM;_ (MX9K-D]<)[B1R,E 8I-+U"%O\ ;;G+0BTR MI>
M2L\=/5>#+6')7CD4%V<*:4*9_P C=3LFZ K:#D3F>6:II:J152&+$L7W#9/;
M-KW2U9^(_-DAQ%WLLM?LRXQ<*V*P,WN-X^OC-ACWAP-P\0ML3R5&UQ",<-Y"
MUP^3G*[)&23DW2QGR[N**T43: !'7A'\^JD,(+D26L7@7S T,N.$R<$>8+7+
MO%']@F<@Y>C*Y?\ +L#2;$!7%L7E*@NUK3Z-5BYI:.A7LPT:"J="4.[CT#Q$
MJ#B+(99)N50U0O$,_MWUYNM./7 ;Y-,I>_>I./N=%1T67X]#]D#F$WAC3*0_
M\TW'WW4?8V?]HS53;9<2%:D;%*5)C3<CN;)"MDG<K#IU1T+MBV7[,$5EB]IR
M@1054P*(&'J8 'KJY/NW8NHY>W-[#*&=]O6[.7UP&VW]6F4OF&I. '^N_P"[
MQT27[^WU7@<PG\,9Y2'_ )IK_?M.^^^*J S";Y-,I!_S2<?=_5O[_P ^G;]_
MPH]OL?M[LO0ZS 8S9P7U:92^,W6#K4G'>*9@V$05';Y]$+[;N6^GV5#N$>?&
M#?V2:"&FI;:U6 ?140Q,\E_RR#D-O,R"!A%OS_ED-_J?*81[M"+'CD&RYOPY
MW3S ELXAB-)MW=UT-IX9/B@R1-^AYMCVC:!7")D8\S68 4"QQ01,R$QC@LMR
M[H$ 1[0#%$-M]:#"F<S:'AVU(=]/H\J) AN)RD;:/Z#-*G$':1M&;\/+_!ZR
MP'FT?/I E8XI2,6<"=(!$[8BAC=HFF! [4Y1^*)R@.VX;J;$Z-PN#MIZ]1Y7
MS<W@0PN>39I7XH[D,MANF0'P7MD?YA::J'I>1AE&T*\\U9/$@%D_,<2+ XW[
M1L(%#M4P,8-MMAR [B,[['++*"85=QQ$RS B9C+JGM8[B+#A_NM=^"]L>><0
M,H8)MC#*.()(7 %,/G#\# 1(&^XE7W 1(8O*(@(AJY@3:/H!M.;:M=@RM.3P
M(L,M\LRDGAKM@U?&\8<*W9Y\7E29(@2N12DF=MR(G$#NBD.7L4U.@$,81W'I
MX#J%W+EY9\V&OK_+J6=A >Y890+QO;=ECEY)VPFA<MW*7]"3LIR91RD88R)C
MSO)8?.O/@$"M"B4QA; 81= (AV7*;?;5#,>3=1WL%NIY;2F#RCC^^4+4%*?&
M4XH<D37H::CQ.P@E0BI)D=K+E[ L:7LSLA$QBJK<H"B3F'G Q1 >N^@#YS :
M&82YS_4P&3OFLDF ;%[7>' USL'MLE/B$M/PHSAAQP->LU?!JQG$NRL<6>+5
M<]HEOVC8ASG%5-/EV4,4?BF,4.G, C06%0S@]#Z7CGHAEG9]#.1MZ96=*O%)
M<AE,+T^ ^"]KCPC[16-IF2B%&T*[!JP?I +-\8PD6\XYNU;[% %4@,8!V#J#
MFH,'TY, [?0,^R@8B2V9N U1>[-GQT3XLEQ%AP_W2NA6+6\\Y@I$?3;&'4<0
M*(KE3W%Q( <")]AW+[E-R&+RCT'?4BU\IW&^0Z,,@J)V-]V=P_&7YI.X6K<:
MK8_A3A6K181=5^/3Y:W%'DSMQ3#<#N2D.04B*=Q#"([CTV[M#<O=R_%U+&J7
M#/PCF9O[/*B[A3GQAINU30PTW*"%PL)_1<2P.\EP%R9V AYD42FYF_-NX 1#
MLN4=]MNNJY+Z@7O%+ <+2QTD@I'FB[?4=>68(.V9-EL)I/RK.;IKT'/,?RGC
MQ4(J0CSMI@?-U($H$\Q$3'[1?8!;DW$5 ,&W7KK N^C7L6R;WB<S=J8IBYJ+
M;V+7],_0ZM\05L&TYAPLI\'+/7_-&EI2Y;)$J1AW7:-4?CM2*&/VR:7*';&
M?J8G3W[]:!^6L3(&FHZ9MG".SV):VELS[Q#POWQ27$TGA.HU\:O:V'F%DK!?
M3,A$*-H1T#1B_2 S-^)A*OYP!NT;<I0[4A3' =@W&"]G:W%PW'@@,LSWL^NK
M- O,&&R3RM-P,QX>+G7/@Q:GGG$(\,,VRB%5X%'ME$!$%Y$#@1/L?TJP<IN0
MP"7Y@,]QSEFU*@+O8B1,WU'[Z0N/A;M@U6C03@*[9K"+JLQZ/85R+4E%VXIG
M$_:."$,04T3_ *4B@B(&..VVXZ5/YC$P+\L]IZV0#/06:T"U],GNHZX79\8B
M6LDT$--R8DN]I4]$Q;!1U+CYPLXYB@S P&%1OS"+@FX=GRF$>@;ZM4&Y-A#"
M&X0 9;,&-QRUNQ_]P,^PZ:E<*,^,GQ5Y!FQAII@)HV(5"(D&)VTR MU(@ 2,
MR$1,59;LP%$G,(G Q-N_2].>6]O/Z>RLLPAR[_\ RM9V)S'JJ+^5*MAK1Q8\
M%ZWP;M%?\TBLH$ MCB5(P[GM6L7\9H4YS]L5($]UA 0Y.<@" []<@D$$?Q&E
MM-<[*N#2;WI8,;A[Z:RW1;'X1R@:*Q'CF.''^1GWF=2A6_GD?6%W+%R";-,H
M.&C@JH NW5  .FH4-CE, AOXC!(T+*/I/5M+L1S7YS;E \MB:_1P8^R,P%W7
M7J(/)&M+-F+?F OU5RX,J((I%[S'$! /'8.H)T'!X]@KWGEW]E%_"M;357'\
M&<*W:+!YW L" 2N1)Y,S;D$1YG($.3LB'#?LS#OS&Z!W]+5^H\3W]^"F9[8,
M/J+:,>,?<,-B&(G;7-A!STD(7>TG&)C(\SJ9W=J.0$H,BB!^=MS;NB\Q>R A
M@'?80U'?2"V<WDQ>>C,ZA'S [?5MW#&^L%)<?/FD>*C),X$/-LQ,WB7'H=\Q
M.WF@[ \.'8&8B(F!=;DW13$P]H!B" [#TU# 0SNP?=SHY[#$NJLS%WN[R3'
M"(:^>:[\]6<;1Q!8H=C7[' =A RZ (6.+4C'"X&3?;J()',8RB10VYS@(<HB
M ;#X@8J!>6D6%V?9]'*IL8>##/955\KW<1D^%#"U?^"]K8!'\0&+!&9D8A1M
M"/ :0EK1 &+\QA(N+H5.U;; ':HD4.'0!'67N.;O!^K]YPI=[WIJRR<'.T-N
M,G5W."O( UK"C&."F7B< )J65\_@(%61CS=HOS"0K@AR *J6_(J3;<I@VW\
M*YD.[:2K<!F VX_X-,I;> _!-QU_]]N']OAHDY>[?0JMN#N(:^V12>6LS20L
M39G:)UBA&0\$4\ZFR;K."M$"MD3E,91F!2>> (&,4"' 1 0'5+ $B6AA.[BT
M6&<N+A1R2ULYS$.+'5KW;(J&FE@&2XK,AS?H><9&,PAU_1#]@=M,!YNI#@"(
ML1,)@75Y/J*?,/: 8O\ O]5_D&H<;L3IO EM,RH0XY,S9EI?,"]K[A*F?[2-
MHSUA]Q\'K+ @VAY]'L+%&*1BS@%$E/JC9(YS"JD0 ^JGWV()B[AML88+'N>6
M@\VWUI8N[ ,W6\]B+O"K!Y7F[#+<)>)X+X*6^.\RS]B@WI:3AE&L,Z\SB;0D
M!6CXQQ*N9SS]HV "%[5(ASAMR[##]<^/O]51]#[</M]KD<%5_-6<+-8\*;>)
MW\W)147T! K2+ >U4*84P<$.4!52$1*J381(8-A'5JVD#E$G/CF;+(AP)9HY
M =&8]5;D,P&';?&F4@]H_!)QT]W17<?N;>_67V/?%:X=^B/7";Y-,I?1-Q]W
M]5[OY_=IR-MNE[^FZ+SZX#;=<:92#OZ!4W ]W_IMO[/?JJ3RW@]&7@<PF#;;
M&F4A_P":3CI_[[^_MT0$Z9.+^L!O?9 Y@-OMZM,I?1)QM_6CU]WW1\-.7*/N
MWJCZ^Q/TGO1'KA-\FF4N_;]B3CN]OZK_ '^;KH@+Y>X]QQ[*5H/)AIN4:Q@T
M3(,5YT<2>?RU<69Q[?8-^=RY,H)4B#W 80[^FVBJD_1%CKY=7&^0LK>3]MM.
MQQ4LEY!E761\:/IO'N*XMW*V&]U".FU'5FJKPC,BJK*&DX\A@<R9D5DF+U*/
M542.7IH@X@/#DL.\EG%Y+?'O"_7N*K'KK'GDP..SAPO#.K3Z">6,T/47..((
M0B$$I!K(=E8%SG4D3 +>..,>4HJ !C((@/(66US&>6KY^^\(2" U3R(#9W9C
M;6(#V*^J82E$0$2@(AOL(@ B&X" ["/=N B [=X"(#TU47J!LW!4%@01!8$A
M0!4$B H" F XH@?EY@2$X 84P'E$P (AN&BC#3)N6B_)&;5,IRIMD"%4VYRD
M2(4#\O=S !0 VWAOOMHC#0=%^O-T.W\Y[%+SCL@0[?LR]MV(&$X)=IMS]F!C
M&,!-^7F$1VW'15AIMRT4-SC=NUS1B]NU12;H)U;( D103*DF43# B(E3(!2@
M)A$1$=NHB(CUZZ( !8 *:M$1HBSU86A_6.+?*ZK%)LH,C$5UBMYP0Y@*BH>.
M,8R8D.40.')WFW#W#TU;C@^O>V67*&)X:=YZ_5]"@'< 'VAOJ*HT1&B+G=_K
M1U_HZW]6;1%F5P5=+78Q'J(VNT=>OB#SW=.\ WWZ[>S;5-)#'(BT[7?O2%#<
M1G=VWXY6%VE=+OKQ=Y) .H[5KN >_LXH.H]>@![OF\=4, "=8:^3Y90PW*A>
M8$6)L<^4@3/!+_%7TSOA0?\ BNQ>&_<D3OVZAW[A[P]F^E)N(+C]/_:F^VF3
MNE39NS$.(9VZAN,L-BX>+C]KWCS^$]*W_DQX'>&VVX[=>@:R"S6;0D ,8ODV
M6[2J\ D2VEHWZ:IYR@B'"Y?1_P"(IP0 ?> >SV[^ ]VP]^^XY@$Z/8J"8:S-
MOR8-TN[62'P@_6\0Z  _ V/WV#;_ "1^G]_[=:JO 890SYVUEB'/%!:HRSU,
M3M]-A98S>2#W]>EN]GK3RY]W:0_LW]WV]M9U]=^_IL%JIN;4>]-_7MUJ!(_M
MN\E &_ZWK>^P^'9Q([]/=L'AW=1'5('E#,YSS@D#E//WA8A[R0S3 %ISFU^J
M7N*T0#/&$N[<8VP?U9.[;N]O4?M>.J XJ%G8/G)%OKR5/[]$O<773AVH&^W[
M)Z=W[[?XKD?M_;[_ !U [ZV/\LS-F=;K-+BFQ+/:\$\$]I3IPMWP '_,DSMW
M=_Q.[KW>S< [A#3/2]QIL>#,]X=4/+\M^5QUX),X+P *''[>-;BQ'Y]_?U#V
M[#[=")>2+.>)/K<VX* _,0VD]W^BA[@Y'\^]H#P&Y6P=OF%[X#L(;;;@/L[M
M6IW.;,'Y:9/]VS0N[VL)W(Y3(R+\EF7>=_\ ^+MFWNZ-L9#U\0YX !#;QV#<
M/?X#TU!<0SL,\PVQFZL>5CF:O4QWKP*UFXK/KS8)$.\&%N .G?NU:@(;_-X;
M]=4%A5R]U2(JF&FVNO3IH2NGBX_:Y4,-M_SPT[__ !<EL/S[[#\_3?4#^:D_
M^0+O/%]7YAUD -HQ+/D9T/*Z>,U^U3O741'T-)[[^WMD>G3V!MI<G)W]08YV
M6@=K$Y7]KZ\62=P7[? Z+$/&I1@_^_$/^K[FK4"Y)M83D'R^O7?+ER# 9]LK
M';]\XBWA& /AE81#]W=R';?VKN_F]@COW;" !XCJF0X9BQ$,8#2&#3??BI40
MX@.XG@;;>YS$NN!\&W&1D7V>9P'> "',)H80V[A[A^U[1T#^4[$7V<<8\WMR
MN8.;D<0Y]F??FJ3>5T_;;<$G^I\J^.W^U(?^_P#-K&8EKGBP,=2%T!8'<TCJ
M_P#&2VUX??K(XM\/SE0/_0$O[[>'=X:M5SQ*P+9:Q:9[U7YXA/K*Y)_@N_[O
M^27^G454%<%8_G#CO;\'(O[0<P@ =!$/;T^?IJU?J)XQNYF;\H609(DS!R9A
M @7NHQX2-AO5JZATO5U'Y]SN_M#L(>'=H0W-CZ-%XC.=E2"&O,W@#S$O%B7=
MK9;%($?T8N3.H?YB#W]#PG?O]KN[@Z?-J/+_ -G)G.FW$$;B0D,6,OJ"W)H9
MGDWZI;XH^O$;B#O /@U-=0Z?Y-X/?X=W\_3QTI+"KE[^VNJ&)SXY9YC7GF0J
MN^6/V'@QP*(^'$%B$0[^_P"#UPZ?-\X_S[:S4Y!+O(?UTV>T'<)2+,'^6H\)
M$Y\A>SJ]O ,/^ -B&VVU@FO#;_;._L#NW]F^H@),D /D(8*[&BJS4X1!#X9V
M/J(_GZO ?=5>AMU'P'V![_FIY$-!][[YAGF+O" ])XOQ;8;!GZDVX5P$>,C(
MH!_P%>V\=AYH3????P[QVVV]^H6:1G?1FN7M[7L[0N"^4#36QS.;'=F=+W%0
M&_$'A;OZ0-C]NW5,VV_W!\0WZ@/36A8R+;Z@>Q-@\G):@.;&.EB-3<"-2JV>
M60W_ "%F&=N_U_X;]_\ F.V!U^[WZR>""(?(WX:[_P 65TN /;U#-?;\(9G?
MKN&_;A[O^OIMXZIOR&N@UEMC90!H=VCI&@^ZME#VIO,3D]!I-%T5H%4J2JZA
MDQ2<";;JD4IA.  (_P"S -^_QU._L>>2/-N^_KHG5HJC1$:(C1$:(C1$:(OF
M?\N1Y22N5?'^0>#O%=GS_1\XQUMQ<[NDUC*C75BO*8RDSM)JWP51R)&L$V,=
M-/:^^1.U?MY%!,CQL+)5R"2JQ#3;GZ]_O*K9Y3]1OV1:"HM\EG8> *1XL,>I
MX3S1Y2>WY47JUA5:5_B'GLF2&,5>:)0/,#.(S$"TA%'C;F,+)11\=OYR!A04
M6()##>=Y[[S0B)#3O>]K#6PV7U9:*(T1&B(T10O:5DD,U8Q.LJFB0:M?R\ZI
MRIE$1] ; !CB "/3NWW[]0D"20!J2RU3176?+11566=J:346S+ $L(<LTA2^
M+UF F 7;8!(7F. KI )"_P"^, G^*7WCL&IYJ9^:F+R(X]0M#!Q2Q&%B$5%J
M2**CYCH&$G82O/GC3<I?.FW,8@J%+VZ6YB!ON<H<VXD#8=S!N ;#UT\U/^5/
M4?=/R<9B?RL1A5Y2?)4PJ-J26BHN(,RLTY1RW-Q89%.1PW,4[:L@F8%DC%.;
M=AN!!YMA,&P]"B(@(=P#OK8JI\H^>EB2P\U+EHA\QH#-HSS7A8H=\'%>F2^%
MB#R @M43Y8!:"6!(N&"TI!\RY -YXUY=P)S><)<O/MOR[\^W-MUY>_W:QYJ?
M\J;M<7TO=;_(QG;\G%=O,WY=;^6SLSL^=E^A>,R\X&=-BBF.RFZZ0=F(CL '
MW/\ $'<!#8VW73S4S\U,7D1QT4&#C'RD86(14'I;#J/F#.],2&EP\(\\:;[>
M=-MP)V@AVZ6_(( ('VYM^00$!YN[80'?KIYJ?\J;/<6UX)^3BL_Y6(WF\K^2
MIO,'>FWZ@QB\%>AT\:"V6 '3<3*-EQ3 %TMU !,^XD^/\8 \1#< \1T\U)CS
M4S_Y!^4H<'% J)PL0"G]1-%7R\8CFLS."UP@6UV$QEVY2GMEH O,NF&XB#O8
M"B)@YA$=M@ 1$1\.F^M&JD ?, "!/F#'A:1I)Y+)P<8U-^3C TL2#AUP!)J,
M0(NPNSD%EU/'"!>+O)1^W0 H%K/,85DBE 0)%@8NXG H&#E'F*(@(#N [==@
MJI9O-2SR/,'#\3%F!M)&R'!QBS86*7'FI'Y=9\POYJ6$TD7(BULU_BK<MPSM
MA8>W0 $XJPB<>V3^)S)I[<^YMB 8! "B;8!W#;OWT!I^8^:D-2'D!OF#$SO#
M3QAAPL5A_2Q2*B0",/$()#N ::99BX#D,7$%E_BW<MC</V/"%<(&/\):4<"
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M(IS!.D/E6[RQJR*O!=ATB*J2ITL_X<[0B:A5#$$(2V!\<I#"8NP].NVPAUZ
M.LFJEB?-2 &<DAAQF'R2G!Q3Y0,+%)JI)H PZWJ#7  D2)$3NK1<(=U9T+A6
MF;8ND1^%>?3LFK'I.44EUTTW*9>4#*&V3YA.&QC% O<'CK555+_JIL"7JIB
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M=NP6_+*B_;JB<YR ;<PCJT_#/ 4_DD>&PQ^121A-YB:*2Y(!)+N:C-^5V/\
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MAXN!7\;\6<''\;3\2QJ",,4XGCJ:L.JCQ!_I@^<586&18>:@1,YNV"EUBO\
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MP4:J0O%EP@HQD,U:)V:,R,O.E2%3>15B8N&9QRBW,H.PM6WU$@D$NY!V-OL
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M/Z=J:#4/E-,$\0J\2.'\;P6<,.0\758]I&N6-BE5VB0K@FH_*F40<GW5$PF
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MOGQJ!Y"]57YV*YJ</68 4S<'>*,?R-3KTN]K3)>2C*DQ8LG1Q7%1NU<"L1=
MGU7E$BA3F*;<HCU'XVJ/A?@**J#3X7"'Y-!PL,@5-107^0 DQ>_4RIB?CO\
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M+AG_ ' I&.2_SBFNBNGS3E53208,"8*Y87X\_%V!3\.HPOC?BZ*?A-6)7\.
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M\F(&:ID@O9P8X,##BSO8P\LD]?IQDY$'V-Z_M[_CP@_]F_\ 2.^DL&F*G8"
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MQX\(@*?.$.XU2NV:?7G[%#PR2UFLBR2DH_;L4U$%R.@05(HY.0ITU.8O(<!
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MEQ=9;/3,C<+T(I%V&BH0J;9W*URSIKOY87-=DVBO81\ZDJU/(/"<ISK$YB
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MES#%4MV0X"L%D39[0B82:@Z9+5"'M5392+A.&G6%?M286)DU?("8OYK(MU7
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MLC1;O)5MB[9;$V",H[;H-7IH=!!E6T&X)"5G4"D,I ("5L<Y@.4=%DQ5808
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MJT27QQ#R!9%<D:E5YR2++/VZT4'Y67<G>% R;L_U1,GQ Z:(I> I0[B@'S
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MGQOS5^L@P_J\X=++ 5]T5$*?C1Q%1;UX\(Q!,L1#E:(.57CL':38Q2H@H47
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MB5]$8TF8:6?KS$:-F@&<G3#2]BIA2.RSD-"!<A6K!I)P<[%;L9H@-'C%!ZR
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%/#1%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g899221g52s92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g52s92.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %HR^5W(X0DE-! 0      %D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  5$96QT81P"!0 K36EC<F]S;V9T(%=O<F0@+2!"96YI=&5C
M("T@1F]R;2 Q,"U+(#@Y.3(R,0 X0DE-!"4      !![^!QJHC*1X[<@^,^/
M3;:(.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           ! @   H4          0                         !
M          *%   ! @                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ! @    !29VAT;&]N9P   H4    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   0(
M    4F=H=&QO;F<   *%     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      P8     0   *    !    !X
M>     O\ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M?2Q]?_324WT#,RABT>KL=:XN:UM;.27':/\ R3U6_:.98)HZ=>9X=:ZNIO\
MY\LN_P# 53ZP>N,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD\'A\30U-F)C=)(F1$5&9&5SA;/""7)UHM2"@[*TXO_:  P# 0 "$0,1 #\
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M+H$7VQ3,J?;7"43(C:_*&FBS(*"V^@U0DVBXPP\IY@J3'5M?6UEQ+:3DH=<
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M)2(R3EYLBMHN4HN*8*NW<B1O3YQP]=,&!_9SOF[XI(IT91JT<&45=-T%N_\
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M;[+J*-UVLU=R4;=M=R1HZSQ[>SPEK9^P7>.=O:E'$]JA4BF=#*.D3H*B( '
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M<QOL72VE-,Z'MGL/I&SQK1$5@R9"0'KK<G,8+USN:QY5+<5]ZM?=(&$(0$I
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MC5<# /(""Z;(%0$!'W@<,4K)!2E(4I"%*0A0 I2% "E*4 X I2@    'H
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M/,<YC1#H *0H.!$QQYX*4H"8PB % 1$,R-G&;M:QQS<877_>&_I^SK5E<O\
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MJ"0!DG Z9/3FHT_.Q^&O]^OT]_G_ !?^ME;R&;^*2? ?R#OCT^YJ-Z/OD_\
M$/VT^=C\-?[]CI[_ .\"+_UL>0S?Q23_ %+F/CVTWH^^3_Q#]M/G8_#7^_8Z
M>_\ O BO]?'D4S\4D_U+GZ]OTZ]*;T??)^,4^=C\-<!X'K8Z>P]>/_.!%>_^
M7CR&;C/DDGQ_F'?#K]SX?W=:;T??)^,?MJ14YU5]-]:3@%9[=6O(I*TUR+M]
M=.\L3)(LS6)H%31,['CWB#B,D006%HZ)^QK F<2"/ Y@YUYM-M6ANX7*#"6X
MDK;1*DLL*6@$I*DAQ:24A0()' ((ZU>1X4R4%*C17WTH.U1::6X$G&[!*4D
MXYQZ*\+[-+I0^^ UA^<[+_6RQ^NS3'Y06?\ .,7YVJ_L1=?Z.F\?]F=_=_13
M[-+I0^^ UA^<[+_6Q]=FF/R@L_YQB_.T]B+I_1TSC_LSO[M9>UYM77&V8MW-
M:TNM>N\2P>#'O7]=D49%LU?%("@M5U$1$$U@3,!^PW B40$/3,M#G0[@R)$&
M5'F,%2D!Z,ZAYLJ3[I.]M2DY3D9&<BK1Z._&7W<AIQES .QU"D*P>APH X/@
M>AJ"6U?$BA=67G=\(ZT%MJRZ^Z<IREP>X=KU]]K\T#5CW9DVD&,B6 D;<QM\
MK&L&;I->25C81PHB0#]B:@@ #=9JC]/\?"N_=?B-1&H;UM2M1V@]K[+JFD=<
M4;:>T=@T^0UZWB:[4KXE*.HUXVA;';X6R32C-E$N7CY"*BG*A$@ $@4/]KBE
M3L&]L7FN1V368R8MT:ZJ7QO@HB": I.V-HM%_"D>PB63I1L4\E)I&21:(.%4
M"BNL0BATPY$%*AC4NO\ @4[?MNA[TU%?^GNS:CTV/4%+-;?(4VRM'VI@>3#!
M6;1?T:Q6%LTE6+N#?(R$(^.W=IF!,S?VA,W>"GT^G6J75'B",;I;XNH[(T'M
MW23J[:DLN[M5'MJ-:G76Q*/42,EIYE&Q--G)Z49W9DUD8Y[\37K1*77;R#4&
MZ2JQCI%4K+72;U;P75BRVRZAM=;#UFYU)LM[K29@]F1C.$L;A^TBX^6)('A4
M'KQW%(N&LB@)6,L5I)H&[BN6B)@XQ3X?[O54M\4K!74Z4INGO<13E*8IJ!82
MF*8H&*8HL5 $!*;D# (>@@/H.6%T)%LN)!((@3,$<$?:[E7$3'E<7/(\H8SG
M_P 5-?D=V-MZHZ\O#+6D=I^6OML=Z\E-BM(^L1U21\Z&A)J)A7[<JLT_C">U
MH_"I'PD,8$S-6ZH$.*XD2-^7MCT]<+Q:EWM_44>U0$7>-9G7Y[]Q5ME2XDB4
MRLHBL2#W:O)RT5 ;@XX@D;-RA]4S[A'AS/(D6YV7(7&=FH;CHC)!99>0TI.7
M5M@*'>;\9QM20#NP#@:)ZV:'-576EI8]-.P#([?D9MEKQBHTUL@ZL#>N1,M,
M34@BJM9BMFR#-O#/4P2=K(K.%R$(W3.)P$-OD]F%VBW"^V][6UG2O3D>*[>7
MD/7Q3<-4V3'BQF5!, K<6ZN4T2IM"T(1N*UC%89K5,-V/ D(LDW;<EN)A(4F
M$DNAEMUU:LF1M2E*&E#!.5*  34U^FR[:[W3'Z*VU2*^BR@[7L+6,E%EDX1B
MPEF9D=BP+95%P1$JA$W+=TBHF*B"RJ*G8"B"RA!*8;33%LO.F.US3VG;I,6Y
M+MVI8$>1W$IUZ,X%$+2I!405-N(4E6%H2M.2E:4G(%2ZRH=ST?<;C%9*69-L
M?6UO:0AU./,4% <!0(*3C@CS@2.3[G5K'[OKVYE]VZEU/-[HA=<[YZS;3MO7
M$=4OC0;;D=#[A>TJHT11^=B\?-)"+/,Q4K#,8]XQ,G#0DB8I#-T% S](%J'>
MNI4O;G8$>=C;YH43@8]!Z^D5\TH!V((Z8.0>N<GJ3P/#T>OK6$-86#JCT+#2
M6N]G=,*NZ+=+VRUK5N[3&A[7-L_:U-I@U7BG\E38MLRAZA7-?NT'+!TZ9BNL
M*"KA!=^82H#X*@L;N\*.!QO 'N>.I/W77KX=*]#.WH,Y."!QD\D'H>#P,Y/7
MQZ73(WO=NS*)=*A,]+;77DFYH^TD(>U5OIDOHC?+A"VJ-C(B'US8V,Q)HU>.
MC*^Z5ET;5:$&SVP*MGB)H"(!LH.0#@GVT$Y3YI<Y P<G@<\]1G&.I-,9&<<'
MC(Z>O))&/0,#KG/JSOTTJ[2VU7>IJK;:Z9:WI0FO-+3WR?V VFK8_O\  W&(
M91D7"3GP=Y4J799I]BZ6N+9K&1C&4.Z2&*91,J";AP2%* QM<4K*@2 YD$9Y
MQA0P!TQG'.,@'-"< #CIX #'@.<''0YZX&">*B#I;<>Y:I-:KTH;I?0O-J,W
MAY&7+?M276R6?=#);:451+#<JG94:Y0B:PUZ[KRTS=(A]>ZHB9@^@9B)!9XQ
M,W<(>U*SDAQ0'( "L8P#C(YRKC!P<G/AT,#S<@8/4X."3\>2/U$^BLJT3<?4
M';JY4AOW1U2M=MK=9[#&3,\RZ;=E3TS57K2K5AXPU/*5>,>N7$+/3%@EK%&1
MFQG+]2-:MX(CR1@VK@ZK1/R<9(2\2<# W\<D@*!\<9!(QT&.:9SGPP>N .2.
M!UQD'G &>OOU@2F:SZFJO/NMNRW3M8MA'6UM0HV'U<\UQ<&L?#NF_3M2;G**
MOVZ2ZGPPZ;7.RS326(+%.9?6&#D6!'2:IT(YE40^4*"D/*0XA94A25[5!27"
M4J2H8*2" I*ARD8(QQF%)2H$+2E22G"@4A22E6!M4/NN#M(Z')&>:W>:AUS0
MXW6/1_L9I5H!A>)'J'U>23M+'7%AU,^<)O3V,C] :E97*TY$M%0+[,JB_<+H
MOBH Y3,9,Y *[]]^677GG'G'%$N+<<4ZM9(]TI:B2H].3STY/%>4MMM,AM"$
MMH0/,2A*4(2 >B4X ">O3X!S6@2,Z=7N\-O[0BJ7KROV*70O&RIZ=DGS"":,
M(V-0NLP1>6GYV5(BRCV?F'32]KD'29#J'(F4QCG*&?-^I8UXN.L]11;:J2KN
MIKKCB4OJ9:CLI0WE;BUK2TRC<< D@;CCK7ZZ]D=VT1I3L$[,+QJ>/;&O+;%"
MBL%5L:FW"Y3G7)"DL18S4=V7-DJ0DK*&T.+"$J4<)'%@V#0J-9D9&+EM7Q!%
MHR6^!'#EI6(Q]'*2?:0Y&K.39LE6+Q1<JA#-_9EU06*<@I]W/KJ<@7J,ZXVZ
MN<"VZ&5*2ZZMLND)(2A:%J0YD$;2DJ2K/'-=PMRM$W2+&E0XM@4F5$\N;:=A
M06)*8OG;GGHSS*'V4ME)#G>H3L(5NQBO<MG3#(4LU<2G-3Q":]HI3;8$<U:5
MB.>.V]9=2LO"I/95NW9'5BU ?P4@15L]*DLF0B:IB 15,PUY4:^PU,)>5."W
MX2)R4(=>6I,=;KK06ZE*E%I6]E8(4 1YO&"*L;1=.SZ^>R2H#-@+=KO;NGI#
MKT*"PRY=&HD.:MB(ZXTE$I)8G1U(<94M*B5)!*D*JQ7>J8..:MGTAK>)8LGG
MHT>NZFQ;M7(^6FL -UU6!4UA%%5)7[0QQ\M0I^.!];%;]T;2E;CTYMM?*%N.
MOH2O@*PDE0SYI!(3X$$ Y%9YBW:4D.N,1X.GWWV0>^99BVYQUHA2F_;&T-E2
M %I4D[@/.2I/48JM)I9FHHV;IZH:J+OVH/F2(4E RKMD90J(/&J81O<NU%51
M)(JZ913\Q0@<@)BAGL+NZBA.ZX%2D=XA(5(W+1N">\ R24[B!NP020.IYMU,
M:,2VZXIC3(;9=,=]:FK8$LOA)4675%(2AS:E2MBB%;0HXP,B]HGI6F)6*1G
MU)"1L*[A;-.1\K.0$/",)1I4'B;">;1CF1;-TGTHT>*E:DC&QCO5UN4T43B4
M>+YJ'J!UI+P,QII34AU#CSRVD.)BK#;Z4%:T[G$+.T- ;E8\T*P:PDJ]=G,2
M8NWEJPRIS,VV09$.!;HDV1$=N[*GX#DIJ*PXJ/%=90752G EAMO!6XG(JTF^
MC$7"[1$VJX]H5ZJR12=/Z>S8,$@?NDV;5PY>NH])JV:J.5"I"Y74(B01'N.
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M'QS5E%O&OID94R+<K^_%;DLQ%OHD25,IDOE(:84YNVAQS<G:C.XY!XR,SO\
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MJ8D!A96AQ26U.E&Q#JD-+(:60K:"H\5)86.\W(2"T<+&Y.X#(!4$Y!4 H@9
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M2&V=<Q>X]^V'<%+G;I Q\=%.:TYA("';LW*S65>J-YA1PT<'(R.C_O=,%!4
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M\R&]I6,A6<I">E;# ^INF6M C1M06IQIP:6D29J[,MNXB78+?-@O-,/(F'9
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M)0A*;AY*(:I<EUD(?>/<J<2C#B5H2L!)!"35J/J=("K.J%[-2&+I<[X]+O\
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MXZREQ4Q2E=XXXXI<=LJ?#A;\UU6].X(+? ((\[H,\U?*U '"1@@8P2 G;NY
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MM<MT??(5^]>*U,[J0?L;;$QLTF]>JKN3N6+8%%#I)$($EA"NI5X_=$=1@X]
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MZ?A#]I??_L&/K[U5G_.JN,8^UHN1CU]S]/AIY!$QCN1C_P"9?[U<?,1='_\
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MS1>O$&ZKE3T^T1(J<IE!]0]"@/O#*3DAAE24.O--J7[A*UI25>\"0:]U[ "
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MK'=^U-FU?J,JM1G8*P",>:PT/9+5)T$$BQ6<+)^S@@DJ* &%90J8'.;@0Y$
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M0\YS:ZFZ,Q(3\V%?;_J:>VI$M$!XI@1%N!6&74@I0D-I(2I6W<1D$D 58M:
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MU16I1"B5D) '/IK,L76H>'=N7[%H5%Z]0;H/%RF/^S@V+VD,8@F$@']XF,
M(_2.9&-;X<1QQV.RAMQX)#BDC!7L "2?6 .O6FY12E"E%00,#/O ?W^^:]L4
MTS'*H)""H0! AQ* G*!N.X"F$.0 > Y !#G+VO.!D' R.AQR/5GT>JOO%33%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*PQM/IST'O%S$/-QZ9UGM!W7U"K0;J
M]TR L[B)4*83E.P6EV+I1J)3B)@\HQ0 PB/OQ2LMQ\>PB6+2,BV;6.CF#=%H
MQ8LD$FK1HU;D*D@W;-T2D21113*4B::92D(4H%*  &*568I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I0?0!'ZOJ]^*5KEMO57
MU005EG(B*Z6VTQ%Q\F[:QTJ-Z]G-(LD5CIMWAF_P(?R#+IE!04N\_8(B7DW'
M([8S;M)*9:4_J*8T\IM*G6TVI3B6W"D%2 L/C<$J. <#/7@&M<=FZC#K@9LT
M=;04KNUJN"$%2 2$DI+1() R1G Z9%6]]F!U7?3TEMO?[_C\/ A^0O>/^3Z\
MJ&VZ,Z?7-.S_ /1U?J[^O'ENIR#BR1O?]DD$?^A0>L#JO^]*;?B^/X^GK_U"
M'_Z_S8]CM&?E-._-"OGZ";J<_P#0D;I_22.I&?P'T'3-<_9@=5_K_6E-Q#Z!
M"_#Z_CY@OJ]?Q /T\!CV-T9C_2:</?LZCZ?1(]/'7^X9NIN?XDC<?]XH^#^9
M&/#GU^/6@]8'5=Z_UI;?\']7WO\ J_N%](>X?XQ /=CV-T9^4T[\SJ^?^'QI
MY=J;C^)(W./^DD>D_P"Q\,>&>N/"N/LP>J_Z.DIM[OIO_P!/U>D%]&/8W1GY
M33OS0KY^GENI_P"@XQQ_WDCU8_F/?Z_X\!U@=5_'_%*;?G\/OY_ZB^KGZ^??
M[L>QNC/RFG?F=7S]1Y=J?/\ F2+CQ/LDCYC^PUS]F!U7_1TE-OQ?'\>?P_W!
M_P GXN1Q[':,_*:=^9U?/U)FZG'_ $'&]_V11\P/IZZ?9@]5_P!Z4V_/_P#_
M (/T8]CM&?E-._-"OGZ>6ZG\+)&/_F*./?\ :/#Q]^N!ZO\ JN$>?L26O<7G
M@1OWJ'U\#\!<\<>\0]_T@'J&/8[1GY33N?\ NA7Z?;Z&9J;(/L'%.!_2*,@G
M& /:/'P]/JKD.L'JN]>>DIM_W@<>OY!'\?KQ]7XWL=HO\IIWYG5_^13RW5']
M"13U'^<4<'PS[3\&/3Z*Y^S ZK_?]B4V /K^/XCS^ /VA#U_0/OQ[&Z+Q_I-
M.S_]'5_^1^RGEVI_&QQAZ<W%!Q[X[D=>G6OG[,'JO^]*;>_^'_T?7S\!?Q>[
M\./8[1GY33OS.KY^GENIN/XDBY]'LBCD>KVCT^JGV8/5@/\ @E-@^OF_\_Q^
MD%[OTX]CM&?E-._-"OGZGRS4_P#0D7\XIZ\Y_P";_P!E<_9@=5_'KTE-OS_]
M/_P./8[1GY33OS0KY^@FZF\;)&_.*.GI_D?>^ ]:?9@=5WWI3;C@/[_^?7Z0
M_P" 0]>/J]/QY/L;HS\IIWYG7\_XU'EVI\\V2,/_ #%'@?\ P?'IZCDD>%2)
MZ>=V;EVC,SC'9>ET]91S!@DXC9%.R?#8R#LRP%5:G1^#F7D 1$04*IW'[QY+
MP''(XJZQ;%';:5:+L_<7%*(>;>A&(&T <*22XO>2KC'&!R>HK(6^1=77'$W&
M S$0$@MJ:DA\J43C"DAM&T 9YR>? 5++,'66IBE1JZA.H&9T:2O'B=26K: 3
MAG17 5J2BH[X)!N!/+%R,G_9O:!,($!$!$O:(F]X9FK1;8%P+PFWJ)9PV$EL
MRF9+P>)SD)\G0LIV\9W=<\=*QMPFRXG=^2VR1<2O.X,.LM]WCIN[U20<^ '-
M1C^<(MX?X)6T_P YJK^C,U];5A_+6T_(;E\S^K@>.*QGLU=OR9G_ "J'\Y3Y
MPBW?>E[3_%\9:MS]/_L\?1]?^D,CZV[!^6MJ^0W+YFGLU=_R9G_*H?P_=T^<
M)MWWI>T_=[_C+5^/_MY_S9/UMV'\M;3\AN7K_P!CZOTBGLU=OR9G_*H?SE/G
M"+=S_P 4O:GX1^,M6^OCZ@Y#Z>0^C(^MNP_EK:>N/\AN7QY[G%/9J[?DS/\
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M%Q2LX>2E^])_R"_HQ2GDI?O2?\@OZ,4IY27[VG_(+^C%*^BE*7]R4I?_ (0
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M4JR:R,;(MEF3]@]03<M'C1RF9)PV<MU2G26062,9-5)0IB'(82F 0'%*U_\
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)*4Q2F*4Q2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g899221g54l59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g54l59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>:^9C X0DE-! 0      %D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  5$96QT81P"!0 K36EC<F]S;V9T(%=O<F0@+2!"96YI=&5C
M("T@1F]R;2 Q,"U+(#@Y.3(R,0 X0DE-!"4      !![^!QJHC*1X[<@^,^/
M3;:(.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !Y@   [8          0                         !
M          .V   !Y@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !Y@    !29VAT;&]N9P   [8    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   >8
M    4F=H=&QO;F<   .V     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      ]R     0   *    !2   !X
MF<    ]6 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M4_;<?'-6WV^B^\.W2.?4LV[=JUL+IV%@![<2OTQ807^YSI(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[>1G3*V4JO3K-T_:+!4'<==,(QE0RSDZS5S,%C95.QDBDI.,JZ3E<KUU,M5
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MG=_)1LC&GZ,F_!,L@Q=LC*ECJL84R.T%$!.!?%@!C$*<3 ':+R( 'EZZAO\
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M1L7>@%QB[PM#.\V03L7VK FU@O[.E_#-G#GNU%O#HJK=TD':54!(ACB1,O\
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MO(?L56[]7M#\O'G^74S\/3]IET?7=UXKP;%GR@$I3&'<ULA*!2B(B;%5M
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M":9S)&,I^Y! E;*7,=9S]H[!%[N:W_49/Z'"K,\?<%HCV'A^3G/VB,BT BX
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M;MFBD\X3;)D5ECMF?[D0,^.!G(I-^44Q4["8B4 '7L(YF5#&SQNB?',T2,=
M"(7->-IIB!?(1&01L7>_Y;?,=5XVH:UD\S&0RT[&RO:V"9YEEA:'$".20LC+
MWL'RN?W;-H@G9;>PR'7-=*:(M+;@X6'L&)[5%SC^SQS)=IRFK47SV/EUWI.T
M9BR%=@4RYF+QR";>00$ 27:G425$$SFUH^TM<Z@[/XS,R.>5\N&UM(QE/2_&
M2NDJZ:6G8&P".0F[Y "\-O'?:!:1<;SLTQC\=PLR&C$<5;33R.KZ@4M-&R":
M.5TCIC+#LO8UA<P;=G. !:X&R_EMXA8> Q16HV%D;3)M4T53K+V]^^D99%\J
MJ8[YF5Q(%*N5@S="JWCVX!W+=JFDDB/=E+KAV6KGUW9[!Y)&31RP8=24<D=1
M2?!2LDI(&4[VO@[N+,.C/^0M)D_W+G7VCR[3M8W'<3=&*+NY:N:>-V'U J::
M1DTCI&R-E$TX+WAP<\;8V7$MV6VV1N[6_6A31$T1-$6L,@YHQ3BE_38G(E_J
MU1ELAVN#H]'B9N89,92U6NR2",7"PD''K+%=R+U\^72023;(J??&^^$  =$^
MVOU^F:U6?>IM=3RS.X/5S-3$LF5LLF68KBLFDF=J_A(H9Z9A/&'[+)6?BH3B
M7D81-P:2:1PE=+-R)#VM$6#Q748V9S>-YW+<9G*K.J!7Y:&@7D\4'J:+J:L*
M9UH2)AT56Q'$T_DT4SJM&T8DZ552**A2B4.=.NN5T&>[KR4I\=Y%I&6:57LB
M8XLT1<*5:X].4@+'!O$GL;),U!,05$'")C%[:2I%$'"1N%&[A)5!8I%$S% G
MVU\%FFB*M+>SMFWWYMO%5G=J>^A?:U4HJLC%V&H)8RKMS+/3WM)XY"P#)RZ:
MKEN86*[9AX-,I$2@U!;DQU#  Y^'+KZ63QZZY\5"K[GYUE_(?NPSOW>7V!:5
MQ_U3S_HY]XZF?/GY\!UPXE^ON?G66\Q^["N_\@M)X_F\+^KC4()W\=_.PN ,
MAEJ#[9EX'I^=9<0  ZPSL/,>1# E)YX'CRX\((>7'D/KY^OO"VRY>.NNIZLB
MNWP[6+W3,742JY.OI\H9!@:W&1MNR"I$-($]MG6S<B;^:-$,1%HP%XL!E.X0
MX3+SR!2\]D*G75ULK1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31%_-55)!)19=1-%%(AE%5E3E3223( F.H
MHH<0(0A"@)C&,(%* "(B !HBPN$R-CNX.G</4\@TVPRB*:I7#.N6F!F9)GP
ME,HHTCWSI9$R0CSRJD!2F .T''EHBZUV5SY#IMER[5L^91W#6#;TRZBECC;_
M 'A=[;V$J&/S;26,O0(Y&2I32.<L:0CE%2.9M/816\:O-HLV[Q19RJN"D_/7
MTW\D&6[KEOW_ %46*7=]ZRDGB9>URVX(N\\MLVSM,95MTG=4HB2VY.\2S+C+
M$G98,K8M5=E]I^T5K;)3+9278V1&(0!P@J9(HS/D=W[MNRXVTWZ<L@3:ULSP
MY6-B;Z<]^2E7LNSWFG%6.,SWO&^,-R6Z"):;:=O!LDX_>*6=U:1W9V$\^RSV
M$6:\E &+R!(JG(VV(B#)1D>FU:$;-4 ,0!O&WGURME^5"!E8@ $CR&F@XY7X
M<E*CY.>Z6?=-V >N&:T>N[S+F=TLQ<_X]FJYN3M=5HMQY=ZU44,W4]W;2-J]
M=?PHKW=$31$T1-$31$T1-$31$T11'W?9=AJ#CB5J:TCX.3O$1(Q3U=!(CMY#
MU1^B>+F95LS$W+B4= [)"UMH8 !]//VI [2+=SV-3B<TKQ_;Z9D4DT]/4U-4
M9W-934F%4D+Y<0K*N1Q#(H&0-=&U[RUID>!?(KW?8G#8XYW]J:_O68=@-32?
M!MAVA48EVCFE:<$PJC#0723/J@RJJ!&USF4D,AV;O9>#NSW:A?)+&CQ%;)%R
MJV/;'.+OW,*V<$BW\NO'M6L)VW(L.Y?@0$XTB:Q5'K00<%4$I#I@'/@OZ:XU
MB]9V:_\ HSV8PCL30S8CBL@Q2ICDQ3%:ILF(5+HI*2CJ7&BIVP0F.D$TFT]Q
M@+@P[_4_U1JXJGM&Q_:G'J_MCB%'0TD4=$PQT&'T?>1">>.:IIVB>?OJF66J
M+([-_P UBX#(648YVYXDQCVG-?J<<M,K=DSNP2:!'\P[.7CLJ+NW *'.<HAR
M10PF6+R/*H\B.O;18!3/F%7BL]7C^(!PD%;C4SJUT;P;AU-3O_Y.CV3_ *_"
MT\1 _P"XFY/S:?'JQT9IJ)D&$T5BT4>&1"E8YIO<32M_YBH)!^8SS/!X!>IN
M5K5;M&*9R.L;.8?)$!->,:PBTPD[5E4Q_<A#)PJR*[E#M"/>MU^\:J%\E4C<
M!QA=MJYU#V6QH,[\OJZ&6C8RGIG54LCIK 1MB;'([YK?[-:"T G:"SNQ<3I.
MTN%O'P^S!4-FD?52LABCC;?:D+WO8 YH-Q\VNN2SG%$+7:]CVL1-42D4()I'
M%(R1EG,FZD$P,HH=8CE:867D!,5<RH%(X5-W:?933X2*0H;S#*\8GAU%6ATC
M^^IH?FEA-/(3&P1';A+(RP@QD6V!>U]ZTV+0OI\2K89&0L>RHDNV!S7P_,=L
M%CVN<' AP)(<<R5L36<M>HJ9CNM=@LJ8TB9::R%'33QV/S98UNE*3L-).ESE
M1?)NI0B9@2,FT'M/"<AX1H)G)N \]>/QS!7U^,X/7C&*ZB.'2&2GI:>E@EAF
M?)9DHD?("\=Y'=AM_J"7 @@K(A[;X=V>CGP*JP5]?/CK6Q1U#8ZIVR&N!8&/
MA(8#$\B1Q.C1<Y*511Y*4?/S !\PX'S#WA[A^(>X=>P6/KF-Z\Z(FB*+6[)I
M-EQ_'3,%;UZD[C[37&)EDXJ E$W:$[+M(A=)4LZT<II&(DZ,HB9#L'%8A -V
MB"8HZS%*2"IA89HH)=B1@:)Z>"H VW!A($\<FR=EQS;:^^X6A[0U>*4-"VHP
MO%ZW"9/B*:*1]')W?>LFF9&6R9C:#0[::+CY@"I(0<<I$PT7%JO%9%2/8-6A
MWRZ3=!9V9NB1,7"B+5-)LD=42]LR:"9$BB803*4H  ;".-L4<<3&M:R-C6-:
MUK6- :T 68P-8T99-:T : +=QB0,8)IY*F4- DJ)C>69_P#W22'>]YNYQWDE
M<F8Q2 )CF*4H>HF$"@'Y1$0#7-<UQ3JP0#(.7LY$- ^+J29-P\O7_&KD]-<2
MYHS+F@<20/NNE]13L_WGA9K_ +RL;IKJX:;U'C<=D;#),(Y2"V7FC"P;TFR.
M"(KV>+[[VBE$NO98MDFS\KL[SV@9L5H5 !5,X,F!0$1#6)63T[::<R2Q!HB>
M?FD:,P#;?>^U:UM^2\_VAK\'=@N*-J:VA<UM%4D,-3$7=\V)_=!K6R;9D[W9
M# T7+K"RY_:S(TN7V_8IE:"[CGU=D*;#.4WD8N9RW7D!9I$EC**G564%X62(
MZ(]*H<5".R*D. &*(!RH71OI('Q.:]CHVG::;@FP#C<YWN#?QNLCLPZD?@&%
MOHBQT#J2(W821WNS:;:))(>)0\/!-PX$$!;_ -9:WR:(FB)HB@3OBVR6#<$]
MVMS=*@*HZL>&]V."<MS4]-$CFLQ&4"B75C.VU"$E'#<[[Q+B/;' D8T72!^I
MPD<# (AHGX/6>_AXJ"^0=K&[[*^[#)=HO^WG$DIA&,>79/;U[*R?#4^*@I6U
M55U7I_+.1:_6XI*U6G)%S:J^Q1DU7AE:]"J 1,JRY>]3F=_#R\/&_'<EA8;C
ME?PY:@#B,_ YFVD:;T_]X-.1KN4JCAVK4]KB3-6&\B8ZV=2.=SWBOO4*+3Y*
MJW24C\DV%61C*^O/&?MW4)$N0,U:)QQ5%D&[M;@%OUX96ZYJW^]_7WYG[ K5
MV=^E*IA#IWY@SA><W[C:-N(H^-LCY(5K.&MPEWJN(:M8YJSS%O;0,9585RVB
M7S>%+-C%O'[8K=*55;BZ3 B?=\WKKKU7'.^ZWO\ KT*O;Z?<U,6/9)M=GK!+
M2,[-R^&:7(2LQ+O5Y&3DGKF+257=OGSI15RZ<*G,)E%EE#J''S,81U!]S]<E
M5,+51-$31%3+U0<-7.$KT7F^B[GMRV-9JSYJV]8V=56D7Z-CJ0QK]YR95Z/8
M58R"<UQXHVD7$1*NEDW0OE03?]ESW8@42:AON^E_Q]?LJ-XYGSS/EGJK&MON
M!PP-7Y:$#+68\M^V9!.3"4S';6MMEHWA$$_!1CIK#PY6S(W^,.B9)414^^ X
M>FJIGOMY?L]>PD!HB:(FB)HBUCF)ME]WCR?0P/(T.*RB<C7YM/\ );69>4Q!
M0'K<7HR[>OE-*J%.P!R1MX8HB#HR)E/P0'T3HJI#">;>JGE+/V=<,.[!LO8$
MVZVB@P]RE$X+*ABV5G<ZZVM(GKJ?<]MHNT8K^#'VC]X=U^$*/=!H@S /%7>%
MYX#M<=KCSX].?JYT1>=$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T10&ZB=<N<_@]HK5H.AV&,@[,TF;G&9,S'8L*4E6M-FKD'!I
MVR5H4WTBU(N=(1A#N$$'@B':%0Q2I''K=UUS5&HU'*U_*X(566QBD6/<_E C
MR;V(8JP9A2H-UI&N[F\(7Z]5&9G[;$O&"T8VIY7B4++VJ$64(Z3DY"9CE8QR
MFF $*[36$^IKY6TRO^N?X*$#(@G/=O'.WLKL-Q.XC&6W&"J1KU!VRX2.0+ K
M6:G3:35AN-LM4O%5^3LTDJC%=XV16)%5ZOR,L_>.G"14D6?"8G6,BD:]=74_
MD_E1R;=4;9I(7*E13"R33^/MZ%.8L,GMZ<]-0H*:R+6W]NI=,G[0H4B\/8K)
M!QB[MK&"T.@FH9LW>N&SA=),26U\-?HMC8#WFX+W3PN18W$R-GBY"(IC2[^S
M[74UZFYLM)O#&4&I9$@453']J5JU!'.U(V14[EZH5(!>-&YCIE,3R.>7*V>?
M+ZE0-^3Q?1VQWY\<Y>OU7N0T0ZE7GZ(FB)HB:(FB)HB:(FB+'K9:86DUR7M5
MA=@RAH1F=Z^<" F,!"B4B:228>:J[A8Z;=ND7[Y5=5-,/,VNBJJ8:.GEJ9W;
M,4+"]Y N;#(-:!FYSG$-:T9N<0!JMCA.%UN-XE1X5AT7?5E=,V"".X:W:(+G
M/>\Y,CB8UTDKW?*R-CGNR:54?2ZC+;Q+_<\GW]TYB\80+=Z= J2:BZ9W39FX
M1B6[-)+A1TQ@&RRKLB94_P!UR*CR0 G>/401\IB9F::O"IY!33.A@Q7MI5L;
MW[L.H8;5F#]D6-#9!(9&B/%,;8QKA,WNJ.5CA+*P_3JK$J##W853X3$S$,,P
MN>3#^SE.][H&8YBDSQ3XYVJJ'7;W8E>'X9@[W.#Z>%AGB>TQL<9K;0:/7J34
M+$A!6"8FA>V)\=TE+-I1L+(C9VZ;L3-TY(P\)OF1$7ANX  $ZPBIRH)A'H_I
M_BCL0P1\3J^6L-+B6*N#):'X'X=E5B554L#6FGI]IDS9!,P .#&N#!L@!H\_
M_4-D QBGDAP:FPKO,/HFO?3U[Z[XIT5)!&=M[IY@UU,6FG)!!DV-IUW7)EWK
MW*\ M,;@+/=J3BFUW"A.8)O.5F/4E^Q86;IZP=-6O KM>[:*)JD66 0!-4!$
MI!\Q 0YUCU3Y8H))(MC:C:76>"6D#,C+,$C1:;'ZFMHL+JJN@= V>FC,UJAC
MGL<QEBYH#,PXC(',#4A9W15K(XJ, YMSN+>V)U'(.I-S#-5V<:HLX 5R^%;N
M3J+)D(B=,@@H81$Y3&]!#79$7F-AD+2\M!<67V;G/*^=K$:K.H#4NHZ=U6^*
M2I?$U\KX6N9$2_YAL-==P :6@WW@E8Y:\U8GHYSHVB_UF,=D'@T<$BD^EN>>
M."Q$;XR3,;GRX*T,//EQSKB^H@C_ -Y6-/#:!=_\(N[<=VX\%CU>-850DBJK
MZ:-XR,8D$DU[VMW,6W*3?<&%5ZY]W8OOL][8FN-L-Y%R)#OK%82$G$HMS7&<
MBY>1XQZC2*";;-U3"P2'V@\=/D6K<K?D""80[>M15XB15T#(:6:=LDD@[P#N
MV@[-K#O-FY&9O:UM-<_"8YVG>[&^SPPW"ZZOB[^HM((I*=M0Y\8C=' 9F-)[
MH'O)'2-8W9T!M<S(^R)N'DO**V_1T0F;^ [LN4(3[T!X[)E8^,C%G!> Y$Q"
MKB//WH&]^MCWM6?]:1K?&2=OK9K2?+AY ^K_ +AVAE [K (H;W^:IQ.&X&XF
M.*)SKC>-KD3JO9[&Z:23X%?"U9 X_P (B-LG7B!1^ '.U9J'*'IR'9$?(?+S
M"_\ .NT^&8-W_4>[3//Y1ERS\-]([4RML#@M*3O JYWM\CLL)&9&XG(VW^N&
M.MPD@(^U=P;..1/_ (QK7<8U],0 1\RI/Y!VNY)P'WH&%,1'^$(<^6H(:LF[
MJL 9?*R!GF-HDGD;7'AOAP[M!+_U>T#(@1FVFPRGR.ZSY7N<+<L_#51(WF[6
MI&\8NBV$WG'-$G(H7:KOFZ3-VD6+,1.132>&4C(MJU2350;+*N&2RSDXI.DT
M122,H!3%Z*K!*C$H1%%55#GLDCD($K(_E#@'$ ;/^H)=D;#A?7RG:_L^^3#8
MA48SC-0\5M,X-!#HK.DV'GNHFL:US6$NC)<;2!I )-Q*.&VL8[&'BDGEFRQ.
M)I1K!$JTSD2T$<KD0:HI%6<))N6ITUU2D ZI# 4P',8#!SKO^ C8=ESYG%GR
MD]^X@D9$W:;&]N)'!>E@[+X:88RZHQ68&-@O/B%4'$!H +F[32UQL"0=#YKG
M4=K&%D_\;7YMZ//(B^O%V<";W_? -@*40^("7CW<<>6K\#3;V./.67__ +7>
MWLK@C3<T\SR=>\K:UU^?_, >RY9';;A%$ +\P(QP !Q^[GDP_$?+CS%[(N!$
M>/>(B(^?/J//+X.F%O\ "W++.YX<2;Z#5=S>S>"-_P#P^(^+WRR'_P#DD=YK
M5FX'"&W^+PMD1*4QE0T&LG692'1<.(M@V40DI-HJUBUTGYTQ<(KH2!VRR)D%
M"K"HF4I!Y'4=A]'.Q\#V4\396F(/D9=H?)9K 2 79OV1<<UJNT&#8!38+B#G
MX91 .II(VO,<;'-D>PLB>V1PNUS)"TM(()(&>:S_ &JQE0@L!XWKU'8QT= U
M^O-(<K6*6*NT"19%[N76!4HB)EG,GXIPX%014%90XJ#VN==T5-%1Q1TL+XWL
M@:(BZ($,VV7:]K0<_E<""3J>.IS^RHIFX#AT5)&R.&*!L9;&X/:96DB9Y(_[
MGR[;W7SVG&^:D+KL7HDT1-$31$T1-$31% /JG_1U[Q/S&W#_ *LGHBR?IQ?B
M'[3.?^0VA^G_ +'1U!]S]<T.I_GWWJ:NJB:(H1]1K<M;=G^S'.>XVC0\//6K
M&-90FHB)GQ<!$O'"DJP8BF]%J8J_=]VZ.8.[, ]H \P#ST1=#K<'\IIW:;B*
M-#T6RX<P[#L(C(N-\CHNHH]@.Y5E,9W*'NL2S4*Y<&3\(]?Q"#9X(!WGAE%.
M[$#\:*_OW\NO!3<VV?*E-X.9,^8=Q/-85PM'0V0<@UBHR;Y@I8Q>M&,U)(,5
MUFG>N#)=^DFJ)D^\*8HF  ,'GSHI:_H>'"^_KP*[O>8\KU'!6*L@YDOR[UM2
M\9U29N=G7CFOCGZ<-!,U'KX6;/O$?$N>Y2,"*/>I@HH)2B<H#R!%UHMQ'5XZ
M:>[:$A)FU88Z@LN>)A),]*EJ1B;*E6C7(RS4YFKP751LK1G*MCK"BH@Y6%TF
M4GWZ?:*(@+(^/Y'[^FY!<:V^OU_ X<X][ >HWL<VQ4;&ENR#ASJ*3.XN,I[V
M%OLW(8WS)=H!](/GJIUU4&$Q830ZPBS29%3<A')JI"4X)B':,)H-V_@?#K@A
M\+'VR]"NT)LXW@X@WRX0AL_81/9OF/,R\]!)M[A!C7+"SE:U)KQ,LT?Q)G3P
M6QT7C=0I %<QC$X,8I#")0J*K'*'R@_;;CG+F5<0QV =T6193$%YF<>6J=H6
M.2SD"6QP2PMY!NW=-WYQ[!5 $R(KE2450$BW=D(H73KKK[I]>'TW;U7]@3K9
M8VQEN7WC9BG-I^\!Q7<^67&4Q46K'$SQ20:-J?16]:E"RR9UB)MU#OV_;; F
MHL"B!P,8Q!#LB171["NK1A'?YDO(F)*)CC,>-+UC:JQMSFH;*]43K2ZT%)R"
M46@X;)B\67$XNEDP*51$A3I]HY3CV1#1,_+WW_C^+9VIZ(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBA9OWV[84W%;>+9%9XJ5N
MO5*H#*3R3\TJ98IFNRT\_JT0^>H1Y%(9P@J^\04ITTF;@%D!6,104C&(714$
M@@@@'B0#:_/+A^M55-TO*I7$\W5&W5C&<-3(21QO-K0W<[[G6<I2-C7A8I1M
M&.<2G6,W:K)IE*F\=@0!@UB&0'@RY@U!^AF3Z^/KS5=P)S!T+0-Y//QSXJT+
M?KM7M.ZC'=.@:1(U"&ME+N8V>*EK46S-CLB.Z[.5M^:'FJA*Q$Y$/3LYM4J_
M<N3MI)AXJ,>(F1="8M7'Z6S]0?MOR\.%;M?Z*5CJT55L-1.:(0=OGSKPCE"]
M)+UE[]D21R#A&AJ4Y@T@I LD,4SK5D>)QLW( Y;JOV8LUV;90Q'0F"6TOG:W
MJ-ZNT;D\[9Z FY^I'GNW; IW2UR[$XNR-$7K=!-4>U$P'AO;U1KY@&-5JEAC
ML8[?CR3^%>2BLVYDDSV"X)N"-+$DU*FQ0;$5(T#\,(@MF3R]O+Q/'\";[MY/
M(G73KGOX[Y.>S/']-ROL%'2[X[+,F9FAWCDP&<.S-;D[;F<KF#@#+N#)BLL(
M>0JJ'$/(=!SZZ^BBO=U431$T1-$31%Q,]*A!0DM-&:.WY8J.>2 LF")G#UV#
M1 ZXMVJ! $ZJZO8["290$QCB   B.NN:3N8I92U[Q%&^38C:7/=L-+MEC1F7
M&U@!J5E4-*:ZMI*)LL4!JZB&G$T[Q'#$9I&Q]Y*\Y,C9M;3W$@!H))7I5"Q)
MVZL05F2CI&)).1C22",EV_A9-CXI$BHM7S;M&,@Y1$PIJI'[*B9RB50B:@&(
M7A2U JJ:"I:R2,3QLD$<K=B5@<+[,C#FUPT+38@Y$ W"[\7PYV$8G788^HIJ
MMU#4RTQJ:.3OJ6?NG%O>T\M@)(G@;3'B[7 W:7-(<<CUWK7*J7='D";W"Y:C
M]L^-5UG$#7'[=;(DNP$3MEYLP'!.NF<$ 4@/'( HN^+W@&; *AU" <S%77G\
M2Q+X1K,29#%62T];\!V<PZ2SHL8[2AI<Z2>,_P"V&8!"75=9( YAJA% [.P/
MU3!<.;@6#N-1(^DQ/M!AYJ<0JVC9GP#L@]X EA<,X\3[2S 4E&T[#Q0=[,P[
M,CP+#:74*_AK'+>#B(]=:/KD4L[=HQ;,7+^1700,N[.W:$'MN73@Q#%00 0$
MP]A,O9Y\LO"L.&%T3HY)9*NJF?-68C62C:GKZZ<F2JJ)/_)\KR0QNC6!C!8!
M?.<;Q4UD\U88C%34\0CI*.G;M"FHZ=NS!30,%KEK + 9O>2222OXXJRU6,NQ
M#^:JL;96,>PD7,6HI8H!S G7>,5U6CU-JFX,)EP9NT%FK@P<=VND=,0Y*.LZ
M"6*9I=$US6@EOS,V,P2"!QL18VRN%Y[#,7@Q>)\U/'5,9'(Z,FJA="2]CBUX
M8'$WV'AS7\' @[B?ZWO,./,<F2:62P(#..TQ4CJI#IJSEPE2\B &C:Q%%=3#
ME+M%$IW0-"LT! 3.'*) ,8++410D![QMD7;&T%TCAQ#&W<1XVL-Y2OQC#\.L
MRIJ&]^\7CI(@9ZR4:?XJ:(.F<+BQ?LA@_P"YP4,-TB.Y#/V#KU7Z-!(X4J\B
MT0.I.6V0,-]E8ANZ27=-_F_&@JS@VSY$I"*D<23UVJB8Y!*V4 Q=8[Z6JQ9C
MZ1DAPYLUFMG>WO)38WMW8($8=:Q)<2!<Y+QO:=_:+&<$K8Z.D;A5*Y@<^2KF
M+:Z:%I#G-[F,.; UX #VF1[[:%N86SL2[8E5<=TIOFN_7_)5B:0$>WE&TE;Y
M)&LJG23_  8(P\89BW%/P_=$'O>TJ8 -WICF$QAK</:QK8YJF:L+ &E[BZ-C
M[  D1--AF.).^ZV6$]FB_#Z/^]5E?75 AC[V)];*:4%M]EK8H^[:YNSLBY!)
ML<\S>1E:Q+C*G]DU:HM9BE2" E<HQ391X AZ&\:Y(L[[7O[0K<\\B(\B.LAD
M$,?^D4;3Q#1?UM?W7HJ;"<,H[&GH:6(C1PB87C??;<"_7.^THP[A+] US-.)
M(V4;T,[H'*3ADK8<GQ]4E1]H.R1P^&AG+1544TAY.BN54 D5P\!PGSWFLEE6
M(F31;=&'N;'W39ZJGAG+GOV7"&.4B1QV;6++ESB&@7%CHL;I:R7%\(GAPF>L
M@B>YTE5&ZI$40.3N],5/+%$(Q_D#GO:'@%I :-I2W5O5*;?>N+?5T#@ <D4G
MXHIP'T[/9%T!A$!\O(O(C[M<Q35+A<4\Q!WB)]O79MN7H'XGAL=P^OHFEN1:
M:J .%LB+&0'+>N./DRD!_B9U%[Z\>S&SV4YX_P#B^SVSD#?5V>>1 0#D?+7,
M4=2;7B+;_P#F6L\<]MS;99\EU'&,-'^M2V3_ /19)/?C;N6/TWKUS9-KH\^'
M9V=WQ[TJK.I%$/CVWC)JF ?6)@#W\\<CJ_!2W^9\#+[W3Q6]G$K@,9I'$MCC
MK97#<RAJ@?\ ^2-@Y9YJO/?[N;IN.Z/4I&5QE+7%-:THL>'EICZG[*5516$A
MC((RJCMT9YV!:@*S8B38%!<"H0Q"CK6UU53X:P5,LV&S@.;"YCL4AI9&&J/<
M-<W;C<) "[Y[$&-H+S< K*9V>_XQM1/AK:$PWJ8I:J@K'QRMA!?*Q@I)+[1C
M#K"06.C07[(._:9N\Q.E2*D=21J%?54K<,H->=Y/HSMY$F.P0,,:JH6><.W"
MK7GNA542!102"90I3"( %9@T+0R7',)C<P;)9'6Q3M#FW!:R1I;WH!! >UMG
MZ@9KN;0XU T04?9O&9J>$-C@F-++&R6)H 9(T37D:US;$-D/>"XVQM7"Y13>
M'0A 18@QDP$!$OLN1?S(F^' 0,#+=KD?+[SM /GQY^0\?[I@0S_N\3Q_[BGG
MGW7L.Z#KGP]UV? ]IR+_ /#LT8L3_P S64U-IOM*6D [KB_.^7&J;Q(P3=EK
M0[:],/'9!K4\E*@;GX*'QX@B(>OF"HAQY\@&N/\ =L$O85==)_\ IX17$6L-
M[F-&>>^VZZY_VSM0?_PK#8Q_[['J%I',-#B+<#FM(;E=S^5'N#[^YQQANY>V
MX^#=R97TG2W,C&-F,>0SB2679V!@U3'NV)5E"*@U451$O>HE%0I0UBUN,T$5
M)4STIQ@2T\$E1"]N$"1IFA89(VO9/*T!CGM;M.(<6LNX D+-P[ :ZNK(*'&H
M,#%#5R-IIV-Q@2R-;,YL>TSNH0#(T.):=L6< ;YA21V2S^0;7MHQC9\FQC>'
MM,_#>U58]O$-(/N(YTLH>).M',DD445W$=X=PH8R95E15!1< 5,< R,.J#64
M-+6.DFD?5P1U,IGIXZ61LLS0^5G=1DM#&O+@QU[N8&N< 20N.(4%)A=;4X=0
MQQ1TM#,^EA[EYD8]D+C&)=LYN=(&A[__ ,Q.9U,KM9JPTT1-$31$T1-$31%
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ME8*;I)&)P' )*QN.GS@I0#@ /XLPAP B83 (Z] _LUVHEN:C%ZIHMF!+AE.
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MZRFU7/<^F"=VWT9O=(B'"C2F5/$-$3,4?X12/H>B^V$@X$2E,21!0H<"!^T
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M41Y\O/GU]_/'/ ^6JHI(F$>R?D?4!]?@ #[^>./,?+S]W'KHBV5\G7^CS_\
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MQ9I$B)J+,U.JF( )C&,/KSKYW\M_/AEF+CS^-\>K?E:28;K<NV?<;C!%@5W
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MIJG*8BY>J4*ET9%=O3ZO"5M)T!0<EAXYLQ%P!'#IT4%S()D,J!73Y\Y %!,
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M """,B%#-$ 29& -.R27- !X$DC/(^AX%93XIKX8'GB4/""D"X.A53!OW(E
MP+=\)N[[H2B!@/VNSV1YYXUC6-]FQVKVV;&][VM;6]\K:W7.XM>XMQW>J\E<
M-S*@@5=$RXI N")52"J* F H+ F!A.*0F$"@IQV!,(!VN1#39<!<@@7V;V-M
MH9D7TO;=JEQQ&E_+CR6C-S5UQ1CC!^0+YFJLLKACRL0JCZ9K3RN-+6:;4543
M91\0R@WK9T@]D960<M8YB0Z8%\4Y3$ZB9 ,<L54%=C&7MIUPOJ=6QKM+9;;L
MF3M2N5Q1;O:+3XZ5<1U%R)(8WN$4:>KB2WAI&#FV\:J^C/%$2\+-,3(=]V%^
MZ@Y6_7VX*F^I(/C?P]?;P5L>JHFB)HB@'U3_ #Z=>\3W?X#;AZ__ +LGHBI4
MV/>74QZ;G AY]&]QR'_VPAQ_F'X^\>=-]^7M?\IQZW!=J?1%0OU??QL.CB/P
MWTP'IZ_^"C"/'\@#[]$6_>NA]%7N]_Y@-?VAA^?Z-$7R>_<'Y1_471%+386'
M.]':\'_IMQ_^T#/4.ASMEKP\51EZ'W!"^J5U0_H[-Y_Z/&2OV?=:IT/7TS]$
M&HYCK?\ 0JCG9P'.T_;GY\?X':('KY>4$U'S\O3G^<>/Y"BDB8![)N!#^";T
M'T#@1^'GY^?U^GH.B+9/R=<0'IZ& .>2[A]Q #S^="?'R^KS]/=Q[M%3J>9^
MJHVPWY[ENHV/ "'V[F5/(>./(S+D Y^/IZ!^74XVW\,K<_,<#PM8*<_#W4HP
M]X" #Y\_4'Q#ZN/< >7N]VKJ.?F$Y+/^CGQ]UHWAAZB&UC'/GQQY!<VGEQQ]
M8>GEJ==:?3]EISK<A_LKV!!]_P!JK:/C_P#.-4/Y_,?B&JFZ_/VM^5#_ ,OK
M_MZCZ?YP_ET1<IM8^EIZ;G/ES;<JAY^\?L>3I@]?R"'QY\^/?IPZW%7CXC[A
M73_*%&IWT#T\&*:15U'N_7$[0J)T)-T107#*=1[*C2&41E':8@?\(T8K(KNB
M=IN59(%14*4ZZZR6"+KE[Q19(QC"(KR20(>'9J* JX)3&"B#F([TC!=943LV
M4I7DUFL%#=Y0\7M7T^[E)])OZ^GU\M=Q0@ZC[3O]FF:&Z8)J@BS@7G/L\Y&P
M-ZS<*_ >(3CXAP+)LF@[6%C#(@X4J-*3%9DH::O\@\<-Y;UW^/EUNX!.NN:[
M!F]/G[D;F[CS'[3!SZCYC_@X9>OUC_3Z:#0<MUO;=RW*_P#=EQWWX[]_W76X
MVJP,ZOMNVQJIU>1617PU@<Z2I;EN4;$<D4R\NDFJ1M"LC0S<BI@%(J,.<T<B
M/*D<<7FG[X=9:*?QH.'\?75;"D*_/?-:P"-6D0 M*LIAYNNZ 0 I=RITA$2B
MP[D0!7\#V%1\,8P"NJ/M7[W5ZZZ_2_YZ]%:]\G6 2].4"F 2G+N&W$@<AE'2
MHD,&09 !(*CX"O5!*(" G>%!T80Y7 %.UHF_T^_Z52^U^::Q+7?P@=QC=BPD
MMQ&X-O,05M8.9.IWQV&5K0M$*WVRH"8N,<D5PS4J^)U5"M4[,T8I-C/DQ<D%
MK!OYGKKSSNJ=W+KGT!D%->[V]PHIE\TG;Z1.@]QM5HFQ'NV-G]4-?)IF>7]C
M/,O$\.E]BS<O3@8)EQF0#-FE\1B&XA))>.*,8RR&5QIX#Z_8Z%3KKKZK*>CA
M)2$KU ^J8[E;')6R0*OMP:.IV<IAZ!8G:K.B2+8Q+155")C'69J"0-9LY$RI
M/)!%=XF4A%RD+5#JWF?H5V2=%4T1-$31$T1-$31$T1-$31$T1-$31%%C>)NB
M@]I&%+%E5_6Y*]SS5%RWIV/8-=%K-72;:Q[R8<1[-TX(=LR;QT+&RDY*/W(
M@SBXQVJ/;4!-,Y.'5N:@&\ZP,1&2U:FI#"$PEA\TKA.DY OZ5MC%9&GY&SOC
MPN1*G#-:P5B+J<AH]DYC(N9F6[A(B3^31,FF*2"X:7_'JK8^Q-O/[6/\K<>V
MCJ$L]Q<=>X?(V.T,%/1P=1<]4]:?O$'+QD[B7,C.9)2'TC)$2CFL-9 &/*E*
MPJQSF26>-R('.(&Y#-0BWCF1IO&H]?MO49/D]Q5G73>;ECW1$7#C,^=P9/"@
M1=-)56ZR/AW  4>PLF4QB*  &X4)QP/ \ZZ:ALKX)F02"*9T3VPRENT(Y2TA
MCRTY.#76);O (7;$YC9HWRL[V-LC'21[6SWC X%[ X:%S;@.&E[JWR(JF4&H
M5 )/(+1\,4[?JV<2PY4_;S5P)Q:(-Q[8BU%KVB@!S]H3 7SY'SUY*CPCM9#_
M &3XKM)#4_!S5+\7M0M8,2AEOW,<>?\ A,.5G$&XT\/2U6)]FI?[M\/@,M/\
M3% W#/\ G'/^!ECMWLDF0[P2V)V1;6W&^W]>S7E5PL]8X"KQRLM9)N*@(Q'R
M4D)A^VCVA#" ]DO?.E4DS*&X^]3*83G'R*41UW04]152"*F@EJ)':1PQNE>1
MQV6 FW$VL-3DN#Y&1MVI'LC;_P"3W!K?5Q 5)M*O>9-Q62K_ (EQW=[,XI4K
M*/6D_<G4Z]>1J%1:O#1SQ&!(L@R=MVTHNT47%XF(/#MG@1R!BIJG<)_+Z/%L
M=P#M+VAP.EQG#L>[3MFBI\.I6=]/2=F8JC#\/K9<=Q0N=)3RNH):J6DI\/VW
M32XA&[:#88RON>+QX)BO9CLYBV*=F8^S^#4\+IZN6"EBHZ_M)5Q5==#!A4+F
M6FACJH(HJB>I+1&RCV7 &:0$YEO$EK!LZC,#P6)).APD&YF![]E/.'*=IM-N
M9M54O:#=)LW."K8S=4C'MJJ)MVCAZS;E B8\AKL>[*34KL)EIL7JFUC:\XG7
M5TLT9KL8QE[7MDJZF25KWN+V/>R-C7"*%CFQ,8&M!7RS'/ZIT^$.,F*.PF&'
M%6G Z/"Y,.KZF/#,&8SOF,PZ*BECB$<4L4%.6/:))99N_DD_WOR.\2T0./MO
MN1K1N':QEAS9F6@SM4JF/TY X,L?UE[&F(Y8L7*)C"B# W+VPV!$$W$L^$D:
MW6*V(F4?<US*F6FGIFP256)U=),QD,+72.I*416FJ'-:'#8BS>]S6[4CR(V7
M) .A['8"^LQ2/'\?%/&8YXB[O]DTM!3&0.BP^(2G8=/,1>:35QN">[99VL>E
MGL@JBU)HFY7)4H%ZD#L5%,5T]Z@Y-6Z&)556TC8EF+XZK>5MS]P10J<D*0MH
MUNFEX "NA.L3T5*^EI\)PS"<-$D>'T-+3M<R6)T,TU>88S6U%4'@/?-WY?&'
M/OLL8&M)&:V^/32U.,XC/*Z(M=52BG;"6]RRG:\MB$8:2T7 +C:UR=!OO7T6
MI31$T1-$31$T1-$31$T1-$31$T1-$31%'#/VVFL[A:Q9JQ:;9?8V-L4&I%&B
MX2R*L8%%T0AS,)-2*(@(+.&KONG!^'"??@D"9C%*8=;W!<?J,#J*>HIJ:CDD
M@F$G>2P!\SFDC;C$I-VM<R[1D;7OFL.JHV53)&/DE:'L+=EK[,O_ -KBVV9:
MZSM1=?WP+MOK&WVMUZL5.TWR0AZ_!(PS>'G+(O(P7> 1(7+]&-41 $72RZ9U
M2G%=04P5,3DP<#J8UCM1C=1/4U--1QRSSNF,D-.(YK7.RQT@=\S6M(:<A>P.
M2M+1QTK&,C?(0QH: Y]V[KD-ME<CRN;:E;$FJ4M*W)G;!]D*C!5]\VKS9VS,
M95"QR!U$U91VY3#O!028E19MRHF!=$CB0[(\+EXP(JH1TKZ;_(!/.QU0YC@-
MJG8&D1L!RVB_:>[:^4EL=[V*[71%THDNT[#"(P1H\WNXD&Y%B!86M\V>:C1(
M;>KHT> [CS1#B,^<)IA:N13_ ,.FY?.B6@[^PJ.[(SDDDWKH\ZT;JLDTA2$K
M,RJ9B&, CZ!F.4CF[+^^$G<=T*B9FT6L::5K( RG=&2QK8'N#BZ_S!INL)U)
M*#=NR1M[1C!L'$]YM/)?M $[31:QL!Z[0G,;Y%M$/D2 G;#&+UNRU"/BJO7T
MVYFAX*713<]\JXDF!FYUDR*"V RB()E< F4>P0"=G6NAKZ&GEP^:&F>*BFJW
MS5,^UM">(N;9K8WW#;C:(!)(N03FN]T$TC9V.>-A\8;&S38=GF7-M>V5] 2-
M++,X;'[J+R8-W[Q'N'&.F%2?%!=P=5:18239TDN5 YQ;IHE037**B:9%%#*%
M[P3\!QC2UPEP\49!#FU\E4S)MFLDC<US=H#:)VBW(DBPY+L9#L3"2]_\(C.N
MK2"#F3EKXA:DWUV6+J&T?/-AFL;M<MQ3"@2_CZ _*^&-G&SDI&JHRJD8122;
M14<58923>QY?',F+)=VT,5PBF8-8LC7PZZURXJLGIL1VVG'NYZ:Q_M\AJ%?D
M;-MWA\AV7,%(R+;\EFI5H>6)K\[,8OWUB7>,X",GYR15LU?9(+HRTDFQD'$T
MD=9LB<(!;+GU]>/-4DG7EN'TZ]E?3JJ)HB:)<:WRXJ ?5/\ HZMXGYC;A_U9
M/1%2IL>$/NF/3<X /H;U_P O^W"('R#G^3^3C4WGD/NG'GOR\/M==J?514+]
M7S\;'HX_ITP/]5#HBW[UT/HJ]WO_ # :_P!-AA]$7R>_<'Y1_471%+;83^.G
MM=_/;C_^OVFB+ZI'5#^CMWG_ */&2OV?=:*MU',?54<;-Q =J&W/U$0P[1 #
M@?\ Z":CSS\0^'](Z**2)_X)_3R ?B''D/ <^7'/'(#QSSZ^HZ(MC_)U/H]#
M_I#[AO\ M/GM0:>EO0<QZ9+D[4>?_P#LY4<X9#]\IU&_/CC>YE8>. X'[YES
MSY?#GU\OJYTO]O<]?=3]=9?SQS4HS<\< 41#U'TY ?,!$?RAQR(<_'S\N*H/
M3Q6P.CIQ]UGWA\?Q6<<^?(__ #R:"'ZQ$?R\^8CY3?KY9<==+^'YU1:;ZW'T
MK^!?T5;1\!_X1J^X?[#I^?7+?UK;?DKN/+[C3Q^V[>H?^H>7'GY^7'_O^OC^
M7CC547)[6.0ZM'3;]! ;=E4/=Y?X/)X0^/G_ #>_W^D.[G]CUDBNF^4+I)KU
MWIYHK-Q=IK;]<3)':!'NY<71%&4Z4S8(E@LW>2HK<]V6-071%\8P-5%4TECF
M ?Q[\N@BPM8PBJL(GX,8[I<ZIUT42B8R98AR^4>Q!.TBB+(25=U88 @&36,3
M$^,&Q!7EYK3RRZ%K6T\QZ:NOWJH-=2!$#;,<SD4;'7$K:KJ]T:*2<'16CK1
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MQS0\R!HL6@ %1)ZCV:,8UR$K.W;,S>(98UW#47,8S5ND[BSI;JNR.-JVPM$
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M:AMS^ 8=HG/P#^X;0./JY]>1$ \_<(#H-!U],O1121. ]@X\\AV1\_4.?/\
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MCD#%(84JM>R:ZLA,-76S05O4ID9=BFI<.K.RV,X6N/E;A'G?($B&[ED_<'6
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M/6)\O[SMJGU\9+E?YA_N8 #[_355RX'U'X7M8XZ4?6)QON5P/N984G:G(67
MDG8Y.!@'.3I5&)F5++!/(%TE)+I11W"9$$'AUT#($Y[PA2F 2B.IPZXY[MV7
M@3OW3EE^,LO92SWM;5>M3OC98/C\@X8V:0+/!V9JYFB*;166[.Y0L4K6D'B#
M:!F@&-8KEAGH/%"O@:+I.%DOP(*%(8_-/.R+A4]H'6R$Z!W6+=GZP@:-.].W
MRI-QR[I0B*C:P.FJS*%2&)?SC'P]>8NX\J04^GHN*_5$8Q5^ZE#SKTX^?UTU
M5Z*U!G'IO=93/6);1B6TXTV?L8ZUL89%W)QN2)A(6<C#S2,BWDV,6G&(L40C
M8ILWK57BO.)K<9XQZ@T>3C]Q*C5%-S*^/>N5EG;-;]L<K@_9;&5FWXI4Q.ZG
MV67K*I*M(I6"1@322#96$*W.\!NCWP)'4!+O#=D3" >9%!W&O2_ZJV.*!CZA
M(8/VQS"-!J=,JB4HONBS5&K2R=.M![,D_681DLA'1ZLB<W@56L>@DT9I@+ED
MFDN(CIUKX]9>2?OKKRLN>5Z;?5:5C'T;]@7:\4KV'D(@5_MJ,YF.F5_D(;^+
M@$QFP24.DJ/LD$3E[@Z >/.07XBKHGZUL=W+3^-%(#8WMWZVVQ3!88&H6&=G
M%LKA+S>;RE)V/,-F2E"N;U.+SCV/.=*(<BN@R67,@V<K*G<J)E ZXF4$QA(?
M3KK=Y*-V.^G;UK\;&RD_@:]MJ;V'(60+_<X:;99@D6(TB)RI9'=ER)26D9\W
M'$=9(*SNW[LJREC1>.H]06[F+%FH@)576>:>75M?NMEN=F'6K)[0]@T#;77B
MMX1O1Z("&?;3)#0L4O1!2Z8M:FEX%Z:RUBX++/E3J6GVG)U\5600;QL$>7Q!
M.OJLQV1;,^KEM%W&9CRG#XDVLC3-PDUC)M;Z\[S3;;"YQ]4Z"R5A$6-0D96/
M<2DJ1O$N508MI=RH= J#9J5<R9.0EM?&WMU]4X=6UZ\UVCM5$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T1?A-))$@)HIII)@)A B9"D( F,)C"!2@!0$
MQA$QA /,PB(\B(CHB]56,C5G7CEH]BJ]\*HR\8JT04=>#5'M*M/$'3%;PJIO
M-1OV^Z./F8@CHB_D,-#C&A##%1HQ )E1"*%BU]F@D0X*%2!CW7A03*< .4@)
M=D#@!@ ! !T1?W28,4'"[Q!DT1=NB(IN723=%-PX3;E$J!%UR$*JJ1 HB5$J
MAC%3*(@0"@/&B+^3J(B7SMB_>QD>\?19U%8UZZ9-G#N/463,DJHQ<*IG6:'5
M2,9-0R!TS'(82&$2B(:(OZ/(]A(IE2D&+-\D4P'*F\;(NDRG#T,4BY#E P>X
MP  A\=$7E./8),PCDF31./!(4 8)MD2,P0, @*(-2D! $A 1 4P)V! 1 0\]
M$7'0U8K5<!<*]7H.!!T8#.0AHEA%@Y,7^"9<&+=#OC%]PJ=H0]PZ(N2:L63$
M%BLF;5F5RX6>. :MTFX+NW!NVNZ6!(A 5<+F^^67/VE5#>9S&'ST1?E['1\D
M1).18LWZ:"Z;I!-ZU0=$1<I<]TX2*N10J:Z7:-W:Q !0G(]DP<CHB]>)A(6!
M:F8P41%PK(RJC@S2)8-(YJ9=8W:66,W9I(I"JJ81,HH).VH8>3&$?/1%Z\=6
M*U$&,>)KT'%F,[5?F-'1+!D8SY9,R2STPMFZ0B[52.=)5R(]\HF<Q#G$IA 2
M*"^Y+;#N(S;FFNS-.W(_8LPZSHCUM)5U'%6+K[,MKXA*M31S^*<WNM3"J,;(
MQ2[[VJ0'!!2=,(\&Y !5<VG1ZZYY9OKUUZ\5M7(^)L^J;6I#%^,<[.F^=V%=
M(S@,RSU1J)/:4PW>G725F:JVBC5=JR7:&+'JH,(PB:2*":B1 4$XB1?C;MA+
M/F,7[J6S%NJN6>"2-=CV7S8GJ+CRK1%?G"&26?R,6^J$+&2#LAC=ZS01?'.D
M#8"*"3ON3:(M4P.UG<\;(TA;+3O2MCFE(Y.7M45C!OB7$*T(\JK>12=Q\-*3
M*U:]N$D%6Q3LW,NW=%D4BB"R#@JP=O1/#=Z++=RN#-S&4\H8PF<+[E'N"Z)%
MPEICLA-XNB4.V3Z[Y;PBU=D*ZZMT'**-1=G,\93K8JZ+<[5JP43(*O>"+KK\
M(L\^Q%F>O;:+)BZLYWDY/,P5BRMJ=F:5IM-B7#"R.O%NJXY=U.&BT*L#".<G
M:LW"*<=^'9D45.!G!A-HG+KC[>ZUSMEVX[A\7S+&Z9GW5SV7)>:JS)*[U <9
MXPJT XMQV37Q4BWGZO7HRQR"$4[!TVBO'N3]XS. KE$P\ 18'?MJN[/(&:\E
MV5IO*F<=XEE$:ZICVIP6),26:4BQ4:.$;9#R\G:JP^?.8OQ#=BXC3G=JJJ>,
M>)+AV$$ TZ^G71N6VMTF&=PF2\346EX2S@GC^W1%@JR5WM4S2J;9D;A5FS=-
MG955X.?AY*$9RRYB#+1Z;-DDV2>F%  (V*4H$%O:PS]_'S65X P1?L/U&VU6
MYYWG,OC/K'/"R,KCW'5("IHJL%&BR#&*I$)%14B"ZYRO53R;9<3JD!(P"B8Q
M!(H]X.VP[RZQ,Q4WE7?%:)J)@[G.+DQM7L58FC:E,T9*3=A6HEW(-:VUFHYR
MK$G:C)FCW"9DW:9@;G @CS+<_4HLPW+[=-QN9<L4N2QMN27P]B=&D6:(N\$U
MQMCB\2SJQJ/8X\$ZBU;O7Y82QLHQ7E6M@9F530#P$8=%,QUG ZJ+F\E;?<[O
M]I;S"V.MP\E'YC8QZ2,)F!_2:0Q+(';RHO$XZ6IT?#A4V\4K&B$.HDRBT^RB
MDFX*'?\ :,8BR3;IMXR9A23FW=XW/9&SO'R44SC(N$N=6H%=8UT6BXJE<QQJ
M;!Q*R@F(=1 $')E&Z1%#BDF4PB(D4L=$31$T1-$31%Q4W P=EC7$-8X:)L$.
M\*!7<5-QS.5C712B!BE<,7Z*[5<I3 !@!5(P ( (>>B+W6C1HP:MV+!JW9,F
M:*39HS:(IMFK5NB0$T6[=NB4B2"*292D222(5-,A0*4H%  T1::R]N,PQ@F
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M]>ROT8,&,6S;1T8R:1T>S1(W9L6+=%HS:H)AP1%LV;D3102('D1-(A2%#R
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M.B6#.,8-P$J#)@V1:-42B(B()-VY$TB (B(CV2AR(\CYZ(H(3G4,PS&;BYK
M[9ZP<,:/*0]+R/D!U-,FD5 Y<MXMAH^'Z]$<+2]SODRV<>TY*-AD#)P$67Q4
M@L4W:2*15MGV^[EM[^X/<A)66IO]I,:_IDEB%QD8<?&NU%W9XH&<G(1@ZN5-
MMKD8*!M549@BXJIRG2ML:)4GZKMW .&\<G.N6NF6?G_(>'&XM]<OK^E>?A[$
ME7PM0:Q0ZRFHY3KU?A()U89$J2UBLAX2-;QJ4K8I,J97$G)KHMB&6<N3J*"/
MD!N #51:QW6[JZ%M0H<5:+4W>V&TW2RQM#Q9CN%4;ELF1K]-=Y[*K4.+M1)J
MV 4T7#Z3E7JJ,?$1;1V_>*D21X,15P;Z<TW;<WM_QY5MOV'6FXB#R//2,5D*
M9QU(3,VYP=8*,]CG Y:QQ=JX+,+3.XIN:"2L)'UL$Y&R3$>9*)=)G9.D1FML
MM^_=KPOUXIUUSZNI8;4-C+K"5[R#F'+632YXRAD.+H$4K9I?'U:IRK=KCYA*
M,86?E8R'2.VD<COVDPJULUQ C-Y*(M&3?PK9)N"8WZ[_ !/LG0'#P"L/T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$4.KON)Q_E:U9IVBX/S=#UO=)$8FFYAD^9Q)K&CCR3EFKJ)@II^"B8P
MCN1AI59F_=0*KL[Q)OW*KEIW*I0.0^?'G;JRH-A=G.X;-^<\+XLO,S UW-&%
M:M8+2PSM"T2;RK:-OECC)9%:#99 R]D%^XI&Y1ED]O.3<P2JE90Q\:6,HJP3
M5B@P[)F?EO\ LF0XZ\K[N.7EKNXGLC[?<"5';KCY"BU9_8)]RZDGUCMURM\N
M[G;=>+C,G*O.VJQRCQ10Z\A)N [0-T 18,&Q$&$>V;,FZ*)"+^.:=SF MNOS
M;^S;E6H8V&W/3,:\6S2:;$\BHDH@DX73((&,FQ:*.6Q'D@L";)J9PB5==,52
M 9<<4SW GDJ"-Z&VW/63\L2^&,QV: S_ $O/^=ZA)XQAVE GIF\57&,P+&$7
MN]*O\:X&G8%5P4T>R<DNQF&,HQS"P4D#3\CW+LT8TXD'+GSW'/R)TT(R\%00
M+\1Z7X>-\LQH>5U=#M#VB)[:(5_(VW)5BS7EZPQ,-7K)DRQ,&5=0^:]82\)5
MJC4:/"*?-BCU>%:%((14"@D5](&7D'RJZID2H<E+WW6Z\<_7DMT9@S[BO!+>
MIJY)LR4,ZO5HC:;3H=NV=2<Y9+!**@1%G$Q$>DX?.DVR?;=R3LB/A8QBDJ\?
M+(-TS* 14!=2>KYLE<B9B)9WF3<N8^R;$0<EMKJ=,C'64\#7IA#-F;:VX#RA
MC2KL'LM4;1)2O>3]2SJT<MW$.^.V,G,-2,5HT\)&_P#-^(MF3XY:%!?7A?F/
MI;EQL%8]L0Z>C';.PJ5EN&0;?D&0I]96@,+TRQLXF$B<#TBQ$;R<K44F-;,A
M&7&X"^,=I.9(FVI[#+(-4&XF02(IW]2Y-[]6^G+A;D+.7SUI&LW4@^73:LF3
M=5TZ<JCV4D&Z!#**JJ&]Q$R%,8P^X '1%4AOLM]MS/A["&==NN4+S;=L[>>?
MR.75ML]N8Q^2)FJ34:M$5^[49XDD[4N"V/;&HC,2>,D"&<W%%-2,,RD3I>R7
MHZ&Z#J_7\>"A-L&Z;:F1EKWE2W6N^47%]UR)-1.2*"PQV7$+;=Q%4B5)*8]R
MW,Q"S:(N6)HFSK2\F.1,70:3"J6RQQ;B::MFL5*J-G#S^GXZMSO;^ /CPW6]
M-,CS"[)J**+9%)NW2(B@BF1)%%(H$3223*!2)ID* %(0A0 I2E  *     !H
MHJX]Q>Y2LYKJN=MLFU7-,(CNM@ZW)*0\,RE%:^Y<NZW(1ZUM@(*XNV*L.UG6
M\<9:,?O&"CYS6'+]N[>HM@+WR<)LGC8VO:X&GV]U39M_V<6O=)N9?Y#I=JW!
M8;E*+48=VUSUD_'#)QF&L(3[M:NY"VY62W69FC#9;FVT(F>7QSN%K[B3L]18
M.TV1)9\1--(;ZZ:_SG[*G+QS.7W&@-[6]^79LQ'BFG82QW6,8T-H\:5FJQY&
M+$9*1>S$J\4$14=R<O+R2SA_*2TDZ.J]D7[M=1=TZ655.;[X  IUUR6+YLW(
M84VYMZ*\S3?X7'[+)-ZA\;4]].'5092=PGDG:L7%G=E3.@R!R5DN'BWJB#1,
MX$(HL4RA $GV77>Z@.-<T6[*68J5D9CE[-#+(-_@K3@^CPS)UD; F4\-S+V*
MA2XQ!A763F0VXYEQVZ]K6.M9E[YB61!F9=]*OXMR_BVCK=_/\^E&[.V>MLQ^
M1^/6X;93L+9;5$&TO;,JVC-EWA*L&-:'.V"*BJI$8]Q&R>H.X>D5NEU@R58:
M/CBS8N+5:B- F;1*-P<NEDFQ$6A&BG775E87HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*"%EV55^K9*P
M;E+;:VJF)IS'%VMCB^QWLURO'Y(Q_DT!7R+&2SDIW$BYL[J7:Q,U"S#U=86S
MMLX14.5NN!2NBBEY0\>4S&,$>LT2";UV"4EIF=/'MEWKE,TM8)%>6F'G>/W+
MM<#OI%TNZ4("H(D.H)44TTP*0"+,]$4(]Y^TB'W$X[R;(5B-ADLZ2N \F87H
M-EL#E\$$RCL@EC7CMA,L$C+,UV*LK"QC@7*C!PZ:"D8[80$PE,09&ZR/:'@6
M_8<HI)'--W99$S598^(:VJ<A6'LFJUR#A$%$JWCNEL  BRE6J*;EZ5E*S +S
M\N\?R#^0<E37;,69%+G1%%3=?M)QANPI\1#7N'%S/4R3/8J3+MI20@G3>3*W
M437@9.5B?[HJ4VTI]B)N4.D!TY>%47:G3,(ET1:AV/;'X[;%!/Y2WMJ2_O[N
MV7>;J[*D,I9"DX?JUV<L7#_'&,BSJZLJSJJB\>C(.FZQ&Z"D@HH=JR9H@1("
M*PG1%PMCKT/;8"9J]@9^T(*P1CR'EV/B'33Q<=((';/&WB62[9XAWR"AR=ZV
M<(KD[7:25(< ,!%"/'O3UPKBF]V9UC]N6"P1<4H&=G-LAF";[%3/*=4FX:9K
MF4:DT<N#+U&:;*0S<TE%Q!4X:6D$T)=PU)($76=$4]2E I0*4  I0 I0#R
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L:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g899221g72g00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g72g00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2.84&AO=&]S:&]P(#,N,  X0DE-! 0
M    (WR^D(0X0DE-! 0      %D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  5$96QT81P"!0 K36EC<F]S;V9T(%=O<F0@+2!"96YI=&5C
M("T@1F]R;2 Q,"U+(#@Y.3(R,0 X0DE-!"4      !![^!QJHC*1X[<@^,^/
M3;:(.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           "4P   S(          0                         !
M          ,R   "4P                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "4P    !29VAT;&]N9P   S(    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   E,
M    4F=H=&QO;F<   ,R     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !D'     0   *    !T   !X
MV8   !CK !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MI6];Q6:,]Y\M?^IW+G@[+N>'W#:S66..YQ_[ZQ0RLA^*6_H0]A:3ZCK:Z@'
M_0_3.:YWL]_M5*?/R)X<<!YR-_\ 1X8_\]&KMOZ_X-CPF!_U3D,]=L/C\G,_
M\BN=WU9AM:^DG&K;ZK[:LBJT[6"Y[7#&I%K]SG>SV>^SZ'^#5IO1\3T@UOJ%
MI/J $B9<T-_.;[/;_P"9IIYK-I<^$]HPA(?XW$D?.!(U"M9#U3_\+_\ 7KIV
M]<R]];:&R';O4MLL9M8!&S]"QOJ9'J?UZ?\ C%-F0;@/6ZA:YW[HVT-U_=])
MOJ?^S3UA'HO3LRI@(M+:'6,VDEKFO);ZS';F_FN9_@_T/^A1L5N+56:*7%K<
M>*R'NF)&]GZ4^VW<W]Q__!_H_P";3CSDX@43DE^G&6/@X?\ #CDE_P"DU'AU
MHW]*_P"Z=_T0.7VF>#Z]X_\ 1SF_]%28'-.F1DL'D]EG_MQ4YRQZ\TXVM=@+
M>]?T@>Y]C?H_UUKX]U>17O9H1H]O<'_R/\I6</,QRZ483_=E_P!S^\H%,QV9
M,4YM;YX;?5[O\ZI^/_Y[0.H]<OP\W[,S%=> &'<PF?=.@;'DBED]I"@ZP-/V
M<V07C2N3Q_9V[/H^W:]BED)$>F7#KO7$D4-Q?X.'9U[*P>I9&2,7)RGW&&L=
M;:*ZZX:W8S$]^)]*G?\ :&-]=_K*WA_6_+OL+;.F6,#6ET-)<XQ&C=S&,]WT
M?YQ:=8:#_/WT'Q#_ %&_^S+;]JLBOJ(;->37:.WJ5ZG^W58QO_@27#*[XM+V
MIBX,G%?N>F[X>$;?NV\=1]9NI]-LNKKP[<MSGGU+K;;[ XASFS77>7UX[?\
M@\?]$KE_UCSL_HUS[<6W'<U^YWHOLJ+F5FJY](R*MF14^[W5>K3]#?6B]2ZC
MUROJ-VW>UN*&;65?0/JEE>C7U[\GV[W_ +GJ?HJUO-LZE9M!./28$_3L,Q/T
M/U;:F8Q+B),C(1/"15-W+EPF $<(A(T>+C,OV/(T_7[/IK90SI-A96 QKK+;
M'NAOM#K+;:GVVN_>LL_2+:POK/E9/V7?@NK^T^F'$DPW>8W?1#MBU?0O=/JY
MSAK!;4&,'P]S;;/_  1%HQ:Z7;VNL>XB"7V/>/\ ,>XL;_9:ILI$@! >V;LG
MY[C^[ZF"X_N_B__0]55?,RVX["9]P$GR'[W_ )%%ML%59>=8X'B>P6!U.QQV
M-<9+R7O/C'M:H\V3V\<I[\(T_O;!1:V1D69-A>\F)D#P_E'^4J ZCTFJ'"Y@
MWS[F-<>=?=M:KC5)Y<T,)+F5R0^QO(T]HW .V-=^<Y8\2<LR9DR,M]=_Y?H(
M7Q;*,FIMU#A94^0UPG\TECN?Y349V+3:!ZM;+-OT=[0Z)T.W>"JXMLVV$66F
MT3]E:6_S@ _1[V[?TNZS]&_U/2_1?N?SBM8[MUC0RRRQNT^L+ 1M=ILB6LV/
MW;V^DU6!@K6_Y?R]/^T4"A.);7:Y^+336' #<W8QQ@#Z44/=_P!-2KJR-_Z4
M$$AVYVX.9! ]/8T-K][7_P#!?]<5P74C1Y],GM8-O_2=[/\ -<A.RZ?W;?\
MMI__ )%.,16R::CL&R(.0XZ1JQG]R9^.',+;#R[=%9<P#0,]NUV[\U7'D*N]
M[00V=3P/O_\ (J"6FVGD*223N2?Q:C\>M@):; 8(,.<\D'Z0V/+U0O\ K75T
MC.?7]E>\5L&\.>*MP<-[?3:]KMVQ:KBHX.#U"_/+J<UU=;";=IJ8_8(#&,K<
M_P#E^Y#ER3FCU-^G4HB8@^H<7A?"W*F?;75W-;=2S*J^T--F/5M9N%;A39:^
M7^M^E_\  [%8;BOI ;N%E?J,L<16&OEOT6[*&[7M=[?>[^;1!CY>.WUK\U^0
MVK>YS7L96' MAK7OJ;^8_P#2;MB!=GX=S-ES*K&3.UUA(D<?X%;5=J50NZ;#
MK  2&6./9H8Z2?#W -3X]]K-VT;'-<6O9.YLZ.T/M^DUS?>J].#AO):ZBATL
M9:U]38 #]^C'@[O;Z>ZJY66U!C2 2XN)<YSC+BX_G.^BD+2:Z-RMV-DO8]];
M?7JDLW %S9T<:W_ROY*#;T;IUN2_*LJ)NLG>[<X3+?1/T7?Z(;4$@@R-".".
M0KF-D^I^CLTL['L[_P R20UQT+I;6.8VHACWFQS0]\;B"PN^E^ZY7:::Z*Q5
M4W8QLPT=I,J:22G_T?2<Y\N97X>X_P#4M_[\LGJC *VY!T95/J.\&_2WE6^I
MY8HRFL%;KK;?;74SZ1@;G?\ 5(=#F9.\7-(=40VS&>-&DC<U[O\ 2[V^ZM_Y
MG]<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 7T"# ,!$0 "$0$#$0'_Q  >   !! ,! 0$
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M[&#X_K_+X_UMA0WZW=TH8)N#^'SZSJ>V@9<D4RD;'UYD8"2HMH@[V_6. $D
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MC\'^TE&Y_K#_ /+]N=>+?^%)[+[^+M!:)_[+:L#R?[Z(^,><8['_ '9]I?\
M+1?"I)G;8!N^_$XD/:OUU6]N5<=TVU(VXN6V)EL;;US<M;LJITVHM3J70:E3
M:7*@-",VRMF:X_5&%,EQ*FE-I62H$ 'T/L#[5>ROM(7F".SAS$G+$LJJ374J
M*80]JT=V4ONA1\/BF(-O,\_GO9?-.SR6%9B& *@J#?<NEP^"-6H%"8%P.3U
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M9X/(! &O-\Q_M!>T>M*NXKZ/+6SLBBHFDJ2.G>KU*/J8)L3,8@56U)/YTI!
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M*IWE"9GS,;$Q:=OJHI#M5MUYQZWZU5Z1[V"ZQ&F.N172.RG(\GWDJ()!PDH
MYX[ZNG,ZIQ*4U"6*E*"0%/MI*P"=@M.DBT7()Y&\8@]U:226RXT3OW2RE*CU
M4D@R?B!B0*9N_N#2W"F:JCW'&/3D3(RJ7,:".Z6G(76PZ5I[KD(20O&>,Z4/
M9<Z '&'J9<&].YWR%3RI+L*$<!!,B^$[NJ024N)=01(#J=!21PE2!!!V\7.V
M^)*H^_-O2%EBX*55K=>! ^H<:34:8I)2#UF=#*@UE7 ;<;ZL8)TON3;J0JEJ
MV'ID=TL]P_-[!MP^*P)D*@\80/N)D/4[B /WT_B-GSU)_+<;&^WPE:B75;EQ
MM!ZAUNFU-!*AB+*;6ZDI)2H+8)#R,$$?G;3\CC5=ZEJ*<P\RMO:Y3X3-Q"Q*
M3/D3B9#S3GY'$JWL#>V_A,'Z8?\ 4&),<XOXH25K].]N,M/-,/R-XK)C1G'G
MD1VQ*D4ZYF8W4^LA+0]Y:#UYRG&1VUX[[=EMM>SK,'7DE;+.892\\E*.\)9:
MK6W'8;_?_#2KP_O;<X[#L(">T=* 8*FJA*;QXE-$)OQ<B_&/SY3MHZE(IM8,
M9VDQZW4K.H=,1._M*E93743$?CLDH7+]@AZ"GH+JDI1( ]M(0I1.OB^D]H%
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M+P2EQ(*D'6V@R)D"#N<0PJN7PDD?[3-P< X'_7<'OV'/X1@ G@'/CCYUR/\
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MRI(GOZ=:@$]84A0<2/-4;^1P]4OT[>F.N1&YU(VOVZJ41] 6W(ATR*\A:%'
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M(@@G%@:9Z=/2164-NT?;+:*IMO!*VU4^GT.8' O^4I]A3F>KQ@<ZH?LC*_\
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M2/!@08C2&(L.'$:0Q&BQF6PEMEAAE"&FFD)"$(2E*0  -:H      L !  Z
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M5)2XTXE;:M)$* 4@$@QJCTQ,5>VA-;M.=8;-X7)1+2GU6!6W*/2&J$TVU4H
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M@S2D>HJM#>7);<73OI*'$I7WQ4F0?"8L1S$8D.^MI4W[:5RV%5;JN*/9ET7
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MTB]+=VXV(V9J%;IEW)I#54KMS7>W;]$BUVK3:RY 5 2FAB$\IR)1Z+4_>G!
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M@?Z''Z '(XSX4 \W@W!-@#O:?D9/.QP=?/Y_/]<)U] 7T%2"Z$]1;ZTE80.
MHH!)"<^2,'CG/8!L#)WCJ1,SM%_.YO &#Y;=?UG^GEY_%-XQP,<?EQDG.1R>
MQ_S/QI!R-Y)D@@;7^!WW@6Z80WCR^_Z>F$+\-E];+JFR'H[GO19+94U)C.X(
M#T62T4/QG@"1[K+B% $C/.IV7WZ8DL/+039:0J4J3/Y7$$E"T@QX5)4">-L,
M6TVZ(<0E47!(D@]4J$%)Z$$1U/._VYNC>ELJ;9D2/[54D+'6Q5G2FKQV!G\L
M&J(2!)4G/2ENI-NK<('7.; )U=]XHZ@ 5+7NKQ%GJ9/X:E$B[[!@)M)4I@IB
M;-*Y@*'VB2TKO43);=)U 7,-N;F-@'-15-UIOBP]I;F6K>!3&@S%0JM@ERB5
M- B5))1D+++2E%N8RD@@R(3DA@D$!S(($;U$\TCO4Z7Z>WX["M;8)B Y$*:4
M00=#J4*@S&'MU"%JT*EMT3+:[*,;E.Z5IFVI"E)FTS;$@:J8GP:,&,+L:.^"
M'V&7@1@AUI#@(/!!"TD8QXT8,0S>?IM]/^X0?-Z;+[97$_(!]V;4;*MYZHJ*
MLDJ%1_#Q.0L$E06F0%!7Y@0>=&$C[^[?'?'Y4O5"Q1]G[C]2NSFUU#AP(E\T
MW<FWK>M>EL2)C5,=I,6O+EL_1LJ?FB57:-+73J,DA87,A,) $>,M*/&,_P"Q
M![8^W#LUVHS)FL1E7LG[8>SW,7JA!2R:C+\VI.RRZ5%,_4:6#19!G=.<TSD!
M0+-#7OE)#S[>OTK*,]&4=BZ_+FE-*J.T>59M3H;5<(>8>KVW2ZE!U!=72+33
MTQB2\RV#*$JAZV3V^L&J[&[>4V[[MWEMF5,LNCQZK:$"X+[C4BB]<-DBE1X2
MX+OLMPL-I2TEPI9<; 8(Z4*U\S^U:I]L65^V;MMG/9/V==A\^;HNV>:UN4]K
MJCLGV6>S/-U-USRD9NY5MOH+SM;=Y3A0%.I=AU(U+3C>R-/9Y_(,O8KLXS*F
M[R@9;J,O375B6&91"F4HTF$HL ),$"#%T^?X=-K4+<RT+3VMK58K]JN;;[LU
M^F1VZ75IEL7B*E?5[W!*EU:@2WE)JS2X=O0J4TJK,-AZ-)E3HZG4.N+Q^A^>
M9-6TGM!J^V;C22KM]V8[--*J*8)<8IZ7(>S5"A^F6Y3#N6%O9PY6)]W[S2MA
MII2 4#'D8J6UY4C+TJ\.75-8K2L05KJ*I>A7B 6N& DA1@A95YX_1C"_A^^E
M=$QBIW%MY)W#JS"@XJI[G75=6X,F0Z"5%Q]NZJO4XBU**CU!,9*#DCIP<:SQ
M8 =,5,6-M/:/:NPFDLV3MM8EI-I2$ 6Y:5!HRBD>%+I\".M?<\J43R>>=&#$
M@H0AM(2VA*$CLE"0E(_0) &C!CUHP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&
M#!HP8-&#!HP8-&#$3[@;J4ZT>JE4MINMW.XV%-T]MP"+3TKR$2:Q(028K7!4
MB.@+EO@ H:2V2\FZQ2)+?O%4LL4P,),2\^J)T4Z#^8\%Q4-I-BHJ\.*SCYU%
MIE/>.\WA#<\N*XZZ0"H] +XH#NOO%'H$QRHU^H&Y[U?;6(-.2I#<6DL.C'0V
MPWENF0B,$I'5.F8277',>ZGSSVC>U7(>P>6$5:T^\.(UT&14SA-76N JT/U2
MR"4,A0\3[R0A(D,-J(*<1*[NF!=>477U P50%03&EM(LVCJ1<_O$F!BC%U75
M<-Z37JA6Z@M;RDN(B-MX$:GI6#THBQU]32>@X)4M*END O+7Y_/[MO[2>T?;
MRN#V;OZ<N9>UTF3TY4U1,("K!24JU.NE!*5/N*4Y<A!0F ,]UYQ]4J_((*6P
M83S!(FY@FY\P.<4BD5/<NHVS=-NW3!;NNH6M6W4"JT*,B-<]O56G/)JMKU]=
M&2IMJLTN5&^BD*73 S*]AZ7$,24ZVYU>C,T'8FDSO(,VR*I7D%+GN6-K-!FM
M0I[(LYH*MI67Y]E*<R.IS+:ZG?%6RA%>7*?OFF*KWBG;4V1<2VTE:%-*4@*2
M" H@H4"2EQ&J#"@=0@DB=)! PKIS5W7O:5351K?ESZ;N&B)6T/S9:*<Y8-]Q
M)++57+K$\M3OPY$F"*G%^B9<=4_(D1RE#3G4*E8OL]V7[0T:<RSABDK.QKC^
M6K:I:?WQ':WLI4,N.4 ;=I==*JM4Q5&@>%2ZA*6667PI3J-.)-"4K3*KHE T
M@D+;($3$C408A4"U[C$V47:2F1?H'I\ZHNM-5"-7Y=NQI13:R[F;3EZK18:V
MU26T.R"N68GU)A_4+6Y[&<'7FF9>T*N?35L4=)1I<=I7\I8SEYG5GJ<C68:R
M]ZH2L,*4VSHI_>0Q[SW* @/0<2";DV$$20->F\ \=;Q)\]\2[%@L1FD1X[#<
M=ALJ]MEAM#32.I9<5TMH"4IZEJ4M1 [DD\ZX-9J*MU3K[CCSJR%*<<6IQ:H2
M$IU+45$E*0 )-@(B(PD@;<D D"9/KS81\9%Y&')J,3CC //YN2,G&0.0,?;@
M?J,BRU2Q:"5& -B0)B ;Q^E^,-*MX$$&#S)G>)W)L3>(&Y-W1J$2 0@J(R0<
M9[D<??&3CC'SSG6DW1WN..."#&_SFWGO$EY)48$""JT08&^Q VOSAR:A$X(Y
M)([=L#(QV'5V\ D:T&Z0<)D@'8"UQ$]3TDGJ3A)TWB>9)(DF9(F.H^7F,.+,
M D\)P3\<GSYY. >,\_?5YNEB)%Q @@R)Y)MQM/TWPFJ2;D3O$B^P$D1?F_/7
M',C?+=#U4IW!W?VYM.A5]%N-PK9DV#=EFV5=2Y%"6W=%J-2A5:K*HL.!4I-0
MA2JFIQ-O5^XF)$!B4F;!H"6W%J]5[.Y#V5-#D^8UC[)J/>'T9A25E91AM]"J
M:L"0RTE]3S2&E)9)-33LPZI"FW:B0@6%)0@%21J_NSQ@*!4' R"%2/"!KLB(
M<DA(23)Q!N[52]<]X7C%JU%;W(I%,V^H=9:KM3M1JY;4ARA3=S:?2X=XPK$8
MI4Z#N+45V[(>??M-N=$5/IB5S(/U(:4A73Y'1=AZ6D+;_P"SW7,PJ:,M-5GN
M]4M >RUY;M&NK+K3F7,^\H2GWSNG>Z=(2L(!D*0D-+820XMM+Y22I*%.A"4%
M [Z3"Y4H)"@$JTGQ"^-I.YGJ]VXNNCU6JV]N[N-9D^_]\+DI@IEJ5Q4IN!0M
MLJG#MFS*W3FH(F,T:X[HF42MV8N8RB+&F0ZE$=D!XLMIKMY+V6S"B<:0]E.7
MY@C*\JI5!VJ:*%/U.=@O5C;Q66N^HZ-MQBJA96MEUMY*-"%**)#1*E%:0UW]
M*VLQ<(;:IW%N(29*T.RX'.$.("-RHBX/H7JOJ#5:-W6#ZD[:O6EW_:]7AURF
MUN['(%316[=NVGLS'F(EQT)Z70YBJ-=46Y8L:F-3%5&E6^[0&);(3[;CG/\
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MGJW*TT>;O99KJJ8M@4;I9I*G5WX4LAU?=H;";DVQ1?%1J:33N! [S2[J;#D
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ME*ITJ6D(FY$@1)&'B]+1H\?;:JT6#$8AQ;<H<BI4(MI0V:;4:#%=J%,F,N
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MI,%(,Q$QMY \6&TR3;;8VF@G*$I2@=1_E2E*>HGDX3@8/Z9SWUBJ*G"25$P
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MVI.QE(L^ZY0E%9F1"OSYB\E1;8,"%)I6%()%BEU;B2+6SZ]X*4EE-])"E?\
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MKJ))R<^>.(SW-,RSW/LVS;.*EZMS.NS&K=JZBI6MQTK[]Q*6Y5,)92$MH2
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M)]W>!UF(21HF3M>+^F,$GU.;>LI?)M[==;D>4W3U,?[)-P Y^)R @Q*<>J@
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MV'Q)\S>1AP'A5\>O V,\]<)KFMR+==NU&@SAEF?'6UR2DI5STJ&,$$$ @_S
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M9#JPAN,SMN+[.*6X ZH(UP%GOTC0FF0O4D)1"=56MQE4)(2T@%(DZU,N9(L
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M8  PFI8)U  0" (L=3@(!N(2$H(!&J2;D0!LS[^.H=7 /(.,%(SP."<<@9/
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M()2E9)/WS[!O9D>RF5#M'F[&GM!G# [MIP>/+LN404,08TO5 "'7E F!#<D
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M?K,P"*AI:JJN9"E@JH_QFFJ9GPD&I+K+1)3<-UH4?\$Q?L%).J$@0L"ZN\6
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MJR%))UX#[=.SK?8KVE9VQE<MY/FZF.TO9YUDZ4*R?/FTYA3(2M.G5W"7BP[
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M>DIGJBH>EU;3:@MTH:$!QQ;BAI;19"$S=1( /$@T&XH%>IK%4@.+5'?"P4N
MMO,R&'%LR8DEE7YV9,60VY'D,. *:=;4E0Z@1KSCM+D6:=D\YJLCS=I+592E
MM84TL.4]52U#2'Z.NHW4C0_1UM,XBHIGD>%QIQ)F3 TZ>J;JV4OMW00H")"D
MK&H+0L6(6E0@I/J;8>_KD(+84^A!=5[: M:4EQP@J]M(44]2\)*@A'4LA*E
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M-I%^HVX V$X3EH8X2<]\9)/?O@XX.3W(/P.,Z43(-M]S'E?U%CUZ\X4D=-N
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M79!R/[P_DX[X(&I?]ENT1WR?,"-4?X"R01:-C*B3L!/$1LGO])N*EF )LL;
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M(7(65R'$C'Y?>6HJ=4?YLX4>VO%GLU>?<*W7W75D(25%:C/=@!L3-]  T@7
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MWCR\HXOCS=3B+GF3>!.UX@R#,3)];1C&7.1^8=N1X'/'G!/<_(X[]M2);-I
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M%TWC.078]#3<=4]DJ(7+>55YQCQT8RHK??=;0 D%1"CT@\:NYR=695'%F4\
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M/3 DR1&.D^SVZ-!W9M%FX:0A$&=&?7!N.@*>9=E4&NL .2H<A;'Y'FW@MN9
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MA:%I,%*T*@I4DV*2)!%]L5-5X(@R00;1>\SMMMO(],(:O5F*-3I-1DI6ZEA
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M=]J:#-<O=H:7*/<^]JQF7?:PI::YXO&J0A("0FG4AUMEL"2$4K*CXBO#Y3
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MX.]C;IA&I X\G['O]P .^>_'./MIR3'&YOQ>]H,#I\_, ,("I -@ >28MOQ
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M]E&1,]M.RSO8O_>V_49IF*.Q&MQ08[/U+:*#,:REJR%JIZI;H>;I*=ON]R)
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M2PW.FK1%C+>Z Z^H-H)4<:,&-^;<0ZA#K2T.-N)2MMQM06A:% %*T+22E25
M@I4DD$$$'&C!AEN>Y:)9UO5FZKDJ$>DT&@4Z55:M492PAB'!B-*=?><4?"4I
M(2D J6HI0D%2@#$^\U3,N/O+#;32%..+48"4I$DG^ W)L+XK5=73T%*_65;J
M6*:F:6\^ZLPEMM E2CSML!))@ $G%$Z/5]X]\)U.OT;F7'M':%Q0KED6);=M
M0Z5(<H7X [3W*+*W&14(4IV;4;ACJJ4V=0/>IWX9";9A^^J0MQ37*(<S+-7&
MZI->]EU*\A]5*TPAL]V62CN_?>\0I2E/I[Q:VO!W:0$ZM5\><4K^?=I%MYF<
MVJ\CH:MNJ5E='2-M*53"F4T:=S-@XE?>O52>^=<I"IH--!+>K43$\>G7>6L;
MDT69;]^TQ% W0M5B Y<-.0VIF'6:34VU.T.[Z(A?*J36XZ2M;0ZC3IZ)-->/
MO1E@:^39DY7L:*ION:UI*%.MQ <;<$M5#8-^[=$V_<4"D[8Z3LMGU1FK+U'F
M;(ILZH T:MI(TM5##P*J6OIA)EBI0)*=V70ME7B21A@W.W)N6[;PJ^T6UE=_
ML_/MFDNUN_;Q998D3:>$,?4Q+1MEF4VY&D7'4F3[TF1T/_A#'MJ<86Z[T"&N
MK7ZFI<R[+W0RMALNU=2 E2VS 4FF82H%*GW!=2O%W8B4DDC'T)V8[-99E&34
M?;#M7EYS&GS2L309!DRUN-,5)*^[>S?-%M%+K>6TR_ TWJ1[XYJ2E82F<-%O
M7_=VU%X4*WKTN"L7MMO=L&AJ9O.X&8J*[M_=-PI2:3;USR84:(Q+I-:/6B#4
MUQ6%0);?T\HA+G6F)FKJ<OJ66:IYRJH:A+<53P2'J.H>([IA\H2@*;=F$N%(
MT*&E6^+F8Y!D_:W)J_,<DR^BR/M+D[U<',DR];RJ'M#E.7$^^9EE;;[CSC-9
M0RE3]('5^\,DNM2I)&+CZZ3'C>#1@Q'FY^Y=O;4VJ_=%P_5R N7$I-%HU,CK
MF5FX[BJCGT]'M^BPF\N2ZE4Y12RRA(Z&T^Y(?4VPRZXF_EN75&:52::GTI.E
M;KSKB@AFGIVAJ>J'EF EMI,J4=R82D%1 ,+[Z*=LN+DB0E*4B5+6HPE"1RI1
ML/F;#%6F/4_N5:*8MU;T[:T"T=M)MT.VC/JMOW*_6;@L*K&2XQ$7?%->AQXJ
MJ6\&^N55:!)J4*"A7OON(C)4Z.E/9K+ZLKI<HS%^KS%%*FL;:>ITM4]<UI"E
MBC<2M2N\3,!I]+:UJ\*03;&>:UYL!RJ82VPIPH4I*RI;*YTCOD@ $'?4A2@!
MO-B+IM2&9+3,F.ZV]'D(;>8>;4%MO,O(#C3K2TDI4AQ"DK2H?E4D@@X(UQJD
MJ02E22E224D&Q"DF""#L0;'TZSC0B28,VD1TW$7V@VCJ/,8\+\@YP >?/!R.
M<>1\_']&X=$C?X;"2!.U[>EN>90NXP3W'?SCMV!SP?![_'@Y<GUX,=?2-C).
MW7GJBA>2-N8@W,2>A,&\<[7LF5V&1_7C&2!SGMVSSWU(#:\&.@X@7\H!N!Z>
MK8B8)(-R/AM?>(F;7YOA"\D$*QR00GOCD9S@9\=_CL>YTI.W2?C,V'U,[V'D
M,-X)&]^O%O/F8 ^5Y*,X&01SR3D_RJY[G)[Y&,#.>1QHW)W]9]>AXB-IZR#A
MMA8[R3')(/F"!-MCU^-:]_-V)MC1*1:%H^W(W"O1QUBF*<8<E1;3M]I2&:U?
MM;9:"BU2Z"V^AQGWTI:E35-,D]'NE.#G.9FC2W34]ZRJE*/"5"G9!2ERK> G
M2VP#(*_"21Y@<SVFSYS+&V*'+]"\WS,J2RI2.\;R^E20FJS:I0F2&*4+"D@P
M''2E-TA6*Z2K,W+VTB-WG8-XWG?]X_VTD1ZA3+AGLS;<W3LX,-S7IL=H-"'0
MIS3'U+U,>I"D,EX,PWD.=75K -/F&7H;JZ.IJZRJ57*0MMYQ*F,PHRD++L04
M-*2 I2"U )2$$$&<<PO+<[R5HYKE&8YEFV9#,5I>IZMX.T>?Y:$!XN(3 ;I'
M@G665TYTSI;.J0<6^LN\J)N%:E'O"WGB[2ZU%4^VEP!,F')9><BSZ=,:R5,S
M:=.CR(<ME7YD/,+\$'774=4S6TS54R9;=3J$@A25 E*FU"+*0H$*'5)@X]%R
MO,J7-Z"ES*D433U304D*$+;4E2FWF74S*76'4+9<!V4G8@@EX=Z<G \\_;&,
M\><YX XY_74\>9%YM;_6]\:0)(!/W/W_ *[E,K."/)R?'8<_J>!_YXT;];_#
M^1PN$BTCR< Y)..1YQWQ]CC'W[ZBO( BQV.PO '4QN.GSPLF/*?O:+'^'EAN
M=Z22>1T@CMSD'OW_ /3'.>^G)U1 L)F3T/'$SY?2<!Y,B>@G]?L&]Q;&!P C
MMWSV.1G(SCG/!_3/WTX&WG:>!MO,=(ZQ:PPGWZX2GSW)Y^/ZC/\ 7G_B1H(,
M&_R!].I,;3'$]<&,6" K.>^><$ XX 'ZD?J,\C4>X]!;UF3Y6$S/PG!A ^%$
M  8.3U=CU?Y_EQS^^3QCD3 N?47(@WL.HMN3;"_R_E]_SPWN\Y&"<#'5V!P>
M/'D8'QY&#W<;7VU';GB_2QD\;W/&$^_N?N=NN$J^4]\G'<^1\#!_7))X/GQH
M%E$W&\\WD;6YM%C;Z'W]_/"1Q"5@I4D*2M.%)5G!"A@@Y&3D9^Q!(T%1"I!T
ME.Q!DR#(/D;3U! YC"@2;BW/2+R#ZB?KBU.R<]4W;ZELN*4MZE2:C275*.5$
MQ9;BFP3_ /*L/-( ^$C6GF4*J$O#:H88>VBY;"%3YE2%$^9.*M(-+1;)DM..
M(^2BH?(* _IB6-4,6<&C!@T8,0+O_1S(MNDW&V5!RUZRS)? 'Y54ZHH53IZG
M2.>AAI\/IR>D.-@D'MK2R_\ %164<2:JG/=\D/,GO6]/FHI*?0D2,5*J4*8>
M!@-.@+V@H<!09/03/-P+'BO:5 <'DC[#/)^Q'SCL._DDDY*3M?:U[ 6)'%YB
M_G%C Q<@W'3^%OI^DXU:^+,IE]4!VC3GI$"4T^Q4:)7:>6T5:W*]!67:=6J4
M^XVX&I45S\KK9!9FQ'),"6AV'*?9< 3&XO<7 D$;[];S8[QO&$PV[9WK5:\U
M4K:O"+'INX=I*8BW1 BI6BFU%E]*_P ,NFWPXM;CU KK+3CT8K6MV%*1+IDP
MHF0WD)0@7X!/3IN.I$Q_ '"B+>1&W^N^'?=/=&W-H+'J]\W*7W(%+:!;A0D)
M=J%1DJ5AN%!:44AQYPDD!12D)"RHX UIY/E-3G68,9=2Z$N.J,N.'2TRBTN.
M*DZ4R0#$W*0F"9Q!4/MTS*WW)TH$PD2HF8"0+23Y8=ML]Q[<W5M&F7E;1F(I
M]1:2OZ>H17(<Z(]_CCRH[H!2XV0?S)ZD+'YD+4"-1YKE=1E-:]0U*FEN,J*=
M;#B76EQRA:3M?8@$&T3@8?14-)=;U:5"0% I4.+@QSMP1L3B14GD'].W_#]=
M4P0 +R-I'IM$S/D/EB;"ML9SP" #YSQ@X.,^/@#MD9^4)W )WOY<[Q8<>4;1
M.#"AHG/3D# )QQSV'GC'?]N?MII(B1)O%SZV,7W$W_H')Z?Z_#SZ;Q)\SA>V
MH@#.!C&, >?Y?D8\_P#'G0")(ZVDCQ;\\;\W/R$!%@1?<F!YW/'46 C?SPK0
M<I! P4\$\=P><<'CC@8&<9XT^+03,VZ3'U.&\_IZ85-DG'! .03\$8&1DX*L
M'&1D^#G!TZ_/P],-($<"/+@7@VVGC^<8J71:G<4&H>J.F4H(A;W5.K3*[;<:
M:V"U)L=BFQJ98E5I2@<SJ=%DN5)B5[9!C3G$-OM(*AU6:%5,BLI5UJ%KI!4-
M*JFVSXU,A0[Q*3M)2(V,B8$G$;X=4R\&"D/=VH-*5.D.D>$JB;"018P1\^8-
M7<,)JUJ-)V[NAZX[=@7GN!O +]0LT^\+THM.>G4.?6+@C!34^V4O-@,P"MHL
ME,=@LME"5'VVG73U2LPJT9Q2N,USN6Y1DB,J(359;EU4\EFKIJ>B7XZ:L4@C
M6\ I2@5K*E#PCA7$N,^[,JHG4+8355E>:H:FJJI905,.N/CPO,!4@(5 %AI!
M%[H>C[8&J7%4HV]5^)H5&HTV12=Q;3L>V%3(5-MZM/T^9&=K#T&5+>+$F=37
MU-2$("&I(:;>4.IH'7)]JL^;IFU9#EHKE>YIJ<LK,SKULU#U;2H<0OW=#S:$
ME;33J 4*6=;9E()"B,:V4Y>7",PJ2PGW@MU;-)3)<:0PZ4E/>+2LD)6I!(4!
MX5;[;W<]-,%<ZU[NW.D)0)>\NX-R7XV$)"$*M]EQBU+)?2@#"3+LFVK>FN$%
M?N2)#KI.7"!YP@6G@_I?RC< >GJ">D<-PF#;<Q;8$'I(DP(B;6OBS+:L#.1S
MQR>>Y&>P[#L/N> ,:D M'43YSU]>O0X: 9B  =C>2+QY7X&PZ@;KTXP<^?@C
M!\=SC)&<_;OII!MM8SU@[P3T,R?IP,)(&KK''-_7?PQ ].)PI:..D# YSSWQ
M\=\9'8\_Y:818&_-[GDQY"3;?F<2 B2 "20('E:1.]MNFV_"I"CW\DXSR!C/
MY<YX') QGN?/E)^ID\1O8;V^^,+%IF1N0;[[DD7ZP1T-Q./LMAV3#E1FGBRY
M(CNL-O#!4TIUM2 YQP5)ZLCQP#H%C]_9],)S$<[;#RL9CKZ$B(WK1Z8O2U;7
MIR;W#<ITR56JIN-=,FY:U4ZBM,F0\M]( CETLM+4RAQQ]T-N=?2X^\KJ(7JG
M24%)0^]&E;*%5M8]7U)*U++E2^$)<4"N2E 2V@)1J*4WT[G'7=J>VN>=L/V&
M,Z=86WV>R6ER'*F:5@4[+&7T9<4V%-A:DJ?7WDNO)"%.!+84D:1*VA,_]'V]
MV[8>$9C9G<"J."S9@0AI.W]Z3WEOKLF4O\J6K7KA^HF6FX IFF31+H*S&CFC
M(D6HC:!\,<K]=K[D^IYQ:32X7!HP8-&#!HP8-&#!HP8-&#!HP8JCZNO1KLUZ
MUMI:[LSO$S<<2TKGJ%LS;AEV-5(ELW)5X]IUJ-7Z71IE>52ZC*5134HK+LJ$
MV&RZE.&W6E86#!B9MH=K;=V4VWM+:RTIMQU"V;*I35%HDB[:]-N:O_A["UJ8
M:GURHE4ZH*82OV6G)*UK0PAMD'H;2 8,0SZF;3NN_7[#M9=-JSNT"*I)N'=*
M;;QB2JZ^:']/(M&C,4>0B2NI4IRX51:Q76D0)@>@4=4););EN+1SV>L5%5[J
MQH>_9VLNU[E/H4\=$>[H2TK47&^^(<> 0HE#>G20HQQ?:VAK<S7EE$6GE9$'
MEU>=.4VA=2OW;0JAID,*"^]955%#]0 VO4TP6XA9.(OJU1:O"L7I5ZC>Z;!V
MBL.$U1]R]PK24+=F;FWM"2E+E)I;<ARJPXM-H[;R*74W(K#];JM<"*(S-0S3
MO:7W,95V1R?]M9LBB=S*IHU5CZZT%K+J'*V4+)K:NG4X$>\.H25H+BR$4X!5
MJ"DA.A24BZZI<2VO0D)13UE12(4P:^J0"(0UJ<0@("]#BX+JB V5E*$@4D5N
M_NO;=P0;WL&B7'>MT655ZY0;;N:]JK1;>8OW9R? 4NCV]7J$S]++@52AU@L3
M(4B9%A..GZ^4\8ZZBIECXX[9_P!J_P!CM#GS#N0UV:UE:A*V<S>IZ IR)"SW
MB5T]#"N^70MN);>8(2ZI!4XGOG)!&KEGLZS89WDN;U=<M2:3,6V,R(<0A^K[
M,/N(6_0MM)9[E-93HERA4XH)+_>*=<"7#$[;877 W'H]L[,;>W#7(&X=UU5Z
M]MU9-S4Q$6_]O$?5>_=EQP*S%=++KM=<>8I-HRD?B,'V^LJER&F_93]&>R7/
M>Q_;'LV_VORO,:?M!E5,M,LE>FI.?5!*TLU24%+S;;:0I;S2@E7=A*-9!./2
M?:+VKKJ[.FF,K:&5!;'[/I?=254*>S%*WW3%,NAJ$.-HK ;J<_(MXJ=2TE20
MLS#=5%?M.Z*KLCN36KJO+;^_:!)J>VL^1]([<52K5+;4[5;8NBYO8B(<%OI"
M+AH,EPP$LQ4ROJY;J64,'N,_HJ//<G5FC5,EEYE8I<UR^B1H;<+A_N=<VE14
MIIM)'=O$K#:' A<@%0.#V%SO,.SF=-"GJ*=#E.KWRBS7-'E+314J;5U(VR"E
M+SM4GPP&GG7&U*;0V%Z7!&'_ $QK\C;2.V=:UOOW=N?3($VW&MRVYE+_ +"R
MGHS[L.%<<.1*G,SZ]*$'V7WE0X)IDFK,2FU3&6B,?,F<_P!IWV5^S[,Z?)NU
M==79[7T#Q9S2E[.-LU2@6C*6W:IUUFG0ZXG0'TI47$DK*4;#&WVOR:DS/-\R
MJ^Q8]WRJNT55$BN;<8]Q<J$I-33I;"25-T[Y<]V(E)9[I*EE25'"W9'U.4RU
M]U+1V\N&O;@HHNY[;M*AQ]UWZ3/JU,W$A,%]I^CW'0EKHLJAW?%:D 4</+FT
MFKQXR$,L1:DAIKV+V?>V#V>>W#*<QJ>QU52,9]D:!6562AM5%6KRE:M*UFC<
M6XIU="X4ZJAI10ME2BHRW)\]J<NS#L_4L-UBGGJ.K/=)J'%!P-U<2!WB4I ;
M? ,(()2X+0%83;P7Y6+YW0N2[13I55H>UU;8VMV5M:'55T:X9.]]Q);CL;E.
MTV0D-5"@4>>B50FI:O?^CIT*XYHI\^'(=+/N&44#5'EU-2E:6GLR9.9YQ5+:
M[UA.2L&59<'4F6WWFU)?*?#K<<IT=XA21.175"E.N. :PPH4U(UJ*5&L=_*\
M4F IM*DZ9A4)2M6DIG&SW[M7?&T%LV[>UUW$_N_2ZO5$G?&B7<IEJUFJS<D1
MZWF;TIL*# "Z;;]&15WJ77*4CWT2:4Y'F(2S(C2'W*]!F=%FU3445)3IRAUI
MLG(WJ4*-46J98J#1.K6M0<?>[I+K#A@I>!1*DJ"<,J&*F@0W4.O+JFUJBM;=
M,MA;J5(2\@(2"E#944+$$*00;$63[7>HNW=AF+BV3OBLUB^E64ZS)VQKUMTZ
M;77+PLFJ R&(29@*F$O6A.=7;LV?,DM1$(896Z^G)QYU[5^V?9#L1EE%VO[3
MYI1]GJ?-%JIGZ*H6D5?[2922ON*-'XSB:IM/O "$>$J(O(QL90Q453CE P%5
M!9 4VZF[:F51$KN-2%2@W%AQ?$DH]<VT<,M"[:/?MG"5*C0H+E0MIZLQYDJ6
MX&68R9-M/5EB,\XZI+;;4UR.IU1PV%<X\M[!>VKV:>TC-D9%V9[4T"LV=U=Q
M1YFHY2Y4E U%-,:X,I>5IN$()6;PDQC6S#+JW+6345%.]W0TRIA"GX)Y4ED*
M*0"#)BV]HC'V\]_KKK59MI&S%I7'<U+H-037-T69EK3X513:C2T1G:-0X=6<
MI<I^XI9?$R$U"CSW'&8;S?L=3B%#V.LRRLRYUOWI+/<NI4$.,U#3X+JB$I)+
M2E0AL$NJ4#,I2F %$C,8J:>I0Z&E.=\%)!2MM;4)2DJ(EQ*4RX0$"38+*@"4
MP=,I.YWJN-2HT:L;63$PX]V+N2X)#%-@%"]L:Y(I\6D6[&+==>4N\*$W,J\^
MJMPT2Y1%"B-/4V**HA35-F=325D !(:?5(\52X 4.H()_NK1*TN*2"8;2I2A
MW@3B=W1"]&\E36\!IK7K09 )>< ;+85IE3JD@'NB57:=&25 ]BD' QC(!/5Y
M!/&><8!R,Z?TGK'23O\ 7RYM>^(C$;;\\QM?@B!<P-C<1A(L@*R.1GG/)R3_
M (<$>/GP=!Z 6V@?R-AS,_6;-($@[DGGB#Q XCD]9YQ52D;67-'WHN_<2ZEN
MR*G<;R(-M5RW)OO4BBV-2HK45BS*[2*I%"TJJY!J4V53T+1(G*>_WMA']RKE
MV\NJD9Q4UE4"5OD)IWJ=>IMFD:2E/NE0RX@%)>NM2FY!5/B2/">1H\CJT]HZ
M[.:Y16_6D,T=51NZF:?*V$)0G+:JG?;G^\$=\ZXS(6ZHPX@6,NUFAT]%NOTF
M'&FP:8VRM:*?;:VZ;)=92I3BX$-;:0F,)*LH<]@Q5_F)0^R.IS6RZPW[NME"
M5MM@$ANFA"R))+:(%@L^$Z=)BVI(DXZI^E831.4S2'&6$I5^#1D,+4F2HM-&
M $!PF"4E&Y\:9)QSBLS=ZZ+(O3<*-ME:M J6W5P5%%3@PJC79L*BVO<\8)IU
M=AT:;%I]3?JXG+CK>JZXD95-:KL>0TU59#QE+3\K]N?[2O8KV5YQF62N-U&>
M5X4VMW*,G6TI.55);02Q5UE0XW3AQ;92X\TP7G$.$%0,DB'L=V)SBGJ,QJ8I
M*#(\T4BLI,M*G7'Z&J #;Y1" WW=2D=Z\$K6$OB4K4%+4)[M#U*F15X-!W'M
MABU':O+8@TVXZ1555FTE3)#B6HD*IR9<2E5.E2YSZD,QG7Z<JF*=4W'-0^I>
M::7T?LM_M-]@/:=F#>1LHK>SV?/2*7+\W+&BN6D2INBJ6%K;<<$$AMSNW% $
MI08,=97Y%64+:GC#K*;K6V#*1?\ ,E0D#J39,@3>UH">#@'!Y![>/\(R>^<C
MP< ]N_T9Z[W^4_T&,?"1SC@ Y\>.<COG@??.>>_W829/E:1P+W!WF\&X%KVD
MA0)_2)W,;Q'']!?#>[DY!& >^#YP3@=_GC)Q^G(T S,?"),7$$W.Q !M,1%L
M!M;H8^_OK;#+,JT"'/H]*D/I;G5U^9'I<<I43*=@1Q*E)2H)*4EMA0</41U
MX!)!&@)WD$F-YZC;D6CYQL+X3# Q>%O38M)G1ZBAV-7*I)HU+<#;@^IJ,23)
MB2(R4E *5-R(DALJ4 DELD$I()-@3R(F1(XF+[]3.]R-L'U_I]<87+PMY")3
MRZ@D-P[G@V@^H-N?W=PU!VGL1*?PD94Z[58"0X IL>^GJ4 E>$TD[6-Y!D?!
M(MR8,]3:XP8P2[IH,=-?+TY#?]G*C$I=;5T.DQ)TZ+3YL5E0"3[BG(U4@NA:
M 4I#Z02"E8"&?#R.!!\[&UO0'@"2(DQ[^OAOSI--:?0N=$C1I<A@'\[4>:IY
M,9U8P $/*CO!'R6U?KH!MN;3:^PL1,\1T'.XL5Z_<?>W]2,?2GA0()'CGG'D
M\]OZ'/!_1TDZ3:_K&XC8_0[&;Q&#^OW_ #\OK@6<X_K_ .F0#SY'V\8TA2!)
MD6Z^EQN9(M8_&<'S_GY?<XG#T^SG5(O6D+(]J!5:;/9'_P M6(CSCV/&.J(G
MQD'/43D:UJH)50Y:\!!4BH9)\F'$A(\K+)&VY@8ILRFIJT3:67 /-Q*M7GP+
M[1$8L9K.Q;P:,&#1@PSW!1HEQ4.JT*<V'8E5@283Z%$@%+[:D Y'(Z5%*@1R
M".-34[RZ=]I]LD+:<2M)&_A,Q\1(^.(W6TNMK;4)2M)21,;[7]8.*#TTNH:7
M"E*4J72WY%*G*<"@Y]93GUQ77%I(3T^^&A(2"$Y;>0L#I4#I^9,&GK7-*0EI
MPI?9T_E++X#J GJ$ZBV;GQ((F;892N!QA!)E8!;7(@]XW*%;@1*DZHMX5 [;
M1/O3OQ;&QT*@2KEIE:J/]I:BNETO\)9B+:3,0A+B43'Y,J.F,AQLE0=4%,H2
MAQ;RVTISK0R7L_7Y^Y4(H.XFD9+[Q?=[L):DB0B"I1! 'A23M;;#:JK9I A3
MVN'%:$Z4E1*HG>(ZF\6!O(QN=&@6W>\NT-S8C4B)5Z?3I;$&;$D)0N91:LTE
M4RAU(,ER+5*:9;46='.%*C3(J7H$EEN3,1+QG$]VM:)E2%%*E $"4DIF% $<
MF("N"!BR#(!XB8W%[_<'&C;[;J>GNSZ:FD[S7?;T1;J2]%MUUR34J[)4XE2$
MKCT&CMRZHZ%@+0APQ?:*@4]0QD,0M: 5-$I4.03^9)!22+2 1JB#>.=@IF J
M+'8CKQM($$].8-\5OVG];&U]H6)0:%'VUWJFMTQAUB15*1MO/-->2F6^IF0D
MOR(LI23'6UPJ(%D)R$'6EG"F:C,JI]A25-/*0XG3$#4VC4)$ '4%2(L3<3?$
M-.E2&6TJG4D%)!\E&(N;1'2>.N++;=^L7T^[C5)B@4V^F+?NA]00W;%ZP*C:
M%:<=40$-,-5V+"CS'EG(2W!DR5J*3@$#.L[: !( X-YGU%M_TQ-AS]2+%PW)
M;-.L>QKNKEK7U7I/O4J10I!CEBGQR$3JG55H9<>53V0XB.TTTZPN7/?BQDNM
MAQ3B-[(#04]2YF&:4+5=E],G\5EQ;B%N/+D--,=TZW+JB"HZ]:$MA:UI\.*E
M9WRVPU3N%M]9A*PE*@A /B4O4E4) -H@E4 $W&-[V)H]\6YMY1Z'N#/-3N.E
M%^'(J*G7'C-9;=6&)/N.@/*+K/227/SI.1E0 )S<R=IGZ^L>HVBS2//N+IV8
M@M-J42E! 40-$Z;6D7/6=D+2TVEQ6IQ*$A:O\R@!J5UN9(G:<3>VO*4Y)R.P
M(Z<>0,'SQ_WNP)QG)UGG>U@.;$2-C8>?0Q,=!B<=8F;0)F#QOZ[WM(M<+6CG
M!R>W(SQG !!^>_V_SU)(,=)(@B9/'IAI!%C]_?\ #"A)*3P>0<@'OU>, \8Y
M&?TYY[NPF]L1ANK854NB/1KNLM^-3=S[$?=JEH5"0"F)4T.-K14K0KBV^E;E
MOW RI34A"B51)?LS&/;>;+@/3RGTG^MO/#+;""+B.;=9F8C^4V&(AN?<3;?=
MFQJC;59VSW6DUNXZ2]2+LMJC[87<:C2IA4N+4J,[<S]*I]M/H2\APQIK->]B
M5$4S+;>0ET8L4E544-4Q6TCA9JJ9Q+S+H2E10X@RE6E84E0$"4J24D2% C#'
MV6ZAEQE] <:<24+1)&I*K$:A"@2+ B\[1C0]O]J[VLVS;UL[9C9&X;!?W I"
MJ'.OG<R][<1,IK+D=^%'JC-,M^M7G493],8E2'H<&0J"@/'VEK:!41>S3/<V
MSI2%9G6*JBUJ[I):890WKC60VPVTB5%(*C$DB1&(*7+Z*A"A2L!K5!60IUQ2
M],Z05.*6JTP!J@$WM;'12TZ!3[5MNA6O2F_9I=O4BG46 RD?E;ATV(W$83W'
M2$-,I&2>>>YR4YP!$<<6B_7?GDVX](E49),^=[&+<S%K^6TP-]H0K)YXSC)[
M]6.V$@\8\Y('P=._K:-]NOP$_P ,(#.D$^GQY,#F#U'2<+FE#!&1@<$G_N@]
MS@\=@/)(_P DXM8^D["QWB;6N3M.%F18Q<SL(^?&_D ;0#A2" KCE/GX'/W/
M^A&?VTTGJ!N3R9 D7W/H3:W$7<!)D$[ #8 ']=MS/(W-L+4*)[\]@,#.0"#@
M?ISS]OGG3.GW?Y>G7"B;&XNJ9-@8B\&-]NH,$85)/4D?8\CD')!'/' .<=O_
M )8'2??\L!L2=YYW%H/)W$=3TCHK:7@*SG@Y QG)P>!CMVSVQ]\<DP!7B!V!
MXZ2!,GU /ZP;8UR^K8IUZ6?<5L56D0Z[$J]+DQE4J=,D4Z/)D>V7(>:G$:>F
MTIQN6AAZ/5(32YU.>;;FQ$_4L-Z,23YP?.)Z$]/X<XH%_#TKGKX,O?RR_75:
ME$I,FT[UHK.Q]R6E+IE6MBY-LE41N*E::W%:AU.I5QBI1''*N]7J51YZWI =
M;IK$9;?4E_O[YX^O3"XZ5:7!@T8,&C!@T8,&C!@T8,&C!@T8,&C!C7+OI]>J
MUK7!3+6K+-O7%/I,V)1J[(A"HLTFHOL+;C3UP5.LIE",XH.AE3J4K*0%$C(-
MFC<IVJJG=JF55%,VZA;S"5]VIUM*@5("X.G4+3TZ;XB>2XMEQ#2PVXI"DH<*
M=00HB K3S&\8KO=_I8MVM[8V+MK1KBJ%"I6W\I-7A!^.U485:KJ(\I*JW<;"
MG8LJ?-5*G3J@5F>VU];+<ENLO/LQEL\%[7^R3OM;[/9KD57G==D7[4>0Z[4Y
M:EHRTTE:6Z)UMP#71 *1K:;4TI7<M@+ U V,H4C*"P6FD.AE) #A5XE*,J<*
MI)UDR=1D228V&*17-:LNRKE-J5:31ZS-*7W%5"V:BBJ0XB&B,-5ALAJ52)SH
M*5MQ)#2TK&?9?=Z5'7Y(>U?V*O>RC,6Z&J[19)GC50I7<"DJFT9HTV9*55F5
ME:WJ=*DFRY<:4KPI<401CU#*LR;S-!4*=YI2 9*TDLR=]+J0$F+V(F(!BPQX
MV\JSUF;W[35NFH'U]=N^%MU.< 5_?T"ZFI3TIN0E"D!X1I%.9DQ2[UIC/+<=
M0CW%J4?0/[(7:3,LC]K*,@IWG5Y5V@RVL:K*34ONN^I^Z735(2#I#C2I\1 )
M1X9TVQG]IJ9M="IT)3WC+B%)5^]I5.H"=I@6X!,1MCH[Z@-DZ-OSMY.LJI3I
M%&G(DQZK0*_"4\B91ZQ!6'8SR5Q9$.4J'(P8M2C,2XYF0G76%.!*B-?K#4!Y
M_+LURUNLJJ!K.,NJLKJJBB4TFJ;IZMLMN+IU/M/,I?0"2TM;2]"K@ P1YNXT
MAQ32RA"W*=U#[.L**0X@RG4$E*BD[* (D6QSNNO:NYMHX5'AW9.LVKRI ;BI
MIMESE-SF&TK+2)#5M3DM2VJ5&:#:7'8S\L1R>@MA"4J'Y0^VW^S0W[-359[0
M=LJ'.<H<<*VF,\?ILM[0NJ4E2W=-,:AY->ZE8(*J=7>.$ZE,HQZ-DF=JK^[9
MJ:-33X'B52A3E,"";R4)4@?E "I N.F()WRM6-7=O+EBMR%P*A ISU>M^KLK
M+4V@7'0$FIT.MP9""'&9%/J,6/(0H'I4E+C+J5LK6A7C/LJ[7YM[.?:1V0[5
MY"\XU54.<4@=8!ENMHJET,5M!4(V73UM*Z]3NH,ZDK)$* (U,YR]C,,NJZ1\
M2AUE5_\ (O\ ,AU)D *;5"TZ;RDDF]^HFVNU%[7+=%E;I[RW!0+HJ5EVX[#L
M*-1:&:3T2ZXQ&_%+PKQ6XM7X_,B-)A-TZ(13*>AZ:XU[SDGJ:_>RKSJA3E[]
M#DM+4T;69.-/U_O#P=4$-@EJB8C9AM:BI3BY=<*4 D!)!\58HJE50W45[[3Z
MJ9*D4X;;T J593[@_P#.J'A"4^!()TB3.+,W!1*3<M$JUNUZ"S4Z)7*?+I56
MIT@++$ZG3V'(TN*Z$*0L-OLN+;44+2M(5U)4E0!'/,/NTSS50PLMO,.(=:<3
M$H<0H*0H2""0H P00=B",:+@0M*FU@*2I)2I)F%)5((Z['<7'&.552])5^;4
MO7/61==N7C:;2T+I54N2JLT"[H5NPVO:I-LNF6PU;TB-;\,)IU,=%0IJY3#3
M3DI#LM:G%?'W]J3V#YQ[5<YJ/:#EG:QMFI:I1W_9K-4-464435,P.^>R[-._
M"6S5+0I]]-:PE*%N.*]X"0$XWNS.9HRIE.7/T^ME)"6ZII2G*ER22$NM:-)*
M =(*%JD #1)C$;2:93J_05^_%=,"IQULR8<UKH<]E2E-KZFR?RJ"D];#K14@
MX;D1W5(+;FOS"=9JNS^9=_15*&LRRBM"FZNBJD/MIJ*5<I<IJNG<6T\@+3(<
M;<4A:; D&_I"TMOLB4E2'$#P+0$G2H1"D$:@;R0H;C81CH9Z7[DJ]R;*6H[7
MYCE0K-%75;;E5%XE:YS5%J<J-2WUND^Z^ZBCII\>1(<+CLB2RZ\ZM;KBE']O
M/97VEJ^V'L\[(]I*Z55N;9.T[5DI">\J&5NTKKI &D%YQ@NV "2HB ,>19BP
MBFKJAA(A#3ATD23"AJ C>P(&G;I(Q(PW,V]7>[FVC=\6JYN$U0';I>LENNTU
M=TLVXQ-CTUVNO45$@U!FE(J$R-#^M=80P9#Z6 LN=0'H(*9BUCR3'R)B8/GU
M$@VJPHWZ@6B#,SO]2=B>;0=B<D1\* D,#\P&/=;ZN 2?\9/2<YR",'  [Z<%
M#J/N>9-N0 ;;'IB,A7 .\6!)'\>LF9' F^$BGV"3_?-$\XRXWC'GLH#GG]3]
MB2$*A:_Z0?78&18W@$\[A=*I)N .(XDB1R.M]QOTPE6M*NM2"E0(.%)/4DG'
M((Y&02,C/!^,:0DD6(V,Q?\ A:VYB)M;#@+C??I&WIS8^<CDXUFL08U5ITVF
M2?<5$J4*7 E!EYQAU4>4TN.\EMYI:'F%EIQ02XVI"TDY!R,ZB4D*2I)) 4E2
M24J*5 *!!TJ20I)@V4D@@W!!$XE!O)&Q$ B1:#?K?X6Q0B^MN;:VQCMTZU;L
M9K\RGLLQX=BSTIDUUN,EI*8[:ZK34%J$A".@-2*Y!83(!!?J*G5+=7^<'MY_
ML_>S'LL,P[24O;MK(<SJW*BN_8&</.9I49@^ZI3RQ2)ITO9DG6X2 XZTXRDK
M&MU"1?M\FS?,*@H8-"JH;3I3WK20TE"4PD:RJ$$ ";*!5!,&<1]<M)@U*B2X
M50B)^FGT]YF9#=(<1T.QU%QI9&4J+:LIZTDCJ3E)P 3\1L5#V59A09EESJZ6
MMHJZG?I:AKPN-NLOI4TXB;A6H!0!!VN!!QUKS2%-+2L)(6E25I41!!!U22;1
M<6$&Q$XN=LI5ZE<&T.V]9J[[LJI5&RZ!)FRGSU/S7S360Y-=(2D%R7T_4*(
M!+N4@)/'[R=GZQ_,,BR:OJ@$U-;E=!55  TP\_2M.."./&HV_CCQ]U(;=<0F
MZ4N+2"#(@*(F29(._.)%7P>^1WSP#WXXR3D9/D'[\ZU5QUCKOM?H/+RF+[#"
M)WVX_IR8O/,^D6PA<XSXP0,>23R03R,$9(.<G]--2-MH(O,;7OO(Z;1SOA/L
M<](@QQ;I'07Q6_=ST^HW8N:WKJ_VM;NV!+MB)*CTR)M[7Z)2*>EZ9E$FH/,5
M.VZTXY.=9Z8RW0\AOV4I2&@H=>G)/!^$D?"+SMTD6M@/E'/7RZ\;QSUQ##7H
M?@1(]-AL>HWU*M1J-4'JK3&47I:@3"J$B0_*?E-9L8DNNR)+[J^HK'6ZK@#
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M6=U;.<]FJ[-\]['AII+_ &9H%F<MJVF@EQ_W&G2A5:U4$+<#BN_?;4KNP @
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M9"&]CV=KDU)R52X0D/KJ3E*=>;6ZE/3& >\82@P PQXGI*-2G0:SW@IN7 R
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MXW-[VCIA/X83J.!G]/@?^'CG'G35':T@G<]#%O+U.PF^\&,"U#'R>P! [?\
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MJ[=KB*&LMUE5*GII;B>DJ1/,9SZ50Z\HR'N@CJ&,]]2LEL/-%T2V'$%P&8*
MH:A:]Q.V&JDI.G\T&)Z\8Y+;2VIZDK^DUO</?BQ2W?ELQ$TT5*-]&F+7+4@X
M"Z?$I316ZQ58KJ7:L5E:S/==E,)&?I(S/8YO4=GWU)RG)GGTY>LEYA=2DH]W
MS!0(*E.*@K8?20R2I">YTMKD@.*.2RW6-?WNH"2^F4O);(/>TXB"$B?Q&KJ
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MXT"_Z?PP3&\[;F.OE-_I8P !A4A>/S>,C()R.1@G QVSGN,8SQDZ6#T.%D7
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MXU^T7;*R;DOJX%N"F6]3)%04PR.N7.?0VKZ6G0FL@O3ITDMQ8C#94MYUU*4
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M.^/OR,<%)!';[GN,:23N3T/68M?X3O\ QP8S @_!/D GC)..V/C4@)B\#IM
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MIR"M3+BT*"U>>J7J42HE2E&5*)U$E1))))DDDDDW)W,XZ,)@    "$@6$"T
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M?-B29_E,'"E+Y'R>.P.?@\#@XX&.3S^O!8^A^LX4P"+C8VF0F(N0+P9]1<
M8P56M4RA4R?6ZS.BTVDTJ,[-J%0F.)8CPXK(ZW7GW%X2A"!R5'/@ 9(!5#+C
MRTM-(4XXM00AM *EE1F E(DDQ'AL-R8PI6 "3$"22K@<FX@3!N0?C&(SOC<B
MLV_3*'>=I4F!?-FO,+D5Z-2Z@TS<9@2FFG8%5MMJ2ZS3ZK[8)$JER'X4IYES
MKAO/RFT0)$K+"7BXTXLM/@GN]2?PBI&I*FG%B2V2L:4K5^&D_G*4F4A7I,Z=
M21O,%0!@A20(! %U#\Q_=U$WC"H;G^G;U*5>5L34)#5SS%4"'>4RC3X$V$J
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M>LV^*@U ;882"IZ0F_GW" KH@]72DER8 )Z ? 1&^WZ<VEZ4Q  ,D@ ;DDD
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M,FQD[  P222 ),X0G2"3: 2>L>0YM\\)XCSSL9IQ](2\M(4M*00$J(ZB .<
M9P 2<8/QH4$A:@D^#4=)4!J4G83:"3>8DWWO. 3 F)B\3$\Q/]+ 8S*RKCCC
MO@9P!SSQ@_L#WSC2" !<P!OL+6B-_NY)&#"50(./CD\XSC!&#_K\?;C3%&2(
MM!YVN.9D'DB+1MR,&$[AQP<'')(_?SP<XSD_8YTWR\^+_P _AZG!A ZX1DY(
MZ@<C(QC/P#DC X./MSC.E N+<C@WC<7^=XVV&#[^_OC"%Q0!)X\ ? R/M\G'
MSD'YQIQ@R8)@$$1XIM\!STY\\&$I(&<D9.1CD<'.?C&?N?L1GLZ#L-HM:Q$6
M$S\X ^$C"_?W-CZ3R//&%> ?& ,?H!\DG_S^VHS)&UR;\DVL1S$3 /!Z[''2
M8OL(O/UCY8GO86WEH@5:\Y38#EPNHC4=2L^XBA024H5R!TIFR@Y*Z<GP<@'&
MM>LBG8IJ%).II)?J;0#4.B8W-VV]*)M(XQ38EUUVH/Y5'NV3O^$C<BY@+6"J
M!;;%@]9V+>#1@P:,&#1@P:,&#1@P:,&/BE!*5*4<)2"HGX &2?V T8,5^V(9
M-;>W,W16L/(W(OVI2*&^G\T=^S[598M&U9L%1.1%J]*HS-8Z0E 6]-<=4"MQ
M1)@Q-5?H-*N:D3:)68C<RG3V5,OLN#D$C\CS2Q^9I]E>'&7D$+;<2E:2"-2L
M/N4[J'FE:5H,BT@@V*5 V4E0D*2;$$@XC<;0Z@MK$I5\""-B"-B#<'@WQ2FY
M[8JNWU8:HM6<=FTJ8X4V]<*T]*)J 244NH*0GH:JT=L8#BBE,](#C?\ ?%07
M;J:=NI;7748"0D35TDRIA9NIU%P54RR;<M'PJE,17:=6TL4[YE1LR\8 >3_E
M.^EU(&W[X@B\X1)5GC[8(X\CGC[?'P<ZRQ,F1<D':=NGZ=#$3R+GQ]?OY'C&
M9*N20"?L!P/&./C'!.?(QH/0D ;3S,WWO>9-XCD[%?\ 7K_/K'D3QA4VY\<#
MD#)SW_YX[=@#]P@6G<W,P/H".>DCDS;"??WZX7-N]BH](3SV')!\C\H(_-\=
M_MI"+^9CF1!X.]Y%C\;1A3''W_K]//"Y*@K/@]N.Q'@^>3D_RC('VP DQ&_!
MOR9DW.VXX_4DIC,#CG[\9\D8^0,<CM@?ISIP/EM$D[\@D]8!%N)Z8,94K((R
M3V^W?D?!R.Q/G/;3[D<7VYMY^OE\\&*R>K&PMZ[QVNJE0],56M.T_492&5-[
M=WG=I>31Z2U-6VBL1:K'88D,UB#+AH(9I=5BS::W4$Q*B8Q?AM*TEAMM'6W)
MY//-^G$P8WCTUN[QP]@MLX_J%CPV=Z*-:42D[D.TRH,U:!6+CH073)-?AS8\
M>(V\U<C<-NNI0F)'+"ZB8ZF@IG.D5!F_2-OUZ>9VOP8*BWWS;KOT(O(^>(WV
M.WGWFO3=:];5OBV*/1+2CN5"JV>\N/(C5Y^AMSQ#B]:DN)BRRUT]<DAA3[0>
M84XX$NH)ZO-\OR&GRF@J<LJ*FIK 44V8*D>Z(J^Y2ZO2%H[Q(5J 0H*T%25@
M1I,Y].]5KJ'FWT-H;\2V!<.EH$H&H@E-HN+$@@FQ&+I!92DE25!!P2LCI'4>
M,=1(^WV)['OKE >0.+"X&^T1$^<[XOGYXSA+F$]*5 KX02G.5*R 1QTJYP1R
M02 "" !IQB).PO\ UP8H/MO8&Z#OJ0NG=&%N94[ILEBJ3;6E4JLH94TY :CM
M..II#L41XS$:#5RAI*3%6\MR"^VM_P#*,]9G-=0')LKRQ&6-T5>PA%6Y4,K5
M"P]J26WTN:UEPMA+H5KTI2L:4 7.?3-.BIJ'S4*=96HMI;6D#3I$ZD$$#3JE
M) 3N)).V.A+;W(SW')!QD CR!X^Y_7'SRMHYG_7SYMQ;];HD'P_E/J>?A'2W
M2\;X4A8.0DX(((5G _ESC'/&?G.,\9QI,.!!V^_OIA2V^L$843C!5C!S@$$D
M]\C&?\^,9T;>6"QZ1]V^/3G$!^I?U)4OTU;?1+[J5 DW2N9<5)MR)18<YNG2
M9+U5?+0>$MV-+;;+)Z5]"F2'!^4%."11S+,V<JI/>Z@.+0'J>G2AN"M;M4^A
MEM(DCE4F]@G@X[3L!V&K/:#VA/9^AJF:!Q.69EFKM54(4XRS3973&I?*D(6E
M1U) 0(,A2IA0VF"5N7:]!LVFWM=%19MZG5*##D-1ICBGYKTR=&$EJD4R'%;5
M.K=6<R6V*?38DB9*+94U'Z0KITM1&YGRB)W]8@QTV-CSQ#K>AUQM)"PVXMO6
MF86$J*4J DPE6DJN;2)Q[K=9N^L6U2JA8D6/2Y=8"77GKHAK$VD4]YE:VI":
M2A\(<J*U!L(C2WO;C(=#DIAU3;D4S,J9U:ZA#JVPDG0RL(4M0G2"LA6A.JZB
M!JTV2H&XB(/[I0%?YE24@&),""HQ8<6O;%?Y7I.H-=OVU=UKBK-1JVX%!+J9
M=;F2.MR='D%?N,K9:#<>&VTA3C<>'":9B,-..!II/5G6D<\S T%7E;);I\NJ
MRV54K:2$H+2T*U:S*UN**$A:W%*4J()($8C]W9#S;ZM2WFPH!P[G4#:!X0D:
MCI   @1>^+$L6-%:W#F[@.39+LJ9;=%MQ$%TH,.%'HLJMRVG8:$I2I#TQZN/
M_6K*E%Q$:($]/M$:SU/+-,U2I"0VT\Z_(G4M;J&FX601*6PT= BQ<5P;/$!2
MUWE24#:R4I4I5K&9*KB38>6)%#P\']LGL20>".!G /<>#CS$8&_-HN;? >DP
M-X\L+,[VB+BP/\QY[GGC'M+XSR3@?_W''89SC)_7C.@F=HM&QZ[==^3P)@7P
MIV$P9MO-XV/0CI?@>6,H?/)/Y1D'.0<'[YQD]OG'G'.D@2=KVY%H^7'''H<
MF]AZ>=R>AV,\3?>V/8>_4 *SA?<#Y\^<_J3XTA /%X$F]IYYVC@QN"< ,&=_
MY<CXX^EY)XXY([?)(SV)^/W&21I0-S)N =Y-IZ"]HZ_' 2#L!:1OU.W4?#^
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MD7F26P[W@N.[ O))),"_H(L//C&:YG*/#+<F<AXRUEM,9QA!6X@HRE+A41T
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M">FM<JKR0ENGUC<&5+?D*"4(9B5.<77%K40.@)84HJ..%9QVQYY4N)=J:AQ
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M^7UQF]XD\GJ[#G@X^<_ 'P.!W^RZAN=_2X\ICXG  ;\1?^/UXZXB#?\ <_\
M<Y?7<?\ 5L+D$?\ Y7I^3X^./UQY)T_[Z83$PM*!98P2,L,=N./:3G(([<#/
MZ?<:01Q%NF$&PYL/OG&9&"/YND$!))!(^_\ 0#SDG[YR%P'])/R''S\O7@Y
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MX$W,>6.<=P>LA=VI=H(V$N:K4>IP:K[<>YH2H ^IM^J5"EUR0\A;;JVVH<B
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M^GZ8P]6%8"L 8SGYX!QCR,_TSQQHC4!(^(YWZBT_J;Q@/J;\?IZV\@.F/"G
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M5)"0A"4@)0VVFR6VT#PH0D6"0/,R23B=EE#"-" 8DE2E&5K4=UK5NI1Y)]!
M &-CU7Q+@T8,&C!@T8,&C!@T8,&C!BBOJUL_U)77=VT<G9VYU4"U+9NRD5RY
M8D6'%?D5-^/,"0Y*=DH>0J-"CN+=;A/QY$)]U(5(;5@8Z7(,RR>A:S%K,\M5
M5NUE(XQ3U'>*":=2T[%I)0J%J "G4.)<0#X3TI5;-2ZI@L/AI+;@4XG2"5@
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M@ 0 "2;"Y)YWM6T^D@#G/@8PG[9QC[#QC)YR=<ZH&)D1,[[^G$\VO$B^+F%
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M;*_>Z49RZRXFJKJE:5-/4%,T5-+_ &6TJ15O.2'5?ATX_P 12?L;L!VLR_\
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MT,'],)\?OKA/M-NE>DZZ+3IE[7/1[HH.[>W+&X5@U>F42/0FZ94HBXO]H[*
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M%>I@=2^F)4&$/M)>0"$N)2L$!8!("L9 )T-/.L*ULNN-+@C4VM3:H.XU(*5
M&+P1@4E*K* ,7$@$3Z$$?,866W;%!M"E,4.VZ;&I-*C$EF%$1[;+94 "4H'
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MTN:Z[D@N5=B#3)E0D4JE4VD4=/0B;-F28DMV3)?<3'AQV$)/]Z^V0X 6W F
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M_?'QQ\,CJ!"N3S@Y Q]CSQD'/<<C2%) DGT'/IY1_3!R/+?;KQO/R//& /\
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MS.T[$GO3R1*Z)]1N3W:F%(!W-U.MJ(/'A'IOADDLW) &:C9-Z0ASD"WYE34
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M!&A(21WH5'(-0\MKU*&%--J,"5()O,XA2% J*B3*6O36&6TO$#]U*G@XM*>
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C8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g899221g83i97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g83i97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1364&AO=&]S:&]P(#,N,  X0DE-! 0
M    %+J^4P8X0DE-! 0      %D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  5$96QT81P"!0 K36EC<F]S;V9T(%=O<F0@+2!"96YI=&5C
M("T@1F]R;2 Q,"U+(#@Y.3(R,0 X0DE-!"4      !![^!QJHC*1X[<@^,^/
M3;:(.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/T       2 #4    ! "T    &       !.$))30/W       <  #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       !JP   [8          0                         !
M      .V   !JP                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !JP    !29VAT;&]N9P   [8    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   :L
M4F=H=&QO;F<   .V     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3004       $     CA"
M24T$#      *W@    $   "@    2    >   (<    *P@ 8  '_V/_M  Q!
M9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1
M%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ 2 "@ P$B  (1 0,1 ?_=
M  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$!
M 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A
M$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$
MDU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%1
M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4
MHQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G
M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]38QE;&L8T,8P!K6M$  :!K0%)"R
M7Y#*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M /_B Z9)0T-?4%)/1DE,10 ! ;[,_OX>   #D$%$0D4"$   <')T<D=205E8
M65H@!\\ !@ #        86-S<$%04$P     ;F]N90
M  $  /;6  $     TRU!1$)%
M                           %8W!R=    ,     R9&5S8P   /0   !G
M=W1P=    5P    48FMP=    7     4:U120P   80   (,=&5X=     !#
M;W!Y<FEG:'0@,3DY.2!!9&]B92!3>7-T96US($EN8V]R<&]R871E9    &1E
M<V,         #41O="!'86EN(#(P)0
M
M                6%E:(        /;6  $     TRU865H@
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ME=IMC(%BWJH[2L^\+<N95B4BCU."F&$HHU(H.ZF=P1HNL9$AQ 2E,<"@80T
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M5[;$47:S;(EBPLE<+1M<MM-CV&NURE%C:"!$81R=5[*K(H(*@#]$I7UO+$5
M!5>'#X!7J-;PG2\I-(308YNH9$<()-AMD'5KA+%1WD1\-%<T^$2+;LT"1,X
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M*50Y2B &$!O0T#JTX=U5 X?33)GOE)3%(4@J)3 J&*  )Q*P=E 3Z?FA*4-
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M@?U(5AQ_7),?_P#*%.'$/1[7L5"KEOQ#RRY!,- '7:FC^[C\3:VN\>/'7O\
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MU]:@ERC&/GD!LSRT@MD"^Y],MWV@EXOG9"*78&,H^6*"IB-8=HN*B6N^D(+
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M'GU1*.\!=T0$9!3&;;3-M7V8^"&R$"*>%KG1$@XXO,' G"Z6NIBM_$W/&3*
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M'^8K#NZ<>-8EZA#04^RD)46TX=5*-4,P04,X)SJZ*K=8#D*9JX240<E25()
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M^G7VSS?7@'  'M[!'SZ5,NX^&S]L2CV])V#./;IY/3/M]755BN@=P>@*]5\
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MAND3:ECTCI' 3BY4U$@2SJO3E//TJLQ^[6S/\_6K4^U0(!DWD\!TZ[M9=O\
M::EU:CV (]?>'M=O:_JI$C_@%2_\:'X<:Z9LI:>5G*#]@AD"[^'?^4CK\/\
M;527**Z_TN7G34 U&0)U!_;ZU](]FOM=E6$9*#_R8N2KWOG3#8#KIU#C6W.O
MC_+J'7I4F[P_5/\ % \.&"[M#S\7!1UZ^/5IU=0]7 1#6F(>&>N4C'0/SF9[
M>O1D\Z_P]G32M)ICIR0[$>O\LD@#SZW0</.(?AV:U"SENQUN[D&AX@([4<>.
M@\! !QQ;/ =0]H T#3B'G#ZN@ZN/V!#[/&NNWC\B-T_N<G/XL=52#C41_&FL
MK:CK^6=[_7GF_P" UI+E2MK#*^RSLU<E<[Q:-N@KD/:/PK;5P>/XE>4*,:C
M% O@0(OF0MUA\8K[RHBKQ!/0H;O'Z3J]5]\9//[U<?Y$]4<X,'^IT;6(AV3^
M3NK^_P O#V1[:Y?*FG0/R:IN'"\;9$ _Q"GIP[=.WAZ-*Z)DS:HS##?T05L\
M[++"7BD\07/L>9!NF7BCQ)5)1:89RBKU!9*6%?G$DRK():I D)1(42B(Z@);
M]*4I2E*5H+'[-HCG#/CA%LW17<AC,[E=)!)-9P<EMOR$,X4(0IUA(41*453&
M$H:Z: -;]I51_+#0);CP=B./9)DN>Y@S_8R]JXC<XVN++D;F263;RNEDREB6
M[.6X+Y@=$QY%:4F99O!0W@@.)#>*HF ;VY-:4A)/97M0D+!6;::T1/73!7)9
M=D8SG<0,+)NN,D01F[5E<?W))2\M!7#%.-"2I%GZZ+HRB+MH8[95)0\^J5I3
M#@B+W,.H]68[E /,'B>W.%;KI2E03S[F/(=F;6&REC>VYI!A9M_KW3Y9Q)V*
M*YYPB+<&S),7BA@6:%8*'\+1\'W#&7 .=,=/X&.JK2T#E1<@=INA., 1'B.@
M*@&HZ< '@'M#W:5PVQ^ ^7O* B/5TA3/#MXP\K];0/KUH7$'ZD_F4-. (W\&
MFG8"C/L^QQ]NH%<MXS4?<D?L8H)*)I&+F;9[<;RI3&*)47B1C$ "CKJ?70!Z
M@ZQZJ^K"W>-OP8CVQ$</_P!HC7,TJ#/*/_I0,J#W-HH?1)M_P^M7-*!KL_[,
M^@#KY78 '@'$/RRBN/LZ>?ZU3,I2E*4I2E*4I2E*4KY[N6[QOLQWW+X@1SCE
MV8MF\Y*T;Q@\=XO@L"1F?+AN])E)Q-V3,U:,;,+MV=ESC(T&U8/[H*NV,K"J
M.8QPX!JNJF::')(6=+V[LJJW5*Q$W"HY@R9>V7(1K.05B6DY<P5XNFJD;)I6
M9CJ;G[<M)&02:\]XD%^64;F PR;5LX-S06@:AIKKP[^SC^'M=M:,R2/Q4,%
M :_E[> #YM+?3\W?]H==.-;TI5?MO"'XXU?X<->@>V]=>O49(=-/PZ]*GP\,
ML#1V+8Y$W!6ZPH*'*)TR+ F84S'(!B;Y"G HG(!RB8NI=XNNM56;:=V3U\[
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M<]^,W?\ >R_^2/5)&SY^D*VQ./\ 7'E/C[0=VOX=O;5CFQ-^E0P1^X"*ZO\
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MZ#Q#\DK=0\0$0%#AP[!T[Z]U//F&52%4)DBUA(8-0$9$I!X"(<2G*4P<0'K
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M$UFUA#%N+'N+;.>O\<V(Y>K,GO..W5I0"KE4P2T@F4#+*1XJ'-N%*4 U$1*
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MA,81$1'41$1[^/,'Q3B!$N\KC?'B)-2DWU+3MU,F\;0"EWCL2AJ;70H=9NH
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MM8^4<1;0]M1F3;&M9KE6VH]*U[GNU90L(2,GK*CF32<<1:\K$RCMBFHX3!1
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MLT"RA4+Q3;.?&:[D9ITX06D7BEQ1[)DLNI'J+$+VZP]D7)F/\2Y Q"IRAEH
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M9MF#)N2XXH2-VC-$C=L@03P!C"1%%,B91,8QMTH;QA'41]SHB>=?2WES7O\
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'2E*4I2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g899221g87u54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g899221g87u54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2T\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M    ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 =
M!U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&
MEN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M 2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F
M)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
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M!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M      #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F
M<      #A"24T#[0      $ "6     0 " )8    !  (X0DE-!"8
MX             /X   #A"24T$#0      !    '@X0DE-!!D       0
M >.$))30/S       )           ! #A"24TG$       "@ !
M(X0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P  /
M____________________________\#Z   .$))300(       0     0   D
M    )      #A"24T$'@      !      X0DE-!!H      S4    &
M        ("   !9@         !                          $
M       68   ("                      $
M  $     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %
M)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G
M1O;6QO;F<   ("     %)G:'1L;VYG   !9@    9S;&EC97-6;$QS     4
M]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M=G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6
MX    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M   $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W
M @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   " @
M!29VAT;&]N9P   68    #=7)L5$585     $       !N=6QL5$585
M$       !-<V=E5$585     $       9A;'1486=415A4     0      #F
M-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6
MAO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M    MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F
M]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M     ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M     X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24
MT$%       !     (X0DE-! P     (S8    !    ;P   *    %0  #2
M  (QH &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D
M="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M       0  ]M8  0    #3+4A0("
M                               !%C<')T   !4    #-D97-C   !A
M   &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=6
M5D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "
M1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M  " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F
M0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M       !)S4D="($E%0S8Q.38V+3(N,0
M                                      6%E:(        /-1  $
M !%LQ865H@                     %A96B        !OH@  ./4   .06%
ME:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M      %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='
M1P.B\O=W=W+FEE8RYC:
M                    !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F
M%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C
M$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                      9&5S8P         L4F5F97)E;F-E(%9I97=I;F
M<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96
MYC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                       '9I97<      !.D_@ 47RX $,\4  /MS  $$P
ML  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                   H\    "<VEG(     !#4E0@8W5R=@        0
M  !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0
M!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
M  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P
M%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 A
MT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0
M,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y!
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M!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,#
MP,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@
MX4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,#
MP,# P,#/_  !$( *  ;P,!(@ "$0$#$0'_W0 $  ?_Q $_   !!0$! 0$! 0
M         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'"
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M2DA;25Q-3D]*6UQ=7E]59F=H:6IK
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!20#E 0$1 /_$ !\  0 " @$% 0
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M)1D<JL+A1BR>3,>[<-VAUQ%8R":A4Q4$3B7M=^L0?H8?3J_80[7O[BU#[_\
M^%T_0P^G5^PAVO?W%J'\G^POJ]6O:*7T^=C..+3#7>A;1MO%.N%=>$D(&S5S
M$],B9N'?)E,5-Y'2+.)2=-')"G,!%D5"*%[0B4P#K<'P\-/I]/QZA;WH[O\
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M5%0\@WP%!C_L-$^K_8YG\G_8?Q:ZBPD,0Y5"1$810A@.0Y6#0IR' >0,4P)
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M'O\ TK9^ ^KQ$.=7Q$_]+)W_ .L+_P#*'T\1U7-\H'_5SI3?V2_ 7^&/M6-
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M6,B[69ZF7C(2'A2N2P\7'11'KE1Z\)',FS(CMZJ4A57;@K9-,%7*A4R%464
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MWUCGG94#3UTLP1[*/D[C:GC=%N23LT[Z"BYEY$44Q=.>T?L$+P4,I"'.H?\
MJ3](K'74FR!AZQ9 R+9:)6*1"VFMWV+J#%@E9;M R0MI.L-(BVN!,_IKJN65
M%25-(Q*7I;]JNXBEC@T=K@,C>$L&43 ]41K5-CR>F.&\5]5%I<-VR=BO$K$1
M;6&0L5K>-44"24XJP9H(KO#I@8Y$RAQP :S+IIIIIIIIIIIIIIIIIIIIIIII
,IIIIIIIIIIIIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483435512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_GoingConcernDisclosureTextBlock', window );">Going concern</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3. Going Concern </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared in conformity with US&#160;GAAP, which contemplate continuation of the Company as a going concern. For the fiscal years ended June&#160;30, 2020, and 2019, the Company had a net (loss) income of $(8.3) million and&#160;$2.6&#160;million, respectively, and net cash (used in) provided by operations of $(7.5) million and $4.8&#160;million, respectively. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of June&#160;30, 2020, the Company had $9.8&#160;million in cash and cash equivalents. The Company has incurred operating losses and negative cash flows from operations since inception, except for the year ended June&#160;30, 2019. Management believes the Company&#8217;s existing cash together with the net proceeds of a&#160;public offering of common stock will be sufficient to fund the Company&#8217;s operations at least for the next twelve months. In connection with the Company&#8217;s&#160;public offering, on August&#160;14, 2020, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> with the SEC.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management having performed a review of the cash flow forecasts, considering the cash flow needs of the Company, believe that current funding and the proceeds of the upcoming capital raise will be sufficient for a period of at least twelve months from the date of this report. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">Although management believes that the additional required funding will be obtained, there<div style="display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">is</div><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;no guarantee the Company will be able to obtain the additional required funds on a timely basis or that funds will be available on acceptable terms. If such funds are not available when required, management will be required to curtail its expenditures, which may have a material adverse effect on its future cash flows and results of operations, and its ability to continue operating as a going concern. The accompanying financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern.</div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484380952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4. Revenue </div>(US$&#8217;000) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensing revenue*</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,273</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">183</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Service revenue*</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,095</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">97</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">11,551</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:2%;">*</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">On July&#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. Pursuant to the Agreement, the Company granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&#8217;s product known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of payments for the Company&#8217;s intellectual property related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> and the transfer of the right to use the intellectual property of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&#160;6, 2019, the termination of the License and Collaboration Agreement with Axovant was announced. The termination of the Agreement was effective as of September&#160;3, 2019. The termination discharges all future performance obligations under the contract at the termination date.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:77%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other revenues (US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Government research and development grants</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">648</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">648</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:57%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal year ended June&#160;30, 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Licensing</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Royalties</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Development<br/>activities</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">$4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">$97</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: 'times new roman';;height:16;"></td><td colspan="16" style="font-family: 'times new roman';;height:16;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal year ended June&#160;30, 2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Licensing</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Royalties</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Development<br/>activities</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,136</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,136</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">137</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">183</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,095</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,415</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,273</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">183</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,095</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,551</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483330280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5. Cash and Cash equivalents </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash at Bank</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,231</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,779</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term Deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">4,570</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">4,939</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,801</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,718</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483383864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_TradeAndOtherReceivablesDisclosureTextBlock', window );">Trade and other receivables</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6. Trade and other receivables </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research&#160;&amp; development grants</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">636</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other receivables*</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,900</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,536</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:2%;">*</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had a contract asset of $0 and approximately $1.7M as of June&#160;30, 2020, and 2019, respectively, related to the contract with Axovant which is included in other receivables on the consolidated balance sheet. </div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_TradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other receivables disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_TradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483450888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other assets</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7. Other assets </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid expenses</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">861</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">375</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Security deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">69</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">103</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other deposit</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">18</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">23</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market value of listed shares</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">949</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">502</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483297864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8. Property and equipment, net </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Software</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,109</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,014</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and fixtures</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">32</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Leasehold improvements</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">77</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,170</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,140</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accumulated depreciation and amortization</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(796</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(670</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">374</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">470</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense was $190,000 and $158,000 for the fiscal years ended June&#160;30, 2020 and 2019, respectively. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483353672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and other payables</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9. Trade and other payables </div></div>&#160;</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Trade payable</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">282</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,474</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued license fees</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">54</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">385</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued research and development fees</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">498</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional fees</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">155</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other payables</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">250</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">76</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">741</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,494</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094519507288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10. Leases </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;1, 2019, the Company adopted ASC 842,<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;Leases</div>&#160;(&#8220;ASC 842&#8221;). ASC 842 requires lessees to recognize at the lease commencement date a lease liability, which is the lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. Lessees and lessors must either (i)&#160;apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or (ii)&#160;recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company elected to use the cumulative-effect transition method upon adoption.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 842 also allows lessees and lessors to elect certain practical expedients. The Company elected the following practical expedients: </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transitional practical expedients: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="font-family: 'times new roman';;vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company need not reassess whether any expired or existing contracts are or contain leases. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="font-family: 'times new roman';;vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company need not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with the previous guidance will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with the previous guidance will be classified as finance leases). </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="font-family: 'times new roman';;vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company need not reassess initial direct costs for any existing leases. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hindsight practical expedient: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Company elected the hindsight practical expedient in determining the lease term (that is, when considering lessee options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon adoption of ASC 842, the Company recognized on its consolidated balance sheet as of July&#160;1, 2019 an initial measurement of approximately $579,000 of operating lease liabilities, and approximately $579,000 of corresponding operating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of</div> use assets, net of tenant improvement allowances. There was also no cumulative effect adjustment to retained earnings as a result of the transition to ASC 842. The Company recorded the initial recognition of the operating lease as a supplemental noncash financing activity on the accompanying consolidated statement of cash flows. The adoption of ASC 842 did not have a material impact on the Company&#8217;s consolidated statement of operations.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The tables below show the changes during the year ended June&#160;30, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:56%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:40%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Operating&#160;lease&#160;right-of-use&#160;assets</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Initial measurement at July&#160;1, 2019</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">579</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of right of use asset</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(184</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">right-of-use</div></div> asset at June&#160;30, 2020</div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">395</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:67%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:29%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Operating&#160;lease&#160;liabilities</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Initial measurement at July&#160;1, 2019</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">579</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal payments on operating lease liabilities</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(174</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Operating lease liabilities at June&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">405</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">213</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Current portion at June&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">192</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020, the Company&#8217;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:80%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2021</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">207</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">218</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease payments</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">425</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(20</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Present value of operating lease liabilities</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">405</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal years ended June&#160;30, 2020 and 2019, total lease expense under operating leases was approximately $208,000 and $221,000, respectively, and was recorded in general and administrative expenses. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483554472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11. Stockholders&#8217; equity </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Common Stock </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2019, BBL entered into a securities purchase agreement (&#8220;SPA&#8221;) with certain sophisticated and professional investors (&#8220;Investors&#8221;) in&#160;the United States&#160;to issue 186,666 shares of common stock at a purchase price of&#160;US$10.50&#160;per share, in a registered direct offering. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrants </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;30, 2019, the Investors were issued 4 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants that are exercisable into 27,526 fully paid shares of common stock should the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants be exercised in full <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Pre-Funded</div> Warrants&#8221;). The exercise price for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants is US$10.50 per share issued on exercise of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrant. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants were exercisable at any time from issue, in whole or in part, provided that the beneficial ownership of the relevant investor in the total number of shares on issue could not exceed 9.99%. All of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants have been exercised.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;6, 2019, the Investors were issued 4 Purchase Warrants that were exercisable into 214,190 fully paid shares of common stock should the Purchase Warrants be exercised in full (&#8220;Purchase Warrants&#8221;). The exercise price for the Purchase Warrants is US$10.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (December 6, 2024). On April&#160;22, 2020, the Company issued 37,417 shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for 107,095 shares of common stock. The Company did not have an effective registration statement registering, the resale of the Warrant Shares by the Holder at the time the Holder wanted to exercise the warrant therefore the Holder carried out a cashless exercise. The formula for conducting a cashless exercise was outlined in the Warrant agreement. Based on this formula, the Holder would have been entitled to receive 107,095 shares of common stock if they had exercised the Purchase Warrants for cash. Because of the cashless exercise, the holder received 37,417 shares. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to warrants during for the fiscal years ended&#160;June 30, 2020 and 2019,&#160;is summarized as follows: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:61%;"></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/>from Warrants</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>average&#160;Exercise<br/>Price (per share)</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July&#160;1, 2018</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">38,326</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">82.50</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at June&#160;30, 2019</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">38,326</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">82.50</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">241,716</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10.50</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(27,526</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">10.50</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cashless exercise</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(107,095</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10.50</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding and exercisable at June&#160;30, 2020</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">145,421</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29.48</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity Incentive Plan </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Share Option Plan </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Plan&#8221;). This includes the Company&#8217;s assumptions of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances . Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the organization, and certain other conditions have been satisfied, generally the employee has 12 months to exercise their options or the options are cancelled. After the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> no new options have been or will be issued under the Plan.</div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity Awards </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which comprised of stock options during the&#160;fiscal years&#160;ended June&#160;30, 2020 and 2019, respectively,&#160;is summarized as follows: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:30%;"></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Options</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/>Exercise Price</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/>Remaining&#160;Contractual<br/>Term</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate&#160;Intrinsic<br/>Value</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July&#160;1, 2018</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">81,591</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">92.10</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3.83&#160;years</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27,333</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43.20</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(22,457</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">125.40</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2019</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">86,467</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">64.20</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3.58 years</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at June&#160;30, 2019</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27,022</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">64.20</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Granted</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(16,306</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">102.66</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at June&#160;30, 2020</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">70,161</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">60.42</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.89 years</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercisable at June&#160;30, 2020</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">41,829</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">69.81</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2.59 years</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity-based Compensation Expense </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:65%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">102.9-104.1</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">102.9-104.1</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">5 years</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">5 years</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1.28-1.67</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1.28-1.67</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Expected Volatility. </div>Due to the lack of Company-specific historical or implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies in the life sciences industry. The Company selected the peer group based on comparable characteristics, including development stage, product pipeline and enterprise value. The Company computed historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the equity-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own share price becomes available. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Expected Life. </div>The expected life represents the period that the equity awards are expected to be outstanding. For stock options with service conditions, it is based on the &#8220;simplified method&#8221; for developing the estimate of the expected life. Under this approach, the expected life is presumed to be the midpoint between the average vesting date and the end of the contractual term. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Risk-free Interest Rate. </div>The Company bases the risk-free interest rate assumption on U.S. Treasury constant maturities with maturities similar to those of the expected term of the equity award being valued. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Expected Dividend Yield. </div>The Company bases the expected dividend yield assumption on the fact that it has never paid<div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div>dividends and does not expect to pay dividends in the foreseeable future. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation Expense </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense for the fiscal years ended: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:80%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal&#160;Year&#160;Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">87</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">221</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">585</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation expense</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;237</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;672</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of&#160;June 30, 2020, and 2019, there was $242,000 and $907,000, respectively, of unrecognized share-based compensation expense related to shares of common stock issued under the Plan. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480338264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12. Income taxes </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before provision for income taxes consisted of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">United States</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(299</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">169</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(7,975</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">2,440</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, serif; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(8,274</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;2,609</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%;font-family: times new roman;font-size: 10pt;margin-top: 0;margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The tax effects of significant items comprising the Company&#8217;s deferred taxes are as follows:</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:72%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred tax assets:</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,153</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,632</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Capital losses</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">250</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">209</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">193</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Lease liability</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">85</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,447</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,075</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less valuation allowance</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(13,290</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(11,075</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Right-of-use</div></div> assets</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(83</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(74</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total deferred tax liabilities</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(157</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred taxes</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. As of June&#160;30, 2020, and 2019, the Company established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation allowance increased by $2,<div style="letter-spacing: 0px; top: 0px;;display:inline;">215</div> during the year ended June&#160;30, 2020. Net operating losses and tax credit carryforwards as of June&#160;30, 2020 are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:67%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Amount</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Expiration&#160;Years</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net operating losses, federal (post-December 31, 2017)</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">629</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">Do&#160;not&#160;expire</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net operating losses, federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-January</div> 1, 2018)</div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">192</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">2034-2036</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net operating losses, state</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,314</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2031-2034</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses, foreign</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">45,847</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">Do not expire</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax credits, foreign</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div>  <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effective rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal&#160;Year&#160;Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Statutory rate</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">21.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">27.50</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent differences</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(2.4</td><td style="white-space: nowrap;;vertical-align:bottom;">%)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">6.18</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenditures</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15.73</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development incentive</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(6.87</td><td style="white-space: nowrap;;vertical-align:bottom;">%)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Share-based payments</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(0.74</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.06</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(42.3</td><td style="white-space: nowrap;;vertical-align:bottom;">%)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in valuation allowance</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(24.12</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(7.3</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign tax rate differential</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">6.26</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(0.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to taxation in the U.S., various state jurisdictions and Australia. The Company&#8217;s tax returns for the tax years 2014 through 2019 are open and are subject to examination by federal taxing authorities and the Company&#8217;s tax returns for tax years 2011 through 2019 are subject to examination by state taxing authorities. The Company is not currently undergoing a tax audit in any federal, state or Australian jurisdiction.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The Company does not have any uncertain tax benefits &#8220;(UTBs)&#8221; as o<div style="letter-spacing: 0px; top: 0px;;display:inline;">f</div>&#160;June 30, 2020 and does not expect its UTBs to change significantly over the next 12 months.</div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fiscal year ended June 30, 2019, the Company was domiciled in Australia where the statutory rate was 27.5%. As a result, the presentation of the tax disclosures, including effective tax rate, were based on Australian statutory rules. In the fiscal year ended June 30, 2019, the net operating losses presented in the effective tax rate could also be viewed as a chance in valuation allowance. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal Revenue Code Section&#160;382 places a limitation (&#8220;Section&#160;382 Limitation&#8221;) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section&#160;382 Limitation. Due to these &#8220;change in ownership&#8221; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Australian income tax legislation, losses can be utilized by the Company if it satisfies firstly the Continuity of Ownership Test (&#8220;COT&#8221;) or if failing that, the Similar Business Test (&#8220;SBT&#8221;). Broadly, the COT requires a company to show that it maintained continuity of majority beneficial ownership from the beginning of the year in which a loss is incurred to the end of an income year in which a tax loss is sought to be recouped. The SBT requires a company to demonstrate that a &#8220;similar business&#8221; has been maintained from the time when the COT is failed and throughout the period until the end of the income year that the losses are being recouped. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a five-year net operating loss carryback for certain net operating losses, suspension of the annual deduction limitation of 80% of taxable income for certain net operating losses, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. The CARES Act also provides other non-tax benefits to assist those impacted by the pandemic. The Company evaluated the impact of the CARES Act and determined that there is no material impact to the income tax provision for the fiscal year ended June 30, 2020. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net operating losses and limits the use of research tax credits for 2020, 2021 and 2022, respectively. The Company evaluated the impact of AB 85 and determined that the new legislation did not materially impact the Company&#8217;s income tax provision for the fiscal year ended June 30,2020. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480256312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Benitec Biopharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001808898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3940 Trust Way Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">780-0819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,875,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484424536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13. Commitments and contingencies </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contract commitments </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;18, 2012, the Company announced the appointment of Synteract, Inc. as its Clinical Research Organization responsible for the progression of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TT-034</div> into Phase I/IIa clinical trials in the U.S. The Company has negotiated a contract for Synteract to continue to manage the Phase I/IIa clinical trial and the long-term patient follow up through 2016 and beyond. The Company announced on February&#160;20, 2016 that it was terminating the HCV program, and at the end of the 2018 financial year had assumed all patients would remain in the study and the follow up would continue to 2021 at a maximum cost of $462,000. However, in July 2018, the Company applied to the FDA for, and the FDA approved, the discontinuation of the study which will result in minimal costs being incurred in the future.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no contingent liabilities as of June&#160;30, 2020 and 2019, respectively. See Note 10 above for lease commitments. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contingencies </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094489195288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14. Related party transactions </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following transactions occurred with related parties: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:83%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Legal services paid/payable to a law firm in which a director of the Company is a partner and has a beneficial interest.</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;1</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All transactions were made on normal commercial terms and conditions and at market rates. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, the Company accrued a milestone payment of $300,000 (AUD 425,411) payable to NantWorks, LLC pursuant to a sublicense agreement.&#160;It was later determined that the milestone was not required to be paid and therefore the accrual was reversed in December 2019. </div><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">Nant<div style="display:inline;">W</div>orks, </div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC&#160;is an affiliate of Nant Capital which owns 26.44% of the issued and outstanding common stock of the Company as of June&#160;30, 2020. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094482317160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15. Earnings (Loss) per share </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:69%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net Income (Loss) attributable to common stockholders</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">($</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,274</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,609</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in calculating basic and diluted earnings per share</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,021,193</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">856,765</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted earnings (loss) per share</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">($</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.10</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.05</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding options to acquire ordinary shares are not considered dilutive for the fiscal years ended June&#160;30, 2020 and June&#160;30, 2019, because they are anti-dilutive, as the strike price was higher than the share price. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484449320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16. Subsequent events </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company is closely monitoring the impact of the pandemic of the novel strain of coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;)</div> on all aspects of its business and geographies, including how it will impact its team members, suppliers, vendors and business partners. While the Company did experience some disruption from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> through the delay of the initiation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials through the date of issuance, of these financial statements, it is unable to predict the impact that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will have on its financial position and operating results due to numerous uncertainties.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;14, 2020, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-246314)</div> with the SEC (the &#8220;Registration Statement&#8221;).</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478452456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April&#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon consummation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation.</div> As a result, the financial statements included in this report reflect (i)&#160;the historical operating results of BBL and subsidiaries prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> (ii)&#160;the combined results of the Company, BBL, and subsidiaries following the completion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> and (iii)&#160;the Company&#8217;s equity structure for all periods presented<div style="font-weight:bold;display:inline;">.</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the SEC. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> adjustments) necessary to present fairly our financial position, results of operations, and cash flows for the fiscal years ended June&#160;30, 2020 and 2019 have been made.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Segment Reporting </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preparation of financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BBL&#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar &#8220;$&#8221; and/or &#8220;USD&#8221; as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive income (loss).&#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020, and 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:76%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exchange rate on balance sheet dates</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD: AUD Exchange Rate</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.6877</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.7014</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Average exchange rate for the period</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD: AUD Exchange Rate</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.6711</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.7149</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exchange rate used to translate amounts in AUD into USD for the year ended June&#160;30, 2018 is 0.7385 as of the balance sheet date. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements.</div> For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:9%;">Level&#160;1:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:9%;">Level&#160;2:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:9%;">Level&#160;3:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of the Company&#8217;s cash and cash equivalents, trade and other receivables, and trade and other payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of June&#160;30, 2020, and 2019, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Trade and Other Receivables</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="width:36%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width:61%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Lab&#160;equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Furniture&#160;and&#160;fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Computer&#160;hardware</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Leasehold&#160;improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">shorter of the lease term or estimated useful lives</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_TradeAndOtherPayablesPolicyTextBlock', window );">Trade and other payables</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and other payables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock', window );">Australian Goods and Services Tax ("GST") and other similar taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Australian Goods and Services Tax (&#8220;GST&#8221;) and other similar taxes </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues, expenses, and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basic and Diluted Net Income (Loss) Per Share </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of June&#160;30, 2020, and 2019, there were 145,421 and 38,326 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted ASC 606 &#8211; <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue from Contracts with Customers </div>(&#8220;ASC 606&#8221;) on July&#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 1: Identify the contract(s) with a customer. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 2: Identify the performance obligations in the contract. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 3: Determine the transaction price. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 4: Allocate the transaction price to the performance obligations in the contract. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Licensing revenues </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Royalties </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of product occurs. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Services revenue </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock', window );">Government Research and Development Grants</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Government Research and Development Grants </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant income is generated through the Australian federal government&#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% (2019: 43.5%) of eligible research and development expenditures. This grant is available for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will not be claiming the Australian Government research and development grants going forward due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> of the Company to the United States.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and Development Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation Expense</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records share-based compensation in accordance with ASC 718, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock Compensation</div>. ASC&#160;718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company adopted FASB Accounting Standard Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-07</div> and accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Accounting for Income Taxes</div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company records unrealized foreign currency translation loss which qualifies as other comprehensive loss.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards recently adopted</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Accounting Standards recently adopted </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases </div>(Topic 842) whereby lessees will need to recognize most leases on their balance sheet as a right of use asset and a lease liability. This guidance is effective for interim and annual reporting periods beginning after December&#160;15, 2018. The Company adopted this ASU effective July&#160;1, 2019.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s only lease is the lease on its research and development facilities.&#160;The Company&#8217;s existing lease commitments&#160;are set out in Note 10. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-07,</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Compensation &#8211; Stock Compensation</div> (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation &#8211; Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for goods and services. Consequently, the accounting for share-based payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> and employees will be substantially aligned. This standard is effective for financial statements issued by public companies for the annual and interim periods beginning after December&#160;15, 2018. The Company adopted this ASU on July&#160;1, 2019. There was no effect on the financial statements on adoption.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock', window );">New Accounting Standards and Interpretations not yet mandatory or early adopted</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">New Accounting Standards and Interpretations not yet mandatory or early adopted </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments &#8211; Credit Losses</div> (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after December&#160;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November&#160;15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</div> amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Australian Goods and Services Tax GST and other similar taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AustralianGoodsAndServicesTaxGstAndOtherSimilarTaxesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Research and Development Grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New Accounting Standards and Interpretations not yet mandatory or early adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_NewAccountingStandardsAndInterpretationsNotYetMandatoryOrEarlyAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_TradeAndOtherPayablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_TradeAndOtherPayablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI http://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484426552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlTableTextBlock', window );">Summary of entities in control</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of the Company are presented in United States dollars and consist of Benitec Biopharma Inc. and the entities it controls: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:65%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:3%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Principal place of<br/>business/country of<br/>incorporation</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">Australia</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec Australia Proprietary Limited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">Australia</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Limited</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">United&#160;Kingdom</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec LLC</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RNAi Therapeutics, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tacere Therapeutics, Inc.</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec Biopharma Proprietary Limited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">Australia</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of entities in control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483459096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock', window );">Summary of foreign currency translation and other comprehensive income (loss)</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020, and 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:76%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exchange rate on balance sheet dates</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD: AUD Exchange Rate</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.6877</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.7014</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Average exchange rate for the period</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD: AUD Exchange Rate</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.6711</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.7149</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="width:36%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width:61%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Lab&#160;equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Furniture&#160;and&#160;fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Computer&#160;hardware</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Leasehold&#160;improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">shorter of the lease term or estimated useful lives</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of foreign currency translation rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483455736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of revenue from customers</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensing revenue*</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,273</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">183</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Service revenue*</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,095</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">97</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">11,551</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:2%;">*</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">On July&#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. Pursuant to the Agreement, the Company granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&#8217;s product known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of payments for the Company&#8217;s intellectual property related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> and the transfer of the right to use the intellectual property of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&#160;6, 2019, the termination of the License and Collaboration Agreement with Axovant was announced. The termination of the Agreement was effective as of September&#160;3, 2019. The termination discharges all future performance obligations under the contract at the termination date.</div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock', window );">Summary of other revenue from customers</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:77%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other revenues (US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Government research and development grants</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">648</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">648</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of disaggregation of revenue</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:57%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal year ended June&#160;30, 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Licensing</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Royalties</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Development<br/>activities</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">$4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">93</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">$97</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: 'times new roman';;height:16;"></td><td colspan="16" style="font-family: 'times new roman';;height:16;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal year ended June&#160;30, 2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Licensing</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Royalties</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Development<br/>activities</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Total</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,136</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,136</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">137</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">183</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,095</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,415</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,273</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">183</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,095</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11,551</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of entity wide information other revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntityWideInformationOtherRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488831720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of cash and cash equivalent</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash at Bank</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,231</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,779</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term Deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">4,570</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">4,939</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,801</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15,718</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488826536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock', window );">Summary of trade and other receivables</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research&#160;&amp; development grants</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">636</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other receivables*</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,900</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">59</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,536</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:2%;">*</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had a contract asset of $0 and approximately $1.7M as of June&#160;30, 2020, and 2019, respectively, related to the contract with Axovant which is included in other receivables on the consolidated balance sheet. </div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfTradeAndOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480327048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,801<span></span>
</td>
<td class="nump">$ 15,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">2,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,809<span></span>
</td>
<td class="nump">18,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,587<span></span>
</td>
<td class="nump">19,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Trade and other payables</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, less current portion</a></td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value&#8212;10,000,000 shares authorized; 1,108,374 and 856,765 shares issued and outstanding at June&#160;30, 2020 and 2019, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">128,826<span></span>
</td>
<td class="nump">127,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(116,636)<span></span>
</td>
<td class="num">(108,870)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(1,864)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">10,238<span></span>
</td>
<td class="nump">16,594<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 11,587<span></span>
</td>
<td class="nump">$ 19,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488831720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Summary of other assets</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid expenses</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">861</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">375</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Security deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">69</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">103</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other deposit</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">18</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">23</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market value of listed shares</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">949</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">502</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094482298648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment net</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Software</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,109</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,014</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and fixtures</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">32</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Leasehold improvements</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">77</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,170</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,140</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accumulated depreciation and amortization</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(796</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(670</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">374</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">470</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488831720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of trade and other payables</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:76%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Trade payable</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">282</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,474</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued license fees</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">54</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">385</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued research and development fees</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">498</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional fees</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">155</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">61</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other payables</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">250</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">76</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">741</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,494</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483450888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Summary of supplemental balance sheet information related to leases</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The tables below show the changes during the year ended June&#160;30, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:56%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:40%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Operating&#160;lease&#160;right-of-use&#160;assets</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Initial measurement at July&#160;1, 2019</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">579</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of right of use asset</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(184</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">right-of-use</div></div> asset at June&#160;30, 2020</div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">395</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:67%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:29%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Operating&#160;lease&#160;liabilities</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Initial measurement at July&#160;1, 2019</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">579</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal payments on operating lease liabilities</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(174</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Operating lease liabilities at June&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">405</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">213</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Current portion at June&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">192</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020, the Company&#8217;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:80%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2021</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">207</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">218</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease payments</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">425</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(20</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Present value of operating lease liabilities</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">405</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484377896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants or rights</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to warrants during for the fiscal years ended&#160;June 30, 2020 and 2019,&#160;is summarized as follows: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:61%;"></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/>from Warrants</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>average&#160;Exercise<br/>Price (per share)</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July&#160;1, 2018</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">38,326</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">82.50</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at June&#160;30, 2019</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">38,326</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">82.50</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">241,716</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10.50</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(27,526</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">10.50</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cashless exercise</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(107,095</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10.50</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding and exercisable at June&#160;30, 2020</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">145,421</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29.48</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of equity awards</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which comprised of stock options during the&#160;fiscal years&#160;ended June&#160;30, 2020 and 2019, respectively,&#160;is summarized as follows: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="width:30%;"></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Options</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/>Exercise Price</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/>Remaining&#160;Contractual<br/>Term</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate&#160;Intrinsic<br/>Value</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July&#160;1, 2018</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">81,591</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">92.10</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3.83&#160;years</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27,333</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43.20</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(22,457</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">125.40</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2019</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">86,467</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">64.20</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3.58 years</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at June&#160;30, 2019</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27,022</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">64.20</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Granted</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(16,306</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">102.66</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at June&#160;30, 2020</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">70,161</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">60.42</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.89 years</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercisable at June&#160;30, 2020</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">41,829</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">69.81</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2.59 years</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of equity-based compensation expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:65%;"></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:4%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">102.9-104.1</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">102.9-104.1</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">5 years</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">5 years</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1.28-1.67</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1.28-1.67</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-basedcompensation expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense for the fiscal years ended: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:80%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal&#160;Year&#160;Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">87</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">221</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">585</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation expense</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;237</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;672</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094482558200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of income (loss) before provision for income taxes</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before provision for income taxes consisted of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">United States</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(299</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">169</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(7,975</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">2,440</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, serif; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(8,274</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;2,609</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of company's deferred taxes</a></td>
<td class="text"><div style="text-indent: 4%;font-family: times new roman;font-size: 10pt;margin-top: 0;margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The tax effects of significant items comprising the Company&#8217;s deferred taxes are as follows:</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:72%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt; font-size: 8pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred tax assets:</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,153</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,632</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Capital losses</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">250</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">209</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">193</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Lease liability</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">85</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,447</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,075</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less valuation allowance</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(13,290</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(11,075</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Right-of-use</div></div> assets</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(83</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(74</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total deferred tax liabilities</div></div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(157</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred taxes</div></div></div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock', window );">Summary of net operating losses and tax credit carryforwards</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation allowance increased by $2,<div style="letter-spacing: 0px; top: 0px;;display:inline;">215</div> during the year ended June&#160;30, 2020. Net operating losses and tax credit carryforwards as of June&#160;30, 2020 are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:67%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:6%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Amount</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Expiration&#160;Years</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net operating losses, federal (post-December 31, 2017)</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">629</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">Do&#160;not&#160;expire</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net operating losses, federal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(pre-January</div> 1, 2018)</div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">192</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">2034-2036</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net operating losses, state</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,314</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2031-2034</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses, foreign</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">45,847</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">Do not expire</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax credits, foreign</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary reconciliation of effective rate of the company's provision (benefit) for income taxes</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effective rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:80%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:5%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal&#160;Year&#160;Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Statutory rate</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">21.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">27.50</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent differences</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(2.4</td><td style="white-space: nowrap;;vertical-align:bottom;">%)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">6.18</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenditures</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">15.73</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development incentive</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(6.87</td><td style="white-space: nowrap;;vertical-align:bottom;">%)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Share-based payments</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(0.74</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.06</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(42.3</td><td style="white-space: nowrap;;vertical-align:bottom;">%)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in valuation allowance</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(24.12</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(7.3</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign tax rate differential</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">6.26</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(0.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure details of operating loss carry forwards and tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488821224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of related party transactions</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following transactions occurred with related parties: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:83%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:5%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Legal services paid/payable to a law firm in which a director of the Company is a partner and has a beneficial interest.</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;1</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094489029464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of earnings (loss) per share</a></td>
<td class="text"><div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:69%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:10%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended<br/>June&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net Income (Loss) attributable to common stockholders</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">($</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,274</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,609</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in calculating basic and diluted earnings per share</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1,021,193</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">856,765</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted earnings (loss) per share</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">($</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.10</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.05</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478050776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Summary of entities in control (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember', window );">Benitec Biopharma Proprietary Limited ("BBL") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember', window );">Benitec Australia Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember', window );">Benitec Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember', window );">Benitec, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember', window );">Benitec LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember', window );">RNAi Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember', window );">Tacere Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember', window );">Benitec Biopharma Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483330280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation Date Of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 22,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CommonStockSharesRedomiciliationDescription', window );">Common Stock, Shares, Re-domiciliation Description</a></td>
<td class="text">one Benitec Biopharma Inc. share for every 300 BBL shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CommonStockSharesRedomiciliationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, shares, re-domiciliation description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CommonStockSharesRedomiciliationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094489214120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">1,108,374<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">1,108,374<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483270888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Exchange rate on balance sheet dates, USD: AUD Exchange Rate</a></td>
<td class="nump">0.6877<span></span>
</td>
<td class="nump">0.7014<span></span>
</td>
<td class="nump">0.7385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AverageForeignExchangeRateForThePeriod', window );">Average exchange rate for the period, USD: AUD Exchange Rate</a></td>
<td class="nump">0.6711<span></span>
</td>
<td class="nump">0.7149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AverageForeignExchangeRateForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average foreign exchange rate for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AverageForeignExchangeRateForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478706536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Summary of property and equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">shorter of the lease term or estimated useful lives<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094476294536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Closing foreign exchange rate</a></td>
<td class="nump">0.6877<span></span>
</td>
<td class="nump">0.7014<span></span>
</td>
<td class="nump">0.7385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share | shares</a></td>
<td class="nump">145,421<span></span>
</td>
<td class="nump">38,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember', window );">Grant Receivable on research and development expenditures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094489215976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (8,274)<span></span>
</td>
<td class="nump">$ 2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in provided by operations</a></td>
<td class="num">(7,535)<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,801<span></span>
</td>
<td class="nump">$ 15,718<span></span>
</td>
<td class="nump">$ 11,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094477406184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of revenue from customers (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 11,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094476228600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of other revenue from customers (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomerOther', window );">Other revenues</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Government research and development grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomerOther', window );">Other revenues</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomerOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomerOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480121992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of disaggregation of revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 11,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Services transferred at a point in time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Services transferred at a point in time [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Services transferred at a point in time [Member] | Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services transferred over time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services transferred over time [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services transferred over time [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services transferred over time [Member] | Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484598728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents - Summary of cash and cash equivalent (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromBanks', window );">Cash at Bank</a></td>
<td class="nump">$ 5,231<span></span>
</td>
<td class="nump">$ 10,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDepositsAtCarryingValue', window );">Term Deposit</a></td>
<td class="nump">4,570<span></span>
</td>
<td class="nump">4,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total</a></td>
<td class="nump">$ 9,801<span></span>
</td>
<td class="nump">$ 15,718<span></span>
</td>
<td class="nump">$ 11,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A bank's noninterest bearing demand deposits in other banks (such as correspondents).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484401576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables - Summary of trade and other receivables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Research&#160;&amp; development grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Total</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 2,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488959560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables - Summary of trade and other receivables (Detail) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480355768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 11,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomerOther', window );">Government research and development grants</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">12,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_RoyaltiesAndLicenseFees', window );">Royalties and license fees</a></td>
<td class="num">(185)<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,001<span></span>
</td>
<td class="nump">4,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,567<span></span>
</td>
<td class="nump">4,614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,383<span></span>
</td>
<td class="nump">9,616<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(8,281)<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction loss</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,274)<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized foreign currency translation loss</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="num">$ (8,363)<span></span>
</td>
<td class="nump">$ 2,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (8.10)<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">1,021,193<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomerOther', window );">Government research and development grants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RoyaltiesAndLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties and license fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RoyaltiesAndLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomerOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomerOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478736088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other assets - Summary of other assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_Otherdeposits', window );">Other deposit</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_MarketValueOfListedShares', window );">Market value of listed shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MarketValueOfListedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market value of listed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MarketValueOfListedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_Otherdeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_Otherdeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478061016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Summary  of property and equipment net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478330504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="nump">$ 158,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483484520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables- Summary of trade and other payables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payable</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedLicenceFeesCurrent', window );">Accrued license fees</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedResearchAndDevelopmentFeesCurrent', window );">Accrued research and development fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other payables</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="nump">$ 2,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedLicenceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued licence fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedLicenceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094477987496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of supplemental balance sheet information related to leases (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use asset</a></td>
<td class="num">$ (184,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset at June&#160;30, 2020</a></td>
<td class="nump">395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Principal payments on operating lease liabilities</a></td>
<td class="num">(174,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities at June&#160;30, 2020</a></td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less: non-current portion</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at June&#160;30, 2020</a></td>
<td class="nump">192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Initial measurement at July&#160;1, 2019</a></td>
<td class="nump">579,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Initial measurement at July&#160;1, 2019</a></td>
<td class="nump">579,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities at June&#160;30, 2020</a></td>
<td class="nump">$ 579,000<span></span>
</td>
<td class="nump">$ 579,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483388952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of maturities of the operating lease liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478091320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jul. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease has a remaining lease term</a></td>
<td class="text">1 year 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,000<span></span>
</td>
<td class="nump">$ 579,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 579,000<span></span>
</td>
<td class="nump">$ 579,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478081368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of warrants or rights (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period</a></td>
<td class="nump">38,326<span></span>
</td>
<td class="nump">38,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">241,716<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod', window );">Exercised</a></td>
<td class="num">(27,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants', window );">Cashless exercise</a></td>
<td class="num">(107,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending of period</a></td>
<td class="nump">145,421<span></span>
</td>
<td class="nump">38,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding</a></td>
<td class="nump">$ 82.50<span></span>
</td>
<td class="nump">$ 82.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod', window );">Granted</a></td>
<td class="nump">10.50<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod', window );">Exercised</a></td>
<td class="nump">10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants', window );">Cashless exercise</a></td>
<td class="nump">10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding and excercisable</a></td>
<td class="nump">$ 29.48<span></span>
</td>
<td class="nump">$ 82.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights excercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights grants in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted - average exercise price of class of warrants or exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or exercised during the period cash less exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094482501512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of equity awards (Detail) - Employee stock option - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options,Outstanding, beginning of period</a></td>
<td class="nump">86,467<span></span>
</td>
<td class="nump">81,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock Options, Forfeited</a></td>
<td class="num">(16,306)<span></span>
</td>
<td class="num">(22,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding, end of period</a></td>
<td class="nump">70,161<span></span>
</td>
<td class="nump">86,467<span></span>
</td>
<td class="nump">81,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable, end of period</a></td>
<td class="nump">41,829<span></span>
</td>
<td class="nump">27,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price, beginning of period</a></td>
<td class="nump">$ 64.20<span></span>
</td>
<td class="nump">$ 92.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Forfeited</a></td>
<td class="nump">102.66<span></span>
</td>
<td class="nump">125.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercise price, end of period</a></td>
<td class="nump">60.42<span></span>
</td>
<td class="nump">64.20<span></span>
</td>
<td class="nump">$ 92.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercisable, end of period</a></td>
<td class="nump">$ 69.81<span></span>
</td>
<td class="nump">$ 64.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Term, Outstanding</a></td>
<td class="text">2 years 10 months 20 days<span></span>
</td>
<td class="text">3 years 6 months 29 days<span></span>
</td>
<td class="text">3 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Term, Exercisable</a></td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488877320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of equity-based compensation expense (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">102.90%<span></span>
</td>
<td class="nump">102.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">104.10%<span></span>
</td>
<td class="nump">104.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.28%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480354968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2018</a></td>
<td class="nump">$ 13,844<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 127,715<span></span>
</td>
<td class="num">$ (112,539)<span></span>
</td>
<td class="num">$ (1,333)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="num">(531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Jun. 30, 2019</a></td>
<td class="nump">16,594<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">127,327<span></span>
</td>
<td class="num">(108,870)<span></span>
</td>
<td class="num">(1,864)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold for cash, net of offering costs of $240</a></td>
<td class="nump">1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold for cash, net of offering costs of $240, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts', window );">Issuance and exercise of pre-funded warrants, net of transaction costs of $240</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssuanceAndExerciseOfPrefundedWarrants', window );">Issuance and exercise of pre-funded warrants, net of transaction costs of $240, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CashlessExerciseOfPurchaseWarrants', window );">Cashless exercise of purchase warrants (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Jun. 30, 2020</a></td>
<td class="nump">$ 10,238<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 128,826<span></span>
</td>
<td class="num">$ (116,636)<span></span>
</td>
<td class="num">$ (1,953)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CashlessExerciseOfPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CashlessExerciseOfPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssuanceAndExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssuanceAndExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of pre-funded warrants, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480306328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of share-based compensation expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094477515528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 06, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognised share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,000<span></span>
</td>
<td class="nump">$ 907,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">107,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CashlessExerciseOfPurchaseWarrants', window );">Cashless exercise of purchase warrants (In shares)</a></td>
<td class="nump">37,417<span></span>
</td>
<td class="nump">37,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PrefundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_NumberOfSeriesWarrantsIssued', window );">Number of series of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PrefundedWarrantsMember', window );">Pre-funded warrants [Member] | Beneficial Owner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises', window );">Percentage of beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember', window );">Purchase warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_NumberOfSeriesWarrantsIssued', window );">Number of series of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  06,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bntc_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CashlessExerciseOfPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CashlessExerciseOfPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_NumberOfSeriesWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of series warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_NumberOfSeriesWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership of common stock post warrant excercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PercentageOfOwnershipOfCommonStockPostWarrantExcercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bntc_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bntc_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483436840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of income (loss) before provision for income taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (299)<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="num">(7,975)<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (8,274)<span></span>
</td>
<td class="nump">$ 2,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478070120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Summary of company's deferred taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 13,153<span></span>
</td>
<td class="nump">$ 10,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">13,447<span></span>
</td>
<td class="nump">11,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(13,290)<span></span>
</td>
<td class="num">(11,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094480141400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 5,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Year Two Thousand And Thirty Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards', window );">Year of expiry of operating losses carry forwards</a></td>
<td class="text">2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Year Two Thousand And Thirty One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards', window );">Year of expiry of operating losses carry forwards</a></td>
<td class="text">2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 45,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, expiration years</a></td>
<td class="text">Do not expire<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NolFromTwoThousandEighteenMember', window );">NOL From Two Thousand Eighteen [Member] | Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, expiration years</a></td>
<td class="text">Do not expire<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NolUptoTwoThousandEighteenMember', window );">NOL Upto Two Thousand Eighteen [Member] | Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NolUptoTwoThousandEighteenMember', window );">NOL Upto Two Thousand Eighteen [Member] | Domestic Tax Authority [Member] | Year Two Thousand And Thirty Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards', window );">Year of expiry of operating losses carry forwards</a></td>
<td class="text">2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NolUptoTwoThousandEighteenMember', window );">NOL Upto Two Thousand Eighteen [Member] | Domestic Tax Authority [Member] | Year Two Thousand And Thirty Six Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards', window );">Year of expiry of operating losses carry forwards</a></td>
<td class="text">2036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure details of operating loss carry forwards and tax credits [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year of expiry of operating losses carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_YearOfExpiryOfOperatingLossesCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PeriodAxis=bntc_NolFromTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PeriodAxis=bntc_NolFromTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PeriodAxis=bntc_NolUptoTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PeriodAxis=bntc_NolUptoTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094510312216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="nump">6.18%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.87%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based payments</a></td>
<td class="num">(0.74%)<span></span>
</td>
<td class="nump">7.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.12%)<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="nump">6.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation percentage net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EffectiveIncomeTaxReconciliationPercentageNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation percentage permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094478153272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets increase in valuation allowance during the period</a></td>
<td class="nump">$ 2,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Expected change in unrecognised tax benefits in the next twelve months</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_UnexpectedEventAxis=bntc_CoronavirusAidReliefAndEconomicSecurityActMember', window );">Coronavirus Aid Relief And Economic Security Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack', window );">Number of years of certain operating losses that can be carried back</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_UnexpectedEventAxis=bntc_CaliforniaAssemblyBillEightyFiveMember', window );">California Assembly Bill Eighty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_EventAxis=bntc_SuspensionOfAnnualDeductionLimitationMember', window );">Suspension Of Annual Deduction Limitation [Member] | Coronavirus Aid Relief And Economic Security Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction', window );">Percentage of annual Taxable income eligible for deduction</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards', window );">Percentage of total owneship control to be maintained by the current shareholders for availing operating loss carry forwards</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards', window );">Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Year 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Year 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Tax Year 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Tax Year 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of years of certain operating losses that can be carried back.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual taxable income eligible for deduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total ownership control to be maintained by the current shareholders for availing operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_UnexpectedEventAxis=bntc_CoronavirusAidReliefAndEconomicSecurityActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_UnexpectedEventAxis=bntc_CoronavirusAidReliefAndEconomicSecurityActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_UnexpectedEventAxis=bntc_CaliforniaAssemblyBillEightyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_UnexpectedEventAxis=bntc_CaliforniaAssemblyBillEightyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EventAxis=bntc_SuspensionOfAnnualDeductionLimitationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EventAxis=bntc_SuspensionOfAnnualDeductionLimitationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483364808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_EstimatedResearchCostsToBeIncurred', window );">Estimated research costs to be incurred</a></td>
<td class="nump">$ 462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingent liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EstimatedResearchCostsToBeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated research costs to be incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EstimatedResearchCostsToBeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094484426552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Summary of related party transactions (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bntc_LegalExpensesMember', window );">Legal Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Legal services paid/payable to a law firm in which a director of the Company is a partner and has a beneficial interest.</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bntc_LegalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bntc_LegalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094488879480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Additional information (Detail) - NantWorks, LLC [Member]<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_MilestonePaymentAccruedDuringThePeriod', window );">Milestone payment accrued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 425,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor', window );">Percentage of the outstanding common stock held by the investor</a></td>
<td class="nump">26.44%<span></span>
</td>
<td class="nump">26.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_MilestonePaymentReversedDuringThePeriod', window );">Milestone payment reversed during the period</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 425,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MilestonePaymentAccruedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment accrued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MilestonePaymentAccruedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MilestonePaymentReversedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment reversed during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MilestonePaymentReversedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the outstanding common stock held by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PercentageOfTheOutstandingCommonStockHeldByTheInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_NantWorksLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_NantWorksLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483387272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments For Stock Issuance Costs</a></td>
<td class="nump">$ 480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094482559592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per share - Summary of earnings (loss) per share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) attributable to common stockholders</a></td>
<td class="num">$ (8,274)<span></span>
</td>
<td class="nump">$ 2,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares used in calculating basic and diluted earnings per share</a></td>
<td class="nump">1,021,193<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted earnings (loss) per share</a></td>
<td class="num">$ (8.10)<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094476293480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (8,274)<span></span>
</td>
<td class="nump">$ 2,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">2,396<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncreasedecreaseInAccountsAndOtherPayables', window );">Trade and other payables</a></td>
<td class="num">(1,696)<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefit payable</a></td>
<td class="nump">57<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncreaseDecreaseInLeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(7,535)<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issues of shares</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issue transaction costs</a></td>
<td class="num">(480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(5,859)<span></span>
</td>
<td class="nump">4,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">15,718<span></span>
</td>
<td class="nump">11,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">9,801<span></span>
</td>
<td class="nump">$ 15,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial measurement of operating lease right-of-use assets and liabilities</a></td>
<td class="num">$ (579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreasedecreaseInAccountsAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreasedecreaseInAccountsAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483364808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Business </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Benitec Biopharma Inc. is a corporation formed under the laws of Delaware, United States, on November&#160;22, 2019. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, since 1997. Since then, the Company has focused on the development of novel genetic medicines. The proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;27, 2019, BBL announced its intention to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domicile</div> from Australia to the United States of America (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Re-domiciliation&#8221;).</div> BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of affecting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> acquired all of the outstanding BBL shares. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation.</div> In accordance with the U.S. Securities and Exchange Commission&#8217;s (&#8220;SEC&#8221;) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company&#8217;s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 exchange ratio share consolidation in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> as if it occurred on July&#160;1, 2018.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">BBL announced that the transaction to redomicile from Australia to the United States was fully implemented on April&#160;15, 2020. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> was approved by BBL shareholders at a Scheme Meeting held on March&#160;26, 2020 and confirmed by the Supreme Court of Queensland on March&#160;30, 2020.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The term the &#8220;Company&#8221; refers to (i), prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> to BBL, an Australian corporation, and its subsidiaries, and (ii), following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL).&#8220;</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The shares of Benitec Biopharma Inc. common stock issued in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> trade on The Nasdaq Capital Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;, and Benitec Biopharma Inc. continues to be subject to the reporting requirements of the SEC and applicable corporate governance rules of Nasdaq.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> BBL became a wholly owned subsidiary of Benitec Biopharma Inc. and delisted from the ASX on April&#160;15, 2020. On August&#160;14, 2020 BBL had a change of company status and became a Proprietary Limited company.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; are to our fiscal year ended June&#160;30 of that calendar year. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of the Company are presented in United States dollars and consist of Benitec Biopharma Inc. and the entities it controls: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:65%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:3%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Principal place of<br/>business/country of<br/>incorporation</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">Australia</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec Australia Proprietary Limited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">Australia</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Limited</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">United&#160;Kingdom</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec LLC</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RNAi Therapeutics, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tacere Therapeutics, Inc.</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">USA</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec Biopharma Proprietary Limited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="text-align:center;;vertical-align:bottom;">Australia</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140094483353672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April&#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon consummation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation.</div> As a result, the financial statements included in this report reflect (i)&#160;the historical operating results of BBL and subsidiaries prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> (ii)&#160;the combined results of the Company, BBL, and subsidiaries following the completion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> and (iii)&#160;the Company&#8217;s equity structure for all periods presented<div style="font-weight:bold;display:inline;">.</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the SEC. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> adjustments) necessary to present fairly our financial position, results of operations, and cash flows for the fiscal years ended June&#160;30, 2020 and 2019 have been made.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Segment Reporting </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preparation of financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BBL&#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar &#8220;$&#8221; and/or &#8220;USD&#8221; as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive income (loss).&#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020, and 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:76%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exchange rate on balance sheet dates</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD: AUD Exchange Rate</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.6877</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.7014</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Average exchange rate for the period</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD: AUD Exchange Rate</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.6711</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">0.7149</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exchange rate used to translate amounts in AUD into USD for the year ended June&#160;30, 2018 is 0.7385 as of the balance sheet date. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements.</div> For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:9%;">Level&#160;1:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:9%;">Level&#160;2:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:9%;">Level&#160;3:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of the Company&#8217;s cash and cash equivalents, trade and other receivables, and trade and other payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of June&#160;30, 2020, and 2019, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="width:36%;"></td><td style="vertical-align:bottom;;width:3%;"></td><td style="width:61%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Lab&#160;equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Furniture&#160;and&#160;fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Computer&#160;hardware</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">Leasehold&#160;improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">shorter of the lease term or estimated useful lives</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and other payables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Australian Goods and Services Tax (&#8220;GST&#8221;) and other similar taxes </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues, expenses, and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basic and Diluted Net Income (Loss) Per Share </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of June&#160;30, 2020, and 2019, there were 145,421 and 38,326 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted ASC 606 &#8211; <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue from Contracts with Customers </div>(&#8220;ASC 606&#8221;) on July&#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 1: Identify the contract(s) with a customer. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 2: Identify the performance obligations in the contract. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 3: Determine the transaction price. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 4: Allocate the transaction price to the performance obligations in the contract. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Licensing revenues </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Royalties </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of product occurs. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Services revenue </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Government Research and Development Grants </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant income is generated through the Australian federal government&#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% (2019: 43.5%) of eligible research and development expenditures. This grant is available for our research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to our activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will not be claiming the Australian Government research and development grants going forward due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> of the Company to the United States.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and Development Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. Clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records share-based compensation in accordance with ASC 718, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock Compensation</div>. ASC&#160;718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company adopted FASB Accounting Standard Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-07</div> and accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Accounting for Income Taxes</div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company records unrealized foreign currency translation loss which qualifies as other comprehensive loss.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Accounting Standards recently adopted </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases </div>(Topic 842) whereby lessees will need to recognize most leases on their balance sheet as a right of use asset and a lease liability. This guidance is effective for interim and annual reporting periods beginning after December&#160;15, 2018. The Company adopted this ASU effective July&#160;1, 2019.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The determination of whether an arrangement is or contains a lease is based on the substance of the arrangement and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s only lease is the lease on its research and development facilities.&#160;The Company&#8217;s existing lease commitments&#160;are set out in Note 10. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-07,</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Compensation &#8211; Stock Compensation</div> (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation &#8211; Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for goods and services. Consequently, the accounting for share-based payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> and employees will be substantially aligned. This standard is effective for financial statements issued by public companies for the annual and interim periods beginning after December&#160;15, 2018. The Company adopted this ASU on July&#160;1, 2019. There was no effect on the financial statements on adoption.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">New Accounting Standards and Interpretations not yet mandatory or early adopted </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments &#8211; Credit Losses</div> (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after December&#160;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November&#160;15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</div> amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MRCX ]S=2FM.)?4&Q<S[^%U!+ P04    " !(AC=1/&OLL@@%  "<$@  &
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*58VV[C-A#]%<(-VEW B47*NCAQ
M#&RR6+1%+\%FMWUF)#HB(HE:DG(V_?H.:462+4IQT8?$NLP,SPS)<X9:/POY
MI#+&-/I>Y*6ZGF5:5Y>+A4HR5E!U(2I6PINMD 75<"L?%ZJ2C*;6J<@7Q//"
M14%Y.=NL[;,[N5F+6N>\9'<2J;HHJ'RY8;EXOI[AV>N#S_PQT^;!8K.NZ".[
M9_IK=2?A;M%&27G!2L5%B23;7L\^X,M;$A@':_$79\^J=XU,*@]"/)F;7]+K
MF6<0L9PEVH2@\+-CMRS/323 \:T).FO'-([]Z]?HGVSRD,P#5>Q6Y'_S5&?7
MLWB&4K:E=:X_B^>?69.0!9B(7-G_Z+FQ]68HJ9461>,," I>[G_I]Z80/0>\
M''$@C0,YU<%O''R;Z!Z93>LCU72SEN(926,-T<R%K8WUAFQX::;Q7DMXR\%/
M;VY%J43.4ZI9BFYH3LN$H7L33J%S]/7^(WIW]AZ=(5ZB+YFH%2U3M5YH&-GX
M+Y)FE)O]*&1DE%_K\@+YWAP1CW@.]]N3W?'JT'T!^;9)DS9I8N/Y8TG74K)2
M(ZH4Y'DY$=%O(_HVXG(L(E49@MJ@Q%RP;S7?T1R&<-9J'RJRH<PVVVU6L8?7
MBUV_(D,C'$0X;JT.8"Y;F,M)F%\D39G%*73&).S#A '2AYPY@>Z#!3T,P>H(
MYM"$!'[H1AFT*(-)E']:;/O)<<$*!F.NEL>XAC:!1]RPPA96.%T\H6D.>[*_
M=ESPPL'0V(N]8X .JS@*1BH7M1"C28AW$OA=ZA<[Q6855L"X>HY*IEU(HP$&
M/UH>X1S:+"//C3)N4<:3*#^R2BCN+EX\G-LC0%,6!W!6+9S5)!PK7>=B>UXK
M-C&MJV&Q5H%[9.QU[.N=L*;&!VW<#Y8)#N+HJ"8NLQ7QQ^#UQ &?1)0YIP\\
MYYJS2;;$'0%C\I^(J*(OHRS4A.HG%RV/Z=)A1):KY4@!.EK'T[S^(4ED#<K(
MBBH7+XRA!U:R[<C:;6(=8/#\8Z!#([R,1G!VO(ZGB?TW!JU,?YKF+5%50IJ&
MR0EXR-ZP;$:P=.R-I^G[D"=[F)P0AD2-<4] FJ(-K4C86P.'2#M"Q].,[J@:
MK$%U4NF&_$VP/P*HHV\\S=_[TKU5LB$E8W\@@ ZKB9)UU(VGN?M6% 771E74
MOM\1I>;E(RL30(O>_2$T0]A_[\0]&=F<5RY511-V/8,#B6)RQV8;Y&P6_W^@
MP^P[I<"K23Z\UR)YRD2>,JE^L@*K7Z8(D71"0*:%P-053C7*##!'9]Z%YWD8
M:%$B:"1K]N,/,<'D"GMS>&[^D,HH)(=HK3,A^3\LO4)X#HW&'"3<SDP<A/,H
M#%X-N5*&R"SEUEIIN(!Y0U0CZ*XA/@Z]J]<.W5J97GL.':*JF#UJY2^N224.
MY3E:B9,FA^7JA(G@:5Y.4VZV)NR6BO+T'(XG":TX[!XG2#Q$0.*8'-.,TR[R
MR0@]D]YY8UKN0$;JHL[M(0O.F#SASGZ,#$7L'.,P'/"AT]"+X['.C'2"1]X4
MO!;I7IH34< VRLS)?0=D*923E,A0UL[Q*CA6/Z=9'([H-.GTC[QQL+'$J1S;
MTPG6H7L>\>-CL ZS,!AK*D@GD.04@>RQO-UO)X,/AB=#1TOH,G.TA(O>IP/S
MW>9W*A]YJ4 'M^#G74001NX_A>QOM*CLUX0'H;4H[&7&H)F3Q@#>;P5(0'-C
M/E"T'Z0V_P)02P,$%     @ 2(8W4<UF\B]M @  BP8  !@   !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6R555UOFS 4_2L6VL,F=>$KD*XB2&FF:ITT+6JT
M[F':@P,WP:JQ,_O2M/OULPU!:4.VC ?PQSWGGG,QEVPGU8.N ) \U5SHJ5<A
M;J]\7Q<5U%2/Y!:$V5E+55,T4[7Q]58!+1VHYGX4!*E?4R:\/'-K"Y5GLD'.
M!"P4T4U=4_5\#5SNIE[H[1?NV*9"N^#GV99N8 GX;;M09N;W+"6K06@F!5&P
MGGJS\&J>VG@7<,]@IP_&Q#I92?E@)[?EU NL(.!0H&6@YO$(<^#<$AD9OSI.
MKT]I@8?C/?N-\VZ\K*B&N>3?68G5U+OT2 EKVG"\D[M/T/E)+%\AN79WLFMC
MDXE'BD:CK#NP45 ST3[I4U>' T X/@&(.D!T+B#N +$SVBISMCY2I'FFY(XH
M&VW8[,#5QJ&-&R;L6URB,KO,X#"?2Z$E9R5%*,DUY5040):63I.W"ZI 8 7(
M"LK?D??D#?&)KLRJSGPTV2V'7W29KMM,T8E,GQLQ(G%P0:(@"@;@\[/AX8>7
M<-]X[HU'O?'(\<4G^)9H+)OCB$2NR0T3QCBCG"RD9NY\_9BM-"ISRG[^)5G<
M)XM=LO')*M>UX5RB+!Z(J2JYI[R!H1JV/*GCL5_@8QZ,@B (,__QL%;_#'LA
M<]S+')\O<^G>,YDU6$G%?D,Y)+?E2PYTA$%[O1)\1N +R4DO.3E;\L5>\ZW6
MS;#>Y%A&&%S&D_$KN<=QETDZ29-AL6DO-OU_L5\;U$A%R<1F2'%ZIN+CN$'%
M_D&KL&WZ"U4;)C3AL#; 8#0Q#*IM?>T$Y=9UCY5$TXO<L#)_"U VP.ROI<3]
MQ#:D_O^3_P%02P,$%     @ 2(8W48^.>I85!0  "Q0  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6RE6-]OVS80_E<(HP\MT$0B9<MRX!AHW*W+L*Q!
MTJP/PQX8B[:%2J1'TG:ROWY'29%DD6("],76C[M/WQV/WY&<'X7\H;:,:?14
MY%Q=CK9:[RZ"0*VVK*#J7.P8AS=K(0NJX59N K63C*:E4Y$') SCH* 9'RWF
MY;-;N9B+O<XSSFXE4ONBH/+YBN7B>#G"HY<'=]EFJ\V#8#'?T0V[9_IA=ROA
M+FA0TJQ@7&6"(\G6EZ-/^&(9A<:AM/@K8T?5N48FE$<A?IB;Z_1R%!I&+&<K
M;2 H_!W8DN6Y00(>_]:@H^:;QK%[_8+^:QD\!/-(%5N*_'N6ZNWE*!FAE*WI
M/M=WXO@;JP.:&+R5R%7YBXZU;3A"J[W2HJB=@4&1\>J?/M6)Z#C@>,"!U ZD
M[S ><(AJAZ@,M&)6AO69:KJ82W%$TE@#FKDH<U-Z0S09-\-XKR6\S<!/+Y:"
M*Y%G*=4L1?<:_F",M$)BC;[NF*0FUPI1GJ*E**!0MF8$#PQ=\Y4H&'K_AU#J
M SI##_>?T?MW'] [E''T;2OV"GS4/-# T7PI6-5\KBH^9( /)NA&<+U5Z!>>
MLO04((#@F@C)2X17Q(OX^YZ?HRC\B$A(0@>AY9O=\<Q#)VH2'I5XT0#>'3LP
MOF<7'JAQ S4NH<9^*(764A1UL3#I3'H%-"V!S,P^+&;3>7#HIL$VP7@RP8W5
M"<5)0W'BI?A%')CDIJ1@SBM&Y6I;%E,*U'.Q*U]L)(6*<[&NL"<=2I,>:=LB
M'B=NRG%#.?92_B8TS8%ME5L7K=CZ* Y)CYC#AN#9S$UMVE";>FNGGI%\@]@3
MZ+CJTSL!31K0Q%]%XIGF.F/5+,^SE0%&:^:./;'B.L-)?U1LHW$T<8<^:UC.
M7JEU=_6X.,ZLST=AB'L<;:/Q))ZZ2>*P5=/07^^,PQ#E)4N:@EYG2ILA.S"G
M%(9V@7=)5$P=5N,8CP>H=H0?OZ'.Q2LE51/%%H4D2J(^4=MJ%N-X@"AIB1(O
MT9=6DY>MIM0ZT;0F)UMB%VE"DGX%.,S(I!/4*=U6W[%?X+_J+9/0!3ND?6*/
M6[7'?KF'90LL2C@(O92,KYX15!97M%H.F>\X<S%VY"+I9\)A-!V8L+B5?NS7
M_FNN&8B^KG/Q$7'FG*[8(>)].7788$(&&+9*C_U2WQVJ87JVE$=#DZ\5<CSU
M?OF!PYH[S_Z#19<9.00CF/$#)&M(TVJ\4^'M)\EA0P8:.&[; _;WAUHGWI0J
M6_@M,;--R)!"M+T!^YO#GTR?3C@G.5OQ016FXSY!VXS$X4#C)FUC(.$;5&%U
MLH8V5'W20%HM)WXM[Y33VJD2.?6J!+&5^RR9]3+C,II$ _5%6GDG?GGOUI>=
M'R=;E[Y;;!U&PVQ;=2?1&]B>\GRU]&K,Z0GA*.[W3X<9":<#RUG2]@TR]I:>
M-3L0=$^DME1Z=R&D%7KB%_HKJK)5M3#+\KWN[]KJ'%08R4D.SOL2YK"*SL.!
M5D1:H2>Q-P7?R]T\2\\H;$?HAE71@^SNM=) '-8_WE2TND[\NOZV5-@Z#1L(
MC&=60=B&":P/XZ%\M)I._)K^Q6RYT-\WK'AD\A]?Y*T&D]G/[FNC5BVC5Y;1
M/[5MK,&[\ZB_0W&8V!O'H'.L AOK37G:I&#R[[FNSA^:I\V)UJ?R'*?W_ I?
M+*MSJ1:F.B:[H7*3<85RM@;(\'P*8RVKDZ?J1HM=>7CS*#3L[LO++:,ID\8
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M0*28$W%Q2M"B>AEOCUWH^8'OF>FY+3UWE-Z#9C#5K30!L2H45258U[,I;>Z
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M%[Q^'U/?2+:IWA\\,BE945VF!">$:X#Z?LV8?+_1KR3:MV*+?P%02P,$%
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M'=!X!W>_(N*#X1/TWYO\#U!+ P04    " !(AC=1^]OU8;T%  #W%0  &
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M#!(G?:M-HC!O=E2QL16= D$!@!+K)L?LP3ZS8#=-?"#3[ ALP&B>D0&X!\J
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M38XWX'MN;>@?^(!A:%__!U!+ P04    " !(AC=14F9<,)@#  "5"   &0
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M(# D-V0->T/X^F^6<QA<0;=]Q1@\:L<EX>B@!4E[0/!S>,P1;G51<K6#G&?
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M$AJ7P/M;K>GHN /ZER[]#5!+ P04    " !(AC=1K-^DN.0"  !$!@  &0
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ME[_IW:MS2^6VX@H8%@8:C,:)![)S<A=HT3CW;(0V7G33TCQ^*&V"V2^$T(?
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M:8PL:)EQAACM!GR^D-*T%U9!]Z'R^C]02P,$%     @ 2(8W448 =%)&"P
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MF4U[S(07:.'"Z;5_:;70SNG*?UT)CAF*"/![H;5K+DA ^Q;SS?\ 4$L#!!0
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M71N/X1R7-5Y#ML$ ]Y4Q_FD3 NS>U\4_4$L#!!0    ( $B&-U$M.D+3!P,
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MC&B!%MB-C76M6ND; V2:!I46>4QWH&*Z$J  9ZMVU5-4!Z JV&BOEJ8QL('
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M?[1^.($977/88/YY1#"6C7YIT37D1V"OB@!1HH$8D3>J!-^DG3J^_/H&0@9
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M2X,F"!LY06)YF:#YE:=.(O@*V,Y>6357C1YV,OR1PGB?><.(-/4G<2JE).^
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M-%Q)T)A/@EE_E R=O3?XSG%C=L;@,EDI=>LFY]DDB)P@%)A:1V#TNL,Y"N%
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MO3T)0#?]L9E85?F>M%*6.IP?%O1+0>T,:#]7RK83%Z#[24W_ %!+ P04
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M>"[P7H&NBH*IPQ*YW,^]T&L7'O)L:^R"OYB5+,,5FD_EO:*9WZ&D>8%"YU*
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MP]\W:VT4)<(_%U ''>K H0Y>0%W5:0QR0\E9D[A1LF@.#94^1^5ER,[1YT!
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M"6+EWB34'N#N5TK9G>(#]*]<_@=02P,$%     @ 2(8W4::K),_% @  UP4
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M,Z/)B]H!Z'RIE#TX[H)ZEH_^ E!+ P04    " !(AC=1:%;6QUX"  #Y!
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MR@;0\[F49GMA"_2?4K-_ 5!+ P04    " !(AC=1NH_@' T%   5#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R55VUSXC80_BL[--?"##&V;##D
MDLSDY=+>S5V;.7+M=#K](.P%-&=+/DF$Y-]W)1N'7('2+_AM]]EG=Q^MQ/E:
MZ:]FB6CAJ2RDN>@LK:W.!@.3+;'D)E 52OHR5[KDEA[U8F JC3SW3F4Q8&$X
M&I1<R,[EN7]WKR_/U<H60N*]!K,J2ZZ?K[%0ZXM.U-F\^"P62^M>#"[/*[[
M*=HOU;VFIT&+DHL2I1%*@L;Y1><J.KM.G;TW^%W@VFS=@\MDIM17]_ ^O^B$
MCA 6F%F'P.GRB#=8% Z(:'QK,#MM2.>X?;]!O_.Y4RXS;O!&%7^(W"XO.N,.
MY#CGJ\)^5NM?L,EGZ/ R51C_"^O&-NQ MC)6E8TS,2B%K*_\J:G#,0ZL<6">
M=QW(L[SEEE^>:[4&[:P)S=WX5+TWD1/2-65J-7T5Y&<OW\M,E0B6/Z&![@.?
M%6AZYP-+T,Y@D#4PUS4,VP,3,?BDI%T:>"=SS%\##(A32XQMB%VS@X@?5C*
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M2//OGBJA:P"G4;-3?WV88TZO:"Q4RMC36\RPG)'(XLC-_2AU\V#$2-$*I+*
M#A3_$TKCZ0<N5ZZ*T8014)R<TL]HCZ-Q8PN&_3A*G&WD;)-]06BBTLJ&9-@?
MDY!?\WIHV[)E>80TTE8:Z5'2T$B#.R.EUO4EI=2#AXXWH%TNS31_F7HO>T!W
MAA+GPO:.VH,.\MDOGMUTOI]XQY""7! 6R6>N55EO44V;7==65KERN!C;L_+0
M;)R^=F-1$(;P!E@:#-WU'NFD)Y$$7 =&TCT- Q8D\*8'HR :D]%GRI7K;.G7
M8HZ/=+*M2N=#.D!)[:>3Q<OHC(9!&A_RHGSIXJJU<>F.@G'J DZ7M ^<SOR:
MJ_BS,R<V89!Z.FD0C@AXYV1OH1(6Q,[X9LGEPJWAW1.7)0&=X<BNF];V=XU^
MW:SQI=H4Q JJ[2A@+O3K84K$7#%[4%]W2GZP=50M42_\@=QMCC0TZE-K^[8]
M\U_51]T7\_H/PR>N%T(:*'!.KE04VKEU?0BO'ZRJ_,%WIBP=H_WMDOZWH'8&
M]'VNE-T\N #M/Z'+?P!02P,$%     @ 2(8W4:66"S^) @  : 4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&ULA511;],P$/XKIS"A34)-FG9L=&VE
M=8  ,:E:-WA /+C)I;'FV,&^+NN_Y^RTH9/6\I+XSG??]]W9YW%C[*,K$0F>
M*Z7=)"J)ZE$<NZS$2KB>J5'S3F%L)8A-NXI=;5'D(:E2<9HD[^-*2!U-Q\$W
MM].Q69.2&N<6W+JJA-W,4)EF$O6CG>-.KDKRCG@ZKL4*%T@/]=RR%7<HN:Q0
M.VDT6"PFT75_-!OZ^!#P0V+C]M;@*UD:\^B-K_DD2KP@5)B11Q#\>\(;5,H#
ML8P_6\RHH_2)^^L=^N=0.]>R% YOC/HI<RHGT64$.19BK>C.-%]P6\^YQ\N,
M<N$+31L[X.!L[<A4VV164$G=_L7SM@]["9?)@81TFY &W2U14/E1D)B.K6G
M^FA&\XM0:LAF<5+[0UF0Y5W)>32]0R4(<ZB%I0V0%=J)T"\'I_=BJ="=C6-B
M(A\>9UO060N:'@#MIW!K-)4./ND<\Y< ,2OL9*8[F;/T*.*WM>[!('D':9(F
M1_ &7=F#@#?X3]GS4/;]?MF_KI>.^Y#1[R,\PXYG&'B&!W@6[5T'4_ -/M3I
MUQI\%-9/ZLC5(L-)Q*/HT#YA-+TO$0JC>,RD7KT\2I-E:VN9O)%4OE BT8W@
M]&%Q\O;-9=J_N$J2Y RXV]AUFS_]#_ =5T*!9Y(9.DZ5>5R+C;\A0 8$*-%
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MA+3 P_6._:O33EJ63.-4YK]X8K*AU_,@P15;Y^9%;K]AK<<E&,M<NR=L:]_
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MH<_?3Q^<B2;L*A-:O?!L969M97Y/%E()?4O^G)&..NG(2D<GI+_K=D)8QDM
MEY1+>76L>HU$8B5,\UB/KP=!$J7N>C>EAZ@@]H8=Z(V]?F>O_U][&98%JB7D
MYI15@J^)/B-H\8ITPQ/V3!X]<HUP?]=TT@_[>Z8/45$R](Z;CCO3\5G3,V-8
MWX3&.3S79(TI,'749GR0M>' \_=<'H+\?F*.UBYJ?@3E#Y+]"K@[':($L;*=
M5NI[7S/57+!NM6OF$]O#]M:G_LVLZ<G_9)H_Q"T6*\(DHK#4DEXOT?D53==M
M)HI7M@\MN-)=S0X+_:,"80#Z^Y)SM9V8#;I?W_@O4$L#!!0    ( $B&-U$?
M]LVSR0(  %P)   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+U674_;
M,!3]*U;$ T@;B9.V:5$;B1:F@4!"=&P/: ]N<MM$)'9G.RW\^]E.ZH;29D-"
MO#3^N.><>X]=V\,UXT\B!9#HN<BI&#FIE,LSUQ5Q"@41IVP)5,W,&2^(5%V^
M<,62 TD,J,A=W_-Z;D$RZD1#,W;'HR$K99Y1N.-(E$5!^,L8<K8>.=C9#-QG
MBU3J 3<:+LD"IB ?EG=<]5S+DF0%4)$QBCC,1\XY/IO@0 -,Q,\,UJ+11KJ4
M&6-/NG.5C!Q/9P0YQ%)3$/59P03R7#.I//[4I([5U,!F>\/^S12OBID1 1.6
M_\H2F8Z<OH,2F),RE_=L_1WJ@KJ:+V:Y,+]H7<6&*C@NA61%#589%!FMON2Y
M-J(!P+T# +\&^+N S@% 4 .,<VZ5F2GK@D@2#3E;(ZZC%9MN&&\,6E634;V,
M4\G5;*9P,KJ'%= 2T%<TK182L;E:GFIPSEE1)P%<H.,+D"3+3U3PP_0"'1^=
MH".44?0C9:4@-!%#5ZJ4-+$;U_+C2MX_((]]=,NH3 6ZI DDKPE<58LMR-\4
M-/9;&:]+>HH"[POR/=_;D]#DO^%XT)).8/T-#%_P#W^-E9?/$C@E.9K4GJ+'
M&Q6/KB04XG>+6L>J=8Q:IUU-[*S<OG6IB$)#I/_KJV@0#MU5TZFW(1AWN]A&
MO4JQ:U/LMJ9XD\7Z$* +N\L>;Z&8 6^KOV?)>Y_@=FC5P@]R>U(1=9M6>GX8
M[+>R;_7[[?KLA>3RY3U&#BSUX!.,Q-[V%/(^:N/63$TO!\'.SMT3@_L'W,:-
MHQ*W)CD%OE*[]SU^8W]+[G^&X]MS"0<?YGCPYB#H[!K^-@1[@^Z.XV[CGE)B
M"W-]"Q2SDLKJA+>C]HEP;B[&G?&Q?CJ8^V]+4[T[;@E?9%2@'.:*TCL-U1[@
MU55>=21;FMMPQJ2JV#13]?P!K@/4_)PQN>EH ?N@BOX"4$L#!!0    ( $B&
M-U&O+(^)@P(  *4&   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;+U5
MVVZ;0!#]E1'*0R*U >-;&F&DV$G;5(T:Q4W[$/5A#8-!67;I[F*G?]_9!5/G
M8J=2I;[ 7N:<.7.6':*U5/<Z1S3P4'*A)UYN3'7J^SK)L63Z6%8H:">3JF2&
MIFKIZTHA2QVHY'X8!"._9(7PXLBM7:LXDK7AA<!K!;HN2Z9^39'+]<3K>9N%
MFV*9&[O@QU'%ECA'<UM=*YKY'4M:E"AT(04HS";>6>]T-K;Q+N!;@6N]-09;
MR4+*>SNY3"=>8 4AQ\18!D:O%<Z0<TM$,GZVG%Z7T@*WQQOV]ZYVJF7!-,XD
M_UZD)I]X)QZDF+&:FQNY_HAM/4/+ETBNW1/6;6S@05)K(\L63 K*0C1O]M#Z
ML 7HC78 PA80/@4,=@#Z+:#O"FV4N;+.F6%QI.0:E(TF-CMPWC@T55,(>XIS
MHVBW()R);W"%HD9X"_/F'$%F($V.BLZHV<J4+%LIJ#0<GJ-A!3\BR.W\' X/
MCN  "@%?<UEK)E(=^8:$67H_:45,&Q'A#A&]$*ZD,+F&"Y%B^IC IXJZLL)-
M6=-P+^.G6AQ#/W@#81 &+PB:_36\]VZ/G'[G<M_Q]5]QV5EY\6!0"<9AUGH*
M=Y\I'BX-EOK'GFR#+MO 91OLR/9E^_A>/(X&/W9X>\]7\3#R5]O^/(\8#4ZZ
MF$>RAIVLX5Y9'^2*ZJ8.8$B;1J:2'.A[H4NWHF92N8VE8L)HN+O"<H%JGQFC
M+NOH/U@_[K*-_]'Z\:O6/X]X;KV_=>.IC*5KA!H260O3W))NM>NU9Z[%/%F?
M4@]N6N8?FJ:!7S&U+(0&CAE1!L=C.EW5-,5F8F3E^LI"&O+2#7/ZCZ"R ;2?
M26DV$YN@^S/%OP%02P,$%     @ 2(8W48X9.NET P  _ X  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&ULK5?1;MHP%/T5*^I#*VU-[  I%2 5V+1-
MJU3!NCU,>S#D E83F]D&6FD?/SL)"2U)1%%>(''N/3GG!)]P>SLAG]0*0*/G
M..*J[ZRT7M^ZKIJO(*;J6JR!FRL+(6.JS:E<NFHM@89)4QRYQ/,Z;DP9=P:]
M9.U!#GIBHR/&X4$BM8EC*E^&$(E=W\'.?F'"EBMM%]Q!;TV7, 7]N'Z0YLS-
M44(6 U=,<"1AT7?N\.V(^+8AJ?C)8*<.CI&5,A/BR9Y\#?N.9QE!!'-M(:CY
MVL((HL@B&1Y_,U GOZ=M/#S>HW].Q!LQ,ZI@)*)?+-2KOG/CH! 6=!/IB=A]
M@4Q0V^+-1:223[3+:CT'S3=*BSAK-@QBQM-O^IP9<=" .Q4-)&L@;QM:%0U^
MUI XYZ;,$EECJNF@)\4.25MMT.Q!XDW2;=0P;A_C5$MSE9D^/9C %O@&T$<T
M31\D$@L4,D672PE+FEAM5F16=CD&35ET9>H?IV-T>7&%+A#CZ,=*;!3EH>JY
MVK"RV.X\8S!,&9 *!IB@>\'U2J%//(3P-8!KY.2:R%[3D-0B?MOP:^1['Q#Q
MB%=":'1R.^[6T/%SB_T$KU6!-R[<A'#O9)E/*4R0P-CMMQUT@YZ[/61^7()Q
MNXWSJE<$6SG!5BW![VQN]B6@W_<0ST#^J='<SB';C6@>I3#M0T$>"?QR09W\
M[IW:NT_$"XWTRRF"@APR:.8A!D>"NOZ;AWA<@F\J%-_D]&[JZ1E"D5B;?-7H
MSB8CTPS4*09T\SMTFS&@>Z2N]4;_<07VNNUR [!7!)E72W *<FM^R II2;E:
M@)2&)]6(HK5@QA:34MJ\@$[Q!!^D)V[&E0RGSI:2$NQAOU-A#"DXDD:-0?_0
M.Q(!%S&(F\G!489SJA%%S.'ZG#O#B//W%2ZB$C>3E4-\'):M"D^*I,3U45GJ
MB=B"/'VS%!&*&\I0?$*(EM3@%JY*D2)'<7V0GNC'._=($;*XF90=X9(0]8-R
M]:3(4')&AI:J?\<KEA1I2AI*TPPGJ/N!D)(XK7K-DB),R1EA6NK0^=%!BD@E
M#44J*?GC>/S.=0_FB!CD,AFO%)J+#=?IW^]\-1_A[I+!Y<WZT(QVZ2!6P*1S
MX3V52\85BF!A(+WKP#P?F8Y:Z8D6ZV1:F0EM9I_D<&7&4Y"VP%Q?"*'W)_8&
M^< [^ ]02P,$%     @ 2(8W42#C3V]6 @  408  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&ULC55=;]HP%/TK5M2'5MK(]X J1"IDTS9I$BKM]C#M
MP<"%6#AV:CO0_?O93HC2$A@OY-H^Y]YS#\Y-<N!B)W, A5X+RN3$R94J[UU7
MKG(HL!SP$I@^V7!18*678NO*4@!>6U)!W<#S/KD%)LQ)$[LW%VG"*T4)@[E
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MHK-S4C'MH] &J!L_5W.--*5^6=$["L8!Z'RA-3X';E3[ESG_ U!+ P04
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M>#<]_OP_/;2!#:DE0VJ)UTO/Z*U'S?^^VQH;3D%_WA!.!^'4"U^?$5XHZ;6
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MLE0?2.!:H.X7C,G=1L_@_I.;_@=02P,$%     @ 2(8W41]1XK\Z P  \0D
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MN@S\,*?;%XQKH.\;K?&C<#=">Y]/_P!02P,$%     @ 2(8W47>=',X8 P
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M4-8 OR^D-/N)=5#V9</_4$L#!!0    ( $B&-U%,<"#V.@,  ,8*   9
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M<?"9"VME/JQ7U-#%3,DM4L[:HKF!SXWWMM$PX;;QVBC[E5D_L[@V,KW))<]
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MH%? 4C41G"$\(1C5!*-.IR>B-I>9!$"$:Y"@-))80^<YZW:,_'C<N"D?EIT
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MD#+H#+!BJFYQM6%DZ;K$7!KL.6Z8XZL RCK@^D)*LS5L@/:=2?X!4$L#!!0
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M_1HUC^*.RS#K]MAL=9N=[?Z(:G-&?G<>;>3>W*??E](A;FV]&#5M1^9/,!3
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M@\D%9Z[MZW:!MHZML;%(C1:G%3V%X$( G6^MQ:=%Z+;^<<W_ 5!+ P04
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MA PZ?0RFJOMO/3%RY5K87!ILB&Y8X),%RAK@_D)*LYW8 ]I'</0'4$L#!!0
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MNW!@ XED4B%M6L>@^#92/;NT[SS;5:T.IT*JIK:KX-X7[?2=Q,:S@)2Q#C#
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M\7]A?7O)Z_+.L/"Q>=$JR\-+$XNNKJ]\VZVZT;S:O=B\>RG[XB=02P,$%
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 2(8W43WPD:GN    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 2(8W
M49E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !(AC=1MP_I<H,%  !%%P  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 2(8W
M43QK[+((!0  G!(  !@              ("!Q@T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( $B&-U'-9O(O;0(  (L&   8
M      " @003  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !(AC=1CXYZEA4%   +%   &               @(&G%0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 2(8W411''9[/!   (1,  !@
M             ("!\AH  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( $B&-U%91'DK*@(  'L$   8              " @?<?  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !(AC=1^]OU8;T%  #W
M%0  &               @(%7(@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ 2(8W4:%ZN;>M!   8 L  !@              ("!2B@
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $B&-U%@0)Z%
M@!@  '5)   8              " @2TM  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !(AC=1WG&&T04%  # "P  &0
M@('C10  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $B&
M-U%29EPPF ,  )4(   9              " @1]+  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ 2(8W4<!Z#U!% @  ^@0  !D
M         ("![DX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !(AC=1/G%J-+P"  #B!0  &0              @(%J40  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $B&-U%UV#204@(  /4$
M   9              " @5U4  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ 2(8W4:S?I+CD @  1 8  !D              ("!YE8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !(AC=1]S>4
MFG$"  !:!0  &0              @($!6@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( $B&-U'ZD]0JQP4  .H.   9
M  " @:E<  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M2(8W4;+Z1C/L!P  M!0  !D              ("!IV(  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !(AC=11@!T4D8+  #1'   &0
M            @('*:@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( $B&-U'SD^FHNP,  $T(   9              " @4=V  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 2(8W46!>O?2$ P
M:P<  !D              ("!.7H  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !(AC=1+3I"TP<#  !_!@  &0              @('T
M?0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $B&-U%<
M;>US=0(  %$%   9              " @3*!  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ 2(8W4?QA"_\K&@  [58  !D
M     ("!WH,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M" !(AC=15^;-YM\"  "P!@  &0              @(% G@  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $B&-U$U_+IUA@,  /0'   9
M              " @5:A  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ 2(8W45B1-QG4 P  ]@D  !D              ("!$Z4  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !(AC=1R5:3<T\"
M  #Q!   &0              @($>J0  >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    ( $B&-U&FJR3/Q0(  -<%   9              "
M@:2K  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 2(8W
M46A6UL=> @  ^00  !D              ("!H*X  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !(AC=1]KI:M+8"  #)!0  &0
M        @($UL0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( $B&-U$R./V2?0(  %(%   9              " @2*T  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 2(8W4>WP)SYU P  D0@
M !D              ("!UK8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !(AC=14);N>/$$  !6#0  &0              @(&"N@
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $B&-U&ZC^ <
M#04  !4-   9              " @:J_  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ 2(8W4:66"S^) @  : 4  !D
M ("![L0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !(
MAC=13D]5<J4"  "9!0  &0              @(&NQP  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $B&-U&X7"04$P0  /47   9
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M970T,BYX;6Q02P$"% ,4    " !(AC=1V)"P#*X"   &!P  &0
M    @('PVP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M $B&-U$?]LVSR0(  %P)   9              " @=7>  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ 2(8W4:\LCXF# @  I08  !D
M             ("!U>$  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !(AC=1CADZZ70#  #\#@  &0              @(&/Y   >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $B&-U$@XT]O5@(
M %$&   9              " @3KH  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ 2(8W4>#5,7)( @  I04  !D              ("!
MQ^H  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !(AC=1
MS&XHSQ$"  "4!   &0              @(%&[0  >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $B&-U$O(6&A>@(  ,X&   9
M      " @8[O  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ 2(8W45J,U(!1 P  6PT  !D              ("!/_(  'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !(AC=1)WD!%4,"   F!0
M&0              @('']0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( $B&-U'"':;[H (  'X'   9              " @4'X  !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 2(8W41]1XK\Z
M P  \0D  !D              ("!&/L  'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " !(AC=1#5S\!E4"  #;!0  &0
M@(&)_@  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $B&
M-U%WG1S.& ,  *,)   9              " @14! 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ 2(8W44QP(/8Z P  Q@H  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( $B&-U&6_=>JD@(  ',&   9
M  " @<L6 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M2(8W40WJ8!$% P  O D  !D              ("!E!D! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " !(AC=1]9-18.H#  #T$@  &0
M            @('0' $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( $B&-U%F^U'29 ,  /8*   9              " @?$@ 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ 2(8W43#_B=5[!0
MDQ8  !D              ("!C"0! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " !(AC=1[I$QYT8"  !H!0  &0              @($^
M*@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( $B&-U$H
MK2OL=0(  $L%   9              " @;LL 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ 2(8W46==#07: @  ^ <  !D
M     ("!9R\! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $B&-U';=K!Q,0(  (DI   :
M          "  5 ^ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( $B&-U&DR,-W^@$  +0H   3              "  ;E  0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !. $X 614  .1" 0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>130</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Basis of presentation and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Going concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcern</Role>
      <ShortName>Going concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Trade and other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables</Role>
      <ShortName>Trade and other receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/OtherAssets</Role>
      <ShortName>Other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Earnings (Loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessTables</Role>
      <ShortName>Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Business</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Revenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Trade and other receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesTables</Role>
      <ShortName>Trade and other receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Other assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/OtherAssetsTables</Role>
      <ShortName>Other assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/OtherAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/StockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Related party transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related party transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Earnings (Loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/EarningsLossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Business - Summary of entities in control (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail</Role>
      <ShortName>Business - Summary of entities in control (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Business - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail</Role>
      <ShortName>Business - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Basis of presentation and summary of significant accounting policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Basis of presentation and summary of significant accounting policies - Summary of property and equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Summary of property and equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Basis of presentation and summary of significant accounting policies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Going concern - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail</Role>
      <ShortName>Going concern - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Revenue - Summary of revenue from customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail</Role>
      <ShortName>Revenue - Summary of revenue from customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Revenue - Summary of other revenue from customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueSummaryOfOtherRevenueFromCustomersDetail</Role>
      <ShortName>Revenue - Summary of other revenue from customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Revenue - Summary of disaggregation of revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail</Role>
      <ShortName>Revenue - Summary of disaggregation of revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Cash and cash equivalents - Summary of cash and cash equivalent (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail</Role>
      <ShortName>Cash and cash equivalents - Summary of cash and cash equivalent (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Trade and other receivables - Summary of trade and other receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetail</Role>
      <ShortName>Trade and other receivables - Summary of trade and other receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Trade and other receivables - Summary of trade and other receivables (Detail) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDetailParenthetical</Role>
      <ShortName>Trade and other receivables - Summary of trade and other receivables (Detail) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Other assets - Summary of other assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail</Role>
      <ShortName>Other assets - Summary of other assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and equipment, net - Summary  of property and equipment net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Property and equipment, net - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and equipment, net - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail</Role>
      <ShortName>Trade and other payables- Summary of trade and other payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Summary of supplemental balance sheet information related to leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of maturities of the operating lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of warrants or rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of equity awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Stockholders' equity - Summary of equity-based compensation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' equity - Summary of equity-based compensation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' equity - Summary of share-based compensation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Stockholders' equity - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' equity - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Income taxes - Summary of income (loss) before provision for income taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income taxes - Summary of income (loss) before provision for income taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Income taxes - Summary of company's deferred taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail</Role>
      <ShortName>Income taxes - Summary of company's deferred taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail</Role>
      <ShortName>Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail</Role>
      <ShortName>Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Income taxes - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income taxes - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Commitments and contingencies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and contingencies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Related party transactions - Summary of related party transactions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsSummaryOfRelatedPartyTransactionsDetail</Role>
      <ShortName>Related party transactions - Summary of related party transactions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Related party transactions - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related party transactions - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bntc-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Earnings (Loss) per share - Summary of earnings (loss) per share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/EarningsLossPerShareSummaryOfEarningsLossPerShareDetail</Role>
      <ShortName>Earnings (Loss) per share - Summary of earnings (loss) per share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[EFM.6.05.40.currentFiscalYearEndDateRegistrantValue] In submission type 10-K, CurrentFiscalYearEndDate value "--06-30", should match the Entity Registrant Fiscal Year End Date "12/31" on record within EDGAR. - bntc-20200630.xml 1639 - bntc-20200630.xml 1639</Log>
  </Logs>
  <InputFiles>
    <File>bntc-20200630.xml</File>
    <File>bntc-20200630.xsd</File>
    <File>bntc-20200630_cal.xml</File>
    <File>bntc-20200630_def.xml</File>
    <File>bntc-20200630_lab.xml</File>
    <File>bntc-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001193125-20-252381-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-252381-xbrl.zip
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M+:OA--?7JMXD5\'IQ]4]=^87^3_IAG[ 8*;N>?(]](+D2X :7#=1X7>8T_5
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M\0CG3JNKR7[Q";WQS")E;PAUK.)FT?0YE^C)1P*&A<=\MU01?H\\,"7&8$O
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M"]8 ',]14-\ '#?NU4MWK[9S5B^<*1H_9P?\G 8DK/%D&D]F*PG;>#*-)],
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M+K[R33CN'IP^_R8\+SB6)K-QF7J6Z4JPMM8[EY>4\G-72'Z<GLD#@K>0NH/
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M4,;)=#K\S5#I-4.436!FR<!,(Q\;^5@B'WN-?)R?B[^04&SI&!BF8.2 ,6C
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M6<:5(!,T>K)Z[V5OTI9J3"K3"'7,+7"*1C)S4,E<<0>AR5WX#;:D15)UG!C
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MT@OPF(B8><4;$.\E$>#^EE!OIMC1L 4SB8I94F(XH1OT8[R',3+2&UP\.W:
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M!!Y_%XK$,#JSHOO^6]"*^/]W2B:*1SBG6EU-D(I/N$MLD4(S)*1#UP33Y[^
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M&2&K#K!QC/C)"96Y16<-OT*-D]-DB"@3DT9O/J_>I #?[BBZ\T3$^D @C)@
MR#$K') '(S0 "FW25:8469UYH!K^-#"KD%'R6EGY@EF0T<S&5#?5<:T79WZG
MM$5%!]_1&#;)2Z2\I*^UP"BE;'$. 83/.7:@(A.FKXDV[9> /^K0EW6ZI+$
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MU.=WA, J!(<9@:M"[C-=% C/1D0[!3ZV\KQ88'/<<<&:G#K$5%06X@@D0"/
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MS?X_W_YW3[=M_Y=3+]PZFT>_]&WGUWT$/HVK[VNO<P">VOX)_.?P\%UA)2!
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MAEU4:#\I[IKV+] +==C-M$)W-?;F@*6T,U5.'D*=FLDU2_\I98J+:A$BE9=
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MJM,=J3QWI(14K^)M*2'5S^"ZE)#JA%0GI'HM$=*$5)>##X14/YT8T)4T$>(
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M)\,"CH?Y"+PY6E@V9O=.+)N^15 Z@ZXZB& :>Z=0[GI)M,>.0H4(K5+@<CE
M72:6;S^2PLBJ+:-?KBU] X^!,0<)LTO:2'//;C6$8M^HTL[@#^8AB^?O$ZHU
MP$R2MK7\,P$A[UZJ[<OX35S:0:[DIXV.=D$&Q>0CV!?;>N(N'J?PM.6*3(?Q
MWS'WUQ?;^Q?'@&7[T3+^DR2Q&ZE(LQ8[;G=7$:FEC?U4!-IB P15T/=A=H%
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M!H'3[:FA&28\"**Z6,C*\X2#9L&'U])2XCN8_N&GIG(-:@P4E>N;7M#N##X
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MFF]$B()/*Y3=17*,>4[L>#(,_3T?<PQAA 8PVL%SX?7/!A/1/09W]\+/N\7
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M"-\+L .$GSZ/>.$]48?_7Z3$(3FFT3%=Q^(1P#UX"4@.?!7PN.AR9E7)$W.
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M'QI\^?3DL2?J)T)67T&%I(]F)C3H+VH'N AN[POC.1=XSH4RUX/*[A1[.-$
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M1.IX:B)*1OZRZ40J/NH9L'UX?8H@J; /AO5&ZOOQ2[P^Q>J-\CZ9]ZB#-A@
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MSWT:K53.3\%2P,YH_#^Y?7EMB7DM9<H;)KGXU3'A1PEIX/=<CT<<>_CNVE_
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M6!,^3P/7CH4!T%H9-PF^)9$HG9HSP%V(Q=;@0@,Z ["Y&%(YL$/4H4:.5?$
M&3TU3K%JD1M@W7J\0I2?53J6)DE<^XYOD'V51'+]U2HX!YJXZ8,H4\TN3+1X
M] +2--I=,3-@GXM'A:EC&:A%2J@U#0^_%$ILIF'S,%U$>I8;)J -52&#WA<B
M?:YS!+"A+B \;Y+-=;$;2J;4U4]+*D!-%@;8<\&L(MB7L2C=WA=@>9&T &#+
M3>0-6 <N+!E6,QF=I>4,J.7"6#%JY4/M'B<*Y7,\U='XCN_"[>P;X9RH@Q'Y
M/9TOLBN:!G0&T'*!JL*L4;P=\E=M[3F48'FX1M4RAN95ADAP/4&W.951+* Q
M(%CIX(X-!,.;1+,?P"L (L[%TY=GV)'IDYV!":W7Y8OZ"5O0K,7$ &\NG&2"
M-Y7II^^-U$<S')V9$PFT() X(%X"ELZ%;0EX%1[%>'_(Q9NVXZVS;@>X:\&]
M-2Y1C\0 9B[69 !SB$5LW:P1MZTD.?(,5';B'?>>J/J*TI7'4^736+9G8\ W
M%W+*; ;)--)L3N14RU0!Q4"HRK.,BH0[20;L\Z"IWI2P]<,%S(!S<"HA749D
MP#47<S+C:@?<_R0L)^0_ &@&\"O()": +0'4&5]8Y!S]1N4Y+BS6V!)R,^5N
M6!G S@69S&"KR'$JRJ"EZB CEK5L+=BRTY*'6I"'[AY4ZA]U:9@C<SF;@2WI
M$]P3"3IL%+78N$\^ X9VRCH]?,=2#'6G?#=@4G=X1AL]28_TL=2W!*,05M*;
M)$/#FVF@UY^'0:*L=FV=T54L:T Z%]W:0'J8PM4^[W$K8@UI#0CF<[+*3HD<
M(*V]QS>5>%Q<()LYV8Z) >1<-*QDE_!&4K-Y-_$ >#$46QMP$T(#L+DX6"FP
M0].MOB\\"5,6/$RCV92X&-&/N4B7>4=Y-KP9%W,W-Y[O.[RMWL9.7 F<89LZ
MZN#5;HJ9 ?XC*_LUK^[>\5JQ<.OH#UX5U!\5V+V'F:4_;7TJ\?&G T&7*U=]
MMUK?6W"8?3I07^H>15_A_B>:]/9EZ49%%.>2+U;KVK/IA5!PQ"+\L''YI[?'
M88X<XC&.E#^PQAT8A!ZO:U 6I!_+')=,ZYJ#).#^>)9@U:YKR49KZ-B><>I#
MU./L)ZK1&(]+BY$EB!6QRQ1-/@XO].?J;SQ;LRDA45>CB&ZD;HV.WHV.C]Z^
M""?4K88"B57U%(CH:BI0_+7[BJ(C B7S?15IZ>^SSPE993Y(;A"J!182CL&5
M(KHS2EA5MCOZ\+O>0\S76[41983112M%PO,6&FB2IHROVN@"+_:BOAXQE?[5
M1CXCU%:?GC_Z6$N!A"SX.4HXU%9!4+N^!R(B]:.-_4*NN++CYWK2(RK]:Y30
M-^F-3H)^FZG=A^!4ZQ9<SC-4JF\X4?W1T8=6*E3LE5+B96O1X9"$W98M1_"R
M<@E.+SV^OL+KZNJDN5PF3&IJET'9 :I /JE5-2(B]6.44-=VC2/Y6,T2QLQ?
M J=V-4]L4K4!)^'EL5%#+3SVM9$BZ9%(<1(=C6&:5\W^(N8HN&RJ#)*F%(D9
MM="D"QT*I4.0[ZW%?SJX]];$51/!"7-NJ*U27JY G707S&"5!'JZ]+ ?P&7E
M-2XXU1+KP")3(3FVQ$\',^*J:590$">5U',>-:GC<ZWM@<6HZZH-!)\.)(^^
M<:JFP?\T"A<^\J?25_2?N>>O(DUP^;Z,A(7IZB@)IE066G<MA*_*J TR+\!M
M*D"?RS+SF0-.E.V9-5:'0T37IE;59(OE!3:JW=$N")%BZW-[@9/8/NVKHD5]
MVZIY3;W-GJ5"I.>>V#3ZM6IP*P7KU?+@%7FAFR9+[$_H_T;G)JBTXMO9;P*B
M;X;VX8EM.G36I!DZ0J7K0?#_FH6'*(G\9R9[J0$U].G:!Q>QS,U 8K^VE^G1
ME<VI].[-(SXGH3$;_9SDE,V+3 ZL:&1Q)2WJ]W.94Z+ZLZ98;#OUD[<2C_ B
MSUS/_AY9@K-%G&:>RNA^U]5QJQKU+3.>:; [*VNIU-+BJ.O2I].M=VNJ49?Z
M-DY\I9U+"?OL>8[JJ!^ /^$$5#R2E\]"1B(?Z)*ZA.NTEQVYH!-5F[3H)VQ$
MZL8]","UMSK$YP*>P/7T1O#/>EZS(Y\T5*Z^%[["<W)"XX,DS%%YB2CLFDG@
M*PY!<%Q\]>0_0'Y1SU5,XI9?$NZN)XZW4B_P=^.DU]&]O@]+1DQ]U'GOCJFA
M4!MKS<<6JR1*L6O;:ZK7QA/141)WKCKQ-'54!:X.9KY[0Y]V[XXF.K9N"^MO
MU(%4$D_Z^,)=.Z2V@FV\4?J-LQTZH:I>;6RO?^S#KKW27N/Z_DHFM^&^]]M9
M9@.#WK)P%6X<2.]EV)&WNM.W^Q%WM\OD4 6#68X\7: 0;OM3N&Y@X UEFFXS
MYMFSD2DUZN-W%F2IG459:FILXE0'<&YPEH_MZFSJ?H'E%/A&=78\E=/6L9FU
MU&EL;;S.R;/OW=0*NC2V<U<V=:7_-;-[USTEL[[>]XS01QR^R0J0RA:]&E B
MO$%DAMC 86>VE(IOWA[<_NM32N9K],X_4M?<W$ZUP<=C>L^]SD<7]X VT'@?
MW@4(F]-5H&&UL;;5^\4ZZC2("#YAM9Y#N"J^?+$7A,WU=D>\A77^3FN;-72%
ML[O.PWT5]:AOX0V9QHO:_FIHD=0&,]I*GT[I;7);1YM6\]Q*@GJ=\M;5J#[6
M5Y3ABI(2-WAQ/)%7A/*_$]>'#MYI!OG%LL3",O%=O<K4\>DDG'#+BL/8^L@;
M7!)B-R/Z:[$ME*L/M@ZL.+#R!.TD3V$[OAL2NX+T"^'?0>IZ<CN[H0*'WF"8
MZL6H$NE=&8BM'&4&65JVSM(*0L>R%P-+I'>71!/(**[N.S*X@C*=V7_N$B'R
M1R &+].N6=$,Z)52R:HITF!*6\P89UE!YI9SX:LQTS#=Z]78$ITZLSN?LM=K
MPF!]I>I;_@T44W#":77$](YC1W([,ZAPZTO5/!UT>SS@XFB["C?F=MS2VZOX
MZF[1+<_8.AK[ID(EZ4C15_=0]/P/X".SJCOSDFKS-Z4=T1_ ?V5&-,@\\=64
M&M=9R!M$Q$EE&\/&L.2 39?$[;A7*I=?WQ[TD:U>&,[1+[?/#+A8T)4^7BZ*
MZMQY0H9RXL%O$W_%HF-#&RO6((H!=K@A/TJ-G\PY0+\!F0I*-$!W,^&]/WN,
MHAM8L;%AH4<C#)(;O"=/SFD, ABOD!B^O5%5T*+W%( >HF.M-6P3+ Q&H<D+
M[2,.F!9F5MJA2_51>X]M4?I"MZE>&EI&7H-AV7/5=V4?G[W'A><+G(%?ZLD#
ML/XZB^TZ-++KMY7T=FW7%AWJV_4/(#S%4+6Y!>42&Z'/^[.LBA;=V?9 7W9O
M6DJ)[BR[9;![RU)*]#F&]?F6IQ,MF\%^.[M\65']D<GL^<09F5D?S!5AUZO"
M.LK4-S4^4#<^5S5[Y&ZR*L%?2\+P]P5%&I6KW7Y55,'\M@J^IDLV#Z_.'%?]
M0_EFBZ8-]D-'$E.;O7J:W)I%MYFU%G#MLZ<K%]\NS/'H2>*JD(***$3)K]X9
M?,&Q"GM5!L[96IVD';S(T:&M\.,6V+-,GK#?17O-_6Z_H9%7-Z:1K]&85-0F
M5 MY?EM0>X'JI/688'WU'GRAM,5'E/\-[Z,NM9P=AMS"BM5UQ]*O1<V#DFIL
MQ#G!.7 E>F-L?%P0>4[8&2AQ%.L%2;+N7]=]+=1KU](G. LE+O8B2JV@2[ET
MZ9SB%;K[ AS?3J?)O>+0U$BK!F/U$_[N*=20DM4FTJ#9]!=HR(AKDO F5H%!
M$8XQ7CJQ4XOO,6A<1YWZUO[&U,>V; E.GQ6K4&J;*K;!L+_*9A#<).>7>XP\
M4>Z+"77NP:4P4YLA<7:K<FW#=P?KB=WC"XOZ.C4Y0LFE."UGE*AP]7+JKL]0
M'1U^6E_A1+]':RMJTBR?V_ ]B/X7$W64:;.\J"2GSP5'784:C,U8?JDV7T:Y
M8_JP*357QSF FIX[O;P"JJ)&9ZEK-S G;OB%R!Y?VQ6*;3"M1D]^\_AWT>M>
MF"*I]77_0ET0$JO0'5FKVV'>8FDBW6N=1E55E\ZJ76:!O(!44E8J?>!OX 9K
MXVOVI-3C/2_<:^C5'GYU-@#?EDC9%_Y&99KG1(^#@SA__7]02P,$%     @
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M]\_NO35Z,;\(='-,BA%Y^:[ -:1KRNZ2B>A<DQ<,ZVQ6,U#M$/IX<4PQ".'
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M+[_+WTB?'''_?"F7FIH<Z]DNDVF*4,*FE7G%\V:IR2:)XP,]<K1E4(]-PAV
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M#PP%>)UX3X3,L?X=QY5R' Y8SD/]0! OCF(,P=S]/163**/):W2/H2Z7XS#
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M&(Y#FFZSQ(T'HJ0ZCRP%?3_9Y4C4H50__2 XQA_2;[Y&&/WQ_P!02P,$%
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MKLZ^?_?]._3G=S_^]"_O?GKW_C_1_W/WR_][=D:Y*/+RMZ>DQH@*4M;_]M6
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MV\PF-5^S691I##I[19FV3F&Z,IBG8B.270O(&W84R XI+DC)S 67J1JA!JU
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M&MSQ :?<*F</&_BZ^3*O4PJ);6547\.QQQ!AAH[F3.%'6R(*#3CS%;8'4 #
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M]IV +,:>3(!++5T-J*\[+KYA18/W>SA]EAAL R>,C+#=X!?F&VHFWF"7A<]
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M55&]R^96EVY8-31R650[(!V70@7 ,,;^:%E3#C*N3G.;,FD&W/O4=QQBIW-
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M.+@]QV7>X/0\)QNZ^EHGK/9+E>.&KCYO\C7]4W;^5/R"UT^XDL6X@"[L0UT
M$?\ :IE /1=HP 9J^4#GYS?HSX(5B^/;0 *"J@R:R?GU5U32K[Y1R1HJQH=
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MQ+ @ ]3(+,@4</-84'V/TVU5T8E$G[=HT=R;#<D(!,AEI-01)\_JJ+1$@3F
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M@L&D(VQQI\VS!""4/^)JW0D2/?;7XF$<\9M!*+P-\+28>I\6(YZ@5^6;:%J
ML*_I,U!*6#U(!UJ@EJ85XCWP#4)[EU;UC[][6[[[PS\FZ\T?#O*7GCE?<>U
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MN[)E-9MC_2L;W5$^BP($@+M2/(!J!996^9K\R/Y.TV0W@6+Q;E_ O)H0F#L
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M3+B<DJ??1CXP=P.AC>6:(7H>,[[';(^L^Q>KEV]IM_(.O!FJG$1$R^R9$+]
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M7^A5: W(1#8B2"6L5(A*,'L0D+V _Y#D,@;X!:=>3W0M &G(]W[5=,,8FJ,
M[S>2OB;8&J%:TI=% #BRV:B:3-=]=Q6EW08W_9OW&8DSH^5<6H<3@Y6@L_*Z
MKH>#^]3P:YS[7'P'9\<'7'CL-[\_)7,O6MP<W],3!>WY+1&./55QP(@<5*F7
MP*;DC #U(=[ZB8J#4LE2KUW3R2=*>&*7!4O*6591#QA"MBO:BMP.61\BK;^0
MF%(44:"#8!K&(:.'O0RJE[ZF)K"$;)2L*G]3;'V(FM[AR&9-!B:0S]A5I2Q'
MXRP(N@U[KM*EFH%DUZ6!C;;<N5KOLP1 G,4V(XKU(8F338@+[3784FOK<J:P
M,TA:B]P<%OXSR?45X#9)23B.(9K;G_/'3-EKWDG\Q0MCIN^79$3+J(UG%JT
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M TI5#; @'[),N!8/*"-H?1E#+,8TA#2Z[#HAX7X=),;P)U)TQ6J46;7#!7J
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MB 2&1YDFO@7\=LWFT3P=KMXX;4.\Q^*9E!?+K&>([_%899.V[R=G0CO<C!N
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MTB(7(/MR@[W[#!?.A%WG=;<3A!S*I4E(^)#9=R_E,6[#]"D<3PR3FE=M$UA
M]L:6"$:W+:H*M0=3]OIM$4J#,+IIP%@8@V?ZY7Q=ANY'V>\&/[TT,+Q_=/DE
M$ +RGMQ*WYHBH =WVZ6A* 3-!RB$V64L>R6PE67%%'Y7X<SGXD,@ NSW42K.
M>2[Q-W6ICG/G6QJ15TF6WR;I+EFED3J(>+>X[X%X7+-6F.L2/1U4N3K>7W]
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MBBJ1T%/LA2\3DGHS4N2AGVD'D[0"D()DH:TG,STFY#=(9>\#>CY)B97X%%5
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M6K3BWBH))" ;+>H+68:J?5%-UJ*]+=*8OXU*B;D-W]4/SNHK 37(=V?U!6X
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M8I>H!;P/*5=7<7;W[$M,>"8I382U@!?D!$3U)*JRB*LQ]R9#ZPY,PZ0GDGI
M4"M>9E,+T$KT6]C:>)B[)V,O6ESA9&J_<T%1@-:*5-DZ\@7;<Q6@'N1?E<QL
MJI.Y:56@"3E)41-SN#%P1^<UI$5= A-N4++AJ/0[>RT1M0*\(6<U,A:NE6XH
MX3:5_[4MI[D6W38U?H*[^".?X"Z0'R R%I'K$]R%/-M$MR?[+<2: YUY(\ :
M<MKG>O*VFO]5%/3@N%?&ICWC[18&*EIJ_E%(3J\"6_C:>+A[\.+\>Y+^R.XC
M7WVVVRT)P)#-- J^!><Y!8@_CW/:C>\%LO5ECU/V+G"LXYQDX'X-(Y+E24P>
MO3FS:0Q\/RU(<%VD83Q^F1#P%9 -9K/:@!W9=F,L(,%PMX2)^A2'2<CIA R+
M/,N]F(5ZL<O")'[.$__'OY,(HACOXC<&6#J)5VL-"$)^0ZF.'M2$C?JZA^'X
M9\F4:?-5)P!)=<BDT<Z#7:490(>SJ;<_]FV-N?'2F +,6.05A<A#1U?WZJ(_
MXEADECU9]L+ $B.KPD1X</)Y_[NN!Y+#_0*C4]'QC7+06^0I54NE>,LD!N+(
M A*041AS@^&7(@S@$?=]2_0[80F%2#"@<P5=,Y;!C9RCTMIQZ66A/XB#ZS J
M<J%#6[T&@5KD1^PJZDA-Q(ZL(E4CA9N9W,SU15.3TX3]WGM%Q3"%YLA88NKF
M]HEU]M7+R+_^?U!+ 0(4 Q0    ( $B&-U$X48+%M@L! !2)$@ 1
M      "  0    !B;G1C+3(P,C P-C,P+GAM;%!+ 0(4 Q0    ( $B&-U'\
M-AUT_1,  //<   1              "  >4+ 0!B;G1C+3(P,C P-C,P+GAS
M9%!+ 0(4 Q0    ( $B&-U&ROE_N@@T  %S$   5              "  1$@
M 0!B;G1C+3(P,C P-C,P7V-A;"YX;6Q02P$"% ,4    " !(AC=1.=\"ER I
M  !V:0( %0              @ '&+0$ 8FYT8RTR,#(P,#8S,%]D968N>&UL
M4$L! A0#%     @ 2(8W4<O5@Y/*:0  *>\% !4              ( !&5<!
M &)N=&,M,C R,# V,S!?;&%B+GAM;%!+ 0(4 Q0    ( $B&-U'7C+ X>4@
M .6L!  5              "  1;! 0!B;G1C+3(P,C P-C,P7W!R92YX;6Q0
52P4&      8 !@"* 0  P@D"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
